0000105770-20-000015.txt : 20200224 0000105770-20-000015.hdr.sgml : 20200224 20200221185652 ACCESSION NUMBER: 0000105770-20-000015 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 126 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200224 DATE AS OF CHANGE: 20200221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 20641598 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-K 1 wst-20191231.htm 10-K wst-20191231
WEST PHARMACEUTICAL SERVICES, INC.0000105770--12-31December 31, 20192019FYfalse73,837,4499,218,126,218———0.30.21.30.8———0.30.50.10.50.5—0.12.50.21.50.13.03.0————0.250.25100.0100.075.375.374.174.11.21.20.620.580.54153551247310—P5Y0M0D13.42.783.673.824.022.3—P1Y66—2000.270.330.670.73—0.034.250.91.5P5Y00001057702019-01-012019-12-31iso4217:USD00001057702019-06-30xbrli:shares00001057702020-01-31iso4217:USDxbrli:shares00001057702018-01-012018-12-3100001057702017-01-012017-12-3100001057702019-12-3100001057702018-12-310000105770us-gaap:CommonStockMember2016-12-310000105770us-gaap:AdditionalPaidInCapitalMember2016-12-310000105770us-gaap:TreasuryStockMember2016-12-310000105770us-gaap:RetainedEarningsMember2016-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2016-12-3100001057702016-12-310000105770us-gaap:RetainedEarningsMember2017-12-3100001057702017-12-310000105770us-gaap:RetainedEarningsMember2017-01-012017-12-310000105770us-gaap:CommonStockMember2017-01-012017-12-310000105770us-gaap:AdditionalPaidInCapitalMember2017-01-012017-12-310000105770us-gaap:TreasuryStockMember2017-01-012017-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-01-012017-12-310000105770us-gaap:CommonStockMember2017-12-310000105770us-gaap:AdditionalPaidInCapitalMember2017-12-310000105770us-gaap:TreasuryStockMember2017-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000105770us-gaap:RetainedEarningsMember2018-12-310000105770us-gaap:RetainedEarningsMember2018-01-012018-12-310000105770us-gaap:CommonStockMember2018-01-012018-12-310000105770us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310000105770us-gaap:TreasuryStockMember2018-01-012018-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000105770us-gaap:CommonStockMember2018-12-310000105770us-gaap:AdditionalPaidInCapitalMember2018-12-310000105770us-gaap:TreasuryStockMember2018-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000105770us-gaap:RetainedEarningsMember2019-01-012019-12-310000105770us-gaap:CommonStockMember2019-01-012019-12-310000105770us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000105770us-gaap:TreasuryStockMember2019-01-012019-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000105770us-gaap:CommonStockMember2019-12-310000105770us-gaap:AdditionalPaidInCapitalMember2019-12-310000105770us-gaap:TreasuryStockMember2019-12-310000105770us-gaap:RetainedEarningsMember2019-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100001057702019-04-010000105770srt:MinimumMember2019-01-012019-12-310000105770srt:MaximumMember2019-01-012019-12-310000105770us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Memberus-gaap:AccountingStandardsUpdate201409Member2018-01-010000105770wst:SmartDoseMember2013-06-300000105770wst:SmartDoseMember2019-12-31xbrli:pure0000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2018-01-012018-12-310000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310000105770wst:PharmaCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310000105770wst:PharmaCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-12-310000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2018-01-012018-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2019-01-012019-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2018-01-012018-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2019-01-012019-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2018-01-012018-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:DeliveryDevicesMember2019-01-012019-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:DeliveryDevicesMember2018-01-012018-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:ContractManufacturedProductsMember2019-01-012019-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:ContractManufacturedProductsMember2018-01-012018-12-310000105770us-gaap:SalesRevenueNetMembersrt:AmericasMemberus-gaap:GeographicConcentrationRiskMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMembersrt:AmericasMemberus-gaap:GeographicConcentrationRiskMember2018-01-012018-12-310000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2018-01-012018-12-310000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2019-01-012019-12-310000105770us-gaap:SalesRevenueNetMembersrt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMember2018-01-012018-12-3100001057702019-01-012019-01-0100001057702018-10-012018-12-310000105770us-gaap:LandMember2019-12-310000105770us-gaap:LandMember2018-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2019-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2018-12-310000105770us-gaap:MachineryAndEquipmentMember2019-12-310000105770us-gaap:MachineryAndEquipmentMember2018-12-310000105770us-gaap:ToolsDiesAndMoldsMember2019-12-310000105770us-gaap:ToolsDiesAndMoldsMember2018-12-310000105770wst:ComputerHardwareAndSoftwareMember2019-12-310000105770wst:ComputerHardwareAndSoftwareMember2018-12-310000105770us-gaap:ConstructionInProgressMember2019-12-310000105770us-gaap:ConstructionInProgressMember2018-12-310000105770srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2019-01-012019-12-310000105770srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2019-01-012019-12-310000105770srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2019-01-012019-12-310000105770us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2019-01-012019-12-310000105770srt:MinimumMemberus-gaap:ToolsDiesAndMoldsMember2019-01-012019-12-310000105770us-gaap:ToolsDiesAndMoldsMembersrt:MaximumMember2019-01-012019-12-310000105770srt:MinimumMemberwst:ComputerHardwareAndSoftwareMember2019-01-012019-12-310000105770wst:ComputerHardwareAndSoftwareMembersrt:MaximumMember2019-01-012019-12-310000105770srt:MaximumMember2019-12-310000105770us-gaap:AccountingStandardsUpdate201602Member2019-01-010000105770wst:WestCompanyMexicoSADeCVMember2019-12-310000105770wst:AluplastSADeCVMember2019-12-310000105770wst:PharmaTapSADeCVMember2019-12-310000105770wst:PharmaRubberSADeCVMember2019-12-310000105770wst:IWPharmaGroupLLCMember2019-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2019-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2018-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2019-11-010000105770wst:DaikyoSeikoLtdDaikyoMember2017-12-310000105770wst:ProprietaryProductsMember2017-12-310000105770wst:ContractManufacturedProductsMember2017-12-310000105770wst:ProprietaryProductsMember2018-01-012018-12-310000105770wst:ContractManufacturedProductsMember2018-01-012018-12-310000105770wst:ProprietaryProductsMember2018-12-310000105770wst:ContractManufacturedProductsMember2018-12-310000105770wst:ProprietaryProductsMember2019-01-012019-12-310000105770wst:ContractManufacturedProductsMember2019-01-012019-12-310000105770wst:ProprietaryProductsMember2019-12-310000105770wst:ContractManufacturedProductsMember2019-12-310000105770wst:PatentsAndLicensingMember2019-12-310000105770wst:PatentsAndLicensingMember2018-12-310000105770us-gaap:InProcessResearchAndDevelopmentMember2019-12-310000105770us-gaap:InProcessResearchAndDevelopmentMember2018-12-310000105770us-gaap:TrademarksMember2019-12-310000105770us-gaap:TrademarksMember2018-12-310000105770us-gaap:CustomerRelationshipsMember2019-12-310000105770us-gaap:CustomerRelationshipsMember2018-12-310000105770us-gaap:CustomerContractsMember2019-12-310000105770us-gaap:CustomerContractsMember2018-12-310000105770wst:NotePayableDue2019Member2018-12-310000105770wst:Revolvingcreditfacilitydue2020Member2018-12-310000105770wst:TermLoanDue2024Domain2019-12-310000105770wst:SeniorNotesDue2022Member2019-12-310000105770us-gaap:SeniorNotesMemberwst:SeniorNotesDue2022Member2018-12-310000105770wst:SeniorBNotesDue2024Memberus-gaap:SeniorNotesMember2019-12-310000105770wst:SeniorBNotesDue2024Memberus-gaap:SeniorNotesMember2018-12-310000105770wst:SeniorCNotesDue2027Memberus-gaap:SeniorNotesMember2019-12-310000105770wst:SeniorCNotesDue2027Memberus-gaap:SeniorNotesMember2018-12-310000105770wst:RevolvingCreditFacilityDue2024Member2019-12-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:DomesticLineOfCreditMember2019-12-310000105770us-gaap:ForeignLineOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2019-12-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:FederalFundsEffectiveSwapRateMember2019-01-012019-12-310000105770us-gaap:LondonInterbankOfferedRateLIBORMemberwst:RevolvingCreditFacilityDue2024Member2019-01-012019-12-310000105770srt:MinimumMemberus-gaap:BaseRateMember2019-01-012019-12-310000105770us-gaap:BaseRateMembersrt:MaximumMember2019-01-012019-12-310000105770srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberwst:RevolvingCreditFacilityDue2024Member2019-01-012019-12-310000105770us-gaap:LondonInterbankOfferedRateLIBORMemberwst:RevolvingCreditFacilityDue2024Membersrt:MaximumMember2019-01-012019-12-310000105770srt:MinimumMemberwst:RevolvingCreditFacilityDue2024Member2019-01-012019-12-310000105770wst:RevolvingCreditFacilityDue2024Membersrt:MaximumMember2019-01-012019-12-310000105770wst:RevolvingCreditFacilityDue2024Member2019-01-012019-12-310000105770wst:RevolvingCreditFacilityDue2024Member2018-01-012018-12-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:LetterOfCreditMember2019-12-310000105770wst:TermLoanDue2024Member2019-12-310000105770wst:TermLoanDue2024Memberus-gaap:LondonInterbankOfferedRateLIBORMember2019-01-012019-12-310000105770wst:TermLoanDue2024Member2019-01-012019-12-310000105770us-gaap:SeniorNotesMember2019-12-310000105770us-gaap:SeniorNotesMemberwst:SeniorNotesDue2022Member2019-12-310000105770wst:SeniorNotesDue2022Member2019-01-012019-12-310000105770wst:SeniorBNotesDue2024Member2019-01-012019-12-310000105770wst:SeniorCNotesDue2027Member2019-01-012019-12-310000105770us-gaap:SeniorNotesMember2019-01-012019-12-310000105770us-gaap:SeniorNotesMember2018-01-012018-12-310000105770wst:SeniorNotesDue2022Member2019-12-310000105770wst:SeniorBNotesDue2024Member2019-12-310000105770wst:SeniorCNotesDue2027Member2019-12-31iso4217:SGD0000105770currency:SGDus-gaap:ForwardContractsMember2019-12-310000105770currency:USDus-gaap:ForwardContractsMember2019-12-31iso4217:EUR0000105770us-gaap:ForwardContractsMembercurrency:EUR2018-12-310000105770currency:SGDus-gaap:ForwardContractsMember2018-12-310000105770currency:USDus-gaap:ForwardContractsMember2018-12-310000105770us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:USD2019-12-310000105770us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ShortMembercurrency:USD2019-12-31iso4217:JPY0000105770us-gaap:LongMembercurrency:JPYus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2019-12-310000105770currency:JPYus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ShortMember2019-12-310000105770us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:SGD2019-12-310000105770us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:ShortMembercurrency:SGD2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-310000105770currency:JPYus-gaap:CrossCurrencyInterestRateContractMember2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USD2019-12-31utr:bbl0000105770us-gaap:OptionMember2017-11-220000105770us-gaap:OptionMember2019-12-31iso4217:USDwst:bbl0000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMember2018-01-012018-12-310000105770us-gaap:FairValueHedgingMember2019-01-012019-12-310000105770us-gaap:FairValueHedgingMember2018-01-012018-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2019-01-012019-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2018-01-012018-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2019-01-012019-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2018-01-012018-12-310000105770wst:ForwardTreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2019-01-012019-12-310000105770wst:ForwardTreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2018-01-012018-12-310000105770us-gaap:CashFlowHedgingMember2019-01-012019-12-310000105770us-gaap:CashFlowHedgingMember2018-01-012018-12-310000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMemberwst:ForeignCurrencyDenominatedDebtMember2019-01-012019-12-310000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:NetInvestmentHedgingMemberwst:ForeignCurrencyDenominatedDebtMember2018-01-012018-12-310000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2019-01-012019-12-310000105770us-gaap:NetInvestmentHedgingMember2019-01-012019-12-310000105770us-gaap:NetInvestmentHedgingMember2018-01-012018-12-310000105770wst:NetSalesMember2019-01-012019-12-310000105770wst:NetSalesMember2018-01-012018-12-310000105770us-gaap:CostOfSalesMember2019-01-012019-12-310000105770us-gaap:CostOfSalesMember2018-01-012018-12-310000105770us-gaap:ForeignCurrencyGainLossMember2019-01-012019-12-310000105770us-gaap:ForeignCurrencyGainLossMember2018-01-012018-12-310000105770us-gaap:InterestExpenseMember2019-01-012019-12-310000105770us-gaap:InterestExpenseMember2018-01-012018-12-310000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2019-01-012019-12-310000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2018-01-012018-12-310000105770us-gaap:NondesignatedMember2019-01-012019-12-310000105770us-gaap:NondesignatedMember2018-01-012018-12-310000105770us-gaap:FairValueInputsLevel1Member2019-12-310000105770us-gaap:FairValueInputsLevel2Member2019-12-310000105770us-gaap:FairValueInputsLevel3Member2019-12-310000105770us-gaap:CurrencySwapMember2019-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770us-gaap:FairValueInputsLevel1Member2018-12-310000105770us-gaap:FairValueInputsLevel2Member2018-12-310000105770us-gaap:FairValueInputsLevel3Member2018-12-310000105770us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2017-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310000105770us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-01-012018-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310000105770us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000105770us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310000105770us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-01-012018-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000105770us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000105770wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember2019-01-012019-12-310000105770wst:StockOptionAndAppreciationRightsMember2019-01-012019-12-310000105770wst:StockOptionAndAppreciationRightsMember2018-01-012018-12-310000105770wst:StockOptionAndAppreciationRightsMember2017-01-012017-12-310000105770us-gaap:PerformanceSharesMember2019-01-012019-12-310000105770us-gaap:PerformanceSharesMember2018-01-012018-12-310000105770us-gaap:PerformanceSharesMember2017-01-012017-12-310000105770wst:CashSettledPSUAwardsMember2019-01-012019-12-310000105770wst:CashSettledPSUAwardsMember2018-01-012018-12-310000105770wst:CashSettledPSUAwardsMember2017-01-012017-12-310000105770wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember2019-01-012019-12-310000105770wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember2018-01-012018-12-310000105770wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember2017-01-012017-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2019-01-012019-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2018-01-012018-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2017-01-012017-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2019-01-012019-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2018-01-012018-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2017-01-012017-12-310000105770us-gaap:EmployeeStockOptionMember2018-01-012018-12-310000105770us-gaap:EmployeeStockOptionMember2017-01-012017-12-310000105770us-gaap:StockAppreciationRightsSARSMember2019-01-012019-12-310000105770us-gaap:StockAppreciationRightsSARSMember2019-12-310000105770us-gaap:StockAppreciationRightsSARSMember2018-12-310000105770us-gaap:StockAppreciationRightsSARSMember2017-12-310000105770us-gaap:StockAppreciationRightsSARSMember2016-12-310000105770us-gaap:StockAppreciationRightsSARSMember2018-01-012018-12-310000105770us-gaap:StockAppreciationRightsSARSMember2017-01-012017-12-310000105770wst:StockSettledPSUAwardsMember2018-12-310000105770wst:StockSettledPSUAwardsMember2017-12-310000105770wst:StockSettledPSUAwardsMember2016-12-310000105770wst:StockSettledPSUAwardsMember2019-01-012019-12-310000105770wst:StockSettledPSUAwardsMember2018-01-012018-12-310000105770wst:StockSettledPSUAwardsMember2017-01-012017-12-310000105770wst:StockSettledPSUAwardsMember2019-12-310000105770srt:MinimumMemberwst:StockSettledPSUAwardsMember2019-01-012019-12-310000105770srt:MaximumMemberwst:StockSettledPSUAwardsMember2019-01-012019-12-310000105770wst:CashSettledPSUAwardsMember2018-12-310000105770wst:CashSettledPSUAwardsMember2017-12-310000105770wst:CashSettledPSUAwardsMember2016-12-310000105770wst:CashSettledPSUAwardsMember2019-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2019-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2019-01-012019-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMembersrt:DirectorMember2019-01-012019-12-31wst:plan0000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2019-12-310000105770us-gaap:RestrictedStockMember2019-01-012019-12-310000105770us-gaap:RestrictedStockMember2018-01-012018-12-310000105770wst:IncentiveStockAwardsMember2019-01-012019-12-310000105770wst:IncentiveStockAwardsMember2018-01-012018-12-310000105770wst:IncentiveStockAwardsMember2017-01-012017-12-310000105770wst:CashSettledPSUAwardsMembersrt:MinimumMember2019-01-012019-12-310000105770wst:CashSettledPSUAwardsMembersrt:MaximumMember2019-01-012019-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2018-01-012018-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2017-01-012017-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-01-012018-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2017-01-012017-12-310000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-01-012019-12-310000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2018-01-012018-12-310000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2017-01-012017-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-01-012018-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2017-01-012017-12-310000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-01-012019-12-310000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2018-01-012018-12-310000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2017-01-012017-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-01-012019-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2018-01-012018-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2017-01-012017-12-310000105770us-gaap:OtherNonoperatingIncomeExpenseMember2019-01-012019-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2018-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2017-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2017-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2019-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000105770us-gaap:ForeignPlanMember2019-12-310000105770us-gaap:ForeignPlanMember2018-12-310000105770country:US2019-12-310000105770country:US2019-01-012019-12-310000105770country:US2018-01-012018-12-310000105770country:US2017-01-012017-12-310000105770us-gaap:EquitySecuritiesMember2019-12-310000105770us-gaap:EquitySecuritiesMember2018-12-310000105770us-gaap:DebtSecuritiesMember2019-12-310000105770us-gaap:DebtSecuritiesMember2018-12-310000105770wst:OtherSecuritiesMember2019-12-310000105770wst:OtherSecuritiesMember2018-12-310000105770us-gaap:CashAndCashEquivalentsMember2019-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2019-12-310000105770wst:InternationalMutualFundsMember2019-12-310000105770wst:InternationalMutualFundsMemberus-gaap:FairValueInputsLevel1Member2019-12-310000105770wst:InternationalMutualFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770wst:InternationalMutualFundsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000105770wst:MutualFundsMember2019-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:MutualFundsMember2019-12-310000105770wst:MutualFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770wst:MutualFundsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000105770wst:PensionPlanAssetsInTheFairValueHierarchyMember2019-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:PensionPlanAssetsInTheFairValueHierarchyMember2019-12-310000105770wst:PensionPlanAssetsInTheFairValueHierarchyMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770wst:PensionplanassetsmeasuredatNAVMember2019-12-310000105770us-gaap:CashAndCashEquivalentsMember2018-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2018-12-310000105770wst:InternationalMutualFundsMember2018-12-310000105770wst:InternationalMutualFundsMemberus-gaap:FairValueInputsLevel1Member2018-12-310000105770wst:MutualFundsMember2018-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:MutualFundsMember2018-12-310000105770wst:PensionPlanAssetsInTheFairValueHierarchyMember2018-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:PensionPlanAssetsInTheFairValueHierarchyMember2018-12-310000105770wst:PensionplanassetsmeasuredatNAVMember2018-12-310000105770srt:MinimumMemberus-gaap:EquitySecuritiesMember2019-01-012019-12-310000105770srt:MaximumMemberus-gaap:EquitySecuritiesMember2019-01-012019-12-310000105770srt:MinimumMemberus-gaap:DebtSecuritiesMember2019-01-012019-12-310000105770us-gaap:DebtSecuritiesMembersrt:MaximumMember2019-01-012019-12-310000105770srt:MinimumMemberwst:OtherSecuritiesMember2019-01-012019-12-310000105770wst:OtherSecuritiesMembersrt:MaximumMember2019-01-012019-12-310000105770country:US2018-12-310000105770srt:MaximumMemberwst:A2018RestructuringPlanMember2019-12-310000105770wst:A2018RestructuringPlanMember2019-01-012019-12-310000105770us-gaap:EmployeeSeveranceMember2018-12-310000105770wst:AssetRelatedChargesMember2018-12-310000105770us-gaap:OtherRestructuringMember2018-12-310000105770wst:A2018RestructuringPlanMember2018-12-310000105770us-gaap:EmployeeSeveranceMember2019-01-012019-12-310000105770wst:AssetRelatedChargesMember2019-01-012019-12-310000105770us-gaap:OtherRestructuringMember2019-01-012019-12-310000105770us-gaap:EmployeeSeveranceMember2019-12-310000105770wst:AssetRelatedChargesMember2019-12-310000105770us-gaap:OtherRestructuringMember2019-12-310000105770wst:A2018RestructuringPlanMember2019-12-310000105770wst:A2016RestructuringPlanMemberMember2019-01-012019-12-310000105770wst:A2016RestructuringPlanMemberMember2019-12-310000105770country:VE2016-12-310000105770country:VE2016-02-170000105770wst:SmartDoseMember2019-01-012019-12-310000105770wst:SmartDoseMember2018-01-012018-12-310000105770wst:SmartDoseMember2017-01-012017-12-310000105770wst:OtherMember2018-01-012018-12-310000105770us-gaap:AccountingStandardsUpdate201609Member2019-01-012019-12-310000105770us-gaap:AccountingStandardsUpdate201609Member2018-01-012018-12-310000105770us-gaap:AccountingStandardsUpdate201609Member2017-01-012017-12-310000105770us-gaap:StateAndLocalJurisdictionMember2019-12-310000105770us-gaap:ForeignCountryMember2019-12-310000105770wst:Year2019Memberus-gaap:StateAndLocalJurisdictionMember2019-12-310000105770us-gaap:StateAndLocalJurisdictionMemberwst:YearAfter2019Member2019-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2019-12-310000105770wst:Year2022Memberus-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2019-12-310000105770us-gaap:ResearchMemberwst:Year2023Memberus-gaap:StateAndLocalJurisdictionMember2019-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMemberwst:YearAfter2023Member2019-12-310000105770us-gaap:InsuranceClaimsMember2019-12-31wst:segment0000105770wst:ProprietaryProductsMember2017-01-012017-12-310000105770wst:ContractManufacturedProductsMember2017-01-012017-12-310000105770us-gaap:IntersegmentEliminationMember2019-01-012019-12-310000105770us-gaap:IntersegmentEliminationMember2018-01-012018-12-310000105770us-gaap:IntersegmentEliminationMember2017-01-012017-12-310000105770country:US2019-01-012019-12-310000105770country:US2018-01-012018-12-310000105770country:US2017-01-012017-12-310000105770country:US2019-12-310000105770country:US2018-12-310000105770country:US2017-12-310000105770country:DE2019-01-012019-12-310000105770country:DE2018-01-012018-12-310000105770country:DE2017-01-012017-12-310000105770country:DE2019-12-310000105770country:DE2018-12-310000105770country:DE2017-12-310000105770country:IE2019-01-012019-12-310000105770country:IE2018-01-012018-12-310000105770country:IE2017-01-012017-12-310000105770country:IE2019-12-310000105770country:IE2018-12-310000105770country:IE2017-12-310000105770country:FR2019-01-012019-12-310000105770country:FR2018-01-012018-12-310000105770country:FR2017-01-012017-12-310000105770country:FR2019-12-310000105770country:FR2018-12-310000105770country:FR2017-12-310000105770wst:OtherEuropeCountriesMember2019-01-012019-12-310000105770wst:OtherEuropeCountriesMember2018-01-012018-12-310000105770wst:OtherEuropeCountriesMember2017-01-012017-12-310000105770wst:OtherEuropeCountriesMember2019-12-310000105770wst:OtherEuropeCountriesMember2018-12-310000105770wst:OtherEuropeCountriesMember2017-12-310000105770wst:OtherCountriesMember2019-01-012019-12-310000105770wst:OtherCountriesMember2018-01-012018-12-310000105770wst:OtherCountriesMember2017-01-012017-12-310000105770wst:OtherCountriesMember2019-12-310000105770wst:OtherCountriesMember2018-12-310000105770wst:OtherCountriesMember2017-12-310000105770wst:CorporateAndEliminationsMember2019-01-012019-12-310000105770wst:CorporateAndEliminationsMember2019-12-310000105770wst:CorporateAndEliminationsMember2018-01-012018-12-310000105770wst:CorporateAndEliminationsMember2018-12-310000105770wst:CorporateAndEliminationsMember2017-01-012017-12-310000105770wst:CorporateAndEliminationsMember2017-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310000105770us-gaap:AllowanceForCreditLossMember2018-12-310000105770us-gaap:AllowanceForCreditLossMember2019-01-012019-12-310000105770us-gaap:AllowanceForCreditLossMember2019-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-01-012018-12-310000105770us-gaap:AllowanceForCreditLossMember2017-12-310000105770us-gaap:AllowanceForCreditLossMember2018-01-012018-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2016-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-01-012017-12-310000105770us-gaap:AllowanceForCreditLossMember2016-12-310000105770us-gaap:AllowanceForCreditLossMember2017-01-012017-12-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-K

(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

Pennsylvania23-1210010
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
  
530 Herman O. West Drive, Exton, PA
19341-0645
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: 610-594-2900

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $.25 per shareWSTNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).           Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑ Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☑

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2019 was approximately $9,218,126,218 based on the closing price as reported on the New York Stock Exchange.

As of January 31, 2020, there were 73,837,449 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
DocumentParts Into Which Incorporated
Proxy Statement for the Annual Meeting of Shareholders to be held May 5, 2020Part III



TABLE OF CONTENTS

Page
BUSINESS
RISK FACTORS
UNRESOLVED STAFF COMMENTS
PROPERTIES
LEGAL PROCEEDINGS
MINE SAFETY DISCLOSURES
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
SELECTED FINANCIAL DATA
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
CONTROLS AND PROCEDURES
OTHER INFORMATION
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
EXECUTIVE COMPENSATION
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
PRINCIPAL ACCOUNTING FEES AND SERVICES
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
FORM 10-K SUMMARY

2

PART I

Unless otherwise indicated, or the context otherwise requires, references in this report to “the Company”, “we”, “us”, “our” and “West” refer to West Pharmaceutical Services, Inc. and its majority-owned subsidiaries.

All trademarks and registered trademarks used in this report are our property, either directly or indirectly through our subsidiaries, unless noted otherwise. Daikyo Crystal Zenith® (“Crystal Zenith”) is a registered trademark of Daikyo Seiko, Ltd. (“Daikyo”).

Throughout this report, references to “Notes” refer to the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K (“Form 10-K”), unless otherwise indicated.

Information in this Form 10-K is current as of February 21, 2020, unless otherwise specified.

ITEM 1. BUSINESS
General

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and additional medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, and enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

The Company was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923.

Business Segments

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products.

Proprietary Products Segment

Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability with active drug products, while also supporting operational efficiency for customers. This product portfolio also includes syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications, as well as administration systems that can enhance the safe delivery of drugs through advanced reconstitution, mixing and transfer technologies. We also provide films, coatings, washing and sterilization processes and services to enhance the quality of packaging components and mitigate the risk of contamination and compatibility issues.

This segment’s product portfolio also includes drug containment solutions, including Crystal Zenith, a cyclic olefin polymer, in the form of vials, syringes and cartridges. These products can provide a high-quality solution to glass incompatibility issues and can stand up to cold storage environments, while reducing the risk of breakage that exists with glass. In addition, we offer a variety of self-injection devices, designed to address the need to provide at-home delivery of injectable therapies. These devices are patient-centric technologies that are easy-to-use and can be combined with connected health technologies that have the potential to increase adherence.

3

In addition to our Proprietary Products product portfolio, we provide our customers with a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. Offering the combination of primary packaging components, containment solutions, and drug delivery devices, as well as a broad range of integrated services, helps to position us as a leader in the integrated containment and delivery of injectable medicines.

This reportable segment has manufacturing facilities in North and South America, Europe, and Asia Pacific, with affiliated companies in Mexico and Japan. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

Contract-Manufactured Products Segment

Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. These products include a variety of custom contract-manufacturing and assembly solutions, which use such technologies as multi-component molding, in-mold labeling, ultrasonic welding, clean room molding and device assembly. We manufacture customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

We have vast expertise in product design and development, including in-house mold design, process design and validation and high-speed automated assemblies.

This reportable segment has manufacturing operations in North America and Europe. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

International

We have significant operations outside of the United States (“U.S.”), which are managed through the same business segments as our U.S. operations – Proprietary Products and Contract-Manufactured Products. Sales outside of the U.S. accounted for 55.7% of our consolidated net sales in 2019. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

Although the general business processes are similar to the domestic business, international operations are exposed to additional risks. These risks include currency fluctuations relative to the U.S. Dollar (“USD”), multiple tax jurisdictions and, particularly in South America, Israel and the Middle East, uncertain or changing regulatory regimes, or political and social issues, that could destabilize local markets and affect the demand for our products.

See further discussion of our international operations, the risks associated with our international operations, and our attempt to minimize some of these risks in Part I, Item 1A, Risk Factors; Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations under the caption Financial Condition, Liquidity and Capital Resources; Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk; Note 1 under the captions Financial Instruments and Foreign Currency Translation; and Note 11, Derivative Financial Instruments.

Raw Materials

We use three basic raw materials in the manufacture of our products: elastomers, aluminum and plastic. Elastomers include both natural and synthetic materials. We currently have access to adequate supplies of these raw materials to meet our production needs through agreements with suppliers.
We employ a supply chain management strategy in our business segments, which involves purchasing from integrated suppliers that control their own sources of supply. Due to regulatory control over our production processes, sole source availability, and the cost and time involved in qualifying suppliers, we rely on single-source suppliers for many critical raw materials. We generally purchase certain raw materials in the open market. This strategy increases the risk that our supply chain may be interrupted in the event of a supplier production or
4

distribution problem. These risks are managed, when and where possible, by selecting suppliers with multiple manufacturing sites, rigorous quality control systems, surplus inventory levels and other methods of maintaining supply in case of an interruption in production or distribution.

Intellectual Property

Intellectual property, including patents, trademarks, copyrights, trade secrets, and know-how, is important to our business. We own or license intellectual property rights, including issued patents and pending patent applications in the U.S. and in other countries, that relate to various aspects of our products. In 2019, more than 150 patents were issued to West across the globe. Some key value-added and proprietary products and processes are licensed from Daikyo. Our intellectual property rights have been useful in establishing our market position and in the growth of our business, and are expected to continue to be of value in the future.

Seasonality

Our business is not inherently seasonal.

Working Capital

We are required to carry significant amounts of inventory to meet customer requirements. In addition, some of our supply agreements require us to purchase inventory in bulk orders, which increases inventory levels but decreases the risk of supply interruption. For a more detailed discussion of working capital, please refer to the discussion in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations under the caption Financial Condition, Liquidity and Capital Resources.

Marketing

Our Proprietary Products customers primarily include many of the major biologic, generic, and pharmaceutical drug companies in the world, which incorporate our components and other offerings into their injectable products for distribution to the point of care and ultimate end-user - the patient.

Our Contract-Manufactured Products customers include many of the world’s largest pharmaceutical, diagnostic, and medical device companies. Contract-Manufactured Products components generally are incorporated into our customers’ manufacturing lines for further processing or assembly.

Our products and services are sold and distributed primarily through our own sales force and distribution network, with limited use of contract sales agents and regional distributors.

Our ten largest customers accounted for 44.3% of our consolidated net sales in 2019, but none of these customers individually accounted for more than 10% of consolidated net sales. Please refer to Note 3, Revenue, and Note 19, Segment Information, for additional information on our consolidated net sales.

Order Backlog

Order backlog includes firm orders placed by customers for manufacture over a period of time according to their schedule or upon confirmation by the customer. We also have contractual arrangements with a number of our customers. Products covered by these contracts are included in our backlog only as orders are received. Order backlog may be positively or negatively impacted by several factors, including customer ordering patterns and the necessary lead-time to deliver customer orders. Order backlog is one of many measures we use to understand future demand, and should not be considered in isolation to predict future sales growth.

At December 31, 2019 and 2018, the order backlog for Proprietary Products was $587.9 million and $407.3 million, respectively. The increase in backlog primarily reflects increases in demand for our products due to several successful customer launches in 2019 and expansion of current customer programs due to the success of their drug
5

products. The majority of the order backlog for Proprietary Products at December 31, 2019 is expected to be filled during 2020.

The majority of Contract-Manufactured Products manufacturing activity is governed by contractual volume expectations, subject to periodic revisions based on customer requirements.

Competition

With our range of proprietary technologies, we compete with several companies across our Proprietary Products product lines. Due to the special nature of our pharmaceutical packaging components and our long-standing participation in the market, competition for these components is based primarily on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost-control programs across their operations.

In addition, there are a number of competitors supplying medical devices and medical device components, including a number of pharmaceutical manufacturers who are also potential customers of our medical devices. We compete in this market on the basis of our reputation for quality and reliability in engineering and project management, as well as our knowledge of, and experience in, compliance with regulatory requirements.

We have specialized knowledge of container closure components, which is integral to developing delivery systems. With our range of proprietary technologies, we compete with new and established companies in the area of drug delivery devices, including suppliers of prefillable syringes, auto-injectors, safety needles, and other proprietary systems.

We seek to differentiate ourselves from our competition by serving as an integrated drug containment and delivery systems global supplier that can provide pre-approval primary packaging support and engineering development, analytical lab services and integrated solutions, regulatory expertise, and after-sale technical support. Customers also appreciate the global scope of our manufacturing capability and our ability to produce many products at multiple sites.

Our Contract-Manufactured Products business operates in very competitive markets for its products. The competition varies from smaller regional companies to large global assembly manufacturers. Given the cost pressures they face, many of our customers look to reduce costs by sourcing from low-cost locations. We seek to differentiate ourselves by leveraging our global capabilities and by employing new technologies such as high-speed automated assembly, insert-molding, multi-shot precision molding, and expertise with multiple-piece closure systems.

Research and Development Activities

We maintain our own research-scale production facilities and laboratories for developing new products, and offer contract engineering design and development services to assist customers with new product development. Our quality control, regulatory and laboratory testing capabilities are used to ensure compliance with applicable manufacturing and regulatory standards for primary and secondary pharmaceutical packaging components and delivery systems.

Commercial development of our new products and services for medical and pharmaceutical applications commonly requires several years. New products that we develop may require separate approval as medical devices, and products that are intended to be used in the packaging and delivery of pharmaceutical products are subject to both customer acceptance of our products and regulatory approval of the customer’s products following our development period.

We continue to pursue innovative strategic platforms in prefillable syringes, injectable containers, advanced injection, and safety and administration systems.

6

We also continue to seek new innovative opportunities for acquisition, licensing, partnering or development of products, services and technologies that serve the injectable drug containment and delivery market.

Environmental Regulations

We are subject to various national, state and local provisions regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. Our compliance with these laws and regulations has not had a material impact on our financial position, results of operations or cash flows. There were no required material capital expenditures for environmental controls in our facilities in 2019 and there are currently no needed or planned material expenditures for 2020.

Employees

As of December 31, 2019, we employed approximately 8,200 people in our operations throughout the world.

Available Information

We maintain a website at www.westpharma.com. Our Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) are available on our website under the Investors - SEC Filings caption as soon as reasonably practical after we electronically file the material with, or furnish it to, the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public over the Internet at the SEC’s website at www.sec.gov.

Throughout this Form 10-K, we incorporate by reference certain information from parts of other documents filed with the SEC and from our Proxy Statement for the 2020 Annual Meeting of Shareholders (“2020 Proxy Statement”), which will be filed with the SEC within 120 days following the end of our 2019 fiscal year. Our 2020 Proxy Statement will be available on our website on or about March 31, 2020, under the caption Investors - Annual Reports & Proxy.

Information about our corporate governance, including our Corporate Governance Principles and Code of Business Conduct, as well as information about our Directors, Board Committees, Committee Charters, and instructions on how to contact the Board, is available on our website under the Investors - Corporate Governance heading. We intend to make any required disclosures regarding any amendments of our Code of Business Conduct or waivers granted to any of our directors or executive officers under the caption Code of Business Conduct on our website. Information relating to the West Pharmaceutical Services Dividend Reinvestment Plan is also available on our website under the Investors - Transfer Agent/Dividend Reinvestment caption. Information on our website does not constitute part of this document.

We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, West Pharmaceutical Services, Inc., 530 Herman O. West Drive, Exton, PA 19341.

ITEM 1A. RISK FACTORS
The statements in this section describe major risks to our business and should be considered carefully. In addition, these statements constitute our cautionary statements under the Private Securities Litigation Reform Act of 1995.

Our disclosure and analysis in this Form 10-K contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public as well as oral forward-looking statements. Such statements give our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and phrases of similar meaning. In particular, these include statements relating to future actions, business plans and prospects, new products, future
7

performance or results of current or anticipated products, sales efforts, expenses, interest rates, foreign-exchange rates, economic effects, the outcome of contingencies, such as legal proceedings, and financial results.

Many of the factors that will determine our future results are beyond our ability to control or predict. Achievement of future results is subject to known or unknown risks or uncertainties, including, without limitation, the risks set forth below. Therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you consider forward-looking statements.

Unless required by applicable securities law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. We also refer you to further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to the SEC.

Our operating results may be adversely affected by unfavorable economic and market conditions.

The current uncertainty in the global economy, including the effects of recession or slow economic growth in the U.S., Europe, and emerging markets in Asia and South America, may negatively affect our operating results. Examples of the effects of these global economic challenges include: our suppliers’ and our customers’ inability to access the credit markets at commercially reasonable rates; reduction in sales due to customers decreasing their inventories in the near-term or long-term or due to liquidity difficulties; reduction in sales due to shortages of materials we purchase from our suppliers; reduction in research and development efforts and expenditures by our customers; our inability to hedge our currency and raw material risks sufficiently or at commercially reasonable prices; insolvency of suppliers or customers; inflationary pressures on our supplies or our products; and increased expenses due to growing global taxation of corporate profits or revenues or changes in, or expirations of, a country’s tax laws or regulations. Our operating results in one or more geographic regions may also be affected by uncertain or changing economic conditions within that region. If economic and market conditions in the U.S. or Europe, or in emerging markets, weaken further, we may experience material adverse impacts on our business, financial condition and results of operations.

Our sales and profitability are largely dependent on the sale of drug products delivered by injection and the packaging of drug products. If the drug products developed by our customers in the future use another delivery system or are reconfigured to require less frequent dosing, our sales and profitability could suffer.

Our business depends to a substantial extent on customers’ continued sales and development of products that are delivered by injection. If (i) our customers fail to continue to sell, develop and deploy injectable products; (ii) our customers reconfigure their drug product or develop new drug products requiring less frequent dosing; or (iii) we are unable to develop new products that assist in the delivery of drugs by alternative methods, our sales and profitability may suffer.

Changes in foreign currency exchange rates could have a material adverse effect on our business and/or results of operations.

Our business is subject to foreign currency exchange rate fluctuations. Sales outside of the U.S. accounted for 55.7% of our consolidated net sales in 2019 and we anticipate that sales from international operations will continue to represent a significant portion of our total sales in the future. In addition, many of our manufacturing facilities and suppliers are located outside of the U.S. Further, we intend to continue our expansion into emerging and/or faster-growing markets outside of the U.S. in the future. Virtually all of our international sales, assets and related operating costs and expenses are earned, valued or incurred in the currency of the local country, primarily the Euro, the Singapore Dollar (“SGD”), and the Danish Krone. In addition, we are exposed to Japanese Yen (“Yen”), as we maintain a 49% ownership interest in, and we purchase finished goods and other materials from, Daikyo. We are also exposed to currencies in emerging market countries, such as the Chinese Yuan, the Indian Rupee, the South Korean Won, and various South American currencies. Our consolidated financial statements are presented in USD, and, therefore, we must translate the reported values of our foreign assets, liabilities, revenues, and expenses into USD, which can result in significant fluctuations in the amount of those assets, liabilities, revenues, or expenses. The
8

exchange rates between these foreign currencies and USD in recent years have fluctuated significantly and may continue to do so in the future. Increases or decreases in the value of USD compared to these foreign currencies may negatively affect the value of these items in our consolidated financial statements, which could have a material adverse effect on our operating results.

In addition to translation risks, we incur currency transaction risk when we or one of our subsidiaries enters into a purchase or sales transaction in a currency other than that entity’s local currency. In order to reduce our exposure to fluctuations in certain exchange rates, we have entered, and expect to continue to enter, into hedging arrangements, including the use of financial derivatives. There can be no certainty that we will be able to enter into or maintain hedges of these currency risks, or that our hedges will be effective, which could have a significant effect on our financial condition and operating results.

If we are unable to provide comparative value advantages, timely fulfill customer orders, or resist pricing pressure, we will have to reduce our prices, which may reduce our profit margins.

We compete with several companies across our major product lines. Because of the special nature of these products, competition is based primarily on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost-control programs across their operations. Companies often compete on the basis of price. We aim to differentiate ourselves from our competition by being a “full-service, value-added” global supplier that is able to provide pre-sale compatibility studies, engineering support, and other services and sophisticated post-sale technical support on a global basis. However, we face continued pricing pressure from our customers and competitors. If we are unable to resist or offset the effects of continued pricing pressure through our value-added services, improved operating efficiencies and reduced expenditures, or if we have to reduce our prices, our sales and profitability may suffer.

Consolidation in the pharmaceutical and healthcare industries could adversely affect our future revenues and operating income.

The pharmaceutical and healthcare industries have experienced a significant amount of consolidation. As a result of this consolidation, competition to provide goods and services to customers has increased. In addition, group purchasing organizations and integrated health delivery networks have served to concentrate purchasing decisions for some customers, which has placed pricing pressure on suppliers. Further consolidation within the industries we serve could exert additional pressure on the prices of our products.

We are subject to regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.

The design, development, manufacturing, marketing and labeling of certain of our products and our customers’ products that incorporate our products are subject to regulation by governmental authorities in the U.S., Europe and other countries, including the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency and the National Medical Products Administration (China). Complying with governmental regulation can be costly and can result in required modification or withdrawal of existing products and a substantial delay in the introduction of new products. Failure to comply with applicable regulatory requirements or failure to obtain regulatory approval for a new product could result in expenses and actions that could adversely affect our business and financial performance.

Products that incorporate our technologies and medical devices that we produce are subject to regulations and extensive approval or clearance processes, which make the timing and success of new-product commercialization difficult to predict.

The process of obtaining and maintaining FDA and other required regulatory approvals is expensive and time-consuming. Historically, most medical devices that incorporate our technologies and medical devices that we produce have been subject to the FDA’s 510(k) marketing approval process, which typically lasts from six to nine months. Supplemental or full pre-market approval reviews require a significantly longer period, delaying
9

commercialization. Changes in regulation on a global scale must be monitored and actions taken to ensure ongoing compliance. Pharmaceutical products that incorporate our technologies and medical devices that we produce are subject to the FDA’s New Drug Application process, which typically takes a number of years to complete. Additionally, biotechnology products that incorporate our technologies and medical devices that we produce are subject to the FDA’s Biologics License Application process, which also typically takes a number of years to complete. Outside of the U.S., sales of medical devices and pharmaceutical or biotechnology products are subject to international regulatory requirements that vary from country to country. The time required to obtain approval for sale internationally may be longer or shorter than that required for FDA approval. There is no certainty that any regulatory approval may be obtained or maintained indefinitely, and our ability to launch products on to the market and maintain market presence is not guaranteed.

Changes in the regulation of drug products and devices may increase competitive pressure and adversely affect our business.

An effect of the governmental regulation of our medical devices and our customers’ drug products, devices, and manufacturing processes is that compliance with regulations makes it difficult to change components and devices produced by one supplier with those from another supplier, due to the large amount of data and information that customers must generate to demonstrate that the components and devices are equivalent and pose no additional risk to the patient. The regulation of our medical devices and our customers’ products that incorporate our components and devices has increased over time. If the applicable regulations were to be modified in a way that reduced the level of data and information needed to prove equivalency for a change from one supplier’s components or devices to those made by another, it is likely that the competitive pressure would increase and adversely affect our sales and profitability.

If we are not successful in protecting our intellectual property rights, our ability to compete may be affected.

Our patents, trademarks and other intellectual property are important to our business. We rely on patent, trademark, copyright, trade secret, and other intellectual property laws, as well as nondisclosure and confidentiality agreements and other methods, to protect our proprietary products, information, technologies and processes. We also have obligations with respect to the non-use and non-disclosure of third-party intellectual property. We may need to engage in litigation or similar activities to enforce our intellectual property rights, to protect our trade secrets or to determine the validity and scope of proprietary rights of others. Any such litigation could require us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. There can be no assurance that the steps we will take to prevent misappropriation, infringement or other violation of our intellectual property or the intellectual property of others will be successful. In addition, effective patent, copyright, trademark, and trade secret protection may be unavailable or limited for some of our proprietary products in some countries. Failure to protect our intellectual property or successfully invalidate or defend against intellectual property protections of third parties could harm our business and results of operations. In addition, if relevant and effective patent protection is not available or has expired, we may not be able to prevent competitors from independently developing products and services similar or duplicative to ours.

Disruption in our manufacturing facilities could have a material adverse effect on our ability to make and sell products and have a negative impact on our reputation, performance or financial condition.

We have manufacturing sites throughout the world. In some instances, however, the manufacturing of certain product lines is concentrated in one or only a few of our plants. The functioning of our manufacturing and distribution assets and systems could be disrupted for reasons either within or beyond our control, including, without limitation: extreme weather or longer-term climatic changes; natural disasters; pandemic; war; accidental damage; disruption to the supply of material or services; product quality and safety issues; systems failure; workforce actions; or environmental contamination. There is a risk that incident management systems in place may prove inadequate and that any disruption may materially adversely affect our ability to make and sell products and, therefore, materially adversely affect our reputation, performance or financial condition.

10

The medical technology industry is very competitive and customer demands and/or new products in the marketplace could cause a reduction in demand.

The medical technology industry is subject to rapid technological changes, and we face significant competition across our product lines and in each market in which our products are sold. We face this competition from a wide range of companies, including large medical device companies, some of which have greater financial and marketing resources than we do. We also face competition from firms that are more specialized than we are with respect to particular markets. In some instances, competitors, including pharmaceutical companies, also offer, or are attempting to develop, alternative therapies for diseases that may be delivered via their own, or without, a medical device. The development of new or improved products, processes or technologies by other companies (such as needle-free injection technology) may reduce customer demand for our products or render some of our products or proposed products obsolete or less competitive. In addition, any failure or inability to meet increased customer quality expectations could cause a reduction in demand.

Significant developments in U.S. policies could have a material adverse effect on our business and/or results of operations.

Changes in U.S. social, political, regulatory, and economic conditions, or in laws and policies governing foreign trade, manufacturing, development, immigration, and investment, could have an adverse effect on our financial condition, results of operations and cash flows.

Our international sales and operations are subject to risks and uncertainties that vary by country and which could have a material adverse effect on our business and/or results of operations.

We conduct business in most of the major pharmaceutical markets in the world. Our international operations and our ability to implement our overall business strategy (including our plan to continue expanding into emerging and/or faster-growing markets outside of the U.S.) are subject to risks and uncertainties that can vary by country, and include: transportation delays and interruptions; political and economic instability and disruptions, including the United Kingdom’s referendum on withdrawal from the European Union; imposition of duties and tariffs; import and export controls; the risks of divergent business expectations or cultural incompatibility inherent in establishing and maintaining operations in foreign countries; difficulties in staffing and managing multi-national operations; labor strikes and/or disputes; and potentially adverse tax consequences. Limitations on our ability to enforce legal rights and remedies with third parties or our joint venture partners outside of the U.S. could also create exposure. In addition, we may not be able to operate in compliance with foreign laws and regulations, or comply with applicable customs, currency exchange control regulations, transfer pricing regulations or any other laws or regulations to which we may be subject, in the event that these laws or regulations change. Any of these events could have an adverse effect on our international operations in the future by reducing the demand for our products or decreasing the prices at which we can sell our products, or otherwise have an adverse effect on our financial condition, results of operations and cash flows.

Disruptions in the supply of key raw materials could adversely impact our operations.

We generally purchase our raw materials and supplies required for the production of our products in the open market. For reasons of quality assurance, sole source availability or cost effectiveness, many components and raw materials are available and/or purchased only from a single supplier. Due to the stringent regulations and requirements of the FDA and other regulatory authorities regarding the manufacture of our products and the availability of such raw materials, we may not be able to quickly establish additional or replacement sources for these components or raw materials or do so without excessive cost. As a result, a reduction or interruption in supply, or an inability to secure alternative sources of raw materials or components, could have a material adverse effect on our business and/or results of operations.

11

Unauthorized access to our or our customers’ information and systems could negatively impact our business.

Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks or information security breaches which, in turn, could result in the unauthorized release and misuse of confidential or proprietary information about our company, our employees or our customers, as well as disrupt our operations or damage our facilities or those of third parties. Additionally, our systems are subject to regulation to preserve the privacy of certain data held on those systems. We maintain an extensive network of technical security controls, policy enforcement mechanisms and monitoring systems, in order to address these threats. While these measures are designed to prevent, detect and respond to unauthorized activity in our systems, certain types of attacks could result in financial or information losses and/or reputational harm. If we cannot comply with regulations or prevent the unauthorized access, release and/or corruption of our or our customers’ confidential, classified or personally identifiable information, our reputation could be damaged, and/or we could face financial losses. We may also be required to incur additional costs to modify or enhance our systems, or to try to prevent or remediate any such attacks. Modifying or enhancing our systems may result in unanticipated or prolonged disruption events, which could have a material adverse effect on our business and/or results of operations.

Raw material and energy prices have a significant impact on our profitability. If raw material and/or energy prices increase, and we cannot pass those price increases on to our customers, our profitability and financial condition may suffer.

We use three basic raw materials in the manufacture of our products: elastomers (which include synthetic and natural material), aluminum and plastic. In addition, our manufacturing facilities consume a wide variety of energy products to fuel, heat and cool our operations. Supply and demand factors, which are beyond our control, generally affect the price of our raw materials and utility costs. If we are unable to pass along increased raw material prices and energy costs to our customers, our profitability, and thus our financial condition, may be adversely affected. The prices of many of these raw materials and utilities are cyclical and volatile. For example, the prices of certain commodities, particularly petroleum-based raw materials, have in the recent past exhibited rapid changes, affecting the cost of synthetic elastomers and plastic. While we generally attempt to pass along increased costs to our customers in the form of sales price increases, historically there has been a time delay between raw material and/or energy price increases and our ability to increase the prices of our products. In some circumstances, we may not be able to increase the prices of our products due to competitive pressure and other factors.

If we are not timely or successful in new-product innovation or the development and commercialization of proprietary multi-component systems, our future revenues and operating income could be adversely affected.

Our growth partly depends on new-product innovation and the development and commercialization of proprietary multi-component systems for injectable drug administration and other healthcare applications. Product development and commercialization is inherently uncertain and is subject to a number of factors outside of our control, including any necessary regulatory approvals and commercial acceptance for the products. The ultimate timing and successful commercialization of new products and systems requires substantial evaluations of the functional, operational, clinical, and economic viability of our products. In addition, the timely and adequate availability of filling capacity is essential to both conducting definitive stability trials and the timing of commercialization of customers’ products in Crystal Zenith vials, syringes and cartridges. Delays, interruptions or failures in developing and commercializing new-product innovations or proprietary multi-component systems could adversely affect future revenues and operating income. In addition, adverse conditions may also result in future charges to recognize impairment in the carrying value of our goodwill and other intangible assets, which could have a material adverse effect on our financial results.

We may not succeed in finding and completing acquisitions or other strategic transactions, which could have an adverse effect on our business and results of operations.

We have historically engaged in acquisition activity and we may in the future engage in acquisitions or other strategic transactions, such as joint ventures or investments in other entities. We may be unable to identify suitable
12

targets, opportunistic or otherwise, for acquisitions or other strategic transactions in the future. If we identify a suitable candidate, our ability to successfully implement the strategic transaction would depend on a variety of factors, including our ability to obtain financing on acceptable terms and to comply with the restrictions contained in our debt agreements. Strategic transactions involve risks, including those associated with integrating the operations or maintaining the operations as separate (as applicable), financial reporting, disparate technologies, and personnel of acquired companies, joint ventures or related companies; managing geographically dispersed operations or other strategic investments; the diversion of management’s attention from other business concerns; the inherent risks in entering markets or lines of business in which we have either limited or no direct experience; the potential loss of key employees, customers and strategic partners of acquired companies, joint ventures or companies in which we may make strategic investments; and potentially other unknown risks. We may not successfully integrate any businesses or technologies we may acquire or strategically develop in the future and may not achieve anticipated revenue and cost benefits relating to any such strategic transactions. Strategic transactions may be expensive, time consuming and may strain our resources. Strategic transactions may not be accretive to our earnings and may negatively impact our results of operations as a result of, among other things, the incurrence of debt, one-time write-offs of goodwill, additional carrying costs of patent or trademark portfolios, and amortization expenses of other intangible assets. In addition, strategic transactions that we may pursue could result in dilutive issuances of equity securities.

Product defects could adversely affect the results of our operations.

The design, manufacture and marketing of pharmaceutical packaging and medical devices involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market. A recall could result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products. Personal injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals. Please refer to Note 3, Revenue, for the discussion of the voluntary recall of our Vial2Bag® product line.

Our operations must comply with environmental statutes and regulations, and any failure to comply could result in extensive costs which would harm our business.

The manufacture of some of our products has involved, and may continue to involve, the use, transportation, storage, and disposal of hazardous or toxic materials and is subject to various environmental protection and occupational health and safety laws and regulations in the countries in which we operate. This has exposed us in the past, and could expose us in the future, to risks of accidental contamination and events of non-compliance with environmental laws. Any such occurrences could result in regulatory enforcement or personal injury and property damage claims or could lead to a shutdown of some of our operations, which could have an adverse effect on our business and results of operations. We currently incur costs to comply with environmental laws and regulations and these costs may become more significant.

A loss of key personnel or highly skilled employees could disrupt our operations.

Our future success depends, in large part, on our ability to retain key employees, including our executive officers and individuals in technical, marketing, sales, and research positions. Competition for experienced employees, particularly for persons with specialized skills, can be intense. Our ability to recruit such talent will depend on a number of factors, including compensation and benefits, work location and work environment. If we cannot effectively recruit and retain qualified executives and employees, our business could be adversely affected. Although we believe that we will be able to attract and retain talented personnel and replace key personnel should the need arise, our inability to do so on a timely basis could disrupt the operations of the unit affected or our overall operations. In addition, because of the complex nature of many of our products and programs, we are generally
13

dependent on an educated and highly skilled engineering staff and workforce. Our operations could be disrupted by a shortage of available skilled employees.

The uncertain effects of climate change and potential climate change legislation could lead to business interruption, significantly increased costs and/or other adverse consequences to our business.

Climate change and potential climate change legislation may present risks to our operations, including business interruption, significantly increased costs and/or other adverse consequences to our business. Some of the potential impacts of climate change to our business include physical risks to our facilities, water and energy supply limitations or interruptions, disruptions to our supply chain and impairment of other resources. In addition, if legislation or regulations are enacted or promulgated in the U.S., Europe or Asia or any other jurisdictions in which we do business that limit or reduce allowable greenhouse gas emissions and other emissions, such restrictions could have a significant effect on our operating and financial decisions, including those involving capital expenditures to reduce emissions, and our results of operations. Our manufacturing operations may not be able to operate as planned if we are not able to comply with new legal and regulatory legislation around climate change, or it may become too costly to operate in a profitable manner. Additionally, suppliers’ added expenses could be passed on to us in the form of higher prices and we may not be able to pass on such expenses to our customers through price increases.

Healthcare reform may adversely affect our results of operations.

Changes in the U.S. or international healthcare systems, including the Patient Protection and Affordable Care Act (the “PPACA”), could result in reduced demand for our products, as our sales depend, in part, on the extent to which pharmaceutical companies and healthcare providers and facilities are reimbursed by government authorities, private insurers and other third-party payers for the costs of our products. The coverage policies and reimbursement levels of third-party payers, which can vary among public and private sources, may affect which products customers purchase and the prices they are willing to pay for these products in a particular jurisdiction. Legislative or administrative reforms to reimbursement systems in the U.S. (including the possible termination of the PPACA and potential replacement thereafter with a different system) or abroad (for example, those under consideration in France, Germany, Italy and the United Kingdom) could significantly reduce reimbursement for our customers’ products, which could in turn reduce the demand for our products.

Moreover, in the coming years, additional changes could be made to global governmental healthcare programs that could significantly impact the success of our products. We will continue to evaluate the PPACA, as amended, the implementation of regulations or guidance related to various provisions of the PPACA by federal agencies, the potential repeal and replacement of the PPACA, as well as trends and changes that may be encouraged by the legislation and other healthcare legislation globally and that may potentially impact our business over time.

LIBOR reform may adversely affect our financial condition, results of operations and cash flows.

Our variable-rate debt, which includes our new senior unsecured, multi-currency revolving credit facility agreement (the “Credit Agreement”) and our new term loan (the “Term Loan”), currently use the London Interbank Offered Rate ("LIBOR") as a benchmark for establishing the interest rate. LIBOR is the subject of recent national, international and other regulatory guidance and proposals for reform. These proposals for reform and other pressures may cause LIBOR to disappear entirely or to perform differently than in the past. If the method for calculation of LIBOR changes, if LIBOR is no longer available or if lenders have increased costs due to changes in LIBOR, we may suffer from potential increases in interest rates on our variable-rate debt, which could have a material adverse effect on our financial condition, results of operations and cash flows. Further, we may need to amend our Credit Agreement and Term Loan as a factor in determining the interest rate to replace LIBOR with the new standard that is established. We will continue to monitor the proposals for reform relating to LIBOR.

No assurance can be given that we will continue to pay or declare dividends.

We have historically paid dividends. However, there can be no assurance that we will pay or declare dividends in the future. The actual declaration and payment of future dividends, the amount of any such dividends, and the
14

establishment of record and payment dates, if any, are subject to determination by our Board of Directors each quarter after its review of our then-current strategy, applicable debt covenants and financial performance and position, among other things. Our declaration and payment of future dividends is subject to risks and uncertainties, including: deterioration of our financial performance or position; inability to declare a dividend in compliance with applicable laws or debt covenants; an increase in our cash needs or decrease in available cash; and the business judgment of the Board of Directors that a declaration of a dividend is not in our best interest.

Our results of operations and earnings may not meet guidance or expectations.

We provide public guidance on our expected results of operations for future periods. This guidance is comprised of forward-looking statements subject to risks and uncertainties, including the risks and uncertainties described in this Form 10-K and in our other public filings and public statements, and is based necessarily on assumptions we make at the time we provide such guidance. Our guidance may not always be accurate. If, in the future, our results of operations for a particular period do not meet our guidance or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our common stock could decline significantly.

We are exposed to credit risk on accounts receivable and certain prepayments made in the normal course of business. This risk is heightened during periods when economic conditions worsen.

A substantial majority of our outstanding trade receivables are not covered by collateral or credit insurance. In addition, we have made prepayments associated with insurance premiums and other advances in the normal course of business. While we have procedures to monitor and limit exposure to credit risk on trade receivables and other current assets, there can be no assurance such procedures will effectively limit our credit risk and avoid losses, which could have a material adverse effect on our financial condition and operating results.

If we fail to comply with our obligations under our distributorship or license agreements with Daikyo, the agreements are terminated early or we are unable to renew these agreements on the same or substantially similar terms, we could lose license rights that are important to our business.

Key value-added and proprietary products and processes are licensed from our affiliate, Daikyo, including but not limited to, Crystal Zenith, FluroTec® and B2-coating technologies. Our rights to these products and processes are licensed pursuant to agreements that expire in 2027. However, if the agreements are terminated early, our business could be adversely impacted. Please refer to Note 7, Affiliated Companies, for information relating to the increase in our ownership interest in Daikyo in 2019.

ITEM IB. UNRESOLVED STAFF COMMENTS

As of the filing of this Form 10-K, there were no unresolved comments from the Staff of the SEC.


ITEM 2. PROPERTIES

Our corporate headquarters are located at 530 Herman O. West Drive, Exton, Pennsylvania.

The following table summarizes production facilities by segment and geographic region. All facilities shown are owned except where otherwise noted.

Proprietary Products
Manufacturing:
North American OperationsEuropean OperationsAsia Pacific Operations
United StatesDenmarkChina
Jersey Shore, PAHorsensQingpu
Kearney, NEEnglandIndia
15

Kinston, NCSt. AustellSri City
Scottsdale, AZ (2)FranceSingapore
St. Petersburg, FL (1)Le NouvionJurong
Le Vaudreuil
South American OperationsGermany
BrazilEschweiler (1) (2)
Sao PauloStolberg
Ireland
Waterford
Serbia
Kovin
Mold-and-Die Tool Shop:Contract Analytical Laboratory:
North American OperationsEuropean OperationsNorth American Operations
United StatesEnglandUnited States
Upper Darby, PABodmin (2)Exton, PA
Contract-Manufactured Products
Manufacturing:
North American OperationsEuropean Operations
United StatesIreland
Grand Rapids, MIDublin (2)
Phoenix, AZ (2)
Tempe, AZ (2)
Williamsport, PA
Puerto Rico
Cayey

(1)This manufacturing facility is also used for research and development activities.
(2)This facility is leased in whole or in part.

Our Proprietary Products reportable segment leases facilities located in Germany and Israel for research and development, as well as other activities. Sales offices in various locations are leased under short-term arrangements.

ITEM 3. LEGAL PROCEEDINGS
None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The executive officers of the Company are set forth in this table. Generally, executive officers are elected by the Board of Directors annually at the regular meeting of the Board of Directors following the Annual Meeting of Shareholders. Additionally, executive officers may be elected upon hire or due to a promotion.

16

NameAgePosition
Silji Abraham48  Senior Vice President, Chief Digital and Transformation Officer since February 2018. Prior to joining West, he most recently served as Executive Vice President and Chief Information Officer of MilliporeSigma, a subsidiary of Merck KGaA, Darmstadt, Germany. Prior to this role, he served as Chief Information Officer at Sigma-Aldrich Corporation, a leading life science and technology company, and worked in various leadership roles at Invensys Operations Management, ArvinMeritor and Chrysler Group.
Bernard J. Birkett51  Senior Vice President and Chief Financial Officer since June 2018. In addition, Treasurer from June 2018 to December 2019. Principal Accounting Officer since October 2019. Prior to joining West, he spent more than 20 years at Merit Medical Systems, Inc., a leading manufacturer of disposable medical devices, where he served in a number of senior global leadership roles, including Chief Financial Officer and Treasurer, Controller for Europe, Middle East and Africa (EMEA) and Vice President of International Finance.
Annette F. Favorite55  Senior Vice President and Chief Human Resources Officer since October 2015. Prior to joining West, she spent more than 25 years at IBM Corporation, an information technology services company, in a number of strategic and global human resources roles, including Vice President, Global Talent Management, Vice President of Human Resources for Worldwide Software Sales, and Human Resources Leader for the company’s Southwest European Region, based out of Spain.
Eric M. Green

50  Chief Executive Officer since April 2015 and President since December 2015. Prior to joining West, he was Executive Vice President and President of the Research Markets business unit at Sigma-Aldrich Corporation from 2013 to 2015. From 2009 to 2013, he served as Vice President and Managing Director, International, where he was responsible for Asia Pacific and Latin America, and prior thereto, held various commercial and operational roles.
Quintin J. Lai53  Vice President, Corporate Development, Strategy and Investor Relations since January 2016. Prior to joining West, he was Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation from 2012 to 2015. From 2002 to 2012, he was at Robert W. Baird & Company, where he held various roles, including Managing Director and Senior Equity Research Analyst of the Life Science Tools and Diagnostic sector and Associate Director of Equity Research.
George L. Miller65  Senior Vice President, General Counsel and Corporate Secretary since joining West in November 2015. Previously, he served as Senior Vice President, General Counsel and Corporate Secretary for Sigma-Aldrich Corporation from 2009 to 2015. Prior to working at Sigma-Aldrich, he held senior legal positions with Novartis AG, a global healthcare company.
David A. Montecalvo54  Senior Vice President and Chief Operations and Supply Chain Officer since February 2019. Senior Vice President, Global Operations and Supply Chain from September 2016 until February 2019. Prior to joining West, he served in a number of senior leadership roles at Medtronic plc, including Vice President, Contract Manufacturing Operations, for the company’s Restorative Therapies Group, Vice President, Business Operations Integration, where he was responsible for directing and leading the global operations integration of Covidien plc into Medtronic, and Vice President, Product Development and Operations for Medtronic Cardiovascular. Prior thereto, he held senior operations and product development roles at Urologix, Inc. and LecTec Corporation.
17

Eric Resnick56  Vice President and Chief Technology Officer since March 2016. Previously, he served as Vice President and General Manager of Integrated Packaging and Delivery within West’s Innovation and Technology Team and President Proprietary Products - Pharmaceutical Delivery Systems from March 2015 until March 2016. He served as Vice President Research and Development and Self-Injection Systems from March 2014 until March 2015, and Vice President and General Manager of West’s Contract Manufacturing Delivery Devices division from 2008 until March 2014. Prior thereto, he held various positions since joining The Tech Group in 2001, and held engineering and operating roles with Eastman Kodak Company and Ortho Clinical Diagnostics.

PART II

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is listed on the New York Stock Exchange (“NYSE”) under the symbol “WST.”

As of January 31, 2020, we had 756 shareholders of record, which excludes shareholders whose shares were held by brokerage firms, depositaries and other institutional firms in “street names” for their customers.

On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo, we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo (the “Stock Consideration”). Please refer to Note 7, Affiliated Companies, for additional information on our ownership interest in Daikyo. The issuance of the Stock Consideration is exempt from registration under the Securities Act of 1933 (the “Securities Act”) pursuant to Section 4(a)(2) under the Securities Act. Our reliance upon Section 4(a)(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of recipients; (c) the negotiations for the issuance of the securities took place directly between the recipients and the Company; and (d) the recipients of the securities were sophisticated, accredited investors.

Dividends

Our common stock paid a quarterly dividend of $0.14 per share in each of the first three quarters of 2018; $0.15 per share in the fourth quarter of 2018 and each of the first three quarters of 2019; and $0.16 per share in the fourth quarter of 2019.

Issuer Purchases of Equity Securities

During the three months ended December 31, 2019, there were no purchases of our common stock made by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act.

In February 2019, we announced a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares repurchased and the timing of such transactions depended on a variety of factors, including market conditions. There were no shares purchased during the three months ended December 31, 2019. During the year ended December 31, 2019, we purchased 800,000 shares of our common stock under the now-completed program at a cost of $83.1 million, or an average price of $103.89 per share.

In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing
18

of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2020.

Performance Graph

The following performance graph compares the cumulative total return to holders of our common stock with the cumulative total return of the following Standard & Poor’s (“S&P”) indices, for the five years ended December 31, 2019: 500 and MidCap 400 Index. The performance graph does not necessarily reflect management's opinion that such indices are an appropriate measure of the relative performance of the stock involved, and is not intended to forecast or be indicative of possible future performance of the Company’s common stock.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus the per-share price change for the period by the share price at the beginning of the period. The Company’s cumulative shareholder return is based on an investment of $100 on December 31, 2014 and is compared to the cumulative total return of the S&P indices mentioned above over the period with a like amount invested.

wst-20191231_g1.jpg

19

ITEM 6. SELECTED FINANCIAL DATA
FIVE-YEAR SUMMARY
West Pharmaceutical Services, Inc. and Subsidiaries

(in millions, except per share data)20192018201720162015
SUMMARY OF OPERATIONS
Net sales$1,839.9  $1,717.4  $1,599.1  $1,509.1  $1,399.8  
Operating profit †296.6  240.3  225.8  195.2  177.0  
Net income241.7  206.9  150.7  143.6  95.6  
Net income per share:
Basic (1)$3.27  $2.80  $2.04  $1.96  $1.33  
Diluted (2)3.21  2.74  1.99  1.91  1.30  
Weighted average common shares outstanding74.0  73.9  73.9  73.3  72.0  
Weighted average shares assuming dilution75.4  75.4  75.8  75.0  73.8  
Dividends declared per common share$0.62  $0.58  $0.54  $0.50  $0.46  
YEAR-END FINANCIAL POSITION
Cash and cash equivalents$439.1  $337.4  $235.9  $203.0  $274.6  
Working capital717.1  610.7  464.0  400.9  359.4  
Total assets2,341.4  1,978.9  1,862.8  1,716.7  1,695.1  
Total invested capital:
Total debt257.3  196.1  197.0  228.6  298.2  
Total equity1,573.2  1,396.3  1,279.9  1,117.5  1,023.9  
Total invested capital$1,830.5  $1,592.4  $1,476.9  $1,346.1  $1,322.1  
PERFORMANCE MEASUREMENTS (3)
Gross margin (a)32.9 %31.8 %32.1 %33.2 %32.6 %
Operating profitability (b) †16.1 %14.0 %14.1 %12.9 %12.6 %
Effective tax rate (4)20.2 %17.2 %36.4 %28.7 %22.6 %
Return on invested capital (c) †13.8 %13.0 %10.2 %10.4 %10.5 %
Net debt-to-total invested capital (d)N/A  N/A  N/A  2.2 %2.3 %
Research and development expenses$38.9  $40.3  $39.1  $36.8  $34.1  
Operating cash flow367.2  288.6  263.3  219.4  212.4  
Stock price range$152.12-93.08$125.09-82.74$103.36-77.97$86.50-53.88$64.59-48.66

(1) Based on weighted average common shares outstanding.

(2) Based on weighted average shares, assuming dilution.

(3) Performance measurements represent indicators commonly used in the financial community. The following performance measures are not in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are included as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

(a) Net sales minus cost of goods and services sold, including applicable depreciation and amortization, divided by net sales.
(b) Operating profit divided by net sales.
(c) Operating profit multiplied by one minus the effective tax rate divided by average total invested capital.
(d) Net debt (total debt less cash and cash equivalents) divided by total invested capital less cash and cash equivalents.

20

(4) As a result of the Tax Cuts and Jobs Act (the “2017 Tax Act”), the federal statutory rate was reduced from 35.0% to 21.0% effective for tax years beginning after December 31, 2017. Please refer to Note 17, Income Taxes, for further discussion of the 2017 Tax Act.

† Reflects our adoption of the guidance issued by the Financial Accounting Standards Board (“FASB”) regarding the presentation of net periodic pension and postretirement benefit cost (net benefit cost).

Factors affecting the comparability of the information reflected in the selected financial data:

▪Net income in 2019 included the impact of restructuring and related charges of $3.7 million (net of $1.2 million in tax), a gain on the sale of fixed assets as a result of our restructuring plan of $1.3 million (net of $0.4 million in tax), a pension settlement charge of $2.7 million (net of $0.8 million in tax), a charge of $1.0 million related to the continued devaluation of Argentina’s currency, a tax recovery of $2.9 million (net of $1.5 million in tax) related to previously-paid international excise taxes, a net tax benefit of $0.3 million related to the impact of federal law changes enacted during the year, and a tax benefit of $10.3 million associated with stock-based compensation.

▪Net income in 2018 included the impact of restructuring and related charges of $7.2 million (net of $1.9 million in tax), a gain on the sale of fixed assets as a result of our restructuring plans of $0.9 million (net of $0.2 million in tax), a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018, a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act, and a tax benefit of $14.3 million associated with stock-based compensation.

▪Net income in 2017 included the impact of a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation and a charge of $11.1 million related to the deconsolidation of our Venezuelan subsidiary.

▪Net income in 2016 included the impact of restructuring and related charges of $17.4 million (net of $9.0 million in tax), a charge related to the devaluation of the Venezuelan Bolivar of $2.7 million, a pension curtailment gain of $1.3 million (net of $0.8 million in tax), and a discrete tax charge of $1.0 million.

▪Net income in 2015 included the impact of a pension settlement charge of $32.0 million (net of $18.4 million in tax), a charge for executive retirement and related costs of $6.9 million (net of $4.0 million in tax) and a discrete tax charge of $0.8 million.

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our consolidated financial statements and the accompanying footnotes included in Part II, Item 8 of this Form 10-K. These historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of this Form 10-K.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. The constant-currency amounts are
21

calculated by translating the current year’s functional currency results at the prior-year period’s exchange rate. We may also refer to consolidated operating profit and consolidated operating profit margin excluding the effects of unallocated items. The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are included in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and additional medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, and enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently. The Company was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923.

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

2019 Financial Performance Summary

Consolidated net sales increased by $122.5 million, or 7.1%, in 2019. Excluding foreign currency translation effects of $52.2 million, as well as incremental sales of $3.3 million from our recent acquisition, consolidated net sales increased by $171.4, or 10.0%.

Net income in 2019 was $241.7 million, or $3.21 per diluted share, compared to $206.9 million, or $2.74 per diluted share, in 2018. Net income in 2019 included the impact of restructuring and related charges of $3.7 million (net of $1.2 million in tax), or $0.04 per diluted share, a gain on the sale of fixed assets as a result of our restructuring plan of $1.3 million (net of $0.4 million in tax), or $0.02 per diluted share, a pension settlement charge of $2.7 million (net of $0.8 million in tax), or $0.04 per diluted share, a charge of $1.0 million related to the continued devaluation of Argentina’s currency, or $0.01 per diluted share, a tax recovery related to previously-paid international excise taxes of $2.9 million (net of $1.5 million in tax), or $0.04 per diluted share, a net tax benefit of $0.3 million related to the impact of federal law changes enacted during the year, and a tax benefit of $10.3 million, or $0.14 per diluted share, associated with stock-based compensation. Net income in 2018 included the impact of restructuring and related charges of $7.2 million (net of $1.9 million in tax), or $0.09 per diluted share, a gain on the sale of fixed assets as a result of our restructuring plans of $0.9 million (net of $0.2 million in tax), or $0.01 per diluted share, a charge of $1.1 million, or $0.02 per diluted share, related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018, a net tax benefit of $2.5 million, or $0.03 per diluted share, for the estimated impact of the 2017 Tax Act, and a tax benefit of $14.3 million, or $0.19 per diluted share, associated with stock-based compensation.

At December 31, 2019, our cash and cash equivalents balance totaled $439.1 and our available borrowing capacity under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”) was $297.5 million.

22

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

Percentages in the following tables and throughout this Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment:

Year Ended December 31,% Change
($ in millions)2019201820172019/20182018/2017
Proprietary Products$1,398.6  $1,308.6  $1,236.9  6.9 %5.8 %
Contract-Manufactured Products441.5  409.1  362.5  7.9 %12.9 %
Intersegment sales elimination(0.2) (0.3) (0.3) (33.3)%— %
Consolidated net sales$1,839.9  $1,717.4  $1,599.1  7.1 %7.4 %

2019 compared to 2018
Consolidated net sales increased by $122.5 million, or 7.1%, in 2019, including an unfavorable foreign currency translation impact of $52.2 million. Excluding foreign currency translation effects, as well as incremental sales of $3.3 million from our recent acquisition, consolidated net sales increased by $171.4 million, or 10.0%.

Proprietary Products – Proprietary Products net sales increased by $90.0 million, or 6.9%, in 2019, including an unfavorable foreign currency translation impact of $43.1 million. Excluding foreign currency translation effects, as well as incremental sales of $3.3 million from our recent acquisition, net sales increased by $129.8 million, or 9.9%, primarily due to growth in our high-value product offerings, including our Daikyo components, our ready-to-use seals, stoppers, and plungers, our NovaPure® components and Crystal Zenith products, and our self-injection systems and FluroTec-coated components.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $32.4 million, or 7.9%, in 2019, including an unfavorable foreign currency translation impact of $9.1 million. Excluding foreign currency translation effects, net sales increased by $41.5 million, or 10.1%, due to an increase in the sale of healthcare-related injection and diagnostic devices.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

2018 compared to 2017
Consolidated net sales increased by $118.3 million, or 7.4%, in 2018, including a favorable foreign currency translation impact of $28.6 million. Excluding foreign currency translation effects, consolidated net sales increased by $89.7 million, or 5.6%.

Proprietary Products – Proprietary Products net sales increased by $71.7 million, or 5.8%, in 2018, including a favorable foreign currency translation impact of $23.8 million. Excluding foreign currency translation effects, net sales increased by $47.9 million, or 3.9%, as growth in our high-value product offerings, including our Westar® and
23

FluroTec-coated components, our ready-to-use seals, stoppers, and plungers, and our NovaPure products, as well as sales price increases, partially offset the impact of the voluntary recall of Vial2Bag products and the deconsolidation of our Venezuelan subsidiary as of April 1, 2017.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $46.6 million, or 12.9%, in 2018, including a favorable foreign currency translation impact of $4.8 million. Excluding foreign currency translation effects, net sales increased by $41.8 million, or 11.6%, despite the impact of the loss of a consumer-product customer in early 2018. Higher sales volume, particularly in Ireland, contributed 10.4 percentage points of the increase, and sales price increases contributed 1.2 percentage points of the increase.

Gross Profit

The following table presents gross profit and related gross margins, consolidated and by reportable segment:

Year Ended December 31,% Change
($ in millions)2019201820172019/20182018/2017
Proprietary Products:     
Gross profit$540.4  $485.4  $449.3  11.3 %8.0 %
Gross profit margin38.6 %37.1 %36.3 %
Contract-Manufactured Products:  
Gross profit$65.5  $60.0  $63.6  9.2 %(5.7)%
Gross profit margin14.8 %14.7 %17.5 %
Unallocated items$(0.2) $—  $—  
Consolidated gross profit$605.7  $545.4  $512.9  11.1 %6.3 %
Consolidated gross profit margin32.9 %31.8 %32.1 %

2019 compared to 2018
Consolidated gross profit increased by $60.3 million, or 11.1%, in 2019, including an unfavorable foreign currency translation impact of $15.7 million. Consolidated gross profit margin increased by 1.1 margin points in 2019.

Proprietary Products – Proprietary Products gross profit increased by $55.0 million, or 11.3%, in 2019, including an unfavorable foreign currency translation impact of $14.3 million. Proprietary Products gross profit margin increased by 1.5 margin points in 2019, due to a favorable mix of products sold, production efficiencies, and sales price increases, partially offset by increased overhead costs.

Contract-Manufactured Products – Contract-Manufactured Products gross profit increased by $5.5 million, or 9.2%, in 2019, including an unfavorable foreign currency translation impact of $1.4 million. Contract-Manufactured Products gross profit margin increased by 0.1 margin points in 2019, due to production efficiencies and lower raw material costs, partially offset by increased overhead costs and an unfavorable mix of products sold.

2018 compared to 2017
Consolidated gross profit increased by $32.5 million, or 6.3%, in 2018, including a favorable foreign currency translation impact of $9.3 million. Consolidated gross profit margin decreased by 0.3 margin points in 2018.

Proprietary Products – Proprietary Products gross profit increased by $36.1 million, or 8.0%, in 2018, including a favorable foreign currency translation impact of $8.5 million. Proprietary Products gross profit margin increased by 0.8 margin points in 2018, as production efficiencies, a favorable mix of products sold, and sales price increases were partially offset by the impact of under-absorbed overhead costs from our new facility in Waterford, Ireland and the deconsolidation of our Venezuelan subsidiary as of April 1, 2017, as well as increased labor and depreciation costs and higher raw material costs.
24

Contract-Manufactured Products – Contract-Manufactured Products gross profit decreased by $3.6 million, or 5.7%, in 2018, including a favorable foreign currency translation impact of $0.8 million. Contract-Manufactured Products gross profit margin decreased by 2.8 margin points in 2018, due to unabsorbed overhead from plant consolidation activities, start-up costs associated with the launch of new programs, an unfavorable mix of product sales, and lower profitability on development and tooling agreements, and higher raw material costs, partially offset by sales price increases and production efficiencies.

Research and Development (“R&D”) Costs

The following table presents R&D costs, consolidated and by reportable segment:

Year Ended December 31,% Change
($ in millions)2019201820172019/20182018/2017
Proprietary Products$38.9  $40.3  $39.1  (3.5)%3.1 %
Contract-Manufactured Products—  —  —  —  —  
Consolidated R&D costs$38.9  $40.3  $39.1  (3.5)%3.1 %

2019 compared to 2018
Consolidated R&D costs decreased by $1.4 million, or 3.5%, in 2019, primarily due to an increase in customer-funded R&D projects via customer development agreements.

2018 compared to 2017
Consolidated R&D costs increased by $1.2 million, or 3.1%, in 2018. Efforts remained focused on the continued investment in self-injection systems development, elastomeric packaging components, and formulation development.

All of the R&D costs incurred during 2019, 2018 and 2017 related to Proprietary Products.

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate:

Year Ended December 31, % Change
($ in millions)2019201820172019/20182018/2017
Proprietary Products$189.9  $185.0  $175.3  2.6 %5.5 %
Contract-Manufactured Products16.2  16.5  15.4  (1.8)%7.1 %
Corporate and unallocated items66.6  61.4  55.3  8.5 %11.0 %
Consolidated SG&A costs$272.7  $262.9  $246.0  3.7 %6.9 %
SG&A as a % of net sales14.8 %15.3 %15.4 %

2019 compared to 2018
Consolidated SG&A costs increased by $9.8 million, or 3.7%, in 2019, including the impact of foreign currency translation, which decreased SG&A costs by $0.3 million.

Proprietary Products – Proprietary Products SG&A costs increased by $4.9 million, or 2.6%, in 2019, primarily due to an increase in compensation costs and incremental costs associated with our voluntary recall and the acquisition of our distributor in South Korea, partially offset by ongoing cost control measures. Foreign currency translation decreased Proprietary Products SG&A costs by $0.3 million.

25

Contract-Manufactured Products – Contract-Manufactured Products SG&A costs decreased by $0.3 million, or 1.8%, in 2019, due to ongoing cost control measures.

Corporate and unallocated items – Corporate SG&A costs increased by $5.2 million, or 8.5%, in 2019, primarily due to increases in stock-based compensation costs and incentive compensation costs, partially offset by a decrease in U.S. pension costs due to the cessation of our U.S. qualified and non-qualified defined benefit pension plans as of January 1, 2019 (except for interest crediting) and ongoing cost control measures.

2018 compared to 2017
Consolidated SG&A costs increased by $16.9 million, or 6.9%, in 2018, including the impact of foreign currency translation, which increased SG&A costs by $2.4 million.

Proprietary Products – Proprietary Products SG&A costs increased by $9.7 million, or 5.5%, in 2018, due to higher commercial sales compensation costs and legal costs. Foreign currency translation increased Proprietary Products SG&A costs by $2.3 million.

Contract-Manufactured Products – Contract-Manufactured Products SG&A costs increased by $1.1 million, or 7.1%, in 2018, due to increases in compensation and miscellaneous costs.

Corporate and unallocated items – Corporate SG&A costs increased by $6.1 million, or 11.0%, in 2018, primarily due to the impact of higher achievement levels on incentive compensation costs and increased personnel costs.

Other (Income) Expense

The following table presents other income and expense items, consolidated and by reportable segment and unallocated items:

(Income) ExpenseYear Ended December 31,
($ in millions) 201920182017
Proprietary Products$(2.0) $(6.3) $(8.9) 
Contract-Manufactured Products0.2  (0.8) (0.1) 
Corporate and unallocated items(0.7) 9.0  11.0  
Consolidated other (income) expense$(2.5) $1.9  $2.0  

Other income and expense items, consisting of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, development and licensing income, contingent consideration, and miscellaneous income and charges, are generally recorded within segment results.

2019 compared to 2018
Consolidated other (income) expense changed by $4.4 million in 2019.

Proprietary Products – Proprietary Products other income decreased by $4.3 million in 2019, primarily due to increased contingent consideration costs. Please refer to Note 12, Fair Value Measurements, for further discussion of this item.

Contract-Manufactured Products – Contract-Manufactured Products other expense (income) changed by $1.0 million in 2019, primarily due to a decrease in gains on the sale of fixed assets during 2019.

Corporate and unallocated items – Corporate and unallocated items changed by $9.7 million in 2019. During 2019, we recorded $4.9 million in restructuring and related charges, a $1.9 million gain on the sale of fixed assets as a result of our restructuring plan, and a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. We expect that our 2018 restructuring plan, which is now considered complete, will provide annualized
26

savings of approximately $14.0 million. In addition, during 2019, we recognized a tax recovery of $4.7 million related to previously-paid international excise taxes, following a favorable court ruling. Please refer to Note 16, Other (Income) Expense, for further discussion of these items.

2018 compared to 2017
Consolidated other expense decreased by $0.1 million in 2018.

Proprietary Products – Proprietary Products other income decreased by $2.6 million in 2018, primarily as we recorded income of $9.1 million attributable to the reimbursement of certain costs related to a technology that we subsequently licensed to a third party in 2017, partially offset by foreign exchange transaction gains in Europe in 2018. Please refer to Note 16, Other (Income) Expense, for further discussion of the $9.1 million attributable to the reimbursement of certain costs.

Contract-Manufactured Products – Contract-Manufactured Products other income increased by $0.7 million in 2018, due to gains on the sale of fixed assets.

Corporate and unallocated items – Corporate and unallocated items changed by $2.0 million in 2018. During 2018, we recorded $9.1 million in restructuring and related charges, a $1.1 million gain on the sale of fixed assets as a result of our restructuring plans, and a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018. Please refer to Note 16, Other (Income) Expense, for further discussion of these items.

Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:

Year Ended December 31,% Change
($ in millions)2019201820172019/20182018/2017
Proprietary Products$313.6  $266.4  $243.8  17.7 %9.3 %
Contract-Manufactured Products49.1  44.3  48.3  10.8 %(8.3)%
Corporate(66.3) (61.3) (55.2) 8.2 %11.1 %
Adjusted consolidated operating profit$296.4  $249.4  $236.9  18.8 %5.3 %
Adjusted consolidated operating profit margin16.1 %14.5 %14.8 %
Unallocated items0.2  (9.1) (11.1) 
Consolidated operating profit$296.6  $240.3  $225.8  23.4 %6.4 %
Consolidated operating profit margin16.1 %14.0 %14.1 %

2019 compared to 2018
Consolidated operating profit increased by $56.3 million, or 23.4%, in 2019, including a favorable foreign currency translation impact of $0.6 million.

Proprietary Products – Proprietary Products operating profit increased by $47.2 million, or 17.7%, in 2019, including a favorable foreign currency translation impact of $0.6 million, due to the factors described above.

Contract-Manufactured Products – Contract-Manufactured Products operating profit increased by $4.8 million, or 10.8%, in 2019, due to the factors described above.

Corporate – Corporate costs increased by $5.0 million, or 8.2%, in 2019, due to the factors described above.

Unallocated items – Please refer to the Other (Income) Expense section for details.
27

Excluding the unallocated items, our adjusted consolidated operating profit margin increased by 1.6 margin points in 2019.

2018 compared to 2017
Consolidated operating profit increased by $14.5 million, or 6.4%, in 2018, including a favorable foreign currency translation impact of $6.6 million.

Proprietary Products – Proprietary Products operating profit increased by $22.6 million, or 9.3%, in 2018, including a favorable foreign currency translation impact of $5.9 million, due to the factors described above.

Contract-Manufactured Products – Contract-Manufactured Products operating profit decreased by $4.0 million, or 8.3%, in 2018, including a favorable foreign currency translation impact of $0.7 million, due to the factors described above.

Corporate – Corporate costs increased by $6.1 million, or 11.1%, in 2018, due to the factors described above.

Unallocated items – Please refer to the Other (Income) Expense section for details.

Excluding the unallocated items, our adjusted consolidated operating profit margin decreased by 0.3 margin points in 2018.

Interest Expense, Net

The following table presents interest expense, net, by significant component:

Year Ended December 31,% Change
($ in millions)2019201820172019/20182018/2017
Interest expense$9.4  $9.3  $10.5  1.1 %(11.4)%
Capitalized interest(0.9) (0.9) (2.7) — %(66.7)%
Interest income(3.8) (2.1) (1.3) 81.0 %61.5 %
Interest expense, net$4.7  $6.3  $6.5  (25.4)%(3.1)%

2019 compared to 2018
Interest expense, net, decreased by $1.6 million, or 25.4%, in 2019, due to an increase in interest income in 2019 resulting from higher interest rates on our deposit accounts and higher average cash and cash equivalents balances.

2018 compared to 2017
Interest expense, net, decreased by $0.2 million, or 3.1%, in 2018, due to lower interest expense resulting from less average debt outstanding during 2018, as compared to 2017, and an increase in interest income, partially offset by a decrease in capitalized interest due to the completion of several major projects in 2017, including certain components of our new facility in Waterford, Ireland. The Waterford facility began commercial production during the second half of 2018.

Other Nonoperating Expense (Income)

2019 compared to 2018
Other nonoperating expense (income) changed by $6.8 million in 2019, primarily due to a decrease in the expected return on pension plan assets and a pension settlement charge of $3.5 million recorded in 2019, as we determined that normal-course lump-sum payments for each of our U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year. Effective January 1, 2019, except for interest crediting, benefit accruals under these defined benefit pension plans ceased.
28

2018 compared to 2017
Other nonoperating income increased by $3.6 million in 2018, due to an increase in the expected return on pension plan assets and a decrease in recognized actuarial losses for 2018.

Income Taxes

The provision for income taxes was $59.0 million, $41.4 million, and $80.9 million for the years 2019, 2018, and 2017, respectively, and the effective tax rate was 20.2%, 17.2%, and 36.4%, respectively.

During 2019, we recorded a net tax benefit of $0.3 million due to the impact of federal law changes enacted during the year, as well as a tax benefit of $10.3 million associated with stock-based compensation.

During 2018, we recorded a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act and a tax benefit of $14.3 million associated with stock-based compensation. Please refer to Note 17, Income Taxes, for further discussion of the 2017 Tax Act.

During 2017, we recorded a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation.

Please refer to Note 17, Income Taxes, for further discussion of our income taxes.

Equity in Net Income of Affiliated Companies

Equity in net income of affiliated companies represents the contribution to earnings from our 25% ownership interest in Daikyo, which increased to 49% during the fourth quarter of 2019, and our 49% ownership interest in five companies majority-owned by a long-time partner located in Mexico. Please refer to Note 7, Affiliated Companies, for further discussion. Equity in net income of affiliated companies was $8.9 million, $7.6 million, and $9.2 million for the years 2019, 2018, and 2017, respectively. Equity in net income of affiliated companies increased by $1.3 million, or 17.1%, in 2019, primarily due to favorable operating results at Daikyo. Equity in net income of affiliated companies decreased by $1.6 million, or 17.4%, in 2018, primarily due to the impact of gains on the sale of investment securities by Daikyo in 2017.

Net Income

Net income in 2019 was $241.7 million, or $3.21 per diluted share, compared to $206.9 million, or $2.74 per diluted share, in 2018. Our 2019 results included the impact of restructuring and related charges of $3.7 million (net of $1.2 million in tax), a gain on the sale of fixed assets as a result of our restructuring plan of $1.3 million (net of $0.4 million in tax), a pension settlement charge of $2.7 million (net of $0.8 million in tax), a charge of $1.0 million related to the continued devaluation of Argentina’s currency, a tax recovery of $2.9 million (net of $1.5 million in tax) related to previously-paid international excise taxes, a net tax benefit of $0.3 million related to the impact of federal law changes enacted during the year, and a tax benefit of $10.3 million associated with stock-based compensation.

Net income in 2018 was $206.9 million, or $2.74 per diluted share, compared to $150.7 million, or $1.99 per diluted share, in 2017. Our 2018 results included the impact of restructuring and related charges of $7.2 million (net of $1.9 million in tax), a gain on the sale of fixed assets as a result of our restructuring plans of $0.9 million (net of $0.2 million in tax), a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018, a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act, and a tax benefit of $14.3 million associated with stock-based compensation.

Net income in 2017 was $150.7 million, or $1.99 per diluted share, compared to $143.6 million, or $1.91 per diluted share, in 2016. Our 2017 results included the impact of a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and
29

liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation and a charge of $11.1 million related to the deconsolidation of our Venezuelan subsidiary.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the years ended December 31:

($ in millions)201920182017
Net cash provided by operating activities$367.2  $288.6  $263.3  
Net cash used in investing activities$(228.0) $(100.8) $(133.6) 
Net cash used in financing activities$(36.8) $(80.7) $(109.0) 

Net Cash Provided by Operating Activities

2019 compared to 2018
Net cash provided by operating activities increased by $78.6 million in 2019, primarily due to improved operating results and changes in assets and liabilities.

2018 compared to 2017
Net cash provided by operating activities increased by $25.3 million in 2018, primarily due to improved operating results and a decrease in pension plan contributions in 2018.

Net Cash Used in Investing Activities

2019 compared to 2018
Net cash used in investing activities increased by $127.2 million in 2019, primarily due to the increase in our ownership interest in Daikyo, an increase in capital expenditures, and the acquisition of our distributor in South Korea.

2018 compared to 2017
Net cash used in investing activities decreased by $32.8 million in 2018, mostly due to a $26.1 million decrease in capital spending due to the completion of several major projects in 2017, including certain components of our new facility in Waterford, Ireland.

Net Cash Used in Financing Activities

2019 compared to 2018
Net cash used in financing activities decreased by $43.9 million in 2019, primarily due to borrowings of $90.0 million under our Term Loan, partially offset by net repayments of our outstanding long-term borrowings under our Credit Facility and increases in purchases under our share repurchases programs and dividend payments.

2018 compared to 2017
Net cash used in financing activities decreased by $28.3 million in 2018, primarily due to lower debt repayment activity in 2018.

We paid cash dividends totaling $45.1 million ($0.61 per share), $42.1 million ($0.57 per share), and $39.1 million ($0.53 per share) during 2019, 2018, and 2017, respectively.

30

Liquidity and Capital Resources

The table below presents selected liquidity and capital measures as of:

($ in millions)December 31, 2019December 31, 2018
Cash and cash equivalents$439.1  $337.4  
Accounts receivable, net$319.3  $288.2  
Inventories$235.7  $214.5  
Accounts payable$156.8  $130.4  
Debt$257.3  $196.1  
Equity$1,573.2  $1,396.3  
Working Capital$717.1  $610.7  

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at December 31, 2019 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at December 31, 2019 included $217.2 million of cash held by subsidiaries within the U.S. and $221.9 million of cash held by subsidiaries outside of the U.S. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. In general, it is our practice and intention to permanently reinvest the earnings of our foreign subsidiaries and repatriate earnings only when the tax impact is de minimis, and that position has not changed subsequent to the one-time transition tax under the 2017 Tax Act, except as noted above. Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $214.2 million of undistributed earnings from foreign subsidiaries to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.

Working capital - Working capital at December 31, 2019 increased by $106.4 million, or 17.4%, as compared to December 31, 2018, including an increase of $11.3 million due to foreign currency translation. Excluding the impact of currency exchange rates, cash and cash equivalents, accounts receivable, inventories, and total current liabilities increased by $102.4 million, $33.3 million, $23.2 million, and $60.0 million, respectively. The increase in accounts receivable was due to increased sales activity and longer customer payment terms. The increase in total current liabilities was primarily due to increases in accounts payable, accrued salaries, wages and benefits, and other current liabilities, as well as our adoption of Accounting Standards Codification (“ASC”) Topic 842 (“ASC 842”), which required us to record operating lease liabilities for operating leases where we are the lessee in our consolidated balance sheet as of December 31, 2019.

Debt and credit facilities - The $61.2 million increase in total debt at December 31, 2019, as compared to December 31, 2018, primarily resulted from borrowings of $90.0 million under our Term Loan, partially offset by net repayments of our outstanding long-term borrowings under our Credit Facility, foreign currency rate fluctuations, and an increase in unamortized debt issuance costs.

Our sources of liquidity include our Credit Facility. At December 31, 2019, we had no outstanding borrowings under the Credit Facility, as we repaid the outstanding long-term borrowings denominated in Euro and Yen in November
31

and December 2019, respectively. There was no material gain or loss on the repayment under the Credit Facility. At December 31, 2019, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.5 million, was $297.5 million. We do not expect any significant limitations on our ability to access this source of funds. Please refer to Note 10, Debt, for further discussion of our Credit Facility.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2019, we were in compliance with all of our debt covenants, and we expect to continue to be in compliance with the terms of these agreements throughout 2020.

We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

Commitments and Contractual Obligations

The following table summarizes our commitments and contractual obligations at December 31, 2019. These obligations are not expected to have a material impact on liquidity.

Payments Due By Period
($ in millions)TotalLess than 1 year1 - 3 years3 - 5 yearsMore than 5 years
Purchase obligations (1)
$249.1  $61.3  $113.6  $62.0  $12.2  
Debt (excluding unamortized debt issuance costs)258.0  2.3  46.6  136.1  73.0  
Interest on debt and interest rate swaps (2)
37.4  7.0  13.2  9.8  7.4  
Operating lease obligations88.0  12.1  19.0  15.1  41.8  
Other long-term liabilities (3)
6.6  0.9  1.3  1.5  2.9  
Total contractual obligations (4)
$639.1  $83.6  $193.7  $224.5  $137.3  

(1)Our business creates a need to enter into various commitments with suppliers, including for the purchase of raw materials and finished goods. In accordance with U.S. GAAP, these purchase obligations are not reflected in the accompanying consolidated balance sheets. These purchase commitments do not exceed our projected requirements and are in the normal course of business.

(2)For fixed-rate long-term debt, interest was based on principal amounts and fixed coupon rates at year-end. Future interest payments on variable-rate debt were calculated using principal amounts and the applicable ending interest rate at year-end. Interest on fixed-rate derivative instruments was based on notional amounts and fixed interest rates contractually obligated at year-end.

(3)Represents acquisition-related contingencies. In connection with certain business acquisitions, we agreed to make payments to the sellers if and when certain operating milestones are achieved, such as sales and operating income targets.

(4)This table does not include obligations pertaining to pension and postretirement benefits because the actual amount and timing of future contributions may vary significantly depending upon plan asset performance, benefit payments, and other factors. Contributions to our plans are expected to be $1.4 million in 2020. Please refer to Note 15, Benefit Plans, for estimated benefit payments over the next ten years.

Reserves for uncertain tax positions - The table above does not include $5.0 million of total gross unrecognized tax benefits as of December 31, 2019. Due to the high degree of uncertainty regarding the timing of potential cash flows, we cannot reasonably estimate the settlement periods for amounts which may be paid.

32

Letters of credit - We have letters of credit totaling $2.5 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $3.2 million at December 31, 2019, of which $0.9 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.

OFF-BALANCE SHEET ARRANGEMENTS

At December 31, 2019, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management’s discussion and analysis addresses consolidated financial statements that are prepared in accordance with U.S. GAAP. The application of these principles requires management to make estimates and assumptions, some of which are subjective and complex, that affect the amounts reported in the consolidated financial statements. We believe the following accounting policies and estimates are critical to understanding and evaluating our results of operations and financial position:

Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606 (“ASC 606”). Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of December 31, 2019, there was $5.6 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.7 million was included in other long-term
33

liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.

Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience.

Contract assets and liabilities result from transactions with revenue recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet in other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Considerable management judgment is necessary to estimate fair value. Amounts and assumptions used in our goodwill impairment test, such as future sales, future cash flows and long-term growth rates, are consistent with internal projections and operating plans. Amounts and assumptions used in our goodwill impairment test are also largely dependent on the continued sale of drug products delivered by injection and the packaging of drug products, as well as our timeliness and success in new-product innovation or the development and commercialization of proprietary multi-component systems. Changes in the estimate of fair value, including the estimate of future cash flows, could have a material impact on our future results of operations and financial position. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.

34

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.

Employee Benefits: We maintain funded and unfunded defined benefit pension plans in the U.S. and a number of other countries that cover employees who meet eligibility requirements. In addition, we sponsor postretirement benefit plans which provide healthcare benefits for eligible employees who retire or become disabled. Postretirement benefit plans are limited to only those active employees who met the eligibility requirements as of January 1, 2017. The measurement of annual cost and obligations under these defined benefit postretirement plans is subject to a number of assumptions, which are specific for each of our U.S. and foreign plans. The assumptions, which are reviewed at least annually, are relevant to both the plan assets (where applicable) and the obligation for benefits that will ultimately be provided to our employees. Two of the most critical assumptions in determining pension and retiree medical plan expense are the discount rate and expected long-term rate of return on plan assets. Other assumptions reflect demographic factors such as retirement age, rates of compensation increases, mortality and turnover and are evaluated periodically and updated to reflect our actual experience. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. Under U.S. GAAP, differences between actual and expected results are generally accumulated in other comprehensive income (loss) as actuarial gains or losses and subsequently amortized into earnings over future periods.

Changes in key assumptions could have a material impact on our future results of operations and financial position. We estimate that every 25-basis point reduction in our long-term rate of return assumption would increase pension expense by $0.4 million, and every 25-basis point reduction in our discount rate would decrease pension expense by $0.1 million. A decrease in the discount rate increases the present value of benefit obligations. Our net pension underfunded balance at December 31, 2019 was $43.8 million, compared to $52.5 million at December 31, 2018. Our underfunded balance for other postretirement benefits was $6.6 million at December 31, 2019, compared to $6.0 million at December 31, 2018.

Income Taxes: We estimate income taxes payable based upon current domestic and international tax legislation. In addition, deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and country level. Changes in tax legislation, business plans and other factors may affect the ultimate recoverability of tax assets or final tax payments, which could result in adjustments to tax expense in the period such change is determined.

When accounting for uncertainty in income taxes recognized in our financial statements, we apply a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Please refer to Note 1, Summary of Significant Accounting Policies and Note 2, New Accounting Standards, to our consolidated financial statements for additional information on our significant accounting policies, recently adopted accounting standards, and accounting standards issued but not yet adopted.

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. These risk factors can impact our results of operations, cash flows and financial position. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial
35

instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

Foreign Currency Exchange Risk

Sales outside of the U.S. accounted for 55.7% of our consolidated net sales in 2019. Virtually all of these sales and related operating costs are denominated in the currency of the local country and translated into USD for consolidated reporting purposes. Although the majority of the assets and liabilities of these subsidiaries are denominated in the functional currency of the subsidiary, they may also hold assets or liabilities denominated in other currencies. These items may give rise to foreign currency transaction gains and losses. As a result, our results of operations and financial position are exposed to changing currency exchange rates. We periodically use forward exchange contracts to hedge certain transactions or to manage month-end balance sheet exposures on cross-currency intercompany loans.

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2019, the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. As of December 31, 2018, the total amount of these forward exchange contracts was €10.0 million, SGD 601.5 million and $13.4 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD38.4  —  33.6  
Yen6,550.4  37.8  20.6  
SGD29.4  16.5  4.6  

In November and December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Euro and Yen, we de-designated these borrowings as hedges of our net investments in certain European subsidiaries and Daikyo. The amounts recorded as a cumulative translation adjustment in accumulated other comprehensive loss related to these borrowings (prior to de-designation) will remain in accumulated other comprehensive loss indefinitely, unless certain future events occur, such as the disposition of the operations for which the net investment hedges relate.

In December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Yen, we entered into a forward exchange contract, designated as a cash flow hedge, to manage our exposure to fluctuating foreign exchange rates. This forward exchange contract matured on December 30, 2019.

In December 2019, we entered into a five-year floating-to-floating forward-starting cross-currency swap (the “cross-currency swap”) for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month USD LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Yen LIBOR plus a margin.

Interest Rate Risk

As a result of our normal borrowing activities, we have long-term debt with both fixed and variable interest rates. Long-term debt consists of our Term Loan and Series A, B and C notes.

36

The following table summarizes our interest rate risk-sensitive instruments (excluding unamortized debt issuance costs):

($ in millions)20202021202220232024ThereafterCarrying ValueFair Value
Current Debt:
U.S. dollar denominated$2.3  $2.3  $2.3  
Average interest rate - variable2.8 %
Long-Term Debt:
U.S. dollar denominated42.0  53.0  73.0  168.0  176.3  
Average interest rate - fixed3.7 %3.8 %4.0 %
U.S. dollar denominated2.3  2.3  2.3  80.8  87.7  87.7  
Average interest rate - variable2.8 %2.8 %2.8 %2.8 %

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. In recent years, raw material costs have fluctuated due to crude oil price fluctuations. We expect this volatility to continue. We will continue to pursue pricing and hedging strategies, and ongoing cost control initiatives, to offset the effects on gross profit.

From November 2017 through October 2019, we purchased several series of call options for a total of 352,682 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.

During 2019, the loss recorded in cost of goods and services sold related to these options was $0.4 million. During 2018, the gain recorded in cost of goods and services sold related to these options was $0.1 million.

As of December 31, 2019, we had outstanding contracts to purchase 135,967 barrels of crude oil from January 2020 to June 2021, at a weighted-average strike price of $70.71 per barrel.
37

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

CONSOLIDATED STATEMENTS OF INCOME
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2019, 2018 and 2017
(in millions, except per share data)


 201920182017
Net sales$1,839.9  $1,717.4  $1,599.1  
Cost of goods and services sold1,234.2  1,172.0  1,086.2  
Gross profit605.7  545.4  512.9  
Research and development38.9  40.3  39.1  
Selling, general and administrative expenses272.7  262.9  246.0  
Other (income) expense (Note 16)(2.5) 1.9  2.0  
Operating profit296.6  240.3  225.8  
Interest expense8.5  8.4  7.8  
Interest income(3.8) (2.1) (1.3) 
Other nonoperating expense (income)0.1  (6.7) (3.1) 
Income before income taxes291.8  240.7  222.4  
Income tax expense59.0  41.4  80.9  
Equity in net income of affiliated companies(8.9) (7.6) (9.2) 
Net income$241.7  $206.9  $150.7  
Net income per share:  
Basic$3.27  $2.80  $2.04  
Diluted$3.21  $2.74  $1.99  
Weighted average shares outstanding:  
Basic74.0  73.973.9
Diluted75.4  75.475.8

The accompanying notes are an integral part of the consolidated financial statements.
38

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2019, 2018 and 2017
(in millions)

 201920182017
Net income$241.7  $206.9  $150.7  
Other comprehensive income (loss), net of tax:  
Foreign currency translation adjustments4.9  (39.2) 68.8  
Defined benefit pension and other postretirement plans:
Prior service cost arising during period, net of tax of $0—  (0.3) —  
Net actuarial (loss) gain arising during period, net of tax of $(0.3), $(0.2) and $1.3(1.9) (0.7) 6.3  
Settlement effects arising during period, net of tax of $0.82.7  —  —  
Less: amortization of actuarial (gain) loss, net of tax of $0, $0.3 and $0.5(0.2) 1.1  3.6  
Less: amortization of prior service credit, net of tax of $(0.1), $(0.5) and $(0.5)(0.5) (1.5) (3.5) 
Net loss on investment securities, net of tax of $0, $(0.1) and $(2.5)—  (0.1) (4.7) 
Net (loss) gain on derivatives, net of tax of $(0.2), $1.5 and $(0.1)(0.4) 3.8  (1.0) 
Other comprehensive income (loss), net of tax4.6  (36.9) 69.5  
Comprehensive income$246.3  $170.0  $220.2  

The accompanying notes are an integral part of the consolidated financial statements.
39

CONSOLIDATED BALANCE SHEETS
West Pharmaceutical Services, Inc. and Subsidiaries at December 31, 2019 and 2018
(in millions, except per share data)
 20192018
ASSETS  
Current assets:  
Cash and cash equivalents$439.1  $337.4  
Accounts receivable, net319.3  288.2  
Inventories235.7  214.5  
Other current assets64.6  54.3  
Total current assets1,058.7  894.4  
Property, plant and equipment1,820.1  1,752.7  
Less: accumulated depreciation and amortization980.8  930.7  
Property, plant and equipment, net839.3  822.0  
Operating lease right-of-use assets70.1  —  
Investments in affiliated companies192.7  91.2  
Goodwill107.8  105.8  
Deferred income taxes14.0  24.7  
Intangible assets, net29.8  20.3  
Pension and other postretirement benefits4.3  —  
Other noncurrent assets24.7  20.5  
Total Assets$2,341.4  $1,978.9  
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$2.3  $0.1  
Accounts payable156.8  130.4  
Pension and other postretirement benefits2.2  2.3  
Accrued salaries, wages and benefits73.0  64.5  
Income taxes payable6.4  9.8  
Operating lease liabilities9.6  —  
Other current liabilities91.3  76.6  
Total current liabilities341.6  283.7  
Long-term debt255.0  196.0  
Deferred income taxes15.5  13.1  
Pension and other postretirement benefits52.5  56.2  
Operating lease liabilities62.4  —  
Other long-term liabilities41.2  33.6  
Total Liabilities768.2  582.6  
Commitments and contingencies (Note 18)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding in 2019 and 2018
—  —  
Common stock, par value $.25 per share; 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million in 2019 and 2018; shares outstanding: 74.1 million and 74.1 million in 2019 and 201818.8  18.8  
Capital in excess of par value272.7  282.0  
Retained earnings1,549.4  1,353.4  
Accumulated other comprehensive loss(149.6) (154.2) 
Treasury stock, at cost (1.2 million and 1.2 million shares in 2019 and 2018)(118.1) (103.7) 
Total Equity1,573.2  1,396.3  
Total Liabilities and Equity$2,341.4  $1,978.9  

The accompanying notes are an integral part of the consolidated financial statements.
40

CONSOLIDATED STATEMENT OF EQUITY
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2019, 2018 and 2017
(in millions)
 Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
Balance, December 31, 201673.7  $18.4  $260.4  0.6  $(46.1) $1,071.6  $(186.8) $1,117.5  
Effect of modified retrospective application of a new accounting standard—  —  —  —  —  (4.1) —  (4.1) 
Net income—  —  —  —  —  150.7  —  150.7  
Activity related to stock-based compensation1.5  0.4  44.1  (0.1) 11.4  —  —  55.9  
Shares purchased under share repurchase program—  —  —  0.8  (74.4) —  —  (74.4) 
Dividends declared ($0.54 per share)—  —  —  —  —  (40.0) —  (40.0) 
Other adjustments to capital in excess of par value—  —  4.8  —  —  —  —  4.8  
Other comprehensive income, net of tax—  —  —  —  —  —  69.5  69.5  
Balance, December 31, 201775.2  18.8  309.3  1.3  (109.1) 1,178.2  (117.3) 1,279.9  
Effect of modified retrospective application of a new accounting standard (see Note 3)—  —  —  —  —  11.4  —  11.4  
Net income—  —  —  —  —  206.9  —  206.9  
Activity related to stock-based compensation0.1  —  (27.3) (0.9) 76.2  —  —  48.9  
Shares purchased under share repurchase program—  —  —  0.8  (70.8) —  —  (70.8) 
Dividends declared ($0.58 per share)—  —  —  —  —  (43.1) —  (43.1) 
Other comprehensive loss, net of tax—  —  —  —  —  —  (36.9) (36.9) 
Balance, December 31, 201875.3  18.8  282.0  1.2  (103.7) 1,353.4  (154.2) 1,396.3  
Net income—  —  —  —  —  241.7  —  241.7  
Activity related to stock-based compensation—  —  (11.1) (0.8) 65.6  —  —  54.5  
Shares purchased under share repurchase program—  —  —  0.8  (83.1) —  —  (83.1) 
Purchase of investment in affiliated companies—  —  1.8  —  3.1  —  —  4.9  
Dividends declared ($0.62 per share)—  —  —  —  —  (45.7) —  (45.7) 
Other comprehensive income, net of tax—  —  —  —  —  —  4.6  4.6  
Balance, December 31, 201975.3  $18.8  $272.7  1.2  $(118.1) $1,549.4  $(149.6) $1,573.2  
The accompanying notes are an integral part of the consolidated financial statements.
41

CONSOLIDATED STATEMENTS OF CASH FLOWS
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2019, 2018 and 2017
(in millions)
 201920182017
Cash flows from operating activities:  
Net income$241.7  $206.9  $150.7  
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation100.0  101.7  94.3  
Amortization3.4  2.7  2.4  
Stock-based compensation24.4  15.1  16.1  
Non-cash restructuring charges2.3  2.2  0.7  
Pension settlement charge3.5  —  —  
Venezuela deconsolidation—  —  11.1  
Contingent consideration payments in excess of acquisition-date liability(0.5) (0.6) —  
Loss on sales of equipment0.8  1.8  1.6  
Deferred income taxes15.3  0.9  41.7  
Pension and other retirement plans, net(2.6) (7.9) (6.9) 
Equity in undistributed earnings of affiliates, net of dividends(6.7) (5.9) (7.0) 
Changes in assets and liabilities:
Increase in accounts receivable(33.3) (43.8) (39.7) 
Increase in inventories(18.6) (7.0) (3.6) 
Decrease (increase) in other current assets2.6  (6.2) 0.3  
Increase in accounts payable25.3  0.4  12.6  
Changes in other assets and liabilities9.6  28.3  (11.0) 
Net cash provided by operating activities367.2  288.6  263.3  
Cash flows from investing activities:  
Capital expenditures(126.4) (104.7) (130.8) 
Purchase of investment in affiliated companies(85.1) —  —  
Acquisition of business(18.9) —  —  
Cash related to deconsolidated Venezuelan subsidiary—  —  (6.0) 
Other, net2.4  3.9  3.2  
Net cash used in investing activities(228.0) (100.8) (133.6) 
Cash flows from financing activities:  
Borrowings under revolving credit agreements108.5  —  —  
Repayments under revolving credit agreements(136.3) —  —  
Issuance of long-term debt90.0  —  —  
Repayments of long-term debt(0.1) (0.1) (34.9) 
Debt issuance costs(1.2) —  —  
Dividend payments(45.1) (42.1) (39.1) 
Contingent consideration payments up to amount of acquisition-date liability—  —  (0.7) 
Proceeds from stock-based compensation awards25.1  27.4  35.7  
Employee stock purchase plan contributions5.4  4.9  4.4  
Shares purchased under share repurchase programs(83.1) (70.8) (74.4) 
Net cash used in financing activities(36.8) (80.7) (109.0) 
Effect of exchange rates on cash(0.7) (5.6) 12.2  
Net increase in cash and cash equivalents101.7  101.5  32.9  
Cash, including cash equivalents at beginning of period337.4  235.9  203.0  
Cash, including cash equivalents at end of period$439.1  $337.4  $235.9  
Supplemental cash flow information:
Interest paid, net of amounts capitalized$8.6  $8.4  $8.0  
Income taxes paid, net$47.5  $42.0  $31.0  
Accrued capital expenditures$17.0  $15.0  $20.1  
Dividends declared, not paid$11.8  $11.3  $10.4  
Purchase of investment in affiliated companies, treasury stock$4.9  $—  $—  
The accompanying notes are an integral part of the consolidated financial statements.
42

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1:  Summary of Significant Accounting Policies

Principles of Consolidation: The consolidated financial statements include the accounts of West after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our consolidated financial statements since the acquisition date.

As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 16, Other (Income) Expense, for further discussion.

Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents: Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.

Accounts Receivable: Our accounts receivable balance was net of an allowance for doubtful accounts of $0.5 million and $2.0 million at December 31, 2019 and 2018, respectively. We record the allowance based on a specific identification methodology.

Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. The following is a summary of inventories at December 31:

($ in millions)20192018
Raw materials$100.9  $90.4  
Work in process37.4  42.2  
Finished goods97.4  81.9  
$235.7  $214.5  

Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other (income) expense. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

Leases: Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured
43

at the present value of the unpaid lease payments at the lease commencement date. We had no finance leases as of December 31, 2019. Please refer to Note 6, Leases, for additional information.

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.

Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.

Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.
44

Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.

Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience. Please refer to Note 3, Revenue, for additional information.

Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred.

Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations.

Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.

Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other (income) expense. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, Stock-Based Compensation, for a more detailed discussion of our stock-based compensation plans.

45

Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.

Note 2:  New Accounting Standards

Recently Adopted Standards

In July 2019, the FASB issued guidance which clarifies or improves a variety of ASC disclosure and presentation requirements by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. This guidance was effective upon issuance. The adoption did not have a material impact on our financial statements.

In June 2018, the FASB issued guidance which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.

In February 2018, the FASB issued guidance to address a specific consequence of the 2017 Tax Act by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis, but elected to not reclassify from accumulated other comprehensive income (loss) to retained earnings the stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate.

In August 2017, the FASB issued guidance which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.

In February 2016, the FASB issued guidance on the accounting for leases, ASC 842. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. Please refer to Note 6, Leases, for additional information.

Standards Issued Not Yet Adopted

In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.

In April 2019, the FASB issued guidance which clarifies and improves areas of guidance related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of
46

this guidance. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. We believe that the adoption of this guidance will not have a material impact on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under current guidance, an entity reflects credit losses on financial assets measured on an amortized cost basis only when it is probable that losses have been incurred, generally considering only past events and current conditions in determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements, primarily as we have not historically had a material amount of accounts receivable write-offs.

Note 3:  Revenue

Adoption of ASC 606

On January 1, 2018, we adopted ASC 606, on a modified retrospective basis, applied to those contracts which were not completed as of January 1, 2018. As a result of our adoption, we recorded a cumulative-effect adjustment of $11.4 million within retained earnings in our consolidated balance sheet as of January 1, 2018, to reflect a change in the timing of revenue recognition under ASC 606, from point in time to over time, on our Contract-Manufactured Products product sales, certain Proprietary Products product sales, development and tooling agreements, as well as an acceleration on a portion of the remaining unearned income from a nonrefundable customer payment.

Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods.

Revenue Recognition

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance
47

obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. As of December 31, 2019, there was $5.6 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.7 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.

Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience.

The following table presents the approximate percentage of our net sales by market group:

20192018
Biologics25 %21 %
Generics20 %21 %
Pharma31 %34 %
Contract-Manufactured Products24 %24 %
100 %100 %

48

The following table presents the approximate percentage of our net sales by product category:

20192018
High-Value Components42 %41 %
Standard Packaging29 %32 %
Delivery Devices5 %3 %
Contract-Manufactured Products24 %24 %
100 %100 %

The following table presents the approximate percentage of our net sales by geographic location:

20192018
Americas48 %48 %
Europe, Middle East, Africa44 %44 %
Asia Pacific8 %8 %
100 %100 %

Contract Assets and Liabilities

Contract assets and liabilities result from transactions with revenue recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet in other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.

The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:

($ in millions)
Contract assets, December 31, 2018$9.1  
Contract assets, December 31, 20199.8  
Change in contract assets - increase (decrease)$0.7  
Deferred income, December 31, 2018$(33.4) 
Deferred income, December 31, 2019(34.9) 
Change in deferred income - (increase) decrease$(1.5) 

The increase in deferred income during 2019 was primarily due to additional cash payments of $114.4 million received in advance of satisfying future performance obligations, partially offset by the recognition of revenue of $110.4 million, including $20.8 million of revenue that was included in deferred income at the beginning of the year, and $2.5 million in other adjustments.

49

Practical Expedients and Exemptions

We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less.

In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less.

Supply Chain Financing

We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of December 31, 2019 and 2018, we derecognized accounts receivable of $10.1 million and $5.7 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our consolidated income statements for 2019 and 2018 were not material.

Voluntary Recall

On January 24, 2019, we issued a voluntary recall of our Vial2Bag product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold reflecting our inventory balance for these devices at December 31, 2018. During 2019, we recorded a net provision of $5.4 million for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the products back on the market.

Note 4:  Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

(in millions)201920182017
Net income$241.7  $206.9  $150.7  
Weighted average common shares outstanding74.0  73.9  73.9  
Dilutive effect of equity awards, based on the treasury stock method
1.4  1.5  1.9  
Weighted average shares assuming dilution75.4  75.4  75.8  

During 2019, 2018 and 2017, there were 0.1 million, 0.4 million, and 0.4 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive.

In February 2019, we announced a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares repurchased and the timing of such transactions depended on a variety of factors, including market conditions. During 2019, we purchased 800,000 shares of our common stock under the now-completed program at a cost of $83.1 million, or an average price of $103.89 per share.

In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated
50

transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2020.

Note 5: Property, Plant and Equipment

A summary of gross property, plant and equipment at December 31 is presented in the following table:

($ in millions)Expected useful lives (years)20192018
Land$22.1  $20.9  
Buildings and improvements15-35572.9  569.1  
Machinery and equipment5-12817.0  806.7  
Molds and dies4-7123.8  115.8  
Computer hardware and software3-10155.6  151.1  
Construction in progress128.7  89.1  
$1,820.1  $1,752.7  

Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $100.0 million, $101.7 million and $94.3 million, respectively.

There were no capitalized leases included in buildings and improvements and machinery and equipment at December 31, 2019 and 2018.

We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2019, 2018 and 2017 was $1.0 million, $0.9 million and $2.7 million, respectively.

During 2019 and 2018, as part of our 2018 restructuring plan, we recorded within other (income) expense $0.3 million and $2.2 million, respectively, for non-cash asset write-downs associated with the discontinued use of certain equipment. During 2019 and 2018, as part of our restructuring plans, we recorded within other (income) expense $1.9 million and $1.1 million, respectively, for gains on the sale of fixed assets.

Note 6: Leases

Adoption of ASC 842

On January 1, 2019, we adopted ASC 842, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. As a result, we were not required to adjust our comparative period financial information for effects of ASC 842 or present the new required lease disclosures for periods prior to the date of adoption. As of December 31, 2019, we had operating leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2047. Certain of our operating leases include options to extend the lease term for up to five years, and certain of our operating leases include options to terminate the leases within one year. We had no finance leases as of December 31, 2019.

As a result of our adoption of ASC 842, we recorded operating lease right-of-use assets of $71.0 million and operating lease liabilities of $73.1 million for operating leases where we are the lessee in our consolidated balance sheet as of January 1, 2019. The operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct
51

costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.

Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our operating leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our operating leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:

($ in millions)2019
Operating lease cost$12.9  
Short-term lease cost0.8  
Variable lease cost3.3  
Total lease cost$17.0  

Lease expense for 2018 and 2017 was $14.5 million and $13.3 million, respectively.

Supplemental information related to leases was as follows:

($ in millions)2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$12.5  
Right-of-use assets obtained in exchange for new operating lease liabilities9.1  

As of December 31, 2019, the weighted average remaining lease term for operating leases was 11.7 years and the weighted average discount rate was 3.76%.

52

Maturities of lease liabilities as of December 31, 2019 were as follows:

($ in millions)Operating
YearLeases
2020$12.1  
202110.4  
20228.6  
20237.8  
20247.3  
Thereafter41.8  
88.0  
Less: imputed lease interest(16.0) 
Total lease liabilities$72.0  

Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows:

($ in millions)Operating
YearLeases
2019$13.0  
202010.5  
20217.8  
20226.9  
20235.5  
Thereafter37.8  
Total$81.5  

Practical Expedients and Exemptions

We have elected to adopt the leasing package of practical expedients, which allows us to not retroactively reassess: i) any expired or existing contracts containing leases under the new definition of a lease; ii) the lease classification for any expired or existing leases; and iii) initial direct costs for any expired or existing leases. We have also elected to adopt practical expedients around land easements, the combination of lease and non-lease components, and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases.

We have elected not to recognize operating lease right-of-use assets and operating lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.

53

Note 7: Affiliated Companies

At December 31, 2019, the following affiliated companies were accounted for under the equity method:

LocationOwnership interest
The West Company Mexico, S.A. de C.V.Mexico49%  
Aluplast S.A. de C.V.Mexico49%  
Pharma Tap S.A. de C.V.Mexico49%  
Pharma Rubber S.A. de C.V.Mexico49%  
I&W Pharma Group LLCUnited States49%  
DaikyoJapan49%  

On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo, we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.

Unremitted income of affiliated companies included in consolidated retained earnings amounted to $82.4 million, $75.8 million and $69.9 million at December 31, 2019, 2018 and 2017, respectively. Dividends received from affiliated companies were $2.2 million in 2019, $1.7 million in 2018 and $2.2 million in 2017.

Our equity in net unrealized gains of Daikyo’s investment securities and derivative instruments, as well as pension adjustments, included in accumulated other comprehensive loss was $0.4 million, $0.4 million and $0.5 million at December 31, 2019, 2018 and 2017, respectively.

Our purchases from, and royalty payments made to, affiliates totaled $115.1 million, $86.3 million and $86.7 million, respectively, in 2019, 2018 and 2017, of which $20.8 million and $12.9 million was due and payable as of December 31, 2019 and 2018, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. Sales to affiliates were $9.2 million, $9.6 million and $8.1 million, respectively, in 2019, 2018 and 2017, of which $1.9 million and $1.6 million was receivable as of December 31, 2019 and 2018, respectively.

At December 31, 2019 and 2018, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $179.3 million and $77.8 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $13.4 million at both period-ends. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

54

Note 8: Goodwill and Intangible Assets

The changes in the carrying amount of goodwill by reportable segment were as follows:

($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
Balance, December 31, 2017  $77.6  $30.1  $107.7  
Foreign currency translation(1.6) (0.3) (1.9) 
Balance, December 31, 2018  76.0  29.8  105.8  
Goodwill recorded due to acquisition2.6  —  2.6  
Foreign currency translation(0.5) (0.1) (0.6) 
Balance, December 31, 2019  $78.1  $29.7  $107.8  

In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded goodwill of $2.6 million. The goodwill was recorded within our Proprietary Products reportable segment.

As of December 31, 2019, we had no accumulated goodwill impairment losses.

Intangible assets and accumulated amortization as of December 31 were as follows:

20192018
($ in millions)CostAccumulated AmortizationNetCostAccumulated AmortizationNet
Patents and licensing$21.5  $(16.0) $5.5  $19.6  $(15.1) $4.5  
Technology3.3  (1.5) 1.8  3.3  (1.2) 2.1  
Trademarks2.0  (1.8) 0.2  2.0  (1.8) 0.2  
Customer relationships40.3  (21.6) 18.7  29.3  (20.0) 9.3  
Customer contracts11.0  (7.4) 3.6  11.0  (6.8) 4.2  
$78.1  $(48.3) $29.8  $65.2  $(44.9) $20.3  

In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded a customer relationships intangible asset of $11.2 million, which is being amortized over ten years.

The cost basis of intangible assets includes a foreign currency translation loss of $0.3 million and a foreign currency translation loss of $0.3 million for the years ended December 31, 2019 and 2018, respectively. Amortization expense for the years ended December 31, 2019, 2018 and 2017 was $3.4 million, $2.7 million and $2.4 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2020 - $4.0 million, 2021 - $3.5 million, 2022 - $3.5 million, 2023 - $2.9 million and 2024 - $2.6 million.

55

Note 9: Other Current Liabilities

Other current liabilities as of December 31 included the following:

($ in millions)20192018
Deferred income$27.5  $25.5  
Dividends payable11.8  11.3  
Accrued commissions, rebates and royalties9.7  5.7  
Accrued retirement plans (excluding pension)7.9  2.3  
Accrued taxes other than income6.5  5.5  
Accrued professional services5.9  4.9  
Accrued interest3.3  3.4  
Restructuring obligations1.5  3.3  
Other17.2  14.7  
Total other current liabilities$91.3  $76.6  

Note 10:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2019.

($ in millions)20192018
Note payable, due December 31, 2019$—  $0.1  
Credit Facility, due October 15, 2020—  28.6  
Term Loan, due December 31, 2024 (2.78%)90.0  —  
Series A notes, due July 5, 2022 (3.67%)42.0  42.0  
Series B notes, due July 5, 2024 (3.82%)53.0  53.0  
Series C notes, due July 5, 2027 (4.02%)73.0  73.0  
258.0  196.7  
Less: unamortized debt issuance costs0.7  0.6  
Total debt257.3  196.1  
Less: current portion of long-term debt2.3  0.1  
Long-term debt, net$255.0  $196.0  

Credit Agreement - Credit Facility

In March 2019, we entered into the Credit Agreement that replaced our prior revolving credit facility, which was scheduled to expire in October 2020. The Credit Agreement, which expires in March 2024, contains the Credit Facility of $300.0 million, with sublimits of up to $30.0 million for swing line loans for domestic borrowers in USD and a $20.0 million swing line loan for our German Holding Company and up to $30.0 million for the issuance of standby letters of credit, which Credit Facility may be increased from time-to-time by the greater of $350.0 million and earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the preceding twelve month period in the aggregate through an increase in the Credit Facility, subject to the satisfaction of certain conditions. Borrowings under the Credit Facility bear interest at either the base rate (the per annum interest rate of the highest of the Prime Rate, the Federal Funds Rate plus 50 basis points or the daily LIBOR, plus 1.00%) or at the applicable LIBOR rate, plus a tiered margin based on the ratio of our net consolidated debt to our modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for LIBOR rate loans. The Credit
56

Agreement contains financial covenants providing that we shall not permit the ratio of our net consolidated debt to our modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Credit Agreement, upon the occurrence of a qualified acquisition for each of our four fiscal quarters immediately following such qualified acquisition, the ratio shall be increased to 4.0 to 1. The Credit Agreement also contains customary limitations on liens securing our indebtedness, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2019 and 2018, total unamortized debt issuance costs of $1.1 million and $0.6 million, respectively, were recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the Credit Facility. A portion of these costs relate to our prior revolving credit facility.

At December 31, 2019, we had no outstanding borrowings under the Credit Facility, as we repaid the outstanding long-term borrowings denominated in Euro and Yen in November and December 2019, respectively. There was no material gain or loss on the repayment under the Credit Facility. At December 31, 2019, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.5 million, was $297.5 million. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedges that had been associated with this facility.

Credit Agreement Amendment - Term Loan

In December 2019, we entered into a First Amendment and Incremental Facility Amendment (the “First Amendment”) to the Credit Agreement. Pursuant to the First Amendment and the Credit Agreement, we established the Term Loan in the amount of $90.0 million, which is due on December 31, 2024. Borrowings under the Term Loan bear interest at the three-month LIBOR plus 87.5 basis points. As of December 31, 2019, there were unamortized debt issuance costs remaining of $0.2 million, which are being amortized as additional interest expense over the term of the Term Loan.

At December 31, 2019, we had $90.0 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $87.7 million was classified as long-term. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Private Placement

In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes is 3.87%. As of December 31, 2019 and 2018, there were unamortized debt issuance costs remaining of $0.5 million and $0.6 million, respectively, which are being amortized as additional interest expense over the term of the Notes.

Covenants

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2019, we were in compliance with all of our debt covenants, and we expect to continue to be in compliance with the terms of these agreements throughout 2020.

Interest costs incurred during 2019, 2018 and 2017 were $9.4 million, $9.3 million and $10.5 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, were as follows:
$2.3 million in 2020 and 2021, 2022 - $44.3 million, 2023 - $2.3 million, 2024 - $133.8 million, and thereafter - $73.0 million.

57

Note 11:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

Foreign Currency Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2019, the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. As of December 31, 2018, the total amount of these forward exchange contracts was €10.0 million, SGD 601.5 million and $13.4 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD38.4  —  33.6  
Yen6,550.4  37.8  20.6  
SGD29.4  16.5  4.6  

In November and December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Euro and Yen, we de-designated these borrowings as hedges of our net investments in certain European subsidiaries and Daikyo. The amounts recorded as cumulative translation adjustments within accumulated other comprehensive loss related to these borrowings (prior to de-designation) will remain in accumulated other comprehensive loss indefinitely, unless certain future events occur, such as the disposition of the operations for which the net investment hedges relate.

In December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Yen, we entered into a forward exchange contract, designated as a cash flow hedge, to manage our exposure to fluctuating foreign exchange rates. This forward exchange contract matured on December 30, 2019.

In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month USD LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Yen LIBOR plus a margin.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

58

From November 2017 through October 2019, we purchased several series of call options for a total of 352,682 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.

As of December 31, 2019, we had outstanding contracts to purchase 135,967 barrels of crude oil from January 2020 to June 2021 at a weighted-average strike price of $70.71 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 12, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of December 31, 2019 and 2018.

The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:

Amount of Gain Recognized in IncomeLocation on Statement of Income
($ in millions)20192018
Fair Value Hedges:
Foreign currency hedge contracts$(6.9) $(6.3) Other (income) expense
Total$(6.9) $(6.3) 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2019 and 2018 were $8.7 million and $3.7 million, respectively. We expect to recognize $5.6 million in earnings, pre-tax, for forward point components in 2020.

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:

 Amount of Gain (Loss) Recognized in OCIAmount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
($ in millions)2019201820192018 
Fair Value Hedges:
Foreign currency hedge contracts$4.8  $—  $(4.6) $—  Other (income) expense
Total$4.8  $—  $(4.6) $—  
Cash Flow Hedges:     
Foreign currency hedge contracts$0.8  $0.4  $(0.9) $0.6  Net sales
Foreign currency hedge contracts(0.2) 2.2  (0.6) 0.3  Cost of goods and services sold
Forward treasury locks—  —  0.3  0.3  Interest expense
Total$0.6  $2.6  $(1.2) $1.2   
Net Investment Hedges:     
Foreign currency-denominated debt$0.6  $0.8  $—  $—  Other (income) expense
Cross-currency swap(1.1) —  —  —  Other (income) expense
Total$(0.5) $0.8  $—  $—   

59

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our consolidated statements of income for the years ended December 31:

($ in millions)20192018
Net sales$(0.9) $0.6  
Cost of goods and services sold(0.6) 0.3  
Other (income) expense(4.6) —  
Interest expense0.3  0.3  

The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:

Amount of Loss (Gain) Recognized in IncomeLocation on Statement of Income
($ in millions)20192018
Commodity call options$0.4  $(0.1) Cost of goods and services sold
Total$0.4  $(0.1) 


During 2019 and 2018, there was no material ineffectiveness related to our hedges.


Note 12:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

60

The following tables present the assets and liabilities recorded at fair value on a recurring basis:

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2019		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.3  $11.3  $—  $—  
Foreign currency contracts7.7  —  7.7  —  
Commodity call options0.1  —  0.1  —  
 $19.1  $11.3  $7.8  $—  
Liabilities:    
Contingent consideration$3.3  $—  $—  $3.3  
Deferred compensation liabilities12.8  12.8  —  —  
Cross-currency swap1.4  —  1.4  —  
Foreign currency contracts0.3  —  0.3  —  
 $17.8  $12.8  $1.7  $3.3  

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2018		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$8.7  $8.7  $—  $—  
Foreign currency contracts6.5  —  6.5  —  
 $15.2  $8.7  $6.5  $—  
Liabilities:    
Contingent consideration$1.7  $—  $—  $1.7  
Deferred compensation liabilities9.8  9.8  —  —  
Foreign currency contracts0.2  —  0.2  —  
 $11.7  $9.8  $0.2  $1.7  

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 11, Derivative Financial Instruments, for further discussion of our derivatives.

Level 3 Fair Value Measurements

The fair value of the contingent consideration liability related to the SmartDose technology platform (the "SmartDose contingent consideration") was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this
61

obligation are recorded as income or expense within other (income) expense in our consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.

The following table provides a summary of changes in our Level 3 fair value measurements:

 ($ in millions)
Balance, December 31, 2017$4.9  
Decrease in fair value recorded in earnings(2.6) 
Payments(0.6) 
Balance, December 31, 20181.7  
Increase in fair value recorded in earnings2.1  
Payments(0.5) 
Balance, December 31, 2019$3.3  

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million compared to a carrying amount of $255.0 million. At December 31, 2018, the estimated fair value of long-term debt was $192.6 million and the carrying amount was $196.0 million.

Note 13: Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
($ in millions)(Losses) gains on derivativesUnrealized gains on investment securitiesDefined benefit pension and other postretirement plansForeign currency translationTotal
Balance, December 31, 2017  $(4.2) $0.5  $(39.0) $(74.6) $(117.3) 
Other comprehensive income (loss) before reclassifications2.6  (0.1) (1.0) (39.2) (37.7) 
Amounts reclassified out1.2  —  (0.4) —  0.8  
Other comprehensive income (loss), net of tax3.8  (0.1) (1.4) (39.2) (36.9) 
Balance, December 31, 2018  (0.4) 0.4  (40.4) (113.8) (154.2) 
Other comprehensive income (loss) before reclassifications5.4  —  (1.9) 4.9  8.4  
Amounts reclassified out(5.8) —  2.0  —  (3.8) 
Other comprehensive (loss) income, net of tax(0.4) —  0.1  4.9  4.6  
Balance, December 31, 2019$(0.8) $0.4  $(40.3) $(108.9) $(149.6) 

62

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):

Detail of components20192018Location on Statement of Income
Gains (losses) on derivatives:
Foreign currency contracts$1.0  $(0.7) Net sales  
Foreign currency contracts1.0  (0.5) Cost of goods and services sold  
Foreign currency contracts6.9  —  Other expense  
Forward treasury locks(0.5) (0.4) Interest expense  
Total before tax8.4  (1.6) 
Tax expense(2.6) 0.4  
Net of tax$5.8  $(1.2) 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit0.6  2.0  (a) 
Actuarial gains (losses)0.2  (1.4) (a) 
Settlements(3.5) —  (a) 
Total before tax(2.7) 0.6  
Tax expense0.7  (0.2) 
Net of tax$(2.0) $0.4  
Total reclassifications for the period, net of tax$3.8  $(0.8) 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.

Note 14:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2019, there were 3,119,314 shares remaining in the 2016 Plan for future grants.

Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.

63

The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:

($ in millions)201920182017
Stock option and appreciation rights$9.1  $8.6  $7.8  
Performance share units, stock-settled9.5  2.5  4.1  
Performance share units, cash-settled0.1  —  0.1  
Performance share units, dividend equivalents0.2  0.1  0.1  
Employee stock purchase plan0.9  0.9  0.8  
Deferred compensation plans and restricted share awards4.6  3.0  3.2  
Total stock-based compensation expense$24.4  $15.1  $16.1  

The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2019 was approximately $21.2 million, which is expected to be recognized over a weighted average period of 1.6 years.

Stock Options

Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.

The following table summarizes changes in outstanding options:

(in millions, except per share data)201920182017
Options outstanding, January 13.0  3.5  4.5  
Granted0.3  0.5  0.5  
Exercised(0.6) (1.0) (1.5) 
Forfeited—  —  —  
Options outstanding, December 312.7  3.0  3.5  
Options exercisable, December 311.6  1.7  1.9  

Weighted Average Exercise Price201920182017
Options outstanding, January 1$58.93  $48.76  $38.11  
Granted103.40  90.36  84.09  
Exercised46.42  35.95  26.15  
Forfeited92.71  75.32  60.92  
Options outstanding, December 31$67.02  $58.93  $48.76  
Options exercisable, December 31$53.12  $45.32  $35.44  

As of December 31, 2019, the weighted average remaining contractual life of options outstanding and of options exercisable was 6.1 years and 5.0 years, respectively.

As of December 31, 2019, the aggregate intrinsic value of total options outstanding was $227.8 million, of which $158.6 million represented vested options.

The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2019, 2018 and 2017: a risk-free interest rate of 2.3%, 2.7%, and 2.0%, respectively; stock volatility of 22.5%, 19.8%, and 19.9%, respectively; and dividend yields of 0.7%, 0.7%, and 0.7%, respectively. Stock volatility is estimated based on historical data and the impact from expected
64

future trends. Expected lives, which are based on prior experience, averaged 6 years for 2019, 2018 and 2017. The weighted average grant date fair value of options granted in 2019, 2018 and 2017 was $24.72, $20.16 and $18.08, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.

For the years ended December 31, 2019, 2018 and 2017, the intrinsic value of options exercised was $46.9 million, $61.3 million and $91.7 million, respectively. The grant date fair value of options vested during those same periods was $7.5 million, $8.3 million and $6.7 million, respectively.

Stock Appreciation Rights

Stock appreciation rights (“SARs”) granted to eligible international employees vest in equal annual increments over 4 years of continuous service. All awards expire 10 years from the date of grant. The fair value of each cash-settled SAR is adjusted at the end of each reporting period, with the resulting change reflected in expense. As of December 31, 2019, SARs outstanding were 35,993, of which 23,833 were cash-settled and 12,160 were stock-settled. Upon exercise of a cash-settled SAR, the employee receives cash for the difference between the grant date price and the fair market value of the Company’s stock on the date of exercise. As a result of the cash settlement feature, cash-settled SARs are recorded within other long-term liabilities. Upon exercise of a stock-settled SAR, shares are issued in exchange for the exercise price of the stock-settled SAR. As a result of the stock settlement feature, stock-settled SARs are recorded within equity.

The following table summarizes changes in outstanding SARs:

201920182017
SARs outstanding, January 139,819  51,368  116,087  
Granted3,364  3,480  2,792  
Exercised(6,790) (14,629) (67,511) 
Forfeited(400) (400) —  
SARs outstanding, December 3135,993  39,819  51,368  
SARs exercisable, December 3127,781  30,285  39,769  

Weighted Average Exercise Price201920182017
SARs outstanding, January 1$46.48  $38.55  $31.13  
Granted102.51  89.64  83.47  
Exercised42.08  28.45  27.65  
Forfeited63.43  63.43  —  
SARs outstanding, December 31$52.36  $46.48  $38.55  
SARs exercisable, December 31$40.73  $36.91  $30.77  

Performance Awards

In addition to stock options and SAR awards, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.

65

The following table summarizes changes in our outstanding stock-settled PSU awards:

201920182017
Non-vested stock-settled PSU awards, January 1296,037  341,944  378,062  
Granted at target level84,309  102,307  92,045  
Adjustments above/(below) target(50,556) (2,284) (11,369) 
Vested and converted(48,964) (121,984) (116,684) 
Forfeited(16,204) (23,946) (110) 
Non-vested stock-settled PSU awards, December 31264,622  296,037  341,944  
Weighted Average Grant Date Fair Value201920182017
Non-vested stock-settled PSU awards, January 1$76.84  $64.38  $54.47  
Granted at target level103.40  90.45  84.01  
Adjustments above/(below) target83.89  33.86  42.85  
Vested and converted102.51  93.00  50.06  
Forfeited69.09  68.65  73.64  
Non-vested stock-settled PSU awards, December 31$66.03  $76.84  $64.38  

Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2019, 2018 and 2017 was $103.40, $90.45 and $84.01, respectively. Including forfeiture and below-target achievement expectations, we expect that the stock-settled PSU awards will convert to 84,670 shares to be issued over an average remaining term of one year.

The fair value of cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities.

The following table summarizes changes in our outstanding cash-settled PSU awards:

201920182017
Non-vested cash-settled PSU awards, January 11,592  1,972  2,451  
Granted at target level806  560  598  
Adjustments above/(below) target(206) (30) (107) 
Vested and converted(211) (910) (970) 
Forfeited—  —  —  
Non-vested cash-settled PSU awards, December 311,981  1,592  1,972  

Weighted Average Grant Date Fair Value201920182017
Non-vested cash-settled PSU awards, January 1$79.48  $92.25  $25.28  
Granted at target level102.51  89.64  83.47  
Adjustments above/(below) target56.95  41.53  66.61  
Vested and converted102.51  93.00  86.93  
Forfeited—  —  —  
Non-vested cash-settled PSU awards, December 31$150.33  $79.48  $92.25  

66

Employee Stock Purchase Plan

We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 51,391 shares, 55,669 shares and 56,218 shares for the years 2019, 2018 and 2017, respectively. At December 31, 2019, there were approximately 3.8 million shares available for issuance under the ESPP.

Deferred Compensation Plans and Restricted Share Awards

Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, deferred stock awards are granted on the date of our annual meeting, and are distributed in shares of common stock. In 2019, we granted 14,579 deferred stock awards, with a grant date fair value of $121.40. Similarly, a non-qualified deferred compensation plan for eligible employees provides for the conversion of compensation into deferred stock units. As of December 31, 2019, the two deferred compensation plans held a total of 366,159 deferred stock units, including 6,274 units to be paid in cash.

In addition, during 2019, we granted 13,308 restricted share awards at a weighted grant-date fair value of $116.39 per share to employees under the 2016 Plan. During 2018, we granted 15,942 restricted share awards at a weighted grant-date fair value of $96.77 per share to employees under the 2016 Plan. There were no grants of restricted share awards in 2017. The fair value of these awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period.

Annual Incentive Plan

Under our annual incentive plan, participants are paid bonuses on the attainment of certain financial goals, which they can elect to receive in either cash or shares of our common stock. If the employee elects payment in shares, they are also given a restricted incentive stock award equal to one share for each four bonus shares issued. The incentive stock awards vest at the end of four years provided that the participant has not made a disqualifying disposition of their bonus shares. Incentive stock award grants were 1,300 shares, 1,500 shares and 1,800 shares in 2019, 2018 and 2017, respectively. There were no incentive stock forfeitures in 2019. Incentive stock forfeitures of 200 shares and 800 shares occurred in 2018 and 2017, respectively. Compensation expense is recognized over the vesting period based on the fair market value of common stock on the award date: $106.14 per share granted in 2019, $93.00 per share granted in 2018 and $86.93 per share granted in 2017.

Note 15:  Benefit Plans

Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we provide minimal death benefits for certain U.S. retirees and pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. Benefits for participants are coordinated with Medicare when possible. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $15.6 million for 2019, $6.5 million for 2018 and $5.7 million for 2017. The increase in 401(k) plan contributions in 2019 was in response to the cessation of our U.S. qualified and non-qualified defined benefit pension plans as of January 1, 2019 (except for interest crediting).

67

Pension and Other Retirement Benefits

The components of net periodic benefit cost and other amounts recognized in OCI were as follows:

Pension benefitsOther retirement benefits
($ in millions)201920182017201920182017
Net periodic benefit cost:
Service cost$1.4  $10.8  $10.4  $—  $—  $—  
Interest cost9.2  9.4  9.8  0.2  0.2  0.3  
Expected return on assets(12.0) (15.7) (13.5) —  —  —  
Amortization of prior service credit0.1  (1.3) (1.3) (0.7) (0.7) (0.7) 
Amortization of actuarial loss (gain)2.1  3.8  4.9  (2.3) (2.4) (2.6) 
Settlement effects3.5  —  —  —  —  —  
Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
Net loss (gain) arising during period$1.5  $3.5  $(9.0) $0.1  $(1.4) $(1.1) 
Prior service credit arising during period—  0.3  —  —  —  —  
Amortization of prior service credit(0.1) 1.3  1.3  0.7  0.7  0.7  
Amortization of actuarial (loss) gain(2.1) (3.8) (4.9) 2.3  2.4  2.6  
Settlement effects(3.5) —  —  —  —  —  
Foreign currency translation 0.6  (1.2) 2.6  —  —  —  
Total recognized in OCI$(3.6) $0.1  $(10.0) $3.1  $1.7  $2.2  
Total recognized in net periodic benefit cost and OCI$0.7  $7.1  $0.3  $0.3  $(1.2) $(0.8) 

Net periodic benefit cost by geographic location is as follows:

 Pension benefitsOther retirement benefits
($ in millions)201920182017201920182017
U.S. plans$2.4  $4.8  $7.3  $(2.8) $(2.9) $(3.0) 
International plans1.9  2.2  3.0  —  —  —  
Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 

During 2019, we recorded a $3.5 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for each of our U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year. Effective January 1, 2019, except for interest crediting, benefit accruals under these defined benefit pension plans ceased.

During 2019, we contributed $2.6 million to our U.S. qualified defined benefit pension plan.

68

The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:

Pension benefitsOther retirement benefits
($ in millions)2019201820192018
Change in benefit obligation:
Benefit obligation, January 1$(267.0) $(288.0) $(6.0) $(7.1) 
Service cost(1.4) (10.8) —  —  
Interest cost(9.2) (9.4) (0.2) (0.2) 
Participants’ contributions(0.3) (0.6) (0.7) (0.6) 
Actuarial (loss) gain(30.8) 20.4  (0.2) 1.4  
Amendments/transfers in—  (0.3) —  —  
Benefits/expenses paid6.8  18.0  0.5  0.5  
Settlement effects15.0  —  —  —  
Foreign currency translation(1.0) 3.7  —  —  
Benefit obligation, December 31$(287.9) $(267.0) $(6.6) $(6.0) 
Change in plan assets:
Fair value of assets, January 1$214.5  $239.5  $—  $—  
Actual return on assets41.3  (8.3) —  —  
Employer contribution8.0  2.7  (0.2) (0.1) 
Participants’ contributions0.3  0.6  0.7  0.6  
Benefits/expenses paid(6.3) (18.0) (0.5) (0.5) 
Settlement effects(15.0) —  —  —  
Foreign currency translation1.3  (2.0) —  —  
Fair value of assets, December 31$244.1  $214.5  $—  $—  
Funded status at end of year$(43.8) $(52.5) $(6.6) $(6.0) 

International pension plan assets, at fair value, included in the preceding table were $39.4 million and $33.4 million at December 31, 2019 and 2018, respectively.

Amounts recognized in the balance sheet were as follows:

Pension benefitsOther retirement benefits
($ in millions)2019201820192018
Noncurrent assets$4.3  $—  $—  $—  
Current liabilities(1.5) (1.6) (0.7) (0.7) 
Noncurrent liabilities(46.6) (50.9) (5.9) (5.3) 
$(43.8) $(52.5) $(6.6) $(6.0) 

69

The amounts in accumulated other comprehensive loss, pre-tax, consisted of:

Pension benefitsOther retirement benefits
($ in millions)2019201820192018
Net actuarial loss (gain)$69.4  $73.0  $(7.0) $(9.4) 
Prior service cost (credit)0.8  0.9  (1.0) (1.7) 
Total$70.2  $73.9  $(8.0) $(11.1) 

The net actuarial loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year are $1.8 million and $0.1 million, respectively. The net actuarial gain and prior service credit for the other retirement benefits plan that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year is $1.6 million and $0.7 million.

The accumulated benefit obligation for all defined benefit pension plans was $283.9 million and $263.0 million at December 31, 2019 and 2018, respectively, including $73.9 million and $64.0 million, respectively, for international pension plans.

As of December 31, 2019, our U.S. qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2019, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets.

All of the defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets as of December 31, 2018.

Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows:

 ($ in millions)Domestic International Total
2020$21.0  $1.3  $22.3  
202113.5  1.3  14.8  
202215.0  2.0  17.0  
202313.7  1.5  15.2  
202413.5  1.9  15.4  
2025 to 202960.5  13.3  73.8  
$137.2  $21.3  $158.5  

In 2020, we expect to contribute $0.7 million to pension plans, none of which is for international plans. In addition, we expect to contribute $0.7 million for other retirement benefits in 2020. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.

Weighted average assumptions used to determine net periodic benefit cost were as follows:

Pension benefitsOther retirement benefits
201920182017201920182017
Discount rate2.70 %2.91 %3.48 %4.20 %3.45 %3.90 %
Rate of compensation increase2.41 %4.00 %4.01 %—  —  —  
Long-term rate of return on assets5.54 %6.71 %6.47 %—  —  —  
70

Weighted average assumptions used to determine the benefit obligations were as follows:

Pension benefitsOther retirement benefits
2019201820192018
Discount rate2.79 %3.76 %3.20 %4.20 %
Rate of compensation increase2.49 %4.01 %—  —  

The discount rate used to determine the benefit obligations for U.S. pension plans was 3.35% and 4.30% as of December 31, 2019 and 2018, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 1.28% and 2.19% as of December 31, 2019 and 2018, respectively. The rate of compensation increase for U.S. plans was 4.25% for 2018, while the weighted average rate for all international plans was 2.49% for 2019 and 2.60% for 2018. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans, which accounts for 83.86% of global plan assets, was 5.60% for 2019, 7.00% for 2018 and 7.00% for 2017.

The assumed healthcare cost trend rate used to determine benefit obligations was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. A change in the assumed healthcare cost trend rate by one percentage point would have an immaterial impact in the postretirement obligation. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. The effect of a one percentage point increase or decrease in the rate would have an immaterial impact in the aggregate service and interest cost components.

The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:

20192018
Equity securities33 %23 %
Debt securities65 %74 %
Other2 %3 %
100 %100 %

Our U.S. pension plan is managed as a balanced portfolio comprised of two components: equity and fixed income debt securities. Equity investments are used to maximize the long-term real growth of fund assets, while fixed income investments are used to generate current income, provide for a more stable periodic return and provide some protection against a prolonged decline in the market value of equity investments. Temporary funds may be held as cash. We maintain a long-term strategic asset allocation policy which provides guidelines for ensuring that the fund’s investments are managed with the short-term and long-term financial goals of the fund, while allowing the flexibility to react to unexpected changes in capital markets.

Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.

During the three months ended December 31, 2018, in anticipation of benefit accruals under our U.S. qualified and non-qualified defined benefit pension plans ceasing effective January 1, 2019, except for interest crediting, we changed the U.S. target asset allocations from 65% equity securities and 35% debt securities to 30% equity securities and 70% debt securities.

71

The following are the U.S. target asset allocations and acceptable allocation ranges:

Target allocationAllocation range
Equity securities30%  27% - 33%  
Debt securities70%  67% - 73%
Other—%  0% - 3%

The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.

Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2019Level 1Level 2  Level 3
Cash$2.2  $2.2  $—  $—  
Equity securities:
International mutual funds15.5  1.3  14.2  —  
Fixed income securities:
Mutual funds21.7  3.8  17.9  —  
Pension plan assets in the fair value hierarchy$39.4  $7.3  $32.1  $—  
Pension plan assets measured at NAV204.7  
Pension plan assets at fair value$244.1  

Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2018Level 1Level 2Level 3
Cash$1.7  $1.7  $—  $—  
Equity securities:
International mutual funds17.7  17.7  —  —  
Fixed income securities:
Mutual funds13.9  13.9  —  —  
Pension plan assets in the fair value hierarchy$33.3  $33.3  $—  $—  
Pension plan assets measured at NAV181.2  
Pension plan assets at fair value$214.5  

72

Note 16:  Other (Income) Expense

Other (income) expense consisted of:
($ in millions)201920182017
Restructuring and related charges:
Severance and post-employment benefits$2.6  $3.1  $—  
Asset-related charges0.3  2.2  —  
Other charges2.0  3.8  —  
Total restructuring and related charges$4.9  $9.1  $—  
Argentina currency devaluation1.0  1.1  —  
Tax recovery(4.7) —  —  
Venezuela deconsolidation—  —  11.1  
Development and licensing income(0.9) (0.9) (10.6) 
Contingent consideration2.1  (2.6) (2.4) 
Other items(4.9) (4.8) 3.9  
Total other (income) expense$(2.5) $1.9  $2.0  

Restructuring and Related Charges

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of the approval. The plan was expected to require restructuring and related charges of approximately $16.0 million. Since its approval, we recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.

During 2019, we recorded $4.9 million in restructuring and related charges associated with this plan, consisting of $2.6 million for severance charges, $0.3 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $2.0 million for other non-cash charges.

During 2018, we recorded $8.8 million in restructuring and related charges associated with this plan, consisting of $3.1 million for severance charges, $2.2 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $3.5 million for other non-cash charges.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance and benefitsAsset-related chargesOther chargesTotal
Balance, December 31, 2017$—  $—  $—  $—  
Charges3.1  2.2  3.5  8.8  
Cash payments(0.8) —  —  (0.8) 
Non-cash asset write-downs—  (2.2) (3.5) (5.7) 
Balance, December 31, 2018$2.3  $—  $—  $2.3  
Charges2.6  0.3  2.0  4.9  
Cash payments(3.5) —  —  (3.5) 
Non-cash asset write-downs—  (0.3) (2.0) (2.3) 
Balance, December 31, 2019$1.4  $—  $—  $1.4  

73

On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. During 2018, we recorded $0.3 million in additional charges related to this restructuring plan. Our remaining restructuring obligations related to our 2016 restructuring plan as of December 31, 2019 were $0.1 million.

Other Items

During 2019, we recorded a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. During 2018, we recorded a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018.

During 2019, we recognized a tax recovery of $4.7 million related to previously-paid international excise taxes, following a favorable court ruling.

On February 17, 2016, the Venezuelan government announced a devaluation of the Bolivar, from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD, and streamlined the previous three-tiered currency exchange mechanism into a dual currency exchange mechanism. In 2017, as a result of the continued deterioration of conditions in Venezuela as well as our continued reduced access to USD settlement controlled by the Venezuelan government, we recorded a charge of $11.1 million related to the deconsolidation of our Venezuelan subsidiary, following our determination that we no longer met the U.S. GAAP criteria for control of that subsidiary. This charge included the derecognition of the carrying amounts of our Venezuelan subsidiary’s assets and liabilities, as well as the write-off of our investment in our Venezuelan subsidiary, related unrealized translation adjustments and the elimination of intercompany accounts. As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary.

During 2019, 2018 and 2017, we recorded development income of $0.9 million, $0.9 million and $1.5 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information. In addition, during 2017, we recorded income of $9.1 million attributable to the reimbursement of certain costs related to a technology that we subsequently licensed to a third party. The license of technology to the third party may result in additional income in the future, contingent on commercialization of the related product.

Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 12, Fair Value Measurements, for additional details.

Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. Other items primarily changed in 2019 as a result of foreign exchange transaction gains of $5.6 million in 2019 and a $1.9 million gain on the sale of fixed assets as a result of our restructuring plan, as compared to foreign exchange transaction gains of $5.5 million in 2018 and a $1.1 million gain on the sale of fixed assets as a result of our restructuring plans.

Note 17:  Income Taxes

As a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. During 2019, the statute of limitations for the 2015 U.S. federal tax year lapsed, leaving tax years 2016 through 2019 open to examination. For U.S. state and local jurisdictions, tax years 2015 through 2019 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2012 through 2019.

74

A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:

($ in millions)20192018
Balance at January 1$3.9  $3.2  
Increase due to current year position1.6  0.8  
Increase due to prior year position—  0.4  
Reduction for expiration of statute of limitations/audits(0.5) (0.5) 
Balance at December 31$5.0  $3.9  

In addition, we had balances in accrued liabilities for interest and penalties of $0.2 million at both December 31, 2019 and 2018. As of December 31, 2019, we had $5.0 million of total gross unrecognized tax benefits, which, if recognized, would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $0.5 million during the next twelve months, which would favorably impact our effective tax rate.
The components of income before income taxes are:
($ in millions)201920182017
U.S. operations$161.2  $132.9  $96.5  
International operations130.6  107.8  125.9  
Total income before income taxes$291.8  $240.7  $222.4  

The related provision for income taxes consists of:

($ in millions)201920182017
Current:
Federal$10.8  $2.1  $2.1  
State2.4  3.3  0.1  
International30.5  35.1  37.0  
Current income tax provision43.7  40.5  39.2  
Deferred:
Federal and state10.3  1.4  41.8  
International5.0  (0.5) (0.1) 
Deferred income tax provision15.3  0.9  41.7  
Income tax expense$59.0  $41.4  $80.9  

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.

75

The significant components of our deferred tax assets and liabilities at December 31 are:

($ in millions)20192018
Deferred tax assets
Net operating loss carryforwards$21.9  $18.4  
Tax credit carryforwards2.8  10.5  
Pension and deferred compensation25.6  27.2  
Other9.2  11.4  
Valuation allowance(15.9) (16.0) 
Total deferred tax assets43.6  51.5  
Deferred tax liabilities:
Accelerated depreciation37.9  31.3  
Tax on undistributed earnings of subsidiaries6.3  6.6  
Other0.9  2.0  
Total deferred tax liabilities45.1  39.9  
Net deferred tax (liability) asset$(1.5) $11.6  

A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:

201920182017
U.S. federal corporate tax rate21.0 %21.0 %35.0 %
Tax on international operations other than U.S. tax rate2.7  4.8  (4.5) 
Reversal of prior valuation allowance—  —  (0.5) 
Adjustments to reserves for unrecognized tax benefits0.4  0.2  (0.2) 
U.S. tax on international earnings, net of foreign tax credits0.4  (0.2) 0.1  
State income taxes, net of federal tax effect1.4  2.3  0.2  
U.S. research and development credits(1.0) (0.9) (0.8) 
Excess tax benefits on share-based payments(3.5) (6.0) (14.1) 
Impact of 2017 Tax Act—  (2.9) 15.9  
Tax on undistributed earnings of subsidiaries(0.2) (1.3) 4.4  
Venezuela deconsolidation—  —  1.7  
Other business credits and Section 199 Deduction—  —  (0.6) 
Other(1.0) 0.2  (0.2) 
Effective tax rate20.2 %17.2 %36.4 %

During 2019, we recorded a tax benefit of $0.3 million due to the impact of federal law changes enacted during the year, as well as a tax benefit of $10.3 million associated with stock-based compensation.

During 2018, we recorded a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act and a tax benefit of $14.3 million associated with stock-based compensation.

During 2017, we recorded a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation.

76

The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include, but are not limited to, a federal statutory rate reduction from 35.0% to 21.0% effective for tax years beginning after December 31, 2017. Changes in tax rates and tax laws are accounted for in the period of enactment. As a result, during the year ended December 31, 2017, we recorded a discrete charge based upon our understanding of the 2017 Tax Act and the guidance available as of the date of that filing. A significant portion of the discrete tax liability was attributable to a one-time mandatory deemed repatriation tax of post-1986 undistributed foreign subsidiary earnings and profits (the “Transition Toll Tax”) of $27.9 million. Additionally, due to the reduction of the federal statutory rate, we revalued our deferred assets and liabilities and recorded a provisional $11.4 million federal tax expense, net of state tax impact, during the year ended December 31, 2017.

On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. We recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities and included these amounts in our consolidated financial statements for the year ended December 31, 2017. As of December 31, 2018, we finalized our calculations and tax positions used in our analysis of the impact of the 2017 Tax Act in consideration of proposed regulations and other guidance issued during 2018. As a result, we recorded a $7.5 million tax benefit related to a reduction of the Transition Toll Tax and an incremental tax expense of $4.0 million related to other adjustments. The final measurement reduced the Transition Toll Tax expense to $20.4 million from $27.9 million. The net impact of these adjustments resulted in a benefit of 1.45% to the 2018 effective tax rate.

The 2017 Tax Act created a provision known as global intangible low-tax income (“GILTI”) that imposes a U.S. tax on certain earnings of controlled foreign subsidiaries. We made an accounting policy election to reflect GILTI taxes, if any, as a current income tax expense in the period incurred.

As of December 31, 2019, we have fully utilized all of our U.S. federal net operating loss carryforwards. State operating loss carryforwards of $226.9 million created a deferred tax asset of $15.5 million, while foreign operating loss carryforwards of $49.4 million created a deferred tax asset of $6.4 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been fully reserved. State loss carryforwards expire as follows: $15.4 million in 2020 and $211.5 million thereafter. Foreign loss carryforwards will begin to expire in 2027, while $48.7 million of the total $49.4 million will not expire.

As of December 31, 2019, we have utilized all available foreign tax credit carryforwards against the Transition Toll Tax. During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. The $2.0 million of state research and development credits expire as follows: $0.5 million expire in 2023, $0.5 million expire in 2024, and $1.0 million expire after 2024.

In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. In general, it is our practice and intention to permanently reinvest the earnings of our foreign subsidiaries and repatriate earnings only when the tax impact is de minimis, and that position has not changed subsequent to the one-time transition tax under the 2017 Tax Act, except as noted above. Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $214.2 million of undistributed earnings from foreign subsidiaries to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.

77

Note 18:  Commitments and Contingencies

At December 31, 2019, we were obligated under various operating lease agreements. Please refer to Note 6, Leases, for additional details.

At December 31, 2019, we were obligated under various defined benefit pension plans in the U.S. and other countries that cover employees who meet eligibility requirements. Please refer to Note 15, Benefit Plans, for additional details.

At December 31, 2019, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $249.1 million, of which $61.3 million is due to be paid in 2020.

We have letters of credit totaling $2.5 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $3.2 million at December 31, 2019, of which $0.9 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.

Our SmartDose contingent consideration is payable to the selling shareholders based upon a percentage of product sales over the life of the underlying product patent, with no cap on total payments. Given the length of the earnout period and the uncertainty in forecasted product sales, we do not believe it is meaningful to estimate the upper end of the range over the entire period. However, our estimated probable range which could become payable over the next five years is between zero and $3.7 million.

Note 19:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

The following table presents information about our reportable segments, reconciled to consolidated totals:

($ in millions)201920182017
Net sales:
Proprietary Products$1,398.6  $1,308.6  $1,236.9  
Contract-Manufactured Products441.5  409.1  362.5  
Intersegment sales elimination(0.2) (0.3) (0.3) 
Consolidated net sales$1,839.9  $1,717.4  $1,599.1  

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

78

We do not have any customers accounting for greater than 10% of consolidated net sales.

The following table presents net sales and property, plant and equipment, net, by the country in which the legal subsidiary is domiciled and assets are located:

Net SalesProperty, Plant and Equipment, Net
($ in millions)201920182017201920182017
United States$814.7  $766.1  $734.6  $337.1  $315.3  $323.8  
Germany236.3  235.9  226.4  95.4  99.3  108.8  
Ireland173.8  138.1  100.5  162.0  165.4  173.2  
France150.6  145.0  142.6  53.3  50.1  51.6  
Other European countries251.1  230.5  201.0  59.1  59.5  63.2  
Other213.4  201.8  194.0  132.4  132.4  134.4  
$1,839.9  $1,717.4  $1,599.1  $839.3  $822.0  $855.0  

79

The following tables provide summarized financial information for our segments:

($ in millions)Proprietary ProductsContract-Manufactured ProductsCorporate/ Elimination/ Unallocated ItemsConsolidated
2019
Net sales$1,398.6  $441.5  $(0.2) $1,839.9  
Operating profit$313.6  $49.1  $(66.1) $296.6  
Interest expense—  —  8.5  8.5  
Interest income—  —  (3.8) (3.8) 
Other nonoperating expense (income)—  —  0.1  0.1  
Income before income taxes$313.6  $49.1  $(70.9) $291.8  
Segment assets$1,480.6  $386.0  $474.8  $2,341.4  
Capital expenditures91.2  37.2  (2.0) 126.4  
Depreciation and amortization expense82.2  17.9  3.3  103.4  
2018
Net sales$1,308.6  $409.1  $(0.3) $1,717.4  
Operating profit$266.4  $44.3  $(70.4) $240.3  
Interest expense—  —  8.4  8.4  
Interest income—  —  (2.1) (2.1) 
Other nonoperating income—  —  (6.7) (6.7) 
Income before income taxes$266.4  $44.3  $(70.0) $240.7  
Segment assets$1,342.3  $301.4  $335.2  $1,978.9  
Capital expenditures77.0  20.7  7.0  104.7  
Depreciation and amortization expense83.9  17.2  3.3  104.4  
2017
Net sales$1,236.9  $362.5  $(0.3) $1,599.1  
Operating profit$243.8  $48.3  $(66.3) $225.8  
Interest expense—  —  7.8  7.8  
Interest income—  —  (1.3) (1.3) 
Other nonoperating income—  —  (3.1) (3.1) 
Income before income taxes$243.8  $48.3  $(69.7) $222.4  
Segment assets$1,321.3  $286.4  $255.1  $1,862.8  
Capital expenditures107.2  18.6  5.0  130.8  
Depreciation and amortization expense77.1  16.4  3.2  96.7  

Please refer to Note 16, Other (Income) Expense, for a discussion of unallocated items.
80

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of West Pharmaceutical Services, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of West Pharmaceutical Services, Inc. and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2019, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2019 appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Changes in Accounting Principles

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019, and as discussed in Note 3 to the consolidated financial statements, the Company changed the manner in which it accounts for revenues from contracts with customers in 2018.

Basis for Opinions

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

81

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Income Taxes

As described in Notes 1 and 17 to the consolidated financial statements, the Company’s consolidated deferred tax assets were $43.6 million, net of a valuation allowance of $15.9 million, as of December 31, 2019, and income tax expense was $59.0 million for the year ended December 31, 2019. As a global organization, the Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. Management estimates income tax payable based upon current domestic and international tax legislation. Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to estimates of future taxable income, generally at the respective subsidiary company and the country level.

The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are that there was significant judgment by management in determining the income tax provision due to the Company’s global footprint and the complexity in the various tax laws applicable in determining the Company’s effective tax rate and in assessing the realizability of deferred tax assets. This in turn led to a high degree of auditor judgment, effort, and subjectivity in performing procedures and in evaluating audit evidence related to the income tax provision and significant assumptions used in management’s assessment of the realizability of deferred tax assets, including projections of future taxable income. Also, our audit effort involved the use of professionals with specialized skill and knowledge to assist in performing procedures and evaluating the audit evidence obtained from these procedures.

82

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to income taxes, including controls over the determination of the income tax provision and the realizability of deferred tax assets. These procedures also included, among others, (i) testing the income tax provision, including performing procedures over the Company’s rate reconciliation, return to provision adjustments, permanent and temporary differences, and financial data used in the income tax provision calculation, (ii) testing the accuracy of the income tax rates utilized in the provision, and (iii) evaluating management’s assessment of the realizability of deferred tax assets, which included evaluating the reasonableness of assumptions underlying management’s projections of future taxable income. Evaluating the reasonableness of the assumptions related to projected future taxable income involved evaluating whether the assumptions used by management were reasonable considering the current and past performance of the Company and evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of management’s application of relevant income tax law in certain jurisdictions.

/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 21, 2020


We have served as the Company’s auditor since 1963.


83

Quarterly Operating and Per Share Data (Unaudited)

($ in millions, except per share data)
First
Quarter
(1)
Second
Quarter
(2)
Third
Quarter
(3)
Fourth
Quarter
(4)
Full Year
2019
Net sales$443.5  $469.7  $456.1  $470.6  $1,839.9  
Gross profit146.8  157.9  147.8  153.2  605.7  
Net income55.4  66.1  56.3  63.9  241.7  
Net income per share:
Basic$0.75  $0.90  $0.76  $0.86  $3.27  
Diluted$0.73  $0.88  $0.75  $0.84  $3.21  
2018
Net sales$415.7  $447.5  $431.7  $422.5  $1,717.4  
Gross profit134.4  142.2  135.6  133.2  545.4  
Net income43.6  56.1  55.2  52.0  206.9  
Net income per share:
Basic$0.59  $0.76  $0.75  $0.70  $2.80  
Diluted$0.58  $0.75  $0.73  $0.69  $2.74  

The sum of the quarterly amounts may not equal full year due to rounding.

Factors affecting the comparability of the information reflected in the quarterly data:

(1)Net income for the first quarter of 2019 included the impact of restructuring and related charges of $0.4 million ($0.01 per diluted share) and a tax benefit of $1.4 million ($0.02 per diluted share) associated with stock-based compensation. Net income for the first quarter of 2018 included the impact of restructuring and related charges of $2.7 million ($0.03 per diluted share), a net tax charge of $0.3 million ($0.01 per diluted share) for the estimated impact of the 2017 Tax Act, and a tax benefit of $2.1 million ($0.03 per diluted share) associated with stock-based compensation.

(2)Second quarter 2019 net income included the impact of restructuring and related charges of $1.1 million ($0.01 per diluted share) and a tax benefit of $3.8 million ($0.05 per diluted share) associated with stock-based compensation. Second quarter 2018 net income included the impact of restructuring and related charges of $1.6 million ($0.01 per diluted share), a net tax benefit of $4.8 million ($0.06 per diluted share) for the estimated impact of the 2017 Tax Act, and a tax benefit of $3.4 million ($0.04 per diluted share) associated with stock-based compensation.

(3)Net income for the third quarter of 2019 included the impact of restructuring and related charges of $1.4 million ($0.01 per diluted share), a pension settlement charge of $2.1 million ($0.03 per diluted share), a charge of $0.7 million ($0.01 per diluted share) related to the continued devaluation of Argentina’s currency, a tax benefit of $1.0 million ($0.01 per diluted share) related to the impact of federal law changes enacted during the quarter, and a tax benefit of $4.0 million ($0.05 per diluted share) associated with stock-based compensation. Net income for the third quarter of 2018 included the impact of restructuring and related charges of $0.9 million ($0.01 per diluted share), a net tax charge of $0.4 million for the estimated impact of the 2017 Tax Act, a tax benefit of $7.7 million ($0.10 per diluted share) associated with stock-based compensation, and a charge of $1.1 million ($0.02 per diluted share) related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018.

84

(4)Fourth quarter 2019 net income included the impact of restructuring and related charges of $0.8 million ($0.02 per diluted share), a gain on the sale of fixed assets as a result of our restructuring plan of $1.3 million ($0.02 per diluted share), a pension settlement charge of $0.6 million ($0.01 per diluted share), a tax recovery related to previously-paid international excise taxes of $2.9 million ($0.04 per diluted share), a tax charge of $0.7 million ($0.01 per diluted share) related to the impact of federal law changes enacted during the quarter, and a tax benefit of $1.1 million ($0.02 per diluted share) associated with stock-based compensation. Fourth quarter 2018 net income included the impact of restructuring and related charges of $2.1 million ($0.02 per diluted share), a gain on the sale of fixed assets as a result of our restructuring plans of $0.9 million ($0.01 per diluted share), a net tax charge of $1.6 million ($0.03 per diluted share) for the estimated impact of the 2017 Tax Act, and a tax benefit of $1.1 million ($0.02 per diluted share) associated with stock-based compensation.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this annual report, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our CEO and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls include some, but not all, components of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Form 10-K. Based on this evaluation, our CEO and CFO have concluded that, as of December 31, 2019, our disclosure controls and procedures are effective.

Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our CEO and CFO to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2019 based on the framework established in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has determined that our internal control over financial reporting was effective as of December 31, 2019.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. No evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within West have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Also projections of any evaluation of effectiveness to future periods are subject to the risks that controls
85

may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included herein.

Changes in Internal Controls
During the fourth quarter ended December 31, 2019, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

On January 1, 2019, we adopted ASC 842. Although our adoption of ASC 842 resulted in no change to our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, we did implement changes to our internal controls relating to leases. These changes included the development of new policies, enhanced contract review requirements, and other ongoing monitoring activities. These controls were designed to provide assurance at a reasonable level of the fair presentation of our consolidated financial statements and related disclosures.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information is incorporated by reference from the discussion under the heading Proposal 1 - Election of Directors; Corporate Governance Documents and Policies - Ethics and Our Code of Business Conduct; Voting and Other Information - 2021 Shareholder Proposals or Nominations; and Board and Director Information and Policies - Committees - Audit Committee in our 2020 Proxy Statement. The balance of the information required by this item is contained in the discussion entitled Information About Our Executive Officers in Part I of this Form 10-K.

ITEM 11. EXECUTIVE COMPENSATION
Information about director and executive compensation is incorporated by reference from the discussion under the headings Director Compensation, Compensation Committee Report, Compensation Discussion and Analysis, and Compensation Tables in our 2020 Proxy Statement.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information required by this Item is incorporated by reference from the discussion under the heading Stock Ownership in our 2020 Proxy Statement.
86

Equity Compensation Plan Information Table

The following table sets forth information about the grants of stock options, restricted stock or other rights under all of the Company’s equity compensation plans as of the close of business on December 31, 2019. The table does not include information about tax-qualified plans such as the West 401(k) Plan or the West Contract Manufacturing Savings and Retirement Plan.

Plan Category
Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights (a)
Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights (b)
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans (Excluding Securities
Reflected in Columns (a)) (c)
Equity compensation plans approved by security holders3,281,507  
(1)
$67.05  
(2)
7,226,236  
(3)
Equity compensation plans not approved by security holders—  —  —  
Total3,281,507  $67.05  7,226,236  

(1) Includes 1,207,157 outstanding stock options, 264,691 restricted performance share units, 25,892 restricted retention share units, 64,544 deferred stock-equivalents units, and 494 restricted stock-equivalents units granted to directors under the 2016 Plan. Includes 1,462,578 outstanding stock options, 12,160 outstanding stock-settled stock appreciation rights, 13,459 restricted retention share units, and 108,074 deferred stock-equivalents units under the 2011 Plan (which was terminated in 2016). Includes 68,400 outstanding stock options and 54,058 deferred stock-equivalents units granted to directors under the Non-Qualified Deferred Compensation Plan for Non-Employee Directors under the 2007 Omnibus Incentive Compensation Plan (which was terminated in 2011). The average term of remaining options and stock-settled stock appreciation rights granted is 5.9 years. No future grants or awards may be made under the terminated plans. The total includes restricted performance share units at 100% of grant. The restricted performance share unit payouts were at 49.39%, 96.6%, and 89.8% in 2019, 2018 and 2017, respectively. The total does not include stock-equivalent units granted or credited to directors under the Non-Qualified Deferred Compensation Plan for Non-Employee Directors to be settled only in cash.

(2) Restricted performance share and deferred stock-equivalent units are excluded when determining the weighted-average exercise price of outstanding options.

(3) Represents 3,829,712 shares reserved under the Company’s Employee Stock Purchase Plan and 3,119,314 shares remaining available for issuance under the 2016 Plan. The estimated number of shares that could be issued for 2019 from the Employee Stock Purchase Plan is 277,210. This number of shares is calculated by multiplying the 190 shares per offering period per participant limit by 1,459, the number of current participants in the plan.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information called for by this Item is incorporated by reference from the discussion under the heading Corporate Governance Documents and Policies - Related Person Transactions and Procedures in our 2020 Proxy Statement. Information about director independence is incorporated by reference from the discussion under the heading Corporate Governance Documents and Policies - Director Independence in our 2020 Proxy Statement.

87

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
Information is incorporated by reference from the discussion under the heading Independent Auditors and Fees - Fees Paid to PricewaterhouseCoopers LLP and Independent Auditors and Fees - Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services in our 2020 Proxy Statement.

PART IV

ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) 1. Financial Statements

The following documents are included in Part II, Item 8:

Consolidated Statements of Income for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Comprehensive Income for the years ended December 31, 2019, 2018 and 2017
Consolidated Balance Sheets at December 31, 2019 and 2018
Consolidated Statement of Equity for the years ended December 31, 2019, 2018 and 2017
Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017
Notes to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm

88

(a) 2. Financial Statement Schedules

Schedule II - Valuation and Qualifying Accounts

($ in millions)
Balance at
beginning of
period
Charged
to costs
and
expenses
Deductions (1)
Balance at
end of
period
For the year ended December 31, 2019
Allowances deducted from assets:
Deferred tax asset valuation allowance$16.0  $—  $(0.1) $15.9  
Allowance for doubtful accounts2.0  0.1  (1.6) 0.5  
Total allowances deducted from assets$18.0  $0.1  $(1.7) $16.4  
For the year ended December 31, 2018
Allowances deducted from assets:
Deferred tax asset valuation allowance$20.9  $(3.0) $(1.9) $16.0  
Allowance for doubtful accounts0.5  0.7  0.8  2.0  
Total allowances deducted from assets$21.4  $(2.3) $(1.1) $18.0  
For the year ended December 31, 2017
Allowances deducted from assets:
Deferred tax asset valuation allowance$18.7  $2.5  $(0.3) $20.9  
Allowance for doubtful accounts0.4  (0.2) 0.3  0.5  
Total allowances deducted from assets$19.1  $2.3  $—  $21.4  
__________________________
(1)Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments.

All other schedules are omitted because they are either not applicable, not required or because the information required is contained in the consolidated financial statements or notes thereto.

(a) 3. Exhibits - An index of the exhibits included in this Form 10-K is contained on pages F-1 through F-3 and is incorporated herein by reference.
(b) See subsection (a) 3. above.
(c) Financial Statements of affiliates are omitted because they do not meet the tests of a significant subsidiary at the 20% level.

ITEM 16. FORM 10-K SUMMARY

None.


89

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer



February 21, 2020
90

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Eric M. GreenDirector, President and Chief Executive OfficerFebruary 21, 2020
Eric M. Green(Principal Executive Officer)
/s/ Bernard J. BirkettSenior Vice President and Chief Financial OfficerFebruary 21, 2020
Bernard J. Birkett(Principal Financial Officer and Principal Accounting Officer)
/s/ Mark A. ButhmanDirectorFebruary 18, 2020
Mark A. Buthman
/s/ William F. Feehery, Ph.D.DirectorFebruary 18, 2020
William F. Feehery, Ph.D.
/s/ Robert F. FrielDirectorFebruary 18, 2020
Robert F. Friel
/s/ Thomas W. HofmannDirectorFebruary 18, 2020
Thomas W. Hofmann
/s/ Paula A. Johnson, M.D., MPHDirectorFebruary 18, 2020
Paula A. Johnson, M.D., MPH
/s/ Deborah L.V. KellerDirectorFebruary 18, 2020
Deborah L.V. Keller
/s/ Myla P. Lai-Goldman, M.D.DirectorFebruary 18, 2020
Myla P. Lai-Goldman, M.D.
/s/ Douglas A. MichelsDirectorFebruary 18, 2020
Douglas A. Michels
/s/ Paolo PucciDirectorFebruary 18, 2020
Paolo Pucci
/s/ Patrick J. ZennerDirector and Chairman of the BoardFebruary 18, 2020
Patrick J. Zenner


91

EXHIBIT INDEX
Exhibit NumberDescription
3.1  
3.2  
4.1  
4.2  
4.3  
4.4  
4.5 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.1  
10.2  
10.3  
10.4 (2)
10.5 (2)
10.6 (2)
10.7 (2)
10.8 (2)
10.9 (2)
10.10 (2)
10.11 (2)
10.12 (2)
10.13 (2)
10.14 (2)
10.15 (2)
10.16 (2)
F-1

Exhibit NumberDescription
10.17 (2)
10.18 (2)
10.19 (2)
10.20 (2)
10.21 (2)
10.22 (2)
10.23 (2)
10.24 (2)
10.25 (2)
10.26  
10.27 (2)
10.28 (3)
10.29 (3)
10.30 (3)
10.31 (3)
10.32 (3)
10.33 (3)
10.34 (4)
10.35 (4)
21
23
31.1  
31.2  
F-2

Exhibit NumberDescription
32.1*  
32.2*  
101.INS  The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH  Inline XBRL Taxonomy Extension Schema Document
101.CAL  Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB  Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE  Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF  Inline XBRL Taxonomy Extension Definition Linkbase Document
104**  Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.

(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

(2) Management compensatory plan.

(3) Certain portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment order of the SEC.

(4) Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment.

* Furnished, not filed.
F-3
 EX-4.4 2 ex44descriptionofregis.htm EX-4.4 Document

Exhibit 4.4

WEST PHARMACEUTICAL SERVICES, INC.
DESCRIPTION OF SECURITIES

As of December 31, 2019, the common stock of West Pharmaceutical Services, Inc. (“West” or the “Company”) is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The summary of the general terms and provisions of the Company’s common stock set forth below does not purport to be complete and is subject to, and qualified by, reference to the Company’s Articles of Incorporation (as amended, the “Articles”) and Bylaws (as amended, the “Bylaws,” and together with the Articles, the “Charter Documents”), each of which is incorporated by reference as an exhibit to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission of which this Exhibit is a part. For additional information, please read the Company’s Charter Documents and the applicable provisions of the Pennsylvania Business Corporation Law of 1988 (as amended from time to time, the “PBCL”).

Description of Capital Stock

Authorized Capital Stock. The Company is authorized under the Articles to issue 103,000,000 shares, divided into 100,000,000 shares of common stock, par value $.25 per share, and 3,000,000 shares of preferred stock, par value $.25 per share. As of December 31, 2019, the Company had 74,085,095 shares of common stock outstanding and zero shares of preferred stock outstanding. The outstanding shares of the Company’s common stock are fully paid and nonassessable.

Voting Rights. Except as otherwise provided by law or any certificate creating any series of preferred stock, the holders of common stock have the exclusive voting power, and every holder of common stock is entitled to one vote for every share of common stock standing in the name of the shareholder on the Company’s books. Except as otherwise provided in the PBCL or the Charter Documents, whenever any corporate action is to be taken by vote of the shareholders of the Company (other than the election of directors), it shall be authorized by the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. Subject to the Charter Documents, the persons receiving a majority of the votes cast shall be elected as directors; provided, that in contested elections, directors shall be elected by a plurality of the votes of the shares represented in person or represented by proxy at such meeting and entitled to vote on the election of directors. The Board of Directors of the Company (the “Board”) shall have the full authority permitted by law to determine the voting rights, if any, and designations, preferences, limitations, and special rights of any class or any series of any class of preferred stock that may be desired to the extent not determined by the Charter Documents.

Holders of common stock do not have cumulative voting rights in the election of directors, except upon:

•the public announcement by West or a shareholder that such shareholder has become a 40% Shareholder (as described below), and

•such 40% Shareholder engages, directly or indirectly, in a proxy solicitation or participates in an election contest, seeks to advise or influence any person with respect to voting shares of the Company, or executes a written consent in lieu of a shareholder meeting of the Company.

A “40% Shareholder” means any person who, together with affiliates and associates, beneficially owns 40% or more of the voting stock of the Company, other than the Company or its wholly-owned subsidiaries or employee benefit plans.

Dividend Rights. Holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board, in its discretion, out of funds legally available therefor, subject to any preferential dividend rights of outstanding preferred stock.



Liquidation Rights. In the event of a liquidation, dissolution or winding up of the Company, the holders of the Company’s common stock are entitled to share ratably in all assets remaining after the payment of all of the Company’s liabilities and after all amounts to which holders of any outstanding preferred stock are entitled have been paid or set aside for payment.

Other Rights and Preferences. The Company’s common stock does not carry preemptive rights, is not redeemable, does not have any conversion rights, is not subject to further calls and is not subject to any sinking fund provisions. The rights and preferences of holders of the Company’s common stock are subject to the rights of any series of preferred stock that the Company may issue.

Listing. The Company’s common stock is listed on The New York Stock Exchange under the trading symbol “WST”.

Certain Anti-Takeover Provisions

Vote Required for Certain Significant Transactions. The Articles require that, in addition to any vote required by law or the Articles, the affirmative vote of the holders of at least 80% of the voting power of then outstanding shares of voting stock, voting as a single class, is required for any of the following transactions (each, a “Significant Transaction”):

•any merger or consolidation of the Company or any of its subsidiaries with any Related Person (as defined below) or any other corporation which is or would be an affiliate of a Related Person;

•any sale, lease or other disposition to or with any Related Person or any of its affiliates of any assets of the Company or any of its subsidiaries having a fair market value of $1.0 million or more;

•the issuance or transfer by the Company or any of its subsidiaries of any of their securities to any Related Person or any of its affiliates in exchange for cash, securities or other property having a fair market value of $1.0 million or more;

•the purchase by the Company or any of its subsidiaries of any shares of voting stock of the Company in exchange for cash, securities or other property having a fair market value of $1.0 million or more;

•the adoption of a plan or proposal for the liquidation or dissolution of the Company proposed by or on behalf of a Related Person or any of its affiliates; or

•any reclassification of securities or recapitalization of the Company, or any merger or consolidation of the Company with any of its subsidiaries or any other transaction which has the effect, directly or indirectly, or increasing the proportionate share of the outstanding shares of any class of equity or convertible securities of the Company or any of its subsidiaries which is directly or indirectly owned by any Related Person or any of its affiliates.

The higher vote requirement described above does not apply to a Significant Transaction if it is approved by a majority of Continuing Directors (as defined below) and certain fair price provisions and other requirements set forth in Article 6 of the Articles are satisfied.

“Related Person” means any person (other than the Company or any its subsidiaries) who (i) beneficially owns more than 10% of the voting power of outstanding voting stock or (ii) is an affiliate of the Company and at any time during the preceding two years beneficially owned 10% or more of such voting power, or (iii) is an assignee or has otherwise succeeded to any shares of voting stock which were at any time during the preceding two years beneficially owned by any Related Person, if such assignment or succession occurred in the course of a transaction not involving a public offering.

“Continuing Director” means any member of the Board who (i) was a member as of May 5, 1983, or (ii) is not affiliated with a Related Person and was a member of the Board prior to the time the Related Person became a


Related Person, or (iii) is a successor of a Continuing Director who is unaffiliated with the Related Person and is recommended to succeed a Continuing Director by a majority of the Continuing Directors.

Evaluation of Certain Proposals by the Board. The Articles provide that the Board, when evaluating a proposal from another party to acquire the Company or engage in a similar transaction, shall give due consideration to the following when exercising its judgment in determining what is in the best interests of the Company and its shareholders:

•the character, integrity, business philosophy and financial status of the other party or parties to the transaction;

•the consideration to be received by the Company or its shareholders in connection with such transaction, as compared to: (i) the current market price or value of the Company’s properties or securities; (ii) the estimated future value of the Company, its properties or securities; and (iii) such other measures of the value of the Company, its properties or securities as the directors may deem appropriate.

•the projected social, legal and economic effects of the proposed action or transaction upon the Company, its employees, suppliers and customers and the communities in which the Company does business;

•the general desirability of the Company’s continuing as an independent entity; and

•such other factors as the Board may deem relevant.

Potential Issuances of the Company’s Preferred Stock. Although the Company does not currently have any shares of preferred stock outstanding, it is authorized under the Articles to issue 3,000,000 shares of preferred stock, and the rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock that the Company may designate and issue in the future. The Articles also authorize the Board to establish, from the authorized but unissued shares, one or more series of the shares of preferred stock and to determine, with respect to any such series of the Company’s preferred shares, the terms and rights of such series, including, for example, the designation, the number of shares, the dividend rate of the shares, the right, if any, of the Company to redeem shares, the voting power, if any, the obligation, if any, of the Company to retire shares, the terms and conditions, if any, upon which shares shall be convertible into or exchangeable for shares of stock of any other class or classes, and any other rights, preferences or limitations of the shares of such series.

The Board has authorized the issuance of 50,000 shares of preferred stock as Series A junior participating preferred stock in connection with its adoption of a shareholder rights plan that has expired. No shares of the Series A preferred stock are outstanding, and the Company does not intend to issue any of these shares.

The authorized shares of the Company, including shares of preferred stock and common stock, will be available for issuance without further action by the Company’s shareholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which the Company’s securities may be listed or traded.

Provisions for Shareholder Nominations and Shareholder Proposals at Annual Meetings. The Company’s Bylaws establish an advance notice procedure for shareholders to nominate candidates for election as directors or to bring other business before annual meetings of the Company’s shareholders (the “Shareholder Notice Procedure”). The Shareholder Notice Procedure requires that written notice of nominations or proposals for substantive business must be delivered to the Company not less than 90 days prior to the first anniversary of the date of the prior year’s annual meeting of shareholders; provided, that if less than 21 days’ notice or prior public disclosure of the meeting date is given, the notice must be delivered not later than the earlier of (1) the 7th day after notice of the meeting date was mailed or disclosed, or (2) the 4th day prior to the meeting. The nomination must contain information about the nominees as specified in the Bylaws. The notice must include information specified in the Bylaws, including, among other things, information concerning the nominee or proposal, as the case may be, and information about the shareholder's ownership of and agreements related to shares of the Company’s common stock.



A shareholder who wishes to recommend a candidate to be considered by the Nominating and Corporate Governance Committee of the Board for nomination as a Director must deliver the recommendation in writing to the Secretary of the Company following the Shareholder Notice Procedure described above and include the information set forth in the Bylaws. The Nominating and Corporate Governance Committee will consider all recommended candidates when making its recommendation to the full Board to nominate a slate of Directors for election.

Provisions Relating to the Election of the Company’s Board of Directors. Under the Articles, shareholders are entitled to only one vote for each share held in all elections for directors. Directors are elected by a majority of votes cast, except in the case of contested elections, as described above. Holders of common stock do not have cumulative voting rights in the election of directors, except upon certain circumstances described above.

Director Vacancies. Under the Articles, vacancies in the Board of Directors, including vacancies resulting from an increase in the number of Directors, shall be filled only by a majority vote of the remaining members of the Board though less than a quorum, and each person so selected shall be a Director to serve until the next annual meeting of shareholders, and until a successor has been duly elected and qualified.

Amendment to Articles. Any amendment to the articles requires the affirmative vote of a majority of the votes cast by all shareholders entitled to vote thereon and, if any class or series of shares is entitled to vote thereon as a class, the affirmative vote of a majority of the votes cast in each such class vote, except for amendments on matters specified in Section 1914(c) of the PBCL that do not require shareholder approval; provided that alteration, amendment supplementing or repeal of the following provisions of the Articles requires the affirmative vote of the holders of at least 80% of the outstanding shares of capital stock entitled to vote generally in the election of directors, considered as one class:

•Article 6, which relates to the vote required for certain significant transactions, as described in “Vote Required for Certain Significant Transactions” above

•Article 7, which relates to the evaluation of certain proposals by the Board, as described in “Evaluation of Certain Proposals by the Board” above

•Article 8, which relates the Board, including vacancies and cumulative voting in certain circumstances

•Article 10, which relates to the vote required to amend the Articles

Amendment to Bylaws. Except as restricted by applicable law, authority to adopt, amend and repeal the Bylaws is expressly vested in the Board, subject to the power of the shareholders to change such action.

Special Meeting of Company Shareholders. The Charter Documents do not contain a provision permitting shareholders to call a special meeting.

Shareholder Action by Written Consent. The Charter Documents do not contain a provision permitting action by written consent of the shareholders.

Pennsylvania Anti-Takeover Statutes. Under Section 1715 of the PBCL, directors stand in a fiduciary relation to their corporation. In discharging their duties, directors may, in considering the best interests of their corporation, consider various constituencies, including, shareholders, employees, suppliers, customers and creditors of the corporation, and upon communities in which offices or other establishments of the corporation are located. Absent a breach of fiduciary duty, a lack of good faith or self-dealing, any act of the Board of Directors, a committee thereof or an individual director is presumed to be in the best interests of the corporation. The PBCL expressly provides that the fiduciary duty of directors does not require them to (i) redeem or otherwise render inapplicable outstanding rights issued under any shareholder rights plan; (ii) render inapplicable certain of the anti-takeover statutes set forth in Chapter 25 of the PBCL described below; or (iii) take any action solely because of the effect it may have on a proposed acquisition or the consideration to be received by shareholders in such a transaction.



Chapter 25 of the PBCL contains several anti-takeover statutes applicable to publicly-traded corporations. Corporations may opt-out of such anti-takeover statutes under certain circumstances. The Company has not opted-out of any of the following statutes.

Section 2538 of Subchapter 25D of the PBCL requires certain transactions with an “interested shareholder” to be approved by a majority of disinterested shareholders. “Interested shareholder” is defined broadly to include any shareholder who is a party to the transaction or who is treated differently than other shareholders and affiliates of the corporation.

Subchapter 25E of the PBCL requires a person or group of persons acting in concert which acquires 20% or more of the voting shares of the corporation to offer to purchase the shares of any other shareholder at “fair value.” “Fair value” means the value not less than the highest price paid by the controlling person or group during the 90-day period prior to the control transaction, plus a control premium. Among other exceptions, Subchapter 25E does not apply to shares acquired directly from the corporation in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended.

Subchapter 25F of the PBCL applies to a transaction with an interested shareholder (defined generally to be any beneficial owner of 20% or more of the corporation’s voting stock). Subchapter F prohibits such a corporation from engaging in a “business combination” (as defined in the PBCL) with an interested shareholder unless (i) the board of directors of such corporation gives approval to the proposed transaction or gives approval to the interested shareholder’s acquisition of 20% of the shares entitled to vote in an election of directors of such corporation, in either case prior to the date on which the shareholder first becomes an interested shareholder (the “Share Acquisition Date”); (ii) the interested shareholder owns at least 80% of the stock of such corporation entitled to vote in an election of directors of such corporation, and no earlier than three months after such interested shareholder reaches such 80% level, the majority of the remaining shareholders approve the proposed transaction, shareholders receive a minimum “fair price” for their shares (as set forth in the PBCL) in the transaction and the other conditions of Subchapter F are met; (iii) holders of all outstanding shares of common stock of the corporation approve the transaction; (iv) no earlier than five years after the Share Acquisition Date, a majority of the holders of the remaining shares entitled to vote in an election of directors approve the transaction; or (v) no earlier than five years after the Share Acquisition Date, a majority of all holders of the shares of the corporation approve the transaction, all shareholders receive a minimum “fair price” for their shares (as set forth in the PBCL) and the other conditions of Subchapter F are met.

Subchapter 25G of the PBCL provides that “control shares” lose voting rights unless such rights are restored by the affirmative vote of a majority of (i) the disinterested shares (generally, shares held by persons other than the acquirer, executive officers of the corporation and certain employee stock plans) and (ii) the outstanding voting shares of the corporation. “Control shares” are defined as shares which, upon acquisition, will result in a person or group acquiring for the first time voting control of (a) at least 20%, (b) at least 33-1/3% or (c) 50% or more of the outstanding shares, together with shares acquired within 180 days of attaining the applicable threshold and shares purchased with the intention of attaining such threshold. A corporation may redeem control shares if the acquiring person does not request restoration of voting rights as permitted by Subchapter 25G. Among other exceptions, Subchapter 25G does not apply to a merger, consolidation or a share exchange if the corporation is a party to the transaction agreement.

Subchapter 25I of the PBCL mandates severance compensation for eligible employees who are terminated within 24 months after the approval of a control share acquisition. Eligible employees generally are all employees employed in Pennsylvania for at least two years prior to the control share approval. Severance equals the weekly compensation of the employee multiplied by the employee's years of service (up to 26 years), less payments made due to the termination.

Subchapter 25J of the PBCL requires the continuation of certain labor contracts relating to business operations owned at the time of a control share approval.

The Company has opted out of Subchapter 25H of the PBCL, which relates to disgorgement by certain controlling shareholders following attempts to acquire control.

 EX-10.2 3 ex102firstamendmentand.htm EX-10.2 Document

Exhibit 10.2


FIRST AMENDMENT AND INCREMENTAL FACILITY AMENDMENT

THIS FIRST AMENDMENT AND INCREMENTAL FACILITY AMENDMENT (this “Agreement”) is entered into as of December 30, 2019 (the “Incremental Term Loan Effective Date”) among WEST PHARMACEUTICAL SERVICES, INC., a Pennsylvania corporation (the “Company” or “Borrowers’ Representative”), each of the Lenders party hereto (including each Incremental Lender), and Bank of America, N.A., as Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement (as defined below) or in the Amended Credit Agreement (as defined below), as the case may be.

W I T N E S S E T H

WHEREAS, pursuant to that certain Credit Agreement, dated as of March 28, 2019 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among the Company, certain subsidiaries of the Company party thereto (together with the Company, the “Borrowers” and each a “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and an Issuing Lender, the Lenders have agreed to provide the Borrowers with the credit facilities provided for therein;

WHEREAS, the Company has requested pursuant to Section 2.14(d) of the Credit Agreement that each Lender party hereto with a commitment in respect of the Incremental Term Facility (each, an “Incremental Lender”) provide a portion of an Incremental Term Facility to the Company under the Credit Agreement;

WHEREAS, the Borrowers’ Representative, in such capacity, has requested that the Lenders make certain amendments to the Credit Agreement; and

WHEREAS, each Incremental Lender has agreed to provide a portion of an Incremental Term Facility to the Company and the Required Lenders have agreed to amend the Credit Agreement as provided herein with such amendments not constituting a novation of the Credit Agreement (the Credit Agreement, as amended hereby, the “Amended Credit Agreement”).

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.Establishment of Incremental Term Facility.

(a) Subject to the terms and conditions set forth herein, a new term loan in the original principal amount of $90,000,000 (the “Incremental Term A Loan”) is hereby established as an Incremental Term Facility pursuant to Section 2.14(d) of the Credit Agreement.

(b) Subject to the terms and conditions set forth herein, each Incremental Lender severally agrees to make its portion of the Incremental Term A Loan in a single advance in Dollars to the Company on the Incremental Term Loan Effective Date in an amount not to exceed such Incremental Lender’s Incremental Term A Loan Commitment to such Incremental Term Facility; provided, that, after giving effect to such advances, the outstanding amount of the Incremental Term A Loan shall not exceed the aggregate amount of Incremental Term A Loan Commitments of the Incremental Lenders. The Incremental Term A Loan Commitments of each Incremental Lender and the Commitment Percentage of each Incremental Lender’s portion of such Incremental Term Facility, in each case as of the Incremental Term Loan Effective Date, shall be as set forth on Schedule 1.01 attached hereto. The Incremental Term A Loan may from time to time be (i) LIBOR Loans, (ii) Base Rate Loans or (iii) a combination thereof, as determined by the Company and notified to the Administrative Agent in accordance with Sections 2.04 and 2.05 of the Credit Agreement.



(c) The Incremental Term A Loan shall be subject to mandatory prepayment as set forth in Section 2.15(g) of the Credit Agreement.

2. Amendments to Credit Agreement.

(a) The reference to “MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED” on the cover page of the Credit Agreement is hereby amended to read as “BOFA SECURITIES, INC.”.

(b) Each reference to “MLPFS” in the Credit Agreement is hereby amended to read as “BofA Securities”.

(c) The following new definitions are hereby added to Section 1.01 of the Credit Agreement in the appropriate alphabetical order to read as follows:

“BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.

“BofA Securities” means BofA Securities, Inc. (as successor to Merrill Lynch, Pierce, Fenner & Smith Incorporated), in its capacity as a joint lead arranger and joint bookrunner.

“Covered Entity” means any of the following: (a) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (b) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (c) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Covered Party” has the meaning provided in Section 9.21.

“Default Right” means as defined in, and interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“First Amendment” means that certain First Amendment and Incremental Facility Amendment, dated as of the First Amendment Effective Date, by and among the Borrowers’ Representative, the Lenders party thereto and the Administrative Agent.

“First Amendment Effective Date” means December 30, 2019.

“Incremental Term A Loan” means the term loan made to the Company pursuant to the First Amendment.

“Incremental Term A Loan Commitment” means, as to each Lender providing the Incremental Term A Loan, its obligation to make its portion of the Incremental Term A Loan to the Company pursuant to the First Amendment in the principal amount set forth opposite such Lender’s name on Schedule 1.01. The aggregate principal amount of the Incremental Term A Loan Commitment of all of the Lenders in effect on the First Amendment Effective Date is NINETY MILLION DOLLARS ($90,000,000).

“Incremental Term Loan Commitments” means the Incremental Term A Loan Commitment and any other obligation of a Lender to make its portion of a term loan to a Borrower pursuant to an Incremental Term Facility.

“Incremental Term Loans” means any term loans which have been incurred pursuant to Section 2.14(d) under a then existing or additional Incremental Term Facility, including the Incremental Term A Loan.

“Net Cash Proceeds” has the meaning provided in Section 2.15(g).



“Permitted Transfers” means (a) sales or dispositions of assets permitted by Section 6.04(a) - (i); (b) licenses, sublicenses, leases or subleases granted to others not interfering in any material respect with the business of the Borrowers and their Subsidiaries; and (c) the sale or disposition of Cash Equivalents for fair market value.

“QFC” means a “qualified financial contract” (as defined in, and interpreted in accordance with, 12 U.S.C. § 5390(c)(8)(D)).

“QFC Credit Support” has the meaning provided in Section 9.21.

“Relevant Governmental Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York for the purpose of recommending a benchmark rate to replace LIBOR in loan agreements similar to this Agreement.

“SOFR” with respect to any day means the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark (or a successor administrator) on the Federal Reserve Bank of New York’s website (or any successor source) and, in each case, that has been selected or recommended by the Relevant Governmental Body.

“SOFR-Based Rate” means SOFR or Term SOFR.

“Supported QFC” has the meaning provided in Section 9.21.

“Term SOFR” means the forward-looking term rate for any period that is approximately (as determined by the Administrative Agent) as long as any of the Interest Period options set forth in the definition of “Interest Period” and that is based on SOFR and that has been selected or recommended by the Relevant Governmental Body, in each case as published on an information service as selected by the Administrative Agent from time to time in its reasonable discretion.

“U.S. Special Resolution Regimes” has the meaning provided in Section 9.21.

(d) The definition of “Commitment Percentage” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:

“Commitment Percentage” means with respect to any Lender at any time, (a) with respect to such Lender’s Revolving Credit Commitment, the percentage (carried out to the ninth decimal place) of the Commitments represented by such Lender’s Revolving Credit Commitment at such time; provided, that, if the commitment of each Lender to make Revolver Loans and the obligation of each Issuing Lender to make L/C Credit Extensions have been terminated pursuant to Section 7.01 or if the Commitments have expired, then the Commitment Percentage of each Lender shall be determined based on the Commitment Percentage of such Lender most recently in effect, giving effect to any subsequent assignments and to any Lender’s status as a Defaulting Lender at the time of determination and (b) with respect to such Lender’s portion of any outstanding Incremental Term Loan, the percentage (carried out to the ninth decimal place) of the outstanding principal amount of such Incremental Term Loan held by such Lender at such time. The initial Commitment Percentage of each Lender is set forth opposite the name of such Lender on Schedule 1.01, or in the Assignment and Assumption, any documentation executed by such Lender pursuant to Section 2.14(d), or other documentation pursuant to which such Lender becomes a party hereto, as applicable. The Commitment Percentages shall be subject to adjustment as provided in Section 2.25.

(e) The definition of “LIBOR Successor Rate Conforming Changes” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:



“LIBOR Successor Rate Conforming Changes” means, with respect to any proposed LIBOR Successor Rate, any conforming changes to the definition of Base Rate, the definition of Interest Period, the timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters as may be appropriate, in the discretion of the Administrative Agent, to reflect the adoption and implementation of such LIBOR Successor Rate and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent determines that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such LIBOR Successor Rate exists, in such other manner of administration as the Administrative Agent determines is reasonably necessary in connection with the administration of this Agreement).

(f) The definition of “Loans” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:

“Loans” means an extension of credit by a Lender to a Borrower in the form of a Revolver Loan, a Swing Line Loan or an Incremental Term Loan, as the context may require.

(g) The definition of “MLPFS” in Section 1.01 of the Credit Agreement is hereby deleted.

(h) The definition of “Required Lenders” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:

“Required Lenders” means, at any time, those non-Defaulting Lenders holding more than 50% of the unused Commitments, Total Exposure, outstanding amount of Incremental Term Loans, and unfunded Incremental Term Loan Commitments of such non-Defaulting Lenders; provided, that, the amount of any participation in any Swing Line Loan or Letter of Credit that a Defaulting Lender has failed to fund that has not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the Swing Line Lender or the applicable Issuing Lender, as the case may be, in making such determination.

(i) The definition of “Termination Date” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:

“Termination Date” means, (a) with respect to the Revolver Loans, Letters of Credit, and Swing Line Loans, subject to Section 2.26, the earlier of (i) March 28, 2024 and (ii) the date the Commitments are terminated as provided herein; and (b) with respect to the Incremental Term A Loan, December 31, 2024.

(j) The definition of “Tranche” in Section 1.01 of the Credit Agreement is hereby amended to read as follows:

“Tranche” means specified portions of Loans outstanding as follows: (a) any Loans to which a LIBOR Rate applies which become subject to the same LIBOR Rate under the same Notice of Borrowing and which have the same Interest Period, which are denominated either in Dollars or, in the case of Revolver Loans, in the same Optional Currency, shall constitute one Tranche, (b) all Revolver Loans to which the Base Rate applies shall constitute one Tranche and (c) all Incremental Term Loans to which the Base Rate applies shall constitute one Tranche.

(k) The instances of “Revolver Loans” in Section 2.02 of the Credit Agreement are hereby replaced with “Loans”.

(l) The instances of “Revolver Loans” in Section 2.04 of the Credit Agreement (including the title thereof) are hereby replaced with “Loans”.



(m) The following clause (d) is hereby added to the end of Section 2.04 of the Credit Agreement to read as follows:

(d) This Section 2.04 shall not apply to Swing Line Loans.

(n) Section 2.09(g) of the Credit Agreement shall be amended to read as follows:

(g) Subject to the provisions of this Agreement, the Borrowers may select different interest rates and different Interest Periods to apply simultaneously to Loans comprising different Tranches and may convert to or renew one or more interest rates with respect to all or any portion of Loans comprising any Tranche, provided, that, there shall not be at any one time outstanding more than (i) six (6) Tranches in the aggregate with respect to Revolver Loans (excluding Swing Line Loans and with Base Rate Loans being considered, to the extent any such Loans are outstanding, one Tranche) and (ii) six (6) Tranches in the aggregate with respect to the Incremental Term Loans.

(o) Section 2.13(c) of the Credit Agreement is hereby amended to read as follows:

(c) Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Company or Required Lenders notify the Administrative Agent (with, in the case of the Required Lenders, a copy to the Company) that the Company or Required Lenders (as applicable) have determined, that:

(i) adequate and reasonable means do not exist for ascertaining LIBOR for the applicable currency for any requested Interest Period, including, without limitation, because the LIBOR Screen Rate is not available or published on a current basis and such circumstances are unlikely to be temporary;

(ii) the administrator of the LIBOR Screen Rate for the applicable currency or a Governmental Authority having or purporting to have jurisdiction over the Administrative Agent has made a public statement identifying a specific date after which LIBOR for the applicable currency or the LIBOR Screen Rate for the applicable currency shall no longer be made available, or used for determining the interest rate of loans, provided, that, at the time of such statement, there is no successor administrator that is satisfactory to the Administrative Agent, that will continue to provide LIBOR for the applicable currency after such specific date (such specific date, the “Scheduled Unavailability Date”), or

(iii) syndicated loans currently being executed, or that include language similar to that contained in this Section, are being executed or amended (as applicable) to incorporate or adopt a new benchmark interest rate to replace LIBOR for the applicable currency,

then, reasonably promptly after such determination by the Administrative Agent or receipt by the Administrative Agent of such notice, as applicable, the Administrative Agent and the Company may amend this Agreement to replace LIBOR for the applicable currency with (x) for Dollars only, one or more SOFR-Based Rates or (y) another alternate benchmark rate, giving due consideration to any evolving or then existing convention for similar syndicated credit facilities denominated in the applicable currency for such alternative benchmarks and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar syndicated credit facilities for such benchmarks, which adjustment or method for calculating such adjustment shall be published on an information service as selected by the Administrative Agent from time to time in its reasonable discretion and may be periodically updated (the “Adjustment;” and any such proposed rate, a “LIBOR Successor Rate”), and any such amendment shall become effective at 5:00 p.m. on


the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Lenders and the Company unless, prior to such time, Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders (A) in the case of an amendment to replace LIBOR for Dollars with a rate described in clause (x), object to the Adjustment; or (B) in the case of an amendment to replace LIBOR for the applicable currency with a rate described in clause (y), object to such amendment; provided, that, for the avoidance of doubt, in the case of clause (A), the Required Lenders shall not be entitled to object to any SOFR-Based Rate contained in any such amendment. Such LIBOR Successor Rate shall be applied in a manner consistent with market practice; provided, that, to the extent such market practice is not administratively feasible for the Administrative Agent, such LIBOR Successor Rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent.

If no LIBOR Successor Rate has been determined and the circumstances under clause (i) above exist or the Scheduled Unavailability Date has occurred (as applicable), the Administrative Agent will promptly so notify the Company and each Lender. Thereafter, (x) the obligation of the Lenders to make or maintain LIBOR Loans shall be suspended (to the extent of the affected LIBOR Loans or Interest Periods), and (y) if the applicable currency is Dollars, then the LIBOR Rate component shall no longer be utilized in determining the Base Rate. Upon receipt of such notice, the applicable Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of LIBOR Loans denominated in the applicable currency (to the extent of the affected LIBOR Loans or Interest Periods) or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Loans (subject to the foregoing clause (y)) in the amount specified therein.

Notwithstanding anything else herein, any definition of LIBOR Successor Rate shall provide that in no event shall such LIBOR Successor Rate be less than zero for purposes of this Agreement.

In connection with the implementation of a LIBOR Successor Rate, the Administrative Agent will have the right to make LIBOR Successor Rate Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such LIBOR Successor Rate Conforming Changes will become effective without any further action or consent of any other party to this Agreement.

(p) Section 2.14(a) of the Credit Agreement is hereby amended to read as follows:

(a) (i) The Revolving Credit Commitments and the Swing Line Commitment shall be automatically terminated on the Termination Date whereupon all Revolver Loans and Swing Line Loans and accrued interest thereon shall become due and payable, except as provided in Section 2.26 in respect of any Extended Revolving Credit Commitments.

(ii) The Company shall repay the outstanding principal amount of the Incremental Term A Loan in installments on the dates and in the amounts set forth in the table below (as such installments may hereafter be adjusted as a result of prepayments made pursuant to Section 2.15), unless accelerated sooner pursuant to Section 7.01:



Payment Dates (the last Business Day of the fiscal quarter of the Company ending)Principal Amortization Payment
March 31, 2020$562,500
June 30, 2020$562,500
September 30, 2020$562,500
December 31, 2020$562,500
March 31, 2021$562,500
June 30, 2021$562,500
September 30, 2021$562,500
December 31, 2021$562,500
March 31, 2022$562,500
June 30, 2022$562,500
September 30, 2022$562,500
December 31, 2022$562,500
March 31, 2023$562,500
June 30, 2023$562,500
September 30, 2023$562,500
December 31, 2023$562,500
March 31, 2024$562,500
June 30, 2024$562,500
September 30, 2024$562,500
Termination DateUnpaid principal balance of the Incremental Term A Loan.

(q) Clause (i) of Section 2.14(d) of the Credit Agreement is hereby amended to read as follows:

(i) the aggregate amount of all Incremental Facilities effected after the First Amendment Effective Date pursuant to this Section 2.14(d) shall not exceed the greater of (A) $350,000,000 and (B) EBITDA for the most recent period for which financial statements have theretofore been delivered to the Lenders pursuant to Section 5.01;

(r) Section 2.15(a) of the Credit Agreement is hereby amended to read as follows:

(a) The Borrowers shall have the right at any time and from time to time to prepay Loans in the currency or currencies in which such Loans were made, in whole or in part, without premium or penalty (but in any event subject to Section 2.18), upon delivery of a Notice of Loan Prepayment to the Administrative Agent given, in the case of Base Rate Loans denominated in Dollars, no later than 11:00 a.m. on the day of any proposed prepayment, in the case of LIBOR Loans denominated in Dollars, no later than 11:00 a.m. three (3) Business Days before any proposed prepayment, and in the case of Optional Currency Loans, no later than 11:00 a.m. four (4) Business Days before any such proposed prepayment (or such shorter period as the Administrative Agent shall agree in its discretion). In each case the notice shall specify (i) the date, amount and currency of each such prepayment, (ii) whether the prepayment is of Revolver Loans or Incremental Term Loans (and, if applicable, the specific Tranche(s) of Incremental Term Loans to be prepaid), and (iii) whether the prepayment is of LIBOR Loans or Base Rate Loans, or


a combination thereof, and, if a combination thereof, the amount allocable to each; provided, however, that, each such partial prepayment shall be in the principal amount of at least (x) with respect to prepayments of Base Rate Loans, $1,000,000 or in whole multiples of $100,000 in excess thereof, and (y) with respect to prepayments of Revolver Loans in Dollars that bear interest at the LIBOR Rate, $3,000,000 or in whole multiples of $100,000 in excess thereof, (z) with respect to prepayment of Revolver Loans in an Optional Currency, the Dollar Equivalent of $3,000,000 or in whole multiples of the Dollar Equivalent of $100,000 in excess thereof (or, with respect to Revolver Loans in an Optional Currency, such other minimum and increments as the Administrative Agent and the Borrowers shall agree). Any prepayment of an Incremental Term Loan shall be applied to the remaining principal amortization payments of such Incremental Term Loan in inverse order of maturity.

(s) Section 2.15(f) of the Credit Agreement is hereby amended to read as follows:

(f) Prepayments of Revolver Loans pursuant to this Section (other than subsection (b) hereof) may be reborrowed, subject to the terms and conditions hereof.

(t) A new clause (g) is hereby added to Section 2.15 of the Credit Agreement to read as follows:

(g) (i) The Company shall prepay Incremental Term Loans as hereinafter provided in an aggregate amount equal to 100% of the aggregate cash or Cash Equivalents proceeds (including any cash or Cash Equivalents received upon the sale or other disposition of any non‑cash consideration received by any Domestic Borrower or Domestic Subsidiary in connection therewith) net of (A) direct costs incurred in connection therewith (including, without limitation, legal, accounting and investment banking fees and sales commissions), (B) taxes paid or payable as a result thereof, (C) the amount necessary to retire any Indebtedness secured by a Permitted Lien (ranking senior to any Lien of the Administrative Agent) on the related property and (D) the amount of any prepayment required to be made to comply with the terms of Section 10.3 of the Note Purchase Agreement as in effect on the First Amendment Effective Date (“Net Cash Proceeds”), received by any Domestic Borrower or Domestic Subsidiary in respect of any asset sale, disposition or involuntary disposition (other than a Permitted Transfer) within three hundred sixty (360) days of the date of such disposition; provided, however, that so long as no Default shall have occurred and be continuing, such Net Cash Proceeds shall not be required to be so applied at the election of the Company (as notified by the Company to the Administrative Agent) to the extent the Company or such Domestic Borrower or Domestic Subsidiary reinvests all or any portion of such Net Cash Proceeds in operating assets (but specifically excluding current assets as classified by GAAP) within three hundred sixty (360) days after the receipt of such Net Cash Proceeds; provided that, if such Net Cash Proceeds shall have not been so reinvested, such Net Cash Proceeds shall be immediately applied to prepay Incremental Term Loans.

(ii) Immediately upon the receipt by any Domestic Borrower of Net Cash Proceeds received from the issuance by any Domestic Borrower of any Indebtedness (other than Indebtedness permitted hereunder), such Domestic Borrower shall prepay Incremental Term Loans as hereinafter provided in an aggregate amount equal to 100% of such Net Cash Proceeds.

(iii) Each prepayment of Incremental Term Loans pursuant to this clause (g) shall be applied to the principal repayment installments of outstanding Incremental Term Loans in inverse order of maturity. Subject to Section 2.25, such prepayments shall be paid to the Incremental Lenders in accordance with their respective percentage (carried out to the ninth decimal place) of the outstanding principal amount of Incremental Term Loans at such time.

(u) The instance of “Term Loans” in Section 9.06(b)(ii) is hereby replaced with “Incremental Term Loan”.



(v) Section 9.19 of the Credit Agreement is hereby amended to read as follows:

9.19 Joint and Several Liability of Borrowers. Notwithstanding anything to the contrary in this Agreement (other than Section 2.22), all Obligations shall be joint and several, subject to the limitations set forth in Section 2.22.

(w) A new Section 9.21 is hereby added to the Credit Agreement to read as follows:

9.21cknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for any interest rate cap agreement, interest rate swap agreement, foreign currency exchange agreement, netting agreement, hedging agreement or any other agreement or instrument that is a QFC (such support, “QFC Credit Support”, and each such QFC, a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States): In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.

(x) Schedule 1.01 to the Credit Agreement is hereby amended to read as Schedule 1.01 attached hereto.

(y) Exhibit C to the Credit Agreement is hereby amended to read as Exhibit C attached hereto.

(z) Exhibit I to the Credit Agreement is hereby amended to read as Exhibit I attached hereto.

3. Conditions Precedent. This Agreement shall be effective on the Incremental Term Loan Effective Date upon:

(a) receipt by the Administrative Agent of executed counterparts of this Agreement duly executed by the Borrowers’ Representative, the Required Lenders, each Incremental Lender, and the Administrative Agent;



(b) receipt by the Administrative Agent of satisfactory opinions of legal counsel to the Company (as requested by the Administrative Agent), addressed to the Administrative Agent and the Lenders, dated as of the Incremental Term Loan Effective Date;

(c) receipt by the Administrative Agent of (i) copies of the Organization Documents of each Domestic Borrower certified to be true and complete as of a recent date by the appropriate Governmental Authority of the state or other jurisdiction of its incorporation or organization, where applicable (or, as to any such Organization Documents that have not been amended, modified or terminated since the Closing Date, a certification that such Organization Documents have not been amended, modified or terminated since the Closing Date and remain in full force and effect, and remain true and complete, in the form delivered to the Administrative Agent on the Closing Date), and certified by a secretary, assistant secretary or other Responsible Officer of such Domestic Borrower to be true and correct as of the Incremental Term Loan Effective Date, (ii) such certificates of resolutions or other action, incumbency certificates (including specimen signatures) and/or other certificates of Responsible Officers of each Domestic Borrower as the Administrative Agent may reasonably require evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the other Loan Documents to which such Domestic Borrower is a party, and (iii) such documents and certifications as the Administrative Agent may reasonably require to evidence that each Domestic Borrower is duly organized or formed, and is validly existing, in good standing and qualified to engage in business in its state of organization or formation;

(d) receipt by the Administrative Agent with respect to the Incremental Term A Loan of (i) a Notice of Borrowing and (ii) funds disbursement instructions;

(e)  receipt by the Administrative Agent of certificate dated as of the Incremental Term Loan Effective Date and executed by a Responsible Officer of the Borrowers’ Representative certifying that after giving effect to the incurrence of the Incremental Term A Loan, on a pro forma basis, the Borrowers are in compliance with the financial covenant set forth in Section 6.01 of the Credit Agreement for the most recently completed four fiscal quarter period for which financial statements have been delivered to the Lenders pursuant to Section 5.01 of the Credit Agreement;

(f) (i) receipt by the Lenders and the Administrative Agent of all documentation and other information that the Administrative Agent or any Lender determines is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the PATRIOT Act, and that the Administrative Agent or any Lender has requested at least five (5) Business Days prior to the Incremental Term Loan Effective Date, and (ii) if any Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, receipt by the Administrative Agent and any Lender requesting the same of a Beneficial Ownership Certification with respect to such Borrower to the extent requested by the Administrable Agent or such Lender at least five (5) Business Days prior to the Incremental Term Loan Effective Date; and

(g) receipt by the Administrative Agent and the Lenders of all fees required to be paid on or prior to the Incremental Term Loan Effective Date, and receipt by the Administrative Agent of all expenses (including the fees and expenses of counsel (including any local counsel) for the Administrative Agent).

4. Representations and Warranties of the Borrowers. The Borrowers’ Representative hereby represents and warrants to the Administrative Agent and each Lender that (a) the representations and warranties of each Borrower contained in Section 3 of the Credit Agreement or any other Loan Document are (i) with respect to representations and warranties that contain a materiality qualification or are qualified by Material Adverse Effect, true and correct and (ii) with respect to representations and warranties that do not contain a materiality qualification and are not qualified by Material Adverse Effect, true and correct in all material respects, except to the extent that such representations and warranties specifically refer to an earlier date, in which case such representations and warranties are (1) with respect to representations and warranties that contain a materiality qualification or are qualified by Material Adverse Effect, true and correct and (2) with respect to representations and warranties that do not contain a materiality qualification and are not qualified by Material Adverse Effect, true and correct in all


material respects, in each case, as of such earlier date; and (b) no Default or Event of Default exists, or will result from the extension of the extension of the Incremental Term A Loan.

5. Authority/Enforceability. The Borrowers’ Representative represents and warrants as follows:

(a) It has taken all necessary corporate or other action to authorize the execution, delivery and performance of this Agreement.

(b) This Agreement has been duly executed and delivered by the Borrowers’ Representative and constitutes legal, valid and binding obligations, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

(c) No consent or authorization of, filing with or other act by or in respect of, any Governmental Authority or any other Person (including stockholders and creditors of the Borrowers) is required in connection with the execution, delivery, performance, validity or enforceability of this Agreement, except to the extent that such consent or authorization has been obtained or such filing or action has been completed prior to the Incremental Term Loan Effective Date.

(d) The execution and delivery of this Agreement does not violate any Requirement of Law or material Contractual Obligation of any Borrower or any of its Subsidiaries.

6. Reaffirmation. The Amended Credit Agreement and the obligations of the Borrowers thereunder and under the other Loan Documents are hereby ratified and confirmed and shall remain in full force and effect according to their terms.

7. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. Delivery of executed counterparts of this Agreement by facsimile or other secure electronic format (.pdf) shall be effective as an original.

8. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

9. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

10. Headings. The headings of the sections hereof are provided for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement.

11. Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

[signature pages follow]


Each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.



BORROWERS’ REPRESENTATIVE:  WEST PHARMACEUTICAL SERVICES, INC.


By: ________________________________
Name:
Title:




ADMINISTRATIVE AGENT:   BANK OF AMERICA, N.A.,
as Administrative Agent


By: ________________________________
Name:
Title:




LENDERS:   BANK OF AMERICA, N.A., as a Lender, Swing Line Lender and an Issuing Lender


By: ________________________________
Name:
Title:




JPMORGAN CHASE BANK, N.A., as a Lender


By: ________________________________
Name:
Title:




MUFG BANK, LTD., as a Lender


By: ________________________________
Name:
Title:




WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender


By: ________________________________
Name:
Title:




HSBC BANK USA, NATIONAL ASSOCIATION, as a Lender


By: ________________________________
Name:
Title:




PNC BANK, NATIONAL ASSOCIATION, as a Lender and an Issuing Lender


By: ________________________________
Name:
Title:




U.S. BANK NATIONAL ASSOCIATION, as a Lender


By: ________________________________
Name:
Title:













Schedule 1.01
Lender and commitment Information

LenderRevolving Credit CommitmentCommitment Percentage of Revolving Credit CommitmentsIncremental Term A Loan CommitmentCommitment Percentage of Incremental Term A Loan Commitments
Bank of America, N.A.$75,000,000.0025.000000000%$22,500,000.0025.000000000%
JPMorgan Chase Bank, N.A.$45,000,000.0015.000000000%$13,500,000.0015.000000000%
MUFG Bank, Ltd.$45,000,000.0015.000000000%$13,500,000.0015.000000000%
Wells Fargo Bank, National Association$45,000,000.0015.000000000%$13,500,000.0015.000000000%
HSBC Bank USA, National Association$30,000,000.0010.000000000%$9,000,000.0010.000000000%
PNC Bank, National Association$30,000,000.0010.000000000%$9,000,000.0010.000000000%
U.S. Bank National Association$30,000,000.0010.000000000%$9,000,000.0010.000000000%
Total:$300,000,000.00100.000000000%$90,000,000.00100.000000000%





EXHIBIT C

[FORM OF]
NOTICE OF BORROWING

TO: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT

FROM: WEST PHARMACEUTICAL SERVICES, INC.

RE: Credit Agreement (the “Agreement”), dated as of March 28, 2019 by and among West Pharmaceutical Services, Inc. (the “Company”), certain subsidiaries of the Company party thereto (together with the Company, the “Borrowers” and each a “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and an Issuing Lender. Capitalized terms used but not defined herein shall have the meanings given to them in the Agreement.

Pursuant to Section 2.01(c) or 2.04 of the Agreement, as applicable, the undersigned hereby makes the following request:

1. This request is for (choose one):

☐ A Borrowing of [Revolver][Incremental Term] Loans

☐ A Borrowing or [U.S.] [Euro] Swing Line Loans

☐ A [conversion] or [continuation] of [Revolver][Incremental Term] Loans

---

1. On (a Business Day)

2. In the amount of [$] [in the following currency: _______].

3. Comprised of: ☐ Base Rate Loans

☐ LIBOR Loans

4. For LIBOR Loans: with an Interest Period of __ month[s].

5. On behalf of ____________________________ [insert name of applicable Borrower]

[With respect to such Borrowing, the Borrowers’ Representative hereby represents and warrants that [(i) such request complies with the requirements of Section 2.01 of the Credit Agreement] 1 and (ii) each of the conditions set forth in Section 4.02 of the Credit Agreement has been satisfied on and as of the date of such Borrowing.]2

[With respect to such Borrowing of Swing Line Loans, the Borrowers’ Representative hereby represents and warrants that (i) such request complies with the requirements of the first proviso to the first sentence of Section 2.01(c) or 2.01 (d) of the Credit Agreement, as applicable and (ii) each of the conditions set forth in Section 4.02 of the Credit Agreement has been satisfied on and as of the date of such Borrowing of Swing Line Loans.]3



[signature page follow]


1 Include for Borrowings of Revolver Loans.
2 Include for Borrowings.
3 Include for Borrowings of Swing Line Loans.

The undersigned certifies to the accuracy of the foregoing.


Date:
WEST PHARMACEUTICAL SERVICES, INC.,
as Borrowers’ Representative
By:_____________________________
Name:
Title:

Exhibit I

[FORM OF]
Notice of Loan Prepayment

TO:  Bank of America, N.A., as [Administrative Agent][Swing Line Lender]

RE:  Credit Agreement, dated as of March 28, 2019 by and among West Pharmaceutical Services, Inc., a Pennsylvania corporation (the “Company”), certain subsidiaries of the Company party thereto, (together with the Company, the “Borrowers” and each a “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and an Issuing Lender (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

DATE:  [Date]


The Borrower hereby notifies the Administrative Agent that on _____________4 pursuant to the terms of Section 2.15 of the Credit Agreement, the undersigned intends to prepay/repay the following Loans as more specifically set forth below:

☐ Optional prepayment of [Revolver][Incremental Term] Loans in the following amount(s):

☐ LIBOR Loans: $ 5
In the following Optional Currency:
Applicable Interest Period:

☐ Base Rate Loans: $ 6

☐ Optional prepayment of Swing Line Loans in the following amount: $


Delivery of an executed counterpart of a signature page of this notice by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this notice.

[signature page follows]





[WEST PHARMACEUTICAL SERVICES, INC.,
a Pennsylvania corporation


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES OF FLORIDA, INC.,
a Florida corporation


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES GROUP LIMITED,
an entity organized under the laws of England & Wales


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST ANALYTICAL SERVICES, LLC,
a Delaware limited liability company


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES OF DELAWARE, INC.,
a Delaware corporation


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[TECH GROUP NORTH AMERICA, INC.,
an Arizona corporation




By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[TECH GROUP GRAND RAPIDS, INC.,
a Delaware corporation


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST CONTRACT MANUFACTURING, LLC,
a Delaware limited liability company


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES DANMARK A/S,
an entity organized under the laws of Denmark


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES HOLDING GMBH,
an entity organized under the laws of Germany


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]


[WEST PHARMACEUTICAL SERVICES SINGAPORE PTE. LTD.,
an entity organized under the laws of Singapore


By:_____________________________________
Name: __________________________________
Title: ___________________________________ ]

 EX-21 4 ex21listofsubsidiaries.htm EX-21 Document

Exhibit 21

SUBSIDIARIES OF THE COMPANY

Jurisdiction of Incorporation
Stock Ownership
West Pharmaceutical Services, Inc.PennsylvaniaParent Co.
Citation Plastics Co.New Jersey100.0  %
Tech Group Europe Limited (dba West)Ireland100.0  
Tech Group Grand Rapids, Inc. (dba West)Delaware100.0  
TGPR Holdings LimitedIreland100.0  
W.P.S.F. LimitedEngland100.0  
WD SG Pte. Ltd.Singapore100.0  
West Analytical Services, LLCDelaware100.0  
West Contract Manufacturing, LLCDelaware100.0  
West Pharma. Services IL, Ltd.Israel100.0  
West Pharmaceutical Packaging (China) Company Ltd.China100.0  
West Pharmaceutical Packaging India Private LimitedIndia100.0  
West Pharmaceutical Products Ireland, Ltd.Ireland100.0  
West Pharmaceutical Services Argentina S.A.Argentina100.0  
West Pharmaceutical Services Asia, Ltd.Taiwan100.0  
West Pharmaceutical Services Australia Pty. Ltd.Australia100.0  
West Pharmaceutical Services AZ, Inc.Arizona100.0  
West Pharmaceutical Services Beograd d.o.o.Serbia100.0  
West Pharmaceutical Services Brasil Ltda.Brasil100.0  
West Pharmaceutical Services Colombia S.A.S.Colombia100.0  
West Pharmaceutical Services Cornwall LimitedEngland100.0  
West Pharmaceutical Services Danmark A/SDenmark100.0  
West Pharmaceutical Services Delaware Acquisition, Inc.Delaware100.0  
West Pharmaceutical Services Deutschland GmbH Co KGGermany100.0  
West Pharmaceutical Services France S.A.S.France99.9  
West Pharmaceutical Services Group LimitedEngland100.0  
West Pharmaceutical Services Hispania S.A.Spain100.0  
West Pharmaceutical Services Holding Danmark ApSDenmark100.0  
West Pharmaceutical Services Holding France SASFrance100.0  
West Pharmaceutical Services Holding GmbHGermany100.0  
West Pharmaceutical Services Holding II GmbHGermany100.0  
West Pharmaceutical Services Holding Ireland North, Ltd.Ireland100.0  
West Pharmaceutical Services Holding Ireland South, Ltd.Ireland100.0  
West Pharmaceutical Services Holding Japan, GKJapan100.0  
West Pharmaceutical Services Holdings Ltd.Israel100.0  
West Pharmaceutical Services Italia S.r.L.Italy100.0  
West Pharmaceutical Services Korea Ltd.South Korea100.0  
West Pharmaceutical Services Lakewood, Inc.Delaware100.0  
West Pharmaceutical Services Normandie SASFrance100.0  
West Pharmaceutical Services of Delaware, Inc.Delaware100.0  
West Pharmaceutical Services of Florida, Inc.Florida100.0  
West Pharmaceutical Services Shanghai Medical Rubber Products Co., Ltd.China100.0  
West Pharmaceutical Services Singapore (Holding) Pte. LimitedSingapore100.0  
West Pharmaceutical Services Singapore Pte. Ltd.Singapore100.0  
West Pharmaceutical Services Venezuela C.A.Venezuela100.0  
West Pharmaceutical Services Verwaltungs GmbHGermany100.0  


 EX-23 5 ex23consent2019.htm EX-23 Document

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-133863 and 333-145186) and Form S-8 (No. 333-106977, 333-143129, 333-156492, 333-171453, 333-174153 and 333-211088) of West Pharmaceutical Services, Inc. of our report dated February 21, 2020 relating to the financial statements and financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 21, 2020 



 EX-31.1 6 ex311ceo302certificati.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this Annual Report on Form 10-K of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: February 21, 2020

EX-31.2 7 ex312cfo302certificati.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this Annual Report on Form 10-K of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: February 21, 2020

EX-32.1 8 ex321ceo906certificati.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of West Pharmaceutical Services, Inc. (the “Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: February 21, 2020

 EX-32.2 9 ex322cfo906certificati.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of West Pharmaceutical Services, Inc. (the “Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: February 21, 2020


 EX-101.SCH 10 wst-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENT OF EQUITY link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2105102 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - New Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Revenue Revenue link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Revenue Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Revenue Adoption of ASC 606 (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Revenue Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Revenue Contracts Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Revenue Supply Chain Financing (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Revenue Voluntary Recall (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Property, Plant and Equipment (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Adoption of ASC 842 (Details) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Lease Weighted Average (Detail) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2128107 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - Affiliated Companies (Tables) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Affiliated Companies (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2132108 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2333307 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Goodwill and Intangible Assets (Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2435419 - Disclosure - Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Goodwill and Intangible Assets (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2137109 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 2338308 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2140110 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2341309 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Debt (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2345310 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - Derivative Financial Instruments (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2447425 - Disclosure - Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 2148112 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2349311 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2450426 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2451427 - Disclosure - Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details) link:presentationLink link:calculationLink link:definitionLink 2452428 - Disclosure - Fair Value Measurements Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2153113 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2354312 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2455429 - Disclosure - (Components of AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2456430 - Disclosure - (Reclassifications AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2157114 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2358313 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2459431 - Disclosure - Stock-Based Compensation (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2460432 - Disclosure - Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2461433 - Disclosure - Stock-Based Compensation (Stock Options Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2462434 - Disclosure - Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2463435 - Disclosure - Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2164115 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2365314 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2466436 - Disclosure - Benefit Plans (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2467437 - Disclosure - Benefit Plans (Components of Net Periodic Benefit Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2468438 - Disclosure - Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details) link:presentationLink link:calculationLink link:definitionLink 2469439 - Disclosure - Benefit Plans (Amounts Recognized in Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 2470440 - Disclosure - Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2471441 - Disclosure - Benefit Plans (Expected Benefit Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 2472442 - Disclosure - Benefit Plans (Assumptions Used) (Details) link:presentationLink link:calculationLink link:definitionLink 2473443 - Disclosure - Benefit Plans (Allocation of Plan Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2174116 - Disclosure - Other Expense link:presentationLink link:calculationLink link:definitionLink 2375315 - Disclosure - Other Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2476444 - Disclosure - Other Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2477445 - Disclosure - Other Expense Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2478446 - Disclosure - Other Expense Other Items (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2479447 - Disclosure - Other Expense Development and Licensing Income (Details) link:presentationLink link:calculationLink link:definitionLink 2180117 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2381316 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2482448 - Disclosure - Income Taxes (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2483449 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details) link:presentationLink link:calculationLink link:definitionLink 2484450 - Disclosure - Income Taxes (Income Before Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 2485451 - Disclosure - Income Taxes (Components of Income Tax Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2486452 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2487453 - Disclosure - Income Taxes (Effective Income Tax Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 2188118 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2489454 - Disclosure - Commitments and Contingencies (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2190119 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2391317 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2492455 - Disclosure - Segment Information (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2493456 - Disclosure - Segment Information (Sales by Product Group) (Details) link:presentationLink link:calculationLink link:definitionLink 2494457 - Disclosure - Segment Information (Sales and PPE by Geographic Location) (Details) link:presentationLink link:calculationLink link:definitionLink 2495458 - Disclosure - Segment Information (Segment Financial Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2196120 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Notes) link:presentationLink link:calculationLink link:definitionLink 2497459 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 wst-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 wst-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 wst-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Percentage of current market price for sales to eligible employees Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Forward Contracts [Member] Forward Contracts [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Dividends received from affiliated companies Proceeds from Equity Method Investment, Distribution Operating loss carryforwards, foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Borrowings under revolving credit agreements Proceeds from Long-term Lines of Credit New Accounting Standards Accounting Changes and Error Corrections [Text Block] Amount receivable from affiliates Due from Affiliates Concentration Risk Type [Domain] Concentration Risk Type [Domain] Unrecognized compensation expense for all nonvested awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Performance-Vesting Shares [Member] Performance Shares [Member] Restructuring Type [Axis] Restructuring Type [Axis] Number of shares reduced for each award granted Reduction in Number of Shares Available for Grant For Each Award Granted Reduction in number of shares available for grant for each award granted. Other items Other Operating Income (Expense), Net Inventory balance for recalled product Inventory, Finished Goods, Gross Pension and other postretirement benefits Assets for Plan Benefits, Defined Benefit Plan Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Debt issuance costs Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net, Classification Lease, operating lease, terminate term Lease, operating lease, terminate term lease, operating lease, terminate term Purchase of investment in affiliated companies Purchase in investment in affiliated companies in cash Payments to Acquire Interest in Subsidiaries and Affiliates Depreciation Depreciation Schedule of Intangible Assets by Major Class Schedule of Intangible Assets by Major Class [Table Text Block] Schedule of Intangible Assets by Major Class [Table Text Block] 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Stock Options, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Defined Benefit Plan, Plan Assets, Contributions by Employer Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer Pension settlement charge Pension curtailment gain Curtailment Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Other changes in plan assets and benefit obligations recognized in OCI, pre-tax: Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Long [Member] Long [Member] Aggregate intrinsic value of total options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Debt Instrument [Axis] Debt Instrument [Axis] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Vested and converted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Goodwill [Table] Schedule of Goodwill [Table] Summary of Investment Holdings [Line Items] Summary of Investment Holdings [Line Items] Income taxes payable Accrued Income Taxes, Current Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement, Option [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Maximum number of shares per employee Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Employee Stock Purchase Plan (ESPP) [Member] Employee Stock Purchase Plan (ESPP) [Member] Employee Stock Purchase Plan (ESPP) [Member] Net actuarial gain (loss) arising during period, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax In-Process Research and Development (IPR&D) [Member] In Process Research and Development [Member] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Interest Rate Swap Contracts [Member] Interest Rate Swap [Member] Statement [Table] Statement [Table] Foreign Exchange Forward [Member] Foreign Exchange Forward [Member] U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Domestic Singapore, Dollars Singapore, Dollars Changes in assets/liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Shares available for grant/issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of deferred stock units payable in cash Deferred Stock Units Payable in Cash Deferred Stock Units Payable in Cash Reduction for expiration of statute of limitations/audits Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and earnings Derivative Instruments, Gain (Loss) [Table Text Block] Total lease cost Lease, Cost Debt Debt Disclosure [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Expiration Period [Axis] Expiration Period [Axis] Expiration Period [Axis] Germany [Member] GERMANY Restructuring and Related Cost, Expected Cost Restructuring and Related Cost, Expected Cost Disclosure of major customers Segment Reporting, Disclosure of Major Customers Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Other nonoperating expense (income) Other Nonoperating Income (Expense) Deferred Tax Asset Valuation Allowance [Member] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercises in Period, Weighted Average Exercise Price Long-term Debt, Fair Value Long-term Debt, Fair Value Mutual Funds [Member] Mutual Funds [Member] Mutual Funds [Member] Net impact to the 2018 effective tax rate, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act, Measurement Period Adjustment, Increase (Decrease) in Effective Tax Rate Equity Method Investee, Name [Axis] Investment, Name [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Finite-lived intangible assets, net Finite-Lived Intangible Assets, Net New Accounting Pronouncement, Early Adoption [Axis] New Accounting Pronouncement, Early Adoption [Axis] Development and licensing income [Line Items] Development and licensing income [Line Items] [Line Items] for Development and licensing income [Table] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Fair Value Hedging Fair Value Hedging [Member] Other Deferred Tax Liabilities, Other Accrued liabilities for interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating loss carryforwards Operating Loss Carryforwards Product Concentration Risk [Member] Product Concentration Risk [Member] Estimated annual amortization expense, 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Operating lease liabilities Operating Lease, Liability, Noncurrent ASSETS Assets [Abstract] Notional amount, nonderivative instruments Notional Amount of Nonderivative Instruments Americas [Member] Americas [Member] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Cash and cash equivalents Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment Unrecorded Unconditional Purchase Obligation Increase in accounts payable Increase (Decrease) in Accounts Payable Prior service cost (credit) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Limitation on payroll deductions of employee's base salary, amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount Construction in Progress [Member] Construction in Progress [Member] Credit available for the issuance of letters of credit Credit available for the issuance of letters of credit this refers to Credit available for the issuance of letters of credit France [Member] FRANCE Document Fiscal Year Focus Document Fiscal Year Focus Other Postretirement Benefits Plan [Member] Other Postretirement Benefits Plan [Member] Title of Individual [Axis] Title of Individual [Axis] Grant date fair value of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Interest paid, net of amounts capitalized Interest Paid, Excluding Capitalized Interest, Operating Activities Foreign Currency Translation [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Cash related to deconsolidated Venezuelan subsidiary Cash Divested from Deconsolidation Fair Value Measurements Fair Value Disclosures [Text Block] Pharma Customers [Member] Pharma Customers [Member] Pharma Customers [Member] Gain (Loss) on Hedging Activity Gain (Loss) on Hedging Activity Foreign Currency Transaction (Loss) Foreign Currency Transaction Gain (Loss), Unrealized Other (income) expense Other Income Expense Total other expense Other Income Expense The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Expiration Period [Domain] Expiration Period [Domain] [Domain] for Expiration Period [Axis] Customer advance cash payments Increase (Decrease) in Customer Advances Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Retained Earnings [Member] Retained Earnings [Member] Segment [Domain] Segments [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Other Other Sundry Liabilities, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Customer Relationships [Member] Customer Relationships [Member] Impairment of Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Interest income Investment Income, Net Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Long-term Debt Obligations , Net of Current Maturities Schedule of Debt [Table Text Block] Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Operating lease liability payments due Lessee, Operating Lease, Liability, Payments, Due Reconcilliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Land [Member] Land [Member] Amount of (Gain) Loss Reclassified from Accumulated OCI into Income Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] IRELAND IRELAND High-Value Components [Member] High-Value Components [Member] High-Value Components [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Total Equity Balance Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Schedule of Stock Options Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Summary of Investment Holdings [Table] Summary of Investment Holdings [Table] Business Segments [Axis] Segments [Axis] Aluplast S.A. de C.V. [Member] Aluplast S.A. de C.V. [Member] Aluplast S.A. de C.V. [Member] Net Investment Hedges [Member] Net Investment Hedging [Member] Other (Income) Expense Other Income and Other Expense Disclosure [Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] 2023 Long-term Debt, Maturities, Repayments of Principal in Year Four Purchases and royalty payments made to affiliates Purchases and Royalty Payments from Equity Method Investees Purchases and Royalty Payments from Equity Method Investees The West Company Mexico, S.A. de C.V. [Member] The West Company Mexico, S.A. de C.V. [Member] The West Company Mexico, S.A. de C.V. [Member] New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Goodwill [Line Items] Goodwill [Line Items] Accounting Standards Update 2017-07 [Member] Accounting Standards Update 2017-07 [Member] Revenue Benchmark [Member] Revenue Benchmark [Member] Year 2038 [Member] Year 2038 [Member] Year 2038 [Member] Lease, Cost Lease, Cost [Table Text Block] Vesting [Domain] Vesting [Domain] Measurement period adjustment, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Increase due to prior year position Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions 401 (k) plan contributions Defined Contribution Plan, Cost Summary of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Supply Chain Financing [Abstract] Supply Chain Financing [Abstract] Supply Chain Financing [Abstract] SARs Activity [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Federal and state Deferred Federal, State and Local Income Tax Expense (Benefit) Deferred Federal, State and Local Income Tax Expense (Benefit) Other, net Payments for (Proceeds from) Other Investing Activities Losses on Cash Flow Hedges [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Other Current Liabilities Other Liabilities Disclosure [Text Block] Unamortized debt issuance expense Unamortized Debt Issuance Expense Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Acquisition of business Payments to Acquire Businesses, Gross Curtailment Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax Employee Benefits Pension and Other Postretirement Plans, Policy [Policy Text Block] Generics Customers [Member] Generics Customers [Member] Generics Customers [Member] Asset-related charges [Member] Asset-Related Charges [Member] Asset-Related Charges [Member] United States of America, Dollars United States of America, Dollars Equity in undistributed earnings of affiliates, net of dividends Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Gain (Loss) on Disposition of Assets Gain (Loss) on Disposition of Assets Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Change in contract assets - increase (decrease) Contract with Customer, Asset, Increase (Decrease) Contract with Customer, Asset, Increase (Decrease) Net loss on investment securities, net of tax of $0, $(0.1) and $(2.5) Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Cash [Member] Cash and Cash Equivalents [Member] Cash payments Payments for Restructuring Total Operating Leases, Future Minimum Payments Due Foreign Currency Transaction Gain Foreign Currency Transaction Gain, before Tax Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansAssetsNoncurrent Assets, Defined Benefit Plans, Noncurrent Amount of assets, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Derivative [Table] Derivative [Table] Operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Other charges Other restructuring charges Other Restructuring Costs Number of reportable segments Number of Reportable Segments Entity Registrant Name Entity Registrant Name Segment Reporting, Revenue Reconciling Items [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Indexed Mutual Funds [Member] Indexed Mutual Funds [Member] Indexed Mutual Funds [Member] Commodity call options Other Assets, Fair Value Disclosure Treasury Stock [Member] Treasury Stock [Member] Year 2039 [Member] Year 2039 [Member] Year 2039 [Member] Debt Yen Denominated [Member] Debt Yen Denominated [Member] An obligation resulting from borrowing money. Purchases of shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Intangible Assets by Major Class [Table] Schedule of Intangible Assets by Major Class [Table] Schedule of Intangible Assets by Major Class [Table] Accumulated other comprehensive loss Balance, beginning Balance, ending Accumulated Other Comprehensive Income (Loss), Net of Tax Biologics Customers [Member] Biologics Customers [Member] Biologics Customers [Member] Increase due to current year position Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] City Area Code City Area Code Accrued taxes other than income Accrual for Taxes Other than Income Taxes, Current Development and licensing income Development and licensing income Development and licensing income The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer. 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Stock Options Activity [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Corporate and Eliminations [Member] Corporate and Eliminations [Member] Corporate headquarter items not allocated to segments and intersegment transactions (e.g. intersegment profits). Reconciliation of the total of reportable segments' amounts of revenues, measures of profits or loss, assets, or amounts for every other significant item of information disclosed, to the consolidated amount. Pension Plan Assets In The Fair Value Hierarchy [Member] Pension Plan Assets In The Fair Value Hierarchy [Member] Pension Plan Assets In The Fair Value Hierarchy [Member] Amounts reclassified from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Operating loss carryforwards, state and local Deferred Tax Assets, Operating Loss Carryforwards, State and Local Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Ultimate healthcare cost trend rate, benefit obligation Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Amortization Amortization Change in Benefit Obligation [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Equity Securities [Member] Equity Securities [Member] Venezuela currency devaluation Foreign Currency Transaction Loss, before Tax Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Pension and other retirement plans, net Pension and Other Postretirement Benefit Expense, Net The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period); net of cash contributed during the reporting period by the entity to fund its benefit plans. Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Work in process Inventory, Work in Process, Net of Reserves 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description Cash Flow Hedges [Member] Cash Flow Hedging [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Asset impairment charges, patent Asset Impairment Charges, Patent Amount of write-down of patent recognized in the income statement Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Options exercisable (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Deferred compensation assets Assets Held-in-trust, Noncurrent Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Pharma Rubber S.A. de C.V. [Member] Pharma Rubber S.A. de C.V. [Member] Pharma Rubber S.A. de C.V. [Member] Property, plant and equipment Property, Plant and Equipment, Gross Business acquisition, recognized property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Foreign Currency Hedge Contracts [Member] Foreign Currency Contract [Member] Foreign Exchange Contract [Member] Less: amortization of actuarial (gain) loss, net of tax of $0, $0.3 and $0.5 Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Geographical [Domain] Geographical [Domain] Geographical [Domain] Excess tax benefits on share-based payments Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Restructuring obligations Balance, December 31, 2017 Balance, December 31, 2018 Restructuring Reserve Title of Individual with Relationship to Entity [Domain] Title of Individual [Domain] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Repayments of Long-term Debt Repayments of Long-term Debt Customer [Axis] Customer [Axis] Hedging Designation [Axis] Hedging Designation [Axis] Treasury stock, at cost (in shares) Treasury Stock, Shares Restricted Stock [Member] Restricted Stock [Member] Award Type [Domain] Award Type [Domain] Tax on undistributed earnings of subsidiaries Effective Income Tax Rate Reconciliation, Undistributed Earnings of Subsidiaries, Percentage Effective Income Tax Rate Reconciliation, Undistributed Earnings of Subsidiaries, Percentage Business acquisition, recognized intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Loss Contingencies [Table] Loss Contingencies [Table] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Benefits/expenses paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Total recognized in net periodic benefit cost and OCI Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Proceeds from stock-based compensation awards Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 2018 Restructuring Plan [Member] 2018 Restructuring Plan [Member] 2018 Restructuring Plan [Member] Income Statement Location [Axis] Income Statement Location [Axis] Contract assets, December 31, 2018 Contract assets, December 31, 2019 Contract with Customer, Asset, after Allowance for Credit Loss Award Date [Axis] Award Date [Axis] Insurance Claims [Member] Insurance Claims [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Balanced Mutual Fund [Member] Balanced Mutual Fund [Member] Balanced Mutual Fund [Member] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Defined Benefit Pension and Other Postretirement Plans [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Options outstanding, beginning Options outstanding, ending Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Equity Method Investee, Name [Domain] Investment, Name [Domain] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Schedule of Restructuring Obligations Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Notes payable and other current debt Notes Payable and Other Debt, Current Notes Payable and Other Debt, Current Operating profit Operating profit Operating Income (Loss) Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Environmental Remediation and Compliance Costs Environmental Costs, Policy [Policy Text Block] Outstanding uncondintional contractual commitments due to be paid in 2020 Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months Argentina currency devaluation Foreign Currency Transaction Gain (Loss), before Tax Year 2022 [Member] Year 2022 [Member] 2022 [Member] Outstanding, beginning Outstanding, ending Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Net gain (loss) on investment securities, tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax Stock volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Development and licensing income [Table] Development and licensing income [Table] Development and licensing income [Table] Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Other [Member] Other [Member] Other [Member] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Components of Income Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Contingent consideration payments up to amount of acquisition-date liability Proceeds from (Payments for) Other Financing Activities Less: amortization of transition obligation Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, after Tax Forward-Start Interest Rate Swap [Member] Forward Start Interest Rate Swap [Member] Forward-start interest rate swap Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Total Liabilities Liabilities Domestic Plan [Member] Domestic Plan [Member] 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year Three United States [Member] UNITED STATES Basic (in dollars per share) Earnings Per Share, Basic Target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Amortization of actuarial loss (gain) Defined Benefit Plan, Amortization of Gain (Loss) SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Actuarial (loss) gain Actuarial (loss) gain Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Less: amortization of prior service credit, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Stock-settled SARs, outstanding Stock-Settled Stock Appreciation Rights, Outstanding Number of stock-settled stock appreciation rights outstanding. Number of deferred compensation plans Deferred Compensation Arrangement with Individual, Number of Plans Deferred Compensation Arrangement with Individual, Number of Plans 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four VENEZUELA VENEZUELA Capitalized interest Interest Costs Capitalized Contingent consideration, estimated outcome, low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Accrued Salaries, Wages, and Benefits, Current Accrued Salaries, Wages, and Benefits, Current Accrued Salaries, Wages, and Benefits, Current Non-Employee Directors [Member] Director [Member] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Treasury stock, at cost (1.2 million and 1.2 million shares in 2019 and 2018) Treasury Stock, Value Total Assets Segment assets Assets Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Number of deferred stock units Deferred Compensation Arrangement with Individual, Share Equivalents Balance Deferred Compensation Arrangement with Individual, Share Equivalents Balance Foreign Line of Credit [Member] Foreign Line of Credit [Member] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Currency [Axis] Currency [Axis] Gain (Loss) on Sale of Assets and Asset Impairment Charges Gain (Loss) on Sale of Assets and Asset Impairment Charges U.S. tax on international earnings, net of foreign tax credits Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Weighted average remaining contractual life of options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Plan Name [Domain] Plan Name [Domain] Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] SmartDose [Member] SmartDose [Member] SmartDose [Member] Document Fiscal Period Focus Document Fiscal Period Focus Deferred income taxes Deferred income tax provision Deferred Income Tax Expense (Benefit) Document Type Document Type State income taxes, net of federal tax effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Schedule of Assets and Liabilities at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other current liabilities Other Current Liabilities [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Type of Deferred Compensation, All Types [Domain] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Prior service credit Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Senior Notes [Member] Senior Notes [Member] Increase (reduction) in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Goodwill [Roll Forward] Goodwill [Roll Forward] Entity Interactive Data Current Entity Interactive Data Current Tax on international operations other than U.S. tax rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Income tax expense Tax expense Income tax expense (benefit) Income tax expense Income Tax Expense (Benefit) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Deferred income, noncurrent Contract with Customer, Liability, Noncurrent Dividends declared Dividends, Common Stock, Cash U.S. research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Other [Member] Other Securities [Member] Other Securities [Member] Total current liabilities Liabilities, Current Settlement effects arising during period, tax Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Term Loan Due 2024 [Member] Term Loan Due 2024 [Member] Term Loan Due 2024 Line of Credit Facility, additional borrowing capacity Line of Credit Facility Additional Borrowing Capacity Additional borrowing capacity under the credit facility. Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 2020 Operating Leases, Future Minimum Payments, Due in Two Years Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Reversal of prior valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Granted at target level Granted at target level Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period International operations Income (Loss) from Continuing Operations before Income Taxes, Foreign Summary of Inventories Schedule of Inventory, Current [Table Text Block] Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Assumed healthcare cost trend rate, benefit obligation Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Award Type [Axis] Award Type [Axis] Allocation of Share-based Compensation Costs by Plan Share-based Payment Arrangement, Cost by Plan [Table Text Block] Benefits/expenses paid Defined Benefit Plan, Plan Assets, Benefits Paid Amount reimbursable by the insurance company Loss Contingency, Receivable Net (loss) gain on derivatives, net of tax of $(0.2), $1.5 and $(0.1) Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures in Period, Weighted Average Exercise Price 2020 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Intersegment Elimination [Member] Intersegment Eliminations [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Total restructuring and related charges Charges Restructuring and Related Cost, Incurred Cost Other Current Liabilities [Abstract] Other Current Liabilities [Abstract] Other Current Liabilities [Abstract] Amortization of transition obligation Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Total liabilities Liability, Defined Benefit Plan Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Transfer of accounts receivable under supply chain financing agreements Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount Schedule of Sales by Significant Product Group Revenue from External Customers by Products and Services [Table Text Block] Unremitted income of affiliated companies Retained Earnings, Undistributed Earnings from Equity Method Investees Options outstanding, beginning (in USD per share) Options outstanding, ending (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Letter of Credit [Member] Letter of Credit [Member] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding in 2019 and 2018 Preferred Stock, Value, Issued Debt instrument, maturity date Debt Instrument, Maturity Date Current income tax provision Current Income Tax Expense (Benefit) Weighted average of the coupon interest rate Long-term Debt, Weighted Average Interest Rate, at Point in Time Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Other Deferred Tax Assets, Other Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Raw materials Inventory, Raw Materials, Net of Reserves Shares purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Tax credit carryforward Tax Credit Carryforward, Amount Interest expense Interest Expense, Debt Leases Lessee, Leases [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Customer Concentration Risk [Member] Customer Concentration Risk [Member] Contingent consideration payments in excess of acquisition-date liability Payment for Contingent Consideration Liability, Operating Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt instrument, Term Debt Instrument, Term Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Estimated annual amortization expense, 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Shares repurchased for employee tax withholdings (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Forfeited (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Customer Contracts [Member] Customer Contracts [Member] Employee stock purchase plan contributions Proceeds from Other Equity Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Year After 2023 [Member] Year After 2023 [Member] After 2023 [Member] State Current State and Local Tax Expense (Benefit) Other increase (decrease) in deferred income Increase (Decrease) in Contract with Customer, Liability Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Prior service credit that will be amortized from accumulated other comprehensive loss Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year Outstanding, beginning (in USD per share) Outstanding, ending (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other Financial Instruments [Abstract] Other Financial Instruments [Abstract] -- None. No documentation exists for this element. -- Operating lease, term of contract Lessee, Operating Lease, Term of Contract Segment Reporting [Abstract] Segment Reporting [Abstract] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Year 2020 [Member] Year 2020 [Member] 2020 [Member] Pharma Tap S.A de C.V. [Member] Pharma Tap S.A de C.V. [Member] Pharma Tap S.A de C.V. [Member] Effect of exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Accrual for insurance obligations Loss Contingency Accrual SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Derivative Contract Type [Domain] Derivative Contract [Domain] Commodity Call Options [Member] Commodity Option [Member] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Revenue Recognition Revenue [Policy Text Block] Foreign currency translation gains (losses) Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Share repurchase program, number of shares authorized Stock Repurchase Program, Number of Shares Authorized to be Repurchased Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Retirement Benefits [Abstract] Retirement Benefits [Abstract] Foreign currency translation Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Foreign Exchange (Gains) Losses and Other [Member] Foreign Currency Gain (Loss) [Member] Entity Address, Address Line One Entity Address, Address Line One Current assets: Assets, Current [Abstract] Operating lease cost Operating Lease, Cost Shares issued under stock plans (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Credit Facility [Axis] Credit Facility [Axis] International Mutual Funds [Member] International Mutual Funds [Member] International Mutual Funds [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Net actuarial (loss) gain arising during period, net of tax of $(0.3), $(0.2) and $1.3 Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Net Income Per Share Earnings Per Share [Text Block] Asia Pacific [Member] Asia Pacific [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Weighted Average Exercise Price Derivative, Excluded Component, Gain (Loss), Recognized in Earnings within Twelve Months Derivative, Excluded Component, Gain (Loss), Recognized in Earnings within Twelve Months Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings within the next 12 months Document and Entity Information [Abstract] Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Maximum [Member] Maximum [Member] 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Equity in unrealized gains (losses) in securities available-for-sale and derivative instruments Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Schedule of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Title of 12(b) Security Title of 12(b) Security Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Goodwill recorded due to acquisition Goodwill, Acquired During Period Revenue [Abstract] Revenue [Abstract] Revenue [Abstract] Limitation on payroll deductions of employee's base salary, percent Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Aggregate annual maturities of long-term debt [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Other charges [Member] Other Restructuring [Member] Expected contribution to the plan Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Domestic Line of Credit [Member] Domestic Line of Credit [Member] Derivative, Nonmonetary Notional Amount Derivative, Nonmonetary Notional Amount Income Statement Location [Domain] Income Statement Location [Domain] Foreign Currency - Denominated Debt [Member] Foreign Currency, Denominated Debt [Member] Foreign currency-denominated debt designated as a hedge of our net investments in foreign operations. Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Fair value of plan assets Balance Balance Defined Benefit Plan, Plan Assets, Amount Schedule of Nonvested Performance-based Share Activity Schedule of Nonvested Share Activity [Table Text Block] Aggregate carrying amount of investment in affiliated companies that are not accounted for under the equity method Cost Method Investments Capital expenditures Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total benefit payments expected Defined Benefit Plan, Expected Future Benefit Payments Defined Benefit Plan, Expected Future Benefit Payments Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Patents and Licensing [Member] Patents and Licensing [Member] Patents and Licensing [Member] Capital in Excess of Par Value [Member] Additional Paid-in Capital [Member] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Unrecorded Unconditional Purchase Obligation [Line Items] Unrecorded Unconditional Purchase Obligation [Line Items] Total liabilities at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Venezuela deconsolidation Venezuela deconsolidation Deconsolidation, Gain (Loss), Amount Oustanding, beginning (in USD per share) Oustanding, ending (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Revolving credit facility, due 2024 [Domain] Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Base Rate [Member] Base Rate [Member] Income Taxes Income Tax, Policy [Policy Text Block] Shares repurchased under share repurchase program Payments for Repurchase of Common Stock Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Goodwill Balance, beginning Balance, ending Goodwill Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Adjustments to reserves for unrecognized tax benefits Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Amendments/transfers in Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Impact of 2017 Tax Act Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Note Payable Due 2019 [Member] Note Payable Due 2019 [Member] Note Payable Due 2019 [Member] Estimated annual amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Maximum number of shares per employee, per year Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year Foreign currency translation Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Exercisable (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Line of Credit Facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Capitalized leases Capital Leased Assets, Gross Funded status at end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Balance (in shares) Balance (in shares) Shares, Issued 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three Issuance of long-term debt Proceeds from Issuance of Other Long-term Debt Restructuring and impairment charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring and Impairment Charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring and Impairment Charges Type of Restructuring [Domain] Type of Restructuring [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Actual payout range Share-based Compensation Arrangement by Share-based Payment Award, Actual Payout, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Actual Payout, Percentage Weighted average discount rate for operating leases Operating Lease, Weighted Average Discount Rate, Percent Asset-related charges Asset Impairment Charges Commodity Call Options Held [Member] Commodity Call Options [Member] Options Held [Member] Accounts Receivable Accounts Receivable [Policy Text Block] Contract Manufactured Products [Member] Contract-Manufactured Products [Member] Contract Manufactured Products [Member] Contract Manufactured Products [Member] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Foreign currency exchange rate, remeasurement Foreign Currency Exchange Rate, Remeasurement Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Unrecorded Unconditional Purchase Obligation [Table] Unrecorded Unconditional Purchase Obligation [Table] Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months Computer Hardware and Software [Member] Computer Hardware and Software [Member] Computer Hardware and Software [Member] Settlement effects arising during period, net of tax of $0.8 Other Comprehensive Loss, Defined Benefit Plans Settlement Effects, Net of Tax The adjustment out of other comprehensive income for settlement effects recognized as a component of net periodic benefit cost during the period, net of tax. Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets [Axis] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Aggregate intrinsic value of total options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Position [Domain] Position [Domain] Schedule of Nonvested Performance-based Units Activity Schedule of Nonvested Performance-based Units Activity [Table Text Block] Other Expense (Income) [Abstract] Other Expense (Income) [Abstract] Other Expense (Income) [Abstract] Less: amortization of actuarial loss, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Long-term rate of return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Fed Funds Effective Rate Overnight Index Swap Rate [Member] Fed Funds Effective Rate Overnight Index Swap Rate [Member] Accrued professional services Accrued Professional Fees, Current Balance at beginning of period Balance at end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Customer [Domain] Customer [Domain] Entity Public Float Entity Public Float Curtailment Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Stock compensation expense Share-based Payment Arrangement, Expense Stock-settled PSU awards [Member] Stock-settled PSU awards [Member] Stock-settled PSU awards Contracts and Liabilities [Abstract] Contracts and Liabilities [Abstract] Contracts and Liabilities [Abstract] Year 2023 [Member] Year 2023 [Member] Year 2023 [Member] Line of Credit Facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other adjustments to capital in excess of par value Adjustments to Additional Paid in Capital, Other Net deferred tax (liability) asset Deferred Tax Assets, Net Derivative, Notional Amount Derivative, Notional Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Business acquisition, transaction costs Business Acquisition, Transaction Costs Actual return on assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Scenario [Axis] Scenario [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Assumed healthcare cost trend rate, net periodic benefit cost Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year, Net Periodic Benefit Cost Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year, Net Periodic Benefit Cost Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] International Current Foreign Tax Expense (Benefit) 2016 Restructuring Plan [Member] [Member] 2016 Restructuring Plan [Member] [Member] 2016 Restructuring Plan [Member] [Member] Other noncurrent assets Other Assets, Noncurrent Entity Current Reporting Status Entity Current Reporting Status Deferred compensation liabilities Deferred Compensation Liability, Classified, Noncurrent Summary of Changes in Level 3 Fair Value Measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Credit Facility is available for swing-line loans Credit facility is available for swing-line loans This refers to credit facility is available for swing-line loans Diluted (in dollars per share) Earnings Per Share, Diluted Restructuring Plan [Domain] Restructuring Plan [Domain] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Segment Information Segment Reporting Disclosure [Text Block] Euro Note B [Member] Debt [Member] Inventories Total inventories Inventory, Net 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months Pension and deferred compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits 2025 to 2029 Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter Service cost Service cost Defined Benefit Plan, Service Cost Weighted average assumptions used in benefit obligations: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Operating leases, option to extend Lessee, Operating Lease, Renewal Term Stock Appreciation Rights (SARs) [Member] Stock Appreciation Rights (SARs) [Member] Undistributed earnings of foreign subsidiaries Undistributed Earnings of Foreign Subsidiaries Percentage of global plan assets Defined Benefit Plan, Assumptions Used in Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets, Percentage of Total Plan Assets Defined Benefit Plan, Assumptions Used in Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets, Percentage of Total Plan Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Activity related to stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Less: amortization of prior service credit, net of tax of $(0.1), $(0.5) and $(0.5) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax Net loss (gain) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax 2023 Operating Leases, Future Minimum Payments, Due in Five Years Restructuring Charges Restructuring Charges Entity Address, State or Province Entity Address, State or Province Current portion of long-term debt Debt, Current 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two Debt Disclosure [Abstract] Debt Disclosure [Abstract] Level 3 Fair Value Measurements [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Document Transition Report Document Transition Report Vested and converted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Basis spread on variable interest rate Debt Instrument, Basis Spread on Variable Rate Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Granted (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Venezuela deconsolidation Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent Severance and post-employment benefits Severance charges Severance Costs Long-term debt, current portion Long-term Debt, Current Maturities Weighted average grant date fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Asset impairment charges, patent and equipment Asset Impairment Charges, Patent and Equipment Amount of write-down of a patent and certain equipment, recognized in the income statement. Tax on undistributed earnings of subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Molds and Dies [Member] Tools, Dies and Molds [Member] EMEA [Member] EMEA [Member] Weighted average remaining contractual life of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Document Annual Report Document Annual Report Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Awards, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Operating cash flows from operating leases Operating Lease, Payments Geographical [Axis] Geographical [Axis] Annual effective interest rate Debt Instrument, Interest Rate, Effective Percentage Business acquisition, recognized goodwill Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Foreign Plan [Member] Foreign Plan [Member] Increase in accounts receivable Increase (Decrease) in Accounts Receivable Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Entity Address, City or Town Entity Address, City or Town Total deferred tax liabilities Deferred Tax Liabilities, Gross Financial Instruments Derivatives, Policy [Policy Text Block] Other business credits and Section 199 Deduction Effective Income Tax Rate Reconciliation, General Business Credits and Section 199 Deduction Effective Income Tax Rate Reconciliation, General Business Credits and Section 199 Deduction Valuation allowance Deferred Tax Assets, Valuation Allowance Entity Filer Category Entity Filer Category Entity Voluntary Filers Entity Voluntary Filers Equity: Equity [Abstract] Unrealized Gains on Investment Securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Schedule of Intangible Assets by Major Class [Line Items] Schedule of Intangible Assets by Major Class [Line Items] [Line Items] for Schedule of Intangible Assets by Major Class [Table] Finance Lease Finance Lease, Liability Research and Development Research and Development Expense, Policy [Policy Text Block] Provisional tax charge, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Deferred Tax Liability, Provisional Income Tax Expense Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Deferred Tax Liability, Provisional Income Tax Expense Changes in other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Purchase of investment in affiliated companies, treasury stock Other Significant Noncash Transaction, Value of Consideration Given Trademarks [Member] Trademarks [Member] Long-term debt Long-term debt Long-term Debt Retirement Plan Type [Axis] Retirement Plan Type [Axis] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Cash-settled SARs, outstanding Cash-Settled Stock Appreciation RIghts, Outstanding Number of cash-settled stock appreciation rights outstanding. Statement [Line Items] Statement [Line Items] Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Weighted average shares outstanding: Weighted average shares outstanding: [Abstract] -- None. No documentation exists for this element. -- Pension and other postretirement benefits Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Amendment Flag Amendment Flag Award Date [Domain] Award Date [Domain] Euro Member Countries, Euro Euro Member Countries, Euro Contingent consideration, estimated outcome, high Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Revolving credit facility, due 2020 [Member] Revolving credit facility, due 2020 [Member] Revolving credit facility, due 2020. Net gain (loss) on derivatives, tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Vesting [Axis] Vesting [Axis] Charged to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Entity Central Index Key Entity Central Index Key Accrued retirement plans (excluding pension) Liability, Other Retirement Benefits SARs, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Debt Instrument, Description of Variable Rate Basis Variable rate basis Debt Instrument, Description of Variable Rate Basis Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance [Abstract] Accumulated Other Comprehensive (Loss) Income [Member] AOCI Attributable to Parent [Member] Provisional Transition Tax, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense Loss on sales of equipment Gain (Loss) on Disposition of Property Plant Equipment Delivery Devices [Member] Delivery Devices [Member] Delivery Devices [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Change in deferred income - (increase) decrease Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized All Currencies [Domain] All Currencies [Domain] Product and Service [Domain] Product and Service [Domain] Type of Adoption [Domain] Type of Adoption [Domain] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Pension plan assets measured at NAV [Member] Pension plan assets measured at NAV [Member] Pension plan assets measured at NAV [Member] Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Shares repurchased for employee tax withholdings Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Forward Treasury Lock [Member] Forward treasury lock [Member] -- None. No documentation exists for this element. -- Entity Shell Company Entity Shell Company Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Other European countries [Member] Other Europe Countries [Member] Other Europe Countries [Member] Voluntary Recall [Abstract] Voluntary Recall [Abstract] Voluntary Recall [Abstract] Year 2037 [Member] Year 2037 [Member] Year 2037 [Member] Stock-based Compensation Share-based Payment Arrangement [Policy Text Block] Allowance for Doubtful Accounts Receivable [Member] SEC Schedule, 12-09, Allowance, Credit Loss [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Non-cash restructuring charges Non-cash asset write-downs Restructuring Reserve, Settled without Cash Plan Name [Axis] Plan Name [Axis] Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Equity Component [Domain] Equity Component [Domain] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Participants’ contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Common Stock [Member] Common Stock [Member] Other Operating Income (Expense) Other Operating Income (Expense) [Member] Schedule of Other Income and Expense Schedule of Other Income and Expense, by Component [Table Text Block] Schedule of Other Income and Expense, by Component [Table Text Block] Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Derivative [Line Items] Derivative [Line Items] Ratio of debt to EBITDA Ratio of debt to EBITDA Ratio of debt to EBITDA Options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Net Sales [Member] Net Sales [Member] Net sales member Accounts payable Accounts Payable, Current Debt issuance costs, net Debt Issuance Costs, Net Estimated useful lives Property, Plant and Equipment, Estimated Useful Lives Current Fiscal Year End Date Current Fiscal Year End Date Machinery and Equipment [Member] Machinery and Equipment [Member] Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Annual Incentive Plan [Member] Incentive Stock Awards [Member] Incentive Stock Awards [Member] Incentive Stock Awards [Member] Income Tax Authority [Domain] Income Tax Authority [Domain] Outstanding Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Accrued interest Interest Payable, Current Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Granted at target level Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average asset allocations Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage Inventories Inventory, Policy [Policy Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Foreign currency translation OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes Schedule of Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Total recognized in OCI Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Forward Treasury Locks [Member] Treasury Lock [Member] Finished goods Inventory, Finished Goods, Net of Reserves Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Estimated useful life of finite-lived intangible assets Finite-Lived Intangible Asset, Useful Life Stock-Based Compensation Share-based Payment Arrangement [Text Block] Term Loan Due 2024 [Domain] Term Loan Due 2024 [Domain] Term Loan Due 2024 [Member] International Deferred Foreign Income Tax Expense (Benefit) Net actuarial loss (gain) Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Shipping and Handling Costs Cost of Goods and Service [Policy Text Block] Schedule of Sales and Net Property, Plant and Equipment, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Estimated reduction in the liability for unrecognized tax benefits Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Cash-settled PSU awards [Member] Cash-settled PSU awards [Member] Cash-settled PSU awards [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Asset impairment charges, trademark Asset Impairment Charges, Trademark Amount of write-down of trademark recognized in the income statement. Shares purchased under share repurchase program, average cost per share Treasury Stock Acquired, Average Cost Per Share Ownership interest Equity Method Investment, Ownership Percentage Total lease liabilities Operating Lease, Liability Revolving Credit Facility Due 2017 [Member] Revolving credit facility, due 2017 [Member] Revolving credit facility due on second date. Performance-vesting Shares or Units Dividend Equivalents [Member] Performance-vesting Shares or Units Dividend Equivalents [Member] Performance-vesting Shares or Units Dividend Equivalents [Member] Schedule of Stock Appreciation Rights Award Activity Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Long-term debt, gross Long-term Debt, Gross Weighted average period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Increase in inventories Increase (Decrease) in Inventories Loss Contingencies [Line Items] Loss Contingencies [Line Items] Debt Instrument [Line Items] Line of Credit Facility [Line Items] Debt Instrument [Line Items] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Short-term lease cost Short-term Lease, Cost Total assets at fair value Assets, Fair Value Disclosure Estimated annual amortization expense, 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Commitments and contingencies (Note 16) Commitments and Contingencies Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cross Currency Interest Rate Contract [Member] Cross Currency Interest Rate Contract [Member] Prior service credit arising during period, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax Federal Current Federal Tax Expense (Benefit) Research and development Research and Development Expense Pension Plan [Member] Pension Plan [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Year 2018 [Member] Year 2019 [Member] Year 2019 [Member] 2021 Operating Leases, Future Minimum Payments, Due in Three Years Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Trading Symbol Trading Symbol Interest rate swap contracts Interest Rate Derivative Liabilities, at Fair Value Adjustments above/(below) target Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Document Period End Date Document Period End Date Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Contract with customer, liability Deferred income, December 31, 2018 Deferred income, December 31, 2019 Deferred income Contract with Customer, Liability Balance Balance Defined Benefit Plan, Benefit Obligation Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Effect of modified retrospective application of new accounting standard Cumulative Effect of New Accounting Principle in Period of Adoption Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Sales to affiliates Sales to Equity Method Investees Sales to Equity Method Investees Common stock, par value $.25 per share; 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million in 2019 and 2018; shares outstanding: 74.1 million and 74.1 million in 2019 and 2018 Common Stock, Value, Issued Deferred compensation conversion unit Deferred Compensation Arrangement with Individual, Conversion Unit Conversion unit of deferred stock units Cost of Goods and Services Sold [Member] Cost of Sales [Member] Debt issuance costs Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Interest Expense [Member] Interest Expense [Member] Transitional Tax, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Purchase of investment in affiliated companies Stock Issued During Period, Value, Acquisitions Severance and benefits [Member] Employee Severance [Member] Deferred income Deferred Revenue, Current Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] 2019 Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months Scenario [Domain] Scenario [Domain] Cost of Goods and Services Sold Cost of goods and services sold Cost of Goods and Services Sold Proprietary Products [Member] Proprietary Products [Member] Proprietary Products [Member] Pension and other postretirement benefits Current liabilities Liability, Defined Benefit Plan, Current Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Net income Net income Net income, as reported, for basic net income per share Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Prior service credit arising during period Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Stock Option and Appreciation Rights [Member] Stock Option and Appreciation Rights [Member] Stock Option and Appreciation Rights [Member] I&W Pharma Group LLC I&W Pharma Group LLC [Member] I&W Pharma Group LLC Litigation Legal Matters, Contingencies and Legal Costs [Policy Text Block] Legal Matters, Contingencies and Legal Costs [Policy Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement [Abstract] Income Statement [Abstract] Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Income taxes paid, net Income Taxes Paid, Net SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Amortization expense Amortization of Intangible Assets Restructuring Plan [Axis] Restructuring Plan [Axis] Assumed stock options exercised and awards vested, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Use of Estimates Use of Estimates, Policy [Policy Text Block] Total current assets Assets, Current Discrete tax charge, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense Hedging Designation [Domain] Hedging Designation [Domain] Line of credit, noncurrent Long-term Line of Credit, Noncurrent Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Estimated annual amortization expense, 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Derivative, Average Price Risk Option Strike Price Derivative, Average Price Risk Option Strike Price Participants’ contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Equity method investments Equity Method Investments Buildings and Improvements [Member] Building and Building Improvements [Member] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Local Phone Number Local Phone Number Contingent consideration, payable period Contingent Consideration Arrangements, Range of Outcomes, Payable Period Contingent Consideration Arrangements, Range of Outcomes, Payable Period Retirement Plan Type [Domain] Retirement Plan Type [Domain] Total Liabilities and Equity Liabilities and Equity Capital in excess of par value Additional Paid in Capital Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Leases of Lessee Disclosure Leases of Lessee Disclosure [Text Block] Dividends declared, not paid Dividends payable Dividends Payable, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity Components [Axis] Equity Components [Axis] Reduction in Transition Tax, Tax Cuts and Jobs Act of 2017 Tax Cuts and Jobs Act, Decrease in Deferred Tax Liability due to Transition Tax Award Types Other than Stock Options and Stock Appreciation Rights [Member] Award Types Other than Stock Options and Stock Appreciation Rights [Member] Award Types Other than Stock Options and Stock Appreciation Rights [Member] Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) lessee, lease Cash Flow and Supplemental information lessee, lease Cash Flow and Supplemental information [Table Text Block] lessee, lease Cash Flow and Supplemental information [Table Text Block] U.S. federal corporate tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Amount due and payable to affiliates Due to Affiliate Amortization of actuarial (loss) gain Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax New Accounting Principles, Early Adoption [Domain] New Accounting Principles, Early Adoption [Domain] Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Number of shares to be issued upon conversion Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting Ultimate healthcare cost trend rate, net periodic benefit cost Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Net Periodic Benefit Cost Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Net Periodic Benefit Cost New Accounting Pronouncements and Changes in Accounting Principles New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Other Income Tax Expense (Benefit), Continuing Operations Other Income Tax Expense (Benefit), Continuing Operations Interest cost Interest cost Defined Benefit Plan, Interest Cost Accelerated depreciation Deferred Tax Liabilities, Property, Plant and Equipment Common stock, shares issued (in shares) Common Stock, Shares, Issued Position [Axis] Position [Axis] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Adjustments above/(below) target Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value Non-vested PSU Awards [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Decrease (increase) in other current assets Increase (Decrease) in Other Current Assets Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Total Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Actuarial net loss that will be amortized from accumulated other comprehensive loss Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year Other [Member] Other Countries [Member] Other Non-European Countries [Member] Internal Revenue Service (IRS) [Member] Internal Revenue Service (IRS) [Member] Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Variable lease cost Variable Lease, Cost Gain (Loss) on Derivative Instruments, Net, Pretax Gain (Loss) on Derivative Instruments, Net, Pretax Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Amounts Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Entity Small Business Entity Small Business Entity File Number Entity File Number SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Operating lease liabilities Operating Lease, Liability, Current Contingent consideration Business Combination, Contingent Consideration, Liability Principles of Consolidation Consolidation, Policy [Policy Text Block] Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Short [Member] Short [Member] Repayments of Lines of Credit Repayments of Lines of Credit Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Weighted average assumptions used in net periodic benefit cost: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Product and Service [Axis] Product and Service [Axis] Depreciation and amortization expense Depreciation, Depletion and Amortization Transition obligation Amortization of transition obligation Defined Benefit Plan, Amortization of Transition Asset (Obligation) Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Other current assets Other Assets, Current Standard Packaging [Member] Standard Packaging [Member] Standard Packaging [Member] Current liabilities: Liabilities, Current [Abstract] Amortization of prior service credit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax 2020 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Selling, general and administrative expenses Selling, General and Administrative Expense Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Schedule of Equity Method Investments Equity Method Investments [Table Text Block] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Credit Facility [Domain] Credit Facility [Domain] Balance, beginning Balance, ending Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Income Taxes Income Tax Disclosure [Text Block] Assets: Assets, Fair Value Disclosure [Abstract] 2022 Operating Leases, Future Minimum Payments, Due in Four Years Debt issuance costs Payments of Debt Issuance Costs Amount of Gain (Loss) Recognized in OCI Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Interest expense Interest expense Interest Expense Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Euro-Denominated Revolver [Member] Euro-Denominated Revolver [Member] Euro-Denominated Revolver [Member] Class of Stock [Axis] Class of Stock [Axis] Accrued commissions, rebates and royalties Accrued Sales Commission Granted Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Weighted average remaining lease term for operating leases Operating Lease, Weighted Average Remaining Lease Term Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Deferred income, current Contract with Customer, Liability, Current Nature of Expense [Axis] Nature of Expense [Axis] Leases [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Minimum [Member] Minimum [Member] Percentage of net sales Concentration Risk, Percentage Shares purchased under share repurchase program Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Japan, Yen Japan, Yen Total gross unrecognized tax benefits Balance at January 1 Balance at December 31 Unrecognized Tax Benefits Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] 2024 Long-term Debt, Maturities, Repayments of Principal in Year Five Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Daikyo Seiko, Ltd. [Member] Daikyo Seiko, Ltd. (Daikyo) [Member] Daikyo Seiko, Ltd. (Daikyo) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Outstanding, beginning Outstanding, ending Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Business acquisition, recognized inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Debt Securities [Member] Debt Securities [Member] Deferred Compensation Plans [Member] Deferred Compensation, Share-based Payments [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Long-term debt Long-term debt, excluding current portion Long-term Debt, Excluding Current Maturities Net sales Net sales Revenues Other long-term liabilities Other Liabilities, Noncurrent Gross profit Gross Profit Dividend payments Payments of Ordinary Dividends, Common Stock Provision for product returns Provision for Product Returns Provision for Product Returns Class of Stock [Domain] Class of Stock [Domain] Year After 2018 [Member] Year After 2019 [Member] Year After 2019 [Member] Cash payments received in advance Contract with Customer, Liability, Increase (Decrease) due to Additional Cash Payments Contract with Customer, Liability, Increase (Decrease) due to Additional Cash Payments Prior service cost arising during period, net of tax of $0 Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Average remaining term of shares issued at conversion Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Other current liabilities Other Liabilities, Current Currency Swap Currency Swap [Member] Contract with Customer, Asset and Liability [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block] Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block] Outstanding amount Letters of credit supporting the reimbursement of workers' compensation and other claims Long-term Line of Credit EX-101.PRE 14 wst-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 wst-20191231_g1.jpg GRAPHIC begin 644 wst-20191231_g1.jpg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圲_7-% 'CG["/P!^/_ .R]^SAX?^ _[0?[3%M\6=0\,6$>GZ;X MP_X1!](O+FTC&V(78:]NA/*J;4\T%"P0%PSEG/L=%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9 end XML 16 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
Cost of Goods and Services Sold 1,234.2 1,172.0 1,086.2
Gross profit 605.7 545.4 512.9
Research and development 38.9 40.3 39.1
Selling, general and administrative expenses 272.7 262.9 246.0
Other (income) expense (2.5) 1.9 2.0
Operating profit 296.6 240.3 225.8
Interest expense 8.5 8.4 7.8
Interest income (3.8) (2.1) (1.3)
Other nonoperating expense (income) 0.1 (6.7) (3.1)
Income before income taxes 291.8 240.7 222.4
Income tax expense 59.0 41.4 80.9
Equity in net income of affiliated companies (8.9) (7.6) (9.2)
Net income $ 241.7 $ 206.9 $ 150.7
Net income per share:      
Basic (in dollars per share) $ 3.27 $ 2.80 $ 2.04
Diluted (in dollars per share) $ 3.21 $ 2.74 $ 1.99
Weighted average shares outstanding:      
Basic (in shares) 74.0 73.9 73.9
Diluted (in shares) 75.4 75.4 75.8
ZIP 17 0000105770-20-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-20-000015-xbrl.zip M4$L#!!0 ( !>755 'P&E\S$8 'U6 P : 97@Q,#)F:7)S=&%M96YD M;65N=&%N9"YH=&WM?6EW&KFVZ/?W*_3V])-5%@/"0NL/JL/HUK4$G:VO/T^_\]NVSU_[AJ MLTDT==G5E_?GG1;;>?'RY=?#ULN79_TS]JG_^9P=U?<;K!]P+Y21]#WNOGS9 MOMAA.Y,HFKU]^?+FYJ9^]X!?Y?\.&[ M__/[_WWQ@IWY3CP57L2<0/!(#%D<2F_,O@Y%^(V]>*&?:OFS>2#'DX@=[!_L MLZ]^\$U>R&$T>=O8W_^OTQUZZ-WO(]^+8+ WE0_ MU0 +PT3B>_2"NW+LO:7YX@#X@KD_X,ZW<>#'WO"%X[M^\#88#W8/CH]KYE^V M7]_?.U7W?MFG?TYQ@!?]="@,6+4 1RI!X, MY3\")@_KH#]O],)@'%=ZXH5>:*-QC*MK?Y_(@8Q88[]^D%_:&HLJV9#RMQP MC @>^-J3;^%1V1;2=(?"\0..^/"6P;Q$@(_!O#]TNKT^:WYN7YS!O_#KXHQU M+EK=-O[5/&:?_1_K(#]E-"5/RHK>'KV!!F7'^BL-(CN;5WM^==_U/ MG1Z[^TZRW6@B0_;;+V\.#O9/S095=Z$K#U)S' BAR%O5U['SCK:\<;K'8/OI MJ )5EU[D,QXR?\3.A".F Q&PP_T:D//&"4)*; F@.A[P,004=UE?!%-V[G./ MM4.'>ON2]5?Q,Z[N88A\X,MV?OW?A#X M-R((<3F-UZ>L*V:!"!';$+FJO[H4KVI,<&>"Y!!1XUS@*D,VXT$T9Q.@F$ M M=Z7GN/$0I6%Z-DM:U LP"O>&[#WWON%(S2E,RN$U=E%O(CZ&K#F<2D^&44#[ MPYIC>+O.6--UF<-G$D:"N0\9D.AI"((W_,1O2X^&]?R(^3"[X$:&@@W%"%:3 M/!!.. PRX3 J+F J .>]<0@?=0(YP#'U*N!9?* %3 #$S(2/L5V8GAES(%S_ M9@_/J7X:5@+K&Z[S%JT3WW$XS'+*YW"]OB .;:'@N?/N*^NP/KM@;=:#_[7A M]RLAH;DB:JQ)7// #D M.WAC9!6XRM7QK#$@/A$^"MC\/=+7PG@VA&W)$NT'78)_W"D(V !41*:/KME^.3T\=@M<^'9V<)ZP0@'(B_ M8^"YL*]9;E[] [\2;WMH&P M^:#>.-H=[E5_-3OO$J97%-!)L"*JJG$MI](0 MPJ!I8#J5$3T/S!2$J!GL@!ERP8+R06'5G.WBN$@#MH1>+RITU5]0QC)D:")G M,S^@ PP01+*Z%( D>*<(37M1>HPLI;P7I;S%/E)C)+H";H+R#S")0 ;-$U7" MWBP;G/)O(I%Z2>U!\(0)),O@ANS5PNXNL%MBWB'@+,H@]\8W%'OP[R[ 6Z)1 M?HFP0W N)^\\(]EH2Q#1=#I5F?.!MB/']P ,44QZ+H=+U]S,NMPB5':5Y#JM M;],7!UNE."TS=%5_62DC6+2V661?W*V+RZ\UUD>,_W#9;1,I1@0!3 IR: $$ M>RI#^#!B*]F.V-CWA_3G-7=C/G!%_DV%#X%PA)Q%]%P8CT;2D<)SYCCLS40B M=@9"(Q"#K?'\&U<,QVBPHJ^"E(9JBY;3B!8@YHU\U_5O@)\U1F[ MOX,@>\ZWX;SN\KW??FF\VC_MQ8._4 W30H/R"2$U 6(SI%BOD(4B0H,&,'S% M_-'IZ\%$\&'FHJ=;.W#\0(ZE!X=C%DC/D3/XQ:>P:#H\OY[LUV!5^.\V>887 M<*))SO_JKRH?L:%YA# HKQPA*^5,:XNIHBWF 5[0K2-R@P<1N67Z62BN009S MW;D2F$@M)HU9@@J44=)*S5J*.B#!Y Q#7D&LX\-K[CD"KYV!X,6#L*C"^5[Y M8"511C2R9\@N*F0PEOCNH))'ZMKB@K39(%PZV59JN(/!%D;)405E"Z@^ JTD M!T;9K?XR=M[5-GVST?I4_27@1O-1A'J9O*;@'$*[!"$T$H=*L?+C"!BI1U$\ MJ02TBB"HR!K$5XVL^# ? X$9(U:G@]R.I&'9M[31!X3@_HI9% 991@&-22E# M&*Y$@!$F?"Q6O)A0F@R57$U.2&.FT2C0AY>N;1DMK.E='="+*8&'#U?_P*V6 M5QP0T&+@'8WZ?J/Z:P%IA4<1QTEK6\,MYQ #NA:]P@#'7;G'SCOO+[OT'&#; MKH0K[_%L=!%/Z"K&W\!UN$%.IP&H)'3:R"'KC\BX.!0H!:B(LOF"O13P4,7L M:$9 M6^&8^2J3[&T@7$*J;/I5-BMKI_PU/@A]-X[$Z<"/(G_Z=G\Q?6NI;K/<*IG] M_TF0&BC'XL4@$/S;"Q(!WG+WAL_#G1^62;9UBIBC%;%5-#_AU6&JK<&GASSR M@SD:R&=\;KQ1*2^7F\_+4]O#\>YXRVP/9<>:4.09^X0.Z@H9J@_IVYV825S M)KHRG\*%N17DG&?(>2!&(%6C! RG0)OT/[>[W<[Y.3O_XZ+UJ<:N.NUNJUUC M']H7%^TN/'3XYI3U/G?ZGS"'[+)[==EM]MMG2>*2LG8Y_C4%DBF-LC1V(+5; MFU@!F /P:;)=Z[F\O_S09+UVZTNWT^^8M#7]J3L<@+O [3D>"6-J;:.N7GHF MSJ\^] R(EZ4'K050?P0 %4X<4,RM!>6/%-94) ":L=#A1SE8VEZ>#2P8:D@9 M40:M$LN15L&>SV:!/PLD6;?%P!(P?36X:N M*DRWP]7Z_E.+-4$Q:(Y&TI6;E5)-47LZ+!K3)L-,0#,WZS'/8K89V47)PR[3 MY,=8I2R@U4-B.A]H19'*+"M8HFJL<<"^U'OU5ITUWAPU=K_M[2765IK%?0FF M1:XM1:X\6ZW^:E+44OA46$ -#0UU@TJ."$.?N,IG$032==GYW,.T@BN)C@N0 M387GB<#(IE,TYL+[NIB!&.Z1(P(=O":(FL(CV%\^X"%SB5,% ??&VCNBK@]\ M_UL0X\ 6VRRVY>M)7%.!E+87;4CX7![9*"I!"7B)B$@"&@.,VTMS*QV]3D'K M3'(P0YUS4&!O%%JV'F]KU3_4NW6&DNKK4W9P?%!_#H=?TP^3RZGYR2&7SH=7[8! [?'-1Q RRAL82FC-!3^ M!\CUD0DW5.[:;.9*![-V+/)8Y,D5!Y5!&+'$>5;]U131)U=$J; :0J:L@S]) M%D@>R9=90@Y?'*,8Q#=0,5EI89Y;$YX7BZN9PCPFI*352.;2 $%@=PXB"PU4Z?.LM%5:KD2"M!SO@N0ZIIYP<8\*K;H*W.7#:- M'%806TOB+(G+XLD%J#0M'D[85>!C'8"-HF[/P&>_05EZ3T):;%[O??)Z+ MOZKO'\':J[\:D"=?;/JF[\J-V.@T"-B5CO!"3 8(XT'ZARMXJ# %+ZL_QH#[ MD4IC(V.'JF9-@4% $5":HY$1A^&F//@&$B.6"+:1 M1I:OY;#U?S^TJK^"!=.("9K_.X8C0S681M+CGH,8Y\!H 7>B;)[[9G3?\6B8I(9%*8>_$,K=O57]"S4LAM$+TE+!6=ZLKS MVQ6NN$;;_D?,T/&T9?B]/]RH+)W4F?A!8&<*EW4%C'F-PB\/J'_%;[\!:9&HW/LK' M3=,^=+N ]$UE9P*!"X$H7?YH5O])22H7XVITH??4DMS9RT;3#6FO7J2 M9% PU@4*D9BS(9]GB&V(90Z0%"+KP%>-D@14BBC3+#9='$9DY7 F-,(RQIKT.^43RYFNI<:6&A>I\0NL*SVDPM+5 M7TU1)L,%(!90K '^84^X/>&Y$Z[,&7# -\Q0:(T:%5F*-6I8FI(_OPFSJ?XZ MK"+SXW!W_%FQ[9=.,DIKG.*K&BT+;R=5 MG+QTP@.2%>$M$KR2.P_73!9;X*3*G4_-OJ0'*YBJN'Q4L:2C&][H+Z[8KI(N M*[K.72!XZ'O4=W8H0R<0.+RE]Y;>9^D]>E)9;R;(.POZ/8;NX2GLBC%.H?JK MLU)EY9922:ER4VMY#S.UO$LY6VD+MTR9]O5*>J\JVWZ_9N(_JTB[91]/2)A* M#U_UUU0TM979ZTVGQ$@E>\'7:Q2C6WRV+%^]*ZY]EYI,:DQ+]TG5-IJES19W M'1X$&"7EQTGZ// O^ AL.HC/+B/_Y%Z"NYD.CX$IFZ1DQ#M.!=>FBI3#XFS; M5]OV]6Z;O3EM7^5(]Z/)%B/(ELTP^<\*6>""ZD)I:HWELZ95:]0PC!&I"@.< M4[A"$G#6_AX)+R0U-4T.54HPE5#;PO30UQM2V@*U>+E(40E,XOM, @!K*F_T M]CZYIJVXZ7^7-708H\+*43*$FTW],$+[ MQUYVE]C-IBVV+E81V$XN]8==4+ M0?Y1RZ"3F^5C"3\((Q[%H:I]K\N 9LXQ%K3&TDMH1H!YF86HLT]Q[H/U.&"V MB@#:<#+ME$MSP!_,%K-?**M24MZEF*HE3(1;9)\YUJBKH)#H#2^N=19D6%;; MAA;!IPLPMZ5MGH K( %0>-E,,(?../P93\FZ6%.1&[X33U5M2A_3R(43+PI< MVTC+-RC5G\"I:ISDP94%BRK3D 7: .VX(DP:^Z@BH\4"P K_2_$^+.UZRH>H MA9I>IUMHB#JH'VQ$RV-KB'HT0Y2XS1"E FA[2<@7M7-O^>3:(/US@MUUPJTR M3=ED>9LL7[VIKB3A:Z)I]5>Y4 ZSS(J'+2I]5,'*EJW$.R==NZ/6;O2-/)G# M6$+]VN+-@G^Y9M0HRCH F7(4D);FS+-JE0GV5?K:E)-C73=)IQQD:4;%^TJZ MB80S\;#-9BT;K(ON8!2 0('BNJ[1E$<192Z'\'.. DJF866-6 M*':6QWYOJ "#WA>I%!. 90A/XT-T&G1V]0QS3M&IONL'B3FH=.A$===E\I.% M:D4VH]?2(HL?D"KK/ \:F-A(\% .5&XX#>SY"^^:[)7"CJS<3RIJ%1(XZ2%U M2/3>X)SS8VD7Z6U+EYGH@3GS!'Z1!V2-@!WV--M.TN87)YQ/E*EB3NZFBF&C M6\4P-%UNE9!EA8GJ"A.;6KX1"*J>:6Z*D ME$/A8HT*V[?^T2 VN0UB784D0U,^W+*YJL-T.]A<\=Q5?SF+O2*R<2S1!+/C M/=][L> "! SQ7?*B3?T /5; Q8[W_\N@5.S%J$UG7*8UUO>1O;6_@Z(=!S!Z MUA67.N#*2S^KDC^Q-XH)'6^MTYYH0^63MU$L-HIE6Z-82--.T(F,$3R()#JZ MB?/IZG8E@NBY0%,0U:%3'%&9-DK\_QA#/>+259P1D3)-@D"[!@6P ,,$3NEP M76R/S%NQ287@GC)!+,9$ %[3\_"'\;BGG4"2+ R\E%V"=I!KRTCBDRL$X*0B M-1KIE+V+C"+:J*;RY[/1#%;0?C2Q3=XFMO4S0238Q<6*;56'Z7:(;<5S5_WE M+(AM91''*MLL&ZE8TR0^3&F\$JP*S$"54351"M7?CG5C$5Y5?RF&@PL.\U?, M& @G^\P#X$P';["?Y\&1"K&34M62'7(=,I:5?WD@LA&DV? 2I)'2R]2D+8G5 M6]D6+NTOVE#SL4SRT9CD7[@I!4@B/-_0>"%)HP**< 8+XLCE@\2! M3PH/?*TH$.C;])W+F8X):&%7*L^9U[1>AN[R2$9QA-TU!=-GHD:< ^\7\B&2 M3:/:Z"8<(MFU56,F1=+QD7)3T$.&MXSJT1C5MPRCDAZBDR/"G T^>R9*V-5! M??]@*;O"LZWYE2Z\.50R2HGWVGI6'@VH[B, ]6@I4'?SC=( /5UA GGVJ@]R M&\1YGR#.346%:085E(! D7\NCX'A[ [WLA+U4,O3I+AA"-YH/82P(OA/JXH MT*J^#+NF'6/_J/I+V7FG!3$*V+#>5H!.S'B]+H[S1&/+U9 MT!U)>U+H&,II[(*$)_PX5-BIU"M09FSA[IAY<&BJ], &\GVB;U2=ZUEU?E*'<]H$O**Y$B MJQ@<1">589\Q5Z71-N@6".5WMOMJ+T5/;<[A8Z @8[2*%!&O8*K9%=^-2E;D MS%E2L>EVOY"W)%XQ -= ]V-# K63P6C!P-HPL_0AQ);=O>'.0)-+?X22!Y MH!-T\H*&8<8Z* <#@LYT?GRX=B;4KC++YJN!)'(F?!Q(38AO\@$6H\+T(SE" M&4& ?!/LU4SX3@L$ )I,P(H1E4@B 2++I[.KFO\5K-[*%9X?JD;]AV9SLSGZ MJWLJQ.BV>>SF4O_WE,4^+>BBVE4\1(#^@:2HL?]F,\^YB2#B0P"'21/,U*]5 MGI^A3XR44MY4U>'0 5&5JT1*Y9(9+4:*.=KID10JIE3,,*)PTX(#)C%DJFQ2 MK#WCRJE4F8TU] B1F8CBUE0Z'G IX2DF:G+_KKETN<[URU?ZU7.)L"R05(R8 M^*DC \!)8Y9%OAI[KOPFE/@^0(__%,1IP/!\@.LCGX_G>?;,X5O:+F<1TJM. M&774R=6 ;L9PD@*)Y44XE7"B5&%%S]1@ M!7$#"B+'8;*IT-&DH%XB %SESJR^S&]UQ*IL]N;HB(5R:\0+$DPV*B2QE64] MNI*XZ1 V(AQQ!ZXEDL^25'Y\XT8J7SI0H)@JQ^L3N@994$1$S35'7787KRD[ MUW9$S)@29T/VQ=/43+I(U3 '(9F]+3M8E[*66A"NX+ZUBJ(N!MJ7<'B MKK5LG1-@@=,9XFJ&P^5M'JN*TJBN,$+.HM6/)?F+&"=8J#186_Z>J45L;!?H MJZ%C6#3XW.4T*BB)+O3<>2WG]"GT4L0 1+8[WTN2O;@+NX3!BH7^ MRDG1VF$L$KNRKO.CZC,EU*B' C=:PJW M'] UG@UI%W:W1]9L)CM?_86@8'E\/>#A,>J MFA;FG4R429EWR#AT7)A>D$9WEL[[)I!1!)Q8R6I*':,O+GJ-FGM%UQ3PQMRZ M%H4R(V^1$,:5+C 4P.[D0,DO)BCU.ZKLN=BBE#\HAP#*8^_O,865JY^/(@6?-,&59I[M7)*E(L-0@$_TG4W M4L2B@AYYY2MO$%KDX76&@LF2Z+"_ANQ(G094FX\*-!%*2L56MUTNY@N%R&RKX=D;HA"N%7](@.@,3 M([CF SM4JG#U,6(E4ANV)C>B+PSC _]:E\DV 0TK'7D$3M\A27C!P+_"/DL. MU<2"'/K9@#:CON"IR#2)4GUE *E1>ZJ1&39:Z#:7EL@*DRYS:+8#"0"E 'TD M54!NIA5-.-,>BCQETP-RTNR3JO@Z>3Y82"K0A@(T]>I0P3)E 2BC5F4R'=,R M&?*HD?E>J@CF@D/B"/;^'T7UBL$@27PR[-07&"(QL!>-Z(69)65[56'=:_^; MT!WJ5?BD#@!3 6&9/'U_5-/Y#Z$VS/J!<9(G ,ENV9KVY@<"@=+]L2J;VA<> MU=1IRU55([56)V\8!=NL$XX*5C->ONR%2/#=0M$#>$6,?7RX^DB_%O6:;P3U M2C1Z7?%2&=":K2?'^F>N$[) MX'*)$! ;[5PJ'>0?$?B$LA0R&(J2;#)["AY-S"MO<+'8X8270NXV^2 I_Q+@ M1].NL>NUY"GQEY>ELW.T"=8MWX<$E6@#KCB34A3->>N 77G:YF4@5?@HFK MQL^,XD!Y3G70J[)!B+3"J9J@ZLU'JZG4L=_00[X[6TS].<+R2#^GQIBE.@L MX1H@N5*J*SJWIYZ13')?IC]E:E*((U_'*6 N05HW4'WI^(H0_X](S/5;"+^.Z(V1:WR-R(LI2XY2;W M4E/=-NHI"(U51_#)J>]619#N,?5//V,N4,@3", 791BXI<7UBMJ>%%B#=9]< M5Y?1]Y(2HPJ%B0>Y>33O5D88+%V/2T'K@^]YVMK1^O2'MR=<7IQI' M1[;VV4\(UH$1% W43TQY,):>>@#%K%-]@50[=67@!W "\4"Y?!:*M^9'%EKX M_FEV:_" #&4X<_G\K?3H:-!W]6J.7]=?G1S0@B)8130T\]&+K:O%OHR&BS>/ MC^JO7KU:?G_ERRMO'C7JAX=':[[\DB:N)@];$@*S^]?.X4YQZR-_]O9@]CUA M\?J$X:4UL36SS=BN702G:!U%85A?A4\8(.'7&B",PG&60X88;NXHT2)_*R]V M9.00!?U&>KK-JC(DH%%" M8F)7D*M.9&[+R[4@R7A/Q01Q'%A4J1Z$+*I4!!!9C<5B2@4! M9#&E(H!8T%@LNE002A9=*@*(HL9BL:6"0++84A% Y#260XLJU8.0196* "*K ML5A,J2" +*94!! +&HM%EPI"R:)+10!1U%@LME002!9;*@*(G,9R9%&E>A"R MJ%(10&0U%HLI%020Q92* &)!8['H4D$H;0.ZZ.]N,2X5"[-M("8]'$B;C&9? MO!F'N:9UN@;<-?U"5A3JJB^BY4LJ_Y*I4?/P0FET90/KI/VMRR.VDAKTN)VY M,I;#GU7&\LZ[^AP+6YIZEE1:;@R0&&.1R;1D'1:XRV+"A[2#I3#ET=/F8A]D M$ ) DY96[:2H+-6NS)8KVZ)&R>9<5W\U.^\R/8VPN* M'N_78"+XK^HO\'Z/M=]W^F?-I(G*U,?NR +9CV[V2;=4!],1<$:@JG!>P@@& M5I4$36WE0$0^EJLW/3D*C=Y,+X4MK&UWO#FU[4[N2V,?MWKH!E+48+%V\[&M MW?R$ .&9DLVF\4B8;7F9UGOGJNJYJ=Q>4L\=_JNJH^KBRJ:EG.DD@A72U6]D MD7!7$415EIW>@*\+JJI:4[=]5^B"[UA%O9:47X?/3&4\Q7LSX7$WFK/=01R9 MRO"Z44':!:3ZA&5=7OJF^DM1=5FQ"K?F7W/5<^!"-2+%MA-8U/]D7?JX,(G?:JIU%T MQUK=:(2ZQLQ)73)%GVM&", 8V06)*DC2:%4 M//4Q*FBXNK40]:R0HTRG)-4V0S>W<5@_ .EN(G9#XFI+AH$#/]#3D$/3ITK> M.LU"KZ4"$M3PFJV5^PP;6W/L4C8P%C?5OF!48\E9+;^=:[TYK6DS#!D$>#1Z9)A:TNA%2S5E;2% ZW % MUGK&!I/4TLJT^TBT#=T38D$HK+%?&XFE1FD12J.8QFXD9ZYJ1O9K0S\!M]'J M0YW+4@)*[2-O^6Y!>D@%0=4\;2!XD#:7X5&APR1,\_!AT]S]9]44RV<(4N&" M\*A8@IH[:_\=RVONZ@'6F>+REY?.'>7)VL++9;81IE ITBUV0M48#CW+5$31WMM/JUMEC1,LI M'Y\:H&!G3U2'A\H8.>51',AH7L%6-IMJG@K+S%,C:YYZ,H",-$"N5A+<+76= M5'\5.^^ @&MUE6]\[[,P'H0:\7<'F^&P4EQTC[I7#9#=#!0S&]98H031Z%6EZU60>#&G:-8_WLIQBJ/E$ELDLY3!+^,ER,X]U M\M\19..R[I7Y)G;:J;'$EL=#W9I6N?JSS2"!)B[$#8B_8W@?X(K6JJ2;>O*4 MP\,)BM@M_&\J1E.3271)AVP7!$DWQHTG4^W2%ZC=_#5,A$SQ9*/DRIVB2#:V M:=+&/6/^]GSOMU_>'.R?G-*HV,X6EJ)H93H>'F)X^,P'.$3221O6P]#)Q1X0 M4SF4V+A7YMH2D^2/$O\>X$ADO.I#&2"Q^X>61T T$<6M"-)--91@B;=RKD6,_ MXM_A.@5#H:])]?[,M01,M;#6'LO:U&#:H.G@!A 21U+;UCN 08-(#,GP#@PG M#O2>LBL,FXO0EW N!3"A0,\R%)[$R *?WJ=[^MR4*39[QJ]!AEXRW_LS@3V( M29T]V\M.,O%[)&I. =4ZI"#@7+&X4_8FID[3YM**WZ2B5]J[-RLK8V:Q!%TMX4@$ROI! M1B3T,4U@ _$ A_([^H4/7^WOH8\OL5&@!RG1MS/?L39O:X?=8ILWV2)#G[D^ M\L,07<1G8L21AV7B/7Q'\UYD%D#_@?\" XV)U1+"+%"R3-0ROB _;,38%MGZ/<:\97O3:U0BD.98200COA M(>*-:*Y3\UVR 4!YD,-R)6D@?0M5.(IQ"E/_5KZ]K/5+3J,2 "<2EPJS M@W% ,8DI!V/50 L*1E9VRMV8)6(4*C"$8GNU9?3R9^C!Y2?]OL:IVT[3,SVI MYJBV>2Y&:D6HTK89UQ.C7/77L?-N;ZEG,?4G9H+$O!" YR9N$C^.X )U/%X" MW4KMP>LE7+12DUP"J+4533 MI2R=,=E** $XL U#$E^,"5$&QC2$RAR((Y@NQ<= FAT>!$CJT*RKA_6D!V_! M9LHIQA"YW!&)6SY+YLI"B);)*Y%:$J8N5%'*V%0?6&RD88:>%.)).G-8FW)3 M&&@#(QX0@P\G]?U7NX,]$JI3IQF<.@3Y4!T>/4XI7/60]P7H@QQD-L2Z/,1Z MC2VO^J&^+D0&G=0;)T^;JOU\7;:X]PH:E6* J+"@1[/Y*#FBH#NA"6%'J=4=?=H1I[L"@I87BST:_ MZMES-X*OW^0"ME+N?M H"]FZ2XB6Y>WWX^T'U:H"<7>N[GSS_!M7#,?J>'3% MF ?$#S&?H!?/T)\(Q^E_/[3":EF&EGFQ6+_@834I+)B9<.8[\=0$J*'!'S@$ M+1$=SK"*\81Q-HYYP+U(I-%G-S(4-2J*@AZ+)#DF4"%P,Y6$8=*OLS?#F_Q= M3%F&\YUF 8OO#D@18Y%]R!.1\LVFER8 H-PEX^Y5DDCN,NJP03Q-%B\Q_ O@ MQW95*K19\':$*N'"-)'3I[7Z"TIBE53.5IIU!HN!2UL"F1SQJ/Y:L@%DY++ M#$",MTPI)$%+509(V>="/ICRHI)MA'*FC+.3P@?%D#2G,T%F%-;QPC@@@U/+ M#V9Z&]4NWO)\TU&B;E]&KF"=3IK2-AR^^("QF.PKRL6]"*:+=!U(CTHX:X'T M"^0A0*=EI$4('&TW\L#>%(/!$G$+U5Y<>X4(D(Q&7'#[225BDG6PW@3TQ2 HN!MT*#GJF MA@2&?^1TYV5,EO"E*$=0^@?,;\0=BL&BNF(F FOL@^;FI3%5+K])(B%[D0Z% MQ-WZPP^^X?B__7+T^M1/$.R+)W$P>C3,,\G0O+[PW)[*4L#2'B0Y4#T>#HBB MJIFUO0AM'(:9(F&@("]>6-XWNJO)7/X![ B'#BC_7.3D8#' M5=%7SE8CO")MD8[:78%&^-A >&(D4V0K0RV##6ER-5SP$TL&!>8%>G)+/K5D M[%J":53\BGQ821P]!>U38/[BF";F<''(/17*0W=S)P&X@S*WB"3T73.]D$\3 ML5NG,B>[=^/'[C#_5LKE5L,!(]((_=?=C72GZ0&SW;7L7N,3BWNUITIZK2)" MBP1F!6&I+R,I:B?I[?>?6L1^FZ.1=*4>J?CD8YUH$T+;54M/05 @W$3KIE1( M+5& B $0X2L_2+CA)IX/!\@MTDF.7#/#P8U>R7X]];+XNI F9!U&#'/L4X"R)'=%ZPLCW MAZEX.E2[K@\XG76!L7YIY0,CW1:%5VYV$$^5\HAK RN@"6R\/L@J)R:IMA>: M8+XBI2@.ON:A6;0//E\']7?CRW,F8AB#\-6H[S>6FO=6.O/R0_ HXGB!J3JN M#_)!/^, @KF&3_O[1 X %JW[P29]W<+E4>#R3P$NG8?!I;, E\6@]&=2%_>P M7D%_]GWTFZ2RP!7&KR-(JK\D\EWW\_[HQ .:"M MGX*T.@,1"T&,7U%*:]>DM>F81EW9;#':L98(M&63?4CQHC@(A52CS >4F5X,M@S#U3VRY5YDUE MYL7$,@=;,XUD8I:(@ECH*D73F2LBH:'/33L-2M[7\^(S-#,%9.+Y2*8"?3:: M,2C[@0ZC(T.:L@R8TB=_Q8$,AS+)0Y:JZ$C&882/9M92P[K,@6BZNL:D_5.O' A^Z;1;E^:)+BM#-!1KLC>ELHRE<[YAC MBOF:,/8EWWZ,SQI[!Z MPD1TI>STT%#9E%!@+7$>S!$>H40?2I1>3*'>%>$,*]H@]"Y'L(49&_3BR5PX MCP%5J+D;,=*UQ^D3*> 4OJ0>S3"=(W?4<<,2.-,!!33DWLL4_Z'D\BEF# .) MP50C$>[E_#$R94/WJ/^K(< 4'7OI*OF:0=K[EI$##9M0&%>VT M?K8KQ>*&4.P'.:RR5=M5*9&&Z.),Q.N.V28DYN08^&-,1T''AR8/@&Z M?']B:,W22/-5GM12L5SX7EQX> \18]6,]FGD0G MJ#3_L;S&*[JFESZ!NH#;[0TC:\CER>^F2 <;<&#@M?Q\R']%9!V$"9G+(X"3FQ*^R09K.I49<3<,WE$ LO42*2\/0R@=2WF;M MU!X*I4AB:[ ML(I"B>2+J>^).7,Y#8'\)XA=8?SR280EJ5&KZH3BRJZ:_6[GLH\1(\9VN_Z: M)SD;6-*K8H3/[QX7&VS- EW&";]8(7)$<]0 B7555#-[=$!HTJIP0Y8$O:@HLOKGK,L;=/DBTKW M%JH-JCJ]I(G>$]?6E,QQ N+[3'AAWB9#(JFI*9P\@**\MJ$7BC=CUZW$P+Z7 M2$FE5O0G"%O8O)-UM!V>]*SJ1=8C.$Y?>8!)5!EK^Z8EB/?7T#+3@A_JJEK[ MC5I[>*O[B$QDFNH3(\?NPBKQ8G%';W([2J^FC@E8$9>>JE]7_?U=2VDXK/XZ M5JB0N=2#G-66# 0H#1?EB%N 3@=$ QH$E2D&P(*8@K*3%J^X^TQOZY+U99Y8DD 7*VW//J>(7@+69;YC)8KC# M=T?,HH(LEGJ?;EE*KA!N($9"5[,'I(-#BLH#CTS/9VE:P:XS,$&^46G('VP0 MX&W\R'WB1S9*0BK!;9EIP%S3-F9"OBQV)BH/-D?*%@\'%&E?:[G87",WDVI( M3,DMNE=&4LN6Z$>8"<)?N+#$8'P'(?C1(NHV#\;'VR$%)V$Q1SH LD M57]I:XN\RV3=>Q<4L;&D9;&DG8C,=1'_)A2S2QOTF,@?40S$("G%Q!YH0H7N M-#*2:7^#"F>8B8#,IHG/*QMR\"35"+<3FH.D2UQ9540SR)L?"N]$/M?4A/<0.0#U:9XD.&\QE.R@L)8V)"7 M,N=4DIFQ4^F/F_+?#NE;?KHK.@\-5&LLF."J8PYSTA>P@+N,:&JZZ"I:X'=O M)JKB079T@%2(E6#(K);F6*IF4#B*2MR,<)8/,W-97"D+Y[SPZ3P;)5K3,Y,$ M66.8)@N'@LYIE@ BN%2WY[3R08V4\&71EED5_0HP#)LW92+6(M_Y-O'=Q$65 MG+D%B]9>SH=4&M-52HMK64*L<5;/K(!L"T3Z5AUWZ1XFQ,QIRG*-DG,"FKF@5D7L6OJN"K.9FP010TW/^0U" M/5&V6C[6OG0B['F1EEHT2;[9OD2$0"HD.>E,),6]^V \=U7HU7:H0ET!S%MJ MMWSUUY+H/DV=_[E@S4V"<#-U1XM,@*55D>CYU(%=&KJ+)C#C/N Z0%S++$_![Q!W2;#(*N^JDJ]H+!KXG'1V,SG;K ML^%HKRRE%R-GTL7<@<,^%\1^LQV(_?'R/^WN1>?B(SMO?JW^6A1F?^KT6/-C MM]W^W+[HL^;%&?S[!VN=-SN?>S76NKSH=W%9O3]J[*S3N_K2;[/++FLUO_3@ MQP?6;/4[EQ=L]^NG=O]3N\LZ%^H=N([/]2^[]-]+O/FUTVOOL??-7ON,?;FZ MO*BQ9K?3P_VZ_-+'P>#!;ON\V<=+_MWO\ 5F&>SU;KLGC4O6FWVM=/_5*/! M 7(X$_S9ZS?[M,:+]E?VQV7W?^[$E)^Q+'RR'>C\TW5 KSN\35+EG_V3IP:NQO!Z9\ M$IP,K=5?1J(P3O24D\QM9?139QW-)8%(6XMBO"2(FM?"DRK9R--FZK0EM1:! M;T RSM18FPKN:<,/%R>2Z MQRL4509T.9UQ%=MM:HGIV),L!U1OHXV)7RM7!24UCSCZ"#PQ]B.IC4LJ[ J[ MR*D4Q=M6G9TU>1S48YFKY"0 \N%/0=G4=J-$#U;51:FUNQ^2JCGS0Y5W23R= M)\S\+C.IFZ9ZJ6-CI/(G-; I4HPVQXG1[Y>K=)&EBC2 ]G@'*EXV_U'=[C$[ M<.+:R8[ZLPBB>@\3!T50=?+WVR\GC8J0/OKP6QG!]CGK3#TI)L$PC,Y$H%1C M+;=N^N'R(!D;P+AF :S-$S;:VHQ9HAFAN]7!?M]#K)R3FA5+^)!BAJO"1]+D M>R*<(QE@Q?&!#\K638"UE4MHX2KR]K![587&^\MN]_)KN]M+HFO:5]UVKWW1 M;_8[_VE3*)N2#=7_?VWW^NSJ4[/[N=EJ?^EW6LUSUFMW_]-IM7LUUKEH/=ZF MEIWY@\8&M"E[/U?]%/Z\Y9_M6?$%GXKUHQXW8DG45Z9\30\]T):Y;4MT?O/L M<^>BT^MWB5BRYD>@FPLD4_W_^^;%_Y"E_W.["U2SQB[JS7KM#OBR>;L#'+@L M\^]1UGQ7EO$S1JHJ'"P_VH(E67[TI,K6B\;143%83UVJ^+DY;U^>^:$?2-.\]T( M^T8LR1+VGT[82VC&YB'_OZ\^7W8_-B]8ZU.SUV9(R4O(]_*S<9<]N.68/=Y0 MEBIO(@E[7E3YUC7=]8C;EB"/)*1O*L7X_.7#1TW S_MG:Q+PNRS\\8BN)=^6 M?&_ DBSYWECR7?&3];5]?MYC'YK=CY=&YFYB#'WSG#5[O@"R)'T+EF1)^L:2](J?K*N+UKK2^ .\ MEY:@6X)N";HEZ-M T#>/8GRI]^I*1K^=QE>,"%MR;LGY!BSI!X2B/"AA\%%? M^^$K>'C)H=5OR>&_=N2?^W\>GNP\WB9:AKF"858RB?7UW=/BG8D8QJY@C4P; MRDU?\,?%+?/WFSYLLO"8P*E'! PAGW_K5SN%,,G8O\V=N#V?&NO@J#FD.*XS=F@,H^EBPPR*EOJKB]A;OYL+Y,J+7" M@<:B/',+#J]-"_(D9$VZ8PA"@MD:-G;7?^RN=\6U[U)7<5TUMI408PN*GPN* M=.>QG#ON"4A,F 6_ D:A!=+/!=*25DE;C#;Z\00@2YZO*L"68M7MD,PCUP^0 M!#/ ,FOKX]K\ +^ M6]_??RI86.38>7=P7-\W__R718HG18J#@]KQDR/%QLL$3XLUELD_#43^??69 M.JNQU@2[$2//MXS^Z<'RZY%E]-6 1,,R^JJ XM?&H67TF\'HEV.-9?1/ Q&5 M+$OL_3P:6O9NV;M%"\O>JP0*R]XM>[=T[)X0^2I<-V0?>##VC1)/P3S8N3H, M?4?F0WNV$JFJ#B/+]:L""6Y5<,0+\> M[EN67PE(-/8MRZ\(*'X]J0!.6([_(*2Q'/]I($(5&ZQ^7TG86&9?%4A89E\9 M4%AF;YF])6/W@X@JW8'JO67V58.-9?95@81E]I4!A67VEMG_;#*F/_RDN/4S M\BG[?L3=?)6A#6(VSP5*(!9LNESP7$#5V-]\P>&YP.K7DRI@535@M>%U 5:@ M'8D>+ZFPTV-4F3.5WXY>;U;E-UO?[?&JG;7_WZ?.^TZ?M7Y:&<6J[L1OOYPT M3C]<=C^SRP_P^_"6 IR;M+2+RWZGU<:&S.\ON]W+KYV+C_>H5?GDJUM67O0R MTX5Z2>?I9H\USSYW+CJ]?K?9[_RGS9H?VQ?]+=J%#]W+SYE]^-KN]=G5IV;W M<[/5_@+@;YZS7KO['S@'O1KK7+3J=^,5)<4V7U"US1S[I2N;5V6XV\[LG"YE MU1P'@JKPL-UH(MAOO[PY.-A/:$)U5[.R9&>RJ.JO PDR;'GC=*_&ACP20RS$ M[8_89QXX$W;PIL8.]ALG;#!7C1>FOC=F7T48L:L)#Z;<$3')H*PG@FOIB+"& M=97JVP3,EC\%H7Y>_55D0>F ;L"EQ\)X$,JAY($4!%8$BUX0F_$@FN.50$0^ M0,P?"_R#WHO(XM3B 6J M2&G(1H$_91%\B 'JT']SV%0CF)56+J-.!\WA5'HRC )2W8 ) J^HL=Z-Q(XV M,(>5S6[JK,5G,@+6_P^0:Y"+IR&+0_@YB"/F^1$;BA&,,60X%Z0!$^ZZ;,+A M0[B$J> >#!:R,7S:H_E/Q)3!@W@W85V+@LOC"">;*/1=Q4$8'/FNZQ,A"\3?,4B*]^U(4=4]:M098_V)#,T"&?P< MP1G==2:^'PKF>V+O[HLNHZ[&@%?E[?CMEY/71T>GC#698NL(>CA&9.=1E8M% M0(8>NE*LNDIWJ/!J>.0X;&:B-Q! LM57T9SL.?/5G5F:PFYC=1-HHQ_>N MD5;YGMHNLY]P/9)>3*1:WZG*D:VDQ7/)=K]X\>*'&+0WZ,0UZLJ>=>EMNI#" M5O]3_=7A$G8Y>Q^'<"<,V1F?[SUS>GB@3V=':7=\"E.+$EKW:\X!4]UU/.#8 M5G]QL ("AE; 4_G9B8- >(YNS6=Z\Q'(UE/.M_=8'^ICC1;*0*+MPQ]E? N) M%/ >B\EV>72;<)0/;GBSO^Z^+7^OJCN7;,UYY_UE]P=MR\)QVCQ?U9$^81] M8LQLE<9%,I&C80[E&O*&P&=\/(6 IFP*PT\(I\.[8NMC-"'=T!T_3@6I@9AP M=Z1V<_D_%:'M].&W9(]UUL1 )/8P8,0\/J5>)*F%A1G;^!JQ$8]V<#;JG-#^ M?44$!,R;"8>LLF'L3%*U69FI$E\/FO ;KT]95\S@%53DR.JN35>!N1J2N?V& M!P''/Z()CQ1GWI5[Z@/&X., VW'1HY:XRO".5%HB^=FJ<30?Q4I<_:6D=LMB M4$$.B<)X]K/G_ZI^O,X"2B(Y84VP\S#EBF\\HLRN! 0A!Z4&@^-[0PHS#%DH M(C2. IK(C5>0#58@Y>25BP#>'86^-XZ>QNPG)UW6^&<;;#=X8;XPLM)>L%/:]ER99?R0]AR&:%9]6&35 M]\V^V5"WV[V,"AB2P:,XP&"TL;$DE]L1'KIE/R7]Z G.['']S?T/[5,J;"=K MTIZ.Y[CQ4%# 2D(^PK3+M @T]2@Y%IL&CX.-A<M9 JDM@!3 MR.V3\ZQ;TL<*@8.8H2!'J/AI;8X[3AQP9YZH?'X@QC[:'-:R@F?W8'U?R>UO MO?N=$H'-RU,>C*6G/&(\COQ3?4&E.=,5G1@-.^OR62C>FA\+A1&R$\%=',IP MYO+Y6^G1_M%W]1$Y.:F_>GU"IT371-'ST2>HKDZ0R43/W3QZ5=]_O>+^RI=7 MCWQ2/SE<]^4J%739N(I&9R#V5[+HRGH[6?F@WMOS.&MWIB=572LHD[=8\C8L M(ON]"I%9Y2O^7QY9N[IKZ,W+)%K:C'<4\AP%3C.#ZZ M4S6.)]^XTIH#*^UB[>\3.9 1Z]B:$UM<<\('CDP60513V%4@9GR>33W_ 4#? M$%]7KF"%+ENQ-".3CDA96F::!["0GKGV4;IW*-<+TA)S,M:&1G?E:C^45X!X MS ($ %-V)3POG+O7W),;0]6 MV"H/58)"]9=1Q2H/;!<]^E/\/:RQJ3]$8RG\@AW7US#P'!DF_IJYP GAEQ\ M59W-7&*HP$L75K!-Q5R* D3UEY,<-!"&3DZ94U['0]?MP&.!Y3Q\/&XW,A1) M88]E%3UR41UE(0;KI<,]5E&/S54=SIK]17F5E !EB/T1+O4%.\;F;5L_$R1H MH@'A!&LW#]:5**&(*B[0KU@8TA)!KM2F6(G8FM()ESIFCZH45[[) O,L4Q8( M3[4:6LM]^.7I]2K\*R;?D]$;]B&VPA0UJE ML^^&CU1NI['_9H/V=2$K]=?JX^K]$_DKQ6OONK92-GR\,AM%'\F#Q@8XE#M% MO$Q0OI4M8;#%QW,]\G*T 8[89II#4$ANWW88+H7EG=G(1M6!*)3(T 4.MIJ7 M;"E#>;4.0WE(%8]-.=)+),YB2.\R>7*+I2EKM"JQ]0E7 CY1W#'WF/@NG!A- MYPZ>!1&@Q9]NL4)Z#2F=,B0#ER/003WBWUD4P%RF,L22@VB-)^,M$RZHU('O M28=-N73S3^V*^KAN3/*SX<@XA*A6(5V$;30."FW['0@F1B/4TZ\%:JG#["+@ M&UY,JNJRQ60F?DMT]39%!ZW*G:H&MM\U[:LTXVM#O)X;FY:V9!I/EQ*RM97* M&FOTUUD>E[UY2UX>L_03*]=MVSE:)SK\UBCQS5MV$B6^LH;:UBT[#21?8]U_ MLM4AG!:Y'DRDL4GLN8WT^@-\20XMJ;:DVI)J2ZHKO=VWD^J/W1*_E NB@N.?GT0GN8+*6VE-I2ZJIL]UK6Q[/V>?-KL]O> M1O-C0KJM_=$2:TNL+;&N\'83L>ZW6Y^TG?'BLMO_Q)J?VUT@V5M(G#W6#.0_ MOE=1Y]"SC)39W.-D6=-S6K9E34_*FCYVFQ=GK-N\ZIQM992951LL;;:TV=+F M3=CNU,;3NKSH=YNM/OOT"[FU>7W3:[ZK?K M[+Q_MEVNH[6H> \6Q6=^L-A'SAXU2\755#!5Y2U( @ *\6 0 : 97@R,6QIN^_3G) T'C$$96/W4>['WK'GX=[Q#?3 M@ P_OCX8]$BM[KJ?5GNNNWN\2_:/WQ^0-:?1),>:RD@8H20-7'?OL$9JOC%A MVW5GLYDS6W64GKC'1VZRJ#4W4"KB#C.LMMU-IMB?G++MO[J/ZG6RJ[QXRJ4A MGN;4<$;B2,@)^<1X=$KJ]<6K>BJ<:S'Q#6DU6@WR2>E3<4:S^4:8@&_GR^FZ MV=]=-WV3[EBQ^7:7B3,BV*N:^-+XTK35<.V$;&IDY@%_5?-YLO3V6LO97 ]- M9R:8\=O-1N-)IY:^;KM[HJ2QB].VJ>"I1NZ\GX>6M]?27_GS2Z7UX/]PY_'SWE;QK-E.J)T+6Q\H8-6UOA&G(AHX#GI=9O"+@)Z9-8Z/R M(FF39%/&2C.NDS0#&D:\G?_2N?!^2?GL;R&9?>]VTD^8B,* SMM"IKFD[[OX M$&QM.2_75]//@;%K9%A>G\5GQ,D^(ZYAW\_N<1LRXIS1-*MTFMEY<)R^SJS.0=GJX MF'5E\XEN55ZW&AGEG?[NG>G#3'(=^2)(C+@^$QZ/5HA%Q3GO K^;(A5*>V;>*/R50JI/OLSVU3/>$3;]G(_>$2;=-9!C0R*Y0M&1[(]A;@DT6]M9N MX/G\AVFV*HM1]@VN0FG:X933>/JXN='H7(WSH2.L:@>\/BU\E.^>Y)-+(6*+ M<[\TC[GGD[Y]94CV8JU"3@[$5"1[S)^S,27)8/D%>NW];G >%];9\@1#05;[,\ Y85FO6LEG]EOX[ 97S]T[..A!<.S?KE*6 M !R PY=K ._9-]'4,^0]E?&)_276MLXP'(;#P!E<0* MTD$Z2 ?IY9(^D$Q0,M3BC)KS:WQ@>@'C]"18F [383I,+\5TK5CLF8@L3F?& M+A><'P[,@3DPKW@#WW3C*;*C)UP:(2D9.3O0O("XSQ.%Y_ 1XK4 ?J0!VHEXOZ/[C3 M=W'[6<0WA;TL8U .S($Y,"\;+3JUX\CT9)81-"_BVJ%%I/ %ZR MYUK.:!#@PB'PW-X7OD&OM'S72JG5)^2G:>/US8[(W!>Q!VWTDC!.3@' MY^"\7,X7=_LC.]Z_L8A$\@AIG."">RF"=M .VJO>P+?0'IO(\Y,]!:0_'>^3 MGB+O^F#]_K'WN0U4XI:5"4<)R6 Y>?L+RP0"<@W-P#L[!>;4;>#G.LV>BD4.EC8\'6N!1^4;>"G:WU(;ZPKIOP/H]T\\#1.<@W-P#LX? M@O,(8_.BQN:1IARW1(?EL!R6EVOYP- @O;!(.P>PO C+;: X-@K*03DH+Y?R M=TISBC%Y49>()H<@W-P7O4&OI'S M0Y6<-,T$K@_%]:$52Q*6PW+H<@?+U]0:^3?0WMK!@ M%* 7-D#/ H7G\!R>P_-2/1_Y5$Y\*LA[SM(Y1_%XS#49:L5BSR1/CG9P:5%1 M3='SA83S?%'PD-X"/] MPF>N8\@.U($Z4 ?JU6[@&U'_FTO^+>8!)3T\T*B0N,\3A>?P')[#\Y(]US,: MF#BY)P#NLHN[[%8L2GC^AWKN&CH.N/V7B;/M;OHCJ_ XF;FH>S[OO*U5)(Q0 MMGWL<,F(,]Z9"69\F[/MN/XBXI:SN9Z]VW4EZ3A206QX9]$_&A<7<;G,A17W MN#1755 D9J%P<0, #@, M 3 97@R,V-O;G-E;G0R,#$Y+FAT;=56ZX_:.!#_WK]BFM6U78F\"*^% M%.D*;(MNRR)(A>Y399()L3;8D>V0TK_^G ?JMJ6K54]JNTA8'GOFEWEY9OSG MT]M)\.]R!HG:I[#\\.9F/@'#M.V--['M:3"%=\'[&^A8C@N!($Q213DCJ6W/ M%@88B5+9T+:+HK *S^)B9P9CO MD2D(!1*%$>22LAUL(I1W8)H-UX1G1T%WB8*VTW9@P\4=/9#Z7E&5XOB$X]LU M[=O51_PMCXYC/Z('H-%K@WYT/KI:#5L?U*=2'5-\;218H@\[;:O?S=2HH)%* MAJ[C_#4R*KZQ'W.F-)S0PO6VQO@.2>$G99*4[MBPTK@$* 5.]UL2WNT$SUED MACSE8BAVVU?M;K=U^H-C.9>C^N["J7ZC$L",R9ZFQ^'+@.Y1P@(+6/$]82]; M4D?#E"AH7#-*^AFU\MJ.BBQJV_H:)Z4,S<96MUU9-_N4T"W5CO6^-NR\2:%V M,8J336?\\1BQW^Z*SCE75.I&&')!RLP>@M8+13VP^+8+YX"]?SU?M?YM/S8G^ROXWQ!B%!@=LC MA)S)L@@H#BI!H$Q'(6L" ?I>8*P965A>51PKW%&I&H:UTI6C?/P2-'7-Q1[6 MI@>O%MP"S_-,U_,&/0\(BVJRTW4'OR[OZ2B";VN-_^Q,BZK61IKG#4*.9\/\O^S"SQU5K/ MU-5T/_X/4$L#!!0 ( !>755!*><]N30< *@F : 97@S,3%C96\S M,#)C97)T:69I8V%T:2YH=&WM6FUO&S<2_GZ_@G5PB0/HU2]U*[L&'-NY"MA^_3U#KBS)DJ]._,6JST 4[7(XG"&?F7E(\>R[ MJX^7HW]_NA:Y+[3X],]WOPPOQ5Z[V_U\>-GM7HVNQ,^C7W\11YU>7XRL+)WR MRI12=[O7'_;$7NY]->AV9[-99W;8,7;2'=UT6=515QOCJ)/Z=._\C-_@DV1Z M_I>S[]IM<662NJ#2B\22])2*VJER(CZGY&Y%N]U(79IJ;M4D]^*@=] 3GXV] M55,9V[WRFLX7>LZZ\?FL&P8Y&YMT?GZ6JJE0Z4][ZK?>;WV8T<6+^-;YN::? M]G)B[8.C@\[)<>5/9RKU^:#?Z_WU="_(G9]EIO109]$Y?HTZ-C1Y^N+;4JM) M.0@6LP+NL&@?R^1V8DU=INW$:&,'=C+>/S@^;BW^B5ZG]_8TMKWJA;]35M#. M9*'T?/!FI IRX@/-Q(TI9/FFY; :;4=695'0J?\0C(^ M]@^"=]?_^GGX;C@2A_U.?]VU.[>?I^EAHE-*C)6,Q(& 7619#%Y=7M^,AN^' MEQ>CX<;0MJ)*MO>5(,?J^>#W0=FH]]9 M./M\K5R;XWZO?$IE[:0"=5>)1#]!]FI2LBUQ+!,.EC^'U_2\A_L[/*_DPZ+CA4N MYN*V-#--Z81:$04V+G]J8$-I4!@QA%2ED.4<*<[;FN I2F6HFL"%% 6>K (< M,IG@E16F4%YX$^4V!$H"8IRTKT[#2X/TX9\/TB0R50(TC+\E2%K ,\31;%?:59DAY85ZCN^)KE/H!!!7 M$-$"B)75P,O=&QIAE ;*VF*)6D, P#9 7QC.!7L2Z7*1 M:3-S"]1;FBCGP7>]D/PRV@TK6RO@=0MC-JQ]:?@]VEG\CM86^XUKL-G0*TY> M)LM0:^V^>QLP,!324D ;T*/&FA@5 D5:CK5R.?=@L0*YF_,W/Z?*)=JX&OTX MJUNC(^PJ:Q)*\=J)?: L)< V0NGZ2Y++,T M/L5'C$6VC'!G_8*SZDH41%2R+8\>*%L;*,- [.?]V( $,YHG,="3@YW#N]PY MO/<[O9,PKU?DL$G%ZH?R_50+[E1)!$Q2:\E%!VX%(Y:\!3TB"UHE M;_@V)A9$74!_2I]4!W8P+L8[%Q>+.K >%H_.IQO1\?A,_.@@06!-52EV'9,IHH2P#N593K+/;0I+!FQY1%N+C=L8)-1_;'^TXQ7FQG0C!3G /8$X#+ [P@\*8[!]Z[9![!L0DR/DQI"&]H MN8?AKTC>S%A,DM260;1"#];T%<9YO$EXOYK!)JCXO0:O@-+]#>$,$8!4>D^N M,1,[5 JG/GP@%(X+HRUOHR6Y='?\B9-PB!A*0W4*WC>58RZTNB7=' '=DV\] M84*>'!\[N.D]WMGX^(9-;SBW3A=QU5HF2L[;JSA?YDS&ZU<0J0V&#[LD^+TW MUMVQEO "RHI">4^TM1*-#1@1MZ0*-H7N^X@#)'['A07_\_YB$;#T>ZU@<@C1 MNDS"H=#;_^]GGY^5#_"4"PW*"@JM %@^DN##C401X-4PCKM]Y8SD+5.(2&$# MB0CD.QR=+PX$OPJTS18P'@AM2;$R14='=QEV"\ ;L@YAR[]I(K("@W&@+ZXN M@"),4'"CJ6!;#TU?(CO9W:WF!4A(9I')6L /AYP+^S\L&KU\= MG9RZ\+G^Z[Q8_NV4M]CTK;JQ8[9_PIY/<8(+Z?(R5Y2)ZR^4U+QU%!\CH?G3 M(!.;'"2+P%/$>QI;;!?FKU_UO^^='O1;\;K4@\6@,O$6UR">KDYI]>+3O2M1 M>]M[RK$SNO9T.C;>FV+0V[P[M>5F%!-$LHO*\N"UJN8SWN$*M\G._PM02P,$ M% @ %Y=54))P;"U/!P N"8 !H !E>#,Q,F-F;S,P,F-EU:VW+;.!)]WZ_ *+6)4Z6[[7A&]KC*M]1H+DG*T4YFGZ8@HBFB M#!(, $K1?OT> )0L6?*.$[]8XTU5:)%H-+J)T]T'($Z^NWQ_,?KWARN6N5RQ M#_\Z_W5XP1JM3N?3_D6GEAT9K-9>[;?UF;2&5UWO*J#CM+:4ELXT3@]\4]P)2Y._W'R7:O%+G52Y50X MEACBC@2KK"PF[),@>\-:K5KJ0I=S(R>98_UNO\L^:7,CISRV.^D4G2[TG'3B M_4DG#'(RUF)^>B+DE$GQ8T/^V?VS!S,Z>!"?6C=7]&,C(Z]]<-!O'QV6[G@F MA-('=ZDNK"09U!Y_@SZMC0Y.B+:W$E)\4@6.P5^ Z+]C%/;B9& M5X5H)5II,S"3\5[_\+"Y^,^Z[>[KX]CVHAO^'7L%K93G4LT'KT8R)\O>T8Q= MZYP7KYH6L]&R9&0:!:W\#\%X^!%N9]&W(^A1LJ!6[6NO'[R[^N.GX?EPQ/9[ M[?ZZ:TNWGZ;IX44+2K3A'HD#!KO(>#%X=7%U/1J^'5Z$F^J<(-6 M[WN,6G(A$'(M1:D;[+_!DYR;B2Q:3I>#'\JG ^![7DFOO7#VZ5JY]HY[W?9A M>*U#EO$I,4-323.D/I=)R\Z*HN**75.IC6.Z8&^UR5FOV_J%Z91](NO8AXR; MG"=4.9E ]".9J4S(-MFP2-J8_A^>T_3W=W;ZS[G%I&.&\SF[*?1,D9A0,Z+ MQ.D7&C84&M410W!9,%[,D>>HEZ&T@E<<);CSDC (>4)'AFF<^F8TU%N M0Z @(,9R,_MWN$>12MZAR+>Q5N,Y3FB6NAG M/JNN1$%$I;?EP0.E:P.E&,C[>3&4?WL67^#$!9O5(D33HRD!!Z:FK#?D84E0$/7X1Z+#MP*1MSR%O2(+&B5O.'7F+P@Z@+Z MDWA4'=C!N!CO7%PLZL!Z6#PXGVY$Q\,S\8.#!($UE<)CGUM=<%]RN$7<>$;N M X(;L0 GPD7RL532S3V3V3:L#]6 XP#1&&5KHBN,/E2V+[5#965*A(@-S"M) MM!'!@,#M)U2 4"E$"EJH]"'H1;!NB=& 4)4EBLMSBX=DY^)A62>NIEQ5(9EZ MM%":@ES+*>;9;B')X$T/* OQ=CMC#LA'1Z1T&WGY6%?N_K$?4KCX4IK\HB/] MZW4G&R^6,R&8*;X#V!. ZP=X1N 5.P?>93*/X-@$F=],J0EO:+F#X:](WIZQ MZ"2IC ?1"CU8TY=KZ_ D\>O5%#9!Q><*O )*]S:$4T0 4ND=N=I,K% I[/KX M#:&P71AM>1TMR;A=\B>?A$/$D C5*7A?5XXY4_*&5+T%=$>^^8@7\NCXV,%% M[^'.QL5,^(WGD)$"AM(1"#?8>M\ ML2'X5:"MEX!Q0VA+BN4"'2TM,^P6@-=D'<+&?]A$9 4&8T%?;)4#17A!P8VZ M@FW=-'V.[&1WEYIG("&I029K C\4,B\0&#Z9U%!MQJHNBZE64_*EO>"3^LN/ MJ9,UY:72G[JW+I0ZGNH:Q(W6*:T>A+IS1*JQO27 M55#DFKH*^@, "D/ : 97@S,C%C96\Y,#9C97)T:69I8V%T:2YH=&W= M5VUOXC@0_GZ_8I;JNJU$7H%M"RP2#?2*KELJ2-7=3RN33,!J8N<R\ZW>FN11 1SW@\SS,S'KO_;C0-PB]78UCI+(6KZ].+20 -RW%N6H'C MC,(1G(>?+J!MNQZ$BHF":RX%2QUG?-F QDKKO.LXZ_7:7K=LJ99..'.,J;:3 M2EF@'>NX,>B;$7HBBP<_]-]9%HQD5&8H-$0*F<88RH*+)=S$6-R"96VU IEO M%%^N-/BN[\*-5+?\CM5RS76*@YV=OE._]YUJD?Y"QIM!/^9WP../#?[5_>J1 M&PX-U*.%WJ3XL;%"8[W;]NVC3JY[:Q[K5==SW1][C4IOT$^DT&1.T>3Z;VWC MF26-]]IB*5^*;N6Q,6 F[.0+%MTNE2Q%;$4RE:JKEHL#O]-I[G[@VNYAKY;M MN=6G9PQ8",=P;<_MP(;Y.*BD7JOCOAWDPSD,1].K<#QZ GL' M]L3] -.SMP,W/!_#?#@['5Z.Y];T\\7X"PR#D"#2ON3ZSW#^4;+_N>P_)Z'] M,@D3 9$4 B/3 &#-]0KT"F$H1,E2F&$NE0:2G$F5@>=:/X-,X 8+#5(21258ODY+., 45, MK6*$$68+5/M[W@>WU_*:% 7OI FL@(2GI/#@VQRC4E'#(A:8B&%\'ZV86"+U ME2SC16%PT-=HQM2$8(4*R>?'#M6P=OZ0QTT8*Q[!)QM^4HBB"5<*"QZ;5F:6 M"%8<$UJ(%M;\#F&:) 15&2J,U2V^)M"8Y@G]R4M5E(QF:_EXU]BR;':-"AB+ M96[:Y&/UG9*IMJW].5,+)K"PIO/>&\K) ^\00L*] MS;ZD3-,-96F6IR;F#WF@\)>2*S0'A<(0\HW> W8(E&->YR ^?"#Q6]8\9,R6 M2>^DU:[CD56Y2'R>]$S@WQ*G?LTI%U1]&:N(HL+7C%1C&JTXVA'.N"+&7UW)VN\/),M M"IF6&GL+J;7,NN[SR]O?N8X\>=:7R.HZ._@-4$L#!!0 ( !>755!OB*WR M!@0 &P/ : 97@S,C)C9F\Y,#9C97)T:69I8V%T:2YH=&W=5VUOXD80 M_MY?,4?47"+A5^"2 (=$#%%HTQ"!T]Q].BWV&%:Q=]WU.H3^^L[:D$LN4=_4 MJDV0L>R=V=EYGIG9\?;?C:9!^/EJ#"N=I7!U?7HQ":!A.A8J+@FDO!4L<97S:@L=(Z[SK.>KVVURU;JJ43SAQCJNVD4A9HQSIN M#/IFA.[(XL%W_7>6!2,9E1D*#9%"IC&&LN!B"3G[]3O?:=:I+^0\6;0C_D=\/AC@W]QOWCDAD,#]6BA M-RE^;*S06.^V??NHD^O>FL=ZU?5<]_M>H](;]!,I-)E3-+E^K&T\LZ3Q7ELL MY4O1K3PV!LR$G7S!HMNEDJ6(K4BF4G75V([*1U0O<#(OSCM_\IA,)Z%D[-), PGTTNJ MG=G\>G@90C@%[QBN[;D=V# ?!Y74:W7GP\OQW)I^NAA_AF$0$D3:E]SGY?-[R?['LO^81J]Y']Q>RVM2%+R3)K "$IZ2PH-OT$->JJ)D-%O+Q]O(EG:S MC51(62QSTSL<]]Y0DAYX MAQ 2[FTZ)F6:;BAMLSPU2?"0& I_*;E"\^50&$*^TGO #H$BZ74.XL,'$K^F MT4,*;9GT3EKM.AY9E9S$YTG/!/XM<>K7G')!Y9BQBBC:"30CU9A&*XYVA#.N MB/&<:L!PVS1BEJ9 TVAURG\2Y$1VT:QF)0]U00;CZM.RJAK2*M,Z-))JOUJS M^*9F[']XWWU]H:GZ:(R1K GJ OF%RJA1U/;WVD>]HKJ_L&6]*IR-P:L'\)<; MQ)M)TL9@1+5?]1DXPX4JF=K4G=NO.K?__+/XSQP6/OF M6-=X>29;%#(M-?864FN9==WGY[^_/ ;4$L#!!0 ( !>7 M55#0F*[O"!X "*X : 97@T-&1EWF7&\3K/WYN%9.]WIIPY$0A)BBE0(4E[U MU_<\ ! @*5N^[7;LM3*3Q.(#/ #.^X6W?WCWR]G5WR_.Q:R>Y^+BU^]^?'\F MGNT=''P\/CLX>'?U3OQP]=./XOG^X4A<5;(PNM9E(?.#@_.?GXEGL[I>O#DX MN+FYV;\YWB^KZ<'5AP,'1H?A85M=Z*?E^K>M< M?>O&>7O O]\>T$?>CLML]>W;3"^%SO[R3/_C\!]'(X#C *[P95.O;2H3VYT5L_>C X/_W3RC![Z]NVD+&H8K((W^4\>H#=,K3[5>S+7T^(- MP8L#X ON_EBFU].J;(IL+RWSLGI33<<[1R]>).Y?<;A_N'O"][XZI'].<("] MB9SK?/7FZRL]5T;\K&[$AW(NBZ\3 WNQ9U2E)_R@T?]4 #S,@W[>V(G!.+DN MU)Z=Z&CT F=W_FFFQ[J&;7T>SVQX3BFLL*K?;A_<75^U]^ M%K]\#],\^_7#^ZOWYY>]*=YSJW]K3*TGJP>#]\^'YW]J1#D1[U2JYF-5B>-1 M IQE]#H1]4R)M)S/RP) +]-K?.RC,K6XF,EJ+E/5U#J5N;A4U5*GR@!B%.F^ MV/GS5Z^.C@Y/\%'ZD0$8ERI% MIBI&1SOC7?PRO@\7FPJ8+2J5O0)0 G3C'\#)("["5WZO8%)3#1L[7B5 ,), %N*5.';0R"<5H"=N2(0 M 2]+_)0DE-IIL20)T=*]X?$2O_K=*I(YOU.54P1.5N-$P97S6 M#1R]>09$!$OJI;[_;"*43&<(]LU,PQ^P%-K#3[,/)H]@%4)9T;5N*8H"UDY\ M4+3:L +?E]5D@# L.I>+J!$>?:X):W<-4SC63(7X8_I5C MC/9Q<"&SS.I$ #OL_9Q6/A&PP=(H@%]F@Y#V%H57%)Z4BP6@L!SG:@#]+E11 MF%6^E(66XCM4FY2!P8(]_U'>,)=X]2K<2S&IRKFH@:AH[>#_T1Y=?'?VH]L6 M1_8/F94_#9YVASA7)JWTHK:X>B87R/W$);*BS[,\&C"IJ-\*J92O$E=K)L&(1,F0D>F!KC0)F>)P :/BO,,"$ MD%G#/FOD$;J QT9\,W@ L2N45ZH,+' M>7G#]]O7[M0#X$$Q:?)\!;/4&7VY !%A##!K9.R?B7M]:>3YM[+&A?^ U\SC MH$G0(]2B1F6E1,WH1ALKQ3/69W*4SJ U :G"FAS I(>%$'R@S"2K@1^?0W1 M(.;-RARHNX_K,[E4](#ZE.:@&<"O)2_@HKQ1%9.F6BK0=WF(W@C 1 !_T)." MNAVH3S2"0I76OD@TT'O/DX@N"( "= Y')_2&^UXQ2#KCLKPV=RR='1G5%&=B M]32H!-0UT. !4%Y?IT@*R0:6-E;_KN6U*G W:'9]0+M$+G8((K@D&0R56YL- MGLMT!3_*RH Z"^HA#)/G^)& '<.72+&;3#3IATL5?7DN?X,':S)#+).!C3?H M'X-I V,T^*4*=$E[F8>$M?FT$K+F,92J'9,+]Y"_PU [,P- @'7;%Y?>[%BW MGGB9OX]V:ZI 3. W(HCQ&?P*L$!I@OG3&@$0L)]^B?[\U8O7)WY3<7Q)-V"L]: (M]-$:[;18IH&%/Y-5G,0!UAJ?%?* M*B,9YJ?01:C0L,*GO27&<_6TC%+$H1+,%."?Z[IN>0D E2FT5X$9N45 R,D/ M"8NH)T@+3/N9,B .I%W>A3>MX$>N85AW!Y\U"Y5J4(=X' 2?2"H'&>;X5\NF M@EM]F4I[/)PGX:FEAXY/5&C>+G%^6",,LI*6E? ( MUJ_)/=MIL<,QU4%,3E",(#]N%F4!=/OJY+,N_][H%4QX@=9T,=W+U>31[@A1 M\C421^".A3O1-7#.\ M.@.V/U: DB#VQ//#/XG+X":Z)3(R7L=([^@JVR6VLT6QIX!BA"Q=G%#%5$Z5 M%_M@.@&FP<[97PDR*VG%M"D!/:V\PL?0&P<7%A+E/SY7M#S-JA8)B"MU30J@ MS):H6M+P$[ _R;E8K)QN0!Y"4 T65C6R+'/0^DMP%/5)I0U^68J;"H4S?=2I M;[E6#[=>L3#J>:%2TD8\*MO,QN0/6 MJ6=H18>&!1M72H"Y*L/?V\C1'/(1]L\Y+H*J$+H/C%$UND+F4A?D MUD#D9.>.7,T=S/#DFD^"+!V#0/7!4GZ?AI[#-M2D5G&H- ">I.)ZAA##3H;J M6('N1!YS6"6,I4L0G^Q^M(!N9>5&=/0+Z2A,0;1C%ZVSYW%0U-5=F.]3*U)9 M52290+LB'X=W??%]0#BXA7(M:5\B=&,G<;$$?$7*[+P7B+Y)4]&"IH#RQB5M M=)XACY@NKA'34:X&L7N>3=7N1N!Z0T*Y+\&;V&\;N^C6!@_84 ]55E0D*":X MI:H-I9-!N^ +(2"-?)U\[G )G\9O_[VLKCD$WF;$M,'DNI(<"5W-QV7N#+6/ MEU?6.'M2]NN:I(PS5=4@9L4I2+:]*WFM2HQ'77AFL"6U#2._2GQ0H$.1A0,* M@%O72Y@714UA.I21SL&]UHI^$,BQ9EJ"",WG9%0\0>+,[."RR61.H%"\J7++ MT(:/^ZEVZV*+H3Y6"\Q)J\4K]'A$G@X*$-MKQ9JDA] IDKA?F%^&8F\*5B-% M@!).<0TVCM1 _MJDS//R!M^K@YT3.Y@%"*:M8RAKMMB%R+;!B"?C*28M1553 M1,Z*O*IE[NS#3D2UQ31T=D2>-_8)PLT/Z"@ M+Q@SR&'(28<=*0@A!^%U;T@ MJ](GJ*+]5C9Y1B'^HG4ULMD7?X'"W5M,?2J8:B3:&)SW"VC"2 2VO_,X44Y- MM18=8PP.?-A6L[=F_.9X#T8.IVM,I*Y VZ^NP:3FE#MX_(^C_4,!RY-;KP0Z MP+<(^V00%G$(C3^)X2]4*5#0@KWHTR_NQB_GXR&$U.BQ\2GU5G_9%,,U)O9; M$9OA8$%S ^U%X(492?I5MQY(2<,=J)O/)D+:Z MECUSUF99;?'P*> AHD"ER)CG['2+5C%G@R>X8$;_<\@<2QPR;6B]>9UXD"V' M1EG@.7 A)S#C*/HVF:BT7I] 1#\QT9YZ#9"(0.JHJ'JO5FUN>[VV\"-*=$4G M1[VR4UMB,C_&SL-EVMQ"==;E,.R"TTDPZWESI>J).O7O+OJ=P05 I-"W1C'0 M-B-1CLNE:H-%6)"Y(I5VG?<1TS-L:>@"XSXN13W,DS\#Z'31($*U:>$#+@@, M$*76V4EZPJ+2:50*BD\P,03@FZ#X&-W/[!T4WS@L]$Y'BB !$1HL,-XBR3H& M?GC2]>6LR3_KUH9TR+U+Z[N8(B9V].Y *AKEH-% H_4NVI SQ?II!<-JZC'0 M=4R%<%$ OR;8*%DH W;E^:%*%0UE#"@HSBC#E*YXPKC1B4%A:# MA0>*[,Q95-\#[Z9*99R\<(ONS0P2QE;_)NR#/)32JV@:#"FG1%0,G:T%3X&M M5VTA4EHVE;%.OU D(;_0Q;+,K:9O4ZE+D$T(ZI;>UM/; (/L$]V<:T(M3G.A MC2.H&XI&V"OHP4DHT9O158,NHCG,, MGM/O9JH[Q!C4)$J!WV:QW=4YZ9$@:Y=S1*S.<8RR8LXP@-*$K?!L4W3Q;P!] M;*I)A844MHT#)GDQTUPS?D_Q8.;?5SZ>*"^Z;RCZ'!TTWFAQ8>@+:Y.;*-GV M,0:A;35FFQYDTX:QEE8H.WF69=X/@1G'LK#>+8FN+13?J8MF1TH0%W9P^8;1 M,"$9&7&)K7B<8N0Z:Q39B0"/C;M9_MI&CAFL3ZI*-=EQJ%_]UF33N:VW<(6$ M_*RLN:D,#3+&^B6-C;K@CYYY1K16FZ@.>!MJ?C)N#U+J8.L!*UԱ(@=- MQ-AUV5G,=%Z:-UXA K)PA4G<4C$YE"U"0U;Y^Y3PJXN M8QLK5_>1#00INKS(ULD7MJZ-5 :R62)F*BG+;R&YRIKX%^G&! !:,$7M @_L M5RBK-@(QE'UJ@Q?6#]=ZM]@I3/HT.=\ B^:DNDR:N@$I,#1H0I.Z?42D+%:H M:'),3*#_FR8HO[O_X,(Z"=NF IC]BIG![+*!Q0#H/Z]*M*7&!T2-L.>_<3,) M*@[,$ZZ#XI8/0&?E',QV=BE[M//1%&OLE[$[&BOE^QCIBOX,5E-A:S>D97+R MP5Z7<_>+.<1\WA2,K[KPS>=:MD N22>/MN+C22&L:TY)/32X'F>UCFFGK;G' M;1-Q0Q>*=I5K;E:>VVXQZ"E@4"!,)Y(%H)6([,WRTK!2.1A]1;V_WF6U=0\$ M>'%1UK8>]KW-IEI;R'/A"W(>49/!T[R>EXL)E MF_4LW*BAH).BKHXKK++BJBN]U"#D>T57MQ18\:BVXEIF6"JFL%2:] +;GS>N MP>HFW=^_),NU:7+M@7$!K >#=>O]V($C*QGGSPV^TY>RRTQ3.!'O< M5N)WW$=4Q$\<-'PG#HNY5\E+ -LRM4#=-F2-+K7AM0 IS^4B07\ TD%9<;2[ MY9NGA5D*U.B3%HHSV*CL'U>NW6*?]!8DQ+OV7_2'LJW"VOM#E =/!\W%^I@4 M;.,3=4C?G;' Y(R1TX!VXP3>B7AQ!X-$>7_)M'@?KCYL#WVC; =,W%$'.XG$5$0D;D+BJ:FL] MQQXP+Q!"%QBPMR)'3RS'ZGU7S[!"+NB>'A3+54T>Y/<2W#YY%Q,U&K#$R7OU M>U/:OE)F96K@YN6 '=X"U_J7K([@2FK),Y ]V02;>VO1;783XDK8&.SG$A0* M*ST0U\)[;10.F(WM_?\3M]9ZQ'T.[$$,7G>C%)IL2<0#3,]F@Z4J0S^K%]I. MZ:RQ\R,M&8A\9* 9E5B06N2:HH4]605G,8PIDX;EN(]XC+$+$')56EG;M&RM M[A:!$78XC;>3)G#A)N /*:&EN.U)1^:&98OKM697!& J DP)TJ9Y[IB#!?*$ M"F3]_.9 +]Q+*8?K06=2)VA0QA#'H:RLUX123&7IJ,9\D.#L&TX^;VA(D&M,!83G%ICZ4VUS9O*BZ:T/#2A8[&KT679@U7K%R9_8Q;'[-E+OU%+;)?[,'S;P5VSX4I"R M1F=)@9+B>34;\JB.!'R ,DQ]^AZ1L)6\;+HXL/AIC NBR8%46%HS&OLZ!HJ' M4UZ"=AMWJ5;=V@>F6>8CY&@(>4E89]!E1/=;%K(4W=I20[DPU3'07BGK:RZO M7<979U&<*H;-\KWOTVO!4IC_]J(226SG=#LPE@76&D0GITCGC!4SE6>N*Z,_Z8(>"DZ0:'&4Q@Z/ MO C3>MLS-WRK?E>;((T]HV7@5(VH]3H1^_HNM?_90P1\55.J*Q@-K3%T$'>A MV9+B)ICIY<7?9(I9B(^EK^,0/2W=%+Q Z3&+T!79/@YZ8),3+MJ,9%?@Z0-F M;:@G&,I'1"8@?JC_'9!L3%]A"ZVV;RJ7@9A8FMOP:&N82W0B5LW<'KB$U&]+ MQ0QHKXZ>VW."6MF/VJVJEMARK]8Y3P!P]0Y7 7^'7PDK$/@(!I";60/S\\?Q MA.>+;HEMLV,"4=.@!'/8(8>WCR/7_Q0SVT/P*0+<:4#'1MM0"[E;CWI"D@$< MCL1A[[0D-"<5E[*X*&4;1VQCP=:JT[>-@'JR;3+W_X(7.W:0+,;H <. =[V0 MHFYU;JT,>O[YI*R.[>W/:WX]>KZ3^A.;Z6@RFZ^X46!Y<'RSQV[_%K M,J]MBOD5+",PKK-LK;#/!;?G%D\E/\_7JB0VWLRHNO"DC48\C"7Z_!U1'\8\-\!:/$T<5?\MI3\E2G^YAM)55&_I MJ'PQ6&_YA='X?4I-'\8,M]2]I>Y!ZG[5H^Y9<"!1WY3G@IBNBTFO<1IM<>DI MX=+H<".E$).,*7P3VCY;!\>]'1PNG//PT08DIC\S'&OZ*^U=Y5$68!*?3!3>#<.:CL'1LJE_W4&OG+')Y(++UX[C#OKW')<0H.GS+ MG]+M4DRV6+415@4.N5.??/S1YA.>\=FM7SY.M7G7W6-K!]C8%K4VBY"KHC"K M?"D++3M' %UBDQ#LRRD>A63E0)WW=;\[O,]%9 PRI6K&F MUJ9FZ.@T#3HP$9,3 <&F-C\%GLB:6K#8DM0R'_L,ME&>SD$W^C=2J# ME5'ILJ&J:$"K&D]\[A:-Q?&TH9+]I%.OGX+*J3E_>F*+]X-O4T2.8MY#)?WE M9*+3L$.X3_6VD8?>B)0*D)6G+I/5HJ07!>!NAC&.5R& ]='OZ<]N^*3BFVUG*URISK%G%5H2-\>$>;FV! M9;B8ITDI'F7AFWQ1CPM81'MPB:VBN:N#3;==#2N\H5=^FY*Y34&"6%+?BS7T$A 8("17/>2K/:Z^"AD,"-ZSX!>A/=B!>_8L;,;5X6\PY0]Z MHJ(*'DJY0 8$XZK,C3QX )H;^XGJ57BD^5L6WD7%7#RQQ4\,JMR7FKF9^L;>&?8<'!H $ "^X'WMWY ![V^JU)F MW%3QTA#R>'D'J19RP2 T73.-.(J[ M:@?= ^**AU KQ'Q3W'%F??:\F[B^OJW.C_)0:H>RU&*>^JGM.SRU=[[W=^(V MS 09-6"+J^,HB01[ZQO76XZ.\K9!*^3G%; _2E7I+%/0QOOUX1X5T, VE9T> MRW:$N-_=(F\H+ \5QKILYJ,A!,0NG]W!.0&:Y3PB\.4&R &S[U/6QDO[L? M8N#WJ&W/])C/""!=.40N0B)JGVLYAS\AU1>P@FTVMG4DCDC#(R6L\87+LGO7 M]&UIO6L6.7:V8% H;+6D$$:L'C4^KC8K9#I?QAET PE7CZM\QEJ,H,1^=%#.7I^;8MO:WZ]Y<)58>B]*6_ENM72@$-%/7,V/I4 M>G$-W.2P4!;=$>PZ[CP=%?9[UW&K8ZS+[, M\W79EF%QQI"3*%B9;I]A^,YRM[=[$UP9/BR#]\Y7BO7P,QE(K@V@'MBP>U+F MK="C=^,_"S\N)"LK&*V]E=,XB MLEILA2GNH&?2A]GY/.BWCLZ>1SP8755(1 M*FLMTKAA2.;:IF:!&F!;#''Y#RM&79."9TZE0=9YR9*:#FJQL+KMQ767NZTT M!0TC$3OCX,KQ\=[HSU\]?WER3!H?9OV_Z"M_?:8-F4;BU#N?6UY*&U@X-T"06N0R] >V)&BS9:#$I,-XB9SN:?(SL/GLQ)A#84AMY9&J(*7%#<^VO@T>R\0F# M2?=\PD^PM_N8/$-"+;<]"YN^C[BIC XUVVS\Q:+OK$KO2J,M6RH M^%I/J1>AC[:1-PMWC)M(^I-Q@$*.GL_U)KXM'3 M6([K[]F_R'J*XKE4'^180GO*V*"3PH)A002KSR^$PNH[]J+<*'4-($1+X\(S MCOO.L<(1#5HO1=RMKXT% '5U52W1X[(#K \@.?J&;^TF[)]9R!4['>8RXU-6 M'+;;E=ZZ_3; \?\==ONY;==%/VT]EV,^'[3&@T5L'Q-;-N^->#RQP+6MHD/J M;*R39-40BV1?6[]I#R62>3 NLQ7\;U;/\V__!5!+ P04 M" 7EU50T&R,=36:! >YT( $ '=S="TR,#$Y,3(S,2YH=&WLO6M76\?2 M+OI]_XH=%\GKIV==6__[_3_M%/GV@T[@T'_WDB?Q9/?OK_GO[[ M_VJ:_SY[^^JG]6$ZZ=-@\M/S$>&$\D^?>Y/]GSYF&A_^5$;#_D\?AZ/#WB=L MFNDQSX?'9Z/>WO[D)R64^.K#T:_1&"6*3DW,)3: *)O@(S819;$85)3)_VOO MUZ*LB]J5AG*1#60E&P^4&R"7^$"9BDK_RK\*P"(Q@[$A0T ,CJ+7*67CHK#9 MU[$\FQ[_^\LOGSY]_KN_\/!SM_:*$T+_T!N,) M#A(]N?Q^[W1R][=[@Z/>@.KC^64RPL&X#$=]G/#CX_-(TPC5*'MUDC0\&4Q& M9U].-#W)F-+/>\-/OUQ^6 ]SC9"-EE>'G8R;/<3C+X<5',?IM2\_J(>$VX?T MQD-0TOW5#[SXQM4!I^/;3^.SOOJJ_.6_G5?OTC[UL;GCJ31\_[>.O/H]?_=@ M_(W;S=2[^Z'P!W?\NG0R&M$@_=F#O/STC@,_CV^C^)G&D^-]Y!O[.0W[TP.D MNOYZ/6W^ZLXNGXK]Y>+#JZ^.1Y,_XL-OWG$3)Y/1G^(2?N%/KY_NGWU/ZAN/ M]_+K=\$G0PB_G%;:7YV3#SK\"U;4CR..OP!\^H?OWSIS_?0)RQ5A?OKO/DWP MI_K-AO[/2>_3?YX\'PXFK"V:[;-C/F&Z>/6?)Q,ZG?PRO:=?GOZO__6__CWI M38[H*4/37#W_?_]R\=Z_?[DXY-SX^PK-?!\,! M\?5[I[_6+]+HXL]>SC28_LF?=UECC7KIXO*GD[=4_O.DITM6A( .9(*H2PC& M.8A99&.M2^[W]7HK0C)NUYP88+]>FGJ_;@SX_L[>TEYO7*D]Z?(G3W[J93YS MUA_.XOKPTROU]M..[ISD@XU/NR_#P=;!FMCYN'.Z\_&-Z&[OF-WU-V;GXX;I MJ@^]K?7NP8YZ([MJ\W.W_T:_TMVCG?/AY^[+%_W.QQ>'W?7W:HN/V_KX8G]K M.Q_M'.R=[ZCN87<[]SKKNX==Z<4KM7NV\S'9SLN.V5H__+R[_>9\]^,F=->/ M#COKAZ;S<;??W7[_>>=@0^T>[)WN;*=/^>6+7GSYWNZN/SO:VC[\W%U_=M ] M?['??;EC.MN'Y[L'NWV^+^@WCP\[+]V9K>TWP M=77GXX;8/3@\W=KN]KM]/GI][ZR[OO:Y\_)M?_?(G[_:WIATWHG35]MKOVMG M@B76 UJA;\!1:9"D;H3F/VV4F@GVY.G'C7?;/[W^G[6WG;7G&^^W-Y^OO?KI MW<;;#YO/-][]ZZ?-[O.?__W++9@?'O7GS.$1'FT.,IW^;SI;P?YWL(N;L/-C M51Y -YG1;T!DW7A)HD'E0W$ID8_BR5/!_TC!X(A'A/?YU&Q,7O3&"8]V"$<; M@[S.7LX*X;]#6-Y$6$H@F[5MLM3LU37S&#V^8S[&<_.&%\:W(3_RK=]S5<>YA7VWX@]O-K>O,1^X_/6 M]B;\#D9$&24T.6-J( 9L@A6V23&IG"QYX?V3I^N4J!]I]).6__JIXO6(DGX% M];6HO^!WQBNP_PYL<\N"VV+!4V@":<$6/*7&>PY=LL.HDT5?!/MF=YU,IK@!__CU)BQ0E-4X7:,""9/^L$.OR:(NSCJ-K?/+TQXM\+S[_%\=P//2 +(F=B8%$,#*84&4RB-+-$ZX]@X6_OD:<&C,?T) MI"]&F&KX_M/)H'26(2W@ H#"5A225%FPE-#+]OUF00 M1[",;:;4Z_,E__-DL_OBMK$>G/3S<'+YA3N\\&&?3?F[R3 =OIO>Q=;)I*8F ML#*P6 M-WDB[L62UR?QJ)=>' UQLB+%MY/BC,EP_H44SK,+!P0-^AG\IZ?\EE:W__1%>?)>1N"9(8VXSY)Q&PXSC_2MR7*9,?]V:[-.( MM[ST$_]%X,M9DGE3L5^I\^?K;_M ML\_./.SHG8-#L=/?..^>YW[GH"->Z;?[._W3([XWM?.Q<]H]8'YLOSWJGK\Y MVUK?@*WU/=%93Y^[YSNPV]\\ZS*?KX[A:YWLJO>6K[^_<[ZA.NMKI]V7[W5W M?1,ZVWM\[!L^;DUW#_;[.P>;8N?\J'1Z-ZR5TM7[\+GQJ)ESCL,''S53,'!H MZ:S"8LV3I__/_^V55/_OC[ MIT@AZ0A% W!L@NRW"J]UH@!&8YBRS5^QS:_8 MMCQLNS9[&J-B!R@V#H5I0+&&"RZPAO.8TX&"-G)TK(T14N'*HC"?M=, MV#8#2SKN[0WXKV\EV#HS9D#Y)HVZ-'G/!P]'D]XYY9?8&U06KHUZ8_;4UT]& M_.^+*)V9M>+4?3AU=L->:NV\RY :*G4U)9?2L&YA-68L*Y;" 5ZF)T_%SWK. MMG+%IT7FT[5%%$61R,DV!)DM(M85FJ2I<5'FI$$GX6+EDYJS-5S1: %I=&WJ MHM.&42T-2,PUG\ :249J!-H, I/(63]Y*G],+NTQTT>D>3 MR='4,;KPBE8,^G$&=6^FH666A3+DAOUQII&@T/CBH5%21L&&AP-"J(KHAU(. M#QP$KGBU*+RZ-G!&F1P\6S3)_]2BPMB@DJ$Q,8F2O?]RJ=;@Z*8D ME64F):*<#0,?/R1U3[.P#ZSZCB]&1C9\MXH=S M$#,PIRO"M9IPUW;6!ZTE1L6Q0:X^7-U)$EUIO(]8%*@0\C1)8=J51)TF(BXR M$[,AVVOVZ$;O:/2IE^@Y?_?YB')OLJ+>/:EW $8K9SJ.MD^X[JBWB)2[]K,IN#LU)D3)6 MNQ1L9EUHG#"$E,!+<#^L M]>9C9E?46T3J71M$3/I'5/E':6346_2HY6_=E_ZW%RD+,H'&[UI$EG;0(JV\2JY1J'SF8HT M(KD61Z4KULR0-=?V+A>.'1WZQMK KI:1N:H?:HH@RKF8)(S\85=K3O9NQ9C9 M,>9&7*B"=8IB0UZRAR02ZQFI3(/9*&-%M@;5DZ=J[F;J.QBS3J/>)_://M'X MS0D>])B!85IQ95Y<.;M9G1R# -48-C\-!&>:8$DTQ$@FIYUT1+6LH84AV(HT MLR7-C6T4L90<*#61 R=6,%8UH039("0=R&>A4KBG'W/G_BLG1::,/ACE0$?R MQ2M6,@%+2%F(?+&OYN]5R^L1%1IQT'QCD]7:R61_.*H54XO" ]VYXL%!=W_K M)6.YO7;:.?_M:'>;K_?QO6&,3-UJT]G>^-P]>''(QQU<\R QWGE_Z^/[L[H5 MIWOPYKR[OF9VSM\>[1Z\.65<3W?YV.[!IOJ:!\R9SUVU87:W-V%K>XTYV.%S M'1UT7W[H=]7!N1:!6P M0%KV,#@&ABQ-$SV['LP/!*(((I19\.#[]<&WI%'N8L?F>'RR8L;]F'$S3Q)\ M1EWWYCKP'+^ B(U'#H"5<,4&7636\!UYDAEKB14['I,=UWH#T7!(JTL3C?:7 M'704A[@ 8*S)VN7T/;4="Z([[MK&O:+(WU/D5M%LX5B6"E+C3)0-1 A-%#8T M)I?:UL$4B+&]"F1%D>^FR(TMCR(H]CI9BUC%%*F-(6(NKI$ZU6UHUB7S/3:& MP]C7-)KB-!-5,FT+<9L2-SH_O,;1UNC=I'8B_8!')W1]Z<78Z]\.6MPL'*3H M6'E$TZA<,QLI8!.=\HW%3#9G*%&;:1;L?JF-/^'$]^F.%2<>@Q/7JJ)X9SE" M91O"X6GM_V :7VQ-?B&[HLHY0'%?3CQHYN(/O6%6X>KWL>!FVB*6H!75'1+) M4 -!I(M=RX9C%)L=O];JR5,IQ,(D+E8TF!D-KI6!DZ4$P;BKI!W[#9;]!H.E MX9 50E40P=-L:/!@VF 5@-Z? C?3$U2<\Y%]19=$;("M0Q.5IL:6F HK!W8M M.0!UYCZ%WH^K"%8,^!X&W"A!9)AC+*8!2CLQM$6*%_ M'_1O90PH2X%U!2MBN.@"'%W6'!QXU.PH"D.BUD+;;H!RONU%]8@_7>IUZF01Y?77J] M;O@;W? 1YYPU.NLJ]WKWXX;HU%(3M2&[+SN?NQ]?'.V^W#CM;N\? M=3]V*VQ\'YTOG4.[Y^F<*:%WUS_L\_'GW9?=P\[Y46_KY8[8V5Z##D._TW\/ M.^?IJ\ZA0]T][S E\F'WX\;Y[G9'\&\YW_JX";L';_<[ZWNG?!^]W>W] [[/ M*[W _ST$_NSW9$HPD+ IY'+U%V43OBR.-0 M9/.:(ML;OX><66>@;W2V-:7@:Z=Q4_MQ@,Y"8TK*3G>5W*_'RY]0Y ?+ZE84 M>1R*=&Y3Q$D#X%53,K&=$2 ;[X$9(T1 MC_6NXN-1_!G%+FS'WTL$;PHH@2+ MX/@":%PPVON$3+U+=7%W/_KK!-I;93QARDPH MOQ]3.3EZ52LJYXO^:6=][=/NX+?]W?.A[)[GWN[+-WIG.U770K!Y9]._=]99 MWY",'NPR$SK]CMY]'OB>?ALS@F?\W<_=;;Z/\TUV!0[%[GH'=@[6S&Z_<]9= M_]#;43OG_+?<>G=YS']_VX_]S*[);_O=\S7)^!]T#G;.MK;?,FOV^;Z.^GPN MOOYO![L'7?[[O?GO^9=I(I/.VN_!6Q^=2HV)0C15A[-NJ"TM6(JE56"=J0[& MEY6';YE"X(0+2@IOA$E07130NB0+RL@8O;0KU.> >NZ&N,K*3ZMD14 !\\BC( _^'-;]Q%N0*]3F@OG,3 M=1*H<\K81!5J#U,K&J\%-F2=P)B+-368N!?HVH!1WOFB1(:JUGT2R; O6!S' MDF8EZO, /=T$W=;M63F&QF7!H!>CFA"T;$0*&9U@ PUU65'=!W5B.^$S*XLL M"B1C?0(A2%)V08(P?S5F9H7Z0Z&^\?GF[*BLLF+D15U-+G4-B9I 7C29 S:; MZDY@8YX\A?N@;C7E*%*=/$:0R ?%X9\*+I7HC @K!3\7U$]OHHZ0(W&DQ88\ MUD@O8L/^%C8Z:L@Z.M8$+.SN7AJ>0P"1(FL+I8'JT% *P2DG4RBH!*Y0GP?J MMT9^NL#.%J!M6!YKFCC+)FJIFJR=D]4/KU.HG^I[.7-:&NDC:LM^.VOWH"@Z M+V+1.E,V*UF?"^JWQX#6<5_@4^,$^W!0=V)[XV,33*T82(:#,*B%(M\\;.R/ M.R2_;TE ?%OE\7,\[DWPZ!7AF/+:>$R3\!K]KXF13KOO.RH3I]_TW8ZV]U^>] Y MW^/K[1_N]%\<=EY^Z'4KT=0;Q:2XZ>Q)3 [1NT;KVC4+2#7HF1T224(T6F;S M]W7I=\?TV16=O?4*$(2UR)$C6)+6&[8$P=Y<&KR-\RMB;&F+=0%.>H.]*=YO M:4"?\6B;1OUY)^RV#]55PJZ[O5%!/^MN_W;8[6_H*KG\N=S9[O*#W^'O)K%S ML'/:7:_#OSY _I_?CG;5T:=X,)1UQ:BSOBD[_3?J@B2;IUO;-8GWMK=[L'G: M/7_;ZQYLB&X=&[A^:.JU6.9-Y_S-^>\ZEU =6,400,&/:MRLDT&DFS(P0N7 MGSQ];79$1ZP_NCS?M/^SL=N_;[<6D^?69&+ MG7Y';+WDZV[G0U;4O<['>K]O/G^1]2NY[>_N[ZC-LZWU]] ]?\:*_&UOY_P- M[/)O[*HW?)^;I[OK1U7V#[_*PDG%3K42EKUU$&S!BV\BBRJ':Z&D$K)EEYMU MN?[Y3].O?X1_<%*G_WZ]?J.B5RBC3Q9!^N"173D14Y::C!'PS9L$UBE.-@?C MR6@Z#':3+S%B(KQELWY1&OZ:1HD_P+WKNO!&S9L8VWM7Q#C;[3-(:D?MKB?5 M?IW=[N=F;+GL36]@:__M!G MW?/YO^?OKXG![[..^%VQFPU$U @JLDYZL V*X!L.PDN0=:*[JG. ?W;W6+^Y MDQU>"PV:/"L@!77+2G F*2.-)=#.Z!4[%HD=:[\K*E:H')OBA*YVH^YTSZDA MP_9>&"E0JKK#V;H?)$;)9%+4,6;O@'+V6=1Q2#%4/F1;5L28.S%N97IE$2$+ MGQN!TPKBF!K&RC>0A(A2A6QTKL3P]R@*N),84IH08I(EUJ%%RM0F/TP54;(P MP;NP(L;CWJ#U#O&H\W!#N%H^_-P<=S05K#C M\(:WL7;>/4^_&\5>!5IJ&+Z:.9:N01O8*_667<0B70FF>AOSGG3W+3F&ZV9+ MU[IE?-4:_BVEX=Z@[E;:'%ST9]H7NZ(;@UL7FY\WGW9 M.>U^W*E)B?T._YZOAF#W=]??<\#U_K13KU,S80=OF.F;L+/]['#G?$/N'OQV MU'VY<=;Y<+.4;:-V=CK[74N-TEO7:$6U@U.03= 4&_2Z"(BHV>']OO1%T*I4 MQ[E8:YAS#H/U@MTC3\Y&7\PWY#.G!4?/:K*J=O:BP?BBB_)HA(.]BP[)9]=? M>7VAH=8^XVB:^)R6^DQ6 M?O\Y_YCZ.T\NDB9SSY>>7Z7&CH]8M_0[BL_?Y]JGW-(W-OIOSBJC*HILBZ_WMW>.^]\ MW-WOJM\.MUZ^.?MO9>/!^]^-A:"TRXV7A1U>A;FI>J01@FI/> T!X,G3UW+G M/KENZ5P() JK-H+$2BF#+UHHTM85"W G-VYHGV9,Z==\,CIC W0G:>+?DR9^ M39H7V!M-MU>OC<;)P>L]ZA7!D@Y\Z SA4#V-JLR<[Z?G_WY8[J;+\7 MK#L^L]XY9<1D][RC^3[.:F':[KLOUJU7K=GN=M4_T^YN?*VW1SO;O[&EV^UU MUSMGW8,]8 MU_H>,>7^S6K.CSL&'@\[!WFEEVN[+#_N=?O>@V]_D:V^JK?6] MSYWUCODZ.5IL, *H"4ZI!FQF[1*4;%!'II.)T3@FC[W7DJAP+N5@E68[9J1$ M %U,0HZ+?"HEW6G&5M1I"75Z7ZC#OK$5)>8F*V)/"$UNL'BJ5?G14#8F6/IS MZGQC+*6C*XQFK<,TD,"CEC+;)#5DH]#XORF_GP95?S?)[KN-V-K4]O [PY/) M0L9BK2#5FYOZR"E)A-$TWJ?$^DB'!EU&-FOL'&<0)N?O&5-^=]XWD#1"EZ#8 M1&;^5\PY4B2GZE[S6+Z%6RL6+0Z+;JBFS*X/^RD-A]JUSU""6MSOZE1$B=X8 M@X(C>B7^M%O G8;-&%F+'H] M/.HE#N4YO'K'?NV$]OA%%T>C::RV3N,TZDT-U]SYSO;:Z:CJD^[ M(^J2TL[V>^; B_T:2?%Y>KLO-V3G>@GXG+$6N^L?#ID5?,X-_IOOZ2.?;WOG M;*OZQ.=U.>B-V?HZAC_H,-9O#[L?W[!WO5E[Z-:EI_WJ)W!;:RP' %YTL;[:3.9>U4!12I>,O"6XW0 TMY' M#I^\EW*ZDO@M=9XK/CPB'Z[U@[+9VEA"$[+(#6C0C8<0&@>&E*E.C9O.=];W MJ@\2:(,GDWSQ$< 8KY(4OF10D.OFGQ4?%H@/MY::O3?28<3&>JJ32XMD_9!$ MDZ)-P@EAPD4#,GLO_9!K3Y*"-@=1(.J$EK2&)(!?!H/?DE]9\>$1^7"M'X2. M2EH/[#!H4W=^^<:3@L9%CFJA)F3Z= M%F+%AP7BPZVM051$4C;:QM!T0YAARZ$B-G'!$T=3=O8YW3.FD6[S0= M RO^3$5\8Y :M-0Y.$MU;UIQT8-Q2B6-?'F)XD_*T^#O67(C$?:^!JUXE$Z. MIM6(EU_:BD>]O6D06U>=[;W]SL? MWPN&W.ST=SBZW50R%U1 PQV*U5[WI2N&BK/6=\G>N,A;[W9<;Y[MU)65]1];K[=3UE7Y'=@XVSK>V]TX[:O-L M=_VWP^LBY>/^UC2[L6-JIF%';0A6 [#SD:_/JF5K6G_VAH_;/>J>?4.>81$K#_F[]AN,^*"@]$ MA6O+PK)*)BC=2%"N@:!8(Y14J]B\%$)0@2+_^LNJR M?=_E\^S4Q7C8VM[=GQ:6;B>YRSY!=WM3=;]>FF4T=P\2G_N]ZO8_''0/WO:[ MZWNFV]\XK07QW?,/_4[=ML)W6[>@;6T?_JX+!WR&H=11UQ)FJDTK 1L3==!" M>V>#GM:P_\%'J*_W>SG3!:K3AO0T2#1^^N^CWN#PUW':ISXRM#^=3E]/SHX9 MJ7&O?WS$PG?QWOZH(L_H?4'TYU/6"7SRVZ>XN-K-2TQ?CH4_IY M;_CIE^>;_YNU'_\C!5](_/N7KP]^>O76[;,?3]EW]6H\P=%DG9V9I_6F&KXY M(:^.N_[LRVWFZZ]*U6AY?8F+3ZY>7UWDEUL/ZNH\51]/']K)]-E?O-F?M@.C MI[WQ$)1TO[Y_MWYU^-5'5Z_K\7=BX(NQ!8U2&!$T.&0V)8J>0U==TY(7!65L M[<4"//K>H%9S3"X?O&WT]8DN/[GGT[QLU_;U [T$<_KAO9]H[2H626(2W@ H M#"5A227%NJO,Q&GAIN('L1!DOGZB2E0J7_/S.Y_HS>Y%5Q_F:7.AFU^=:BB< M#$??2>4_'%_?7*?!L-\;W'7:;P7TUBE^N7WW?X?[]Q3>S9\ M[29_W9MYG]$ MF]V6E^_H:K5@S\U]^W-S,WMN]R@%GO_CNJ6Y;SV!^^F96T_@'ION%NH)^)D] M@5 ;1]@2(Z$$P?^%).M. <%T,!R<39^ ?8PG<,E\VJM>_,7+S!<[/:ZYPTF' M:E+JI]SKU_AN.+A1BU7W($SWKD]K.6MZ:#BH@<#::8\-\QVMZB[.=7$/?[C$ MEZ?VY4[N!XV=&3286!0-90O6@[0?MP2FR.YND!(\. ^E.#0A6)L].BR"LE@:F&XU#VX).*9HJ50H5F4" 6SL MO'+)L-I7DIQ9'O7VEB98,^L;.*HUZ>.6X"-]SE9+=C>* !(1C2$C588 4CIC ME@:?M91.^G5A@_*?32!O"6361W86I>.P1()$BCG9A!DKE-)2>CS(YO4$E*^M M/"Q$IBAK_!R+<\9BW:!M"=)%OXU'"3.62:FXV3%48]911Q>+!W;IT/A,Z\G ,;Q_Z @1@ KG;<+\(952.1=0ZQ0,!%0H MR6)V(2,JHV1:/DCG$K;,'VC+EC5@IFAD E%WOK/[9%U)*ED#Z)?&PW^LK.CL M7-O:'L!Z9&\V:1"9HTZC(((TI;;ETVEIH)E'5G1V,!6%+M6@. <-(1IOY@.M-81\S5Y/H05/V(8GL-:!F MZRG3G5M,V@WN8V91]APCVDPD52F: M;'$&EP::>61<9@>3R3&GG+7&8*#6TLA20I F":-8MF!I8'J\C,OLP$G>RI % M$5D$XR22,[HH=C^UM$H]8J'Q,IJO!X&L$.LYX0)'] A@D9V.))R5)8(V!N]L M/=IN[!XYHG^LG6^W]]A(?PM':C^G@1_5P MC3*5,*V#P0+9*[32*9DXZG/:>[RSVU6[ 9U/1#\7<.M*NV:#*3CZ P\V6,A: MAD+*%2?<$DKK8T;T'9/&5"9 +TS'.P9CC!LY'!O^2"=?T0_%Z!K M 05J02#00W8EI!25)B>B3KI8>+S=A6TVL ^R[1& 75E/J L 8&2;6;,LABBR M'Z2-7!IHYA'1SPZF9$A!#1'K!$(!$',H)@>+B?'#%)8&IL>+Z&<'CJG;QW3M M5P0)*+I@(&(I0MF45$YN:&#-B>.]71M/%)[: 1=@K/1)VEBP)<+NSZ0HU-@-TKXTP)15V8 MA>F"\J+A=*7O-P?LTN+1VG']XK3[W45ON^<75H"5_L4,O.T1\I'3[GBW[,5Z MKUQV6'M&D\]$@[?TB08G]/*DEY'?W1Q<'/^,RG!$=F=!H>WC<2U;8O^'$ M-_^*M7QP?S^ M.#,7(X8&7%F[Q]4>*.5%YZSG8\H:]QB*\L1;1VL#>BI&7+=/T8[1,^UX2 M=NO$3]HJ=7;58'RI.J;C9_I5BH?CA_4Y](_T;KL-A; I@Z^3G22 8QB<]&A) M2,D(J+*X;F)5U"PJ^21-MD;O:/2IEQX=AQ_R_;YT?+ML.'WU_NV6:\?\Y]4) MOKF#7M2I4#8:'42P/D452I$^)*6=4S:TP"Q?9Y<&=13319_3M[WQX;.S9ZR\ M]QG?P]NZ\1T>U0&\4V7>IBP!V&7Q5J1<$B23:J-DQ1Z*YM"(V/%L40G< MBLN+P^7Y=&IT['%;*J)D!%V29Y\[9"AUAK"3N-++/\BBES2H?9N_F42+(3CM M5,N9L!3E2F;7L;;/E"D$H#@=PBYLFS;\K*B\,%2>BU8N2NKHG8:,"D+) 3)9 M!50*IB35G0/"%HS*?\6DU_LXZN-C\&B)G)E6ZF0HA,I"-J019+316"@A&H+ M;D>0+=#)*R(O&)'GL^VI**%3G:3 =&9_ K/7SCAKV<^HP[=:H)'_&>SZ(7GF MBTWJS)P.#D[8U-:,:E[J5$:DJ!*57$0JH!5%6TQT.4B3O2G)M$ _KVB]T+2> MC__L74H)=:P3<-#H8)*,(2=M7%$^MJE*^9M8=;GJ,'-2S5VV_GI)Y7]Z>_L? M\.B$KBMQEE%)AZ1 H7YYA6;Y\;F^62!S1H.RCK6DP@&BNWOX^8K-K6/S537(:TR'N-<;["VE9LX%A2R*?";P.D5- M%#*$F%SU-FBEF5=<;HM>QN2+S+)$71SDHM ;T@'04W3&BCLGSJ^XW#HNK]-1 M[Q.-SM:IOK^4_K+R*DM!0AK#_K%R,8"79 VKYF13TBNMO&)R.W1R]IY=9%6, M- F$G;%B\E_DYRZ_O90*VK-63CJF@+74*)@H#9K$FKHN M=FO?\DJ-%:WG3^OY:&LG:UO:X@5&<"9Z[3TK9])2Q9S;GG5^/$9]V6;YDH9[ M(SS>[R4\NMX+M=:O94CXN.5'U[?RCZC;2,E \)@E@@22)I; 'G02)DF)2K>I M<>N*R@M#Y?GT($X*7 K*&BF@Y%#K-KSW+ALFN')MZAK7CB7N[^?7CXK4U1UL M=#;6EE$K2T!KM09A:KHY25;0(6>P"K*UQK8\L;&B\GRH/)\*C4C)>4NQN+K9 M4T=6SC'*VG*ZI&SL2BO/QL$8]_ U)OZ%J26"TTK%3#)K)6RQA!D@B&"P=B]@ MMX.0^8TKQ;QB86#/'NU\2#] MOT+1F61BPU8(3+$1C \@4TR)0O)A\9OD+Q8RL^N%+YQ*$:T1#@U$XX+D@%" MMDH@)J&63&:>G?3XK(,]_M[5GYO]X]'PTT5+HI:(DX^8.5:7SEFL[4,]%1\] M)=!"10W+)D[S!&V&@T("5(MZ)I\+] ZF/9[ QJ= MW?QB6^1+4,"(7I7(,J5E),UA6:S[_XT%Y9=,OAX?JME)E?(%#".5+'KP[.N1 M1Y8HEUWRUH9ELU_;P^'1>+U'8_YB9WB4VV*Q *!0BM(42>"="Z2,J%-X;,HZ M"+MD$O6X,,U.FJPQ*D3OI8,W0^\M. M2[92[%4 >^Z(#%,PGBP6:;1>%LFZD0X=3T8GJ:8W-P=\Z-Z(QFTQ5LFI4+*V M%"" E,'G8%-BE9C(>KSJ)+S":A'D*I8(7M3)P1P*.ZC]7ETPVON$H',K^LY] M=U_U)8FVY[_LYH0+2@IOA$D J&MCSI(XTC,R1G:&6DJB;^KUOB+1K'8+92SH MV:J# E 1HB /_)^(K)(LM*%J=\$TT2/E)>9/'6W *.]\42)#-5T^B60"F.*2 MP585L3PXP ^G"5M)'0)V=K(R*HL"R5B?0 B2E.M*#J/; NHLF-9YA-S-_&EC M->4HDHP2B,,:'Y1'JX)+)3HC0AN,U:. N](VMPV59@A33"$K#:1E"!2"4TZF M4% ); %M%D3;/'I6:_[D83(8Z2-JRZ$5FZF@*#HO8M$Z4S9+IW-^#.*5YKD= MHF=7=/;6*T 0UJ+2"2Q)ZTUMSVX7-W_ZF#@]2#I42U<'[J M*D..QHMBD#L#_$"$@)E=WW6:+WB]P.5]+H9MAP830*5A=O-8>2 6!T8X MSY8OV:2NI&X!H[F60L=2-Z-(3FI3 !1FZS44C@5D@\?C=Q2EN M3K$:#8]'/9K@Z.SAVK,]"#PA2IN=MC(H U*P!2.*TE!P,I%3:BG@>=PV>@^" M$T=EA2) $B#KAN@ H@ ['-+7'B"A31,L%D6>YM\F(&8D5'6"0Z[-XF1 "1A$ M40FMYU!\N4#]IS6S3 I+*MED8<)T>U9,+B8P1K'T.@F+&RHLFJ0^2#A@5,!" MA30:"1R[(84@K<=$'(7+TH):]X63N0?!"2FJ3%IF[QQH0J]E]-J"C4D!V=BB MQ?-%D:=%6-0V-F'06'0$(G8[V06-RE@30W3YZP8Y+0?UG]:=O"A51.+0'#BH MF#8,E5;9 D*"RPAI!"<'AFS0-H!)'/79: PKS( ^.U39+_ RP15.+WJ#WH1>]3Y1WASP8]CK MQ2-:&X]I,GYV=C%K]0C'-X6*<:TP#O*K7JIG>XA)40\"EI&%G49/L=1V0HF- MV;1L2-4).I&]_\5W)Q<>K-GYE$%D=B>U-"6RV@.(4!3+&":1321H0>^,>X%U M==!TCVMB=?F6QH2CM,_0K=,G.AJVJ4=-%LK$'(6&'#F:YI!-("J1')JZ"TTL MF:0M G@S[+,1HS:,5' "Z[CT&M0I:R*=R.D '%''DIVRJ)5G:;*+7./Z M0S@]/QE/AGT:O:6C:2/A\7[ON"VB%32+EBZ"BN/PRS-8)I"WN;CD*846)!Y; M MGLI(S8@0^!!"1A(!,$E;P-P24TV;G8@HCYAR"[BJ7;(F$Q(&#@?]A@08PE M9JC^AE=6:8MJ68W7X\(U0^GB1\C1<@A8)*A@HM+\NBB4-F(,;O'A>C4<[$UH MU%^G.+F]#:X[G-!K/$.&;_VD;I\)+0&ED$Q%:!%*(J"8 Q63#/C(OKL*V (K M]>>@O*5/PZ-/O<%>&E'N30JFWA'?>:X *=$2@*QUMH3L"UK%(91"Y:5UU4\/ M(E-L00[CSP':YG=?#7$P%1D%Z\,^]@8+;W8P4"W?3D'I DYKE$'[.JT@F1@I M+W U_M\C\HX&O>&H:K/Q!2@/O0EP9MYVW21KK(U* @2I,457M)6LS912H055 M&'>#\F4IY!J866WCKQ?:G';&JWE M:?$%\Z\A>78#$Y@5"V9%NT51!"XJ%3.[EREH\*9$E54IP;')E,*9!=ZY\8\G MP0PU04DQZ)PEE 2:W26+61*235!]J!:,(OAK$CR_00*W7"2886Y;Z& DRNR@ M>LXE)!2 5%A#"$FV!4,._K$DF)TF (/2)8RB6 <8 V8;+45MF!8BBP5N+W"/ M^/;Y-+Y]<1G??IMM6!0IC765%V1!52QH"#XD'[4@)P*D;/^Y 'WS]6^?_+; MH-:*M?%P47G!@ESRK=5438NS?39Z&\E]E*VX:&H&W0'"\HTPB/7IP, M\GBC%$J3WB=Z]QF/W^)D.;OW^:PRUN[H"4'6G5EUZT@N(BOP19D6\>JO<&7. MY3H&@7D7<7"XQ=#RMRNHKS:?;;U=/B4T?V8%7S.224*.!3*Q"M$T)*:@B MV\"LAV\J^E>"]#(!7)8S84?!9:*2=:0(X90OA=1%S> MIJ"%0,=" 4IR$++WPF@7ZZ(3^\5F-?QE9>T6C[/.DP-O8P!7H(10XS8MP7CG MC(Q)M8"SR\^LE9Z]O:O'1L/GB[[.M?&(M=K"6(-&)EUD:L,^U8?7LRLE=[.6 MS84BB_**/*NV%-"GG,C[; 06ZUM F)6&>4S"8#$&11$ E($D>J,H(3A1K"*1 M5X1I)ZQDI9(0G/1@0601DA0V2)]2LR*1M\JQ+VLX)F 2+;=IKQ")0R(B9T3*82 M4#NM39UF$*S-;1;[[@@M3ES[ 0,Q3KK=91D@%@/UK69BR@ M30:CM6W37+QY8C-_]2I+-%9(%T5D_*+U0& +^:!-HFC;M%8YNR+[5B+I(+- M:FO9QZFC@&H3B21$L RM+V9YD+Q/D70KD=2U^:*.(JFBP5&(096B793H.##" M-BQ=+(#O,W\Y2)Q449GVU@E$2I;?1]&QI:S=7OF!4F)X/>!2#CO?SE0?<)QRMH;#T%)]^N[E^M7AU]]=/6Z'G^W6X)$#*^I:YL<]^=@LTTARJQD D+W"2A M+D0_/QF-:) N$Z/I\M7U@_BQ\'[4^X2UFOZ:/6][X\,_[ _YC*/LH'L5!@3%H0PNZ>CT(U#]"X"\P+/!&W5*R%"0DQ6PA.H_!IFC9 M;?8*67DW6L:@KQ_&O%[F5L"^KP9AA@PZE MU\[]KCO_-5_@?RGN]P=XZ MC7M[ _SCM:X^H+PVOOSN-5-FMQCUC2RLNYDW3M-^K>B\).4#6K2_DK!%\84Q M5R?8947:@-$E>/2FJ!# 0&''9O$Y_H]GX%\+^[O]X>B'?V;[2/[%\S\X/OM3 MS_^WUSOW]OP)2\R&C7TB"9I*4#9&F:;)NA)3"UJ!/)Q1^ N:?'G4*V.SD)'R M[E=&F!D[\K[WX1O/N_2ILL"L=!%H'91U#:@B"'=5*5K15N5(R5+8A@ M__$,G*]WWP:2F^@]V9RL*!S"HHY%1&.3=D!1DS2+3_)OX]?ST7 \OL)INO.! MQI.ZX^'+>-$'I/OX)?8&K_@&GIU=BMG-V3FW;[1+D\W!)[ZY>N#EM_]Y$>CM M;4!HG$7(J"B!BR:"4X9=:GZW%A4L<-3XT![UXW!_47B A@(B<%Q5QP)Q6!4 ME:?,1EI)P!:DVQ9$5[5/'WS)2,5X](>,U,ED]"N_?^]L5/1)6H&2B%4*FSTO M30Q9IY(HDE$708R34JEV\VGKN)J:!Q5RUTC9*#4#(5?9 D>34EM+D')$9VQV M%A1E%ZDLY]XF?T\TO=OE'CG R''TMFE?)XB]J MY6[Q_,/Q]'\C\;>._N7VC?^=8E"@?215($"&I#&R^Y%4 M"@&L\:#;U(!VM1CWPU3'?$@9?!UY5)N/)6%\4E?H&]T0<\.J$9 MN<,_%)D^G,\T_QT*I22T*@F=?-TD#9Z5+[H22!8?))46[5!8\;Z=O)_+C@X, MOD@FNK'2 U@7K66OL* EHXOSI47Z_I$YUTHU5\?_\O^MRT8!^N@Y!HA:.0<. M013=(C77,KCG(MTR&IFU#Z@Q0$AR6G<*2B6V;Z90FQJS_:55FTZIIL$85G4^8KJBT3U^7138&H;J7(RQ4%R-EH.PP-K=-;K4'QJ MD5;_:\I5U^6RK&5[-$U8G[$P',Z*:M\D9U>+B1NGQWS\#X]J:2?-YZ+112+6 MY"Y$0P%R%JBB=ZFF5VTJMK3)05_1O!4TGU-O'*8V1YU!>0DH=&#/Q10K*"AI M@M(MU^:+B_9\W-3BHTLI%BP95-W1KT%/>Y(Y:7+\)R52_P&RK722>W]EG];*:V.O:$@E TH M#-3I0"IDR!F$54&: ,LFK8\+Z7RD-#D7T06JD_.$IJ@L>"EB$K($"6V:H;=( M-7_W2GH,!_E+2Z1'SO0.^_UA9A ?:E_X_'56HH)."2,2$ ACL5 *HJ#W%""! M73:=M2+X_ @^%PUN; !-FGP("D1D8MN@$:PP"6TL;?*S'I-HK51F"B29(@4" M$9"52(Y$4E;[D#F0:E.XU":LYR/7[(R)E&7 &@D['5%&&[)E*4?IL 4]\KYL M\WUV=KWCE\^(H[1_]HH^T=&?; O>'!R?3,;3;\C90_L@7<)2*3890E*Q@ 5 M0&3@Z,@KT 7B8(?XS MT'I89V9V:!E(DA6?\D .7/+!:!\-.AV\PZSS9?O7!4;K2P)RX_^<\'T]'_:/ MAX,:O=\&:2VED_[)40W/NS2YBNQ?C(;]ZP$ 6Z,W)WC4*V<7K"T?G%S@UQ+< MK#1:$)EL 4$7X=E'X0!# F#QUH9EQ&U[Q$A=)$);AQ=[^P5$29AC@%ARR.02 M,H:60W@A3(M2UBTU?/-/98.I+H]S[.( 2.L\U,W:("F[(A+&9>? XYK+^>.M M1$K.F6"D!DA*AVATCC8XFEE)"4 M+,NMX1_)-,\?99%US>A45* U MH!/.Q[HIGY)PEWO(VE%6UU+#-_]RNQ QN)*E+49 1O9^FPNF%-W87Q;&QB %NV'6::J#QUHP3[VEYOMA MZH@R>0QHZ[_!&Q\5.JT41"!73&E!O5D+#/'#E-R"]D4*H27'/P4U:@-*^YBC MD2:VH4!ZX4WJPQ3?)G9]4.4HB@"*'FN2(7DABG22+FO!E@RWQX];9RAGBEBL MBDHI9& 7-CCMH?C:/I00%+7(JWE+Z0C'8S[+Q4;'K9/)5KD!T]9DGT85SA'M MUV-K"6_=(7D;U^\]R^-N5'S@D2 M]2$6P'TLX')$Q&(S:&$#NQPV19N]$=:I M-C7G6XG32ISFO8I(!&AL2-Z: )15J+OEI#0:"A%[A2OKM)#B=-4(Y2W?TBRW MP"R#',VG$T^A8"/+C<+$7IZL03&+4K)!>.5$FP;[K.1H)4?SVV2O),CBHM6I M )CL$Z!7 -9:*AG>-RT*4 D?$Y@Y0V%8Z1(.SW!6 /[)TN1P"UDKM2Z!!YD!&>P%2Y:AM!*^,150V^=7.JQ5G%T[/4BR^ MF*1MB1:RL%@*^PG>66%DCJLU@44AQWS<24K>DY8(T8-6*40GE+:6A%,QQ39- M6%IJ^2C4)#1.EM23J%3$(DPU%C>X&LD].^O#6>"N?V/@YN MX#E>&^3IR[5CEMG4FTKUV][>_F0Y\P/"Q2B-#%HD<"I%L"R]WDD?M:#0IHF^ M=T!] U>&]9^!*+H('&0(5KG(03+XH*.2#H2)R1;"%IGHQ4-T+G:U;I((V1CK M5 $G'&*1V:J<2PI&Z(O,A[M"=*&;+2T>HN[;$74S0]1;1]*@ 6O8+S*>80P9 MM:]AEY49VZMUK]Y^3:,R'/5QD.C=/HZ6,[ENB]$<*B>A MIWKA7->[/N%17>I:1GU;6Q[5:2X<5M:26\<^3U;1116-,*)5(Y_;@/%\RMF* M+2X:#*9DR-)ZJQD 3V2*9IVLVZV-%P[CN>AJG;4/+D%,C+%D!6VLR&R&DZZ9 M0-VF\I@[,+ZU\/+Z9)3V<4RUI&!C?/P PYGFKY9K1T%M0[&>)&@VO4GE[)U& M$-FS)+=;+<\3SOFD<(5S$D(!93,@>121=;&-PG& BM!R#3Q/..>B; -;5-1> MLFL,((2.7OI21+'L,7M(;1K3_B<9HW4J-!I1KJ4+?,@T'S\UJ\\8VOP:S_I+ MZQ#GX A$! QL2]G VA)UBS7O0F$[%S6<5"PJ LNMTT!)A2C("8N0 MLX"H4WO5\$)A.Q>=7$ULRL$J7334UMD =7$&@Q(^E59-.5B8ZJ/Y+,=(:0." MT]$IR#X'G8*Q%KSRB@S$]@OIXP,Y%XE,QH><<])L3B&%_Y^]+VUN&]?2_BNL MW)EYNZLL-P "!)#,I,IM*VGWC>3$5I)K?TEAHTU'$GU%*8[]Z]\#D-3B)7%R M[9:HUBQI2^("X&S/67!@-?P/_(590HVBB6P^2KJG4.QHY_!H':&14DQJ4*=@ M+PWER"D;;Q6M?+..6&.XX-3VDHH+>QY S\?RR)8GSUC\A;,=(\WFEX&J6< M)9JG8(.\RZ>2A!LF;:*<)5J6I[\F&](\F#3)XRDTH U5*K:)P50* O !P#S! MU%*5:M.D-A:K0*/EPWK$I786<4P9I59C30EBH (U0UHBQ9H/ZY='T.5DG&(F M&$I%S/TN$9I* N+H8D>X]>4!LG&08UJ-_/2U'4\"-%*P7%)*!?_/J,5$&Z:1 M LQ!0.2<(HT#&LLAR",>:NVPD(C&VH>24\X%!@0HL%44!$:F2>/@Q7((\GB@ M0L8DI5@E:9(PFL8Q6C\_-"WBB\IXC]VLF$VF P>JW',BDCL4NPG2*DA/I^F M4$HU_&4MMAR $4HPL$@3=LK4(IHH+A)GE(M12@S7LI&>_5].C\=S[%-* MJ&%&ZT3!GP)K@AQ-06,F5N)4\$8Z]G\Y/1[/K]>*V 1H$<+*"2@N;3B6,2/* M2 +?-1*"_N7T>#P$*I&*$TIB@T!?:>D=!(6,[SNK<<();B0]_N(JYZN=C5J^DAF8AH-T-NR9*[27C9P9YZ,U8E6,8"*0LI(PJZFCPG*A M8Q+SU"C*$Z+3)ITR=$\EPJ$KQJ/,C%W9RG!-U,!B"RU?))X0XTBB*9%(<$X0 MXBY.$O"\18/;W"V'B$O) &D0-PP>@F^!1C&&3T8FEG'"C=32Z>9*HC=*^T/C MG_NE]!C6-UJH##(NCL%TFIARZ5- 2+$D8;XX7##<7%%<$A67(HM!IPH6PJ:84)5SA6'"=QG&,L(IYLT[N6%'"+F=?1<*02C2W./:M96)E M4T&0PYL5X-+UP_MBP]=?. DOM.Z4R)@PU3DNPO,1HJ[5P2/ F=6%L$JV7<\@] MHX@PHUB:&.I],JNYX2AQU*3.)6J-%/8JT7HI.ER;-$8B49@)1)U+98)EHF.: M.J"^(DW*H#Z9L/P$F:=(#1XU!Q+2'3<@Y5DM@F6*4" MO!\J+!,.$).+L1/ 9B)%C35U&]9:MO5## FJ4$RM2*A22E/K.R.D).8TY8TZ M2&_#6JME$!6B3 B 5-I:FG"FP>M+N=$.(R'BN$D=H1L!K.I+7^4CEYV&P:RC M,:2".)XP9!T'1:5!;\64H325PEJ+49,Z'6S8:G4,8:P-THZE& /&2JF6"1&2 MQ%))$^-4-JG%[H:M5L<(TI@[*F/-$RNHM$HG#"?^)!,,/W#5I/8Z?R7@:3:G M+<4N&H*](?1'XR0T3@W KA0G7$O?6]"R)G6'W'#:2IM*8A!'&B58@DY#S$=, M4X53YVCB#*D.8EH/4[GAM*5:SX1(X5R,8D,3WWU#6X0D1UQ84&_<-_K8(UN-13<1 (HH) RD*O6^U MWY]A'$FQD29IP%%*J^*X/8U0I81:)H32X/5C1*0E2DF#!&7*(MLXI+X2Y'D\ M,,%B#/00-DE!>HQV(G%:*1R#FRP5Y^E:2,_3U(X]B;@@DMA4"XD]3&!,:4Y2 M% .\TRKE0M$&A2Y6HZAO.4%UDX!RXTPD%E&)F*:QB)%0-B4R%KI))ZBN!A67 M<\9Q2F-_$(+%!B"[$@+ >VJX9KX_.T9-ZN.P&E1<3CV1Q0ZAV/?9PY3%6A@< M6T<(PUP0D33 PBW"O!G,-@(NK3ZW'0X_&IV6Z-3[3#S!_W$#3AD;M5I M]7ARI1QS)C&2I 2<9L.$/XK8)(F6 CZ1=9,KWW FA*8:)U0Z==(RK(7@FDHA M18*%1B[AV#DDT;H)U5]-J$?,1@*DB)EQ!DM'-4JT4$BAE&C,$">X ;'=G])^ MOHW3SM#Z_WB(\47U77.ZRR(FTX1A&2>QHQS H)&.Z(007V(KG%I]FKU2V>B# MZD_<[U?3/_^ )ZJ1.;MZX[ZX_HWX87W1_O!B,B["%?BQZH/^?@QD$LU9FC+! MDI@"!PGMA$72M_63@$_-ZC/0#VOG?9C^:!C<>M7O3,83U7\U&3;FN N=Z"0U M@'&8M"OL(3L!2F,0RI'U7!^$88#)) M-+*,6LTV[+,4]B$-89_8(.>XY$?5*> M,HJLU YSFDBE=54,E\A)D20H43OHC8 M-B"TTERGHID<(V(GI)?E& /'.*D%QLXI$5/FV[S;U>>8)R32!D?(V'+.!#C>LDHH5YHP*DOK3HXT$]K$Q03JUBENR MCM!AKEPX7%/L#WMG[C:E&T)!#2*.$4UI"GA/*JZ9(K'64CFNB.\'M_(4;#:N M6#-V(A;\A]AA[;BFL4H4,)+E0AII79RZ!K#3LBBX021WL!.B-$Z3)+$,$ZJ5 M\B>6)"K%S%)&-&W& 8T_Q4[^/$L5V*DZS=*J<7?G0T/HQB6/;>PXI113T 5" M)@Q1+ 4RA"M'UBR_O,2LT^.EFJU(F"48F] =%FN%G7 \1D1@$\K/_+*@F+'ARE)K,6Y J5]SS7HS.4;AQ IN$N>TZXXAC9!R8,AI8J30#"&'G%0:G.FX 7:]V3*_9NR$ M#5,V=:FU2%&LC>0 \!-M8^P,PBQ=?79J4A3F$3?),YSRQ%J7&$6M HHAK)E( M$,>^(WD3CH+^Z;.9G]9/?_I];\O?#*Y=*C"P29(H =YA+(0W*4( 9O159DTX M"/BG3V[><,]_RCU()5(X9D0J-*6,"6(P$JFEA%HC91..&5]1W?/4.P.7SSLV M1E*E*K$2I7[KITI<'%.#*'R4K%%=Q)^>PD^G!!O).P11+"26SJ28:BRE YQJ M"#8"'-@8H0;PSHKIG;]D\^3R&2?6U)'$@IU*).4V448D"2!HE3HD.74-8)R_ MB+P;C;/ .#+&L94\<2G1-.5:4,8),;$B5F*%XM7WCE>A%=DC!KP=E483P]-8 M4<>04H8;(157R/<(7N&.I4_OKARZ8CR:F#$(^O TJ(2I#MCQ1+CU>T/J31+, M4^)+S 1C0',I))>:Q8(PG# =-\';6"$2+5^G"N<;DW& A=N"[) HRYS'3H>L#(]O=,S4Z;4SKD#1%"5<" M@0.-*"=*I5HC&UOFJ)%$K0.!%OI#+US=$!HE,8J%CKE6<4HI!G+PU-=)QI@; MP)2H831:.J)XQ"0XR [8'&YBQ*@_UM7&\#%.$HI5(G!C$<623=$*0 L0,7#I M-2?^J$+-=**P<#%.B4D3&S?)SU\= [9\LC(EG+0@I C@" D.H#_#)U66T53S M)L3]5M+L+9^R0L'Z*B^<"%.58HUXS)D53"/$>;S"_OPJ*N"G.2P!.4$9L04S)5@!G.6:LD0&"U5@HID%>GC$S=']=&WKUU^ M.E(79YE1_<5;S*7VY=S)QB3/BT)LB+!E?9<(%%;%E2XH8$$H%.5ED[ I1RHE'"/ MRYVR*7,4@4'2L:%""7\@*N;*-NA I:43<"EG*1G%,$E]61=CE&FDB$#*&AMS M7QV@TG60P.#WKJ/T*:0HB)P0@@O?#D91ERBK# /#Z&(3-\C^[=CS23'V-Q6O M\E'77>Z8 $0\/!_E0_C3!+QRHQYX=A4@FJ%5(UN\O["PG %\R76TF2IUR@F= MQD)QZE L49H0YN*86&N(31HDL8TD^E(DG7/G"WQB(V-'"= ?H%*,D+3&<"ZK MVNUFV-E&$GTIMIE(#130SFH#"!EY/Q\IQ8D5CL16-" ,LS\T^<#UU->=R?@L M'\'0%HD:W-"=H?45M?T_)Z.LL)GQI;4-"<0P\#U!#'6*"Z3!AP% FRP.W(V&^^J MT>@JS4>7@((6^<'G?7W_C(V&>&A37L)#>;:5CBH'R"K6*3>,&L%)3,3J,L5# M+ 7Y7C/;#>LM<6.. 2M$A34B0=0WC^+:&6I3;"R)4]R 4\S_0J9X$+=_[VB M#>M-*[B=2Q4XES'5-#%(I98RFU*L4P% :<-ZS81BWQ6 E>$_JF)E$@U\9V@L MN7 F-MQJE*!8L62%_;.:V&_RHMC-0SC*#4WFBM^OZO3#[.L;#+(_+":A='6W MK[+!"M='3H992:CJY5,B5)V^ M]5O]6/J'^J/_MGW&WVDB35<3A\25-DJ,;. M,)Y0:0Q/M.$-BF1.BRA^GQ39T!7%4?F(^69IH_QBE+FQ&EW!GW9BGJ)E]?(C ME4*F8$><5"D7E,=62>8+TQ.@GR5)RM:+J%["1\J,.VHX294O(G-VG:F+N U MS87"OH,#HTIRQ?SI)2FVJ5.\06G&[U!WIJK!H%9/;_>S05:VQ5['=*(SR#$N MI<4XI0YD&%$I6"J83$!R1=R@=.)*$W7BYQEU.ZPU/AM+, G1 U::HQ=YP@29.82?BS 6KY@:6HC]M:9_DZESJ: M(I'$3N"8)@G2!B5*:Z20[]&2H ;HW.53;BD*%6,J8BT,XII0A8@_.8!((9%* MB=12-T"A+I]R2]&6EB;,.J+35"I*-1,&:,-C)KC@B+(53O\LA6!/LQF66V:( ML=(*1*W!,N6)Y,B)1#D&>G!U>WHLFP:/U[TC1M97$RGAD*:)C(6RCC.=*LM1 M[$RYEW*CN.Z@ 7^\_5NIA^$84$!,?4\V9;3OLY&H5!%J&N%0/Y 8>X^ZB6CY MR T1S3E1"4;640>D2]-$()LZS6B2,K8^R.T)*;<<5]BF4AN!B$T-C8E42#N_ MQ8BD6(DT62/D]H246TX9;"H2IXW/55(:)T@(;2UXN,)7:SBTPMFBI1#L:>ID M0&BD5$)QI*C'"Q9<($0)Z#KBS[]H/')[,AH\'G)SB"7@P$B,_&'/@)DQ!PF0 M::((8#J4-!ZY/1D-'@^Y49Y0*A5H(H*ID!IT+*+0>Y.8X=V'E :HZ"U=$L=<*E M! BJJ4G$^B"W)Z3<4I";2WG"9&*Q5)AJE@""(*EUQ+N[+%GE[3%+(=B3(#>P M2HF0W/=F2GS84\2..;!8-$U(ZO *]SI>-@T>\Z!A8;!A/G- J+!)N=$XCH6V#A2=]59?I G"J<6. M$+4^R.T)*;<4Y*83:V.1$))P13$7BOHS1Y@B.F;*2M=XY/:X!'L2Y&8EL2I) M$V=Y3%.N5"Q38^,4C)4@V*SPZ5G+IL$C'AU=2^"[GBE'A#[)".$8Q>#?-1V[3)E7MR2B_<&6S MA34]3)+%/ ;,K< +2FF,F4@%Q[$0Q"C)4[8&<;@E47-9L3D?"0=+E0)&UU1; MJZW1*:"%1">\";MY5I.:RT%]A A):!)CI2@E0L0":V4#6@>_J[FH[Z\CXM-D M7R5'R/F6SB:EA#&%#;)84 ;^59S&I+%(<"ET><1:.BPE9EHX8RG5$FMC2&)4 M2E+*$L:;&]=;"ET>#S$:J8E#<8P$XS1.$E&&CY2@?JLQ7X/ZNBF!UAHK:J-E M IC0:2II@HE6R%EE"<=&8R2;T.IRU>BXG#ZUJ:.<4^HC%]1JK@B+#8M3SN*$ MN(2L$4I<:WPHM$P3ECJ2,.1;MDLBM."2,@'.&T.L^?BP:<@PQ508A@ /$D<= M,9(G-$&$ ' W'%?'BVT4XU^("37E1#*KL;()==P(^(LYEL946&JJFH>-BOL+ MT6"BL>."&Y:DDH*P2&2 /E8Z#IZME$U @S_4G&)TD8]4:$4TMP%Z+?&A!$>8 MT!A;@;3OBNVA81+;!&,M+7(K;(]6DJ!/$[M($@(TTK'3*>B_6$AA ?T!?OHQ6NO:UI]$'U)V')=_K] M_-(W+RQFIPL7O:N+&T<,W[[^(-USJ1N-G/6M,_TQT4W1G391ADLK"(@9>-E< M:@IX1;)$,*6TT WR&QI"QN5[%"HU5B$6 WT!V+A8@,D$L47&2I-*AE;?HV@( MJ9_HG' G/*&$,RF52F@M8T']:2Q*8!3S]=.WT\M>Y:.R(;+O3-L0!>L<*-)$ M,F8%IC'7DA$E$$FILHI8V:3C6U>5;LO7J,0YE")F6&+ /\0(Q),CG28*V]2D MU?ZC#6U7184J\ U%+)!"J:"I2K6V JBGE33*6F=6WZUHG@%\S% WQ0Z!">0N MI3%3TEG#6)P*HF+P$$6#@FT-(>/RPW!4**NE2BE.,<56:U^CGE*6)H[KA/+U MD]@E*-A'%%$,"^@00!S!J4B) !7K# &*:9PF<9/BX:M*M^7+)'B/B&,KG=) M9!'+F!., =U:SC2X)$$FDW6B[?*M:/)XY8,3Z2>P2K.CCB:B,F<9@ M.Y6."4T)>)6:,K\ISS"_T[@)%86K3K>_6":SK\]'KE^F=\ZRBTB-S"CO+U+# MW[*=CTY_(Z"@?ZNN^,T?P=)*\WP\S,?N692.\L&A2PLOU/&'*[V7?WE##K\< MQYV)/6]_.7DMSP_.=]#QQ^.OQQ_?H6[OF)WLO6/'']NL2SYD!WO=\V/R#G?) M_F5W\"Y^$W?[Q]?Y9??UJT'GXZO/W;WWY #N._CXZNR@9_O'YZ?7QZ3[N=NS M66?OY',7BZ\'O>,O)\,_STZN<];IG:+N^8=!Y_P].^BU46?OS\\'_KO!.WKR M\<,9/.MK=\_$)[L2QO1G<=++K[L?W\4GYZ_@O>]I&.->=P#WX./!/CG9V[GN MO#X\/^[MQ ='U3W_^O-,#VS_X+R#3_8LC//#>;=W=@;S0AURS [V/F3'YR>? M.WN=RY/7W;/.GF'_NFY?ONEUQITC]/5-;^<31H@C(75+6L);%/S(EK8(M0@& MIS)!U%HFHLV*?G-%WX\[5WXUV^/.SB? \%@:I%N:PUI2)6A+.(U;!J4::1N# M=4DV"_KM!?T\OZ"6@#?$#&U)XDR+T'<+9DG#RFF,6\(X,$LH$2W%"6TEB@"H=IJ!'MTLZ'=DGLS+/!+* 41* M6XQ3U:+ F1Y#B9:S2$JC#*-T8^B_MZ)?YU=4@^F14L0MB1UHT52#O&/N6BE/ M.(^9I,2@9U$_&WX^_+:+$/P#?]VS:)PWU"DX^=<9,H,/0_513@[./W\]V'M' MNA^/K[J]S_"<=Y>=P3OFOSO9.^N?P'A/]MJH>VT_PZ)>=Z[-IP0)EAK-6[&* M0>!CZUH2?.46!L;46&I-8_DLRD?6C?[OF?>2?[OABJV7;]8Y-S49OIZ\?O>U M\_$P.QGL?_7\>7Q^#,M[ F3I?SX^__/L&):WNW>,CZ]J>;C(CLE[(!V\BQRC MSODQZI+.U3'(Q\GY"?#Y:7RRUS_KD#_[![LWY&'PY_E)[QWI!'EZ=]4]?QP@WN+G\NWS&K2?YD&E+];/3X7/C_(FG M_A'WW?TD]PW4Z#0;MG0^'N>#YPG,!YXT5KKOZGNJ*_HN'3]7DW%>WS(*BQ"^ MT6'!6R;O]]5%X9[7?[R8>Y^_O_R<#7VT_3F"=]FLN.BKJ^?9$-C:M<)[JP65 M_E&*;82^\?O"S;^%QY>O@('[E?N_9_&S M^HX+96TV/&V-\XOGY.+KB_ISM6+^*ZW,Y]-1/AE:OP3YZ/GH5/]"&-NJ_S]" MV^C7%[<7_XL;C?W&W.I;>$6]E/YM\<4XLOG$D^(?*/S/].6!&!@6L/ZB) 8N MR>>G4 \_S8?C5I%=N^?8_QH^7I;\R^&!X7.J!EG_ZOG_ZV4#5T1==QD=Y@,U M_'];A1H6K<*-LO1%.;%Z' ^<\;.7[[O[O?9>=-3;Z;6/IFRY>LO>N(4]:N^^ M/]SO[;>/HIWN7M3^U^X?.]W7[6CWH-/9/SK:/^BNZ&J7C_S/%APM8<$_*C ? MP]-Q/MR*]K9WM__G'SA!+\I_"6)4WE[OWX(^VZCOM5/?83%N\/4@LQ9F/Z>_ M@8>C(N]G=JJ^JQ^K=]_^_6%"\1!&JB]XX-P69>+!HC0GDN0.D0Q,48&E"A^] M.CCL1#X.,3 MAVBH?+K?NNSY7FXF/C/NT^W/JHJ0)2'D-^3DZOBC24[.#:#B?G;RL7O>&8"[ ML&?H\?EG>/=[VH'_PF=RTCN^/.[M?+&O7V7Z]?NDVWM_#>^^ N1,3E[#WWOO M\N3_'Q=1N=O#Z^\BB\O.<#O(L-3WHY[O8ZL4?=71C'2:\#<_LP M ->$P;77!WL?SCN]P\\GY_M7,,9+<$\J-P7FG=U YX-WE\=DGP(2'YRJ\&Q]?@!GU\=^63T >]S[C3:Q-X3WS0ZWRRB926*/#% MF0'7'!SQEK+9../\"#_ ML.(Q\-*C*_DT'PW4&.Z&12J< 2"9][7J]_.QSK_>90-VAL.)ZA^ZBWPT;K(M MN&[3SO7GR^XY/+OW/N[N'7[N#-K7W=X.AG>C\ SXNW/=OFD+XD[O]/J@MT-@ M'F?=GD'=U^_ IG1PQ]_7@[E>GYW!W]>=#XNVX.#=)T$8$2)E+>'#U-0A"W\1 MT?*'[Q&52IH*^>SE__Q#
  • W*O!*^%:)['Y*YR-G6[W_;3/% 5)F/HO&9B]*L +I'5TZ-(@?FR3X^U)S30L^M[WL!3SRSZLJ_ MTPWO4D-O0Z%DNRR?;*0>^D#M'W_V3TC_BSZ_&'2O7WT^^/AG_YATKDX^'GL= MDAWT#L].>J=7!T&GG/2[Y[^?=5Z)KYV]SZS;\]C1X] =]HDRI+'&M&6M,BVJ M?05(@I*6T898DSB!!(#"/6?*,ML8;T5^[;^-$)O N?1NSLU'&Y"W 7D;D/?3 M(*\W@DED/KO3>*!W/'@%#GO[NO,1W.SS5_TN.-E=\NK\&#X?^SQCSUR?[+WJ M=_9N KV+[/CC8;_3ZWP])J"6/[Y')X,...;=LV-R<@9*&G>ONY_A^\M%H+=_ MV3G])!D50*:D19EB /2,;JE$B59B8IDJAA+B7 7TZ ;H/3+0ZQWN=(_V Z+; M@+WO@3VR /;&4\F/RKTHH2II/BS_G_P[SO^"Y.MJ+_1N/AADA=_D%+W* &. MS'M,]H31VW;8QN1?5KZKD[" M+XW4,B5D//GXCAR\?@4P#\;4:\?=O>.OG>M3TKVV@X/7'78\>/?UY*,O;OM\ M$S+V3_:.Z?''5^>AY,W'!L_;UP=[QW&7P/?7, Z FB>#[N!@$3)^O9TGV@?8 MZ>'FNZ^=P3Z,X]W52>]5=G+^ZJP3UN;=]?'U:=R]?D]NY(E89^_]IY@SF3C, M6C$!U$FY2UO*X;B%8G_DO<;^<*9G+S^VCP ;_;%SV-G9;;_O[>_NO $,=/AA M?[=]M!7M=W>WFQ&A"J/U5F7%@XBA/H]&4>2-51,6%,W[CLHVR892-B\B< MJ1',Z=P)!7O"Z5/$*2C?EB1984OU-&53=Z'0IW:WGCQ>4?A>R!>C M_(N7UL5X<&EZ]H>FZH4,N#IT3BZ/X;C:S6V3+5$7WM'9ZUQW>CM7W;W?S[I[ M'\[ )\4'O3_!PK3!TAR>=3^VZ4'O]%;% LSG$NX$_+N/.J_;"*Y#Q[WWK#/H M?N[X+4?PG./>*3MXM6")2.?R$XL-$JEF+4S2&(Q'K%M2<]R**<,B!4^82/7L MY5LW'!97_2]JF*E5B6!LA.K!<*VGONY7#3I,D)L&>X=_M;2TI]+2/?VD.=/. M"M-*$^=+DH[3EJ,IL=BE@B?ILY6JY M^26H_R@?1;D_CBDZGXRRPF8FA+0 Z&7SIB)<-CH%#78=/O^Z6GJKJ238WS[< M/MJ.VH.+?GX%-%C4,U7(Z]>E\_U3A+N7L=YE;'6=D@8KLHJKPI0_I =6T2=_ M8,7)DV.>'6M'KBBJ_[R!$> -WOD>WKF>JV&+NS?WW,/U!WO'Z)CL^[@3ZIP? MGG=>=[/CZS[,X<_SX^OC^,371U^;F_7,OO[N$TXQED#,ED%&^V2I;2DETY:S M,1: IQ RXME+%J/H#P=.X3 ZV(X^NF(<[8VR+^XFE-IZ^CQ*Q3N[\.?!J)=? M#C<,M#0&ZE[O?*()DXE@IJ6U4BV* 7@+A62+&JP52A4V*G[VLOUUG ^7QRT! MDQZ,WH[R+X _-Q&)9;+,NT]IJH!A?.\4%!I&,-_>0*(65KX]O,!2IO39R[<[ M#]A!L8XNPEI$-RK!>YL78]4_R2XV@< 'BMTLM'&P\XD1YQ)JDI8AB?6A#9 4 MC5W+Q,9)E6HLF'SVTI?&X!9**&M(:*.)[LDO%4?[&,;%"*Q(=J'ZD?OJS&0, M2 B^!O_:%2L6P6CD2H.ZB+R^N"-"T;QZKULETF49TBQ9_S__$ 3S%T4T=GUW M<98/730, 9HM'ROK3SRI(C5R"EC)NN=1O2BK,+E[:JR>T+IXW+\#B]%8>_)8 MA50[Z!-W,C;&L):2<=*B))$M26/5PDQ0X:M<6>*>O4QN1[Q;3TB@-SEHG[>> MC1N:@H,M:8M(=']NXN]: MKGD$]G64C3-X8EDBXD;.1A>343'QM2+C/((K0E0;DU_TK]XZ^S+:'3-^OA:U M'6);,O&3M1UX&[,GV8."R381[$FJ1M VJ^;;I*J1AGJ!O6S<#]573IFSR/15 M4:P6?&WJNHY40&U'5P.=]S=+^@A+VJWJ! .GNJ_F3 U/X8MA='F6P39L0)*K,^A4F.BBA1J+$.C348<=D/SZ^?@^(KW_6?7U,C@$A=C[ZZN4.[KP^ M!D38S;H?W]T.#5WWSX_/[;GO>G#PL8U\3?/!:]]OLG_6@>>=G'_&';*/3P!9 MSM6(Q9W33T2AF//$M)QFJ$73F+>$XKPE+6:&5PL]>?CSJ;81BY87B9IVRQP6W2Y1K6].N4$/# M=\?\=7)3M\_>IYV=3U())XCO<2%2T:*QQBV98MUB1A@E4J<8<0#3@%^.\]'G MTN)$]9)_/R_1O,#N8P0L3A<"%E&T4L'=>R+7W7SH'BTLM:(S+N^*F3GLJX9VV-HG(?\;.TZYF M3SK*_VR,JZT 4:4 FT%J^N(>=;ONNGB8C^&;?T\R;WG!X*:^S\,H--(I[K;$ ML=^(,/T4.I+,['*ED$'DH^C&PFYDZ"?'^.36[4/>GPS':A3Z;HR*O[=58Y]L M2AF+A6C%1J4M2JUJ"6)Y2RDP=Y@0Q?P>J6[>=*.VOIKN\LR%_50WU-TO^-?H M#."EUW$V4OW^5-'-:T#MJ@O@F8M*;T'9S0'1VG/S"M#_[&O,(@N_#D_#I1$H ,'V7@,6M/U01>. M\J&/#/>O(O?%C:ZB?1]X42:4I>ZIL2H;G=VP![-GS"/B^=#$H3N=E$>,14>M M7O2+9PO^(B(QV9X&+[+0FN7"MV9Y:NM0#C@8A(L<]'JM_5WQZP_K]B5H^SFB M>)I4RO_OK>WC3T0C1[26K90XTJ)I0EH:I:Z%N5,BD2CF1-ZI[1N@HS8J?Z/R M'T7EA_!R7XT C2MC0.6/E-?;7O?YV/+PSF\C$);6G3\4 [ 5\)91#3Q!VPU@ MK:ZVO$, CP,4[6L;3R-8LS=E>BX)1LHUQ_),]R]$V MYP\MOOS!;NAQ@I^D7A1OX_A)^I>1&,;\T#[K/[P8#QWRJG1 V)0;W%5N$(!= M4%Q>F9_FHZN[FJ.%".1N=4$C 5]9>-#IO3KO]OX\Z^R=7G=[';\/,H-KV<'' MSA4\?P#@#_YKX/V=FX4'7SL?.[@S:%\>[,%_K_T^R'T AY_9\;6?RTG_Y!S^ M>PUS73B^;9]UWGU*@#2:A2::A+9H'..6[X'6LH0RHAU)I&'/7KZYV^*L2A'/ M4F3J40]%N!EH_3LLX*97T(JNXLYM.?\;+>CCRS5=S;Y+363-[EUNUX8]'Y,] M[U[ AJS.4P#=%1I*3:>_$;\_P3(>W1?W^%LM[)H!Y7M\!-TOH M&/GD1FT]1[,^BNX)+$C[[F#XQGXTU7[4!'T=Z+E;DG-C1[YG1ZX6[,CI)Y%2 MF4K"6H9QU:*%?_RK_\,H-7PVNC(,^(N+L1I:-;)%Y(\HR>Q]VZWB7]2O=^;]OEII?]6 M]KDX<_U^S0S1+W?L9[HWK?KK=N3KYJL2^B>JMOE1,.ZGTV0=^F@E./03Q01T M(:C ./5MJ82)6PIKZM,MW (-&!'QO1JQ)&=3=L2L59UX#^1,G9Z"I'I1]A+L MQE5WATH*O^25?O1;<8'C0_EW* M)?=4TW%;4ERX>OP9?_CD9NI*X,2I/JP\% M>>H"=.S7#&3-]:^B_ZKD^%4H; ,=.QEFI11/"OML4:Q%RI)4,4*45C2F7/%$ M&J>%)CC&<8P_[0>Q3F+T#'2+@5?TB_][AA9$^_EP,K#YN/KYMEB_G>A^9E[U M+_6TMV3Y )5/8.8?EYX9KH J7=1*,WTH:G9!??L_+Y=5--< MB=LI)4,-)VIT50D']L)!0$2\Z731I?_G7JD(S5:*&X*!'8B!P\H@P2@E2J9& MI28U.K%.,2V]8!"$L#=S,\'8[[[Z(=$H&\$$VAR%41Q,Q@$X 5'_OK)RWD:? MG+7(Q2EM:283L'K8M:1,P3>0.B48$>D2^NPEC[=$S+QJ MRBX\I2+.9PO_@\*Q>BT1MMG##A;9.]A]WVEW>T?^3-.#P[<'ASN]]E[T^W%T MV'[5/FQW=]MK4GQ'DI\\B3/AVPP_]+S,'ZLW$]M4K'+!V1HUJ@NS B5'X/Q_#-T!9\>3KFQ_P,4STJL7 MQ!?CR.83K]A^[)STU8E#OP5WX2H*YZ]XUI]NS=P9 HKJ1QWG@H\"MC/ DK.\ M#_,OJCU*P6?IJ*N(E2AK)05G_4@&XA/M[^\_1I.F^Y!,@)F?T"?^[(ZG7>1E M;/#YR/G]9U]J\QK 1 4LJ S8X]G=-RI=Y/W)V+VHJ(+FG_#L.TAK_M^ST8RQ M3EU+CYSZ#.XSS/"YZE^JJ^+9;PLCJ$;'"8SMAU^YBA /HX>UO>KM_/ZF'1V\ MBG8/P ,%I/=8T'9UP9[/Y7-6_0T=G(QS_^X!$9'W=2-?^MZA"?#['<2 M<*F@_=0M'9NONQ)ID*88YK>41/SLY7ZOW8GP]@]IB=7DE)61RF MBXYZ.Z]\%+;368C"-FUQ-_I^909]4X0QVRC\C<)_B,(GI%+X9*/O'S=%>WCP MMGW8VV]O%/QJZ^VHZ.=5^W><;2W M?[3[YN#H_>$&U:^8XFR^MA<_JNV3U6>T5>:F!K',;6T?8]#VW5<'AYV=WOY! M-]KY_>!]+SIX?QBU_]7>?=_;_^ K?5_M[[9]0O$'S$%=35N^5D13-(=7 M[U%OGF%_%LQ.R]AA0*M53[H9V;=&MO%1&J0D5J'&/*9UC7F3B\S_[N+V\*9Q M*RYK#1*H.Q BK^(!;!,/>-QXP,[A/]N]"+!W=-A^O7_4.]SI]JH^$D>AJ@/P M>/O=^_W>\19<\2:T43CJ'>S^\X^#-WOMPP@@>P]@>;33W8OVCX[>PU=OWQ_N M_K%SU#[RV_/*>Z,CP/&'^YL$XLK!VN9C<5 -OIO0)K"\,23?-R04588DV1B2 MQ^T@WW[3WO7&X=5^=Z>[N[_S)MK;Z>ULM/U**<[&:WLOO[XOQTIK^XW/L!*J MOMZ^R3>J_I%]AN[.Z[8O]YXZ"CZ5^/[H* 3OP1& "]X<'^T'!V!F#W8/NGO[ MO?J:P_;1^S>]<(FO+0R1_XUSL%J:M_GF G0 P1MSL3$7WS47K*X=YYO]H(]K M+]Z]W^GV]GL[(8_K53]\\:;^/%>$4N5]JY"4WT6Z,0;8O.- M17B81:B+S<7&(#RJ09BY!$=@!=IEHV9O&([>OWW[)GS>.3S>Q(]63YDVWP* M3,>KGBW8. 2KH/YQ4G>(D1O]_ZCZ?_>/G>[KMN_-'[0^N [KP_;E1WXN-_[ M(]K9W3UX#U; ?^'C1>7'_>[K<,-9TOD)OF M8H^K\ ]Z?[0/H[D-81M5OU):L_FJWLNNV.S?^EN-;&/!&Z0E5F'_%N9LNH%K MLX.KN0*WB::O!EZN6[I@M,'+CXJ7]_8/VZ'9^M8=_1)"U&1Z!&[T^N!#^]!' MSSR!P;0\VQRL]KCV8&8'=@\[;=O=H$T19 M/=79?'WO!7CE]?T&_*^&LJ>ULM]T9G_L?;>AL<)Q=/"Q"W#_C_VWX5#D]F%O M9[\;_=[NML$/\*4RY>_!'9AMX*IV8MW;UF%C-%9*_ZZ!T: ;H[$Q&@\T&G73 M'[SI]O[()365>0B:W^^[!;-QM& +?!^@HYW=\.-65:591IFB_>Y>&[R*O?8F MB+1JJG8-[ /(O-@<\+(?^\2G_>[N_EMP'.:*[U^UV]5& MK?;AA_W=31'FBJG2YNM_+]#B)_=GK4*5R69DS2T46">SOMZ5.3*N*W,^; IS M-O*V JS;(*&Z"T;7.UWQIK_R8^=B_]C_?;]WM!7=T?0@.MK]H[WW_LT&1Z\8 M)%T#')W\/(Y>64[;&( G,P#U[E6\Z8O\R+UN#@Y]R6OKG]'1^TYGY_!XH^I7 M2FNN@:KW^U;E)F3R=QK9W_4(Q8T%O^_ 7$2>O3S:?]W=Z97-$3:G)&XLTY(M M4^!)^9/-^E=!RVY&MK%,JZ#_&VZ9V#0,%FJ'_K4Q3AOCM +&"=CR52OPXCI, MY9N''/PV5KKOZN^GVN[E_^K1;S=N\NR:V?][%EQ+]&S^ZUK,\B(+XQFY/@SL MBWMQF=GQ63GF:OR,W+\GV<@56_!7ZD9N:&!$V1"NS@KXZB(?C:-Q'OES=@AZX9^QFP]@$:[" M-_C%5OW3I;OYS:2X^4T^&55?16IHZV\_NF)GJG10!DW";8O M.G*C+YGQ8]T?FNTH/",;%]% G>>C;'S5RB^'SD;%1!>9S=0H<\5VM$X4WNGW MH_%(63=0H\]%F/_(G68%B##,>^Z720&?;U!1C5P$!(@N1OD%H(FKK[HZMB M#.0Z<4-X0;W$Q>3BKU[69)L]9%WOV'OQ[.7__ -S^@(&/[E8;9Z(?JG$:''9 M*X'Z-0(&4'=R292G-<6.7/8YWXK>C.WV]''E3_5CMM=)C'HE9^>3\;R +&C MF"#F8R =*#E"K^@KYP>3=0(C!1.T N"MR*""+ICM8H+ M9[(T@]7Z04,Q@ZCQ71 5!.PT&]:.'R:WLX*KAH?*Y"M8U=_?'^UWVT='J\HA M]XS_M1NZD>JO$]-_=,%HJZCOE'?KH]-^KD%%P),GJ3+CRCH,(\ M2E39"09M6'BU7(UNJQPSC.G6P+>\>KAT@*+@O_X-(UC%N>4,;U9#U;\J M 6=?Z:BH0&>)-F>+-!U4.4$S*4#2W6@V0T^5FG Z*RFP%9UZ-O5_7"Q@VRU M8>ITF,/43#D!'\GQS_?T=C8,QSH_$ABX!^!9C=-==)F/^K8\'?6\CDYSN,@;L_KN:G4\*(%Y#+)QH# 84??5 &&\]?73ND&3PF1P MF1]027+/TV%)_,L O17EJ^$N\&S]$\LU=$//GQX.^S=<@.&%Q8\N 1X%5#M/ M,P"_MC3MU9)%A4H=8.0TA=G %R5'S1;//V^L.?O6CY5Z8P2/]U_VJ] M?(_>S/6++E5@\WQTD9?"$.)")<>KRZ*$-.'R03Z\##K!?_?6#8?%51_T3Z8\ M3_PY@44C?"O"DL3-A"OW&*/?)P5\"4CCR)T&!-C(R=W#"5[/Z'J"WI>LE81W M,$>G0-WK@'0]3+[,*W0=#$51K<96]!:<4*_^O=9_6\N4EY_=2BNW.C,C9Z>7 MK!63W+D&%<,TOY' MK?E6!48R'P');QON$F$MQJ7",*;&I (\]:AO0Q^X[N+"S](_J@#M> M0S6Z> M I?+L\R-R/E,@&R"0 =%QPS./BLO7@.&?<16\I<2W=3RL!M WL.A6-,B^ M^N$O8-(9^O:QR(_5&L-J?^ T-_0:97E,/>6AV2J7( E@Y2DP?;AAE!4A$!0D"Y9(36'U(B=E M13%Q#56_]P(:X-M*[U3'R'^?CRLAN],WF7'P8BANRV/=*P.,&>5]EP+6O,C[ M5R \6S6 ][$-3X4O&;QMJQ:68E%:@JBY8N99><8M QPU/ZGRX[QC-QV@9Y73 MOBI*Y':;MM7+AB6^CR87_@8@AF=$0'D@K6[X)1OEP\J"ERH#C//$^"G/,U/( M+/D[@GBYKR!W1:E]P@"VH_WAU+V!![E2ZR^ZA(7KIZU2O/W@2]<'7CNO_> 9 M(X]!_+N]2@B@O%Z*<>L,%-2"',]I"Q\ 4A?9;%&K%P0-6P'[EL_X>94_+\3E MG/Q53A57K7'>FA1NNG8ZZ#2=^0&&"0.K#.&=KG:-[WC6F?I2RN)%/O9.#O#- M.' 0[UHH%YWN M$H]$8"I/72F>=\&QF5:]!\IYQ.9:8/GA)?#3K5A2C6BJB !\Y*@>"F#/ZZY: Y;"K^K8V^VQS".> M>\S(;6 [57[S@ :T;*[LW:LW71F/#\M8127-/A02[O:1J5GT\"'!OT4%&F)2 MW@5 >;)S$/6^6V9@X;9KL;XOSW:K>"!S 5DL[ELE/\_4&N+W.$)%Y), M$8A=4V7DGK#%MR,TZQK ^,ZL[] 97@N[2MNF$Y]ZF=.R=?QLJXR0^SJ*^3S. MUGR.IS)#$S";X5Z T&Z@^U>EWS:XZ+NO,Q,QBUYXGOU>DN%F9F'>JU]P->Y, MVU2.>IU(:=V6@>E0Y^Q;&#[,UB>94!/3F,1CF,J[JSLF)A@O5X@BL^M\33F5 M@874NT^'S,03_(HB^-!E;O7],/,*+-28%=,"L??;1]NSVK!9SJ!,C-MI#+L, M@@7SE75#!Z J/ 54%4%8;M321BVMRFKL],=G4]$Z+6O19M(UE[T9>0F' M$:AI':D%X.D1Y)Q3D,TKN9LY=@!.>3&-@->K[X/O4]P>/DQ!>UD;Z3-W?9#% M2?6H.AQ<#R/(XE[>]R.;ZI.CO9DZ"1\ ?/ M^S?>JUB_JY"85SH\^NTEP5J M+Q\5+U9C"M_90[!8D\Z;NO"=:?W?-*&[-^/T$(/U.80B*XO$IY7Z@%VJW(:_ MYM 5H.G")03< ]@!?*#/.E+J? ;*P/- M#$'<$QD]5)=@:'W5J.K_X(:#>[8MHA7:MGA_U-0G@\9G(W!OM2HR$XU@'0;U M.M05+O/)OLKEK?W\YY'KJRKQZ6O')^"F3@9EH;?_(3/;47MZQ32J HMT%H'G M.QG5D8BK(;S)!W*F;P]YQFIK:O^JC.\J$S)5(7KC_CWQE;B^F,@GH>9-?9[].:&[4']V49]+0N^126H(SA!N^\>NCHWCC;"I/4#2[Z.0#]_[//P%> EGP!^^=F>4#Q;JI>J5 MJJ-'P_$H[WM*9*,HOX2%*EV,4)<:!K0=[4U"X&PN1%7?EOO-8S&*DO*NM7Y?E;T\B8R8NR]&H,RUI/(.2=0TUO>E47M84QAP*[D?/E #!0 M^*GO6M7C9_/RH:V!W[EE1E7H;('! IM604MX4+54,)(J*'>G1.47;EA%U*I- M '-$*8M7BUE9<%C9LI7$ D6O?,UL""*-)A?CNFL%<,"7S2L;5P:/+GVUMB^W++)0_*&O M?"F[KV*?%]I20T\#ZHMIDI M8*9U(^!A7_0G7B"]L'@= MU/<3L*OIU2S7U//=^9HTK/7?W$_%8;3]Y;\STW^5G7H%DISH4:EZ9V MUGG(5S5?7(7V@_7WP/]@#<951N#S,+]LG>676WYW>C8()2KE!O!Y,QX,DK>\ MP'C@CKAA41J)6\.)ZE?-%0CY3)"M!U?".#><&_#"+K':WI29Z+ IL!*=D)0N M&QX%XQ6L23#ZO@0N#X74?J=[<1-/AOTM/C^]%0W 4?5W#R/,T'1(EUY%5,.L M6UTI,\JKK2R^RX/;CHY\CN2SN_*%3!/74M;WCZGZ.\PV1\ZGX!>SC-6ZV1+N ME.U\RKV)WUK)$J-JYWRIN$LG/JT;A41:/ROWII5YW1#/FU:55PL71C_*+\OM MWO,$K6H8R^QEN2$F;"\:@EXLD90.:BC,=;HM:N+A>D.WT=^C48Z YMV#.B:U[BE3-.VJ?9/8J MT!)ZTO]<=NZ8<_AJW^,6+ +P$EEWRS69>G4+"&C;]Y<"[R.H< O:-NO#0BPF MSB\K#C E!VQ%%S?JD4)UP>R66]V_-IG63:9U1;(7#\ZTKL9$OSVMAM:6W6-H MRNPI*)I&3NI'NX+,-HC.]K+4,=<0PZIJ1T/7U[LZ:]W;H>/.OEES=J/N9U25 MGBYL 2E]@KS:[%E4[6U"A'"^<4<]B?2&QUP;@XL\*\-:H4=:V&C?'V<^MA:! MC^+WDH^B5GEEN0F]F8S\\QNI;O=1FZ=YH-C4XO35Z-3[3C^ZRZGF@^WO#F;& M [/HJ"?<0O.KP H+6YNK$=Z(Z_@%*3FC+L.K'+;@58UFFY/6C>0+3NJL X^O MA/5[>,)FGUI6O.<^:\ SUX(XQ.%#]3>LH'&+=Y79D+''8]7.VGXV" 7RDS*\ M-6WV5SX"L$LMV+ZR--0N3A^6C]:L;71H# @.?2TO,QE;++VG=#M^8.G]5@#3 M_DB,65EX1US$1'TWQ5E[GC/[=+^D"V/FXJ7#WT^8](([%3J MS+(X039UO:M=R-%A%Z(P M,5U.;-95*LU\_Z<0QO E![ZYF+Z:TZ=5^G96P/ EM$L"ESG+;5# /E/L%>TH MQ+FGT+0P9\Y.^KXO8S0!*..9Q[^L9"A]57JPU7MF_8O;(H@91TZ;H(59<+4L^]%:CJ!>D#$09 MEWWQ7;H75[#*'Y=QZ"^N/,-@Z$Y5]2D#I!>"S2$-]R5LRDG+POS;'>?\9/S3 MJTR!W]=03)/R0^>1F@K!)&5;8<'GFL4N/J&X.4X?!BE-94"S S!MH3KVLJI> MRU**;5Q<19VM/BH:F@Q-?2;Z$;ETF6@#53M8UR,/-8=U\\H M;789DE\73(-9V&\UCO: ))X%RZ9G<6CRCF58+_A#E#M7\@4Z>$&ZT^GT'6W_ MBPF^+2,8;;\.4/T717P[KK_R78)"RB?SI2 M@^GCP][/\M$5=LNJS@2;BHJ?4.EL4U'Q,(F=I4=[=?2F:E7Y W*J[A5[4+'S MJ44=NFN&D'WI??L#(-9%!"&3?VXGHM5C6)/_5V>EB!CCFK_P6$ M=E!G;.MM?<5$GX>-DWF%/WS%I?N2%2%VKU75R^;N_$\CE__>/DB#"S?.YEV+ M1DWKOM1?O;-SVEENOMY@OEM/J#PT815<57):6:Y9I+4J:_ANO\ 0&YM654Z; M_<*S0H7MK&9W,:Y[;Y-;?ZUO MT*D*I$='YWV$M)R=HSVY[?V;4&9")X;$/C._],-X7GX[ LQ3@\R<&3RUXV 17XHLVK MN6(8P"(WYCE;T&G)1(G"3T]]!]3L2UDUVJI+Q*8V?U96XDM9ISFV9@KB]WM3 M!LPWJH]-F7DH-7T!]U>Y7K_\BW'AXKY8\>T.U?./OD&I^;-9 %:>Y>580M?G M:7_7F6=7L?6-D91EXY5DU<<=534W59\P7^H^O7WD+B:E@@[<6Q<,EN'-?E8W M />5/'/]+ZN2H:#-%T[.F+6C\@_W%5M@1X,NV)J>\#'*JJ,Z2N&!E_B/@2D7 MMNTW7?E_KUE+J:7"B0?S"U6WT?2N8;D5A]TM?,C2\*EN3+O8( M X;X#]3R$"8=Z%:7<=UL-^D9"MA4UZYKQ2>'+ W'RXVS*L58N+ Q M(93GU1G'V@B%>,7H2Q#3HB[.K;8KW.I!?N<93=594=/B^6FK^[H9[V-TS?WQ MTQ4>TF?WKC:[N[.E?N N]**8EDSZJPV8N*E.7<"[1EVHN5,10F.*ZG/9 M-1P,>95KO)AS-J8EVNO7L>8!R=@;I[R4RB)PV917O[AI5Y5PB,4,TU6.WCQ7 MA]Z1%<<7 P7NV6B6?YMI)"!(2%759)UVD5PPKMO1:WC[<+9EYL)#H1!6@Z^N M?)S/;4VSQXNMI_MY_KGI='],<^JA:@E9AU*QB)4#'64MKOSR@T'V!0UZ*K*]G MF>$3SZMSQ^UXA1J.<)BFV161>PW=L4L M6):%X7MT5(P7;$!6E1],JC9:U0DZ-X%LM4] W]JA4]4-U*^;G8@7>NY6IK0L M=H#AV6!8'^BXWD)^Z\2/_D X-PIN_3PG5.IYGJD62T5"_JMRD>ZH[EK8SV'" MH7/]J>]13*,25\#WH,&[\Z\)J.C2U<,)":6Z\+AP%RJ4@TU1DF^?NNBI;/]SI9GO]FSPR70L_F%G8+6P\GL;7_';BBW%@VAO[ M4&ZRZ70:5O?!]M76:YY49# M:EMK9GQN=NRC.T6Y/>XNUV>N&'#J GHNJ0^-FAYI4R7V2L^H//#SKB.J?G*K MW29C ?QZ33TG('GPT2;#TK"&"A8#*K2H0G+E1K2 M/JLC6*N"QQLV8 8H%OS(VR_W>L55_O4&ZFW[L&R[=EQ7*$Z M/^AY;P(;..T7)7J>!Z_%>):A$F/6T*#*._'6ZD#H&V"R3"F$XW'G M['(8I6_+[DL[SI3U&XZJ<57%*W795SK=J5$KZ5".4.^?F>\4/?*[NL^B%&QX MZ83#"H8]I\-\MJ5K^IIJ\U+P"OT6D.!!>R%V"PQ6X>RBKM99/ !G6HLPB[_/ MVI[ :WWHSR<&1]Z&#H?S[[_UWI"I;203WR>IP<=WZ^5;[@2VNSL9'T+0963# MARH\[OP:-CD ,X@M@A#@R-Q'U6J_=,:\5MV#S/LE#U?8/)W MU*8V:H(/"#HH8 3M0Z<^EKH:!;@_6DE\>7FY?>F*<>F<;8-:7XUY?*>Q6;!! MK_RYHABU_KGE^W..0.&" !Z&+T]W=;52N]\:U?1>N?I7<"9L"6]9_! M!N;!*I;7IF%K;+FO95BFEX(7535V.*HL)8Y_4;_ZRS#[Q?Y:&T[X=3(J[4C[ M:VC][7PTSO^,94RC7_Q%53OR^0OJON1E?G4J5)6UK-ENMD]S-:CVH]RW/_SB MBI"V;D5'[=WH5>://FI$;[WISEA -T5>_G=4]@'PL?P+'ROPH6P]=* MCO*0^?$'6&7E0:TSJ' 93M.=,5J4>0;;FC7PF&.F<'I-S2\^\)25>Y/KUO:P MFC4+U7U]TG)Q9QG[&5O5N&^BPS&^7RJF*@\C<6.OW@(SEP\-T92UT'R%,]NG M^9?5F,#W5-XZ6='>/ [*BGE5?KFP_] GD<(FJ5"/47=LF]\W$G)9WO,N'87R M (#>-#-8VHNLWZ_JMJ\.1[_ >8$*Q-9=34?GBP]+UM' M/H,7DF8^LQ&BO:45O.OMT]?=:SG*KE>J;E\-(RS1+4%;:VCHU<[R7+3'A+!BS+0VJ)+^MURQ+#65U.'O+Y]36OI]< M$>$BG^"M#VHJSU_ZO4[N^\X/$[-8^)7=.83_S]Z;=[=M)/W"7P7'3V9>^QR* MX2)JL6;F'$:2$TTLR2,I\>O\,PWRNIJG R+?^VSD>D:TIDR,^00++03%PNU%T MI["?7#F A6Y&B&"OPI";NTO5>*WE+S$2+K(:54%PAHOP?MRO&'Z;YK$ESQ@ M$(NA&\LYG%/3C9 Z>Q$[HO:]#'C-150+"^U1,@EZK5, )=I0+ @WR29;H&/\4 M8&U<4C;7MUAY$-0]UEIT$%EFBM'%>)#@TCBV/J9]FJ2!+ MEH,'L._*CMVJ\_^S8/-456H: "A *3&,N'<@IQH:R'A&R^0&=?K>Q7@8AZ24 M4:XD1DE^]EP3+*<;3VM+!:\&^].OUYQ.N^'\(K"SP;FL\R].8M"W-?"R4TQ& M?.I2P*;YT(RU[_WSC?_?QG^;>V_F)+(KC$B_"#/VYO3<:7;KCG-U=OVK\Z%[ M?'-Y=;UA+(B5FXEREA+=@Y#(4)XGDG[L]Q0($P,BES!/6=C MIW!JT:$F$841=JB/>5)8(FP)5ERB H[R!V#E(=.")TCP1$6).QYC>9N!. YW M08L X:>74:LW=3)"GKJ+L')1%1O+B(W:CYH,T^C/Z57+G[(O4/Z46.!VYA:8 M "Y_AL/$J#=/J"_R%A%>'Y?]Q=1"CX"=22@2/+YHTJ5* @QX[5- MFU-NC=N73)B/:X4E:DAE!GFNE6I>Y6]M =8C#I=]6X#U6)5NM)>B@C *0)2N MP*"EEB;/+*HB+! Q&&!\K\9E%XE0PX;1GJ,6#X(@@F>&.T)E3^3G6,L)H"1!.D(;(+J3 M!4C(5#5' @NHI<@YS=1'HT]MS/QQQ@)94A& 2HLPZ0Q\BWT^G'#VL<:*2ZN1 MN N/N[KS)NQUE'N.G,MU MIMK/K16-J4*)7FXI,F(@[B<=\?G :Q61O!,,7^Z!9N]G["G5ZTR3K?O=9'[[IQ^<\>43%*5K_ERV>HNO!VL%*R((!#8'J$,\O4VYT@UCL[W1K*Z75I_N_M3UMB"B!8H?T3\+]!XQI('V M=_L26,*8":=._@Q?U>>B7[1#%^_')/9I9K>/6):W=%,UAH&A!0IK@C. :Z5Y MY(UJ\Y7!XGQZ8A%/[4BF'QEYS=,6KZ(X2A#NLN37U/WFJHKN/-<*-QOX?-;$ MC.'*BR/+."'\"\H^37Q=?HTH&7)ZT%3'0^#N7/Q--]*UWURA,*M4\1P*R<0G MP-RA0#R7R8BPEH;T&)19.N]0]Q8TKJH!4]?;FX\0RCV&?F&, MQ-PR^,T\3Y:4)4C%3E=2& SUB1BE MPTS.G5'=F&28#BB; :_G1=Q0%"TA#'L7J)00VW0CV6&5:4N\Y]Q&C88L=B.G MW%B12DZ8.5!51Y=G$&]!-U8>[IW/-<02;_UWI7T?N'Y0'O$%UB&B\\M66WXF MS7F=,T'A".XY4D>=0Y%'F(\+AG\-)1_AC>"(\\H[;5[)0 M%7Z:]RQ1A=O6)8^;K;SX;#I=W0 K1+E/3@YC7,ZUJ!TWFF<7P>7I$U,%F')[ MHAAIDH++H>[9XT%(ZS2UCIW7[WXU3.5P@"]5Y% MXA)-:H04H\$ .-R1VYN,?*/= C4[$KR($--+-(Z1(VTA,95&,= L)M?(K9?2 MZJT59G@(,A(Y1'@-#W4G:-*>1 $F<'0Y_L\G>46P,D1.7*KR_S4&6[BTG5)+ MPZHC">+Q;Q=(C?[G%Y%7^_@TQ46"O1_XDCX/[LCF_X'OY MLK-E&$5>8<*N=M60OVMZT*;L7"43W5BEI)OT)4OVLCES5$7/D0['(Y_?+'-E MJ/4,[%]045?91 A)67+I?P72PN>?%;Z ZI8M./RAL0K5K&J(=6YF&WDS?!,Q.NO)/:2MF4.P3U^@L->UL MU8K,25)$C^:J<7P9&2]$A]I0$Z:RTQAW-+&0619CR?<\F1T[>C!C6=ELWR/. MJP.;[5N-4"4KJ"?2.\'X9HDH'^WJL )1X, /\@(CW+#AI-@?3?Q<*H*I].JG MA:/6 ]L\FCT]%60]V=4&?CU>Q8-Z09)P!03=)OVUA9M*:X %&XVQ47<2%$#P4E0;:WU$$ M2DZNX%!;#PP3GV'\2/M(E>SF)V6D?!OSGG3D[54,K)S#OI,E-+1VX>6G"QO0IE#0)35^/8R! MDMEFS$$IA^WEI+&<1W&4"".D:!0&/*YZE"O+\=(9<:7&$1PN%QVXTHI5D#H6A5FGBM22[CR/XF^*^5S/K8\RU)>+&.B MEFX;]CMV:LD[1@,L$5?$+4.+$\.Q)^./'P-AW!.,EBZ=,:SYW9'83M*WW(&3 M2GBJZ&\N9C%V=Y3$#Z&+*;)-M$E]&3I+4M#&5*EDH$]*!&$3=+H +Y5$$RRZ M]-G-GR EYV,0(WEB9T/042IW1 M.5)51#1]%HMK2DG7)8\TYV<:Y-8$J"'C 4T+(0$ADWC:QF0M4TP<!882B@/!)E(MKEP MC]Q\[)=7BEXAF2?*9&8TO"%HY+^D 5N"3^#H!G)C=WJZ ;KCL'PI(-U:B^\H9#=!IC(V.N=-N$9%6Q=0_G'3SF+H*[T\P['R.!<@T MY1R;4V6A$%YQH7(2YQ(^68\8*#\#0]WN.[91>4H/&;N%MS4((1UJ-(!E;*L8 M$<[A#B./SH)4%M/A7;W8O6,X9"TFA;TKIM-!_;JZ@L]'6UM57LE*U5Q??0!A MDH$)DL?I#)[X@ADYU#V4_SCJ$5_-PW FE-4"0CJ+;/[J>4('7Z6OX/7<=)F1 M46C>,R G<\]F0X5_@3;^M%02"]"SL].AL&9WK)!M3I]DOND4/IV^,T:^? MRQ9/9B:R[GJ8 C!8"IE!*F"*E7::C;=?WYF'4S[2ARBC6"F=3B2N6D"MB3R$ MQ?^&-PVQ[60,!!\E=4;RO$:#3TA]2X!KU(\N=F2B4C\%1S^*.]TR4#2[\6%1 M.,3V1,*-K[$2Q67:5-HC&/[0IM)6(]2,,JP[1OV183^8,1T>B$+YZQZ) P9E MA%<\/ZF:-1\9 MP=J2D>C/9<+P,I+#?VGGK$E/4!4I"-MWPHQF)5@*^3%,89 M<@I1&2X"(5NZVF%#A=?S([WFZ7=^N9]\NED?^_H14UXL>TNJO'C8J[+NNYRM MOE'=DUB:/V=H9"E* ?IR 95*[U>LUUED$Q*1;K'TG72VK+'AA=.?7)Q (^GU MV99;CP63D4*;A<<&4^4%2E6-5V$O0B%#I^^+-Z'C5-Y59;;\9$Y6BT&A9HU7 M^4!>(-<7J>.:BDL\@>4V"!==FS>MC8>@YU25>4X]S[5P_JO/N'BE+U>:.L/, M)50IL5WPTH::X]*;7-65J\!ET2]Q\9A<&SG*WASNID,T/*)DB MZAPH:X%%#NC\ :Z+7?_"%M2*8X2*98G:&4".E7[;W$&K,I*#ZLU/BU:_3'[/ MS)CB14JMRU7[H1WJ'R.V2%4,"O0# M%D%=P#>X@$B9F=L9.),1ZP"@;O)U%L!)H!3O*I95S:,;2;MEA3&8\TYU>: M*@&=XF*6)/?\YY.,,DDZ 5]"L:+T=RQDSI_N;MP.9X=3I-8R%*L?-ZX]54PE+=ZJDQ9RLG)\WA6[Z M&?-<'SEY-ST%(?+&_D2=/,G$L-%AZ3N9%%W\VW@/SJG%W@ZB\TSGTX*>QN6! M:A[C$)Q8Y/D@Q^]"NU2B_KAZ6B=?#>\D,\_+A:)$(G/#2*W10:1@.&1E(G?Q M4N!-31!6*B<43-TP1F)K5 E)IUD(K1C$(9U4JD MVUVI]55/IYT_1%0I#VK2EU$#KES!0J;M2FN<^$F<350%RM*6IX?431L&A01] M]JBILTAQ>2]5ZUV:8Q:+2:9 @TIH5G/J3+?*0%'X?<6]H,GRSMRY5RAKI#Y0 MO)%*<(:-5,D9QSO,.QFIZ$+]H\,U+:HVQ#/0!6A2KNL,X V5&@M3V!QYPI]28W(-(V:(.$ WD\@<0@)U] ,$-&0X$HR0'''U)[I]<()A&QY\ M!,P#!X/?/P(O*S["1DBRO_ B=PR'[)%:OY_'G,A5FIJH':2UI=K13J,>6&V, M??7AL,5+%)5DZO<(M_\K&S4R\$S]R;,#^8!-0QG?UF$X5[J^TD6E%S!M!/4P MY!*L^"&=RWXAW,P#&T6-4]0Q/..E\6(#J6NNH[:2FBCTC=UWQPHBL^,A9"WI]H$T#0-/=W17H =D&%= MCFFS^+)JY?IVMX@'Q'?:4--F2=+_'O*:%1CNQ#='"%-!/1\ NM:-"K=--\PL M^#0Z"XIG*L?8'.%2F0:E&."?G'J:K>**\#3_+)\EBTSSAW"0%4XU#QN5PJ%$ MTY15^F:E%@=;BP%+\TKED*BJ3N"M(8@C)G-R19D#^\C>'>ET4KKG#E'W<_]? M5K67UCKP<0BZ1@8AC"+95 %[Z>D[X9?E@$$.TZOZW>?:.8:Y;Q)@47-$C9<; M84%Y36')2*!D"?T4=PS\ M) T11'PJ;@K'FDN8*BC*C%K)1?=Y7"8/]D>EM&EOJBOW5-?&6]4;CO&20.P, M8J%&89-=HJ7BG=DE5-(O]+X%1B5[C,#42VZM_AI]RB@Q%NY$>.0)]D8)5\70 M:B57D0 ZI>\;E3#&QH+$1P7)]5*5S51 V+Y?X6VDOEMPG%P;BLE@)SH*J&9S M$@5^_Z&>W.N#33$2HT2V)$)M52/RD2ZI&:EJV1Y\IK#131EPH,?;'8W\8NTI /">?X5(K[&>X8!_G6+^+QH)S<:R>"[Z1>[L$ M'FT.]HG9(J-JY$W;@$ +\9H"U+%1;]&;ZFH+LA4>W&B^FIAME7U&S9H\GRI' M*0JY3E+FTF6+9O$D-V!*C0#([,Z6.+KD;R(@M P\8Y\_]8D&^4(XPPSFXMOB MW#P,>A3ZOPFWQ^/&JB?A]KQ[$-=A'+[$>4HO2.!4:JJG7!77^&(]9=XP%$LW M'<,.2J\551E96 HYD ,WZC47&,7F3+4F89:2EW@L4%R)--OJAD?_Y11'_@N1Q;''Z,EAH.O\CTM M3]_ V@>*ZU!+G-$>ZH8?<(QHC@=E^%5@ZP%9.,8&KY8$DY\Y?'1 A$%"N1";JN MC\F$CSH ELP)TJK,&"/PRU05A_;16A6)JO0P4P+2+/PS H(X&'E'@PV_# F8 M=0XTE>PG0/N[3\Z&AF:8!6V:$^!GPE"ZKUSAHFBOCUNC0H*.X@7M%6Q ZFDS M)A*::I,NW"E50]54\YM9B4$3%905/@?#%=]!SK#5"78I\#6ESCB%H5)JB9A[ M'UXA9Q!U3[K$.E_%&%BH*(L@G#WI$B@Y7^(/%+&057\>UFRJ]T6-1;$]\Z>U M C3[BYDPFWENWINRT?N51Y:_BFD!<'FV45@E6;)XFRT++AE#E9C#S6!XN$ : M \3/&&6@YE9/"GU;!8:79 ?ZJ:I1[(C+LQ1PO0[BJS0YAEQP- *%4%1NDQ4P MJ:5+KJW=E[3<@;>'R& ;&5%?T$H2]? MGNH4)8A&H0:3BYD5UG$.DJ'Q+VHJL:]@0-24^YX;XKVDJ>O)AHJ"V2UH3AIU M\V(6A]%(ICW4T"D0*^'3)=\N.6X)_(D8LTSHK:'5S3Y%%H?JE,A;O@F&SI0U M-?R25N0G$@++K"M587U5N5;@EQX>CJJT'6DVX2PG("UQI7-O(#(3\%*NIB?8I1Z41 6YQG"*3"IO!%/LE7T\7\2QTG]\[ E$:N%GN M+8N,'F8\#>'7J1S0I(H8U=T1YCY I(ILS&%DO(_?+P5B[ZD(1JP+H0I2$$)> ML/.N.4:UP>& 10%JQ1AY_JENUB^--=<5G'NXQ MT**9"R7!9B,_6:JF_R3I D1%8FD75911*2:JL9@]AYAD4LJ%>! MX%A<[K5G0"@%TWZ?AC7TYKR\I>I^7 :#IZJD^G[Z$RTM%7>Q[BLC,)5ZQ3@AJ,-\ MAIFV(KQG;ES.41T;N3U+G'4YX!2UD9YL1S;'@EU1$>?GVA8*)AN3R:ASWRW" MU>5"8J"2NCDF"0CM)XT3?=^R:" UIZ@#Y+B M)#L$+];C-650A;M2T&G3M@9[<'[(Y5R%NH=;WTA"%-0JOTC!/)*(:T(:+7E3 M1"F9@?#NA/[C@O5-'G3B8!4GKQJ;]X$Y5#D,0[$2L EE K1]G.;GN0'UQA7 MLY1;#$H K'(< QGAT7^($)WH6SZDDRDE@E3^-(8'XEP ^>8G5$)2*]:/&$"$ M"1=6ZNZZ,O/B9_-%,BD'EQ9)V@) PI40CTM%IM*#- :6:J?:B%?PC<$HB8?< M0XR3!<&;^HN[U?QX+.M$R$AQXYC\83VG!/D'X7^I"[70Z(WC5BEI)R<+/=S; MS0W&;1RJ\#FW54A%<#,:O+-GL!:",=$_^Z +$E^SD@0AX1HND&ECP,A<4B^J M.%BARW4C:7Y/VV'!I.46>X84RU3->J&N2,:\5Z.'>**7 M&A G=>=Z$=%N<62\FG=DUJS*F7Y8V9]*"'1'X>BKD$,Q%666?9:^!5V5")KR M(YRW\(^\O/!=K7!*TT!2*NWW$WF]V<'#AFB.QX%YE+Z,[1OM2[-Z44WKU!<= MY;6E^4!XTN;X9#SHO-+KE;G/4+5<6$OUM(DT+?,F85WLFX.-,(P(W4^?G]14 M'H?R7KJ^EJMUL115*Z=3E+72M)6<%'E%ZZK[D3=@F2OFANBO8A&5R[6\3,(L_!I& M=W(@6XY_4\!\"J::>3E/HR@VITM,+D2^B!,9F\X,(F=8%\]RE:@F6([^R!>W MYNQ>3UG>TBXC7-00/!B:IAVXJJ].IY#F:[F%@BQ/=8VVS(.S' VUK)>']_45 M>H2LH%IZ5Q4*ZR.B2P[R06-MX<9)_N)SZQ\6%)\6)H74$/$.U5_*H^SPMC4I M!K+HF%P%U&HU1%O8H9>[BX&E=W"0#WZI?(A:(;>GW V.7V*P@J%4HC@'KJ$I MR(,H\".I7V UH(6DFZBAWQ5@SJQK4O*;%AQ0"I^5( *R.,E4""KWI3QP$AGF M(TDRBDA2I@#X$"B_RC-/\U(Q+;*1!%EAAH:9 MUBIV&B,KE["1X3W3 M[7PZP%,$+N-SS%1U:3[GL1!(QRKX0+@R6?]G%D_STU?[H+=LUMS,EO6KG\() M!]HZX1&:A!#B!B(NJ=O"@]_*LQ((E8448XD,@/O>5)?V&NAIRR:'E(:$R%G< MILQ3C8K.&W&R1"> QCS38(#S0*6,Z*X@55'=E:\YHTF*+?A)6H+'4W!"DZR' M+9>J?XEKB21=C#H,8]*%;(!>T.=0=S[),@_>.JYS7FW/2W&E'"% 6.DW,-^+]2'%M"$&>O#B(A\8"(V4RNCWLXDNTN3)@P9DV;Q. M3)TH469#P4&6[9UH^/B) GPD%)%,_Q)K1DQ3@Z\P+F"'M98W4)/7KM'9"EAH MG/B[5!@1*?)2+\S,G.##DP*^94IR!IL&K@IG%2F/N]LO,9:*T M #OV5+# R$"Y8;>9.F"!ONT68DY&A"]V1G =4##Y"MX]CL[5)?.\??-KXS>3 M.$M*.&2824TLDS4<-09002 K#,+5YC2NQX+ @WQG$B,N,C!V1KO"NJGLOGRAKK*13*#;0. MD%WU)AX6\0$&(QEG&<-Z82(8WJ+PVOTX\U-60RF/-Z 2[5(ZO^U:#J5X94XPVAUIAJ5)>[X2LF,PI5%!& MRXJ7G*X:EWZ'I: !A2)5]$F!/:OLGYO""=DO+(:))C5Z4X7)282";%)!:\O54\X'"(UD(I]PK MSJGG7/@W8TZ]*@B=Z;554]]KJJXMKY.TJ=''I$;;-C6Z&J4T"#=)"O@$P)04 M;T.V+)^#X1!NP#DA DW1>HAL*5:(AC#-@0WN46(4!U2YC).8=\K/G+:;>: N MP17-BP)9.7,1=\#E=Q+@I)!P*G\9B*&?J-FY!1O42,?E=6"UTC3'27E&7,9Y9"I9JKJA#7,_/]2_U]9<2\>CF%?EQ-@\ M3BO=0'>H3$;3A +YA7?+.TS@C")$4J.]0D*=!":<41%K(:F96%7JIO)WL"!5 M*)N7[^GDEY$T+ \O,'>EA,9#8Z9"MY\WM8VS8*CPTQ7XD1ZQ#9=T$]\MH@5A M.#GQ_+S<0WO%GB%Q9.?0J_,:>!1B$$1WI-:P)"($DP7V;XC>\]BG>*(Y!$9_ M)B/'I4H+H_K0#+(7G<:\LK+8L.6!&9N469)K+3AT(2M@,9 KAYKXG#,GBY9> MQEB?:GY8X)9>SG0FE<;5+P"/ L(@B!O5DQ1J^]6%ID^+X7+&Q#)<6?3I379P M2=&4>)X31JGIXJ91Y,CYXT4P*UNU)W-U-X+ M#M1?\I)]PJ$?<)(3XAC M@Y2B##J^0!ALWZB,0J.U+8*29L,U?U6-].#(UD6SYRX6_KB74>D56*9Y:M5, MK-88?("T N:68U-UF].Q)NX4OU2Y(UT 4DQ7WM!7Z$IB!$7AS[(FDXNA%=!, MP'SF3^$9.IJH ">YFH5SJ]*AY"7+HY.;%J5(2/KI3*A6'!J52S4S2(T$?TXE M&#AW3) NFAIX3687@VMBA)M':-WYJ!3T+9VX9CO.K1)C>?"8I#!F7FCN?EOD M7/!J$U^5,*I(LC2&B#U+YIT)/T7]@>0 2B1"0HCD6@5^]#M:;2^.P-A^.R@V M9%*DFW"WT3Q#3G,5N-0'B3'VL\"!%W!@G,$A.]74+2)TOI-R4[0+Y0E2 MH(7-),5HLP0<4?=: AJX53KQ/(I%1+-V=(*#ZM)H<'2Q9DMJ3WU>TSQ,8$,Y M6KQ0SGRZO[K6&7AGH^(QV8%JAIX+"@%;-#MG\7.M9 M0&M@NP3]#7#V_0@+?QD5$$10=L,IA-I8:&<*O@8?0UH:QMS/@LUTS%=UU9?* M?-(>%CZ51E\%$5#1_.D-?OH1/C5,+IT+S&3/^$?86Q"/,[0 $=W*N:0CS7.N MJ"+^#?'*FW=<%]N#5QA182H=;B:Z>4NLHE7#%Y'@BIXLA'ZN*NWG?&;=4C>_L97(8GM>)F0 :<@EJG_J2 M8MDLCD8,#Z/*SWN>=AR:B6T]Z9E'M=+CP>#L&U.H^4$:),$?Y"0*(SG&K#@X MD6(7(5FE$H.A&/Y1K?VY64]WU&@!#+S"U7E&K$=C%%"YI;%I&EYZ,95.2DTB\);J; MA80ZA5N[L3PWJ/M7DA/W$REN<#GOC GS,ILZ!"A M<8O)/I-BZ"8W45[8+M"R7.;-">N[YDO_(LQ^W'9U%Y%QD6D*S>> MH4?I\MA8OC8WG> 6RCB3V7Q]%S;KP'',^'O=!V)BC-G MX(-!(C4AH4@J;*C+L8UD5QB9!V@'F$,+. :O;2:\YDCK(^W'_9EY0]/[G+/E M/.:N0&/J<,C?@P=;R\7TA!S%C4;$5AW>EXM[XS"3IYKK5-Z!AKII\UR64:E) M+=6HXE_8@K" O6*+WM1R?M&Q4%8&3KCL:CZSHK$MM2*6 M]45>(FN3]7WD>$XL"R-= +^X [6P$T315UFZDLKI"0]2I=PEM6 E">2?NSW M5'H9UO !_8%F8^=76=C(:5KV5OG-!WZ@^UGE1_G::JH$G)'[%/23C\XK#>G. MQC*93IX4#FI.-?01?J;(3$:=(@X?.)I4NGV8C [9=9NQFW\VJ!4MS=KB9!J# M)YB!?]X;3)1K91*93Y9.5''\T\!HOH;7=X-IHKK\*"LL(]B%&\WR@QJN3E-= M"WB3!)2(HA'UOZHZ0(&04Z(8M]U0YV0Q:@]50\BZ_312(2J:-,X($.@%)!3! M\6_5W!)C'+V0)DG"H7')%B':#=0)&'/58UZ,0A))]\>N 5J.P.R^QU4!< M.S"UY@UJQ**R1(2;>?XNT'S= B@:3=$S ,T0 [#$:1GL$_EZM]PB?O_^ M:\!/>BS-Q_5458D*HN"-N6YR;PYMS:*'7HVQT!=>UV*\F'6BL@OQKLT): MUN]D<>'YU$IU&X$;SS#?SQ0K*T&A;2-2&)>B8PM:N7J'F!W.NJ%4^IP[)0@9 M3 7[O0S-]I$_8;B1/A:Y&, R?),3U_\ZC60((_\.Q40Y@H)L6@[USF ( ]M@ M>)TBR\;O9:E!XHX9A".75ZR"E0W8!))3RP'A \P JX7**7UZMC:/1G2Y<&%K MV^E^%5.&U]OA"B@5S%?(@>5:=SDLFW)Y3#A/(M1@1\4 [2)"2U+;;!93IJ0( M%;I,"M\681-KSH<@BZ,;T;>MN"_GY\[93W7'^>WBZO3Z\N/OIR?.]4WWPP?G^/+\_/3B MYGJ;3J!N#BU,3K6LFS.\<&4>W@FRI<$8P,)R;.QF/%Q4&AKMY)JZ6^0=KT^/ M'\LQK=8LQU2;OLO8J07<].GJ\M/IUZ)2I]-N.+]0/9]SB3EBT"\G,<&?G7Y+T=7Z),(PF0;@*?GN5AEY-U2QCGT- MI'ZY9RL;CUTHH@-=1H_!S[$(A"J">V")V;\(!EA'ST2'36Y M1\,])UBSBF*;#R4&&_#!H/F+,XGP#D,_W)%)R#W.5\HWY-_(*P(Q2-^[X*&H MGY"%PY_T:/37#OGEDT2\5W\<&<_#W_._?6JZ>X^T1TR(P)V^]T.B.CU79OD. M&_6#/:I7^D<:P__WU'ID$K#.2< ?4V_V2S"0]EJ'B[]?^N.E7[;KNWO[+W'C M5KO>/MQ[D3O7&YT7N7$;B-%IK?CC'VD3>2.!/9 ___FFV7F3)X,]]')VP!%X MWYI\.U+_EHR)'ZVH%69YO.1KC'W/"X1B6GQ@ /?Z:D-XQ" M87+!>B^=RVGMEV4T4FXE-N,;+F>S&4:J-J?0&WM8H4 >R7N.8*'JQJ)SL_GM M_0KL4S4RVZ7:I59.?;R,AI@-HKS@Z7(1Q>G(Z8X%5@>"[Z!3I]];1SR98>WF M/WCSN)N-KV VOB+*>3/,*IR#A35/%\?VZ-VZW;W& M:6]9DHH@L+N[?;L;^\ZQGTZMH_FL5.W#RA//16C([A_.V]8[*SI;Z),PL*?= MVBWAUE-E2\%)>J0MG$[;62F.%B51!:=R(P_'7Z-;?O.*J MBHJBZH_;A9]4BV!V979EKRBV_UR5'&N"_8P";\>%.YSXPKF)H@#!5R;?'?]S M8[7T)JS&RL?CY>,8'AV[_=3IXE _>EGGH]O#:Z-X^GYC*ALVL^#,8H^^XLVW MV*.O[M8>JNL&CU,+ M0KJ5._Q3Y(W]<"/K:^WFWGOJR7%VW8=HQ2J$.;_SRB30G&2:U'MI6; MOPVI'5L,LX6QTVIMM=UAVSIFE2/&D\T=DV!74[W56)%\ M:M^]'P2^.TXF49QN9,V.74WU5E-EJ=R0.,RG#%XEE]%HT%-R81UC=99:\ MU_8NT?5FY"?.V*P1=> O/_#3J0/?N$$2.5DB/&<0Q4XL$N'&_9&#J59/W(H@ MFHQAWQSXK7_KI[Y(ZEN]SZW-WF=S9P/AXK;ZH7,WB@+AP/;"WQ,W3F>W<*D< M5YD6;_YUF<58.S^)?9&Z\537T0,O8Z@2=9F3B"%Q,9%$4PF8V0FBOILRE>0P M'F+]LR1V1;!4)&J.FSAW(@CP?Z-T)&)32)QK-X#;1X.!WX?_A=O?NK$?9?*) M6([GN+%0FT3UW$XR@@7O@&(=PW>Q&PX%/FB.Q"U7N[[WSS?^?QO_;77>S)'2 ML1L/_5 ?L(T*">7^_!T^NSD]=]IUQ_EX^G/WH_/IZO+X]/3D[.+G:V?#>/4B M"L6C=_/@3?7><]F.[<*.G9]=G#K7W0^G-U^OS;S=GO MI\[EAP]GQZ=7U]4_2=_\:Y$&V4A6O!D)1WP3_0R.(2'/GA@/(0>.)^#*E:#G005F'0S 4L1L$T]J\.^%/12#Z>&+VIG37GR(W]O 1 M)WX,7T1X51AF> O'3>F26 RSP(V=L1 IFI]R/7-^.8B"(+K#:_""+MW'.<]_ M=CV"%8 Q X!B:0EXFG#1R7&<21^,( M;_-0T54!\2BA5;S'>EA\_M&=[Z4CV#38$[D_^RT^9>?]S.V!@YNEV"%))W+# M_/V;U1RPJC)D.2FSX1$DUU M3OHAD8N>F[].O2%?24:ZY(+D]W7^3H40"E^VFO56>W_Q]TM_O/3+3GWOL/42 M-][;KS?VFRO^N-)9J2%7EO?FDLB+\4!$6H0_.SN_@#SF?8I'X'D4NCT>^0+]KB,W( M%-B\B>%9X!&.2;,ZE^Q".8D?PB\_B%Z<86RUU6@>U.%&>$]PGOZ,_! ]L\\B M@9N"QS:.DA3DDBL6U M/QR[-?#7DJP'/_9Q.?B]B/M?G5]_=KLUA),;)ZGKP5ID+-=8*SFY<10(6FB^ MM,5/!^^5'KK3#;S8[X_ @8XG\NC!A03"Q;UW G\ -^S[ DF%+Y2*_BB$;1E. M@6')YZ[1YW=1_)5#S3H6#+< 1W7D3VAI"3[S++P583)-C,9MY]P-70X&UYQN M?.N'\-H^>,R2?O$TP7G&/P-'3.H/.?^D3W50U5RH75B%"_0V4B'^).(0PT[_ MKCL_^2".:6H-FZ?2M-.TAHTU;"I@V!CFQ <_=,.^#]9-T93Y=Q8*:<:(HW%^&9H.)V#0C'OP%7QP2"8%W'D"M^[V^[!4"DX7GW+9 M3Z/"#Q;82\D$5ST&\P;L$Z!MJ^%,A1N3'4!'//S7HX$8U],D%>.D!JONUTWK M(Z_L8(,) XQ10N',L?RM)VXQ"5US[D8"GI2;/V")N$Z8T;O!3Q.FZ3"(>O"K MLFU2@\O[048/741CMB0E)<',1*"[*$#;!#/I#$E3 YL.$0&=4S?A'>L.$*#( M>7MZ?MI]1Y^4MC5" RU%SH".[80CV#;AO=>>#>QN! M.ED<@[3&SJK&3L<:.];8J9:Q\TL&#W*N1!)E,5:;+31&.@N-D62>-=+)K9&S MG\Y+\8\0[($\:&+$/-"XH*(W'?PHVQDIW$0,_3Z]@C0W1O0.L7Z'&9NC',/Z MF7]WXP:X:C-",FL]E F$ULCG* Z\.[C$N8X&Z1V6-E#-'L=JRK_X2-80_1!+ M$^2K_?W_#EK-_:,$;I&EHSN@I*-Q]Z[@#9%0/2KP@^^I@&'B^J$U6[9]89MG MME2XMHE+(D[!1W#.Z\[/L1#A RIUK*7S:$NG82T=:^E\Y]YILF?R=%'1DNE. M8C\@.X;.Z/R(YZ_-.,UB2P=.[[O[4E(%XP'/^RO5!'#N8M X<7H9/%,DB9.% M?KHT5<0!)5A2&]?"2_O 'S4.Y4?M4E)JSI+(P,&W4-62M6),Q(CNX.O!;R=1 MF/@8!T*CI9OXKO/)[?L#:79]A-^%"AR:;9X)$PQODT:XHL#3F2HP>.!2"O;@ MI9'*3<&_R5*S-LVV+VSS;)H*Z;7_9#[&B3'M]-'U;13FR;9)V]HFUC;YOF2< M*:*19SP:'D97X#5'-V0?87@+1@>QBF72FK5,U$'890 BX$1 MI6_939((+!;<(/4DN$WI"77'6BY;OC!KN3P%=5U$\1 $KTZE>"*VMLM3*;IG M,TC6=JE"!JFFNCWA",_"1 1E(T+T8\948)O%-$XPIW,1W1;C+>(63WQLQBQ$ M,Y[X< Q?W&O#Z%"*&?C!@EM<<-D(JFDC19:\!&(("U$MF8ESYZ><"R^-H]#O.Y.@OZQ 18UY=@H#>HWWJ2TL M)[FBZ ZA23@W([A^@EA5U-]3+F^I.3^I5)1!*4P-#56ISM+$D$>A$;*2@+JJ MJA@7)0V>*+^KG]\5B70<@6;W18B$P.^BG#:U.66\-07-9<;+Z#ICX;BDG,+' M;NSY8(8E?000T=N89Z@*5EQ4Y)2)?)H)8Z=W\;<8BY5P[ \65'-&3/1O1-\T M+JUEM^T+6PYX::%=ED"[[%MH%POMLDW0+AMIE%%9')@+<%I^M6[5D]VJ/>M6 M6;=JG6EEPY^ZR4OJB^[3.65&5>9X0=!USFU5P)5KY6/55H<6/?SF$RR8\[*4 M414!V#O@/V$H%)PC])>T>W(6AF"4DQM '7_Y0F^$.RY5T,W%YMUQ/HW<>.SV M148;F#]/-CJR:Z??M"/=.O/5?UGRNEPN=(%4MCV/81=C]@@-B?O$ M3B2ZNW#_)K\2W4"$L/="Q(H!I#,%_V*?B4+BV+*)?1&_1I[[-0>41!1 MJ%-]W?G#WUZ[5Q^ MD+]UKD^/?[LZNSG;+D!A!#3'?KF[J\:)NHUR6\ M6U5>U085UVJT&C7G#A2EZSG[G3TG,5!D\>(8$>4\C)-AK*APV=TH M2@1_A*COL52[O:G3BZ.OH"J!_ ,_Q@Y]3Y 2!H4L.!#%X/!^".HPS631-%V+ M:ECN1I+&0J1.Z (MY*ZHZ* /[) !)XP)]':K (LOC20R[53SD+H%^U$8RM.9 MSAWD7J!,Z(UE 1P80ZE+%^9EZ4.@(.'E\V].7/_K-**-AY,P%K(-#X[GNU#& M=#&>&6,RFP_+^3&&;3T9XE3B#08! MC1 )AX(BG!?1*EP]FN:3]:[__3@]P@SYO=7$E^P= .?#%(V+T"(:M5XE7N MQ)$[%)X(L*/9'(O_-Y_Q-*/5R4+SDR1#8 M5[CAGX_$T$-_$>"*Y-A9#GQIJ M\;M1:1ZVVT6N*ERBSXM)%N,B4N2E:RF$NV_==V];[Q;> MO^[@H16#04NK)Z#M\F_5*Q47YH?TTBKGD.3?8K*">V?I=OAM#@^.5G04)^\= MN#E]5:9".W6&&2(N2=RXL$/9XE\@#P?,\)(US:;13<"H0( MSWK OH@K3O;QD?.V]XY-<#X*HA#!SN&0'OOX@#R-!">+/_%1)\%O^KS24 RC MU#?2'?@:#S^5([T?TP5OO7?FZ.33" MUTBBRKRXD75[SW(7,NWG]OQ?L?;A5GGH$Z@%?[E('? M3Q.+\KKU7']NY LOX-H3#HG@]C)' /^F(SCIX,#Q=&,G>Y=M;2D:*CB,\.#* MJ165Q6#L>D*J>6H/F*JKY&GHYH:'NE&L+7$X03PQ@&53HCM- _P M;&N;YZ+VQ>A4W*8M.@N+115D6;MA""OL8PQ."FDL%/DP 3^,W3$= <11>CWCINEHRCV_U(;;_P2MB:;H %RT&C4X+U*QG1A8\D*2N%5">45_U=: M"]$$3L@Q]>NJV6=\\@?3'74(P\(-,R#!C09] \=XJH=RF3MJ;CU;;$;)""\Q M?PM/G\>P*I\'F"09*,#"$\%;9";'8"J%\41*O"E-'+/"1+X,>$=L9B:T!D,$ MY!KR%7@KR96C1*KN&()(.[7@0MK\_#$K;%,N(F%TMX,%+X%@:XR9Q$WA]?L1 MM_K\<-#.O:P:"ZSCWK*;#;O(AM(/S4:[?G"8GQ";>08LEK<"\.#3Y*W56$W> M=@\V3-Y@$3VQ3.KLX)['5'<<5*>ZH]J4FJO4[T!S2M*RN6XW-5(R+4BLBIM *NLL_Q^YDM)$OMV2$6Q[FF!BO.L17Y4I1 MTGM8-IJ-,U9=P 6(Y!^+-(M#9 DCH#BCP75(=='OE8>FUW&=NGB8J([?3U$4 MZ^RF2CI?=!S)!V8FU%D5XQC@^=^Q.'""2X$ '"_FZ4)"!H=:\RZ1 MRJ.@!EDV]",5XP#V=,&7)D- QSUBP?$LY(QWSB3(6)J ZCNL<=G"-*+^\FL_ MTF,/S0OEF,.>&/IAZ.<##OD7S+HS^Y>_IO%:ZF5]%?JD"@LG7ZXT>QOX15E\ M=A7O21WA\=B+>\5<"JZ6!WP.2 I:4KT(&?16%"A Z@.CG5\Q*8, V'*!PGOD M",6YYI$_'CI)W/_GF[LDW4'MT&RUF_\=-NM_3H9O'#=(%WQ3M#HZS<[DFS0[ M.FTL-4+K9-D*_LR2U!],E85V7ZI^MS%OR+*U+9?8EH?5L2WG5PXW6[-58E6S M@JCL8J_N.->G'T^/L8#BP]E%]^+XK/O1.>G>=#=,[7\X^_UTY\MI]\JY_NW\ MO'OU9F]C>F[KOMF[&ZSH(C>:F M)>3S$/+ $O)Y"+EO"?D\A-RSA'P>0G8J.85Y0^DI/2(L?+_\='K5O3F[O+A> M@5.?E6C20< ] @(Y213XGJ->Y!YF:M8/V8?VP(GW:_6JP/-MK'A;UGL4 MZ^TVZE49.&A9[W6Q7JMCC1K+>FNQJ \[]99E/=>767+W@ MA_UH+*Q /X,%W:SO6X&V9\DZJE'W;+F(9;VUF#&=AM5ZEO76PGJ[;1LMM:RW M#D(>=BSG6=^M(KY;W@3[_GMWS*Q&-+L:NYJGC:^T:N*Q:N(G-_'[SMOF3&M\ M5>A7*6K90J25R-2NMZS/9VL!K0BN,>17/[#9(RN"5@37*8(-VQUF1="*X!I# MP/5#&X>S(FA%<)TBV+9UPS84ODZ*GOB((^TY;UN+ 2!M;NL!P1W;Z&FSJFMQ MJ/:M0V4Y;SU^A*V?LYRW'LZSIZWEO/4X;C:#8!VW=5+T,ST*IS#)N:=JY)<< MS9FE"4YE@S>P\OYD8N_OVGXS>]*LA?/:MCO%+>\=BE-N#QG*>Y;Q7Q7D6,,YRWGHXSQK7 MEO/6$U"P.L^Z=>NML[SU/1%ZB>.)?@ >G4?0 V;2SE:6V\KRYR)3H[YGL5EM MDG*;POI]VKG=.+$^?#V47WXOBL^]'Y='E] M=G-V>6%1<>UJMFPU5ED\25D_! MA-QKVMG+EO76$]O>LVAREO76PWJ-A@TG6=9;2S:A;5JAMN?)6B#8:X?[!]:8L6>9;#_/M'79LT-XZ;<6>V:/Y&8YF3_12:VT_/<+:V;>C4*RCMQ9'[W#/NGF6 M]=;#>ONV0,:RWEH.W-:!K3.WK+<6UCL\J%O,9AM77;_SAI@>Z=2*]#,D2SK[ M;2O4]CQ9#_.UP86ST0/+?&MAOM;^H:W.LLRW'N9K-O?K'E6/*2L'M6.%^Y<+=.6Q5K2?,"K<5;BO%/4SEV%7;5;^N5=L4QY,T\*?3 MJP^75^?=B^-3Y_RT>_W;U>GYZ<7-M?.V_:Z:37AV-78UCUZ-U19/TA8_QU&2 M.&,W'OJA\]9=K"%LI<.J)&VWJA8*K#@/_LTRW=.9KFEAMRS3?7]-5['0B66Z M[6Z:R3]B1B7DY$[*:P0&<21P,_=7M^X*=3YVWOG?/W M_SMHM79MA?HSY((JE^6M.%O:@^49F,[.O+%,MP:FLYK.,MUW9CH;%K5,MP:F MLWZ;]=O61,S3P4#T4_]6.*G[S0$73CAO=VV*[3E&S]L8H#U+OO=9LF^9SC+= M]PX\[U6M:= RW=8S7>O CE&R3/>]FD @^+]Y^)[.6\]FW9Z!T#]VK91;[&C+>);Q+.-9QK.,]X+)$!LZ ML%[<=^ :[SHJ@%<''DFFW8:T-*X)6!-=Y"A[:+E K@E8$UUO= M;XOAK A:$5RC"%HLA">+H(U]/1.\4]]-1LX@B.YL./L9SE;;KVFS=VOJGSNP MO4R6]=;">GMM&UBSK+<6UFL>VMISRWKK8;W*S5;>/-:S7MR3*'J=1OVOSB3V M^\*)W7 H5ABV5#6YKAQ1?VAV6O5F:^>P76\<6((^!T%;G7KC<.>@5=_?M01] M#H(VP.+>V]G?KQ_N6X(^ T$/]NJ=QDZG73^P$O\<]-S;K7<.=W8/ZGM[L^?] MCZG;"P3\K^??_NL?\!^U:**&'WHB3-_O--OUCO&F_.K\F7S7?_VC%__X+WW_ M)]Y-_6S%ERQ29F6"YOO2;,S9F, /Q8XCK+/33:=VYP2^B((CND-Z3V:D>%OLDHR@*/GM03O' 7'NXD62])_31+<:$QO0FL?^+&J*PW"*-Q9=A6]'ZPQR#Q^)+P^,",5',,J$GSB&%]>W+I!QKF9*(N!\$D6 MP 9$ R?BI$T4)O0F/1'XXI9^Z:;P'S^!GQ-=\1J_ UW!WVB@CI.G1S M?",_3'#SX7_3B!X4W1)Y"YN#C\E?91(E_GPQ69,&;S.>6Q-%O_SOTY[SP&A0"JSN?7 MCD(AF0IUEIC%?S9(I$[ ^3WK=6?K1=%C4<3>?>F31*>VUG3=TT8IB:P5/-E1&-Z""CL$G(9'X=]1+ MG&X?Y0Z^DC9:J]'H:O[_*GIR%8+_2'N2=;%7F MH5HU%OE0,E>$.Y8O$F5AD,4@5S$<94D_2Q(T(:68FD)8&=M^,Q2?!&EU'.=* M# +0/ GY4JX735*#PL/,]\BA\I,DDV8$?/Q!NU;=W).]Q@B.&X-;\%,$_Z/= MV0_=ZY^T)QN+(7R'E^-]I&ONJD>B)0Q&HQ^!I^Y@+ZOR%^"<3V.1^NS5@U(, M!1J4Y(V\Q5^9G[RSO/ @7OC@]BDJXO(1)/=&!1%X?*;D!]-/CYEQ\@!*(N2_ M<\_;43VK./;=1WYSU6Z2-X1!JP'N(WH!^UYKU HWXP[T[&S\#VTUA6UKJ=":ZPEN_!C_,I%K=K'-RGT4?HV)3N;+#>:3ME%=F M/A\4\ZT?94DPW9FX/DHXV)XAK0"D6GSK^PDYZA2-)K6-CU5*F%^]O>C%*OP!6L(UCAO-/*=I/@CV/\(P$_RM5+]FJ=Y?)-4NN8'@"G"L[%')_1 P!'LT96D#>@Q@:_L MYYX;H!]%R5OG3@0!*XLRW[?;AH"ORO=2ADPUL41/>*@$DB@ QTXI"E14O\,J M_LH$&D:84?0]'S3"(Q(25M@JL]15A6WO:4=H<]^PE_59=F@8MK-GV0Q/%@Q< M_,C@QY^ 66_=N&QFFS8Y&,"IZP=DE/,QO=BXGV>2DP MTBR&C6X%XC4(1&?Q MZ;/<"6RW#*[/SB7 6!BQ*NI?AA;Y[EN#LK;?

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

    ."C!WZLFPIDF,H]@5BP&3!HBGK) I ML)!HIW %EY#T&G2"P.(TG*2$=P!BN@)8"I?Z HB2R9%S%.%0I8.CP M.4R*<#+".NXA3 H AK>*J&4 "(3OF.(#T! ^W2PWV']#U M3L5V49Z]Q@5NRH;7'" Y.P^4@ZOZ6:Q'#H=CU/CUU7,>XY@\G);B1: *(FO=HTY7SKUH^87SA?*NR;N,&,G,F MB1&YF/!Q$4[42W(N=&X *AYM%$X/#A<+WLL8[9*"S4"X'4"BO+&'Q"DHY(A3 M;#\!QEBI?,BC) :\9Q>]1M? T-[MG7Y@?^GOWBAG^3@)%<\RNK_BY_H*&.8P M"8= ;N 8Y&^N,E 5%-VN;"FC6I=(J#=F?F>>'6 G&%/8PP(Y%[TUVO1V0I#& M2E],?]26?:O U*U6L MZ\12W+TSHK9"R*TS-.O0INIE>Y?=>4A';%;B=((6#S-3. +,-#&;9&0$OJ

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

    : MH6C<\ 7?.)H$^5K)E)DQ9\\L>^:YL(@\Z%L_"Y)73-6:V]Q+,QP?>@2>'SHK M)K?BE]E7E*/- N)+'!$\4*BXP@E/Y\4@ER! ":+SP#8XP08L(XQF.!I_ M,9I/(8T%JER3W'<_4:TUUU8R]W5V9D/^1<%L@;Y&:,02.-&-I9S1Y8:FV8\* M;)CQ=P(OP?J8\MK675YJSZFM]=_?/7X==G)R?M9?6>)IOC+=_)L>:T0LS4Y;?Z9.K78">K0F'UPX"'M0T7):A M"I$>W:*=9?::*3SM;II[Q/ J,UVB;_/YQ(DI4@*>Q M+%RN3?7>%9*:=F.%>K'BDLJ+9UP+<$IPPW(CI72!S)!H)XH.-.0@FCZGZ+;" MDY14ICZ#=@MS99Z/=!A+62<7'XW.'E:9N^V3K9VYHD.:FQ[6>L&W;!FCVY<# M[E)G2$P0=?OFATIW^_4Z>HL'\V5]; .4YS+M7E1$"@W M1,*8L8'K-5#@WL-+HSL9K7!T.B^+:]C=$II@LA M#4$$/3"F@O8-5">**/4.*.F T3K727%[4'?=EXKRWEM&!$:;-%I]5.T9ELS? MO&BLF4K8C DO0'FCP0,EH[27S&QX@ -NNIL--#)?%[ !87J5]8-@I6V3R,A, M7/V3Q*]7CKU+?[VB->_C"(I_WPY(9K/*FYYLT\9!VU6[9E//SZ7!W.OGQ=-/=3,Z8W4;3KUG*D(]_ MB]=^A^HV7<82[N-%X82BCA%R;P9"$F(ZL-9Q*E[=;3;#U6UAR*%I%\Y6&[>J MT; ]6]\Z[X0*C"KH>PP"TH+LX0"'&HAJ,=N6D;VRU M/+>0Y=U/:S-Z_%YP6*N_]J5+?J M:.^A8&=FF?O@#YF^69VS$U';]O63!H(#R]?DVOMH35I60Q$*6FEZ-A?.7)!+ M,%UJV)M!FV#F?@;7L$V3B);I:PY]U<4D!X -]#@&&21'IE7Y2I#N; M2'KO14INH_&KT$D[E5WDDQZG*#"&](\%6@FT?_O SRS!)/HNUNA(1$.,[M&W M5HV$!O&EU-Q P\+]I-B4V!MG#$_#!6LKIOB.%9J*8J&W.=F/K]#*$ MTV3]2NCNNU?"=1[YG<[F?QN]KW,OQVE=U=^ @X]@M'#F0S;@#YOCZCJ%/,&\ M;:H?@QHTA;5-?IQX%(78@J^C6D3).L4@%&N3(D.VZCVJTY.5V(14"[<*LQ$> M3,Y!4>P:TK!RF$.LT:O1?=HRGEAJ(9:D*QVL!+?;U^#1-F%Z.V1\W*HMM?N3 M5;: )7^JE#,/ AH>RWS"!OQ&$Q$42S:0@6AS9DB@60*]-5_F%2DR?7%'PZ61 M\.=@L?:GB@>#X=6!&X9N-YP+W&W<7[;?4=9^X?AQSJ9[N.P1QP\V8(G<1]^% MZ@Z0H+5#GO($:UF"9R@_I55+#DML>'@I(!YFF"U!.&"_3) MUUM.CQ;7@D5GTE_/'N3Z5'A2ZHJO8MZ04BL4+(_A#,G:7GP;O!^5@6Z&9;)@ MZM?C=R'%J(8TARP3X] Z-A PZ]&S3,*?:.H(.'>E_*:5K7.Z8>8M85-?M<\, M::-Y(32H2E[9L:W/?!(I3M5*Z 6+[,MNLB#X/L'S $YXA*#8N==:8ULA7Z0R M9/+YFS_9P_JR].^=]?F0]OC IXZ#6,(]V.-[\:.X]A77<+H'$MX)AM_]NL/A M+3*X.N;._-+Q]F>F7MJ9;YJY]GZ[U^>]&]F_D(=(1U!"VQE0]M-@^2'XP,^H0QM-=7<'\^@P7,P&T;D/EG'92X4*3VR!21BF[!R/,LZ( M%3KRM"EF^P4[#]?-U_N4[/N*M]RO 9C;*;!LA@S5NMO(H2\GQ52S<5I?)/9X M,A0$4_J=MTKF:5.G117'.O*WR;ELM3X1[(;5-=T#V>J+W F%W'/(.X?IGA8*<:I78H\-.#";$?&72'"9^E]:$&64("7%BI[>G^/1KW)9:IUQ>Q0Y7 -IEQUOPBM-&"% MN&NT34UOA)-'[809WUBDGX)H=E=XJH YCSB+&%$E)" M[AMQ]Z1F!$QM];B!E\X+H+J^-^A?2" 4N=S+RKOY].S+0Q4L@27Z9:029'LN M:X@EQZPW%;"^$EH93!V6FK_U($G&R'-9Q_O.E.?]Q!<$8LJ6S.P#Y\QD6 ?B M\:A&ON414BM%?46*[LXPHNBTJG(&K&.E0D#K1/ P$ MZ$Y5(+Y#R)AP4;ELIY[I'BKUG .O'WMNN[*S7>C9R_R[NX;:/[T3X+Z$D$-U M]Z(I=O1P4!.]S%/W95Z0LN;!. 8BF\#KQ'=C?<+3$BJH^XM=WU4^[9R14;XR M%#9XHZ$ 3L#C0>WD"BH?2^ &OMFI5=)H8Q"1;.CD)0Q&$3,V7\+3\K_H7S4_ M;WI.ZG'VZ8XHOJ'6IGU[54L IB^H23\=/X)JR1IH"*3#D3$4=)8/A3G6-GVJ M5WY=IMKA-W'A4U>.S9]*%'TYLV.\\^OFMZ-P3CBA /NX[2E5@<0&,F47E<2; MGE,-^\)E#$HRL%N7#"_)D MJ;Q/(4@#L/*;SGTH*2C0'Z-#F_:?@2#P(\091904AF0T2^#S@NA< M.%&]^TK+\_"NK ?N8$;7U>E4SGOO<6Z#ET\:SZS,(1V$TT]:<);1;SX8^ K0 MG=(962 $KWS6,1NT7.;-[SDY^*8BAG@&R:%O6VSO_-X]7\@=Q!H3Q:]!4E TWL=W3OCUM3S>6S01NX8U,2GFZ6^E.& M![YI%]_."@GR4$H@E.C&!2BXKXP=U5]T1CP/):C- M8%5N2_;[V9RS/![0G&*L8:P@&PA!@_N;B?[+&]24(\EDVVEMY+'M3V(C\^V- M5DP<'SY_OFS<+:2OQY,G^I! L5&&/6AQ'D0I80FU8P%PBJ.(*$L@F*[%4)M M1E.=R&9%'E3/T523TS^LA(ONR+S>!I^\80MAL@'D+ MVNTF7/C*)8K=PDVL:#R'G2^UEL"S0BM>0-WHR$DCB<6US=N2Q,T?W)ZT"_#" M7?!=*S3_\'BM:8P,T"\8[9,4%O J5[K9"D+2E/<-JOLPM HV,.>"]&7>-35D M['L\%0F31CH_?4ZUSI;I#PR%)2VD6+;3]Z-#JUJ.K75E*(HEBR=R9ZX\OUZX M:A(*;;QF/7DY@M0 :HPN?Z/O6C35!0T(#:G4& >O. >2?H=_VJ4=AVMB.J)I M(8]5[6FIQ5*/,AY'/+&RX &8(N FW3G^%;KI4=&Y1_$3,!@#1A#2/GGYNOTS M:DJJ]OJ71Y6.3P9RC!\V<[Q^K*VG[GJ*4N5_$?9F75U MQ;K=U^:M'K5:;&,1*T>]"V"2*-F!48 MN=*?*DHQ9JG7Z%.F+D'L=:['XO3XO1?EN4T:<74A#-@QFB":Q#\3-P$89,_5'=D-8X"TN]3[ :/-%&^5^>LTS!/ M_8E.&B9DO<-Q4@[A;@Q?R%@<3C9>,W[84+RI_ SU8+1W)H=I]A73ZR4K<,(R M&X#J'=&5*/I!QBYP!UT[AMP+DS(U&*;NTF0"1^? M@'%;W(38'<\*X?+-$#.^55\IZGUT6^@H0[R4Q;]"@.7@*2=%_!T[J>%)\4I? M2J)3E\_>"C/0=O<,]K%LVC+2YI[_$CED%\I\UU2X2P"2;%NPA#J,]A@\>#0) MWXA?2:$?=&&83,?O!R7!#.)S6MJ"U91R<))5OJ<2..0?#*DA2UF?;^U5]A+^ENS&,"G!,B_?F6Z9S*(X;W/ M'7J-_'L#6-LM?0C:S+%!:!X8L\+4(/Y5(:K9&S3V O=>I)4D3;)T9:8Z M;KWT\G#3J]"^'ZH8[_O4^&5!:\IP7CJ%S $!S"N6"EA?SX@ [2C5+('&!0=I MB)4,+^F+@;H]2JJL,=:T]/2IN7E/.:<1-Z$ -\G-&Q=M=WCTI(GMOL#QH\$R MWIF),(:0-,#7'NA?P[^W!] M<9=/9B>_RF0R'LWZ!BPHAWU%2D"&OZ:VE4%_N5*F&1(R-#0S.0J5'&T*?S-0 M38!O?0?B)DX^*5%/)]E8KM2W^&J[CM11I6P_[7V9L.WE_/F$^*0Q2TG \?]0 M<_ZV4,[80FUG* Q#* ($L8'6Z@&XX-=:NB'2L^/M^FA+?@S3^Q: MVCOWUNQI??[AQ%V1X9ZJ(_,6RJSK#XV'C>T/3]DIT%T^)_IHZN]3]HG:P6-C MLM7:VTR)@X0 =SDO[_0M=Y]'ZC$KD+I478^W*J/)#"E*NV?K]/?G88=-75;J MM54O=ZOR%MKG]FU9],GB.+=9#_D3! VI^[K1E#/HF0R6H#-5]##:%HPH!QMZ MW0QSR'>(?BV4I%=729[%.I\0[^\?:]?3+2NK7LZ:T%"@64!5LW"\ O)0(+X+ M)AIY2/C]_J6*BL4]CW>VA;-LRLK=3ZMZS-7MW;(1H94(A[8#T 8_A*5&?5X(7!$Q5OS@N MNJ$3D9:A55]/?GU3)W.QN^9+T]'&%^[!M[)Q)(O$"[F=2I)Y]%HB63@FO,?H M_)<[$I3OV44^F:[:^DM'$G>J?LA-!;B9N[X#J(,H2KC_0,Z->"DF&BK3"\!2 MDE=*]6 T<=9 R/#96Y5,#]SM*+!O+.S<)]UB?8%;HR,F%G7I6T898J5]F&V0 M'+Y^"J(;44%<<%O^UT(94^T[].-V2?NZ)3ND[ZCD+;S^:+WWA51JK^P[SJ._ MH2RB"##*:?(-!"1P AQ =6Q_PRR4[2F)[EY4A^QG,K'EB]+^CNVMV0?#S@

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end XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
    shares in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Statement of Financial Position [Abstract]    
    Preferred stock, shares authorized (in shares) 3.0 3.0
    Preferred stock, shares issued (in shares) 0.0 0.0
    Preferred stock, shares outstanding (in shares) 0.0 0.0
    Common stock, par value (in dollars per share) $ 0.25 $ 0.25
    Common stock, shares authorized (in shares) 100.0 100.0
    Common stock, shares issued (in shares) 75.3 75.3
    Common stock, shares outstanding (in shares) 74.1 74.1
    Treasury stock, at cost (in shares) 1.2 1.2

    XML 19 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans
    		 12 Months Ended
    Dec. 31, 2019
    Retirement Benefits [Abstract]  
    Benefit Plans Benefit Plans Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we provide minimal death benefits for certain U.S. retirees and pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. Benefits for participants are coordinated with Medicare when possible. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $15.6 million for 2019, $6.5 million for 2018 and $5.7 million for 2017. The increase in 401(k) plan contributions in 2019 was in response to the cessation of our U.S. qualified and non-qualified defined benefit pension plans as of January 1, 2019 (except for interest crediting).
    Pension and Other Retirement Benefits

    The components of net periodic benefit cost and other amounts recognized in OCI were as follows:

    Pension benefitsOther retirement benefits
    ($ in millions)201920182017201920182017
    Net periodic benefit cost:
    Service cost$1.4  $10.8  $10.4  $—  $—  $—  
    Interest cost9.2  9.4  9.8  0.2  0.2  0.3  
    Expected return on assets(12.0) (15.7) (13.5) —  —  —  
    Amortization of prior service credit0.1  (1.3) (1.3) (0.7) (0.7) (0.7) 
    Amortization of actuarial loss (gain)2.1  3.8  4.9  (2.3) (2.4) (2.6) 
    Settlement effects3.5  —  —  —  —  —  
    Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
    Net loss (gain) arising during period$1.5  $3.5  $(9.0) $0.1  $(1.4) $(1.1) 
    Prior service credit arising during period—  0.3  —  —  —  —  
    Amortization of prior service credit(0.1) 1.3  1.3  0.7  0.7  0.7  
    Amortization of actuarial (loss) gain(2.1) (3.8) (4.9) 2.3  2.4  2.6  
    Settlement effects(3.5) —  —  —  —  —  
    Foreign currency translation 0.6  (1.2) 2.6  —  —  —  
    Total recognized in OCI$(3.6) $0.1  $(10.0) $3.1  $1.7  $2.2  
    Total recognized in net periodic benefit cost and OCI$0.7  $7.1  $0.3  $0.3  $(1.2) $(0.8) 

    Net periodic benefit cost by geographic location is as follows:

     Pension benefitsOther retirement benefits
    ($ in millions)201920182017201920182017
    U.S. plans$2.4  $4.8  $7.3  $(2.8) $(2.9) $(3.0) 
    International plans1.9  2.2  3.0  —  —  —  
    Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 

    During 2019, we recorded a $3.5 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for each of our U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year. Effective January 1, 2019, except for interest crediting, benefit accruals under these defined benefit pension plans ceased.

    During 2019, we contributed $2.6 million to our U.S. qualified defined benefit pension plan.
    The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Change in benefit obligation:
    Benefit obligation, January 1$(267.0) $(288.0) $(6.0) $(7.1) 
    Service cost(1.4) (10.8) —  —  
    Interest cost(9.2) (9.4) (0.2) (0.2) 
    Participants’ contributions(0.3) (0.6) (0.7) (0.6) 
    Actuarial (loss) gain(30.8) 20.4  (0.2) 1.4  
    Amendments/transfers in—  (0.3) —  —  
    Benefits/expenses paid6.8  18.0  0.5  0.5  
    Settlement effects15.0  —  —  —  
    Foreign currency translation(1.0) 3.7  —  —  
    Benefit obligation, December 31$(287.9) $(267.0) $(6.6) $(6.0) 
    Change in plan assets:
    Fair value of assets, January 1$214.5  $239.5  $—  $—  
    Actual return on assets41.3  (8.3) —  —  
    Employer contribution8.0  2.7  (0.2) (0.1) 
    Participants’ contributions0.3  0.6  0.7  0.6  
    Benefits/expenses paid(6.3) (18.0) (0.5) (0.5) 
    Settlement effects(15.0) —  —  —  
    Foreign currency translation1.3  (2.0) —  —  
    Fair value of assets, December 31$244.1  $214.5  $—  $—  
    Funded status at end of year$(43.8) $(52.5) $(6.6) $(6.0) 

    International pension plan assets, at fair value, included in the preceding table were $39.4 million and $33.4 million at December 31, 2019 and 2018, respectively.

    Amounts recognized in the balance sheet were as follows:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Noncurrent assets$4.3  $—  $—  $—  
    Current liabilities(1.5) (1.6) (0.7) (0.7) 
    Noncurrent liabilities(46.6) (50.9) (5.9) (5.3) 
    $(43.8) $(52.5) $(6.6) $(6.0) 
    The amounts in accumulated other comprehensive loss, pre-tax, consisted of:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Net actuarial loss (gain)$69.4  $73.0  $(7.0) $(9.4) 
    Prior service cost (credit)0.8  0.9  (1.0) (1.7) 
    Total$70.2  $73.9  $(8.0) $(11.1) 

    The net actuarial loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year are $1.8 million and $0.1 million, respectively. The net actuarial gain and prior service credit for the other retirement benefits plan that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year is $1.6 million and $0.7 million.

    The accumulated benefit obligation for all defined benefit pension plans was $283.9 million and $263.0 million at December 31, 2019 and 2018, respectively, including $73.9 million and $64.0 million, respectively, for international pension plans.

    As of December 31, 2019, our U.S. qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2019, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets.

    All of the defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets as of December 31, 2018.

    Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows:

     ($ in millions)Domestic International Total
    2020$21.0  $1.3  $22.3  
    202113.5  1.3  14.8  
    202215.0  2.0  17.0  
    202313.7  1.5  15.2  
    202413.5  1.9  15.4  
    2025 to 202960.5  13.3  73.8  
    $137.2  $21.3  $158.5  

    In 2020, we expect to contribute $0.7 million to pension plans, none of which is for international plans. In addition, we expect to contribute $0.7 million for other retirement benefits in 2020. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.

    Weighted average assumptions used to determine net periodic benefit cost were as follows:

    Pension benefitsOther retirement benefits
    201920182017201920182017
    Discount rate2.70 %2.91 %3.48 %4.20 %3.45 %3.90 %
    Rate of compensation increase2.41 %4.00 %4.01 %—  —  —  
    Long-term rate of return on assets5.54 %6.71 %6.47 %—  —  —  
    Weighted average assumptions used to determine the benefit obligations were as follows:

    Pension benefitsOther retirement benefits
    2019201820192018
    Discount rate2.79 %3.76 %3.20 %4.20 %
    Rate of compensation increase2.49 %4.01 %—  —  

    The discount rate used to determine the benefit obligations for U.S. pension plans was 3.35% and 4.30% as of December 31, 2019 and 2018, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 1.28% and 2.19% as of December 31, 2019 and 2018, respectively. The rate of compensation increase for U.S. plans was 4.25% for 2018, while the weighted average rate for all international plans was 2.49% for 2019 and 2.60% for 2018. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans, which accounts for 83.86% of global plan assets, was 5.60% for 2019, 7.00% for 2018 and 7.00% for 2017.

    The assumed healthcare cost trend rate used to determine benefit obligations was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. A change in the assumed healthcare cost trend rate by one percentage point would have an immaterial impact in the postretirement obligation. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. The effect of a one percentage point increase or decrease in the rate would have an immaterial impact in the aggregate service and interest cost components.

    The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:

    20192018
    Equity securities33 %23 %
    Debt securities65 %74 %
    Other2 %3 %
    100 %100 %

    Our U.S. pension plan is managed as a balanced portfolio comprised of two components: equity and fixed income debt securities. Equity investments are used to maximize the long-term real growth of fund assets, while fixed income investments are used to generate current income, provide for a more stable periodic return and provide some protection against a prolonged decline in the market value of equity investments. Temporary funds may be held as cash. We maintain a long-term strategic asset allocation policy which provides guidelines for ensuring that the fund’s investments are managed with the short-term and long-term financial goals of the fund, while allowing the flexibility to react to unexpected changes in capital markets.

    Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.

    During the three months ended December 31, 2018, in anticipation of benefit accruals under our U.S. qualified and non-qualified defined benefit pension plans ceasing effective January 1, 2019, except for interest crediting, we changed the U.S. target asset allocations from 65% equity securities and 35% debt securities to 30% equity securities and 70% debt securities.
    The following are the U.S. target asset allocations and acceptable allocation ranges:

    Target allocationAllocation range
    Equity securities30%  27% - 33%  
    Debt securities70%  67% - 73%
    Other—%  0% - 3%

    The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.

    Balance at
    December 31,Basis of Fair Value Measurements
    ($ in millions)2019Level 1Level 2  Level 3
    Cash$2.2  $2.2  $—  $—  
    Equity securities:
    International mutual funds15.5  1.3  14.2  —  
    Fixed income securities:
    Mutual funds21.7  3.8  17.9  —  
    Pension plan assets in the fair value hierarchy$39.4  $7.3  $32.1  $—  
    Pension plan assets measured at NAV204.7  
    Pension plan assets at fair value$244.1  

    Balance at
    December 31,Basis of Fair Value Measurements
    ($ in millions)2018Level 1Level 2Level 3
    Cash$1.7  $1.7  $—  $—  
    Equity securities:
    International mutual funds17.7  17.7  —  —  
    Fixed income securities:
    Mutual funds13.9  13.9  —  —  
    Pension plan assets in the fair value hierarchy$33.3  $33.3  $—  $—  
    Pension plan assets measured at NAV181.2  
    Pension plan assets at fair value$214.5  
    XML 20 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information
    		 12 Months Ended
    Dec. 31, 2019
    Segment Reporting [Abstract]  
    Segment Information Segment Information
    Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

    We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

    The following table presents information about our reportable segments, reconciled to consolidated totals:

    ($ in millions)201920182017
    Net sales:
    Proprietary Products$1,398.6  $1,308.6  $1,236.9  
    Contract-Manufactured Products441.5  409.1  362.5  
    Intersegment sales elimination(0.2) (0.3) (0.3) 
    Consolidated net sales$1,839.9  $1,717.4  $1,599.1  

    The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.
    We do not have any customers accounting for greater than 10% of consolidated net sales.

    The following table presents net sales and property, plant and equipment, net, by the country in which the legal subsidiary is domiciled and assets are located:

    Net SalesProperty, Plant and Equipment, Net
    ($ in millions)201920182017201920182017
    United States$814.7  $766.1  $734.6  $337.1  $315.3  $323.8  
    Germany236.3  235.9  226.4  95.4  99.3  108.8  
    Ireland173.8  138.1  100.5  162.0  165.4  173.2  
    France150.6  145.0  142.6  53.3  50.1  51.6  
    Other European countries251.1  230.5  201.0  59.1  59.5  63.2  
    Other213.4  201.8  194.0  132.4  132.4  134.4  
    $1,839.9  $1,717.4  $1,599.1  $839.3  $822.0  $855.0  
    The following tables provide summarized financial information for our segments:

    ($ in millions)Proprietary ProductsContract-Manufactured ProductsCorporate/ Elimination/ Unallocated ItemsConsolidated
    2019
    Net sales$1,398.6  $441.5  $(0.2) $1,839.9  
    Operating profit$313.6  $49.1  $(66.1) $296.6  
    Interest expense—  —  8.5  8.5  
    Interest income—  —  (3.8) (3.8) 
    Other nonoperating expense (income)—  —  0.1  0.1  
    Income before income taxes$313.6  $49.1  $(70.9) $291.8  
    Segment assets$1,480.6  $386.0  $474.8  $2,341.4  
    Capital expenditures91.2  37.2  (2.0) 126.4  
    Depreciation and amortization expense82.2  17.9  3.3  103.4  
    2018
    Net sales$1,308.6  $409.1  $(0.3) $1,717.4  
    Operating profit$266.4  $44.3  $(70.4) $240.3  
    Interest expense—  —  8.4  8.4  
    Interest income—  —  (2.1) (2.1) 
    Other nonoperating income—  —  (6.7) (6.7) 
    Income before income taxes$266.4  $44.3  $(70.0) $240.7  
    Segment assets$1,342.3  $301.4  $335.2  $1,978.9  
    Capital expenditures77.0  20.7  7.0  104.7  
    Depreciation and amortization expense83.9  17.2  3.3  104.4  
    2017
    Net sales$1,236.9  $362.5  $(0.3) $1,599.1  
    Operating profit$243.8  $48.3  $(66.3) $225.8  
    Interest expense—  —  7.8  7.8  
    Interest income—  —  (1.3) (1.3) 
    Other nonoperating income—  —  (3.1) (3.1) 
    Income before income taxes$243.8  $48.3  $(69.7) $222.4  
    Segment assets$1,321.3  $286.4  $255.1  $1,862.8  
    Capital expenditures107.2  18.6  5.0  130.8  
    Depreciation and amortization expense77.1  16.4  3.2  96.7  
    XML 21 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Segment Reporting [Abstract]  
    Schedule of Sales by Significant Product Group
    The following table presents information about our reportable segments, reconciled to consolidated totals:

    ($ in millions)201920182017
    Net sales:
    Proprietary Products$1,398.6  $1,308.6  $1,236.9  
    Contract-Manufactured Products441.5  409.1  362.5  
    Intersegment sales elimination(0.2) (0.3) (0.3) 
    Consolidated net sales$1,839.9  $1,717.4  $1,599.1  
    Schedule of Sales and Net Property, Plant and Equipment, by Geographical Areas
    The following table presents net sales and property, plant and equipment, net, by the country in which the legal subsidiary is domiciled and assets are located:

    Net SalesProperty, Plant and Equipment, Net
    ($ in millions)201920182017201920182017
    United States$814.7  $766.1  $734.6  $337.1  $315.3  $323.8  
    Germany236.3  235.9  226.4  95.4  99.3  108.8  
    Ireland173.8  138.1  100.5  162.0  165.4  173.2  
    France150.6  145.0  142.6  53.3  50.1  51.6  
    Other European countries251.1  230.5  201.0  59.1  59.5  63.2  
    Other213.4  201.8  194.0  132.4  132.4  134.4  
    $1,839.9  $1,717.4  $1,599.1  $839.3  $822.0  $855.0  
    Schedule of Segment Reporting Information, by Segment
    The following tables provide summarized financial information for our segments:

    ($ in millions)Proprietary ProductsContract-Manufactured ProductsCorporate/ Elimination/ Unallocated ItemsConsolidated
    2019
    Net sales$1,398.6  $441.5  $(0.2) $1,839.9  
    Operating profit$313.6  $49.1  $(66.1) $296.6  
    Interest expense—  —  8.5  8.5  
    Interest income—  —  (3.8) (3.8) 
    Other nonoperating expense (income)—  —  0.1  0.1  
    Income before income taxes$313.6  $49.1  $(70.9) $291.8  
    Segment assets$1,480.6  $386.0  $474.8  $2,341.4  
    Capital expenditures91.2  37.2  (2.0) 126.4  
    Depreciation and amortization expense82.2  17.9  3.3  103.4  
    2018
    Net sales$1,308.6  $409.1  $(0.3) $1,717.4  
    Operating profit$266.4  $44.3  $(70.4) $240.3  
    Interest expense—  —  8.4  8.4  
    Interest income—  —  (2.1) (2.1) 
    Other nonoperating income—  —  (6.7) (6.7) 
    Income before income taxes$266.4  $44.3  $(70.0) $240.7  
    Segment assets$1,342.3  $301.4  $335.2  $1,978.9  
    Capital expenditures77.0  20.7  7.0  104.7  
    Depreciation and amortization expense83.9  17.2  3.3  104.4  
    2017
    Net sales$1,236.9  $362.5  $(0.3) $1,599.1  
    Operating profit$243.8  $48.3  $(66.3) $225.8  
    Interest expense—  —  7.8  7.8  
    Interest income—  —  (1.3) (1.3) 
    Other nonoperating income—  —  (3.1) (3.1) 
    Income before income taxes$243.8  $48.3  $(69.7) $222.4  
    Segment assets$1,321.3  $286.4  $255.1  $1,862.8  
    Capital expenditures107.2  18.6  5.0  130.8  
    Depreciation and amortization expense77.1  16.4  3.2  96.7  
    XML 22 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Share-based Payment Arrangement [Abstract]  
    Allocation of Share-based Compensation Costs by Plan
    The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:

    ($ in millions)201920182017
    Stock option and appreciation rights$9.1  $8.6  $7.8  
    Performance share units, stock-settled9.5  2.5  4.1  
    Performance share units, cash-settled0.1  —  0.1  
    Performance share units, dividend equivalents0.2  0.1  0.1  
    Employee stock purchase plan0.9  0.9  0.8  
    Deferred compensation plans and restricted share awards4.6  3.0  3.2  
    Total stock-based compensation expense$24.4  $15.1  $16.1  
    Schedule of Stock Options Activity
    The following table summarizes changes in outstanding options:

    (in millions, except per share data)201920182017
    Options outstanding, January 13.0  3.5  4.5  
    Granted0.3  0.5  0.5  
    Exercised(0.6) (1.0) (1.5) 
    Forfeited—  —  —  
    Options outstanding, December 312.7  3.0  3.5  
    Options exercisable, December 311.6  1.7  1.9  

    Weighted Average Exercise Price201920182017
    Options outstanding, January 1$58.93  $48.76  $38.11  
    Granted103.40  90.36  84.09  
    Exercised46.42  35.95  26.15  
    Forfeited92.71  75.32  60.92  
    Options outstanding, December 31$67.02  $58.93  $48.76  
    Options exercisable, December 31$53.12  $45.32  $35.44  
    Schedule of Stock Appreciation Rights Award Activity
    The following table summarizes changes in outstanding SARs:

    201920182017
    SARs outstanding, January 139,819  51,368  116,087  
    Granted3,364  3,480  2,792  
    Exercised(6,790) (14,629) (67,511) 
    Forfeited(400) (400) —  
    SARs outstanding, December 3135,993  39,819  51,368  
    SARs exercisable, December 3127,781  30,285  39,769  

    Weighted Average Exercise Price201920182017
    SARs outstanding, January 1$46.48  $38.55  $31.13  
    Granted102.51  89.64  83.47  
    Exercised42.08  28.45  27.65  
    Forfeited63.43  63.43  —  
    SARs outstanding, December 31$52.36  $46.48  $38.55  
    SARs exercisable, December 31$40.73  $36.91  $30.77  
    Schedule of Nonvested Performance-based Share Activity
    The following table summarizes changes in our outstanding stock-settled PSU awards:

    201920182017
    Non-vested stock-settled PSU awards, January 1296,037  341,944  378,062  
    Granted at target level84,309  102,307  92,045  
    Adjustments above/(below) target(50,556) (2,284) (11,369) 
    Vested and converted(48,964) (121,984) (116,684) 
    Forfeited(16,204) (23,946) (110) 
    Non-vested stock-settled PSU awards, December 31264,622  296,037  341,944  
    Weighted Average Grant Date Fair Value201920182017
    Non-vested stock-settled PSU awards, January 1$76.84  $64.38  $54.47  
    Granted at target level103.40  90.45  84.01  
    Adjustments above/(below) target83.89  33.86  42.85  
    Vested and converted102.51  93.00  50.06  
    Forfeited69.09  68.65  73.64  
    Non-vested stock-settled PSU awards, December 31$66.03  $76.84  $64.38  
    Schedule of Nonvested Performance-based Units Activity
    The following table summarizes changes in our outstanding cash-settled PSU awards:

    201920182017
    Non-vested cash-settled PSU awards, January 11,592  1,972  2,451  
    Granted at target level806  560  598  
    Adjustments above/(below) target(206) (30) (107) 
    Vested and converted(211) (910) (970) 
    Forfeited—  —  —  
    Non-vested cash-settled PSU awards, December 311,981  1,592  1,972  

    Weighted Average Grant Date Fair Value201920182017
    Non-vested cash-settled PSU awards, January 1$79.48  $92.25  $25.28  
    Granted at target level102.51  89.64  83.47  
    Adjustments above/(below) target56.95  41.53  66.61  
    Vested and converted102.51  93.00  86.93  
    Forfeited—  —  —  
    Non-vested cash-settled PSU awards, December 31$150.33  $79.48  $92.25  
    XML 23 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 24 R99.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies (Textuals) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Operating Leased Assets [Line Items]    
    Contingent consideration, payable period 5 years  
    Contingent consideration, estimated outcome, low $ 0.0  
    Contingent consideration, estimated outcome, high 3.7  
    Unrecorded Unconditional Purchase Obligation [Line Items]    
    Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment 249.1  
    Outstanding uncondintional contractual commitments due to be paid in 2020   $ 61.3
    Insurance Claims [Member]    
    Loss Contingencies [Line Items]    
    Accrual for insurance obligations 3.2  
    Amount reimbursable by the insurance company 0.9  
    Revolving credit facility, due 2024 [Domain] | Letter of Credit [Member]    
    Loss Contingencies [Line Items]    
    Letters of credit supporting the reimbursement of workers' compensation and other claims $ 2.5  
    XML 25 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Derivative Financial Instruments (Textuals) (Details)
    € in Millions, ¥ in Millions, $ in Millions, $ in Millions
    Dec. 31, 2019
    EUR (€)
    bbl
    $ / bbl
    Dec. 31, 2019
    JPY (¥)
    bbl
    $ / bbl
    Dec. 31, 2019
    USD ($)
    bbl
    $ / bbl
    Dec. 31, 2019
    SGD ($)
    bbl
    $ / bbl
    Dec. 31, 2018
    EUR (€)
    Dec. 31, 2018
    USD ($)
    Dec. 31, 2018
    SGD ($)
    Nov. 22, 2017
    bbl
    Commodity Call Options Held [Member]                
    Derivative [Line Items]                
    Derivative, Average Price Risk Option Strike Price | $ / bbl 70.71 70.71 70.71 70.71        
    Derivative, Nonmonetary Notional Amount | bbl 135,967 135,967 135,967 135,967       352,682
    Euro Member Countries, Euro | Forward Contracts [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount | €         € 10.0      
    United States of America, Dollars | Forward Contracts [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount     $ 13.4     $ 13.4    
    United States of America, Dollars | Cross Currency Interest Rate Contract [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount     90.0          
    United States of America, Dollars | Cross Currency Interest Rate Contract [Member] | Net Investment Hedges [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount     90.0          
    United States of America, Dollars | Long [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount     38.4          
    United States of America, Dollars | Short [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount € 33.6   0.0          
    Japan, Yen | Cross Currency Interest Rate Contract [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount | ¥   ¥ 9,800.0            
    Japan, Yen | Long [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount | ¥   ¥ 6,550.4            
    Japan, Yen | Short [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount 20.6   37.8          
    Singapore, Dollars | Forward Contracts [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount       $ 601.5     $ 601.5  
    Singapore, Dollars | Long [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount       $ 29.4        
    Singapore, Dollars | Short [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]                
    Derivative [Line Items]                
    Derivative, Notional Amount € 4.6   $ 16.5          
    XML 26 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense Other Items (Textuals) (Details)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    Feb. 17, 2016
    Summary of Investment Holdings [Line Items]          
    Venezuela currency devaluation $ 1.0 $ 1.1 $ 0.0    
    Venezuela deconsolidation 0.0 0.0 $ (11.1)    
    Foreign Currency Transaction Gain 5.6        
    Foreign Currency Transaction (Loss)   $ (5.5)      
    Gain (Loss) on Sale of Assets and Asset Impairment Charges $ 1.1        
    VENEZUELA          
    Summary of Investment Holdings [Line Items]          
    Foreign currency exchange rate, remeasurement       6.3 10.0
    XML 27 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Affiliated Companies (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Nov. 01, 2019
    Schedule of Equity Method Investments [Line Items]        
    Purchase in investment in affiliated companies in cash $ 85.1 $ 0.0 $ 0.0  
    Purchase of investment in affiliated companies $ 4.9      
    The West Company Mexico, S.A. de C.V. [Member]        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00%      
    Aluplast S.A. de C.V. [Member]        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00%      
    Pharma Tap S.A de C.V. [Member]        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00%      
    Pharma Rubber S.A. de C.V. [Member]        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00%      
    Daikyo Seiko, Ltd. [Member]        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00% 25.00%   49.00%
    I&W Pharma Group LLC        
    Schedule of Equity Method Investments [Line Items]        
    Ownership interest 49.00%      
    XML 28 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Goodwill and Intangible Assets (Textuals) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Apr. 01, 2019
    Finite-Lived Intangible Assets [Line Items]        
    Foreign currency translation gains (losses) $ (0.3) $ (0.3)    
    Amortization expense 3.4 $ 2.7 $ 2.4  
    Estimated annual amortization expense, 2020 4.0      
    Estimated annual amortization expense, 2021 3.5      
    Estimated annual amortization expense, 2022 3.5      
    Estimated annual amortization expense, 2023 2.9      
    Estimated annual amortization expense, 2024 $ 2.6      
    Business acquisition, recognized goodwill       $ 2.6
    Business acquisition, recognized intangible assets       $ 11.2
    XML 29 R95.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Income Before Income Taxes) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    U.S. operations $ 161.2 $ 132.9 $ 96.5
    International operations 130.6 107.8 125.9
    Income before income taxes $ 291.8 $ 240.7 $ 222.4
    XML 30 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Net Income Per Share (Details) - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Earnings Per Share [Abstract]      
    Net income, as reported, for basic net income per share $ 241.7 $ 206.9 $ 150.7
    Weighted average common shares outstanding (in shares) 74,000,000.0 73,900,000 73,900,000
    Assumed stock options exercised and awards vested, based on the treasury stock method (in shares) 1,400,000 1,500,000 1,900,000
    Weighted average shares assuming dilution (in shares) 75,400,000 75,400,000 75,800,000
    Antidilutive options excluded from computation of diluted net income per share (in shares) 100,000 400,000 400,000
    Share repurchase program, number of shares authorized 848,000 800,000  
    Shares purchased under share repurchase program (in shares) 800,000    
    Shares purchased under share repurchase program $ 83.1 $ 70.8 $ 74.4
    Shares purchased under share repurchase program, average cost per share $ 103.89    
    XML 31 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Lease Cost (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Leases [Abstract]      
    Operating lease cost $ 12.9    
    Short-term lease cost 0.8    
    Variable lease cost 3.3    
    Total lease cost $ 17.0 $ 14.5 $ 13.3
    XML 32 R84.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Amounts Recognized in Balance Sheet) (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
    Current liabilities $ (2.2) $ (2.3)
    Noncurrent liabilities (52.5) (56.2)
    Pension Plan [Member]    
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
    Current liabilities (1.5) (1.6)
    Noncurrent liabilities (46.6) (50.9)
    Total liabilities (43.8) (52.5)
    us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansAssetsNoncurrent 4.3  
    Other Postretirement Benefits Plan [Member]    
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
    Current liabilities (0.7) (0.7)
    Noncurrent liabilities (5.9) (5.3)
    Total liabilities $ (6.6) $ (6.0)
    XML 33 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    (Components of AOCI) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Accumulated Other Comprehensive Income (Loss) [Line Items]      
    Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
    Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
    Balance, beginning (154.2) (117.3)  
    Other comprehensive (loss) income before reclassifications 8.4 (37.7)  
    Amounts reclassified from AOCI (3.8) 0.8  
    Other comprehensive income (loss), net of tax 4.6 (36.9) 69.5
    Balance, ending (149.6) (154.2) (117.3)
    Losses on Cash Flow Hedges [Member]      
    Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
    Balance, beginning (0.4) (4.2)  
    Other comprehensive (loss) income before reclassifications 5.4 2.6  
    Amounts reclassified from AOCI (5.8) 1.2  
    Other comprehensive income (loss), net of tax (0.4) 3.8  
    Balance, ending (0.8) (0.4) (4.2)
    Unrealized Gains on Investment Securities [Member]      
    Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
    Balance, beginning 0.4 0.5  
    Other comprehensive (loss) income before reclassifications 0.0 (0.1)  
    Amounts reclassified from AOCI 0.0 0.0  
    Other comprehensive income (loss), net of tax 0.0 (0.1)  
    Balance, ending 0.4 0.4 0.5
    Defined Benefit Pension and Other Postretirement Plans [Member]      
    Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
    Balance, beginning (40.4) (39.0)  
    Other comprehensive (loss) income before reclassifications (1.9) (1.0)  
    Amounts reclassified from AOCI 2.0 (0.4)  
    Other comprehensive income (loss), net of tax 0.1 (1.4)  
    Balance, ending (40.3) (40.4) (39.0)
    Foreign Currency Translation [Member]      
    Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
    Balance, beginning (113.8) (74.6)  
    Other comprehensive (loss) income before reclassifications 4.9 (39.2)  
    Amounts reclassified from AOCI 0.0 0.0  
    Other comprehensive income (loss), net of tax 4.9 (39.2)  
    Balance, ending $ (108.9) $ (113.8) $ (74.6)
    XML 34 R103.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information (Segment Financial Information) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Segment Reporting Information [Line Items]      
    Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
    Operating profit 296.6 240.3 225.8
    Interest expense 8.5 8.4 7.8
    Interest income (3.8) (2.1) (1.3)
    Other nonoperating expense (income) 0.1 (6.7) (3.1)
    Income before income taxes 291.8 240.7 222.4
    Segment assets 2,341.4 1,978.9 1,862.8
    Capital expenditures (126.4) (104.7) (130.8)
    Depreciation and amortization expense 103.4 104.4 96.7
    Proprietary Products [Member]      
    Segment Reporting Information [Line Items]      
    Net sales 1,398.6 1,308.6 1,236.9
    Operating profit 313.6 266.4 243.8
    Interest expense 0.0 0.0 0.0
    Interest income 0.0 0.0 0.0
    Other nonoperating expense (income) 0.0 0.0 0.0
    Income before income taxes 313.6 266.4 243.8
    Segment assets 1,480.6 1,342.3 1,321.3
    Capital expenditures (91.2) (77.0) (107.2)
    Depreciation and amortization expense 82.2 83.9 77.1
    Contract-Manufactured Products [Member]      
    Segment Reporting Information [Line Items]      
    Net sales 441.5 409.1 362.5
    Operating profit 49.1 44.3 48.3
    Interest expense 0.0 0.0 0.0
    Interest income 0.0 0.0 0.0
    Other nonoperating expense (income) 0.0 0.0 0.0
    Income before income taxes 49.1 44.3 48.3
    Segment assets 386.0 301.4 286.4
    Capital expenditures (37.2) (20.7) (18.6)
    Depreciation and amortization expense 17.9 17.2 16.4
    Corporate and Eliminations [Member]      
    Segment Reporting Information [Line Items]      
    Net sales (0.2) (0.3) (0.3)
    Operating profit (66.1) (70.4) (66.3)
    Interest expense 8.5 8.4 7.8
    Interest income (3.8) (2.1) (1.3)
    Other nonoperating expense (income) 0.1 (6.7) (3.1)
    Income before income taxes (70.9) (70.0) (69.7)
    Segment assets 474.8 335.2 255.1
    Capital expenditures 2.0 (7.0) (5.0)
    Depreciation and amortization expense $ 3.3 $ 3.3 $ 3.2
    XML 35 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Derivative Instruments, Gain (Loss) [Line Items]    
    Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net $ 0.0 $ 0.0
    Cash Flow Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 0.6 2.6
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income (1.2) 1.2
    Net Investment Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI (0.5) 0.8
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income 0.0 0.0
    Not Designated as Hedging Instrument    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 0.4 (0.1)
    Fair Value Hedging    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 4.8  
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income (4.6)  
    Gain (Loss) on Derivative Instruments, Net, Pretax (6.9) (6.3)
    Derivative, Excluded Component, Gain (Loss), Recognized in Earnings 8.7 3.7
    Derivative, Excluded Component, Gain (Loss), Recognized in Earnings within Twelve Months 5.6  
    Net Sales [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Gain (Loss) on Derivative Instruments, Net, Pretax (0.9) 0.6
    Cost of Goods and Services Sold [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Gain (Loss) on Derivative Instruments, Net, Pretax (0.6) 0.3
    Interest Expense [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Gain (Loss) on Derivative Instruments, Net, Pretax 0.3 0.3
    Foreign Exchange (Gains) Losses and Other [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Gain (Loss) on Derivative Instruments, Net, Pretax (4.6) 0.0
    Foreign Currency Hedge Contracts [Member] | Net Sales [Member] | Cash Flow Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 0.8 0.4
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income (0.9) 0.6
    Foreign Currency Hedge Contracts [Member] | Cost of Goods and Services Sold [Member] | Cash Flow Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI (0.2) 2.2
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income (0.6) 0.3
    Foreign Currency Hedge Contracts [Member] | Foreign Exchange (Gains) Losses and Other [Member] | Fair Value Hedging    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 4.8  
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income (4.6)  
    Gain (Loss) on Derivative Instruments, Net, Pretax (6.9) (6.3)
    Forward Treasury Lock [Member] | Interest Expense [Member] | Cash Flow Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 0.0 0.0
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income 0.3 0.3
    Foreign Currency - Denominated Debt [Member] | Foreign Exchange (Gains) Losses and Other [Member] | Net Investment Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI 0.6 0.8
    Amount of (Gain) Loss Reclassified from Accumulated OCI into Income 0.0 0.0
    Commodity Call Options [Member] | Cost of Goods and Services Sold [Member] | Not Designated as Hedging Instrument    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 0.4 $ (0.1)
    Currency Swap | Foreign Exchange (Gains) Losses and Other [Member] | Net Investment Hedges [Member]    
    Derivative Instruments, Gain (Loss) [Line Items]    
    Amount of Gain (Loss) Recognized in OCI $ (1.1)  
    XML 36 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details) - $ / shares
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Non-Employee Directors [Member] | Deferred Compensation Plans [Member]      
    Non-vested PSU Awards [Roll Forward]      
    Granted at target level 14,579    
    Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]      
    Granted at target level $ 121.40    
    Incentive Stock Awards [Member]      
    Non-vested PSU Awards [Roll Forward]      
    Granted at target level 1,300 1,500 1,800
    Forfeited 0 (200) (800)
    Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]      
    Granted at target level $ 106.14 $ 93.00 $ 86.93
    Cash-settled PSU awards [Member]      
    Non-vested PSU Awards [Roll Forward]      
    Outstanding, beginning 1,592 1,972 2,451
    Granted at target level 806 560 598
    Adjustments above/(below) target 206 30 107
    Vested and converted (211) (910) (970)
    Forfeited 0 0 0
    Outstanding, ending 1,981 1,592 1,972
    Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]      
    Outstanding, beginning (in USD per share) $ 79.48 $ 92.25 $ 25.28
    Granted at target level 102.51 89.64 83.47
    Adjustments above/(below) target 56.95 41.53 66.61
    Vested and converted 102.51 93.00 86.93
    Forfeited 0 0 0
    Outstanding, ending (in USD per share) $ 150.33 $ 79.48 $ 92.25
    Stock-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Number of shares to be issued upon conversion 84,670    
    Average remaining term of shares issued at conversion 1 year    
    Non-vested PSU Awards [Roll Forward]      
    Outstanding, beginning 296,037 341,944 378,062
    Granted at target level 84,309 102,307 92,045
    Adjustments above/(below) target 50,556 2,284 11,369
    Vested and converted (48,964) (121,984) (116,684)
    Forfeited (16,204) (23,946) (110)
    Outstanding, ending 264,622 296,037 341,944
    Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]      
    Outstanding, beginning (in USD per share) $ 76.84 $ 64.38 $ 54.47
    Granted at target level 103.40 90.45 84.01
    Adjustments above/(below) target 83.89 33.86 42.85
    Vested and converted 102.51 93.00 50.06
    Forfeited 69.09 68.65 73.64
    Outstanding, ending (in USD per share) $ 66.03 $ 76.84 $ 64.38
    Restricted Stock [Member]      
    Non-vested PSU Awards [Roll Forward]      
    Granted at target level 13,308 0  
    Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]      
    Granted at target level $ 116.39    
    Minimum [Member] | Cash-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Actual payout range 0.00%    
    Minimum [Member] | Stock-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Actual payout range 0.00%    
    Maximum [Member] | Cash-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Actual payout range 200.00%    
    Maximum [Member] | Stock-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Actual payout range 200.00%    
    XML 37 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Stock Options Activity) (Details) - USD ($)
    $ / shares in Units, shares in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Weighted average remaining contractual life of options outstanding 6 years 1 month 6 days    
    Weighted average remaining contractual life of options exercisable 5 years    
    Aggregate intrinsic value of total options outstanding $ 227.8    
    Aggregate intrinsic value of total options vested $ 158.6    
    Weighted average grant date fair value of options granted $ 24.72 $ 20.16 $ 18.08
    Intrinsic value of options exercised $ 46.9 $ 61.3 $ 91.7
    Grant date fair value of options vested $ 7.5 $ 8.3 $ 6.7
    Stock Options Activity [Roll Forward]      
    Options outstanding, beginning 3.0 3.5 4.5
    Granted 0.3 0.5 0.5
    Exercised (0.6) (1.0) (1.5)
    Forfeited 0.0 0.0 0.0
    Options outstanding, ending 2.7 3.0 3.5
    Options exercisable 1.6 1.7 1.9
    Stock Options, Weighted Average Exercise Price [Roll Forward]      
    Options outstanding, beginning (in USD per share) $ 58.93 $ 48.76 $ 38.11
    Granted (in USD per share) 103.40 90.36 84.09
    Exercised (in USD per share) 46.42 35.95 26.15
    Forfeited (in USD per share) 92.71 75.32 60.92
    Options outstanding, ending (in USD per share) 67.02 58.93 48.76
    Options exercisable (in USD per share) $ 53.12 $ 45.32 $ 35.44
    Share-based Payment Arrangement, Option [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Awards, expiration period 10 years    
    Risk-free interest rate 2.30% 2.70% 2.00%
    Stock volatility 22.50% 19.80% 19.90%
    Dividend yield 0.70% 0.70% 0.70%
    Expected life 6 years 6 years 6 years
    XML 38 R88.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Allocation of Plan Assets) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 244.1 $ 214.5
    Weighted average asset allocations 100.00% 100.00%
    Level 2 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets   $ 0.0
    Cash [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 2.2 1.7
    Cash [Member] | Level 1 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 2.2 $ 1.7
    Equity Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Weighted average asset allocations 33.00% 23.00%
    Target allocation 30.00% 65.00%
    International Mutual Funds [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 15.5 $ 17.7
    International Mutual Funds [Member] | Level 1 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 1.3 $ 17.7
    International Mutual Funds [Member] | Level 2 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 14.2  
    International Mutual Funds [Member] | Level 3 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 0.0  
    Debt Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Weighted average asset allocations 65.00% 74.00%
    Target allocation 70.00% 35.00%
    Other [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Weighted average asset allocations 2.00% 3.00%
    Target allocation 0.00%  
    Mutual Funds [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 21.7 $ 13.9
    Mutual Funds [Member] | Level 1 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 3.8 13.9
    Mutual Funds [Member] | Level 2 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 17.9  
    Mutual Funds [Member] | Level 3 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 0.0  
    Pension Plan Assets In The Fair Value Hierarchy [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 39.4 33.3
    Pension Plan Assets In The Fair Value Hierarchy [Member] | Level 1 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 7.3 33.3
    Pension Plan Assets In The Fair Value Hierarchy [Member] | Level 2 [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets 32.1  
    Pension plan assets measured at NAV [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Fair value of plan assets $ 204.7 $ 181.2
    Minimum [Member] | Equity Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description 0.27  
    Minimum [Member] | Debt Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description 0.67  
    Minimum [Member] | Other [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description —  
    Maximum [Member] | Equity Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description 0.33  
    Maximum [Member] | Debt Securities [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description 0.73  
    Maximum [Member] | Other [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description 0.03  
    XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Derivative Financial Instruments
    		 12 Months Ended
    Dec. 31, 2019
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Derivative Financial Instruments Derivative Financial Instruments
    Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

    Foreign Currency Exchange Rate Risk

    We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2019, the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. As of December 31, 2018, the total amount of these forward exchange contracts was €10.0 million, SGD 601.5 million and $13.4 million.

    In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

    (in millions)Sell
    CurrencyPurchaseUSDEuro
    USD38.4  —  33.6  
    Yen6,550.4  37.8  20.6  
    SGD29.4  16.5  4.6  

    In November and December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Euro and Yen, we de-designated these borrowings as hedges of our net investments in certain European subsidiaries and Daikyo. The amounts recorded as cumulative translation adjustments within accumulated other comprehensive loss related to these borrowings (prior to de-designation) will remain in accumulated other comprehensive loss indefinitely, unless certain future events occur, such as the disposition of the operations for which the net investment hedges relate.

    In December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Yen, we entered into a forward exchange contract, designated as a cash flow hedge, to manage our exposure to fluctuating foreign exchange rates. This forward exchange contract matured on December 30, 2019.

    In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month USD LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Yen LIBOR plus a margin.

    Commodity Price Risk

    Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.
    From November 2017 through October 2019, we purchased several series of call options for a total of 352,682 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.

    As of December 31, 2019, we had outstanding contracts to purchase 135,967 barrels of crude oil from January 2020 to June 2021 at a weighted-average strike price of $70.71 per barrel.

    Effects of Derivative Instruments on Financial Position and Results of Operations

    Please refer to Note 12, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of December 31, 2019 and 2018.

    The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:

    Amount of Gain Recognized in IncomeLocation on Statement of Income
    ($ in millions)20192018
    Fair Value Hedges:
    Foreign currency hedge contracts$(6.9) $(6.3) Other (income) expense
    Total$(6.9) $(6.3) 

    We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2019 and 2018 were $8.7 million and $3.7 million, respectively. We expect to recognize $5.6 million in earnings, pre-tax, for forward point components in 2020.

    The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:

     Amount of Gain (Loss) Recognized in OCIAmount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
    ($ in millions)2019201820192018 
    Fair Value Hedges:
    Foreign currency hedge contracts$4.8  $—  $(4.6) $—  Other (income) expense
    Total$4.8  $—  $(4.6) $—  
    Cash Flow Hedges:     
    Foreign currency hedge contracts$0.8  $0.4  $(0.9) $0.6  Net sales
    Foreign currency hedge contracts(0.2) 2.2  (0.6) 0.3  Cost of goods and services sold
    Forward treasury locks—  —  0.3  0.3  Interest expense
    Total$0.6  $2.6  $(1.2) $1.2   
    Net Investment Hedges:     
    Foreign currency-denominated debt$0.6  $0.8  $—  $—  Other (income) expense
    Cross-currency swap(1.1) —  —  —  Other (income) expense
    Total$(0.5) $0.8  $—  $—   
    The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our consolidated statements of income for the years ended December 31:

    ($ in millions)20192018
    Net sales$(0.9) $0.6  
    Cost of goods and services sold(0.6) 0.3  
    Other (income) expense(4.6) —  
    Interest expense0.3  0.3  

    The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:

    Amount of Loss (Gain) Recognized in IncomeLocation on Statement of Income
    ($ in millions)20192018
    Commodity call options$0.4  $(0.1) Cost of goods and services sold
    Total$0.4  $(0.1) 


    During 2019 and 2018, there was no material ineffectiveness related to our hedges.
    XML 41 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Revenue
    		 12 Months Ended
    Dec. 31, 2019
    Revenue [Abstract]  
    Revenue from Contract with Customer [Text Block] Revenue
    Adoption of ASC 606

    On January 1, 2018, we adopted ASC 606, on a modified retrospective basis, applied to those contracts which were not completed as of January 1, 2018. As a result of our adoption, we recorded a cumulative-effect adjustment of $11.4 million within retained earnings in our consolidated balance sheet as of January 1, 2018, to reflect a change in the timing of revenue recognition under ASC 606, from point in time to over time, on our Contract-Manufactured Products product sales, certain Proprietary Products product sales, development and tooling agreements, as well as an acceleration on a portion of the remaining unearned income from a nonrefundable customer payment.

    Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods.

    Revenue Recognition

    Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance
    obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

    We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

    We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

    We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

    For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

    Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.

    The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. As of December 31, 2019, there was $5.6 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.7 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

    Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.

    Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience.

    The following table presents the approximate percentage of our net sales by market group:

    20192018
    Biologics25 %21 %
    Generics20 %21 %
    Pharma31 %34 %
    Contract-Manufactured Products24 %24 %
    100 %100 %
    The following table presents the approximate percentage of our net sales by product category:

    20192018
    High-Value Components42 %41 %
    Standard Packaging29 %32 %
    Delivery Devices5 %3 %
    Contract-Manufactured Products24 %24 %
    100 %100 %

    The following table presents the approximate percentage of our net sales by geographic location:

    20192018
    Americas48 %48 %
    Europe, Middle East, Africa44 %44 %
    Asia Pacific8 %8 %
    100 %100 %

    Contract Assets and Liabilities

    Contract assets and liabilities result from transactions with revenue recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet in other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.

    The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:

    ($ in millions)
    Contract assets, December 31, 2018$9.1  
    Contract assets, December 31, 20199.8  
    Change in contract assets - increase (decrease)$0.7  
    Deferred income, December 31, 2018$(33.4) 
    Deferred income, December 31, 2019(34.9) 
    Change in deferred income - (increase) decrease$(1.5) 

    The increase in deferred income during 2019 was primarily due to additional cash payments of $114.4 million received in advance of satisfying future performance obligations, partially offset by the recognition of revenue of $110.4 million, including $20.8 million of revenue that was included in deferred income at the beginning of the year, and $2.5 million in other adjustments.
    Practical Expedients and Exemptions

    We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less.

    In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less.

    Supply Chain Financing

    We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of December 31, 2019 and 2018, we derecognized accounts receivable of $10.1 million and $5.7 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our consolidated income statements for 2019 and 2018 were not material.

    Voluntary Recall

    On January 24, 2019, we issued a voluntary recall of our Vial2Bag product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold reflecting our inventory balance for these devices at December 31, 2018. During 2019, we recorded a net provision of $5.4 million for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the products back on the market.
    XML 42 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Affiliated Companies
    		 12 Months Ended
    Dec. 31, 2019
    Equity Method Investments and Joint Ventures [Abstract]  
    Affiliated Companies Affiliated Companies
    At December 31, 2019, the following affiliated companies were accounted for under the equity method:

    LocationOwnership interest
    The West Company Mexico, S.A. de C.V.Mexico49%  
    Aluplast S.A. de C.V.Mexico49%  
    Pharma Tap S.A. de C.V.Mexico49%  
    Pharma Rubber S.A. de C.V.Mexico49%  
    I&W Pharma Group LLCUnited States49%  
    DaikyoJapan49%  

    On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo, we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.

    Unremitted income of affiliated companies included in consolidated retained earnings amounted to $82.4 million, $75.8 million and $69.9 million at December 31, 2019, 2018 and 2017, respectively. Dividends received from affiliated companies were $2.2 million in 2019, $1.7 million in 2018 and $2.2 million in 2017.

    Our equity in net unrealized gains of Daikyo’s investment securities and derivative instruments, as well as pension adjustments, included in accumulated other comprehensive loss was $0.4 million, $0.4 million and $0.5 million at December 31, 2019, 2018 and 2017, respectively.

    Our purchases from, and royalty payments made to, affiliates totaled $115.1 million, $86.3 million and $86.7 million, respectively, in 2019, 2018 and 2017, of which $20.8 million and $12.9 million was due and payable as of December 31, 2019 and 2018, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. Sales to affiliates were $9.2 million, $9.6 million and $8.1 million, respectively, in 2019, 2018 and 2017, of which $1.9 million and $1.6 million was receivable as of December 31, 2019 and 2018, respectively.

    At December 31, 2019 and 2018, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $179.3 million and $77.8 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $13.4 million at both period-ends. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.
    XML 43 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Goodwill and Intangible Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Goodwill
    The changes in the carrying amount of goodwill by reportable segment were as follows:

    ($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
    Balance, December 31, 2017  $77.6  $30.1  $107.7  
    Foreign currency translation(1.6) (0.3) (1.9) 
    Balance, December 31, 2018  76.0  29.8  105.8  
    Goodwill recorded due to acquisition2.6  —  2.6  
    Foreign currency translation(0.5) (0.1) (0.6) 
    Balance, December 31, 2019  $78.1  $29.7  $107.8  
    Schedule of Intangible Assets by Major Class
    Intangible assets and accumulated amortization as of December 31 were as follows:

    20192018
    ($ in millions)CostAccumulated AmortizationNetCostAccumulated AmortizationNet
    Patents and licensing$21.5  $(16.0) $5.5  $19.6  $(15.1) $4.5  
    Technology3.3  (1.5) 1.8  3.3  (1.2) 2.1  
    Trademarks2.0  (1.8) 0.2  2.0  (1.8) 0.2  
    Customer relationships40.3  (21.6) 18.7  29.3  (20.0) 9.3  
    Customer contracts11.0  (7.4) 3.6  11.0  (6.8) 4.2  
    $78.1  $(48.3) $29.8  $65.2  $(44.9) $20.3  
    XML 44 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Net Income Per Share (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Earnings Per Share [Abstract]  
    Reconcilliation of Basic to Diluted Net Income Per Share
    The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

    (in millions)201920182017
    Net income$241.7  $206.9  $150.7  
    Weighted average common shares outstanding74.0  73.9  73.9  
    Dilutive effect of equity awards, based on the treasury stock method
    		1.4  1.5  1.9  
    Weighted average shares assuming dilution75.4  75.4  75.8  
    XML 45 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Voluntary Recall (Details) - USD ($)
    $ in Millions
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2018
    Dec. 31, 2019
    Voluntary Recall [Abstract]    
    Provision for product returns $ 11.3 $ 5.4
    XML 47 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Adoption of ASC 842 (Details)
    $ in Millions
    Dec. 31, 2019
    USD ($)
    Jan. 01, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
    Total lease liabilities $ 72.0    
    Operating lease right-of-use assets 70.1   $ 0.0
    Finance Lease $ 0.0    
    Lease, operating lease, terminate term 1    
    Maximum [Member]      
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
    Operating leases, option to extend 5 years    
    Operating lease, term of contract 12 months    
    Accounting Standards Update 2016-02 [Member]      
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
    Total lease liabilities   $ 73.1  
    Operating lease right-of-use assets   $ 71.0  
    XML 48 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details) - $ / shares
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    SARs, Weighted Average Exercise Price [Roll Forward]      
    Cash-settled SARs, outstanding 23,833    
    Stock-settled SARs, outstanding 12,160    
    Stock Appreciation Rights (SARs) [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Awards, expiration period 10 years    
    SARs Activity [Roll Forward]      
    Outstanding, beginning 39,819 51,368 116,087
    Granted 3,364 3,480 2,792
    Exercised (6,790) (14,629) (67,511)
    Forfeited (400) (400) 0
    Outstanding, ending 35,993 39,819 51,368
    Exercisable 27,781 30,285 39,769
    SARs, Weighted Average Exercise Price [Roll Forward]      
    Oustanding, beginning (in USD per share) $ 46.48 $ 38.55 $ 31.13
    Granted (in USD per share) 102.51 89.64 83.47
    Exercised (in USD per share) 42.08 28.45 27.65
    Forfeited (in USD per share) 63.43 63.43 0
    Oustanding, ending (in USD per share) 52.36 46.48 38.55
    Exercisable (in USD per share) $ 40.73 $ 36.91 $ 30.77
    XML 49 R89.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Other Income and Expenses [Abstract]      
    Severance and post-employment benefits $ 2.6 $ 3.1 $ 0.0
    Asset-related charges 0.3 2.2 0.0
    Other charges 2.0 3.8 0.0
    Total restructuring and related charges 4.9 9.1 0.0
    Venezuela currency devaluation 1.0 1.1 0.0
    Venezuela deconsolidation 0.0 0.0 11.1
    Development and licensing income (0.9) (0.9) (10.6)
    Contingent consideration 2.1 (2.6) (2.4)
    Other items (4.9) (4.8) 3.9
    Total other expense $ (2.5) $ 1.9 $ 2.0
    XML 50 R85.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Pension Plan [Member]      
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]      
    Net actuarial loss (gain) $ 69.4 $ 73.0  
    Prior service cost (credit) 0.8 0.9  
    Total 70.2 73.9  
    Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income 0.7 7.1 $ 0.3
    Other Postretirement Benefits Plan [Member]      
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]      
    Net actuarial loss (gain) (7.0) (9.4)  
    Prior service cost (credit) (1.0) (1.7)  
    Total (8.0) (11.1)  
    Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income $ 0.3 $ (1.2) $ (0.8)
    XML 51 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    (Reclassifications AOCI) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
    Cost of goods and services sold (1,234.2) (1,172.0) (1,086.2)
    Interest expense (8.5) (8.4) (7.8)
    Pension settlement charge 3.5 0.0 0.0
    Income before income taxes 291.8 240.7 222.4
    Tax expense (59.0) (41.4) (80.9)
    Net income 241.7 206.9 $ 150.7
    Reclassification out of Accumulated Other Comprehensive Income [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Net income 3.8 (0.8)  
    Reclassification out of Accumulated Other Comprehensive Income [Member] | Losses on Cash Flow Hedges [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Income before income taxes 8.4 (1.6)  
    Tax expense (2.6) 0.4  
    Net income 5.8 (1.2)  
    Reclassification out of Accumulated Other Comprehensive Income [Member] | Losses on Cash Flow Hedges [Member] | Foreign Currency Contract [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Net sales 1.0 (0.7)  
    Cost of goods and services sold 1.0 (0.5)  
    Reclassification out of Accumulated Other Comprehensive Income [Member] | Losses on Cash Flow Hedges [Member] | Interest Rate Swap Contracts [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Interest expense 6.9 0.0  
    Reclassification out of Accumulated Other Comprehensive Income [Member] | Losses on Cash Flow Hedges [Member] | Forward Treasury Locks [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Interest expense (0.5) (0.4)  
    Reclassification out of Accumulated Other Comprehensive Income [Member] | Defined Benefit Pension and Other Postretirement Plans [Member]      
    Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
    Prior service credit [1] 0.6 2.0  
    Actuarial (loss) gain [1] 0.2 (1.4)  
    Income before income taxes (2.7) 0.6  
    Tax expense 0.7 (0.2)  
    Net income $ (2.0) $ 0.4  
    [1] (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
    XML 52 wst-20191231_htm.xml IDEA: XBRL DOCUMENT 0000105770 2019-01-01 2019-12-31 0000105770 2019-06-30 0000105770 2020-01-31 0000105770 2018-01-01 2018-12-31 0000105770 2017-01-01 2017-12-31 0000105770 2019-12-31 0000105770 2018-12-31 0000105770 us-gaap:CommonStockMember 2016-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000105770 us-gaap:TreasuryStockMember 2016-12-31 0000105770 us-gaap:RetainedEarningsMember 2016-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000105770 2016-12-31 0000105770 us-gaap:RetainedEarningsMember 2017-12-31 0000105770 2017-12-31 0000105770 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000105770 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000105770 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000105770 us-gaap:CommonStockMember 2017-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000105770 us-gaap:TreasuryStockMember 2017-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000105770 us-gaap:RetainedEarningsMember 2018-12-31 0000105770 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000105770 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000105770 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000105770 us-gaap:CommonStockMember 2018-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000105770 us-gaap:TreasuryStockMember 2018-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000105770 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000105770 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000105770 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000105770 us-gaap:CommonStockMember 2019-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000105770 us-gaap:TreasuryStockMember 2019-12-31 0000105770 us-gaap:RetainedEarningsMember 2019-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000105770 2019-04-01 0000105770 srt:MinimumMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0000105770 wst:SmartDoseMember 2013-06-30 0000105770 wst:SmartDoseMember 2019-12-31 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0000105770 2019-01-01 2019-01-01 0000105770 2018-10-01 2018-12-31 0000105770 us-gaap:LandMember 2019-12-31 0000105770 us-gaap:LandMember 2018-12-31 0000105770 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0000105770 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0000105770 us-gaap:MachineryAndEquipmentMember 2019-12-31 0000105770 us-gaap:MachineryAndEquipmentMember 2018-12-31 0000105770 us-gaap:ToolsDiesAndMoldsMember 2019-12-31 0000105770 us-gaap:ToolsDiesAndMoldsMember 2018-12-31 0000105770 wst:ComputerHardwareAndSoftwareMember 2019-12-31 0000105770 wst:ComputerHardwareAndSoftwareMember 2018-12-31 0000105770 us-gaap:ConstructionInProgressMember 2019-12-31 0000105770 us-gaap:ConstructionInProgressMember 2018-12-31 0000105770 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember us-gaap:ToolsDiesAndMoldsMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:ToolsDiesAndMoldsMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember wst:ComputerHardwareAndSoftwareMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember wst:ComputerHardwareAndSoftwareMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember 2019-12-31 0000105770 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000105770 wst:WestCompanyMexicoSADeCVMember 2019-12-31 0000105770 wst:AluplastSADeCVMember 2019-12-31 0000105770 wst:PharmaTapSADeCVMember 2019-12-31 0000105770 wst:PharmaRubberSADeCVMember 2019-12-31 0000105770 wst:IWPharmaGroupLLCMember 2019-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2019-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2018-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2019-11-01 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2017-12-31 0000105770 wst:ProprietaryProductsMember 2017-12-31 0000105770 wst:ContractManufacturedProductsMember 2017-12-31 0000105770 wst:ProprietaryProductsMember 2018-01-01 2018-12-31 0000105770 wst:ContractManufacturedProductsMember 2018-01-01 2018-12-31 0000105770 wst:ProprietaryProductsMember 2018-12-31 0000105770 wst:ContractManufacturedProductsMember 2018-12-31 0000105770 wst:ProprietaryProductsMember 2019-01-01 2019-12-31 0000105770 wst:ContractManufacturedProductsMember 2019-01-01 2019-12-31 0000105770 wst:ProprietaryProductsMember 2019-12-31 0000105770 wst:ContractManufacturedProductsMember 2019-12-31 0000105770 wst:PatentsAndLicensingMember 2019-12-31 0000105770 wst:PatentsAndLicensingMember 2018-12-31 0000105770 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000105770 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000105770 us-gaap:TrademarksMember 2019-12-31 0000105770 us-gaap:TrademarksMember 2018-12-31 0000105770 us-gaap:CustomerRelationshipsMember 2019-12-31 0000105770 us-gaap:CustomerRelationshipsMember 2018-12-31 0000105770 us-gaap:CustomerContractsMember 2019-12-31 0000105770 us-gaap:CustomerContractsMember 2018-12-31 0000105770 wst:NotePayableDue2019Member 2018-12-31 0000105770 wst:Revolvingcreditfacilitydue2020Member 2018-12-31 0000105770 wst:TermLoanDue2024Domain 2019-12-31 0000105770 wst:SeniorNotesDue2022Member 2019-12-31 0000105770 wst:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2018-12-31 0000105770 wst:SeniorBNotesDue2024Member us-gaap:SeniorNotesMember 2019-12-31 0000105770 wst:SeniorBNotesDue2024Member us-gaap:SeniorNotesMember 2018-12-31 0000105770 wst:SeniorCNotesDue2027Member us-gaap:SeniorNotesMember 2019-12-31 0000105770 wst:SeniorCNotesDue2027Member us-gaap:SeniorNotesMember 2018-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2019-12-31 0000105770 us-gaap:DomesticLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2019-12-31 0000105770 us-gaap:ForeignLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2019-12-31 0000105770 us-gaap:FederalFundsEffectiveSwapRateMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 us-gaap:LondonInterbankOfferedRateLIBORMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 srt:MinimumMember us-gaap:BaseRateMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:BaseRateMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 srt:MinimumMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 srt:MaximumMember wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2019-01-01 2019-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2018-01-01 2018-12-31 0000105770 us-gaap:LetterOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2019-12-31 0000105770 wst:TermLoanDue2024Member 2019-12-31 0000105770 us-gaap:LondonInterbankOfferedRateLIBORMember wst:TermLoanDue2024Member 2019-01-01 2019-12-31 0000105770 wst:TermLoanDue2024Member 2019-01-01 2019-12-31 0000105770 us-gaap:SeniorNotesMember 2019-12-31 0000105770 wst:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2019-12-31 0000105770 wst:SeniorNotesDue2022Member 2019-01-01 2019-12-31 0000105770 wst:SeniorBNotesDue2024Member 2019-01-01 2019-12-31 0000105770 wst:SeniorCNotesDue2027Member 2019-01-01 2019-12-31 0000105770 us-gaap:SeniorNotesMember 2019-01-01 2019-12-31 0000105770 us-gaap:SeniorNotesMember 2018-01-01 2018-12-31 0000105770 wst:SeniorNotesDue2022Member 2019-12-31 0000105770 wst:SeniorBNotesDue2024Member 2019-12-31 0000105770 wst:SeniorCNotesDue2027Member 2019-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember 2019-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember 2019-12-31 0000105770 currency:EUR us-gaap:ForwardContractsMember 2018-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember 2018-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember 2018-12-31 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-12-31 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-12-31 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-12-31 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-12-31 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-12-31 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 us-gaap:OptionMember 2017-11-22 0000105770 us-gaap:OptionMember 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000105770 us-gaap:FairValueHedgingMember 2019-01-01 2019-12-31 0000105770 us-gaap:FairValueHedgingMember 2018-01-01 2018-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2018-01-01 2018-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000105770 wst:ForwardTreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000105770 wst:ForwardTreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000105770 us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0000105770 us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000105770 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0000105770 us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0000105770 wst:NetSalesMember 2019-01-01 2019-12-31 0000105770 wst:NetSalesMember 2018-01-01 2018-12-31 0000105770 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000105770 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000105770 us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000105770 us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000105770 us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000105770 us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0000105770 us-gaap:NondesignatedMember 2018-01-01 2018-12-31 0000105770 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000105770 us-gaap:CurrencySwapMember 2019-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 us-gaap:FairValueInputsLevel1Member 2018-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2018-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000105770 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000105770 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000105770 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000105770 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0000105770 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000105770 wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember 2019-01-01 2019-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2019-01-01 2019-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2018-01-01 2018-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2017-01-01 2017-12-31 0000105770 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000105770 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0000105770 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0000105770 wst:CashSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 wst:CashSettledPSUAwardsMember 2018-01-01 2018-12-31 0000105770 wst:CashSettledPSUAwardsMember 2017-01-01 2017-12-31 0000105770 wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember 2019-01-01 2019-12-31 0000105770 wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember 2018-01-01 2018-12-31 0000105770 wst:PerformanceVestingSharesOrUnitsDividendEquivalentsMember 2017-01-01 2017-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2019-01-01 2019-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2018-01-01 2018-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2017-01-01 2017-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-01-01 2017-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2019-01-01 2019-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2019-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2018-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2017-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2016-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2018-01-01 2018-12-31 0000105770 us-gaap:StockAppreciationRightsSARSMember 2017-01-01 2017-12-31 0000105770 wst:StockSettledPSUAwardsMember 2018-12-31 0000105770 wst:StockSettledPSUAwardsMember 2017-12-31 0000105770 wst:StockSettledPSUAwardsMember 2016-12-31 0000105770 wst:StockSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 wst:StockSettledPSUAwardsMember 2018-01-01 2018-12-31 0000105770 wst:StockSettledPSUAwardsMember 2017-01-01 2017-12-31 0000105770 wst:StockSettledPSUAwardsMember 2019-12-31 0000105770 srt:MinimumMember wst:StockSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember wst:StockSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 wst:CashSettledPSUAwardsMember 2018-12-31 0000105770 wst:CashSettledPSUAwardsMember 2017-12-31 0000105770 wst:CashSettledPSUAwardsMember 2016-12-31 0000105770 wst:CashSettledPSUAwardsMember 2019-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2019-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-12-31 0000105770 srt:DirectorMember us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0000105770 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000105770 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000105770 wst:IncentiveStockAwardsMember 2019-01-01 2019-12-31 0000105770 wst:IncentiveStockAwardsMember 2018-01-01 2018-12-31 0000105770 wst:IncentiveStockAwardsMember 2017-01-01 2017-12-31 0000105770 srt:MinimumMember wst:CashSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember wst:CashSettledPSUAwardsMember 2019-01-01 2019-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000105770 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-31 0000105770 us-gaap:ForeignPlanMember 2019-12-31 0000105770 us-gaap:ForeignPlanMember 2018-12-31 0000105770 country:US 2019-12-31 0000105770 country:US 2019-01-01 2019-12-31 0000105770 country:US 2018-01-01 2018-12-31 0000105770 country:US 2017-01-01 2017-12-31 0000105770 us-gaap:EquitySecuritiesMember 2019-12-31 0000105770 us-gaap:EquitySecuritiesMember 2018-12-31 0000105770 us-gaap:DebtSecuritiesMember 2019-12-31 0000105770 us-gaap:DebtSecuritiesMember 2018-12-31 0000105770 wst:OtherSecuritiesMember 2019-12-31 0000105770 wst:OtherSecuritiesMember 2018-12-31 0000105770 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0000105770 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 wst:InternationalMutualFundsMember 2019-12-31 0000105770 wst:InternationalMutualFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 wst:InternationalMutualFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 wst:InternationalMutualFundsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000105770 wst:MutualFundsMember 2019-12-31 0000105770 wst:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 wst:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 wst:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000105770 wst:PensionPlanAssetsInTheFairValueHierarchyMember 2019-12-31 0000105770 wst:PensionPlanAssetsInTheFairValueHierarchyMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 wst:PensionPlanAssetsInTheFairValueHierarchyMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 wst:PensionplanassetsmeasuredatNAVMember 2019-12-31 0000105770 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0000105770 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000105770 wst:InternationalMutualFundsMember 2018-12-31 0000105770 wst:InternationalMutualFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000105770 wst:MutualFundsMember 2018-12-31 0000105770 wst:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000105770 wst:PensionPlanAssetsInTheFairValueHierarchyMember 2018-12-31 0000105770 wst:PensionPlanAssetsInTheFairValueHierarchyMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000105770 wst:PensionplanassetsmeasuredatNAVMember 2018-12-31 0000105770 srt:MinimumMember us-gaap:EquitySecuritiesMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:EquitySecuritiesMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember us-gaap:DebtSecuritiesMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember us-gaap:DebtSecuritiesMember 2019-01-01 2019-12-31 0000105770 srt:MinimumMember wst:OtherSecuritiesMember 2019-01-01 2019-12-31 0000105770 srt:MaximumMember wst:OtherSecuritiesMember 2019-01-01 2019-12-31 0000105770 country:US 2018-12-31 0000105770 srt:MaximumMember wst:A2018RestructuringPlanMember 2019-12-31 0000105770 wst:A2018RestructuringPlanMember 2019-01-01 2019-12-31 0000105770 us-gaap:EmployeeSeveranceMember 2018-12-31 0000105770 wst:AssetRelatedChargesMember 2018-12-31 0000105770 us-gaap:OtherRestructuringMember 2018-12-31 0000105770 wst:A2018RestructuringPlanMember 2018-12-31 0000105770 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000105770 wst:AssetRelatedChargesMember 2019-01-01 2019-12-31 0000105770 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000105770 us-gaap:EmployeeSeveranceMember 2019-12-31 0000105770 wst:AssetRelatedChargesMember 2019-12-31 0000105770 us-gaap:OtherRestructuringMember 2019-12-31 0000105770 wst:A2018RestructuringPlanMember 2019-12-31 0000105770 wst:A2016RestructuringPlanMemberMember 2019-01-01 2019-12-31 0000105770 wst:A2016RestructuringPlanMemberMember 2019-12-31 0000105770 country:VE 2016-12-31 0000105770 country:VE 2016-02-17 0000105770 wst:SmartDoseMember 2019-01-01 2019-12-31 0000105770 wst:SmartDoseMember 2018-01-01 2018-12-31 0000105770 wst:SmartDoseMember 2017-01-01 2017-12-31 0000105770 wst:OtherMember 2018-01-01 2018-12-31 0000105770 us-gaap:AccountingStandardsUpdate201609Member 2019-01-01 2019-12-31 0000105770 us-gaap:AccountingStandardsUpdate201609Member 2018-01-01 2018-12-31 0000105770 us-gaap:AccountingStandardsUpdate201609Member 2017-01-01 2017-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000105770 us-gaap:ForeignCountryMember 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember wst:Year2019Member 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember wst:YearAfter2019Member 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember wst:Year2022Member 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember wst:Year2023Member 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember wst:YearAfter2023Member 2019-12-31 0000105770 us-gaap:InsuranceClaimsMember 2019-12-31 0000105770 wst:ProprietaryProductsMember 2017-01-01 2017-12-31 0000105770 wst:ContractManufacturedProductsMember 2017-01-01 2017-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2017-01-01 2017-12-31 0000105770 country:US 2019-01-01 2019-12-31 0000105770 country:US 2018-01-01 2018-12-31 0000105770 country:US 2017-01-01 2017-12-31 0000105770 country:US 2019-12-31 0000105770 country:US 2018-12-31 0000105770 country:US 2017-12-31 0000105770 country:DE 2019-01-01 2019-12-31 0000105770 country:DE 2018-01-01 2018-12-31 0000105770 country:DE 2017-01-01 2017-12-31 0000105770 country:DE 2019-12-31 0000105770 country:DE 2018-12-31 0000105770 country:DE 2017-12-31 0000105770 country:IE 2019-01-01 2019-12-31 0000105770 country:IE 2018-01-01 2018-12-31 0000105770 country:IE 2017-01-01 2017-12-31 0000105770 country:IE 2019-12-31 0000105770 country:IE 2018-12-31 0000105770 country:IE 2017-12-31 0000105770 country:FR 2019-01-01 2019-12-31 0000105770 country:FR 2018-01-01 2018-12-31 0000105770 country:FR 2017-01-01 2017-12-31 0000105770 country:FR 2019-12-31 0000105770 country:FR 2018-12-31 0000105770 country:FR 2017-12-31 0000105770 wst:OtherEuropeCountriesMember 2019-01-01 2019-12-31 0000105770 wst:OtherEuropeCountriesMember 2018-01-01 2018-12-31 0000105770 wst:OtherEuropeCountriesMember 2017-01-01 2017-12-31 0000105770 wst:OtherEuropeCountriesMember 2019-12-31 0000105770 wst:OtherEuropeCountriesMember 2018-12-31 0000105770 wst:OtherEuropeCountriesMember 2017-12-31 0000105770 wst:OtherCountriesMember 2019-01-01 2019-12-31 0000105770 wst:OtherCountriesMember 2018-01-01 2018-12-31 0000105770 wst:OtherCountriesMember 2017-01-01 2017-12-31 0000105770 wst:OtherCountriesMember 2019-12-31 0000105770 wst:OtherCountriesMember 2018-12-31 0000105770 wst:OtherCountriesMember 2017-12-31 0000105770 wst:CorporateAndEliminationsMember 2019-01-01 2019-12-31 0000105770 wst:CorporateAndEliminationsMember 2019-12-31 0000105770 wst:CorporateAndEliminationsMember 2018-01-01 2018-12-31 0000105770 wst:CorporateAndEliminationsMember 2018-12-31 0000105770 wst:CorporateAndEliminationsMember 2017-01-01 2017-12-31 0000105770 wst:CorporateAndEliminationsMember 2017-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 iso4217:USD shares iso4217:USD shares pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:plan wst:segment WEST PHARMACEUTICAL SERVICES, INC. 0000105770 --12-31 2019-12-31 2019 FY false 73837449 9218126218 0 0 0 -300000 -200000 1300000 800000 0 0 0 -300000 -500000 -100000 -500000 -500000 0 -100000 -2500000 -200000 1500000 -100000 3000000.0 3000000.0 0 0 0 0 0.25 0.25 100000000.0 100000000.0 75300000 75300000 74100000 74100000 1200000 1200000 0.62 0.58 0.54 15 35 5 12 4 7 3 10 0 P5Y0M0D 13400000 0.0278 0.0367 0.0382 0.0402 2300000 0 P1Y P6Y P6Y 0 2 0.27 0.33 0.67 0.73 — 0.03 0.0425 900000 1500000 P5Y 10-K true 2019-12-31 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-0645 610 594-2900 Common Stock, par value $.25 per share WST NYSE Yes No Yes Yes Large Accelerated Filer false false false 9218126218 73837449 2.74 2.74 1839900000 1234200000 1172000000.0 1086200000 605700000 545400000 512900000 38900000 40300000 39100000 272700000 262900000 246000000.0 2500000 -1900000 -2000000.0 296600000 240300000 225800000 8500000 8400000 7800000 3800000 2100000 1300000 -100000 6700000 3100000 291800000 240700000 222400000 59000000.0 41400000 80900000 8900000 7600000 9200000 241700000 206900000 150700000 3.27 2.80 2.04 3.21 2.74 1.99 74000000.0 73900000 73900000 75400000 75400000 75800000 241700000 206900000 150700000 4900000 -39200000 68800000 0 300000 0 -1900000 -700000 6300000 -2700000 0 0 200000 -1100000 -3600000 -500000 -1500000 -3500000 0 -100000 -4700000 -400000 3800000 -1000000.0 4600000 -36900000 69500000 246300000 170000000.0 220200000 439100000 337400000 319300000 288200000 235700000 214500000 64600000 54300000 1058700000 894400000 1820100000 1752700000 980800000 930700000 839300000 822000000.0 70100000 0 192700000 91200000 107800000 105800000 14000000.0 24700000 29800000 20300000 4300000 0 24700000 20500000 2341400000 1978900000 2300000 100000 156800000 130400000 2200000 2300000 73000000.0 64500000 6400000 9800000 9600000 0 91300000 76600000 341600000 283700000 255000000.0 196000000.0 15500000 13100000 52500000 56200000 62400000 0 41200000 33600000 768200000 582600000 0 0 18800000 18800000 272700000 282000000.0 1549400000 1353400000 -149600000 -154200000 118100000 103700000 1573200000 1396300000 2341400000 1978900000 73700000 18400000 260400000 600000 -46100000 1071600000 -186800000 1117500000 -4100000 -4100000 150700000 150700000 1500000 400000 44100000 -100000 11400000 55900000 800000 74400000 74400000 40000000.0 40000000.0 -4800000 -4800000 69500000 69500000 75200000 18800000 309300000 1300000 -109100000 1178200000 -117300000 1279900000 11400000 11400000 206900000 206900000 100000 0 -27300000 -900000 76200000 48900000 800000 70800000 70800000 43100000 43100000 -36900000 -36900000 75300000 18800000 282000000.0 1200000 -103700000 1353400000 -154200000 1396300000 241700000 241700000 0 -11100000 -800000 65600000 54500000 800000 83100000 83100000 0 1800000 3100000 4900000 45700000 45700000 4600000 4600000 75300000 18800000 272700000 1200000 -118100000 1549400000 -149600000 1573200000 241700000 206900000 150700000 100000000.0 101700000 94300000 3400000 2700000 2400000 24400000 15100000 16100000 2300000 2200000 700000 -3500000 0 0 0 0 -11100000 500000 600000 0 -800000 -1800000 -1600000 15300000 900000 41700000 -2600000 -7900000 -6900000 6700000 5900000 7000000.0 33300000 43800000 39700000 18600000 7000000.0 3600000 -2600000 6200000 -300000 25300000 400000 12600000 -9600000 -28300000 11000000.0 367200000 288600000 263300000 126400000 104700000 130800000 85100000 0 0 18900000 0 0 0 0 6000000.0 -2400000 -3900000 -3200000 -228000000.0 -100800000 -133600000 108500000 0 0 136300000 0 0 90000000.0 0 0 100000 100000 34900000 1200000 0 0 45100000 42100000 39100000 0 0 -700000 25100000 27400000 35700000 5400000 4900000 4400000 83100000 70800000 74400000 -36800000 -80700000 -109000000.0 -700000 -5600000 12200000 101700000 101500000 32900000 337400000 235900000 203000000.0 439100000 337400000 235900000 8600000 8400000 8000000.0 47500000 42000000.0 31000000.0 17000000.0 15000000.0 20100000 11800000 11300000 10400000 4900000 0 0 Summary of Significant Accounting Policies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principles of Consolidation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The consolidated financial statements include the accounts of West after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our consolidated financial statements since the acquisition date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 16, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other (Income) Expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for further discussion. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash and Cash Equivalents:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our accounts receivable balance was net of an allowance for doubtful accounts of $0.5 million and $2.0 million at December 31, 2019 and 2018, respectively. We record the allowance based on a specific identification methodology.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventories:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. The following is a summary of inventories at December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:67.404%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.975%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.816%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Property, Plant and Equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other (income) expense. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">at the present value of the unpaid lease payments at the lease commencement date. We had no finance leases as of December 31, 2019. Please refer to Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impairment of Goodwill and Other Intangible Assets:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employee Benefits:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Plans</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a more detailed discussion of our pension and other retirement plans. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Translation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience. Please refer to Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Shipping and Handling Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and Development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Environmental Remediation and Compliance Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Litigation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Please refer to Note 17, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other (income) expense. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock-Based Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a more detailed discussion of our stock-based compensation plans.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net Income Per Share</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.</span> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principles of Consolidation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The consolidated financial statements include the accounts of West after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our consolidated financial statements since the acquisition date.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 16, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other (Income) Expense</span>, for further discussion. 18900000 4500000 600000 2600000 11200000 <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash and Cash Equivalents:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our accounts receivable balance was net of an allowance for doubtful accounts of $0.5 million and $2.0 million at December 31, 2019 and 2018, respectively. We record the allowance based on a specific identification methodology.</span> 500000 2000000.0 Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. The following is a summary of inventories at December 31:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:67.404%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.975%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.816%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 100900000 90400000 37400000 42200000 97400000 81900000 235700000 214500000 <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Property, Plant and Equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other (income) expense. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">at the present value of the unpaid lease payments at the lease commencement date. We had no finance leases as of December 31, 2019. Please refer to Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.</span> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impairment of Goodwill and Other Intangible Assets:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.</span></div> P5Y P25Y <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employee Benefits:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Plans</span>, for a more detailed discussion of our pension and other retirement plans. <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Translation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience. Please refer to Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span>, for additional information. Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales. Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred. Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations. <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Litigation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Please refer to Note 17, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other (income) expense. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock-Based Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a more detailed discussion of our stock-based compensation plans.</span> <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net Income Per Share</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.</span> New Accounting Standards<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2019, the FASB issued guidance which clarifies or improves a variety of ASC disclosure and presentation requirements by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. This guidance was effective upon issuance. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, the FASB issued guidance which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued guidance to address a specific consequence of the 2017 Tax Act by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis, but elected to not reclassify from accumulated other comprehensive income (loss) to retained earnings the stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2017, the FASB issued guidance which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued guidance on the accounting for leases, ASC 842. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. Please refer to Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the FASB issued guidance which clarifies and improves areas of guidance related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">this guidance. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under current guidance, an entity reflects credit losses on financial assets measured on an amortized cost basis only when it is probable that losses have been incurred, generally considering only past events and current conditions in determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements, primarily as we have not historically had a material amount of accounts receivable write-offs.</span></div> Revenue<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of ASC 606</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2018, we adopted ASC 606, on a modified retrospective basis, applied to those contracts which were not completed as of January 1, 2018. As a result of our adoption, we recorded a cumulative-effect adjustment of $11.4 million within retained earnings in our consolidated balance sheet as of January 1, 2018, to reflect a change in the timing of revenue recognition under ASC 606, from point in time to over time, on our Contract-Manufactured Products product sales, certain Proprietary Products product sales, development and tooling agreements, as well as an acceleration on a portion of the remaining unearned income from a nonrefundable customer payment.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for those periods.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. As of December 31, 2019, there was $5.6 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.7 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by market group:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biologics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by product category: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">High-Value Components</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard Packaging</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delivery Devices</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Americas</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Europe, Middle East, Africa</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asia Pacific</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contract Assets and Liabilities</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract assets and liabilities result from transactions with revenue recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet in other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:83.048%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.952%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in contract assets - increase (decrease)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in deferred income - (increase) decrease</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in deferred income during 2019 was primarily due to additional cash payments of $114.4 million received in advance of satisfying future performance obligations, partially offset by the recognition of revenue of $110.4 million, including $20.8 million of revenue that was included in deferred income at the beginning of the year, and $2.5 million in other adjustments. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Practical Expedients and Exemptions</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supply Chain Financing</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of December 31, 2019 and 2018, we derecognized accounts receivable of $10.1 million and $5.7 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our consolidated income statements for 2019 and 2018 were not material.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Voluntary Recall</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 24, 2019, we issued a voluntary recall of our Vial2Bag product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold reflecting our inventory balance for these devices at December 31, 2018. During 2019, we recorded a net provision of $5.4 million for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the products back on the market.</span></div> 11400000 20000000.0 5600000 900000 4700000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by market group:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biologics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by product category: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">High-Value Components</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard Packaging</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delivery Devices</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:67.292%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.951%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Americas</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Europe, Middle East, Africa</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asia Pacific</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 0.25 0.21 0.20 0.21 0.31 0.34 0.24 0.24 1 1 0.42 0.41 0.29 0.32 0.05 0.03 0.24 0.24 1 1 0.48 0.48 0.44 0.44 0.08 0.08 1 1 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:83.048%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.952%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in contract assets - increase (decrease)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in deferred income - (increase) decrease</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 9100000 9800000 700000 33400000 34900000 -1500000 -114400000 110400000 20800000 2500000 10100000 5700000 11300000 5400000 <div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 4:  Net Income Per Share</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.942%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.060%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">241.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares assuming dilution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, 2018 and 2017, there were 0.1 million, 0.4 million, and 0.4 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2019, we announced a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares repurchased and the timing of such transactions depended on a variety of factors, including market conditions. During 2019, we purchased 800,000 shares of our common stock under the now-completed program at a cost of $83.1 million, or an average price of $103.89 per share. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated </span></div>transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2020. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.942%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.060%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">241.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares assuming dilution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 241700000 206900000 150700000 74000000.0 73900000 73900000 1400000 1500000 1900000 75400000 75400000 75800000 100000 400000 400000 800000 800000 83100000 103.89 848000 Property, Plant and Equipment<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of gross property, plant and equipment at December 31 is presented in the following table:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.307%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.701%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected useful lives (years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings and improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15-35</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">572.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">569.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-12</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">817.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Molds and dies</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-7</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer hardware and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-10</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,820.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,752.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $100.0 million, $101.7 million and $94.3 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no capitalized leases included in buildings and improvements and machinery and equipment at December 31, 2019 and 2018. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2019, 2018 and 2017 was $1.0 million, $0.9 million and $2.7 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019 and 2018, as part of our 2018 restructuring plan, we recorded within other (income) expense $0.3 million and $2.2 million, respectively, for non-cash asset write-downs associated with the discontinued use of certain equipment. During 2019 and 2018, as part of our restructuring plans, we recorded within other (income) expense $1.9 million and $1.1 million, respectively, for gains on the sale of fixed assets.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of gross property, plant and equipment at December 31 is presented in the following table:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.307%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.701%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected useful lives (years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Land</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Buildings and improvements</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15-35</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">572.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">569.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5-12</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">817.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Molds and dies</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-7</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer hardware and software</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3-10</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">128.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,820.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,752.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 22100000 20900000 572900000 569100000 817000000.0 806700000 123800000 115800000 155600000 151100000 128700000 89100000 1820100000 1752700000 100000000.0 101700000 94300000 0 1000000.0 900000 2700000 300000 2200000 1900000 1100000 Leases<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of ASC 842</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2019, we adopted ASC 842, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. As a result, we were not required to adjust our comparative period financial information for effects of ASC 842 or present the new required lease disclosures for periods prior to the date of adoption. As of December 31, 2019, we had operating leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2047. Certain of our operating leases include options to extend the lease term for up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA0YWYxYWQ0NTY5ZDQ5YWE5N2ViODNjY2Q1N2IwNmQ3L3NlYzowNGFmMWFkNDU2OWQ0OWFhOTdlYjgzY2NkNTdiMDZkN18yMTk2L2ZyYWc6NTExMDAyNTJkNmE3NDViMTk1YTNkYmYyMTc0YjYxNDYvdGV4dHJlZ2lvbjo1MTEwMDI1MmQ2YTc0NWIxOTVhM2RiZjIxNzRiNjE0Nl8xMDk5NTExNjM5MzQz_3df9f4a3-52e4-45a8-8ae6-d4e15b74807d">five</span> years, and certain of our operating leases include options to terminate the leases within one year. We had no finance leases as of December 31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of our adoption of ASC 842, we recorded operating lease right-of-use assets of $71.0 million and operating lease liabilities of $73.1 million for operating leases where we are the lessee in our consolidated balance sheet as of January 1, 2019. The operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our operating leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our operating leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease expense for 2018 and 2017 was $14.5 million and $13.3 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information related to leases was as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the weighted average remaining lease term for operating leases was 11.7 years and the weighted average discount rate was 3.76%.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of lease liabilities as of December 31, 2019 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed lease interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Practical Expedients and Exemptions</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have elected to adopt the leasing package of practical expedients, which allows us to not retroactively reassess: i) any expired or existing contracts containing leases under the new definition of a lease; ii) the lease classification for any expired or existing leases; and iii) initial direct costs for any expired or existing leases. We have also elected to adopt practical expedients around land easements, the combination of lease and non-lease components, and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have elected not to recognize operating lease right-of-use assets and operating lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.</span></div> 1 0 71000000.0 73100000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 12900000 800000 3300000 17000000.0 14500000 13300000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental information related to leases was as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 12500000 9100000 P11Y8M12D 0.0376 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of lease liabilities as of December 31, 2019 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed lease interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 12100000 10400000 8600000 7800000 7300000 41800000 88000000.0 16000000.0 72000000.0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 13000000.0 10500000 7800000 6900000 5500000 37800000 81500000 P12M Affiliated Companies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, the following affiliated companies were accounted for under the equity method:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.371%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.315%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ownership interest</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The West Company Mexico, S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aluplast S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma Tap S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma Rubber S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I&amp;W Pharma Group LLC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daikyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo, we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unremitted income of affiliated companies included in consolidated retained earnings amounted to $82.4 million, $75.8 million and $69.9 million at December 31, 2019, 2018 and 2017, respectively. Dividends received from affiliated companies were $2.2 million in 2019, $1.7 million in 2018 and $2.2 million in 2017.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our equity in net unrealized gains of Daikyo’s investment securities and derivative instruments, as well as pension adjustments, included in accumulated other comprehensive loss was $0.4 million, $0.4 million and $0.5 million at December 31, 2019, 2018 and 2017, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our purchases from, and royalty payments made to, affiliates totaled $115.1 million, $86.3 million and $86.7 million, respectively, in 2019, 2018 and 2017, of which $20.8 million and $12.9 million was due and payable as of December 31, 2019 and 2018, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. Sales to affiliates were $9.2 million, $9.6 million and $8.1 million, respectively, in 2019, 2018 and 2017, of which $1.9 million and $1.6 million was receivable as of December 31, 2019 and 2018, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019 and 2018, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $179.3 million and $77.8 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $13.4 million at both period-ends. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, the following affiliated companies were accounted for under the equity method:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:55.371%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.315%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ownership interest</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The West Company Mexico, S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aluplast S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma Tap S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma Rubber S.A. de C.V.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mexico</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I&amp;W Pharma Group LLC</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daikyo</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 0.49 0.49 0.49 0.49 0.49 0.49 0.25 0.49 85100000 4900000 82400000 75800000 69900000 2200000 1700000 2200000 -400000 -400000 -500000 115100000 86300000 86700000 20800000 12900000 9200000 9600000 8100000 1900000 1600000 179300000 77800000 13400000 Goodwill and Intangible Assets<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill recorded due to acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded goodwill of $2.6 million. The goodwill was recorded within our Proprietary Products reportable segment. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we had no accumulated goodwill impairment losses.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets and accumulated amortization as of December 31 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.121%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patents and licensing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trademarks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded a customer relationships intangible asset of $11.2 million, which is being amortized over ten years. </span></div>The cost basis of intangible assets includes a foreign currency translation loss of $0.3 million and a foreign currency translation loss of $0.3 million for the years ended December 31, 2019 and 2018, respectively. Amortization expense for the years ended December 31, 2019, 2018 and 2017 was $3.4 million, $2.7 million and $2.4 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2020 - $4.0 million, 2021 - $3.5 million, 2022 - $3.5 million, 2023 - $2.9 million and 2024 - $2.6 million. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill recorded due to acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 77600000 30100000 107700000 -1600000 -300000 -1900000 76000000.0 29800000 105800000 2600000 0 2600000 -500000 -100000 -600000 78100000 29700000 107800000 2600000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets and accumulated amortization as of December 31 were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:24.121%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patents and licensing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trademarks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Customer contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 21500000 16000000.0 5500000 19600000 15100000 4500000 3300000 1500000 1800000 3300000 1200000 2100000 2000000.0 1800000 200000 2000000.0 1800000 200000 40300000 21600000 18700000 29300000 20000000.0 9300000 11000000.0 7400000 3600000 11000000.0 6800000 4200000 78100000 48300000 29800000 65200000 44900000 20300000 11200000 -300000 -300000 3400000 2700000 2400000 4000000.0 3500000 3500000 2900000 2600000 Other Current Liabilities<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current liabilities as of December 31 included the following:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued commissions, rebates and royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued retirement plans (excluding pension)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued taxes other than income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividends payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued commissions, rebates and royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued retirement plans (excluding pension)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued taxes other than income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 27500000 25500000 11800000 11300000 9700000 5700000 7900000 2300000 6500000 5500000 5900000 4900000 3300000 3400000 1500000 3300000 17200000 14700000 91300000 76600000 Debt<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.711%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note payable, due December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit Facility, due October 15, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term Loan, due December 31, 2024 (2.78%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A notes, due July 5, 2022 (3.67%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B notes, due July 5, 2024 (3.82%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C notes, due July 5, 2027 (4.02%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Agreement - Credit Facility </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, we entered into the Credit Agreement that replaced our prior revolving credit facility, which was scheduled to expire in October 2020. The Credit Agreement, which expires in March 2024, contains the Credit Facility of $300.0 million, with sublimits of up to $30.0 million for swing line loans for domestic borrowers in USD and a $20.0 million swing line loan for our German Holding Company and up to $30.0 million for the issuance of standby letters of credit, which Credit Facility may be increased from time-to-time by the greater of $350.0 million and earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the preceding twelve month period in the aggregate through an increase in the Credit Facility, subject to the satisfaction of certain conditions. Borrowings under the Credit Facility bear interest at either the base rate (the per annum interest rate of the highest of the Prime Rate, the Federal Funds Rate plus 50 basis points or the daily LIBOR, plus 1.00%) or at the applicable LIBOR rate, plus a tiered margin based on the ratio of our net consolidated debt to our modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for LIBOR rate loans. The Credit </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Agreement contains financial covenants providing that we shall not permit the ratio of our net consolidated debt to our modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Credit Agreement, upon the occurrence of a qualified acquisition for each of our four fiscal quarters immediately following such qualified acquisition, the ratio shall be increased to 4.0 to 1. The Credit Agreement also contains customary limitations on liens securing our indebtedness, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2019 and 2018, total unamortized debt issuance costs of $1.1 million and $0.6 million, respectively, were recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the Credit Facility. A portion of these costs relate to our prior revolving credit facility.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, we had no outstanding borrowings under the Credit Facility, as we repaid the outstanding long-term borrowings denominated in Euro and Yen in November and December 2019, respectively. There was no material gain or loss on the repayment under the Credit Facility. At December 31, 2019, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.5 million, was $297.5 million. Please refer to Note 11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivative Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a discussion of the foreign currency hedges that had been associated with this facility.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Agreement Amendment - Term Loan</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, we entered into a First Amendment and Incremental Facility Amendment (the “First Amendment”) to the Credit Agreement. Pursuant to the First Amendment and the Credit Agreement, we established the Term Loan in the amount of $90.0 million, which is due on December 31, 2024. Borrowings under the Term Loan bear interest at the three-month LIBOR plus 87.5 basis points. As of December 31, 2019, there were unamortized debt issuance costs remaining of $0.2 million, which are being amortized as additional interest expense over the term of the Term Loan.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">At December 31, 2019, we had $90.0 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $87.7 million was classified as long-term. Please refer to Note 11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Derivative Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Private Placement</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes is 3.87%. As of December 31, 2019 and 2018, there were unamortized debt issuance costs remaining of $0.5 million and $0.6 million, respectively, which are being amortized as additional interest expense over the term of the Notes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Covenants</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2019, we were in compliance with all of our debt covenants, and we expect to continue to be in compliance with the terms of these agreements throughout 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest costs incurred during 2019, 2018 and 2017 were $9.4 million, $9.3 million and $10.5 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, were as follows: </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$2.3 million in 2020 and 2021, 2022 - $44.3 million, 2023 - $2.3 million, 2024 - $133.8 million, and thereafter - $73.0 million.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.711%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note payable, due December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit Facility, due October 15, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term Loan, due December 31, 2024 (2.78%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A notes, due July 5, 2022 (3.67%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series B notes, due July 5, 2024 (3.82%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series C notes, due July 5, 2027 (4.02%)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 100000 28600000 90000000.0 42000000.0 42000000.0 53000000.0 53000000.0 73000000.0 73000000.0 700000 600000 255000000.0 196000000.0 300000000.0 30000000.0 20000000.0 30000000.0 350000000.0 0.50 0.0100 0 37.5 87.5 137.5 3.5 4.0 1100000 600000 0 0 2500000 297500000 90000000.0 0.875 200000 90000000.0 2300000 87700000 168000000.0 42000000.0 0.0367 2022-07-05 53000000.0 0.0382 2024-07-05 73000000.0 0.0402 2027-07-05 0.0387 0.5 million 0.6 million 9400000 9300000 10500000 2300000 44300000 2300000 133800000 73000000.0 Derivative Financial Instruments<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Foreign Currency Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2019, the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. As of December 31, 2018, the total amount of these forward exchange contracts was €10.0 million, SGD 601.5 million and $13.4 million.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.487%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.906%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sell</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Yen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,550.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SGD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November and December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Euro and Yen, we de-designated these borrowings as hedges of our net investments in certain European subsidiaries and Daikyo. The amounts recorded as cumulative translation adjustments within accumulated other comprehensive loss related to these borrowings (prior to de-designation) will remain in accumulated other comprehensive loss indefinitely, unless certain future events occur, such as the disposition of the operations for which the net investment hedges relate.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, in conjunction with the repayment of the outstanding long-term borrowings under our Credit Facility denominated in Yen, we entered into a forward exchange contract, designated as a cash flow hedge, to manage our exposure to fluctuating foreign exchange rates. This forward exchange contract matured on December 30, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month USD LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Yen LIBOR plus a margin.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From November 2017 through October 2019, we purchased several series of call options for a total of 352,682 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we had outstanding contracts to purchase 135,967 barrels of crude oil from January 2020 to June 2021 at a weighted-average strike price of $70.71 per barrel.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for the balance sheet location and fair values of our derivative instruments as of December 31, 2019 and 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.269%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.328%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain Recognized in Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2019 and 2018 were $8.7 million and $3.7 million, respectively. We expect to recognize $5.6 million in earnings, pre-tax, for forward point components in 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.587%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.466%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain (Loss) Recognized in OCI</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.871%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.873%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.168%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019 and 2018, there was no material ineffectiveness related to our hedges.</span></div> 601500000 13400000 10000000.0 601500000 13400000 As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:52.487%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.906%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sell</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Yen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,550.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SGD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 38400000 0 33600000 6550400000 37800000 20600000 29400000 16500000 4600000 90000000 9800000000 90000000 352682 135967 70.71 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.269%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.328%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain Recognized in Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.587%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.466%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.239%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain (Loss) Recognized in OCI</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.871%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.873%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> -6900000 -6300000 -6900000 -6300000 8700000 3700000 5600000 4800000 -4600000 4800000 -4600000 800000 400000 -900000 600000 -200000 2200000 -600000 300000 0 0 300000 300000 600000 2600000 -1200000 1200000 600000 800000 0 0 -1100000 -500000 800000 0 0 -900000 600000 -600000 300000 -4600000 0 300000 300000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.692%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.429%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.168%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> 400000 -100000 400000 -100000 0 Fair Value Measurements<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Derivative Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for further discussion of our derivatives.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the contingent consideration liability related to the SmartDose technology platform (the "SmartDose contingent consideration") was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">obligation are recorded as income or expense within other (income) expense in our consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of changes in our Level 3 fair value measurements:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million compared to a carrying amount of $255.0 million. At December 31, 2018, the estimated fair value of long-term debt was $192.6 million and the carrying amount was $196.0 million.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 11300000 11300000 7700000 7700000 100000 100000 19100000 11300000 7800000 3300000 3300000 12800000 12800000 1400000 1400000 300000 300000 17800000 12800000 1700000 3300000 8700000 8700000 6500000 6500000 15200000 8700000 6500000 1700000 1700000 9800000 9800000 200000 200000 11700000 9800000 200000 1700000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of changes in our Level 3 fair value measurements:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.904%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 4900000 -2600000 600000 1700000 2100000 500000 3300000 263300000 255000000.0 192600000 196000000.0 Accumulated Other Comprehensive Loss<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.487%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.025%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.750%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.378%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.419%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Losses) gains on derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains on investment securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Defined benefit pension and other postretirement plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.987%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.136%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Detail of components</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Plans</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.487%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.025%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.750%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.378%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.419%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Losses) gains on derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains on investment securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Defined benefit pension and other postretirement plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(74.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> -4200000 500000 -39000000.0 -74600000 -117300000 2600000 -100000 -1000000.0 -39200000 -37700000 -1200000 0 400000 0 -800000 3800000 -100000 -1400000 -39200000 -36900000 -400000 400000 -40400000 -113800000 -154200000 5400000 0 -1900000 4900000 8400000 5800000 0 -2000000.0 0 3800000 -400000 0 100000 4900000 4600000 -800000 400000 -40300000 -108900000 -149600000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.987%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.136%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Detail of components</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Plans</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div> 1000000.0 -700000 -1000000.0 500000 -6900000 0 500000 400000 8400000 -1600000 2600000 -400000 5800000 -1200000 -600000 -2000000.0 200000 -1400000 -2700000 600000 -700000 200000 -2000000.0 400000 3800000 -800000 Stock-Based Compensation<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2019, there were 3,119,314 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock option and appreciation rights</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, stock-settled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, cash-settled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, dividend equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plans and restricted share awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2019 was approximately $21.2 million, which is expected to be recognized over a weighted average period of 1.6 years. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in outstanding options:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions, except per share data)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.11 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.95 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.15 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.92 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.02 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.12 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the weighted average remaining contractual life of options outstanding and of options exercisable was 6.1 years and 5.0 years, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the aggregate intrinsic value of total options outstanding was $227.8 million, of which $158.6 million represented vested options.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2019, 2018 and 2017: a risk-free interest rate of 2.3%, 2.7%, and 2.0%, respectively; stock volatility of 22.5%, 19.8%, and 19.9%, respectively; and dividend yields of 0.7%, 0.7%, and 0.7%, respectively. Stock volatility is estimated based on historical data and the impact from expected </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">future trends. Expected lives, which are based on prior experience, averaged 6 years for 2019, 2018 and 2017. The weighted average grant date fair value of options granted in 2019, 2018 and 2017 was $24.72, $20.16 and $18.08, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December 31, 2019, 2018 and 2017, the intrinsic value of options exercised was $46.9 million, $61.3 million and $91.7 million, respectively. The grant date fair value of options vested during those same periods was $7.5 million, $8.3 million and $6.7 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Appreciation Rights</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock appreciation rights (“SARs”) granted to eligible international employees vest in equal annual increments over 4 years of continuous service. All awards expire 10 years from the date of grant. The fair value of each cash-settled SAR is adjusted at the end of each reporting period, with the resulting change reflected in expense. As of December 31, 2019, SARs outstanding were 35,993, of which 23,833 were cash-settled and 12,160 were stock-settled. Upon exercise of a cash-settled SAR, the employee receives cash for the difference between the grant date price and the fair market value of the Company’s stock on the date of exercise. As a result of the cash settlement feature, cash-settled SARs are recorded within other long-term liabilities. Upon exercise of a stock-settled SAR, shares are issued in exchange for the exercise price of the stock-settled SAR. As a result of the stock settlement feature, stock-settled SARs are recorded within equity.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in outstanding SARs:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,368 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,087 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,480 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,792 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,790)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,511)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,993 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,368 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs exercisable, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,781 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,285 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.13 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.08 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.43 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.43 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs exercisable, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.73 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.77 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Performance Awards</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to stock options and SAR awards, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in our outstanding stock-settled PSU awards:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,037 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,944 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">378,062 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,309 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,307 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,045 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,556)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,369)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48,964)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(121,984)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116,684)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,204)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,946)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264,622 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,037 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,944 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.84 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.89 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.86 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.84 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2019, 2018 and 2017 was $103.40, $90.45 and $84.01, respectively. Including forfeiture and below-target achievement expectations, we expect that the stock-settled PSU awards will convert to 84,670 shares to be issued over an average remaining term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA0YWYxYWQ0NTY5ZDQ5YWE5N2ViODNjY2Q1N2IwNmQ3L3NlYzowNGFmMWFkNDU2OWQ0OWFhOTdlYjgzY2NkNTdiMDZkN18xMzAvZnJhZzplY2ZmM2Q5YmJhZWU0YWMzODQ5YmU4MzFmYTdiZDhkMi90ZXh0cmVnaW9uOmVjZmYzZDliYmFlZTRhYzM4NDliZTgzMWZhN2JkOGQyXzU1MjU_5649237d-81f3-42ad-be9c-00e04ab34944">one</span> year.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in our outstanding cash-settled PSU awards:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,972 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,451 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">598 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(107)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(910)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(970)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,981 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,972 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.28 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.95 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.53 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 51,391 shares, 55,669 shares and 56,218 shares for the years 2019, 2018 and 2017, respectively. At December 31, 2019, there were approximately 3.8 million shares available for issuance under the ESPP.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Compensation Plans and Restricted Share Awards</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, deferred stock awards are granted on the date of our annual meeting, and are distributed in shares of common stock. In 2019, we granted 14,579 deferred stock awards, with a grant date fair value of $121.40. Similarly, a non-qualified deferred compensation plan for eligible employees provides for the conversion of compensation into deferred stock units. As of December 31, 2019, the two deferred compensation plans held a total of 366,159 deferred stock units, including 6,274 units to be paid in cash.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, during 2019, we granted 13,308 restricted share awards at a weighted grant-date fair value of $116.39 per share to employees under the 2016 Plan. During 2018, we granted 15,942 restricted share awards at a weighted grant-date fair value of $96.77 per share to employees under the 2016 Plan. There were no grants of restricted share awards in 2017. The fair value of these awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Annual Incentive Plan</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our annual incentive plan, participants are paid bonuses on the attainment of certain financial goals, which they can elect to receive in either cash or shares of our common stock. If the employee elects payment in shares, they are also given a restricted incentive stock award equal to one share for each four bonus shares issued. The incentive stock awards vest at the end of four years provided that the participant has not made a disqualifying disposition of their bonus shares. Incentive stock award grants were 1,300 shares, 1,500 shares and 1,800 shares in 2019, 2018 and 2017, respectively. There were no incentive stock forfeitures in 2019. Incentive stock forfeitures of 200 shares and 800 shares occurred in 2018 and 2017, respectively. Compensation expense is recognized over the vesting period based on the fair market value of common stock on the award date: $106.14 per share granted in 2019, $93.00 per share granted in 2018 and $86.93 per share granted in 2017.</span></div> 3119314 1 2.5 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock option and appreciation rights</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, stock-settled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, cash-settled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance share units, dividend equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plans and restricted share awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 9100000 8600000 7800000 9500000 2500000 4100000 100000 0 100000 200000 100000 100000 900000 900000 800000 4600000 3000000.0 3200000 24400000 15100000 16100000 21200000 P1Y7M6D P10Y <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in outstanding options:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions, except per share data)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.11 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.42 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.95 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.15 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.92 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.02 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercisable, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.12 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.32 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.44 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3000000.0 3500000 4500000 300000 500000 500000 600000 1000000.0 1500000 0 0 0 2700000 3000000.0 3500000 1600000 1700000 1900000 58.93 48.76 38.11 103.40 90.36 84.09 46.42 35.95 26.15 92.71 75.32 60.92 67.02 58.93 48.76 53.12 45.32 35.44 P6Y1M6D P5Y 227800000 158600000 0.023 0.027 0.020 0.225 0.198 0.199 0.007 0.007 0.007 P6Y 24.72 20.16 18.08 46900000 61300000 91700000 7500000 8300000 6700000 P4Y P10Y 35993 23833 12160 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in outstanding SARs:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,368 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,087 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,480 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,792 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,790)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,511)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,993 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,368 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs exercisable, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,781 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,285 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,769 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.13 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.08 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.43 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.43 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs outstanding, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SARs exercisable, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.73 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.77 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 39819 51368 116087 3364 3480 2792 6790 14629 67511 400 400 0 35993 39819 51368 27781 30285 39769 46.48 38.55 31.13 102.51 89.64 83.47 42.08 28.45 27.65 63.43 63.43 0 52.36 46.48 38.55 40.73 36.91 30.77 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in our outstanding stock-settled PSU awards:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,037 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,944 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">378,062 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,309 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102,307 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,045 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50,556)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,369)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48,964)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(121,984)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116,684)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,204)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,946)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(110)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">264,622 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296,037 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341,944 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.84 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.40 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.89 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.86 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.09 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested stock-settled PSU awards, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.84 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 296037 341944 378062 84309 102307 92045 -50556 -2284 -11369 48964 121984 116684 16204 23946 110 264622 296037 341944 76.84 64.38 54.47 103.40 90.45 84.01 83.89 33.86 42.85 102.51 93.00 50.06 69.09 68.65 73.64 66.03 76.84 64.38 0 2 103.40 90.45 84.01 84670 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes changes in our outstanding cash-settled PSU awards:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, January 1</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,972 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,451 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">598 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(107)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(910)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(970)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, December 31</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,981 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,972 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.28 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted at target level</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments above/(below) target</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.95 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.53 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and converted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102.51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86.93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested cash-settled PSU awards, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1592 1972 2451 806 560 598 -206 -30 -107 211 910 970 0 0 0 1981 1592 1972 79.48 92.25 25.28 102.51 89.64 83.47 56.95 41.53 66.61 102.51 93.00 86.93 0 0 0 150.33 79.48 92.25 0.85 0.25 25000 2000 8000 51391 55669 56218 3800000 1 14579 121.40 2 366159 6274 13308 116.39 0 P4Y 1300 1500 1800 0 200 800 106.14 93.00 86.93 Benefit Plans Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we provide minimal death benefits for certain U.S. retirees and pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. Benefits for participants are coordinated with Medicare when possible. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $15.6 million for 2019, $6.5 million for 2018 and $5.7 million for 2017. The increase in 401(k) plan contributions in 2019 was in response to the cessation of our U.S. qualified and non-qualified defined benefit pension plans as of January 1, 2019 (except for interest crediting).<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pension and Other Retirement Benefits</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost and other amounts recognized in OCI were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.032%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of actuarial loss (gain)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss (gain) arising during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit arising during period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of actuarial (loss) gain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total recognized in OCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total recognized in net periodic benefit cost and OCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net periodic benefit cost by geographic location is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.711%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.082%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recorded a $3.5 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for each of our U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year. Effective January 1, 2019, except for interest crediting, benefit accruals under these defined benefit pension plans ceased.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we contributed $2.6 million to our U.S. qualified defined benefit pension plan.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in benefit obligation:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(267.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(288.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Participants’ contributions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial (loss) gain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendments/transfers in</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits/expenses paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(287.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(267.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actual return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employer contribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Participants’ contributions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits/expenses paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Funded status at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">International pension plan assets, at fair value, included in the preceding table were $39.4 million and $33.4 million at December 31, 2019 and 2018, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recognized in the balance sheet were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts in accumulated other comprehensive loss, pre-tax, consisted of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net actuarial loss (gain)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service cost (credit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net actuarial loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year are $1.8 million and $0.1 million, respectively. The net actuarial gain and prior service credit for the other retirement benefits plan that will be amortized from accumulated other comprehensive loss into net periodic benefit cost over the next fiscal year is $1.6 million and $0.7 million. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accumulated benefit obligation for all defined benefit pension plans was $283.9 million and $263.0 million at December 31, 2019 and 2018, respectively, including $73.9 million and $64.0 million, respectively, for international pension plans.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, our U.S. qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2019, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All of the defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets as of December 31, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.149%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> ($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 to 2029</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2020, we expect to contribute $0.7 million to pension plans, none of which is for international plans. In addition, we expect to contribute $0.7 million for other retirement benefits in 2020. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions used to determine net periodic benefit cost were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.570%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.90 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term rate of return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.54 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions used to determine the benefit obligations were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.823%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.79 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.49 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discount rate used to determine the benefit obligations for U.S. pension plans was 3.35% and 4.30% as of December 31, 2019 and 2018, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 1.28% and 2.19% as of December 31, 2019 and 2018, respectively. The rate of compensation increase for U.S. plans was 4.25% for 2018, while the weighted average rate for all international plans was 2.49% for 2019 and 2.60% for 2018. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans, which accounts for 83.86% of global plan assets, was 5.60% for 2019, 7.00% for 2018 and 7.00% for 2017. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumed healthcare cost trend rate used to determine benefit obligations was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. A change in the assumed healthcare cost trend rate by one percentage point would have an immaterial impact in the postretirement obligation. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.25% for all participants in 2019, decreasing to 5.00% by 2024. The effect of a one percentage point increase or decrease in the rate would have an immaterial impact in the aggregate service and interest cost components.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our U.S. pension plan is managed as a balanced portfolio comprised of two components: equity and fixed income debt securities. Equity investments are used to maximize the long-term real growth of fund assets, while fixed income investments are used to generate current income, provide for a more stable periodic return and provide some protection against a prolonged decline in the market value of equity investments. Temporary funds may be held as cash. We maintain a long-term strategic asset allocation policy which provides guidelines for ensuring that the fund’s investments are managed with the short-term and long-term financial goals of the fund, while allowing the flexibility to react to unexpected changes in capital markets.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended December 31, 2018, in anticipation of benefit accruals under our U.S. qualified and non-qualified defined benefit pension plans ceasing effective January 1, 2019, except for interest crediting, we changed the U.S. target asset allocations from 65% equity securities and 35% debt securities to 30% equity securities and 70% debt securities.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following are the U.S. target asset allocations and acceptable allocation ranges:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Target allocation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocation range</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27% - 33% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67% - 73%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0% - 3%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.070%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets in the fair value hierarchy</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets measured at NAV</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.230%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets in the fair value hierarchy</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets measured at NAV</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> 15600000 6500000 5700000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost and other amounts recognized in OCI were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.032%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of actuarial loss (gain)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss (gain) arising during period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit arising during period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of actuarial (loss) gain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total recognized in OCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total recognized in net periodic benefit cost and OCI</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net periodic benefit cost by geographic location is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.711%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.082%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.493%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1400000 10800000 10400000 0 0 0 9200000 9400000 9800000 200000 200000 300000 12000000.0 15700000 13500000 0 0 0 100000 -1300000 -1300000 -700000 -700000 -700000 -2100000 -3800000 -4900000 2300000 2400000 2600000 3500000 4300000 7000000.0 10300000 -2800000 -2900000 -3000000.0 -1500000 -3500000 9000000.0 -100000 1400000 1100000 0 300000 0 0 0 0 100000 -1300000 -1300000 -700000 -700000 -700000 -2100000 -3800000 -4900000 2300000 2400000 2600000 -3500000 -600000 1200000 -2600000 0 0 0 -3600000 100000 -10000000.0 3100000 1700000 2200000 700000 7100000 300000 300000 -1200000 -800000 2400000 4800000 7300000 -2800000 -2900000 -3000000.0 1900000 2200000 3000000.0 0 0 0 4300000 7000000.0 10300000 -2800000 -2900000 -3000000.0 3500000 2600000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in benefit obligation:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(267.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(288.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Participants’ contributions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial (loss) gain</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendments/transfers in</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits/expenses paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit obligation, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(287.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(267.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets, January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">239.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actual return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employer contribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Participants’ contributions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Benefits/expenses paid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlement effects</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets, December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Funded status at end of year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 267000000.0 288000000.0 6000000.0 7100000 1400000 10800000 0 0 9200000 9400000 200000 200000 300000 600000 700000 600000 -30800000 20400000 -200000 1400000 0 300000 0 0 6800000 18000000.0 500000 500000 -1000000.0 3700000 0 0 287900000 267000000.0 6600000 6000000.0 214500000 239500000 0 0 41300000 -8300000 0 0 8000000.0 2700000 200000 100000 300000 600000 700000 600000 6300000 18000000.0 500000 500000 1300000 -2000000.0 0 0 244100000 214500000 0 0 -43800000 -52500000 -6600000 -6000000.0 39400000 33400000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recognized in the balance sheet were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(46.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(50.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(43.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(52.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 4300000 1500000 1600000 700000 700000 46600000 50900000 5900000 5300000 43800000 52500000 6600000 6000000.0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts in accumulated other comprehensive loss, pre-tax, consisted of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net actuarial loss (gain)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service cost (credit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> -69400000 -73000000.0 7000000.0 9400000 800000 900000 -1000000.0 -1700000 70200000 73900000 -8000000.0 -11100000 1800000 100000 1600000 700000 283900000 263000000.0 73900000 64000000.0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.149%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> ($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 to 2029</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 21000000.0 1300000 22300000 13500000 1300000 14800000 15000000.0 2000000.0 17000000.0 13700000 1500000 15200000 13500000 1900000 15400000 60500000 13300000 73800000 137200000 21300000 158500000 700000 700000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions used to determine net periodic benefit cost were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.570%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.740%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.48 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.90 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term rate of return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.54 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.47 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average assumptions used to determine the benefit obligations were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.823%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.79 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.76 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rate of compensation increase</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.49 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 0.0270 0.0291 0.0348 0.0420 0.0345 0.0390 0.0241 0.0400 0.0401 0.0554 0.0671 0.0647 0.0279 0.0376 0.0320 0.0420 0.0249 0.0401 0.0335 0.0128 0.0219 0.0425 0.0249 0.0260 0.8386 0.0560 0.0700 0.0700 0.0625 0.0500 0.0625 0.0500 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following are the U.S. target asset allocations and acceptable allocation ranges:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Target allocation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allocation range</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27% - 33% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67% - 73%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—% </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0% - 3%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.070%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets in the fair value hierarchy</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets measured at NAV</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">204.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.230%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mutual funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets in the fair value hierarchy</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets measured at NAV</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension plan assets at fair value</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> 0.33 0.23 0.65 0.74 0.02 0.03 1 1 0.65 0.35 0.30 0.70 0.30 0.70 0 2200000 2200000 15500000 1300000 14200000 0 21700000 3800000 17900000 0 39400000 7300000 32100000 204700000 244100000 1700000 1700000 17700000 17700000 13900000 13900000 33300000 33300000 0 181200000 214500000 Other (Income) Expense <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other (income) expense consisted of:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and related charges:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and post-employment benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total restructuring and related charges</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Argentina currency devaluation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax recovery</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Venezuela deconsolidation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development and licensing income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other (income) expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of the approval. The plan was expected to require restructuring and related charges of approximately $16.0 million. Since its approval, we recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recorded $4.9 million in restructuring and related charges associated with this plan, consisting of $2.6 million for severance charges, $0.3 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $2.0 million for other non-cash charges. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, we recorded $8.8 million in restructuring and related charges associated with this plan, consisting of $3.1 million for severance charges, $2.2 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $3.5 million for other non-cash charges. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.980%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.908%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and benefits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash asset write-downs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash asset write-downs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. During 2018, we recorded $0.3 million in additional charges related to this restructuring plan. Our remaining restructuring obligations related to our 2016 restructuring plan as of December 31, 2019 were $0.1 million.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Items</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recorded a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. During 2018, we recorded a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recognized a tax recovery of $4.7 million related to previously-paid international excise taxes, following a favorable court ruling.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 17, 2016, the Venezuelan government announced a devaluation of the Bolivar, from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD, and streamlined the previous three-tiered currency exchange mechanism into a dual currency exchange mechanism. In 2017, as a result of the continued deterioration of conditions in Venezuela as well as our continued reduced access to USD settlement controlled by the Venezuelan government, we recorded a charge of $11.1 million related to the deconsolidation of our Venezuelan subsidiary, following our determination that we no longer met the U.S. GAAP criteria for control of that subsidiary. This charge included the derecognition of the carrying amounts of our Venezuelan subsidiary’s assets and liabilities, as well as the write-off of our investment in our Venezuelan subsidiary, related unrealized translation adjustments and the elimination of intercompany accounts. As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, 2018 and 2017, we recorded development income of $0.9 million, $0.9 million and $1.5 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information. In addition, during 2017, we recorded income of $9.1 million attributable to the reimbursement of certain costs related to a technology that we subsequently licensed to a third party. The license of technology to the third party may result in additional income in the future, contingent on commercialization of the related product. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details. </span></div>Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. Other items primarily changed in 2019 as a result of foreign exchange transaction gains of $5.6 million in 2019 and a $1.9 million gain on the sale of fixed assets as a result of our restructuring plan, as compared to foreign exchange transaction gains of $5.5 million in 2018 and a $1.1 million gain on the sale of fixed assets as a result of our restructuring plans. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other (income) expense consisted of:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and related charges:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and post-employment benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total restructuring and related charges</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Argentina currency devaluation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax recovery</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Venezuela deconsolidation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development and licensing income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other (income) expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2600000 3100000 0 300000 2200000 0 2000000.0 3800000 0 4900000 9100000 0 1000000.0 1100000 0 0 0 -11100000 900000 900000 10600000 2100000 -2600000 -2400000 4900000 4800000 -3900000 2500000 -1900000 -2000000.0 16000000.0 4900000 2600000 300000 2000000.0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.980%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.908%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and benefits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash asset write-downs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash asset write-downs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2300000 0 0 2300000 2600000 300000 2000000.0 4900000 3500000 0 0 3500000 0 300000 2000000.0 2300000 1400000 0 0 1400000 300000 100000 1000000.0 1100000 6.3 10.0 -11100000 900000 900000 1500000 20000000.0 9100000 5600000 -5500000 1100000 Income TaxesAs a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. During 2019, the statute of limitations for the 2015 U.S. federal tax year lapsed, leaving tax years 2016 through 2019 open to examination. For U.S. state and local jurisdictions, tax years 2015 through 2019 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2012 through 2019.<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase due to current year position</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase due to prior year position</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction for expiration of statute of limitations/audits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we had balances in accrued liabilities for interest and penalties of $0.2 million at both December 31, 2019 and 2018. As of December 31, 2019, we had $5.0 million of total gross unrecognized tax benefits, which, if recognized, would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $0.5 million during the next twelve months, which would favorably impact our effective tax rate.</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of income before income taxes are:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">291.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">222.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The related provision for income taxes consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal and state</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of our deferred tax assets and liabilities at December 31 are</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension and deferred compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax (liability) asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.365%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.227%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. federal corporate tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on international operations other than U.S. tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reversal of prior valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reserves for unrecognized tax benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. tax on international earnings, net of foreign tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State income taxes, net of federal tax effect</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Excess tax benefits on share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impact of 2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Venezuela deconsolidation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other business credits and Section 199 Deduction</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we recorded a tax benefit of $0.3 million due to the impact of federal law changes enacted during the year, as well as a tax benefit of $10.3 million associated with stock-based compensation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, we recorded a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act and a tax benefit of $14.3 million associated with stock-based compensation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2017, we recorded a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include, but are not limited to, a federal statutory rate reduction from 35.0% to 21.0% effective for tax years beginning after December 31, 2017. Changes in tax rates and tax laws are accounted for in the period of enactment. As a result, during the year ended December 31, 2017, we recorded a discrete charge based upon our understanding of the 2017 Tax Act and the guidance available as of the date of that filing. A significant portion of the discrete tax liability was attributable to a one-time mandatory deemed repatriation tax of post-1986 undistributed foreign subsidiary earnings and profits (the “Transition Toll Tax”) of $27.9 million. Additionally, due to the reduction of the federal statutory rate, we revalued our deferred assets and liabilities and recorded a provisional $11.4 million federal tax expense, net of state tax impact, during the year ended December 31, 2017.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. We recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities and included these amounts in our consolidated financial statements for the year ended December 31, 2017. As of December 31, 2018, we finalized our calculations and tax positions used in our analysis of the impact of the 2017 Tax Act in consideration of proposed regulations and other guidance issued during 2018. As a result, we recorded a $7.5 million tax benefit related to a reduction of the Transition Toll Tax and an incremental tax expense of $4.0 million related to other adjustments. The final measurement reduced the Transition Toll Tax expense to $20.4 million from $27.9 million. The net impact of these adjustments resulted in a benefit of 1.45% to the 2018 effective tax rate. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2017 Tax Act created a provision known as global intangible low-tax income (“GILTI”) that imposes a U.S. tax on certain earnings of controlled foreign subsidiaries. We made an accounting policy election to reflect GILTI taxes, if any, as a current income tax expense in the period incurred. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we have fully utilized all of our U.S. federal net operating loss carryforwards. State operating loss carryforwards of $226.9 million created a deferred tax asset of $15.5 million, while foreign operating loss carryforwards of $49.4 million created a deferred tax asset of $6.4 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been fully reserved. State loss carryforwards expire as follows: $15.4 million in 2020 and $211.5 million thereafter. Foreign loss carryforwards will begin to expire in 2027, while $48.7 million of the total $49.4 million will not expire.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we have utilized all available foreign tax credit carryforwards against the Transition Toll Tax. During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. The $2.0 million of state research and development credits expire as follows: $0.5 million expire in 2023, $0.5 million expire in 2024, and $1.0 million expire after 2024.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. In general, it is our practice and intention to permanently reinvest the earnings of our foreign subsidiaries and repatriate earnings only when the tax impact is de minimis, and that position has not changed subsequent to the one-time transition tax under the 2017 Tax Act, except as noted above. Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $214.2 million of undistributed earnings from foreign subsidiaries to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at January 1</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase due to current year position</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase due to prior year position</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction for expiration of statute of limitations/audits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3900000 3200000 1600000 800000 0 400000 500000 500000 5000000.0 3900000 200000 5000000.0 500000 <div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of income before income taxes are:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">291.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">222.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 161200000 132900000 96500000 130600000 107800000 125900000 291800000 240700000 222400000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The related provision for income taxes consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal and state</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax provision</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 10800000 2100000 2100000 2400000 3300000 100000 30500000 35100000 37000000.0 43700000 40500000 39200000 10300000 1400000 41800000 5000000.0 -500000 -100000 15300000 900000 41700000 59000000.0 41400000 80900000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of our deferred tax assets and liabilities at December 31 are</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credit carryforwards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension and deferred compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax (liability) asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 21900000 18400000 2800000 10500000 25600000 27200000 9200000 11400000 15900000 16000000.0 43600000 51500000 37900000 31300000 6300000 6600000 900000 2000000.0 45100000 39900000 -1500000 11600000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.365%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.227%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. federal corporate tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on international operations other than U.S. tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reversal of prior valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reserves for unrecognized tax benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. tax on international earnings, net of foreign tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State income taxes, net of federal tax effect</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Excess tax benefits on share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impact of 2017 Tax Act</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Venezuela deconsolidation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other business credits and Section 199 Deduction</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div> 0.210 0.210 0.350 0.027 0.048 -0.045 0 0 -0.005 0.004 0.002 -0.002 0.004 0.002 0.001 0.014 0.023 0.002 0.010 0.009 0.008 -0.035 -0.060 0.141 0 -0.029 0.159 -0.002 -0.013 0.044 0 0 0.017 0 0 -0.006 -0.010 0.002 -0.002 0.202 0.172 0.364 -300000 -10300000 -2500000 -14300000 48800000 -33100000 0.350 0.210 27900000 11400000 7500000 4000000.0 20400000 27900000 -0.0145 226900000 15500000 49400000 6400000 15400000 211500000 48700000 49400000 2000000.0 500000 500000 1000000.0 214200000 Commitments and Contingencies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, we were obligated under various operating lease agreements. Please refer to Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, we were obligated under various defined benefit pension plans in the U.S. and other countries that cover employees who meet eligibility requirements. Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Benefit Plans</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $249.1 million, of which $61.3 million is due to be paid in 2020.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have letters of credit totaling $2.5 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $3.2 million at December 31, 2019, of which $0.9 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our SmartDose contingent consideration is payable to the selling shareholders based upon a percentage of product sales over the life of the underlying product patent, with no cap on total payments. Given the length of the earnout period and the uncertainty in forecasted product sales, we do not believe it is meaningful to estimate the upper end of the range over the entire period. However, our estimated probable range which could become payable over the next <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA0YWYxYWQ0NTY5ZDQ5YWE5N2ViODNjY2Q1N2IwNmQ3L3NlYzowNGFmMWFkNDU2OWQ0OWFhOTdlYjgzY2NkNTdiMDZkN18xNTEvZnJhZzo2MWY3M2NlNjZlYzY0ZjQ4OTZhMTE5NTc1ZjMwNTI2Ni90ZXh0cmVnaW9uOjYxZjczY2U2NmVjNjRmNDg5NmExMTk1NzVmMzA1MjY2XzExOTk_3f334523-3b30-4be6-b24a-5b3930387693">five</span> years is between zero and $3.7 million.</span></div> 249100000 61300000 2500000 3200000 900000 0 3700000 Segment Information<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,236.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intersegment sales elimination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any customers accounting for greater than 10% of consolidated net sales.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents net sales and property, plant and equipment, net, by the country in which the legal subsidiary is domiciled and assets are located:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:23.801%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.704%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Sales</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, Plant and Equipment, Net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">814.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">315.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">323.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Germany</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other European countries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">230.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">213.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">839.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">822.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">855.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables provide summarized financial information for our segments:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.980%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.908%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate/ Elimination/ Unallocated Items</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating expense (income)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">291.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,480.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">386.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,341.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,978.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,236.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">222.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,321.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr></table></div> 2 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:51.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.907%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,236.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intersegment sales elimination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1398600000 1308600000 1236900000 441500000 409100000 362500000 -200000 -300000 -300000 1839900000 1717400000 1599100000 10 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents net sales and property, plant and equipment, net, by the country in which the legal subsidiary is domiciled and assets are located:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:23.801%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.698%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.704%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Sales</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, Plant and Equipment, Net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">814.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">734.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">315.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">323.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Germany</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">226.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ireland</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">162.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">165.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other European countries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">251.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">230.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">213.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">201.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">839.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">822.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">855.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 814700000 766100000 734600000 337100000 315300000 323800000 236300000 235900000 226400000 95400000 99300000 108800000 173800000 138100000 100500000 162000000.0 165400000 173200000 150600000 145000000.0 142600000 53300000 50100000 51600000 251100000 230500000 201000000.0 59100000 59500000 63200000 213400000 201800000 194000000.0 132400000 132400000 134400000 1839900000 1717400000 1599100000 839300000 822000000.0 855000000.0 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables provide summarized financial information for our segments:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.980%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.908%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate/ Elimination/ Unallocated Items</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">441.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,839.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating expense (income)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">291.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,480.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">386.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,341.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,717.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">301.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,978.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,236.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">243.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">222.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Segment assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,321.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/></tr></table></div> 1398600000 441500000 -200000 1839900000 313600000 49100000 -66100000 296600000 0 0 8500000 8500000 0 0 3800000 3800000 0 0 -100000 -100000 313600000 49100000 -70900000 291800000 1480600000 386000000.0 474800000 2341400000 91200000 37200000 -2000000.0 126400000 82200000 17900000 3300000 103400000 1308600000 409100000 -300000 1717400000 266400000 44300000 -70400000 240300000 0 0 8400000 8400000 0 0 2100000 2100000 0 0 6700000 6700000 266400000 44300000 -70000000.0 240700000 1342300000 301400000 335200000 1978900000 77000000.0 20700000 7000000.0 104700000 83900000 17200000 3300000 104400000 1236900000 362500000 -300000 1599100000 243800000 48300000 -66300000 225800000 0 0 7800000 7800000 0 0 1300000 1300000 0 0 3100000 3100000 243800000 48300000 -69700000 222400000 1321300000 286400000 255100000 1862800000 107200000 18600000 5000000.0 130800000 77100000 16400000 3200000 96700000 605700000 241700000 545400000 206900000 2.80 2.74 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Schedule II - Valuation and Qualifying Accounts</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.153%;"><tr><td style="width:1.0%;"/><td style="width:42.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance at</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">beginning of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">period</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Charged</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">to costs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">and </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">expenses</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deductions (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance at</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">end of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">period</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset valuation allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowance for doubtful accounts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total allowances deducted from assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the year ended December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset valuation allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowance for doubtful accounts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total allowances deducted from assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the year ended December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset valuation allowance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allowance for doubtful accounts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total allowances deducted from assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:20pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:20pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:20pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:20pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:20pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">__________________________</span></div>(1)Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments. 16000000.0 0 100000 15900000 2000000.0 100000 1600000 500000 18000000.0 100000 1700000 16400000 20900000 -3000000.0 1900000 16000000.0 500000 700000 -800000 2000000.0 21400000 -2300000 1100000 18000000.0 18700000 2500000 300000 20900000 400000 -200000 -300000 500000 19100000 2300000 0 21400000 Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments. (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details. XML 53 R102.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information (Sales and PPE by Geographic Location) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
    Property, plant and equipment, net 839.3 822.0 855.0
    United States [Member]      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 814.7 766.1 734.6
    Property, plant and equipment, net 337.1 315.3 323.8
    Germany [Member]      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 236.3 235.9 226.4
    Property, plant and equipment, net 95.4 99.3 108.8
    France [Member]      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 150.6 145.0 142.6
    Property, plant and equipment, net 53.3 50.1 51.6
    Other European countries [Member]      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 251.1 230.5 201.0
    Property, plant and equipment, net 59.1 59.5 63.2
    Other [Member]      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 213.4 201.8 194.0
    Property, plant and equipment, net 132.4 132.4 134.4
    IRELAND      
    Revenues from External Customers and Long-Lived Assets [Line Items]      
    Net sales 173.8 138.1 100.5
    Property, plant and equipment, net $ 162.0 $ 165.4 $ 173.2
    XML 54 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurements (Fair Value of Assets and Liabilities) (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Assets:    
    Deferred compensation assets $ 11.3 $ 8.7
    Foreign currency contracts 7.7 6.5
    Commodity call options 0.1  
    Total assets at fair value 19.1 15.2
    Liabilities:    
    Contingent consideration 3.3 1.7
    Deferred compensation liabilities 12.8 9.8
    Foreign currency contracts 0.3 0.2
    Total liabilities at fair value 17.8 11.7
    Currency Swap    
    Liabilities:    
    Foreign currency contracts 1.4  
    Level 1 [Member]    
    Assets:    
    Deferred compensation assets 11.3 8.7
    Total assets at fair value 11.3 8.7
    Liabilities:    
    Deferred compensation liabilities 12.8 9.8
    Total liabilities at fair value 12.8 9.8
    Level 2 [Member]    
    Assets:    
    Foreign currency contracts 7.7 6.5
    Commodity call options 0.1  
    Total assets at fair value 7.8 6.5
    Liabilities:    
    Foreign currency contracts 0.3 0.2
    Total liabilities at fair value 1.7 0.2
    Level 2 [Member] | Currency Swap    
    Liabilities:    
    Foreign currency contracts 1.4  
    Level 3 [Member]    
    Liabilities:    
    Contingent consideration 3.3 1.7
    Total liabilities at fair value $ 3.3 $ 1.7
    XML 55 R81.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Textuals) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Defined Benefit Plan Disclosure [Line Items]      
    Fair value of plan assets $ 244.1 $ 214.5  
    Pension curtailment gain 3.5 0.0 $ 0.0
    401 (k) plan contributions 15.6 6.5 $ 5.7
    Accumulated benefit obligation 283.9 263.0  
    Expected contribution to the plan $ 0.7    
    Assumed healthcare cost trend rate, benefit obligation 6.25%    
    Ultimate healthcare cost trend rate, benefit obligation 5.00%    
    Assumed healthcare cost trend rate, net periodic benefit cost 6.25%    
    Ultimate healthcare cost trend rate, net periodic benefit cost 5.00%    
    Defined Benefit Plan, Plan Assets, Contributions by Employer $ 2.6    
    Foreign Plan [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Fair value of plan assets 39.4 33.4  
    Accumulated benefit obligation $ 73.9 $ 64.0  
    Discount rate 1.28% 2.19%  
    Rate of compensation increase 2.49% 2.60%  
    United States [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Discount rate 3.35%    
    Rate of compensation increase 4.25% 4.25%  
    Percentage of global plan assets 83.86%    
    Long-term rate of return on assets 5.60% 7.00% 7.00%
    Pension Plan [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Fair value of plan assets $ 244.1 $ 214.5 $ 239.5
    Actuarial net loss that will be amortized from accumulated other comprehensive loss 1.8    
    Prior service credit that will be amortized from accumulated other comprehensive loss $ 0.1    
    Discount rate 2.79% 3.76%  
    Rate of compensation increase 2.49% 4.01%  
    Long-term rate of return on assets 5.54% 6.71% 6.47%
    Defined Benefit Plan, Plan Assets, Contributions by Employer $ 8.0 $ 2.7  
    Other Postretirement Benefits Plan [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Fair value of plan assets 0.0 $ 0.0 $ 0.0
    Actuarial net loss that will be amortized from accumulated other comprehensive loss 1.6    
    Prior service credit that will be amortized from accumulated other comprehensive loss 0.7    
    Expected contribution to the plan $ 0.7    
    Discount rate 3.20% 4.20%  
    Defined Benefit Plan, Plan Assets, Contributions by Employer $ 0.2 $ 0.1  
    Equity Securities [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Target allocation 30.00% 65.00%  
    Debt Securities [Member]      
    Defined Benefit Plan Disclosure [Line Items]      
    Target allocation 70.00% 35.00%  
    XML 56 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    New Accounting Standards
    		 12 Months Ended
    Dec. 31, 2019
    New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
    New Accounting Pronouncements and Changes in Accounting Principles New Accounting Standards
    Recently Adopted Standards

    In July 2019, the FASB issued guidance which clarifies or improves a variety of ASC disclosure and presentation requirements by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. This guidance was effective upon issuance. The adoption did not have a material impact on our financial statements.

    In June 2018, the FASB issued guidance which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.

    In February 2018, the FASB issued guidance to address a specific consequence of the 2017 Tax Act by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis, but elected to not reclassify from accumulated other comprehensive income (loss) to retained earnings the stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate.

    In August 2017, the FASB issued guidance which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements.

    In February 2016, the FASB issued guidance on the accounting for leases, ASC 842. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. Please refer to Note 6, Leases, for additional information.

    Standards Issued Not Yet Adopted

    In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.

    In April 2019, the FASB issued guidance which clarifies and improves areas of guidance related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of
    this guidance. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

    In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. We believe that the adoption of this guidance will not have a material impact on our financial statements.

    In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

    In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

    In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under current guidance, an entity reflects credit losses on financial assets measured on an amortized cost basis only when it is probable that losses have been incurred, generally considering only past events and current conditions in determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements, primarily as we have not historically had a material amount of accounts receivable write-offs.
    XML 57 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Leases
    		 12 Months Ended
    Dec. 31, 2019
    Leases [Abstract]  
    Leases of Lessee Disclosure Leases
    Adoption of ASC 842

    On January 1, 2019, we adopted ASC 842, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. As a result, we were not required to adjust our comparative period financial information for effects of ASC 842 or present the new required lease disclosures for periods prior to the date of adoption. As of December 31, 2019, we had operating leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2047. Certain of our operating leases include options to extend the lease term for up to five years, and certain of our operating leases include options to terminate the leases within one year. We had no finance leases as of December 31, 2019.

    As a result of our adoption of ASC 842, we recorded operating lease right-of-use assets of $71.0 million and operating lease liabilities of $73.1 million for operating leases where we are the lessee in our consolidated balance sheet as of January 1, 2019. The operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct
    costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.

    Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our operating leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our operating leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

    The components of lease expense were as follows:

    ($ in millions)2019
    Operating lease cost$12.9  
    Short-term lease cost0.8  
    Variable lease cost3.3  
    Total lease cost$17.0  

    Lease expense for 2018 and 2017 was $14.5 million and $13.3 million, respectively.

    Supplemental information related to leases was as follows:

    ($ in millions)2019
    Cash paid for amounts included in the measurement of lease liabilities:
    Operating cash flows from operating leases$12.5  
    Right-of-use assets obtained in exchange for new operating lease liabilities9.1  

    As of December 31, 2019, the weighted average remaining lease term for operating leases was 11.7 years and the weighted average discount rate was 3.76%.
    Maturities of lease liabilities as of December 31, 2019 were as follows:

    ($ in millions)Operating
    YearLeases
    2020$12.1  
    202110.4  
    20228.6  
    20237.8  
    20247.3  
    Thereafter41.8  
    88.0  
    Less: imputed lease interest(16.0) 
    Total lease liabilities$72.0  

    Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows:

    ($ in millions)Operating
    YearLeases
    2019$13.0  
    202010.5  
    20217.8  
    20226.9  
    20235.5  
    Thereafter37.8  
    Total$81.5  

    Practical Expedients and Exemptions

    We have elected to adopt the leasing package of practical expedients, which allows us to not retroactively reassess: i) any expired or existing contracts containing leases under the new definition of a lease; ii) the lease classification for any expired or existing leases; and iii) initial direct costs for any expired or existing leases. We have also elected to adopt practical expedients around land easements, the combination of lease and non-lease components, and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases.

    We have elected not to recognize operating lease right-of-use assets and operating lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.
    XML 58 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Debt
    		 12 Months Ended
    Dec. 31, 2019
    Debt Disclosure [Abstract]  
    Debt Debt
    The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2019.

    ($ in millions)20192018
    Note payable, due December 31, 2019$—  $0.1  
    Credit Facility, due October 15, 2020—  28.6  
    Term Loan, due December 31, 2024 (2.78%)90.0  —  
    Series A notes, due July 5, 2022 (3.67%)42.0  42.0  
    Series B notes, due July 5, 2024 (3.82%)53.0  53.0  
    Series C notes, due July 5, 2027 (4.02%)73.0  73.0  
    258.0  196.7  
    Less: unamortized debt issuance costs0.7  0.6  
    Total debt257.3  196.1  
    Less: current portion of long-term debt2.3  0.1  
    Long-term debt, net$255.0  $196.0  

    Credit Agreement - Credit Facility

    In March 2019, we entered into the Credit Agreement that replaced our prior revolving credit facility, which was scheduled to expire in October 2020. The Credit Agreement, which expires in March 2024, contains the Credit Facility of $300.0 million, with sublimits of up to $30.0 million for swing line loans for domestic borrowers in USD and a $20.0 million swing line loan for our German Holding Company and up to $30.0 million for the issuance of standby letters of credit, which Credit Facility may be increased from time-to-time by the greater of $350.0 million and earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the preceding twelve month period in the aggregate through an increase in the Credit Facility, subject to the satisfaction of certain conditions. Borrowings under the Credit Facility bear interest at either the base rate (the per annum interest rate of the highest of the Prime Rate, the Federal Funds Rate plus 50 basis points or the daily LIBOR, plus 1.00%) or at the applicable LIBOR rate, plus a tiered margin based on the ratio of our net consolidated debt to our modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for LIBOR rate loans. The Credit
    Agreement contains financial covenants providing that we shall not permit the ratio of our net consolidated debt to our modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Credit Agreement, upon the occurrence of a qualified acquisition for each of our four fiscal quarters immediately following such qualified acquisition, the ratio shall be increased to 4.0 to 1. The Credit Agreement also contains customary limitations on liens securing our indebtedness, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2019 and 2018, total unamortized debt issuance costs of $1.1 million and $0.6 million, respectively, were recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the Credit Facility. A portion of these costs relate to our prior revolving credit facility.

    At December 31, 2019, we had no outstanding borrowings under the Credit Facility, as we repaid the outstanding long-term borrowings denominated in Euro and Yen in November and December 2019, respectively. There was no material gain or loss on the repayment under the Credit Facility. At December 31, 2019, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.5 million, was $297.5 million. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedges that had been associated with this facility.

    Credit Agreement Amendment - Term Loan

    In December 2019, we entered into a First Amendment and Incremental Facility Amendment (the “First Amendment”) to the Credit Agreement. Pursuant to the First Amendment and the Credit Agreement, we established the Term Loan in the amount of $90.0 million, which is due on December 31, 2024. Borrowings under the Term Loan bear interest at the three-month LIBOR plus 87.5 basis points. As of December 31, 2019, there were unamortized debt issuance costs remaining of $0.2 million, which are being amortized as additional interest expense over the term of the Term Loan.

    At December 31, 2019, we had $90.0 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $87.7 million was classified as long-term. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

    Private Placement

    In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes is 3.87%. As of December 31, 2019 and 2018, there were unamortized debt issuance costs remaining of $0.5 million and $0.6 million, respectively, which are being amortized as additional interest expense over the term of the Notes.

    Covenants

    Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2019, we were in compliance with all of our debt covenants, and we expect to continue to be in compliance with the terms of these agreements throughout 2020.

    Interest costs incurred during 2019, 2018 and 2017 were $9.4 million, $9.3 million and $10.5 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, were as follows:
    $2.3 million in 2020 and 2021, 2022 - $44.3 million, 2023 - $2.3 million, 2024 - $133.8 million, and thereafter - $73.0 million.
    XML 59 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Current Liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Other Current Liabilities [Abstract]  
    Other current liabilities
    ($ in millions)20192018
    Deferred income$27.5  $25.5  
    Dividends payable11.8  11.3  
    Accrued commissions, rebates and royalties9.7  5.7  
    Accrued retirement plans (excluding pension)7.9  2.3  
    Accrued taxes other than income6.5  5.5  
    Accrued professional services5.9  4.9  
    Accrued interest3.3  3.4  
    Restructuring obligations1.5  3.3  
    Other17.2  14.7  
    Total other current liabilities$91.3  $76.6  
    XML 60 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Property, Plant and Equipment (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Property, Plant and Equipment [Abstract]  
    Summary of Property, Plant and Equipment
    A summary of gross property, plant and equipment at December 31 is presented in the following table:

    ($ in millions)Expected useful lives (years)20192018
    Land$22.1  $20.9  
    Buildings and improvements15-35572.9  569.1  
    Machinery and equipment5-12817.0  806.7  
    Molds and dies4-7123.8  115.8  
    Computer hardware and software3-10155.6  151.1  
    Construction in progress128.7  89.1  
    $1,820.1  $1,752.7  
    XML 61 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Statement of Comprehensive Income [Abstract]      
    Net income $ 241.7 $ 206.9 $ 150.7
    Other comprehensive income (loss), net of tax:      
    Foreign currency translation adjustments 4.9 (39.2) 68.8
    Prior service cost arising during period, net of tax of $0 0.0 (0.3) 0.0
    Net actuarial (loss) gain arising during period, net of tax of $(0.3), $(0.2) and $1.3 (1.9) (0.7) 6.3
    Settlement effects arising during period, net of tax of $0.8 2.7 0.0 0.0
    Less: amortization of actuarial (gain) loss, net of tax of $0, $0.3 and $0.5 (0.2) 1.1 3.6
    Less: amortization of prior service credit, net of tax of $(0.1), $(0.5) and $(0.5) (0.5) (1.5) (3.5)
    Net loss on investment securities, net of tax of $0, $(0.1) and $(2.5) 0.0 (0.1) (4.7)
    Net (loss) gain on derivatives, net of tax of $(0.2), $1.5 and $(0.1) (0.4) 3.8 (1.0)
    Other comprehensive income (loss), net of tax 4.6 (36.9) 69.5
    Comprehensive income $ 246.3 $ 170.0 $ 220.2
    XML 62 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED STATEMENT OF EQUITY - USD ($)
    $ in Thousands
    Total
    Common Stock [Member]
    Capital in Excess of Par Value [Member]
    Treasury Stock [Member]
    Retained Earnings [Member]
    Accumulated Other Comprehensive (Loss) Income [Member]
    Balance at Dec. 31, 2016 $ 1,117,500 $ 18,400 $ 260,400 $ (46,100) $ 1,071,600 $ (186,800)
    Balance (in shares) at Dec. 31, 2016   73,700,000   600,000    
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Net income 150,700       150,700  
    Shares issued under stock plans (in shares)   1,500,000   (100,000)    
    Activity related to stock-based compensation 55,900 $ 400 44,100 $ 11,400    
    Shares purchased under share repurchase program (in shares)       800,000    
    Shares purchased under share repurchase program (74,400)     $ (74,400)    
    Dividends declared $ (40,000)       (40,000)  
    Dividends declared per share (in dollars per share) $ 0.54          
    Other adjustments to capital in excess of par value $ 4,800   4,800      
    Other comprehensive income (loss), net of tax 69,500         69,500
    Balance (in shares) at Dec. 31, 2017   75,200,000   1,300,000    
    Balance at Dec. 31, 2017 1,279,900 $ 18,800 309,300 $ (109,100) 1,178,200 (117,300)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Effect of modified retrospective application of new accounting standard (4,100)       (4,100)  
    Net income 206,900       206,900  
    Shares issued under stock plans (in shares)   100,000   (900,000)    
    Activity related to stock-based compensation 48,900 $ 0 (27,300) $ 76,200    
    Shares purchased under share repurchase program (in shares)       800,000    
    Shares purchased under share repurchase program (70,800)     $ (70,800)    
    Dividends declared $ (43,100)       (43,100)  
    Dividends declared per share (in dollars per share) $ 0.58          
    Other comprehensive income (loss), net of tax $ (36,900)         (36,900)
    Balance (in shares) at Dec. 31, 2018   75,300,000   1,200,000    
    Balance at Dec. 31, 2018 1,396,300 $ 18,800 282,000 $ (103,700) 1,353,400 (154,200)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Effect of modified retrospective application of new accounting standard 11,400       11,400  
    Net income 241,700       241,700  
    Shares issued under stock plans (in shares)       (800,000)    
    Activity related to stock-based compensation $ 54,500 $ 0 (11,100) $ 65,600    
    Shares purchased under share repurchase program (in shares) 800,000     800,000    
    Shares purchased under share repurchase program $ (83,100)     $ (83,100)    
    Shares repurchased for employee tax withholdings (in shares)   0        
    Purchase of investment in affiliated companies 4,900   1,800 $ 3,100    
    Dividends declared $ (45,700)       (45,700)  
    Dividends declared per share (in dollars per share) $ 0.62          
    Other comprehensive income (loss), net of tax $ 4,600         4,600
    Balance (in shares) at Dec. 31, 2019   75,300,000   1,200,000    
    Balance at Dec. 31, 2019 $ 1,573,200 $ 18,800 $ 272,700 $ (118,100) $ 1,549,400 $ (149,600)
    XML 63 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation
    		 12 Months Ended
    Dec. 31, 2019
    Share-based Payment Arrangement [Abstract]  
    Stock-Based Compensation Stock-Based Compensation
    The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2019, there were 3,119,314 shares remaining in the 2016 Plan for future grants.

    Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.
    The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:

    ($ in millions)201920182017
    Stock option and appreciation rights$9.1  $8.6  $7.8  
    Performance share units, stock-settled9.5  2.5  4.1  
    Performance share units, cash-settled0.1  —  0.1  
    Performance share units, dividend equivalents0.2  0.1  0.1  
    Employee stock purchase plan0.9  0.9  0.8  
    Deferred compensation plans and restricted share awards4.6  3.0  3.2  
    Total stock-based compensation expense$24.4  $15.1  $16.1  

    The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2019 was approximately $21.2 million, which is expected to be recognized over a weighted average period of 1.6 years.

    Stock Options

    Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.

    The following table summarizes changes in outstanding options:

    (in millions, except per share data)201920182017
    Options outstanding, January 13.0  3.5  4.5  
    Granted0.3  0.5  0.5  
    Exercised(0.6) (1.0) (1.5) 
    Forfeited—  —  —  
    Options outstanding, December 312.7  3.0  3.5  
    Options exercisable, December 311.6  1.7  1.9  

    Weighted Average Exercise Price201920182017
    Options outstanding, January 1$58.93  $48.76  $38.11  
    Granted103.40  90.36  84.09  
    Exercised46.42  35.95  26.15  
    Forfeited92.71  75.32  60.92  
    Options outstanding, December 31$67.02  $58.93  $48.76  
    Options exercisable, December 31$53.12  $45.32  $35.44  

    As of December 31, 2019, the weighted average remaining contractual life of options outstanding and of options exercisable was 6.1 years and 5.0 years, respectively.

    As of December 31, 2019, the aggregate intrinsic value of total options outstanding was $227.8 million, of which $158.6 million represented vested options.

    The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2019, 2018 and 2017: a risk-free interest rate of 2.3%, 2.7%, and 2.0%, respectively; stock volatility of 22.5%, 19.8%, and 19.9%, respectively; and dividend yields of 0.7%, 0.7%, and 0.7%, respectively. Stock volatility is estimated based on historical data and the impact from expected
    future trends. Expected lives, which are based on prior experience, averaged 6 years for 2019, 2018 and 2017. The weighted average grant date fair value of options granted in 2019, 2018 and 2017 was $24.72, $20.16 and $18.08, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.

    For the years ended December 31, 2019, 2018 and 2017, the intrinsic value of options exercised was $46.9 million, $61.3 million and $91.7 million, respectively. The grant date fair value of options vested during those same periods was $7.5 million, $8.3 million and $6.7 million, respectively.

    Stock Appreciation Rights

    Stock appreciation rights (“SARs”) granted to eligible international employees vest in equal annual increments over 4 years of continuous service. All awards expire 10 years from the date of grant. The fair value of each cash-settled SAR is adjusted at the end of each reporting period, with the resulting change reflected in expense. As of December 31, 2019, SARs outstanding were 35,993, of which 23,833 were cash-settled and 12,160 were stock-settled. Upon exercise of a cash-settled SAR, the employee receives cash for the difference between the grant date price and the fair market value of the Company’s stock on the date of exercise. As a result of the cash settlement feature, cash-settled SARs are recorded within other long-term liabilities. Upon exercise of a stock-settled SAR, shares are issued in exchange for the exercise price of the stock-settled SAR. As a result of the stock settlement feature, stock-settled SARs are recorded within equity.

    The following table summarizes changes in outstanding SARs:

    201920182017
    SARs outstanding, January 139,819  51,368  116,087  
    Granted3,364  3,480  2,792  
    Exercised(6,790) (14,629) (67,511) 
    Forfeited(400) (400) —  
    SARs outstanding, December 3135,993  39,819  51,368  
    SARs exercisable, December 3127,781  30,285  39,769  

    Weighted Average Exercise Price201920182017
    SARs outstanding, January 1$46.48  $38.55  $31.13  
    Granted102.51  89.64  83.47  
    Exercised42.08  28.45  27.65  
    Forfeited63.43  63.43  —  
    SARs outstanding, December 31$52.36  $46.48  $38.55  
    SARs exercisable, December 31$40.73  $36.91  $30.77  

    Performance Awards

    In addition to stock options and SAR awards, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.
    The following table summarizes changes in our outstanding stock-settled PSU awards:

    201920182017
    Non-vested stock-settled PSU awards, January 1296,037  341,944  378,062  
    Granted at target level84,309  102,307  92,045  
    Adjustments above/(below) target(50,556) (2,284) (11,369) 
    Vested and converted(48,964) (121,984) (116,684) 
    Forfeited(16,204) (23,946) (110) 
    Non-vested stock-settled PSU awards, December 31264,622  296,037  341,944  
    Weighted Average Grant Date Fair Value201920182017
    Non-vested stock-settled PSU awards, January 1$76.84  $64.38  $54.47  
    Granted at target level103.40  90.45  84.01  
    Adjustments above/(below) target83.89  33.86  42.85  
    Vested and converted102.51  93.00  50.06  
    Forfeited69.09  68.65  73.64  
    Non-vested stock-settled PSU awards, December 31$66.03  $76.84  $64.38  

    Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2019, 2018 and 2017 was $103.40, $90.45 and $84.01, respectively. Including forfeiture and below-target achievement expectations, we expect that the stock-settled PSU awards will convert to 84,670 shares to be issued over an average remaining term of one year.

    The fair value of cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities.

    The following table summarizes changes in our outstanding cash-settled PSU awards:

    201920182017
    Non-vested cash-settled PSU awards, January 11,592  1,972  2,451  
    Granted at target level806  560  598  
    Adjustments above/(below) target(206) (30) (107) 
    Vested and converted(211) (910) (970) 
    Forfeited—  —  —  
    Non-vested cash-settled PSU awards, December 311,981  1,592  1,972  

    Weighted Average Grant Date Fair Value201920182017
    Non-vested cash-settled PSU awards, January 1$79.48  $92.25  $25.28  
    Granted at target level102.51  89.64  83.47  
    Adjustments above/(below) target56.95  41.53  66.61  
    Vested and converted102.51  93.00  86.93  
    Forfeited—  —  —  
    Non-vested cash-settled PSU awards, December 31$150.33  $79.48  $92.25  
    Employee Stock Purchase Plan

    We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 51,391 shares, 55,669 shares and 56,218 shares for the years 2019, 2018 and 2017, respectively. At December 31, 2019, there were approximately 3.8 million shares available for issuance under the ESPP.

    Deferred Compensation Plans and Restricted Share Awards

    Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, deferred stock awards are granted on the date of our annual meeting, and are distributed in shares of common stock. In 2019, we granted 14,579 deferred stock awards, with a grant date fair value of $121.40. Similarly, a non-qualified deferred compensation plan for eligible employees provides for the conversion of compensation into deferred stock units. As of December 31, 2019, the two deferred compensation plans held a total of 366,159 deferred stock units, including 6,274 units to be paid in cash.

    In addition, during 2019, we granted 13,308 restricted share awards at a weighted grant-date fair value of $116.39 per share to employees under the 2016 Plan. During 2018, we granted 15,942 restricted share awards at a weighted grant-date fair value of $96.77 per share to employees under the 2016 Plan. There were no grants of restricted share awards in 2017. The fair value of these awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period.

    Annual Incentive Plan

    Under our annual incentive plan, participants are paid bonuses on the attainment of certain financial goals, which they can elect to receive in either cash or shares of our common stock. If the employee elects payment in shares, they are also given a restricted incentive stock award equal to one share for each four bonus shares issued. The incentive stock awards vest at the end of four years provided that the participant has not made a disqualifying disposition of their bonus shares. Incentive stock award grants were 1,300 shares, 1,500 shares and 1,800 shares in 2019, 2018 and 2017, respectively. There were no incentive stock forfeitures in 2019. Incentive stock forfeitures of 200 shares and 800 shares occurred in 2018 and 2017, respectively. Compensation expense is recognized over the vesting period based on the fair market value of common stock on the award date: $106.14 per share granted in 2019, $93.00 per share granted in 2018 and $86.93 per share granted in 2017.
    XML 64 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2019
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and Contingencies
    At December 31, 2019, we were obligated under various operating lease agreements. Please refer to Note 6, Leases, for additional details.

    At December 31, 2019, we were obligated under various defined benefit pension plans in the U.S. and other countries that cover employees who meet eligibility requirements. Please refer to Note 15, Benefit Plans, for additional details.

    At December 31, 2019, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $249.1 million, of which $61.3 million is due to be paid in 2020.

    We have letters of credit totaling $2.5 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $3.2 million at December 31, 2019, of which $0.9 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.

    Our SmartDose contingent consideration is payable to the selling shareholders based upon a percentage of product sales over the life of the underlying product patent, with no cap on total payments. Given the length of the earnout period and the uncertainty in forecasted product sales, we do not believe it is meaningful to estimate the upper end of the range over the entire period. However, our estimated probable range which could become payable over the next five years is between zero and $3.7 million.
    JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wst-20191231.htm": { "axisCustom": 1, "axisStandard": 37, "contextCount": 460, "dts": { "calculationLink": { "local": [ "wst-20191231_cal.xml" ] }, "definitionLink": { "local": [ "wst-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "wst-20191231.htm" ] }, "labelLink": { "local": [ "wst-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "wst-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "wst-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 992, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 64, "http://www.westpharma.com/20191231": 8, "http://xbrl.sec.gov/dei/2019-01-31": 9, "total": 81 }, "keyCustom": 57, "keyStandard": 596, "memberCustom": 53, "memberStandard": 92, "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.westpharma.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105102 - Disclosure - New Accounting Standards", "role": "http://www.westpharma.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureOfMajorCustomers", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2492455 - Disclosure - Segment Information (Textuals) (Details)", "role": "http://www.westpharma.com/role/SegmentInformationTextualsDetails", "shortName": "Segment Information (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureOfMajorCustomers", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2493456 - Disclosure - Segment Information (Sales by Product Group) (Details)", "role": "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "shortName": "Segment Information (Sales by Product Group) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i078c4378a1b84554a97a59aedf1dfea7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2494457 - Disclosure - Segment Information (Sales and PPE by Geographic Location) (Details)", "role": "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails", "shortName": "Segment Information (Sales and PPE by Geographic Location) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i63ad3b3b7bf848afa7195c490bcbc124_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2495458 - Disclosure - Segment Information (Segment Financial Information) (Details)", "role": "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails", "shortName": "Segment Information (Segment Financial Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i63ad3b3b7bf848afa7195c490bcbc124_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2497459 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)", "role": "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails", "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i68b43b173ce141aebdc6cada18dd16ec_I20161231", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Revenue Revenue", "role": "http://www.westpharma.com/role/RevenueRevenue", "shortName": "Revenue Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - Net Income Per Share", "role": "http://www.westpharma.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Property, Plant and Equipment", "role": "http://www.westpharma.com/role/PropertyPlantandEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Leases", "role": "http://www.westpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128107 - Disclosure - Affiliated Companies", "role": "http://www.westpharma.com/role/AffiliatedCompanies", "shortName": "Affiliated Companies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132108 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137109 - Disclosure - Other Current Liabilities", "role": "http://www.westpharma.com/role/OtherCurrentLiabilities", "shortName": "Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140110 - Disclosure - Debt", "role": "http://www.westpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Derivative Financial Instruments", "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148112 - Disclosure - Fair Value Measurements", "role": "http://www.westpharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153113 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157114 - Disclosure - Stock-Based Compensation", "role": "http://www.westpharma.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164115 - Disclosure - Benefit Plans", "role": "http://www.westpharma.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2174116 - Disclosure - Other Expense", "role": "http://www.westpharma.com/role/OtherExpense", "shortName": "Other Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2180117 - Disclosure - Income Taxes", "role": "http://www.westpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2188118 - Disclosure - Commitments and Contingencies", "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2190119 - Disclosure - Segment Information", "role": "http://www.westpharma.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2196120 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Notes)", "role": "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsNotes", "shortName": "Schedule II - Valuation and Qualifying Accounts (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Revenue Revenue (Tables)", "role": "http://www.westpharma.com/role/RevenueRevenueTables", "shortName": "Revenue Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Leases (Tables)", "role": "http://www.westpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - Affiliated Companies (Tables)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesTables", "shortName": "Affiliated Companies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333307 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338308 - Disclosure - Other Current Liabilities (Tables)", "role": "http://www.westpharma.com/role/OtherCurrentLiabilitiesTables", "shortName": "Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341309 - Disclosure - Debt (Tables)", "role": "http://www.westpharma.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345310 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349311 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354312 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2358313 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.westpharma.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2365314 - Disclosure - Benefit Plans (Tables)", "role": "http://www.westpharma.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2375315 - Disclosure - Other Expense (Tables)", "role": "http://www.westpharma.com/role/OtherExpenseTables", "shortName": "Other Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2381316 - Disclosure - Income Taxes (Tables)", "role": "http://www.westpharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2391317 - Disclosure - Segment Information (Tables)", "role": "http://www.westpharma.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "icbcb7101f4b347c386f48f408e3ef92f_I20190401", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "icbcb7101f4b347c386f48f408e3ef92f_I20190401", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Revenue Adoption of ASC 606 (Details)", "role": "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "shortName": "Revenue Adoption of ASC 606 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i233817b047df4ab4a84d4b14575f9f25_I20180101", "decimals": "-5", "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Revenue Revenue Recognition (Details)", "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "shortName": "Revenue Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "2", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Revenue Contracts Assets and Liabilities (Details)", "role": "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "shortName": "Revenue Contracts Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Revenue Supply Chain Financing (Details)", "role": "http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails", "shortName": "Revenue Supply Chain Financing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i4ecf186e93644ab891c8d431739b0932_D20181001-20181231", "decimals": "-5", "first": true, "lang": null, "name": "wst:ProvisionForProductReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Revenue Voluntary Recall (Details)", "role": "http://www.westpharma.com/role/RevenueVoluntaryRecallDetails", "shortName": "Revenue Voluntary Recall (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i4ecf186e93644ab891c8d431739b0932_D20181001-20181231", "decimals": "-5", "first": true, "lang": null, "name": "wst:ProvisionForProductReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Net Income Per Share (Details)", "role": "http://www.westpharma.com/role/NetIncomePerShareDetails", "shortName": "Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details)", "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "shortName": "Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i0bb40d435fa14466b3b81d438b389a9f_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Property, Plant and Equipment (Textuals) (Details)", "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails", "shortName": "Property, Plant and Equipment (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "0", "lang": null, "name": "us-gaap:CapitalLeasedAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Adoption of ASC 842 (Details)", "role": "http://www.westpharma.com/role/AdoptionofASC842Details", "shortName": "Adoption of ASC 842 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-6", "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Lease Cost (Details)", "role": "http://www.westpharma.com/role/LeaseCostDetails", "shortName": "Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Lease Cash Flow and Supplemental Information (Details)", "role": "http://www.westpharma.com/role/LeaseCashFlowandSupplementalInformationDetails", "shortName": "Lease Cash Flow and Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Lease Weighted Average (Detail)", "role": "http://www.westpharma.com/role/LeaseWeightedAverageDetail", "shortName": "Lease Weighted Average (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - Maturities of Operating Lease Liabilities (Details)", "role": "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails", "shortName": "Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - Affiliated Companies (Details)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "shortName": "Affiliated Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i89cf005616044c5e8e5067ff128a6379_I20191231", "decimals": "2", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Affiliated Companies (Textuals) (Details)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails", "shortName": "Affiliated Companies (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Goodwill and Intangible Assets (Goodwill) (Details)", "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "shortName": "Goodwill and Intangible Assets (Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i63ad3b3b7bf848afa7195c490bcbc124_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfIntangibleAssetsByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details)", "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails", "shortName": "Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfIntangibleAssetsByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Goodwill and Intangible Assets (Textuals) (Details)", "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "shortName": "Goodwill and Intangible Assets (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Other Current Liabilities (Details)", "role": "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails", "shortName": "Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Debt (Details)", "role": "http://www.westpharma.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Debt (Textuals) (Details)", "role": "http://www.westpharma.com/role/DebtTextualsDetails", "shortName": "Debt (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i2d648861366e4cdba756d7642ed7befe_I20191231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeAveragePriceRiskOptionStrikePrice", "reportCount": 1, "unitRef": "usdPerBbl", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Derivative Financial Instruments (Textuals) (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails", "shortName": "Derivative Financial Instruments (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ib8c160a1ee5b40b5815b9d3cfcebe527_I20171122", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeNonmonetaryNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "bbl", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i68b43b173ce141aebdc6cada18dd16ec_I20161231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENT OF EQUITY", "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "shortName": "CONSOLIDATED STATEMENT OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i68b43b173ce141aebdc6cada18dd16ec_I20161231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "shortName": "Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450426 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities) (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails", "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451427 - Disclosure - Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i63ad3b3b7bf848afa7195c490bcbc124_I20171231", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - Fair Value Measurements Other Financial Instruments (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails", "shortName": "Fair Value Measurements Other Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455429 - Disclosure - (Components of AOCI) (Details)", "role": "http://www.westpharma.com/role/ComponentsofAOCIDetails", "shortName": "(Components of AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456430 - Disclosure - (Reclassifications AOCI) (Details)", "role": "http://www.westpharma.com/role/ReclassificationsAOCIDetails", "shortName": "(Reclassifications AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "iebf8f5c36fb64d06aff88d876051dba3_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459431 - Disclosure - Stock-Based Compensation (Textuals) (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails", "shortName": "Stock-Based Compensation (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460432 - Disclosure - Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "shortName": "Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461433 - Disclosure - Stock-Based Compensation (Stock Options Activity) (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "shortName": "Stock-Based Compensation (Stock Options Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "0", "first": true, "lang": null, "name": "wst:CashSettledStockAppreciationRIghtsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462434 - Disclosure - Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "shortName": "Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "0", "first": true, "lang": null, "name": "wst:CashSettledStockAppreciationRIghtsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i5adbbbefb7884a4ea88745c06aca7389_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463435 - Disclosure - Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "shortName": "Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i5adbbbefb7884a4ea88745c06aca7389_D20190101-20191231", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466436 - Disclosure - Benefit Plans (Textuals) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansTextualsDetails", "shortName": "Benefit Plans (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467437 - Disclosure - Benefit Plans (Components of Net Periodic Benefit Cost) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "shortName": "Benefit Plans (Components of Net Periodic Benefit Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i53a206c33aec4f1e911dfdcf66f06346_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468438 - Disclosure - Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "shortName": "Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i53a206c33aec4f1e911dfdcf66f06346_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469439 - Disclosure - Benefit Plans (Amounts Recognized in Balance Sheet) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "shortName": "Benefit Plans (Amounts Recognized in Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i7e79bcd26cba4c48bace4d172cddc5f3_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i7e79bcd26cba4c48bace4d172cddc5f3_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470440 - Disclosure - Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "shortName": "Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i7e79bcd26cba4c48bace4d172cddc5f3_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471441 - Disclosure - Benefit Plans (Expected Benefit Payments) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "shortName": "Benefit Plans (Expected Benefit Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i53a206c33aec4f1e911dfdcf66f06346_D20190101-20191231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472442 - Disclosure - Benefit Plans (Assumptions Used) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "shortName": "Benefit Plans (Assumptions Used) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i53a206c33aec4f1e911dfdcf66f06346_D20190101-20191231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473443 - Disclosure - Benefit Plans (Allocation of Plan Assets) (Details)", "role": "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "shortName": "Benefit Plans (Allocation of Plan Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2476444 - Disclosure - Other Expense (Details)", "role": "http://www.westpharma.com/role/OtherExpenseDetails", "shortName": "Other Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.westpharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2477445 - Disclosure - Other Expense Restructuring and Related Charges (Details)", "role": "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "shortName": "Other Expense Restructuring and Related Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ia67aaad7c305484ead3aad36641a681f_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionLossBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478446 - Disclosure - Other Expense Other Items (Textuals) (Details)", "role": "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails", "shortName": "Other Expense Other Items (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "wst:Developmentandlicensingincome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479447 - Disclosure - Other Expense Development and Licensing Income (Details)", "role": "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails", "shortName": "Other Expense Development and Licensing Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i1e11b27427cd46d590025400238fdb38_D20190101-20191231", "decimals": "-5", "lang": null, "name": "wst:Developmentandlicensingincome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2482448 - Disclosure - Income Taxes (Textuals) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "shortName": "Income Taxes (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "ieecec5a0e59d4a618aff5d091e295a63_I20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483449 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes (Unrecognized Tax Benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2484450 - Disclosure - Income Taxes (Income Before Income Taxes) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails", "shortName": "Income Taxes (Income Before Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2485451 - Disclosure - Income Taxes (Components of Income Tax Expense) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails", "shortName": "Income Taxes (Components of Income Tax Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2486452 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes (Deferred Tax Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2487453 - Disclosure - Income Taxes (Effective Income Tax Reconciliation) (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "shortName": "Income Taxes (Effective Income Tax Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i3fd2ea4a741c4b3f995774bd0d5667c7_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2489454 - Disclosure - Commitments and Contingencies (Textuals) (Details)", "role": "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "shortName": "Commitments and Contingencies (Textuals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20191231.htm", "contextRef": "i710deda8952743be8f828089af9cd00d_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 150, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GERMANY", "terseLabel": "Germany [Member]" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FRANCE", "terseLabel": "France [Member]" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "IRELAND", "terseLabel": "IRELAND" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails", "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_VE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "VENEZUELA", "terseLabel": "VENEZUELA" } } }, "localname": "VE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro Member Countries, Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Japan, Yen", "terseLabel": "Japan, Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Singapore, Dollars", "terseLabel": "Singapore, Dollars" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r656" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r655" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r658" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r657" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r653" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r654" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Non-Employee Directors [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Domain]", "terseLabel": "Equity Method Investee, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r197", "r309", "r314", "r642" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r195", "r309", "r312", "r639", "r640" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Axis]", "terseLabel": "Equity Method Investee, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r145", "r661" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule of Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsNotes" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]", "verboseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r196", "r309", "r313", "r641", "r649", "r651", "r659", "r660" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r275", "r598" ], "lang": { "en-US": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r199", "r593" ], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual with Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r145", "r661" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.", "label": "Accounting Changes and Error Corrections [Text Block]", "verboseLabel": "New Accounting Standards" } } }, "localname": "AccountingChangesAndErrorCorrectionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201609Member": { "auth_ref": [ "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.", "label": "Accounting Standards Update 2016-09 [Member]", "terseLabel": "Accounting Standards Update 2016-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201609Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201707Member": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2017-07 Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.", "label": "Accounting Standards Update 2017-07 [Member]", "terseLabel": "Accounting Standards Update 2017-07 [Member]" } } }, "localname": "AccountingStandardsUpdate201707Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r26", "r200", "r201", "r310" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "auth_ref": [ "r8", "r48", "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrual for Taxes Other than Income Taxes, Current", "terseLabel": "Accrued taxes other than income" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r18", "r608", "r628" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": { "auth_ref": [ "r18", "r20", "r610", "r627" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions.", "label": "Accrued Sales Commission", "terseLabel": "Accrued commissions, rebates and royalties" } } }, "localname": "AccruedSalesCommissionCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r70", "r77", "r80", "r356", "r504" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension and Other Postretirement Plans [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r246" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r65", "r77", "r80", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Losses on Cash Flow Hedges [Member]" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r66", "r67", "r68", "r77", "r80" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains on Investment Securities [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r74", "r76", "r77" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r77", "r80", "r504" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r64", "r77", "r80", "r504" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r121", "r236" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/NewAccountingStandardsDetails", "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares repurchased for employee tax withholdings", "terseLabel": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "negatedTerseLabel": "Other adjustments to capital in excess of par value" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r386", "r419", "r434" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Allowance for Doubtful Accounts Receivable [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r30", "r206", "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r121", "r228", "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r121", "r243" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset-related charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r187", "r606", "r626" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Segment assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r62" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r547" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r133" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Deferred compensation assets" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r388", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r388", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate [Member]" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Business acquisition, transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r120", "r496" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 6.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r495" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration, estimated outcome, high" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r495" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Contingent consideration, estimated outcome, low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r491", "r492", "r494" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Business acquisition, recognized intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r487", "r488" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Business acquisition, recognized inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r487", "r488" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Business acquisition, recognized property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Business acquisition, recognized goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasedAssetsGross": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.", "label": "Capital Leased Assets, Gross", "terseLabel": "Capitalized leases" } } }, "localname": "CapitalLeasedAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r38", "r123" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, including cash equivalents at end of period", "periodStartLabel": "Cash, including cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r124", "r129" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r117", "r561" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r104" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "negatedTerseLabel": "Cash related to deconsolidated Venezuelan subsidiary" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r518" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r274", "r616", "r634" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r273", "r281" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Option contract in which the underlying asset is a commodity.", "label": "Commodity Option [Member]", "terseLabel": "Commodity Call Options [Member]" } } }, "localname": "CommodityOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r296" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $.25 per share; 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million in 2019 and 2018; shares outstanding: 74.1 million and 74.1 million in 2019 and 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r83", "r85", "r499", "r508" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r175", "r176", "r556", "r557" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r175", "r176", "r556", "r557", "r645" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r175", "r176", "r556", "r557", "r645" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r175", "r176", "r556", "r557" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of net sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r175", "r176", "r556", "r557" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r129", "r500", "r509", "r510" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r304", "r306", "r310" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract assets, December 31, 2019", "periodStartLabel": "Contract assets, December 31, 2018" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r304", "r305", "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "negatedPeriodEndLabel": "Deferred income, December 31, 2019", "negatedPeriodStartLabel": "Deferred income, December 31, 2018", "terseLabel": "Contract with customer, liability", "verboseLabel": "Deferred income" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Change in deferred income - (increase) decrease" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r304", "r305", "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred income, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r304", "r305", "r310" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred income, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in the deferred income balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.", "label": "Cost Method Investments", "verboseLabel": "Aggregate carrying amount of investment in affiliated companies that are not accounted for under the equity method" } } }, "localname": "CostMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r95" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 }, "http://www.westpharma.com/role/ReclassificationsAOCIDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedTerseLabel": "Cost of goods and services sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Goods and Services Sold [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Shipping and Handling Costs" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r342", "r533" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract [Member]" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "verboseLabel": "Effect of modified retrospective application of new accounting standard" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r132", "r473", "r479" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r138", "r476" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r473", "r479" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current income tax provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r132", "r473", "r479" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerContractsMember": { "auth_ref": [ "r490" ], "lang": { "en-US": { "role": { "documentation": "Entity's established relationships with its customers through contracts.", "label": "Customer Contracts [Member]", "terseLabel": "Customer Contracts [Member]" } } }, "localname": "CustomerContractsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r490" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.westpharma.com/role/DebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r18", "r19", "r607", "r612", "r623" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r291", "r612", "r623" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.", "label": "Debt Instrument, Description of Variable Rate Basis", "terseLabel": "Debt Instrument, Description of Variable Rate Basis", "verboseLabel": "Variable rate basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r293", "r568" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Annual effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "verboseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r52", "r550" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "verboseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r134", "r297", "r298", "r299", "r300", "r567", "r568", "r570", "r620" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtMember": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Debt [Member]", "terseLabel": "Euro Note B [Member]" } } }, "localname": "DebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r505" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 3.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedTerseLabel": "Venezuela deconsolidation", "terseLabel": "Venezuela deconsolidation" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.", "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liabilities" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.", "label": "Deferred Compensation, Share-based Payments [Member]", "terseLabel": "Deferred Compensation Plans [Member]" } } }, "localname": "DeferredCompensationShareBasedPaymentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r43", "r569" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of any adjustment recognized to the balance of unamortized issuance costs associated with a share-lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing, due, for example, to default by the share borrower.", "label": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNetClassification": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "If not separately presented, identifies the caption on the statement of financial position in which the unamortized balance of recognized deferred issuance costs related to an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing, is included.", "label": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net, Classification", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNetClassification", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r475", "r479" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r132", "r475", "r479" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "totalLabel": "Deferred income tax provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r463", "r609", "r622" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred income" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r467" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax (liability) asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r465" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r446", "r447", "r448", "r449", "r464" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r439", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r439", "r471", "r472" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Operating loss carryforwards, foreign" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r439", "r471", "r472" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Operating loss carryforwards, state and local" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r440", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r469", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r439", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Pension and deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r466" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r446", "r448", "r449" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r440", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r440", "r471", "r472" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Accelerated depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r471" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "terseLabel": "Tax on undistributed earnings of subsidiaries" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r71", "r77" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "totalLabel": "Total" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r77", "r356" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedTerseLabel": "Net actuarial loss (gain)" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r77", "r356" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r334", "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Actuarial (loss) gain", "verboseLabel": "Actuarial (loss) gain" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r351", "r372", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of actuarial loss (gain)" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r352", "r373", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "negatedTerseLabel": "Prior service credit", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfTransitionAssetObligation": { "auth_ref": [ "r353", "r374" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transition asset (obligation) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Transition Asset (Obligation)", "negatedLabel": "Amortization of transition obligation", "terseLabel": "Transition obligation" } } }, "localname": "DefinedBenefitPlanAmortizationOfTransitionAssetObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]", "terseLabel": "Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r15", "r322", "r323", "r339", "r605", "r625" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r360" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Long-term rate of return on assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r324" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "negatedPeriodEndLabel": "Balance", "negatedPeriodStartLabel": "Balance" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r331", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "terseLabel": "Benefits/expenses paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r328" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "negatedTerseLabel": "Participants\u2019 contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r342", "r343", "r362", "r377" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in Benefit Obligation [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in Fair Value of Plan Assets [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r336", "r342", "r343", "r376", "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "negatedTerseLabel": "Employer contribution", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCurtailments": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "verboseLabel": "Curtailment" } } }, "localname": "DefinedBenefitPlanCurtailments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year", "terseLabel": "Actuarial net loss that will be amortized from accumulated other comprehensive loss" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount included in accumulated other comprehensive (income) loss for prior service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year", "terseLabel": "Prior service credit that will be amortized from accumulated other comprehensive loss" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 6.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter", "terseLabel": "2025 to 2029" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 1.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 5.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 4.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 3.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r345" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": 2.0, "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2020" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions expected to be received by defined benefit plan from employer in next fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Expected contribution to the plan" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r350", "r371", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r333", "r342", "r343", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r322", "r339" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status at end of year" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Assumed healthcare cost trend rate, benefit obligation" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r327", "r349", "r370", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "negatedTerseLabel": "Interest cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInvestmentPoliciesAndStrategiesNarrativeDescription": { "auth_ref": [ "r341", "r377" ], "lang": { "en-US": { "role": { "documentation": "Description of investment policy and strategy for defined benefit plan asset. Includes, but is not limited to, investment allocation decision and factor pertinent to understanding investment policy and strategy for plan asset. Factor includes, but is not limited to, investment goal, risk management practice, permitted and prohibited investment including use of derivative, diversification, and relationship between plan asset and obligation.", "label": "Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description", "terseLabel": "Defined Benefit Plan, Plan Assets, Investment Policy and Strategy, Description" } } }, "localname": "DefinedBenefitPlanInvestmentPoliciesAndStrategiesNarrativeDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r347", "r368", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "wst_DefinedBenefitPlanExcessOfNetPeriodicBenefitCostOverOtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "negatedTerseLabel": "Amendments/transfers in" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r338", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits/expenses paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Participants\u2019 contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r341", "r377" ], "lang": { "en-US": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target allocation" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r354", "r375" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Pension curtailment gain", "negatedTerseLabel": "Pension settlement charge", "verboseLabel": "Curtailment" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r354", "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r325", "r348", "r369", "r377" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "negatedTerseLabel": "Service cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Ultimate healthcare cost trend rate, benefit obligation" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "terseLabel": "Weighted average asset allocations" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Weighted average assumptions used in benefit obligations:" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Weighted average assumptions used in net periodic benefit cost:" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r364", "r365", "r366", "r367", "r377" ], "lang": { "en-US": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "verboseLabel": "401 (k) plan contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r121", "r244" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r121", "r184" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The average strike price on the group of price risk option contracts such as put options or call options.", "label": "Derivative, Average Price Risk Option Strike Price", "terseLabel": "Derivative, Average Price Risk Option Strike Price" } } }, "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r526", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "terseLabel": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r522", "r523", "r528", "r535" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument Risk [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r520", "r522", "r528" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r520", "r522", "r528", "r535", "r536", "r540", "r544" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r525", "r534" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Amount of (Gain) Loss Reclassified from Accumulated OCI into Income" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": { "auth_ref": [ "r526", "r543" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.", "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net", "terseLabel": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net" } } }, "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r527", "r529" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNonmonetaryNotionalAmount": { "auth_ref": [ "r514", "r516" ], "lang": { "en-US": { "role": { "documentation": "Nominal number of units used to calculate payment on derivative.", "label": "Derivative, Nonmonetary Notional Amount", "terseLabel": "Derivative, Nonmonetary Notional Amount" } } }, "localname": "DerivativeNonmonetaryNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r514", "r516" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r140", "r513", "r515", "r516", "r520", "r521", "r524", "r528", "r537", "r539", "r544" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r129", "r141", "r513", "r515", "r520", "r521", "r538" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r8", "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends declared, not paid", "verboseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticLineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, inside the reporting entity's home country.", "label": "Domestic Line of Credit [Member]", "terseLabel": "Domestic Line of Credit [Member]" } } }, "localname": "DomesticLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan [Member]" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r139", "r592", "r593", "r594", "r636" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Amount receivable from affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrentAndNoncurrent": { "auth_ref": [ "r139", "r592", "r595", "r615", "r635", "r646" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due to Affiliate", "terseLabel": "Amount due and payable to affiliates" } } }, "localname": "DueToAffiliateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r148", "r153", "r155", "r156", "r157", "r161", "r618", "r638" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r92", "r148", "r153", "r155", "r156", "r157", "r161", "r618", "r638" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r129", "r158", "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r561" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r137", "r451", "r452" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal corporate tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Reversal of prior valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Impact of 2017 Tax Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent", "terseLabel": "Venezuela deconsolidation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Tax on international operations other than U.S. tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Excess tax benefits on share-based payments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 13.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Adjustments to reserves for unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "U.S. tax on international earnings, net of foreign tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes, net of federal tax effect" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r451", "r452", "r478" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "U.S. research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r420" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized compensation expense for all nonvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and benefits [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EnvironmentalCostsPolicy": { "auth_ref": [ "r129", "r252", "r253", "r254", "r255" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for obligations that resulted from improper or other-than normal operation of a long-lived asset in the past. This accounting policy may address (1) whether the related remediation costs are expensed or capitalized, (2) whether the obligation is measured on a discounted basis, (3) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (4) the timing of recognition of any recoveries.", "label": "Environmental Costs, Policy [Policy Text Block]", "terseLabel": "Environmental Remediation and Compliance Costs" } } }, "localname": "EnvironmentalCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.", "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]", "terseLabel": "Type of Deferred Compensation, All Types [Domain]" } } }, "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/ComponentsofAOCIDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r91", "r116", "r121", "r637" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Dividends received from affiliated companies" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r39", "r188", "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r214", "r511" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Affiliated Companies" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r12", "r17", "r209", "r614", "r624", "r648" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r547", "r548", "r549", "r555" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r342", "r343", "r377", "r548", "r599" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r554" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r342", "r343", "r377", "r548", "r600" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r342", "r343", "r377", "r548", "r601" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r342", "r343", "r377", "r548", "r602" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Level 3 Fair Value Measurements [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r551", "r555" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Level 3 Fair Value Measurements" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r552" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Increase (reduction) in fair value recorded in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r551" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r541" ], "lang": { "en-US": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r578", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance Lease" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful life of finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r235" ], "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Estimated annual amortization expense, 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Estimated annual amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Estimated annual amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Estimated annual amortization expense, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Estimated annual amortization expense, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r229", "r231", "r235", "r239", "r604" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation gains (losses)" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r235", "r604" ], "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r229", "r234" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r235" ], "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-lived intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyExchangeRateRemeasurement1": { "auth_ref": [ "r564" ], "lang": { "en-US": { "role": { "documentation": "Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.", "label": "Foreign Currency Exchange Rate, Remeasurement", "terseLabel": "Foreign currency exchange rate, remeasurement" } } }, "localname": "ForeignCurrencyExchangeRateRemeasurement1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r534" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Exchange (Gains) Losses and Other [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainBeforeTax": { "auth_ref": [ "r558", "r559", "r560" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.", "label": "Foreign Currency Transaction Gain, before Tax", "terseLabel": "Foreign Currency Transaction Gain" } } }, "localname": "ForeignCurrencyTransactionGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r558", "r559", "r560" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 4.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Argentina currency devaluation" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r122", "r558", "r559", "r560" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "terseLabel": "Foreign Currency Transaction (Loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionLossBeforeTax": { "auth_ref": [ "r558", "r559", "r560" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 2.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.", "label": "Foreign Currency Transaction Loss, before Tax", "terseLabel": "Venezuela currency devaluation" } } }, "localname": "ForeignCurrencyTransactionLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r129", "r560", "r563" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r342", "r532" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Currency Hedge Contracts [Member]", "verboseLabel": "Foreign Currency Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward [Member]" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignLineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country.", "label": "Foreign Line of Credit [Member]", "terseLabel": "Foreign Line of Credit [Member]" } } }, "localname": "ForeignLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan [Member]" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r530" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r522" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "terseLabel": "Gain (Loss) on Disposition of Assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnOilAndGasHedgingActivity": { "auth_ref": [ "r522" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (loss) incurred in hedging activities.", "label": "Gain (Loss) on Hedging Activity", "terseLabel": "Gain (Loss) on Hedging Activity" } } }, "localname": "GainLossOnOilAndGasHedgingActivity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r121" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on sales of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Gain (Loss) on Sale of Assets and Asset Impairment Charges" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r221", "r222" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill recorded due to acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r225", "r232" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r520", "r536" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r241", "r250" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development (IPR&D) [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails", "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r136" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S. operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r136" ], "calculation": { "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r136" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/ReclassificationsAOCIDetails": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r91", "r121", "r185", "r210", "r617", "r637" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net income of affiliated companies" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "auth_ref": [ "r121" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "negatedTerseLabel": "Equity in undistributed earnings of affiliates, net of dividends" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r186", "r483" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/ReclassificationsAOCIDetails": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Tax expense", "terseLabel": "Income tax expense", "totalLabel": "Income tax expense", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails", "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r86", "r129", "r444", "r445", "r461", "r462", "r468", "r484", "r650" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Other increase (decrease) in deferred income" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvances": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.", "label": "Increase (Decrease) in Customer Advances", "terseLabel": "Customer advance cash payments" } } }, "localname": "IncreaseDecreaseInCustomerAdvances", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets/liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Decrease (increase) in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Changes in other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r154", "r159" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Assumed stock options exercised and awards vested, based on the treasury stock method (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r230", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r230", "r238" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InsuranceClaimsMember": { "auth_ref": [ "r279", "r643" ], "lang": { "en-US": { "role": { "documentation": "A demand for payment of a policy benefit because of the occurrence of an insured event, such as the death or disability of the insured; the maturity of an endowment; the incurrence of hospital or medical bills; the destruction or damage of property and related deaths or injuries; defects in, liens on, or challenges to the title to real estate; or the occurrence of a surety loss; and the costs to process claims.", "label": "Insurance Claims [Member]", "terseLabel": "Insurance Claims [Member]" } } }, "localname": "InsuranceClaimsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r227", "r233" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r566" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest Costs Capitalized", "terseLabel": "Capitalized interest" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r89", "r183", "r565", "r569", "r619" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 }, "http://www.westpharma.com/role/ReclassificationsAOCIDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/ReclassificationsAOCIDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r98", "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r534" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r112", "r118", "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid, net of amounts capitalized" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap Contracts [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Elimination [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Inventory balance for recalled product" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueVoluntaryRecallDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r32", "r220" ], "calculation": { "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r59", "r217" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r60", "r129", "r165", "r218", "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r34", "r220" ], "calculation": { "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r33", "r220" ], "calculation": { "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r97", "r98", "r99" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedTerseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r39" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in affiliated companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r589", "r591" ], "calculation": { "http://www.westpharma.com/role/LeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r589" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r575" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r590" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Operating lease liability payments due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: imputed lease interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r581" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating leases, option to extend" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r581" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r613", "r632" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r547" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r19", "r612", "r623" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Letters of credit supporting the reimbursement of workers' compensation and other claims", "verboseLabel": "Outstanding amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of Credit Facility, unused commitment level" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long [Member]" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r292", "r612", "r630" ], "calculation": { "http://www.westpharma.com/role/DebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Aggregate annual maturities of long-term debt [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Long-term debt, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term Debt, Fair Value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": { "auth_ref": [ "r143" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r143", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.westpharma.com/role/DebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, excluding current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails", "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r53", "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Line of credit, noncurrent" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r288" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Weighted average of the coupon interest rate" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r274" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Accrual for insurance obligations" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyReceivable": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.", "label": "Loss Contingency, Receivable", "terseLabel": "Amount reimbursable by the insurance company" } } }, "localname": "LossContingencyReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r117", "r119", "r122" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r519" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedges [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPrinciplesEarlyAdoptionMember": { "auth_ref": [ "r147", "r149" ], "lang": { "en-US": { "role": { "documentation": "Represents a group of guidance that has been adopted early.", "label": "New Accounting Principles, Early Adoption [Domain]", "terseLabel": "New Accounting Principles, Early Adoption [Domain]" } } }, "localname": "NewAccountingPrinciplesEarlyAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementEarlyAdoptionAxis": { "auth_ref": [ "r147", "r149" ], "lang": { "en-US": { "role": { "documentation": "The financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.", "label": "New Accounting Pronouncement, Early Adoption [Axis]", "terseLabel": "New Accounting Pronouncement, Early Adoption [Axis]" } } }, "localname": "NewAccountingPronouncementEarlyAdoptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/NewAccountingStandardsDetails", "http://www.westpharma.com/role/RevenueAdoptionofASC606Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r147", "r149" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/NewAccountingStandardsDetails", "http://www.westpharma.com/role/RevenueAdoptionofASC606Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotionalAmountOfNonderivativeInstruments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on a nonderivative instrument.", "label": "Notional Amount of Nonderivative Instruments", "terseLabel": "Notional amount, nonderivative instruments" } } }, "localname": "NotionalAmountOfNonderivativeInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTextualsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating profit", "totalLabel": "Operating profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r582", "r591" ], "calculation": { "http://www.westpharma.com/role/LeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r578" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r578" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r578" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r579", "r585" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r577" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r588", "r591" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseWeightedAverageDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r587", "r591" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseWeightedAverageDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r571", "r572" ], "calculation": { "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "verboseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Commodity Call Options [Member]", "verboseLabel": "Commodity Call Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Commodity call options" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r72", "r74", "r355" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "terseLabel": "Prior service credit arising during period" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax": { "auth_ref": [ "r72", "r74", "r355" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "negatedTerseLabel": "Prior service cost arising during period, net of tax of $0" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r69", "r74", "r355" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net actuarial (loss) gain arising during period, net of tax of $(0.3), $(0.2) and $1.3" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax", "terseLabel": "Net actuarial gain (loss) arising during period, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "negatedTerseLabel": "Amortization of prior service credit" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Less: amortization of prior service credit, net of tax of $(0.1), $(0.5) and $(0.5)" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax", "terseLabel": "Less: amortization of prior service credit, tax" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r66", "r67", "r74" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 8.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Net loss on investment securities, net of tax of $0, $(0.1) and $(2.5)" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r66", "r67", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax", "terseLabel": "Net gain (loss) on investment securities, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r77", "r87" ], "calculation": { "http://www.westpharma.com/role/ComponentsofAOCIDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r65" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 9.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Net (loss) gain on derivatives, net of tax of $(0.2), $1.5 and $(0.1)" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax": { "auth_ref": [ "r65", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax", "terseLabel": "Net gain (loss) on derivatives, tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": { "auth_ref": [ "r74", "r78", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax", "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax" } } }, "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": { "auth_ref": [ "r74", "r78", "r355" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax", "negatedTerseLabel": "Curtailment" } } }, "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r63", "r562" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r82", "r85", "r87", "r296" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.westpharma.com/role/ComponentsofAOCIDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r71", "r74" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "wst_DefinedBenefitPlanExcessOfNetPeriodicBenefitCostOverOtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "totalLabel": "Total recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": { "auth_ref": [ "r75", "r499" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax", "terseLabel": "Prior service credit arising during period, tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r69", "r74", "r355" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "negatedTerseLabel": "Net loss (gain) arising during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of actuarial (loss) gain" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "negatedTerseLabel": "Less: amortization of actuarial (gain) loss, net of tax of $0, $0.3 and $0.5" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax", "negatedTerseLabel": "Less: amortization of actuarial loss, tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of transition obligation" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax": { "auth_ref": [ "r74", "r78", "r79", "r355" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 7.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, after Tax", "negatedTerseLabel": "Less: amortization of transition obligation" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r65", "r74", "r545" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Amount of Gain (Loss) Recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r318", "r437" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "Other (Income) Expense" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r450", "r474" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other current and other deferred income tax expense (benefit) attributable to continuing operations.", "label": "Other Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Other Income Tax Expense (Benefit), Continuing Operations" } } }, "localname": "OtherIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r48" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r99" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other nonoperating expense (income)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense)" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 7.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other items" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r321", "r364", "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits Plan [Member]" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitsPayableCurrentAndNoncurrent": { "auth_ref": [ "r611", "r629" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for retirement benefits, classified as other.", "label": "Liability, Other Retirement Benefits", "terseLabel": "Accrued retirement plans (excluding pension)" } } }, "localname": "OtherPostretirementBenefitsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r121", "r256", "r262", "r268" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other charges", "verboseLabel": "Other restructuring charges" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other charges [Member]" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Purchase of investment in affiliated companies, treasury stock" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r48", "r284" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Contingent consideration payments in excess of acquisition-date liability" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r101", "r104", "r142" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r108" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares repurchased under share repurchase program" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r114", "r258" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r110" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r108" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividend payments" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r102", "r493" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Acquisition of business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r102" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "negatedLabel": "Purchase of investment in affiliated companies", "terseLabel": "Purchase in investment in affiliated companies in cash" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r103" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures", "verboseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "verboseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r18", "r322", "r323", "r339" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Current liabilities", "verboseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r322", "r339", "r611", "r629" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "negatedTotalLabel": "Total liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r20", "r322", "r323", "r339" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Noncurrent liabilities", "verboseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r129", "r364", "r379", "r380", "r382", "r383" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Employee Benefits" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r320", "r364", "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan [Member]" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-Vesting Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r388", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding in 2019 and 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r106" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-term Debt", "terseLabel": "Issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r105", "r422" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from stock-based compensation awards" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r106" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under revolving credit agreements" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r105" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Proceeds from Other Equity", "terseLabel": "Employee stock purchase plan contributions" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r107", "r111", "r142" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Contingent consideration payments up to amount of acquisition-date liability" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r81", "r84", "r115", "r187", "r194", "r499", "r501", "r502", "r507", "r508" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/ReclassificationsAOCIDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income, as reported, for basic net income per share" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r247" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r129", "r242" ], "lang": { "en-US": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r245" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r247", "r633" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r129", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r245" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r77", "r80", "r87" ], "calculation": { "http://www.westpharma.com/role/ComponentsofAOCIDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from AOCI" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r190", "r192" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r109", "r135" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayments of Lines of Credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r109" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of Long-term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r438", "r652" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r129", "r438" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r257", "r259", "r266", "r269" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and Related Cost, Expected Cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r257", "r259", "r266", "r269" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 1.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Charges", "totalLabel": "Total restructuring and related charges" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r121", "r256", "r262", "r268" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r258", "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance, December 31, 2018", "periodStartLabel": "Balance, December 31, 2017", "terseLabel": "Restructuring obligations" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r256", "r263" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Non-cash asset write-downs", "terseLabel": "Non-cash restructuring charges" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r301", "r631" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/RevenueAdoptionofASC606Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees": { "auth_ref": [ "r596" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consolidated retained earnings that represent undistributed (not yet received) earnings from 50% or less owned persons accounted for by the equity method (equity method investees).", "label": "Retained Earnings, Undistributed Earnings from Equity Method Investees", "terseLabel": "Unremitted income of affiliated companies" } } }, "localname": "RetainedEarningsUndistributedEarningsFromEquityMethodInvestees", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r365", "r367" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r365", "r367" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r320", "r321", "r364", "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r320", "r321", "r364", "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r130", "r131" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r90", "r181", "r182", "r193" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/ComponentsofAOCIDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails", "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r586", "r591" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Allocation of Share-based Compensation Costs by Plan" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Long-term Debt Obligations , Net of Current Maturities" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r364", "r365", "r366", "r367", "r377" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r522", "r528", "r536" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r140", "r513", "r515", "r516", "r520", "r521", "r524", "r528", "r537", "r539" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Outstanding Foreign Currency Contracts" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconcilliation of Basic to Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Sales by Significant Product Group" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r547", "r548" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r229", "r234" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Components of Income Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r35", "r36", "r37" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Summary of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r147", "r149", "r163", "r164", "r167" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance-based Units Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance-based Share Activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r527", "r529" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r260", "r261", "r265" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r258", "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Obligations" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r93", "r196" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Sales and Net Property, Plant and Equipment, by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r88", "r90", "r196" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r180", "r187", "r189", "r191", "r225" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r180", "r187", "r189", "r191", "r225" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r388", "r421" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Appreciation Rights Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r394", "r407", "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r460", "r477" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureOfMajorCustomers": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of the extent of enterprise reliance on its major customers. For example, includes revenues from transactions with a single external customer amounting to 10 percent or more of the entity's revenues, the total amount of revenues from each such customer, and the identity of the segment or segments reporting the revenues. A group of entities that the entity knows to be under common control generally will be considered a single customer for inclusion in this item. The federal government, a state government, a local government (for example, a county or municipality), or a foreign government each will generally be considered as a single customer for inclusion in this item.", "label": "Segment Reporting, Disclosure of Major Customers", "terseLabel": "Disclosure of major customers" } } }, "localname": "SegmentReportingDisclosureOfMajorCustomers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Items [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r96", "r216" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r121", "r256", "r262", "r268" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance charges", "verboseLabel": "Severance and post-employment benefits" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r120" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r406" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted at target level", "verboseLabel": "Granted at target level" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted at target level" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Non-vested PSU Awards [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending (in USD per share)", "periodStartLabel": "Outstanding, beginning (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Non-vested PSU Awards, Weighted Average Grant Date Fair Value [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Average remaining term of shares issued at conversion" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested and converted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r405" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested and converted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Stock volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Limitation on payroll deductions of employee's base salary, percent" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The highest quantity of shares an employee can purchase under the plan per period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee", "terseLabel": "Maximum number of shares per employee" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedTerseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedTerseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r395", "r397" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "SARs Activity [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant/issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options exercisable (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of total options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r396", "r421" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending", "periodStartLabel": "Options outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options Activity [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, ending (in USD per share)", "periodStartLabel": "Options outstanding, beginning (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Stock Options, Weighted Average Exercise Price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value of total options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r385", "r391" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r129", "r388", "r392" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Awards, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r413", "r433" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life of options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Grant date fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of current market price for sales to eligible employees" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares repurchased for employee tax withholdings (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short [Member]" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r583", "r591" ], "calculation": { "http://www.westpharma.com/role/LeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r454" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Estimated reduction in the liability for unrecognized tax benefits" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r187", "r225", "r249", "r259", "r269", "r639" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r57", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/ComponentsofAOCIDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs) [Member]" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r24", "r25", "r296", "r301" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchases of shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r296", "r301" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares issued under stock plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r296", "r301", "r400" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r57", "r296", "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Purchase of investment in affiliated companies" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r301", "r387", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Share repurchase program, number of shares authorized" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r497", "r498", "r506" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r597" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r597" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]", "terseLabel": "Summary of Investment Holdings [Line Items]" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "auth_ref": [ "r647" ], "lang": { "en-US": { "role": { "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded one percent of net asset value of the registrant as of the close of the period.", "label": "Summary of Investment Holdings [Table]", "terseLabel": "Summary of Investment Holdings [Table]" } } }, "localname": "SummaryOfInvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017DecreaseInDeferredTaxLiabilityDueToTransitionTax": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in deferred tax liability previously recognized attributable to taxable temporary differences from undistributed earnings of foreign subsidiary and other recognized entity now subject to transition tax.", "label": "Tax Cuts and Jobs Act, Decrease in Deferred Tax Liability due to Transition Tax", "terseLabel": "Reduction in Transition Tax, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsAndJobsActOf2017DecreaseInDeferredTaxLiabilityDueToTransitionTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense": { "auth_ref": [ "r480" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for income tax expense for which accounting for tax effect from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Income Tax Expense", "terseLabel": "Provisional Transition Tax, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "terseLabel": "Measurement period adjustment, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate": { "auth_ref": [ "r482" ], "lang": { "en-US": { "role": { "documentation": "Percentage of increase (decrease) in effective tax rate for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Increase (Decrease) in Effective Tax Rate", "negatedTerseLabel": "Net impact to the 2018 effective tax rate, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": { "auth_ref": [ "r476" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "terseLabel": "Transitional Tax, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ToolsDiesAndMoldsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.", "label": "Tools, Dies and Molds [Member]", "terseLabel": "Molds and Dies [Member]" } } }, "localname": "ToolsDiesAndMoldsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r202", "r203", "r204", "r205", "r207", "r208" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r489" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount": { "auth_ref": [ "r603" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before counterparty netting, of cash proceeds received in transfers of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount", "terseLabel": "Transfer of accounts receivable under supply chain financing agreements" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Forward Treasury Locks [Member]" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails", "http://www.westpharma.com/role/ReclassificationsAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Shares purchased under share repurchase program, average cost per share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r56", "r302" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r56", "r302" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r25", "r296", "r301" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares purchased under share repurchase program (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r56", "r302", "r303" ], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost (1.2 million and 1.2 million shares in 2019 and 2018)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r296", "r301", "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Shares purchased under share repurchase program", "terseLabel": "Shares purchased under share repurchase program" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details", "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/NewAccountingStandardsDetails", "http://www.westpharma.com/role/RevenueAdoptionofASC606Details", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt issuance expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r441", "r485", "r621", "r644" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed earnings of foreign subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r443", "r456" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at December 31", "periodStartLabel": "Balance at January 1", "terseLabel": "Total gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails", "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r453" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued liabilities for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase due to current year position" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increase due to prior year position" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Reduction for expiration of statute of limitations/audits" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Outstanding uncondintional contractual commitments due to be paid in 2020" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Unrecorded Unconditional Purchase Obligation [Line Items]", "terseLabel": "Unrecorded Unconditional Purchase Obligation [Line Items]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": { "auth_ref": [ "r270", "r272" ], "lang": { "en-US": { "role": { "documentation": "Describes each unrecorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.", "label": "Unrecorded Unconditional Purchase Obligation [Table]", "terseLabel": "Unrecorded Unconditional Purchase Obligation [Table]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r168", "r169", "r170", "r171", "r177", "r178", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Deferred Tax Asset Valuation Allowance [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to costs and expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r145" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r584", "r591" ], "calculation": { "http://www.westpharma.com/role/LeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/LeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r152", "r157" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r151", "r157" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "wst_A2016RestructuringPlanMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2016 Restructuring Plan [Member] [Member]", "label": "2016 Restructuring Plan [Member] [Member]", "terseLabel": "2016 Restructuring Plan [Member] [Member]" } } }, "localname": "A2016RestructuringPlanMemberMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails", "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_A2018RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Restructuring Plan [Member]", "label": "2018 Restructuring Plan [Member]", "terseLabel": "2018 Restructuring Plan [Member]" } } }, "localname": "A2018RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_AccruedSalariesWagesAndBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Salaries, Wages, and Benefits, Current", "label": "Accrued Salaries, Wages, and Benefits, Current", "terseLabel": "Accrued Salaries, Wages, and Benefits, Current" } } }, "localname": "AccruedSalariesWagesAndBenefitsCurrent", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "wst_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentAndCumulativeChangesInNetGainLossFromCashFlowHedgesEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect", "label": "Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect", "terseLabel": "Equity in unrealized gains (losses) in securities available-for-sale and derivative instruments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentAndCumulativeChangesInNetGainLossFromCashFlowHedgesEffect", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_AluplastSADeCVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aluplast S.A. de C.V. [Member]", "label": "Aluplast S.A. de C.V. [Member]", "terseLabel": "Aluplast S.A. de C.V. [Member]" } } }, "localname": "AluplastSADeCVMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_AssetImpairmentChargesPatent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of patent recognized in the income statement", "label": "Asset Impairment Charges, Patent", "terseLabel": "Asset impairment charges, patent" } } }, "localname": "AssetImpairmentChargesPatent", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_AssetImpairmentChargesPatentandEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of a patent and certain equipment, recognized in the income statement.", "label": "Asset Impairment Charges, Patent and Equipment", "verboseLabel": "Asset impairment charges, patent and equipment" } } }, "localname": "AssetImpairmentChargesPatentandEquipment", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_AssetImpairmentChargesTrademark": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of trademark recognized in the income statement.", "label": "Asset Impairment Charges, Trademark", "terseLabel": "Asset impairment charges, trademark" } } }, "localname": "AssetImpairmentChargesTrademark", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_AssetRelatedChargesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset-Related Charges [Member]", "label": "Asset-Related Charges [Member]", "terseLabel": "Asset-related charges [Member]" } } }, "localname": "AssetRelatedChargesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_AssetsDefinedBenefitPlansNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "order": 3.0, "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent", "label": "Assets, Defined Benefit Plans, Noncurrent", "terseLabel": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansAssetsNoncurrent" } } }, "localname": "AssetsDefinedBenefitPlansNoncurrent", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "wst_AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Award Types Other than Stock Options and Stock Appreciation Rights [Member]", "label": "Award Types Other than Stock Options and Stock Appreciation Rights [Member]", "terseLabel": "Award Types Other than Stock Options and Stock Appreciation Rights [Member]" } } }, "localname": "AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_BalancedMutualFundMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balanced Mutual Fund [Member]", "label": "Balanced Mutual Fund [Member]", "terseLabel": "Balanced Mutual Fund [Member]" } } }, "localname": "BalancedMutualFundMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_BiologicsCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biologics Customers [Member]", "label": "Biologics Customers [Member]", "terseLabel": "Biologics Customers [Member]" } } }, "localname": "BiologicsCustomersMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_CashSettledPSUAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash-settled PSU awards [Member]", "label": "Cash-settled PSU awards [Member]", "terseLabel": "Cash-settled PSU awards [Member]" } } }, "localname": "CashSettledPSUAwardsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_CashSettledStockAppreciationRIghtsOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of cash-settled stock appreciation rights outstanding.", "label": "Cash-Settled Stock Appreciation RIghts, Outstanding", "terseLabel": "Cash-settled SARs, outstanding" } } }, "localname": "CashSettledStockAppreciationRIghtsOutstanding", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "wst_ComputerHardwareAndSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer Hardware and Software [Member]", "label": "Computer Hardware and Software [Member]", "terseLabel": "Computer Hardware and Software [Member]" } } }, "localname": "ComputerHardwareAndSoftwareMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "xbrltype": "domainItemType" }, "wst_ContingentConsiderationArrangementsRangeofOutcomesPayablePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Arrangements, Range of Outcomes, Payable Period", "label": "Contingent Consideration Arrangements, Range of Outcomes, Payable Period", "terseLabel": "Contingent consideration, payable period" } } }, "localname": "ContingentConsiderationArrangementsRangeofOutcomesPayablePeriod", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails" ], "xbrltype": "durationItemType" }, "wst_ContractManufacturedCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract-Manufactured Customers [Member]", "label": "Contract-Manufactured Customers [Member]", "terseLabel": "Contract-Manufactured Customers [Member]" } } }, "localname": "ContractManufacturedCustomersMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractManufacturedProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Manufactured Products [Member]", "label": "Contract Manufactured Products [Member]", "terseLabel": "Contract Manufactured Products [Member]", "verboseLabel": "Contract-Manufactured Products [Member]" } } }, "localname": "ContractManufacturedProductsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "wst_ContractWithCustomerLiabilityIncreaseDecreaseDueToAdditionalCashPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Liability, Increase (Decrease) due to Additional Cash Payments", "label": "Contract with Customer, Liability, Increase (Decrease) due to Additional Cash Payments", "terseLabel": "Cash payments received in advance" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseDueToAdditionalCashPayments", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ContractsandLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts and Liabilities [Abstract]", "label": "Contracts and Liabilities [Abstract]", "terseLabel": "Contracts and Liabilities [Abstract]" } } }, "localname": "ContractsandLiabilitiesAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_ContractwithCustomerAssetIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Asset, Increase (Decrease)", "label": "Contract with Customer, Asset, Increase (Decrease)", "terseLabel": "Change in contract assets - increase (decrease)" } } }, "localname": "ContractwithCustomerAssetIncreaseDecrease", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_CorporateAndEliminationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate headquarter items not allocated to segments and intersegment transactions (e.g. intersegment profits). Reconciliation of the total of reportable segments' amounts of revenues, measures of profits or loss, assets, or amounts for every other significant item of information disclosed, to the consolidated amount.", "label": "Corporate and Eliminations [Member]", "terseLabel": "Corporate and Eliminations [Member]" } } }, "localname": "CorporateAndEliminationsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "wst_CreditAvailableForIssuanceOfLettersOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "this refers to Credit available for the issuance of letters of credit", "label": "Credit available for the issuance of letters of credit", "terseLabel": "Credit available for the issuance of letters of credit" } } }, "localname": "CreditAvailableForIssuanceOfLettersOfCredit", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_CreditFacilityIsAvailableForSwingLineLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This refers to credit facility is available for swing-line loans", "label": "Credit facility is available for swing-line loans", "terseLabel": "Credit Facility is available for swing-line loans" } } }, "localname": "CreditFacilityIsAvailableForSwingLineLoans", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_DaikyoSeikoLtdDaikyoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Daikyo Seiko, Ltd. (Daikyo) [Member]", "label": "Daikyo Seiko, Ltd. (Daikyo) [Member]", "terseLabel": "Daikyo Seiko, Ltd. [Member]" } } }, "localname": "DaikyoSeikoLtdDaikyoMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_DebtYenDenominatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An obligation resulting from borrowing money.", "label": "Debt Yen Denominated [Member]", "verboseLabel": "Debt Yen Denominated [Member]" } } }, "localname": "DebtYenDenominatedMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_DeferredCompensationArrangementWithIndividualNumberOfPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Compensation Arrangement with Individual, Number of Plans", "label": "Deferred Compensation Arrangement with Individual, Number of Plans", "terseLabel": "Number of deferred compensation plans" } } }, "localname": "DeferredCompensationArrangementWithIndividualNumberOfPlans", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "integerItemType" }, "wst_DeferredCompensationArrangementWithIndividualShareEquivalentsBalance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Compensation Arrangement with Individual, Share Equivalents Balance", "label": "Deferred Compensation Arrangement with Individual, Share Equivalents Balance", "terseLabel": "Number of deferred stock units" } } }, "localname": "DeferredCompensationArrangementWithIndividualShareEquivalentsBalance", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "wst_DeferredCompensationArrangementwithIndividualConversionUnit": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Conversion unit of deferred stock units", "label": "Deferred Compensation Arrangement with Individual, Conversion Unit", "terseLabel": "Deferred compensation conversion unit" } } }, "localname": "DeferredCompensationArrangementwithIndividualConversionUnit", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "wst_DeferredFederalStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Federal, State and Local Income Tax Expense (Benefit)", "label": "Deferred Federal, State and Local Income Tax Expense (Benefit)", "terseLabel": "Federal and state" } } }, "localname": "DeferredFederalStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "wst_DeferredStockUnitsPayableinCash": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Stock Units Payable in Cash", "label": "Deferred Stock Units Payable in Cash", "terseLabel": "Number of deferred stock units payable in cash" } } }, "localname": "DeferredStockUnitsPayableinCash", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "wst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringAndImpairmentCharges": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring and Impairment Charges", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring and Impairment Charges", "terseLabel": "Restructuring and impairment charges" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringAndImpairmentCharges", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_DefinedBenefitPlanAssumptionsUsedInCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssetsPercentageOfTotalPlanAssets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Assumptions Used in Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets, Percentage of Total Plan Assets", "label": "Defined Benefit Plan, Assumptions Used in Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets, Percentage of Total Plan Assets", "terseLabel": "Percentage of global plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedInCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssetsPercentageOfTotalPlanAssets", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "wst_DefinedBenefitPlanExcessOfNetPeriodicBenefitCostOverOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income", "label": "Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income", "terseLabel": "Defined Benefit Plan, Excess of Net Periodic Benefit Cost Over Other Comprehensive Income", "totalLabel": "Total recognized in net periodic benefit cost and OCI" } } }, "localname": "DefinedBenefitPlanExcessOfNetPeriodicBenefitCostOverOtherComprehensiveIncome", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "wst_DefinedBenefitPlanExpectedFutureBenefitPayments": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Expected Future Benefit Payments", "label": "Defined Benefit Plan, Expected Future Benefit Payments", "totalLabel": "Total benefit payments expected" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPayments", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "wst_DefinedBenefitPlanHealthCareCostTrendRateAssumedForNextFiscalYearNetPeriodicBenefitCost": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year, Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year, Net Periodic Benefit Cost", "terseLabel": "Assumed healthcare cost trend rate, net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedForNextFiscalYearNetPeriodicBenefitCost", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "wst_DefinedBenefitPlanUltimateHealthCareCostTrendRateNetPeriodicBenefitCost": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Net Periodic Benefit Cost", "terseLabel": "Ultimate healthcare cost trend rate, net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRateNetPeriodicBenefitCost", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTextualsDetails" ], "xbrltype": "percentItemType" }, "wst_DeliveryDevicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Delivery Devices [Member]", "label": "Delivery Devices [Member]", "terseLabel": "Delivery Devices [Member]" } } }, "localname": "DeliveryDevicesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_DerivativeExcludedComponentGainLossRecognizedInEarningsWithinTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings within the next 12 months", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings within Twelve Months", "terseLabel": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings within Twelve Months" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarningsWithinTwelveMonths", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "monetaryItemType" }, "wst_Developmentandlicensingincome": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherExpenseDetails": { "order": 5.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer.", "label": "Development and licensing income", "negatedTerseLabel": "Development and licensing income", "terseLabel": "Development and licensing income" } } }, "localname": "Developmentandlicensingincome", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDetails", "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "wst_DevelopmentandlicensingincomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Development and licensing income [Table]", "label": "Development and licensing income [Line Items]", "terseLabel": "Development and licensing income [Line Items]" } } }, "localname": "DevelopmentandlicensingincomeLineItems", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "wst_DevelopmentandlicensingincomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development and licensing income [Table]", "label": "Development and licensing income [Table]", "terseLabel": "Development and licensing income [Table]" } } }, "localname": "DevelopmentandlicensingincomeTable", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "wst_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Document and Entity Information [Abstract]", "terseLabel": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_EffectiveIncomeTaxRateReconciliationGeneralBusinessCreditsAndSection199Deduction": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, General Business Credits and Section 199 Deduction", "label": "Effective Income Tax Rate Reconciliation, General Business Credits and Section 199 Deduction", "terseLabel": "Other business credits and Section 199 Deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGeneralBusinessCreditsAndSection199Deduction", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "wst_EffectiveIncomeTaxRateReconciliationUndistributedEarningsofSubsidiariesPercentage": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Undistributed Earnings of Subsidiaries, Percentage", "label": "Effective Income Tax Rate Reconciliation, Undistributed Earnings of Subsidiaries, Percentage", "terseLabel": "Tax on undistributed earnings of subsidiaries" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUndistributedEarningsofSubsidiariesPercentage", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "wst_EmployeeStockPurchasePlanEsppMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock Purchase Plan (ESPP) [Member]", "label": "Employee Stock Purchase Plan (ESPP) [Member]", "terseLabel": "Employee Stock Purchase Plan (ESPP) [Member]" } } }, "localname": "EmployeeStockPurchasePlanEsppMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_EuroDenominatedRevolverMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro-Denominated Revolver [Member]", "label": "Euro-Denominated Revolver [Member]", "terseLabel": "Euro-Denominated Revolver [Member]" } } }, "localname": "EuroDenominatedRevolverMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_ExpirationPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration Period [Axis]", "label": "Expiration Period [Axis]", "terseLabel": "Expiration Period [Axis]" } } }, "localname": "ExpirationPeriodAxis", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_ExpirationPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Expiration Period [Axis]", "label": "Expiration Period [Domain]", "terseLabel": "Expiration Period [Domain]" } } }, "localname": "ExpirationPeriodDomain", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_ForeignCurrencyDenominatedDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign currency-denominated debt designated as a hedge of our net investments in foreign operations.", "label": "Foreign Currency, Denominated Debt [Member]", "terseLabel": "Foreign Currency - Denominated Debt [Member]" } } }, "localname": "ForeignCurrencyDenominatedDebtMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "wst_ForwardStartInterestRateSwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward-start interest rate swap", "label": "Forward Start Interest Rate Swap [Member]", "terseLabel": "Forward-Start Interest Rate Swap [Member]" } } }, "localname": "ForwardStartInterestRateSwapMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_ForwardTreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Forward treasury lock [Member]", "terseLabel": "Forward Treasury Lock [Member]" } } }, "localname": "ForwardTreasuryLockMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "wst_GenericsCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Generics Customers [Member]", "label": "Generics Customers [Member]", "terseLabel": "Generics Customers [Member]" } } }, "localname": "GenericsCustomersMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_HighValueComponentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "High-Value Components [Member]", "label": "High-Value Components [Member]", "terseLabel": "High-Value Components [Member]" } } }, "localname": "HighValueComponentsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_IWPharmaGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "I&W Pharma Group LLC", "label": "I&W Pharma Group LLC [Member]", "terseLabel": "I&W Pharma Group LLC" } } }, "localname": "IWPharmaGroupLLCMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_IncentiveStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Stock Awards [Member]", "label": "Incentive Stock Awards [Member]", "terseLabel": "Incentive Stock Awards [Member]", "verboseLabel": "Annual Incentive Plan [Member]" } } }, "localname": "IncentiveStockAwardsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_IndexedMutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indexed Mutual Funds [Member]", "label": "Indexed Mutual Funds [Member]", "terseLabel": "Indexed Mutual Funds [Member]" } } }, "localname": "IndexedMutualFundsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_InternationalMutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International Mutual Funds [Member]", "label": "International Mutual Funds [Member]", "terseLabel": "International Mutual Funds [Member]" } } }, "localname": "InternationalMutualFundsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_LeaseOperatingLeaseTerminateTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "lease, operating lease, terminate term", "label": "Lease, operating lease, terminate term", "terseLabel": "Lease, operating lease, terminate term" } } }, "localname": "LeaseOperatingLeaseTerminateTerm", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AdoptionofASC842Details" ], "xbrltype": "pureItemType" }, "wst_LegalMattersContingenciesAndLegalCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal Matters, Contingencies and Legal Costs [Policy Text Block]", "label": "Legal Matters, Contingencies and Legal Costs [Policy Text Block]", "terseLabel": "Litigation" } } }, "localname": "LegalMattersContingenciesAndLegalCostsPolicyTextBlock", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "lessee, lease Cash Flow and Supplemental information [Table Text Block]", "label": "lessee, lease Cash Flow and Supplemental information [Table Text Block]", "terseLabel": "lessee, lease Cash Flow and Supplemental information" } } }, "localname": "LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "wst_LineofCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Additional borrowing capacity under the credit facility.", "label": "Line of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of Credit Facility, additional borrowing capacity" } } }, "localname": "LineofCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_MutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mutual Funds [Member]", "label": "Mutual Funds [Member]", "terseLabel": "Mutual Funds [Member]" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_NetSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net sales member", "label": "Net Sales [Member]", "terseLabel": "Net Sales [Member]" } } }, "localname": "NetSalesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails" ], "xbrltype": "domainItemType" }, "wst_NotePayableDue2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Note Payable Due 2019 [Member]", "label": "Note Payable Due 2019 [Member]", "terseLabel": "Note Payable Due 2019 [Member]" } } }, "localname": "NotePayableDue2019Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "wst_NotesPayableAndOtherDebtCurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Notes Payable and Other Debt, Current", "label": "Notes Payable and Other Debt, Current", "terseLabel": "Notes payable and other current debt" } } }, "localname": "NotesPayableAndOtherDebtCurrent", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes", "label": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges", "negatedTerseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlansSettlementEffectsArisingDuringPeriodTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax", "terseLabel": "Settlement effects arising during period, tax" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlansSettlementEffectsArisingDuringPeriodTax", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "xbrltype": "monetaryItemType" }, "wst_OtherComprehensiveLossDefinedBenefitPlansSettlementEffectsNetofTax": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The adjustment out of other comprehensive income for settlement effects recognized as a component of net periodic benefit cost during the period, net of tax.", "label": "Other Comprehensive Loss, Defined Benefit Plans Settlement Effects, Net of Tax", "negatedTerseLabel": "Settlement effects arising during period, net of tax of $0.8" } } }, "localname": "OtherComprehensiveLossDefinedBenefitPlansSettlementEffectsNetofTax", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "wst_OtherCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Non-European Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "wst_OtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Current Liabilities [Abstract]", "label": "Other Current Liabilities [Abstract]", "terseLabel": "Other Current Liabilities [Abstract]" } } }, "localname": "OtherCurrentLiabilitiesAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_OtherEuropeCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Europe Countries [Member]", "label": "Other Europe Countries [Member]", "terseLabel": "Other European countries [Member]" } } }, "localname": "OtherEuropeCountriesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "wst_OtherExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Expense (Income) [Abstract]", "label": "Other Expense (Income) [Abstract]", "terseLabel": "Other Expense (Income) [Abstract]" } } }, "localname": "OtherExpenseIncomeAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_OtherFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Financial Instruments [Abstract]", "terseLabel": "Other Financial Instruments [Abstract]" } } }, "localname": "OtherFinancialInstrumentsAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_OtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/OtherExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Income Expense", "negatedTerseLabel": "Other (income) expense", "negatedTotalLabel": "Total other expense", "terseLabel": "Other Income Expense" } } }, "localname": "OtherIncomeExpense", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails", "http://www.westpharma.com/role/OtherExpenseDetails" ], "xbrltype": "monetaryItemType" }, "wst_OtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other [Member]", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails" ], "xbrltype": "domainItemType" }, "wst_OtherSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Securities [Member]", "label": "Other Securities [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherSecuritiesMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_PatentsAndLicensingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patents and Licensing [Member]", "label": "Patents and Licensing [Member]", "terseLabel": "Patents and Licensing [Member]" } } }, "localname": "PatentsAndLicensingMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "wst_PensionPlanAssetsInTheFairValueHierarchyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pension Plan Assets In The Fair Value Hierarchy [Member]", "label": "Pension Plan Assets In The Fair Value Hierarchy [Member]", "terseLabel": "Pension Plan Assets In The Fair Value Hierarchy [Member]" } } }, "localname": "PensionPlanAssetsInTheFairValueHierarchyMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_PensionandOtherPostretirementBenefitExpenseNet": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period); net of cash contributed during the reporting period by the entity to fund its benefit plans.", "label": "Pension and Other Postretirement Benefit Expense, Net", "terseLabel": "Pension and other retirement plans, net" } } }, "localname": "PensionandOtherPostretirementBenefitExpenseNet", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "wst_PensionplanassetsmeasuredatNAVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pension plan assets measured at NAV [Member]", "label": "Pension plan assets measured at NAV [Member]", "terseLabel": "Pension plan assets measured at NAV [Member]" } } }, "localname": "PensionplanassetsmeasuredatNAVMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "wst_PerformanceVestingSharesOrUnitsDividendEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance-vesting Shares or Units Dividend Equivalents [Member]", "label": "Performance-vesting Shares or Units Dividend Equivalents [Member]", "terseLabel": "Performance-vesting Shares or Units Dividend Equivalents [Member]" } } }, "localname": "PerformanceVestingSharesOrUnitsDividendEquivalentsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "xbrltype": "domainItemType" }, "wst_PharmaCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharma Customers [Member]", "label": "Pharma Customers [Member]", "terseLabel": "Pharma Customers [Member]" } } }, "localname": "PharmaCustomersMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_PharmaRubberSADeCVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharma Rubber S.A. de C.V. [Member]", "label": "Pharma Rubber S.A. de C.V. [Member]", "terseLabel": "Pharma Rubber S.A. de C.V. [Member]" } } }, "localname": "PharmaRubberSADeCVMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_PharmaTapSADeCVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharma Tap S.A de C.V. [Member]", "label": "Pharma Tap S.A de C.V. [Member]", "terseLabel": "Pharma Tap S.A de C.V. [Member]" } } }, "localname": "PharmaTapSADeCVMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_ProprietaryProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Proprietary Products [Member]", "label": "Proprietary Products [Member]", "terseLabel": "Proprietary Products [Member]" } } }, "localname": "ProprietaryProductsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "wst_ProvisionForProductReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Provision for Product Returns", "label": "Provision for Product Returns", "terseLabel": "Provision for product returns" } } }, "localname": "ProvisionForProductReturns", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueVoluntaryRecallDetails" ], "xbrltype": "monetaryItemType" }, "wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchases and Royalty Payments from Equity Method Investees", "label": "Purchases and Royalty Payments from Equity Method Investees", "terseLabel": "Purchases and royalty payments made to affiliates" } } }, "localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_RatioOfDebtToEBITDA": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ratio of debt to EBITDA", "label": "Ratio of debt to EBITDA", "terseLabel": "Ratio of debt to EBITDA" } } }, "localname": "RatioOfDebtToEBITDA", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "pureItemType" }, "wst_ReductioninNumberofSharesAvailableforGrantForEachAwardGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reduction in number of shares available for grant for each award granted.", "label": "Reduction in Number of Shares Available for Grant For Each Award Granted", "terseLabel": "Number of shares reduced for each award granted" } } }, "localname": "ReductioninNumberofSharesAvailableforGrantForEachAwardGranted", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "wst_RevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue [Abstract]", "label": "Revenue [Abstract]", "terseLabel": "Revenue [Abstract]" } } }, "localname": "RevenueAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_RevolvingCreditFacilityDue2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving credit facility due on second date.", "label": "Revolving credit facility, due 2017 [Member]", "terseLabel": "Revolving Credit Facility Due 2017 [Member]" } } }, "localname": "RevolvingCreditFacilityDue2017Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "wst_RevolvingCreditFacilityDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving credit facility, due 2024", "label": "Revolving credit facility, due 2024 [Member]", "terseLabel": "Revolving credit facility, due 2024 [Domain]" } } }, "localname": "RevolvingCreditFacilityDue2024Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_Revolvingcreditfacilitydue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving credit facility, due 2020.", "label": "Revolving credit facility, due 2020 [Member]", "terseLabel": "Revolving credit facility, due 2020 [Member]" } } }, "localname": "Revolvingcreditfacilitydue2020Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails", "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_SalesToEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sales to Equity Method Investees", "label": "Sales to Equity Method Investees", "terseLabel": "Sales to affiliates" } } }, "localname": "SalesToEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block]", "label": "Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block]", "terseLabel": "Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "wst_ScheduleOfIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Intangible Assets by Major Class [Table]", "label": "Schedule of Intangible Assets by Major Class [Line Items]", "terseLabel": "Schedule of Intangible Assets by Major Class [Line Items]" } } }, "localname": "ScheduleOfIntangibleAssetsByMajorClassLineItems", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "wst_ScheduleOfIntangibleAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Intangible Assets by Major Class [Table]", "label": "Schedule of Intangible Assets by Major Class [Table]", "terseLabel": "Schedule of Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfIntangibleAssetsByMajorClassTable", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "wst_ScheduleOfIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Intangible Assets by Major Class [Table Text Block]", "label": "Schedule of Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Intangible Assets by Major Class" } } }, "localname": "ScheduleOfIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "wst_ScheduleofOtherIncomeandExpensebyComponentTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Other Income and Expense, by Component [Table Text Block]", "label": "Schedule of Other Income and Expense, by Component [Table Text Block]", "terseLabel": "Schedule of Other Income and Expense" } } }, "localname": "ScheduleofOtherIncomeandExpensebyComponentTableTextBlock", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseTables" ], "xbrltype": "textBlockItemType" }, "wst_SeniorBNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior B Notes Due 2024 [Member]", "label": "Senior B Notes Due 2024 [Member]", "terseLabel": "Senior B Notes Due 2024 [Member]" } } }, "localname": "SeniorBNotesDue2024Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorCNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior C Notes Due 2027 [Member]", "label": "Senior C Notes Due 2027 [Member]", "terseLabel": "Senior C Notes Due 2027 [Member]" } } }, "localname": "SeniorCNotesDue2027Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior A Notes Due 2022 [Member]", "label": "Senior A Notes Due 2022 [Member]", "terseLabel": "Senior A Notes Due 2022 [Member]" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Actual Payout, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Actual Payout, Percentage", "terseLabel": "Actual payout range" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "percentItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTarget": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target", "negatedTerseLabel": "Adjustments above/(below) target" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTarget", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTargetWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value", "terseLabel": "Adjustments above/(below) target" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTargetWeightedAverageGrantDateFairValue", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfSharesIssuableUponVesting": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting", "verboseLabel": "Number of shares to be issued upon conversion" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfSharesIssuableUponVesting", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRateAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount", "terseLabel": "Limitation on payroll deductions of employee's base salary, amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRateAmount", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeePerYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year", "terseLabel": "Maximum number of shares per employee, per year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeePerYear", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "sharesItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures in Period, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Oustanding, ending (in USD per share)", "periodStartLabel": "Oustanding, beginning (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]", "terseLabel": "SARs, Weighted Average Exercise Price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceRollForward", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "stringItemType" }, "wst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercises in Period, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Non-Option Equity Instruments, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "perShareItemType" }, "wst_SmartDoseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SmartDose [Member]", "label": "SmartDose [Member]", "terseLabel": "SmartDose [Member]" } } }, "localname": "SmartDoseMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_StandardPackagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Standard Packaging [Member]", "label": "Standard Packaging [Member]", "terseLabel": "Standard Packaging [Member]" } } }, "localname": "StandardPackagingMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_StockOptionAndAppreciationRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Appreciation Rights [Member]", "label": "Stock Option and Appreciation Rights [Member]", "terseLabel": "Stock Option and Appreciation Rights [Member]" } } }, "localname": "StockOptionAndAppreciationRightsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "xbrltype": "domainItemType" }, "wst_StockSettledPSUAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock-settled PSU awards", "label": "Stock-settled PSU awards [Member]", "terseLabel": "Stock-settled PSU awards [Member]" } } }, "localname": "StockSettledPSUAwardsMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://www.westpharma.com/role/StockBasedCompensationTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_StockSettledStockAppreciationRightsOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of stock-settled stock appreciation rights outstanding.", "label": "Stock-Settled Stock Appreciation Rights, Outstanding", "terseLabel": "Stock-settled SARs, outstanding" } } }, "localname": "StockSettledStockAppreciationRightsOutstanding", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "wst_SupplyChainFinancingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supply Chain Financing [Abstract]", "label": "Supply Chain Financing [Abstract]", "terseLabel": "Supply Chain Financing [Abstract]" } } }, "localname": "SupplyChainFinancingAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense", "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense", "terseLabel": "Discrete tax charge, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpense", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_TaxCutsandJobsActof2017IncompleteAccountingDeferredTaxLiabilityProvisionalIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Deferred Tax Liability, Provisional Income Tax Expense", "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Deferred Tax Liability, Provisional Income Tax Expense", "terseLabel": "Provisional tax charge, Tax Cuts and Jobs Act of 2017" } } }, "localname": "TaxCutsandJobsActof2017IncompleteAccountingDeferredTaxLiabilityProvisionalIncomeTaxExpense", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTextualsDetails" ], "xbrltype": "monetaryItemType" }, "wst_TermLoanDue2024Domain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Due 2024 [Member]", "label": "Term Loan Due 2024 [Domain]", "terseLabel": "Term Loan Due 2024 [Domain]" } } }, "localname": "TermLoanDue2024Domain", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "wst_TermLoanDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Due 2024", "label": "Term Loan Due 2024 [Member]", "terseLabel": "Term Loan Due 2024 [Member]" } } }, "localname": "TermLoanDue2024Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/DebtDetails", "http://www.westpharma.com/role/DebtTextualsDetails" ], "xbrltype": "domainItemType" }, "wst_VoluntaryRecallAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Voluntary Recall [Abstract]", "label": "Voluntary Recall [Abstract]", "terseLabel": "Voluntary Recall [Abstract]" } } }, "localname": "VoluntaryRecallAbstract", "nsuri": "http://www.westpharma.com/20191231", "xbrltype": "stringItemType" }, "wst_WeightedAverageSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Weighted average shares outstanding: [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageSharesOutstandingAbstract", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "wst_WestCompanyMexicoSADeCVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The West Company Mexico, S.A. de C.V. [Member]", "label": "The West Company Mexico, S.A. de C.V. [Member]", "terseLabel": "The West Company Mexico, S.A. de C.V. [Member]" } } }, "localname": "WestCompanyMexicoSADeCVMember", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year 2019 [Member]", "label": "Year 2019 [Member]", "terseLabel": "Year 2018 [Member]" } } }, "localname": "Year2019Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2020 [Member]", "label": "Year 2020 [Member]", "terseLabel": "Year 2020 [Member]" } } }, "localname": "Year2020Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2022 [Member]", "label": "Year 2022 [Member]", "terseLabel": "Year 2022 [Member]" } } }, "localname": "Year2022Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year 2023 [Member]", "label": "Year 2023 [Member]", "terseLabel": "Year 2023 [Member]" } } }, "localname": "Year2023Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2037Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year 2037 [Member]", "label": "Year 2037 [Member]", "terseLabel": "Year 2037 [Member]" } } }, "localname": "Year2037Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2038Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year 2038 [Member]", "label": "Year 2038 [Member]", "terseLabel": "Year 2038 [Member]" } } }, "localname": "Year2038Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_Year2039Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year 2039 [Member]", "label": "Year 2039 [Member]", "terseLabel": "Year 2039 [Member]" } } }, "localname": "Year2039Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_YearAfter2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Year After 2019 [Member]", "label": "Year After 2019 [Member]", "terseLabel": "Year After 2018 [Member]" } } }, "localname": "YearAfter2019Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "wst_YearAfter2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "After 2023 [Member]", "label": "Year After 2023 [Member]", "terseLabel": "Year After 2023 [Member]" } } }, "localname": "YearAfter2023Member", "nsuri": "http://www.westpharma.com/20191231", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13185-110859" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13231-110859" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6571209&loc=d3e13669-110860" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/subtopic&trid=2175709" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25287-109308" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7656903&loc=SL6757479-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7656903&loc=SL6757497-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(s)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118136717&loc=SL108413206-114923" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28200-109314" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31928-109318" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(b))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(f))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(g))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-04)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355119-122828" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117415099&loc=d3e34841-113949" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=118875152&loc=SL5864739-113975" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061172-113977" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1),(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r546": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45014-112735" }, "r575": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=6918054&loc=d3e56071-112765" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=6462270&loc=d3e57205-112772" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "40", "Subparagraph": "(SAB Topic 5.W)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r653": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r654": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r655": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r656": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r657": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r658": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r659": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r660": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r661": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 66 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Apr. 01, 2019
    Dec. 31, 2018
    Accounting Policies [Abstract]      
    Business acquisition, transaction costs   $ 18.9  
    Business acquisition, recognized inventory   4.5  
    Business acquisition, recognized property, plant, and equipment   0.6  
    Business acquisition, recognized goodwill   2.6  
    Business acquisition, recognized intangible assets   $ 11.2  
    Allowance for doubtful accounts $ 0.5   $ 2.0
    Raw materials 100.9   90.4
    Work in process 37.4   42.2
    Finished goods 97.4   81.9
    Total inventories $ 235.7   $ 214.5
    Minimum [Member]      
    Finite-Lived Intangible Assets [Line Items]      
    Estimated useful life of finite-lived intangible assets 5 years    
    Maximum [Member]      
    Finite-Lived Intangible Assets [Line Items]      
    Estimated useful life of finite-lived intangible assets 25 years    
    XML 67 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Retirement Benefits [Abstract]  
    Schedule of Components of Net Periodic Benefit Cost
    The components of net periodic benefit cost and other amounts recognized in OCI were as follows:

    Pension benefitsOther retirement benefits
    ($ in millions)201920182017201920182017
    Net periodic benefit cost:
    Service cost$1.4  $10.8  $10.4  $—  $—  $—  
    Interest cost9.2  9.4  9.8  0.2  0.2  0.3  
    Expected return on assets(12.0) (15.7) (13.5) —  —  —  
    Amortization of prior service credit0.1  (1.3) (1.3) (0.7) (0.7) (0.7) 
    Amortization of actuarial loss (gain)2.1  3.8  4.9  (2.3) (2.4) (2.6) 
    Settlement effects3.5  —  —  —  —  —  
    Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
    Net loss (gain) arising during period$1.5  $3.5  $(9.0) $0.1  $(1.4) $(1.1) 
    Prior service credit arising during period—  0.3  —  —  —  —  
    Amortization of prior service credit(0.1) 1.3  1.3  0.7  0.7  0.7  
    Amortization of actuarial (loss) gain(2.1) (3.8) (4.9) 2.3  2.4  2.6  
    Settlement effects(3.5) —  —  —  —  —  
    Foreign currency translation 0.6  (1.2) 2.6  —  —  —  
    Total recognized in OCI$(3.6) $0.1  $(10.0) $3.1  $1.7  $2.2  
    Total recognized in net periodic benefit cost and OCI$0.7  $7.1  $0.3  $0.3  $(1.2) $(0.8) 

    Net periodic benefit cost by geographic location is as follows:

     Pension benefitsOther retirement benefits
    ($ in millions)201920182017201920182017
    U.S. plans$2.4  $4.8  $7.3  $(2.8) $(2.9) $(3.0) 
    International plans1.9  2.2  3.0  —  —  —  
    Net periodic benefit cost$4.3  $7.0  $10.3  $(2.8) $(2.9) $(3.0) 
    Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status
    The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Change in benefit obligation:
    Benefit obligation, January 1$(267.0) $(288.0) $(6.0) $(7.1) 
    Service cost(1.4) (10.8) —  —  
    Interest cost(9.2) (9.4) (0.2) (0.2) 
    Participants’ contributions(0.3) (0.6) (0.7) (0.6) 
    Actuarial (loss) gain(30.8) 20.4  (0.2) 1.4  
    Amendments/transfers in—  (0.3) —  —  
    Benefits/expenses paid6.8  18.0  0.5  0.5  
    Settlement effects15.0  —  —  —  
    Foreign currency translation(1.0) 3.7  —  —  
    Benefit obligation, December 31$(287.9) $(267.0) $(6.6) $(6.0) 
    Change in plan assets:
    Fair value of assets, January 1$214.5  $239.5  $—  $—  
    Actual return on assets41.3  (8.3) —  —  
    Employer contribution8.0  2.7  (0.2) (0.1) 
    Participants’ contributions0.3  0.6  0.7  0.6  
    Benefits/expenses paid(6.3) (18.0) (0.5) (0.5) 
    Settlement effects(15.0) —  —  —  
    Foreign currency translation1.3  (2.0) —  —  
    Fair value of assets, December 31$244.1  $214.5  $—  $—  
    Funded status at end of year$(43.8) $(52.5) $(6.6) $(6.0) 
    Schedule of Amounts Recognized in Balance Sheet
    Amounts recognized in the balance sheet were as follows:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Noncurrent assets$4.3  $—  $—  $—  
    Current liabilities(1.5) (1.6) (0.7) (0.7) 
    Noncurrent liabilities(46.6) (50.9) (5.9) (5.3) 
    $(43.8) $(52.5) $(6.6) $(6.0) 
    Schedule of Amounts Recognized in Other Comprehensive Income (Loss)
    The amounts in accumulated other comprehensive loss, pre-tax, consisted of:

    Pension benefitsOther retirement benefits
    ($ in millions)2019201820192018
    Net actuarial loss (gain)$69.4  $73.0  $(7.0) $(9.4) 
    Prior service cost (credit)0.8  0.9  (1.0) (1.7) 
    Total$70.2  $73.9  $(8.0) $(11.1) 
    Schedule of Expected Benefit Payments
    Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows:

     ($ in millions)Domestic International Total
    2020$21.0  $1.3  $22.3  
    202113.5  1.3  14.8  
    202215.0  2.0  17.0  
    202313.7  1.5  15.2  
    202413.5  1.9  15.4  
    2025 to 202960.5  13.3  73.8  
    $137.2  $21.3  $158.5  
    Schedule of Assumptions Used
    Weighted average assumptions used to determine net periodic benefit cost were as follows:

    Pension benefitsOther retirement benefits
    201920182017201920182017
    Discount rate2.70 %2.91 %3.48 %4.20 %3.45 %3.90 %
    Rate of compensation increase2.41 %4.00 %4.01 %—  —  —  
    Long-term rate of return on assets5.54 %6.71 %6.47 %—  —  —  
    Weighted average assumptions used to determine the benefit obligations were as follows:

    Pension benefitsOther retirement benefits
    2019201820192018
    Discount rate2.79 %3.76 %3.20 %4.20 %
    Rate of compensation increase2.49 %4.01 %—  —  
    Schedule of Allocation of Plan Assets
    The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:

    20192018
    Equity securities33 %23 %
    Debt securities65 %74 %
    Other2 %3 %
    100 %100 %
    The following are the U.S. target asset allocations and acceptable allocation ranges:

    Target allocationAllocation range
    Equity securities30%  27% - 33%  
    Debt securities70%  67% - 73%
    Other—%  0% - 3%

    The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.

    Balance at
    December 31,Basis of Fair Value Measurements
    ($ in millions)2019Level 1Level 2  Level 3
    Cash$2.2  $2.2  $—  $—  
    Equity securities:
    International mutual funds15.5  1.3  14.2  —  
    Fixed income securities:
    Mutual funds21.7  3.8  17.9  —  
    Pension plan assets in the fair value hierarchy$39.4  $7.3  $32.1  $—  
    Pension plan assets measured at NAV204.7  
    Pension plan assets at fair value$244.1  

    Balance at
    December 31,Basis of Fair Value Measurements
    ($ in millions)2018Level 1Level 2Level 3
    Cash$1.7  $1.7  $—  $—  
    Equity securities:
    International mutual funds17.7  17.7  —  —  
    Fixed income securities:
    Mutual funds13.9  13.9  —  —  
    Pension plan assets in the fair value hierarchy$33.3  $33.3  $—  $—  
    Pension plan assets measured at NAV181.2  
    Pension plan assets at fair value$214.5  
    XML 68 R90.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense Restructuring and Related Charges (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Restructuring Cost and Reserve [Line Items]      
    Payments to Acquire Property, Plant, and Equipment $ 126.4 $ 104.7 $ 130.8
    Severance charges 2.6 3.1 0.0
    Other restructuring charges 2.0 3.8 0.0
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2017 3.3    
    Charges 4.9 9.1 0.0
    Non-cash asset write-downs (2.3) (2.2) $ (0.7)
    Balance, December 31, 2018 1.5 3.3  
    Severance and benefits [Member]      
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2017 2.3    
    Charges 2.6    
    Cash payments (3.5)    
    Non-cash asset write-downs 0.0    
    Balance, December 31, 2018 1.4 2.3  
    Asset-related charges [Member]      
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2017 0.0    
    Charges 0.3    
    Cash payments 0.0    
    Non-cash asset write-downs (0.3)    
    Balance, December 31, 2018 0.0 0.0  
    Other charges [Member]      
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2017 0.0    
    Charges 2.0    
    Cash payments 0.0    
    Non-cash asset write-downs (2.0)    
    Balance, December 31, 2018 0.0 0.0  
    2018 Restructuring Plan [Member]      
    Restructuring Cost and Reserve [Line Items]      
    Restructuring Charges 4.9    
    Severance charges 2.6    
    Asset impairment charges, patent and equipment 0.3    
    Other restructuring charges 2.0    
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2017 2.3    
    Charges 4.9    
    Cash payments (3.5)    
    Non-cash asset write-downs (2.3)    
    Balance, December 31, 2018 1.4 $ 2.3  
    2016 Restructuring Plan [Member] [Member]      
    Restructuring Cost and Reserve [Line Items]      
    Restructuring Charges 0.3    
    Restructuring Reserve [Roll Forward]      
    Balance, December 31, 2018 0.1    
    Maximum [Member] | 2018 Restructuring Plan [Member]      
    Restructuring Cost and Reserve [Line Items]      
    Restructuring and Related Cost, Expected Cost $ 16.0    
    XML 69 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Maturities of Operating Lease Liabilities (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Leases [Abstract]    
    2020 $ 12.1  
    2021 10.4  
    2022 8.6  
    2023 7.8  
    2024 7.3  
    Thereafter 41.8  
    Operating lease liability payments due 88.0  
    Less: imputed lease interest 16.0  
    Total lease liabilities $ 72.0  
    2019   $ 13.0
    2020   10.5
    2021   7.8
    2022   6.9
    2023   5.5
    Thereafter   37.8
    Total   $ 81.5
    XML 70 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross $ 78.1 $ 65.2
    Finite-lived intangible assets, accumulated amortization (48.3) (44.9)
    Finite-lived intangible assets, net 29.8 20.3
    Patents and Licensing [Member]    
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross 21.5 19.6
    Finite-lived intangible assets, accumulated amortization (16.0) (15.1)
    Finite-lived intangible assets, net 5.5 4.5
    In-Process Research and Development (IPR&D) [Member]    
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross 3.3 3.3
    Finite-lived intangible assets, accumulated amortization (1.5) (1.2)
    Finite-lived intangible assets, net 1.8 2.1
    Trademarks [Member]    
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross 2.0 2.0
    Finite-lived intangible assets, accumulated amortization (1.8) (1.8)
    Finite-lived intangible assets, net 0.2 0.2
    Customer Relationships [Member]    
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross 40.3 29.3
    Finite-lived intangible assets, accumulated amortization (21.6) (20.0)
    Finite-lived intangible assets, net 18.7 9.3
    Customer Contracts [Member]    
    Schedule of Intangible Assets by Major Class [Line Items]    
    Finite-lived intangible assets, gross 11.0 11.0
    Finite-lived intangible assets, accumulated amortization (7.4) (6.8)
    Finite-lived intangible assets, net $ 3.6 $ 4.2
    XML 71 R94.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Reconciliation of Unrecognized Tax Benefits [Roll Forward]    
    Balance at January 1 $ 3.9 $ 3.2
    Increase due to current year position 1.6 0.8
    Increase due to prior year position 0.0 0.4
    Reduction for expiration of statute of limitations/audits (0.5) (0.5)
    Balance at December 31 $ 5.0 $ 3.9
    XML 73 R98.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Effective Income Tax Reconciliation) (Details)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Income Tax Disclosure [Abstract]      
    U.S. federal corporate tax rate 21.00% 21.00% 35.00%
    Tax on international operations other than U.S. tax rate 2.70% 4.80% (4.50%)
    Reversal of prior valuation allowance 0.00% 0.00% (0.50%)
    Adjustments to reserves for unrecognized tax benefits 0.40% 0.20% (0.20%)
    U.S. tax on international earnings, net of foreign tax credits 0.40% 0.20% 0.10%
    State income taxes, net of federal tax effect 1.40% 2.30% 0.20%
    U.S. research and development credits (1.00%) (0.90%) (0.80%)
    Excess tax benefits on share-based payments (3.50%) (6.00%) 14.10%
    Impact of 2017 Tax Act 0.00% (2.90%) 15.90%
    Tax on undistributed earnings of subsidiaries (0.20%) (1.30%) 4.40%
    Venezuela deconsolidation 0.00% 0.00% 1.70%
    Other business credits and Section 199 Deduction 0.00% 0.00% (0.60%)
    Other (1.00%) 0.20% (0.20%)
    Effective tax rate 20.20% 17.20% 36.40%
    XML 74 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Debt (Textuals) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Line of Credit Facility [Line Items]      
    Long-term debt, excluding current portion $ 255.0 $ 196.0  
    Interest expense 9.4 9.3 $ 10.5
    Aggregate annual maturities of long-term debt [Abstract]      
    2021 2.3    
    2022 44.3    
    2023 2.3    
    2024 133.8    
    Thereafter 73.0    
    Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months $ 2.3    
    Senior A Notes Due 2022 [Member]      
    Line of Credit Facility [Line Items]      
    Debt instrument, maturity date Jul. 05, 2022    
    Debt instrument, stated interest rate 3.67%    
    Senior B Notes Due 2024 [Member]      
    Line of Credit Facility [Line Items]      
    Debt instrument, maturity date Jul. 05, 2024    
    Debt instrument, stated interest rate 3.82%    
    Senior C Notes Due 2027 [Member]      
    Line of Credit Facility [Line Items]      
    Debt instrument, maturity date Jul. 05, 2027    
    Debt instrument, stated interest rate 4.02%    
    Revolving credit facility, due 2020 [Member]      
    Line of Credit Facility [Line Items]      
    Long-term debt, gross   $ 28.6  
    Senior Notes [Member]      
    Line of Credit Facility [Line Items]      
    Debt instrument, face amount $ 168.0    
    Weighted average of the coupon interest rate 3.87%    
    Debt issuance costs 0.5 million 0.6 million  
    Senior Notes [Member] | Senior A Notes Due 2022 [Member]      
    Line of Credit Facility [Line Items]      
    Long-term debt, gross   $ 42.0  
    Debt instrument, face amount $ 42.0    
    Debt instrument, stated interest rate 3.67%    
    Senior Notes [Member] | Senior B Notes Due 2024 [Member]      
    Line of Credit Facility [Line Items]      
    Long-term debt $ 53.0    
    Long-term debt, gross   53.0  
    Debt instrument, face amount $ 53.0    
    Debt instrument, stated interest rate 3.82%    
    Senior Notes [Member] | Senior C Notes Due 2027 [Member]      
    Line of Credit Facility [Line Items]      
    Long-term debt $ 73.0    
    Long-term debt, gross   73.0  
    Debt instrument, face amount $ 73.0    
    Debt instrument, stated interest rate 4.02%    
    Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Line of Credit Facility, current borrowing capacity $ 300.0    
    Line of Credit Facility, additional borrowing capacity 350.0    
    Credit available for the issuance of letters of credit 30.0    
    Line of credit, noncurrent 0.0    
    Line of Credit Facility, unused commitment level 297.5    
    Debt issuance costs 1.1 $ 0.6  
    Term Loan Due 2024 [Member]      
    Line of Credit Facility [Line Items]      
    Long-term debt, current portion 2.3    
    Debt issuance costs 0.2    
    Long-term debt, gross 90.0    
    Debt instrument, face amount $ 90.0    
    Debt instrument, stated interest rate 2.78%    
    Long-term debt, excluding current portion $ 87.7    
    London Interbank Offered Rate (LIBOR) [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 1.00%    
    London Interbank Offered Rate (LIBOR) [Member] | Term Loan Due 2024 [Member]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 87.50%    
    Letter of Credit [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Outstanding amount $ 2.5    
    Domestic Line of Credit [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Credit Facility is available for swing-line loans 30.0    
    Foreign Line of Credit [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Credit Facility is available for swing-line loans $ 20.0    
    Fed Funds Effective Rate Overnight Index Swap Rate [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 50.00%    
    Minimum [Member] | Revolving credit facility, due 2024 [Domain]      
    Aggregate annual maturities of long-term debt [Abstract]      
    Ratio of debt to EBITDA 3.5    
    Minimum [Member] | Base Rate [Member]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 0.00%    
    Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 8750.00%    
    Maximum [Member] | Revolving credit facility, due 2024 [Domain]      
    Aggregate annual maturities of long-term debt [Abstract]      
    Ratio of debt to EBITDA 4.0    
    Maximum [Member] | Base Rate [Member]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 3750.00%    
    Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Revolving credit facility, due 2024 [Domain]      
    Line of Credit Facility [Line Items]      
    Basis spread on variable interest rate 13750.00%    
    XML 75 R87.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Assumptions Used) (Details)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Pension Plan [Member]      
    Weighted average assumptions used in net periodic benefit cost:      
    Discount rate 2.70% 2.91% 3.48%
    Rate of compensation increase 2.41% 4.00% 4.01%
    Long-term rate of return on assets 5.54% 6.71% 6.47%
    Weighted average assumptions used in benefit obligations:      
    Discount rate 2.79% 3.76%  
    Rate of compensation increase 2.49% 4.01%  
    Other Postretirement Benefits Plan [Member]      
    Weighted average assumptions used in net periodic benefit cost:      
    Discount rate 4.20% 3.45% 3.90%
    Weighted average assumptions used in benefit obligations:      
    Discount rate 3.20% 4.20%  
    XML 76 R100.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information (Textuals) (Details)
    		 12 Months Ended
    Dec. 31, 2019
    segment
    Segment Reporting [Abstract]  
    Disclosure of major customers 10
    Number of reportable segments 2
    XML 77 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Weighted average period for recognition 1 year 7 months 6 days    
    Stock compensation expense $ 24.4 $ 15.1 $ 16.1
    Stock Option and Appreciation Rights [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense 9.1 8.6 7.8
    Performance-Vesting Shares [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense 9.5 2.5 4.1
    Cash-settled PSU awards [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense 0.1 0.0 0.1
    Performance-vesting Shares or Units Dividend Equivalents [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense 0.2 0.1 0.1
    Employee Stock Purchase Plan (ESPP) [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense 0.9 0.9 0.8
    Deferred Compensation Plans [Member]      
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
    Stock compensation expense $ 4.6 $ 3.0 $ 3.2
    XML 78 R104.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    Balance at beginning of period $ 18.0 $ 21.4 $ 19.1
    Charged to costs and expenses 0.1 (2.3) 2.3
    Deductions [1] (1.7) (1.1) 0.0
    Balance at end of period 16.4 18.0 21.4
    Deferred Tax Asset Valuation Allowance [Member]      
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    Balance at beginning of period 16.0 20.9 18.7
    Charged to costs and expenses 0.0 (3.0) 2.5
    Deductions [1] (0.1) (1.9) (0.3)
    Balance at end of period 15.9 16.0 20.9
    Allowance for Doubtful Accounts Receivable [Member]      
    SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
    Balance at beginning of period 2.0 0.5 0.4
    Charged to costs and expenses 0.1 0.7 (0.2)
    Deductions [1] (1.6) 0.8 0.3
    Balance at end of period $ 0.5 $ 2.0 $ 0.5
    [1] Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments.
    XML 79 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurements Other Financial Instruments (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Other Financial Instruments [Abstract]    
    Long-term debt $ 255.0 $ 196.0
    Long-term Debt, Fair Value $ 263.3 $ 192.6
    XML 80 R83.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Change in Fair Value of Plan Assets [Roll Forward]      
    Balance $ 214.5    
    Employer contribution (2.6)    
    Balance 244.1 $ 214.5  
    Pension Plan [Member]      
    Change in Benefit Obligation [Roll Forward]      
    Balance (267.0) (288.0)  
    Service cost (1.4) (10.8) $ (10.4)
    Interest cost (9.2) (9.4) (9.8)
    Participants’ contributions (0.3) (0.6)  
    Actuarial (loss) gain (30.8) 20.4  
    Amendments/transfers in 0.0 (0.3)  
    Benefits/expenses paid 6.8 18.0  
    Foreign currency translation (1.0) 3.7  
    Balance (287.9) (267.0) (288.0)
    Change in Fair Value of Plan Assets [Roll Forward]      
    Balance 214.5 239.5  
    Actual return on assets 41.3 (8.3)  
    Employer contribution (8.0) (2.7)  
    Participants’ contributions 0.3 0.6  
    Benefits/expenses paid (6.3) (18.0)  
    Foreign currency translation 1.3 (2.0)  
    Balance 244.1 214.5 239.5
    Funded status at end of year (43.8) (52.5)  
    Other Postretirement Benefits Plan [Member]      
    Change in Benefit Obligation [Roll Forward]      
    Balance (6.0) (7.1)  
    Service cost 0.0 0.0 0.0
    Interest cost (0.2) (0.2) (0.3)
    Participants’ contributions (0.7) (0.6)  
    Actuarial (loss) gain (0.2) 1.4  
    Amendments/transfers in 0.0 0.0  
    Benefits/expenses paid 0.5 0.5  
    Foreign currency translation 0.0 0.0  
    Balance (6.6) (6.0) (7.1)
    Change in Fair Value of Plan Assets [Roll Forward]      
    Balance 0.0 0.0  
    Actual return on assets 0.0 0.0  
    Employer contribution (0.2) (0.1)  
    Participants’ contributions 0.7 0.6  
    Benefits/expenses paid (0.5) (0.5)  
    Foreign currency translation 0.0 0.0  
    Balance 0.0 0.0 $ 0.0
    Funded status at end of year $ (6.6) $ (6.0)  
    XML 81 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Lease Cash Flow and Supplemental Information (Details)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    Leases [Abstract]  
    Operating cash flows from operating leases $ 12.5
    Right-of-use assets obtained in exchange for new operating lease liabilities $ 9.1
    XML 82 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Contracts Assets and Liabilities (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Jan. 01, 2019
    Dec. 31, 2019
    Contract assets, December 31, 2018 $ 9.1 $ 9.1
    Contract assets, December 31, 2019   9.8
    Change in contract assets - increase (decrease)   0.7
    Deferred income, December 31, 2018 (33.4) (33.4)
    Deferred income, December 31, 2019   (34.9)
    Change in deferred income - (increase) decrease   (1.5)
    Cash payments received in advance   (114.4)
    Revenue recognized that was included in the deferred income balance $ 20.8 110.4
    Other increase (decrease) in deferred income   2.5
    SmartDose [Member]    
    Deferred income, December 31, 2019   (5.6)
    Deferred income, current   0.9
    Deferred income, noncurrent   $ 4.7
    XML 83 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 1,820.1 $ 1,752.7
    Land [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment 22.1 20.9
    Buildings and Improvements [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 572.9 569.1
    Buildings and Improvements [Member] | Minimum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 15  
    Buildings and Improvements [Member] | Maximum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 35  
    Machinery and Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 817.0 806.7
    Machinery and Equipment [Member] | Minimum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 5  
    Machinery and Equipment [Member] | Maximum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 12  
    Molds and Dies [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 123.8 115.8
    Molds and Dies [Member] | Minimum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 4  
    Molds and Dies [Member] | Maximum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 7  
    Computer Hardware and Software [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 155.6 151.1
    Computer Hardware and Software [Member] | Minimum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 3  
    Computer Hardware and Software [Member] | Maximum [Member]    
    Property, Plant and Equipment [Line Items]    
    Estimated useful lives 10  
    Construction in Progress [Member]    
    Property, Plant and Equipment [Line Items]    
    Property, plant and equipment $ 128.7 $ 89.1
    XML 84 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Affiliated Companies (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Equity Method Investments and Joint Ventures [Abstract]  
    Schedule of Equity Method Investments
    At December 31, 2019, the following affiliated companies were accounted for under the equity method:

    LocationOwnership interest
    The West Company Mexico, S.A. de C.V.Mexico49%  
    Aluplast S.A. de C.V.Mexico49%  
    Pharma Tap S.A. de C.V.Mexico49%  
    Pharma Rubber S.A. de C.V.Mexico49%  
    I&W Pharma Group LLCUnited States49%  
    DaikyoJapan49%  
    XML 85 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Revenue (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Revenue [Abstract]  
    Disaggregation of Revenue [Table Text Block]
    The following table presents the approximate percentage of our net sales by market group:

    20192018
    Biologics25 %21 %
    Generics20 %21 %
    Pharma31 %34 %
    Contract-Manufactured Products24 %24 %
    100 %100 %
    The following table presents the approximate percentage of our net sales by product category:

    20192018
    High-Value Components42 %41 %
    Standard Packaging29 %32 %
    Delivery Devices5 %3 %
    Contract-Manufactured Products24 %24 %
    100 %100 %

    The following table presents the approximate percentage of our net sales by geographic location:

    20192018
    Americas48 %48 %
    Europe, Middle East, Africa44 %44 %
    Asia Pacific8 %8 %
    100 %100 %
    Contract with Customer, Asset and Liability [Table Text Block]
    The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:

    ($ in millions)
    Contract assets, December 31, 2018$9.1  
    Contract assets, December 31, 20199.8  
    Change in contract assets - increase (decrease)$0.7  
    Deferred income, December 31, 2018$(33.4) 
    Deferred income, December 31, 2019(34.9) 
    Change in deferred income - (increase) decrease$(1.5) 
    XML 86 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Derivative Financial Instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Outstanding Foreign Currency Contracts As of December 31, 2019, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
    (in millions)Sell
    CurrencyPurchaseUSDEuro
    USD38.4  —  33.6  
    Yen6,550.4  37.8  20.6  
    SGD29.4  16.5  4.6  
    Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and earnings
    The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:

    Amount of Gain Recognized in IncomeLocation on Statement of Income
    ($ in millions)20192018
    Fair Value Hedges:
    Foreign currency hedge contracts$(6.9) $(6.3) Other (income) expense
    Total$(6.9) $(6.3) 
    The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:

     Amount of Gain (Loss) Recognized in OCIAmount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
    ($ in millions)2019201820192018 
    Fair Value Hedges:
    Foreign currency hedge contracts$4.8  $—  $(4.6) $—  Other (income) expense
    Total$4.8  $—  $(4.6) $—  
    Cash Flow Hedges:     
    Foreign currency hedge contracts$0.8  $0.4  $(0.9) $0.6  Net sales
    Foreign currency hedge contracts(0.2) 2.2  (0.6) 0.3  Cost of goods and services sold
    Forward treasury locks—  —  0.3  0.3  Interest expense
    Total$0.6  $2.6  $(1.2) $1.2   
    Net Investment Hedges:     
    Foreign currency-denominated debt$0.6  $0.8  $—  $—  Other (income) expense
    Cross-currency swap(1.1) —  —  —  Other (income) expense
    Total$(0.5) $0.8  $—  $—   
    The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our consolidated statements of income for the years ended December 31:

    ($ in millions)20192018
    Net sales$(0.9) $0.6  
    Cost of goods and services sold(0.6) 0.3  
    Other (income) expense(4.6) —  
    Interest expense0.3  0.3  
    Derivatives Not Designated as Hedging Instruments
    The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:

    Amount of Loss (Gain) Recognized in IncomeLocation on Statement of Income
    ($ in millions)20192018
    Commodity call options$0.4  $(0.1) Cost of goods and services sold
    Total$0.4  $(0.1) 
    XML 87 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Net Income Per Share
    		 12 Months Ended
    Dec. 31, 2019
    Earnings Per Share [Abstract]  
    Net Income Per Share
    Note 4:  Net Income Per Share
    The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

    (in millions)201920182017
    Net income$241.7  $206.9  $150.7  
    Weighted average common shares outstanding74.0  73.9  73.9  
    Dilutive effect of equity awards, based on the treasury stock method
    		1.4  1.5  1.9  
    Weighted average shares assuming dilution75.4  75.4  75.8  

    During 2019, 2018 and 2017, there were 0.1 million, 0.4 million, and 0.4 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive.

    In February 2019, we announced a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares repurchased and the timing of such transactions depended on a variety of factors, including market conditions. During 2019, we purchased 800,000 shares of our common stock under the now-completed program at a cost of $83.1 million, or an average price of $103.89 per share.

    In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated
    transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2020.
    XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 460 653 1 true 150 0 false 11 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.westpharma.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENT OF EQUITY Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTOFEQUITY CONSOLIDATED STATEMENT OF EQUITY Statements 7 false false R8.htm 1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101101 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105102 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 10 false false R11.htm 2107103 - Disclosure - Revenue Revenue Sheet http://www.westpharma.com/role/RevenueRevenue Revenue Revenue Notes 11 false false R12.htm 2114104 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 12 false false R13.htm 2117105 - Disclosure - Property, Plant and Equipment Sheet http://www.westpharma.com/role/PropertyPlantandEquipment Property, Plant and Equipment Notes 13 false false R14.htm 2121106 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 14 false false R15.htm 2128107 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 15 false false R16.htm 2132108 - Disclosure - Goodwill and Intangible Assets Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 2137109 - Disclosure - Other Current Liabilities Sheet http://www.westpharma.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 17 false false R18.htm 2140110 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 18 false false R19.htm 2144111 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 19 false false R20.htm 2148112 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 20 false false R21.htm 2153113 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 21 false false R22.htm 2157114 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 22 false false R23.htm 2164115 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 23 false false R24.htm 2174116 - Disclosure - Other Expense Sheet http://www.westpharma.com/role/OtherExpense Other Expense Notes 24 false false R25.htm 2180117 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 2188118 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 26 false false R27.htm 2190119 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 27 false false R28.htm 2196120 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Notes) Notes http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsNotes Schedule II - Valuation and Qualifying Accounts (Notes) Notes 28 false false R29.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/SummaryofSignificantAccountingPolicies 29 false false R30.htm 2303301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.westpharma.com/role/SummaryofSignificantAccountingPolicies 30 false false R31.htm 2308302 - Disclosure - Revenue Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueRevenueTables Revenue Revenue (Tables) Tables http://www.westpharma.com/role/RevenueRevenue 31 false false R32.htm 2315303 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 32 false false R33.htm 2318304 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.westpharma.com/role/PropertyPlantandEquipment 33 false false R34.htm 2322305 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 34 false false R35.htm 2329306 - Disclosure - Affiliated Companies (Tables) Sheet http://www.westpharma.com/role/AffiliatedCompaniesTables Affiliated Companies (Tables) Tables http://www.westpharma.com/role/AffiliatedCompanies 35 false false R36.htm 2333307 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.westpharma.com/role/GoodwillandIntangibleAssets 36 false false R37.htm 2338308 - Disclosure - Other Current Liabilities (Tables) Sheet http://www.westpharma.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://www.westpharma.com/role/OtherCurrentLiabilities 37 false false R38.htm 2341309 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 38 false false R39.htm 2345310 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 39 false false R40.htm 2349311 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 40 false false R41.htm 2354312 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 41 false false R42.htm 2358313 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.westpharma.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.westpharma.com/role/StockBasedCompensation 42 false false R43.htm 2365314 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 43 false false R44.htm 2375315 - Disclosure - Other Expense (Tables) Sheet http://www.westpharma.com/role/OtherExpenseTables Other Expense (Tables) Tables http://www.westpharma.com/role/OtherExpense 44 false false R45.htm 2381316 - Disclosure - Income Taxes (Tables) Sheet http://www.westpharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.westpharma.com/role/IncomeTaxes 45 false false R46.htm 2391317 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 46 false false R47.htm 2404401 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.westpharma.com/role/SummaryofSignificantAccountingPoliciesTables 47 false false R48.htm 2409403 - Disclosure - Revenue Adoption of ASC 606 (Details) Sheet http://www.westpharma.com/role/RevenueAdoptionofASC606Details Revenue Adoption of ASC 606 (Details) Details 48 false false R49.htm 2410404 - Disclosure - Revenue Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue Revenue Recognition (Details) Details 49 false false R50.htm 2411405 - Disclosure - Revenue Contracts Assets and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails Revenue Contracts Assets and Liabilities (Details) Details 50 false false R51.htm 2412406 - Disclosure - Revenue Supply Chain Financing (Details) Sheet http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails Revenue Supply Chain Financing (Details) Details 51 false false R52.htm 2413407 - Disclosure - Revenue Voluntary Recall (Details) Sheet http://www.westpharma.com/role/RevenueVoluntaryRecallDetails Revenue Voluntary Recall (Details) Details 52 false false R53.htm 2416408 - Disclosure - Net Income Per Share (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Details http://www.westpharma.com/role/NetIncomePerShareTables 53 false false R54.htm 2419409 - Disclosure - Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails Property, Plant and Equipment (Property, Plant and Equipment, Gross) (Details) Details http://www.westpharma.com/role/PropertyPlantandEquipmentTables 54 false false R55.htm 2420410 - Disclosure - Property, Plant and Equipment (Textuals) (Details) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentTextualsDetails Property, Plant and Equipment (Textuals) (Details) Details http://www.westpharma.com/role/PropertyPlantandEquipmentTables 55 false false R56.htm 2423411 - Disclosure - Adoption of ASC 842 (Details) Sheet http://www.westpharma.com/role/AdoptionofASC842Details Adoption of ASC 842 (Details) Details 56 false false R57.htm 2424412 - Disclosure - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeaseCostDetails Lease Cost (Details) Details 57 false false R58.htm 2425413 - Disclosure - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeaseCashFlowandSupplementalInformationDetails Lease Cash Flow and Supplemental Information (Details) Details 58 false false R59.htm 2426414 - Disclosure - Lease Weighted Average (Detail) Sheet http://www.westpharma.com/role/LeaseWeightedAverageDetail Lease Weighted Average (Detail) Details 59 false false R60.htm 2427415 - Disclosure - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/MaturitiesofOperatingLeaseLiabilitiesDetails Maturities of Operating Lease Liabilities (Details) Details 60 false false R61.htm 2430416 - Disclosure - Affiliated Companies (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesDetails Affiliated Companies (Details) Details http://www.westpharma.com/role/AffiliatedCompaniesTables 61 false false R62.htm 2431417 - Disclosure - Affiliated Companies (Textuals) (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesTextualsDetails Affiliated Companies (Textuals) (Details) Details http://www.westpharma.com/role/AffiliatedCompaniesTables 62 false false R63.htm 2434418 - Disclosure - Goodwill and Intangible Assets (Goodwill) (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets (Goodwill) (Details) Details http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables 63 false false R64.htm 2435419 - Disclosure - Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails Goodwill and Intangible Assets (Intangible Assets by Major Class) (Details) Details http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables 64 false false R65.htm 2436420 - Disclosure - Goodwill and Intangible Assets (Textuals) (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsTextualsDetails Goodwill and Intangible Assets (Textuals) (Details) Details http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables 65 false false R66.htm 2439421 - Disclosure - Other Current Liabilities (Details) Sheet http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.westpharma.com/role/OtherCurrentLiabilitiesTables 66 false false R67.htm 2442422 - Disclosure - Debt (Details) Sheet http://www.westpharma.com/role/DebtDetails Debt (Details) Details http://www.westpharma.com/role/DebtTables 67 false false R68.htm 2443423 - Disclosure - Debt (Textuals) (Details) Sheet http://www.westpharma.com/role/DebtTextualsDetails Debt (Textuals) (Details) Details http://www.westpharma.com/role/DebtTables 68 false false R69.htm 2446424 - Disclosure - Derivative Financial Instruments (Textuals) (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTextualsDetails Derivative Financial Instruments (Textuals) (Details) Details http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables 69 false false R70.htm 2447425 - Disclosure - Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDesignatedasHedgesDetails Derivative Financial Instruments (Effects of Derivative Instruments Designated as Hedges) (Details) Details http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables 70 false false R71.htm 2450426 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities) (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails Fair Value Measurements (Fair Value of Assets and Liabilities) (Details) Details http://www.westpharma.com/role/FairValueMeasurementsTables 71 false false R72.htm 2451427 - Disclosure - Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsChangesinLevel3FairValueMeasurementsDetails Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details) Details http://www.westpharma.com/role/FairValueMeasurementsTables 72 false false R73.htm 2452428 - Disclosure - Fair Value Measurements Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails Fair Value Measurements Other Financial Instruments (Details) Details 73 false false R74.htm 2455429 - Disclosure - (Components of AOCI) (Details) Sheet http://www.westpharma.com/role/ComponentsofAOCIDetails (Components of AOCI) (Details) Details 74 false false R75.htm 2456430 - Disclosure - (Reclassifications AOCI) (Details) Sheet http://www.westpharma.com/role/ReclassificationsAOCIDetails (Reclassifications AOCI) (Details) Details 75 false false R76.htm 2459431 - Disclosure - Stock-Based Compensation (Textuals) (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationTextualsDetails Stock-Based Compensation (Textuals) (Details) Details http://www.westpharma.com/role/StockBasedCompensationTables 76 false false R77.htm 2460432 - Disclosure - Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails Stock-Based Compensation (Allocation of Share-based Compensation Costs) (Details) Details http://www.westpharma.com/role/StockBasedCompensationTables 77 false false R78.htm 2461433 - Disclosure - Stock-Based Compensation (Stock Options Activity) (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails Stock-Based Compensation (Stock Options Activity) (Details) Details http://www.westpharma.com/role/StockBasedCompensationTables 78 false false R79.htm 2462434 - Disclosure - Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationStockAppreciationRightsAwardActivityDetails Stock-Based Compensation (Stock Appreciation Rights Award Activity) (Details) Details http://www.westpharma.com/role/StockBasedCompensationTables 79 false false R80.htm 2463435 - Disclosure - Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails Stock-Based Compensation (Nonvested Performance-based Award Activity) (Details) Details http://www.westpharma.com/role/StockBasedCompensationTables 80 false false R81.htm 2466436 - Disclosure - Benefit Plans (Textuals) (Details) Sheet http://www.westpharma.com/role/BenefitPlansTextualsDetails Benefit Plans (Textuals) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 81 false false R82.htm 2467437 - Disclosure - Benefit Plans (Components of Net Periodic Benefit Cost) (Details) Sheet http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails Benefit Plans (Components of Net Periodic Benefit Cost) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 82 false false R83.htm 2468438 - Disclosure - Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details) Sheet http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails Benefit Plans (Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 83 false false R84.htm 2469439 - Disclosure - Benefit Plans (Amounts Recognized in Balance Sheet) (Details) Sheet http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails Benefit Plans (Amounts Recognized in Balance Sheet) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 84 false false R85.htm 2470440 - Disclosure - Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details) Sheet http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveIncomeLossDetails Benefit Plans (Amounts Recognized in Other Comprehensive Income (Loss)) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 85 false false R86.htm 2471441 - Disclosure - Benefit Plans (Expected Benefit Payments) (Details) Sheet http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails Benefit Plans (Expected Benefit Payments) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 86 false false R87.htm 2472442 - Disclosure - Benefit Plans (Assumptions Used) (Details) Sheet http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails Benefit Plans (Assumptions Used) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 87 false false R88.htm 2473443 - Disclosure - Benefit Plans (Allocation of Plan Assets) (Details) Sheet http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails Benefit Plans (Allocation of Plan Assets) (Details) Details http://www.westpharma.com/role/BenefitPlansTables 88 false false R89.htm 2476444 - Disclosure - Other Expense (Details) Sheet http://www.westpharma.com/role/OtherExpenseDetails Other Expense (Details) Details http://www.westpharma.com/role/OtherExpenseTables 89 false false R90.htm 2477445 - Disclosure - Other Expense Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherExpenseRestructuringandRelatedChargesDetails Other Expense Restructuring and Related Charges (Details) Details 90 false false R91.htm 2478446 - Disclosure - Other Expense Other Items (Textuals) (Details) Sheet http://www.westpharma.com/role/OtherExpenseOtherItemsTextualsDetails Other Expense Other Items (Textuals) (Details) Details 91 false false R92.htm 2479447 - Disclosure - Other Expense Development and Licensing Income (Details) Sheet http://www.westpharma.com/role/OtherExpenseDevelopmentandLicensingIncomeDetails Other Expense Development and Licensing Income (Details) Details 92 false false R93.htm 2482448 - Disclosure - Income Taxes (Textuals) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesTextualsDetails Income Taxes (Textuals) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 93 false false R94.htm 2483449 - Disclosure - Income Taxes (Unrecognized Tax Benefits) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes (Unrecognized Tax Benefits) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 94 false false R95.htm 2484450 - Disclosure - Income Taxes (Income Before Income Taxes) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails Income Taxes (Income Before Income Taxes) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 95 false false R96.htm 2485451 - Disclosure - Income Taxes (Components of Income Tax Expense) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails Income Taxes (Components of Income Tax Expense) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 96 false false R97.htm 2486452 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes (Deferred Tax Assets and Liabilities) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 97 false false R98.htm 2487453 - Disclosure - Income Taxes (Effective Income Tax Reconciliation) (Details) Sheet http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails Income Taxes (Effective Income Tax Reconciliation) (Details) Details http://www.westpharma.com/role/IncomeTaxesTables 98 false false R99.htm 2489454 - Disclosure - Commitments and Contingencies (Textuals) (Details) Sheet http://www.westpharma.com/role/CommitmentsandContingenciesTextualsDetails Commitments and Contingencies (Textuals) (Details) Details http://www.westpharma.com/role/CommitmentsandContingencies 99 false false R100.htm 2492455 - Disclosure - Segment Information (Textuals) (Details) Sheet http://www.westpharma.com/role/SegmentInformationTextualsDetails Segment Information (Textuals) (Details) Details http://www.westpharma.com/role/SegmentInformationTables 100 false false R101.htm 2493456 - Disclosure - Segment Information (Sales by Product Group) (Details) Sheet http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails Segment Information (Sales by Product Group) (Details) Details http://www.westpharma.com/role/SegmentInformationTables 101 false false R102.htm 2494457 - Disclosure - Segment Information (Sales and PPE by Geographic Location) (Details) Sheet http://www.westpharma.com/role/SegmentInformationSalesandPPEbyGeographicLocationDetails Segment Information (Sales and PPE by Geographic Location) (Details) Details http://www.westpharma.com/role/SegmentInformationTables 102 false false R103.htm 2495458 - Disclosure - Segment Information (Segment Financial Information) (Details) Sheet http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails Segment Information (Segment Financial Information) (Details) Details http://www.westpharma.com/role/SegmentInformationTables 103 false false R104.htm 2497459 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Details http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsNotes 104 false false All Reports Book All Reports wst-20191231.htm ex102firstamendmentand.htm ex21listofsubsidiaries.htm ex23consent2019.htm ex311ceo302certificati.htm ex312cfo302certificati.htm ex321ceo906certificati.htm ex322cfo906certificati.htm ex44descriptionofregis.htm wst-20191231.xsd wst-20191231_cal.xml wst-20191231_def.xml wst-20191231_lab.xml wst-20191231_pre.xml wst-20191231_g1.jpg http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 true true XML 89 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Goodwill and Intangible Assets
    		 12 Months Ended
    Dec. 31, 2019
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Goodwill and Intangible Assets Goodwill and Intangible Assets
    The changes in the carrying amount of goodwill by reportable segment were as follows:

    ($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
    Balance, December 31, 2017  $77.6  $30.1  $107.7  
    Foreign currency translation(1.6) (0.3) (1.9) 
    Balance, December 31, 2018  76.0  29.8  105.8  
    Goodwill recorded due to acquisition2.6  —  2.6  
    Foreign currency translation(0.5) (0.1) (0.6) 
    Balance, December 31, 2019  $78.1  $29.7  $107.8  

    In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded goodwill of $2.6 million. The goodwill was recorded within our Proprietary Products reportable segment.

    As of December 31, 2019, we had no accumulated goodwill impairment losses.

    Intangible assets and accumulated amortization as of December 31 were as follows:

    20192018
    ($ in millions)CostAccumulated AmortizationNetCostAccumulated AmortizationNet
    Patents and licensing$21.5  $(16.0) $5.5  $19.6  $(15.1) $4.5  
    Technology3.3  (1.5) 1.8  3.3  (1.2) 2.1  
    Trademarks2.0  (1.8) 0.2  2.0  (1.8) 0.2  
    Customer relationships40.3  (21.6) 18.7  29.3  (20.0) 9.3  
    Customer contracts11.0  (7.4) 3.6  11.0  (6.8) 4.2  
    $78.1  $(48.3) $29.8  $65.2  $(44.9) $20.3  

    In April 2019, we acquired the business of our distributor in South Korea. As a result of the acquisition, we recorded a customer relationships intangible asset of $11.2 million, which is being amortized over ten years.
    The cost basis of intangible assets includes a foreign currency translation loss of $0.3 million and a foreign currency translation loss of $0.3 million for the years ended December 31, 2019 and 2018, respectively. Amortization expense for the years ended December 31, 2019, 2018 and 2017 was $3.4 million, $2.7 million and $2.4 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2020 - $4.0 million, 2021 - $3.5 million, 2022 - $3.5 million, 2023 - $2.9 million and 2024 - $2.6 million.
    XML 90 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Schedule II - Valuation and Qualifying Accounts (Notes)
    		 12 Months Ended
    Dec. 31, 2019
    SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
    Schedule of Valuation and Qualifying Accounts
    Schedule II - Valuation and Qualifying Accounts

    ($ in millions)
    Balance at
    beginning of
    period
    Charged
    to costs
    and
    expenses
    		Deductions (1)
    Balance at
    end of
    period
    For the year ended December 31, 2019
    Allowances deducted from assets:
    Deferred tax asset valuation allowance$16.0  $—  $(0.1) $15.9  
    Allowance for doubtful accounts2.0  0.1  (1.6) 0.5  
    Total allowances deducted from assets$18.0  $0.1  $(1.7) $16.4  
    For the year ended December 31, 2018
    Allowances deducted from assets:
    Deferred tax asset valuation allowance$20.9  $(3.0) $(1.9) $16.0  
    Allowance for doubtful accounts0.5  0.7  0.8  2.0  
    Total allowances deducted from assets$21.4  $(2.3) $(1.1) $18.0  
    For the year ended December 31, 2017
    Allowances deducted from assets:
    Deferred tax asset valuation allowance$18.7  $2.5  $(0.3) $20.9  
    Allowance for doubtful accounts0.4  (0.2) 0.3  0.5  
    Total allowances deducted from assets$19.1  $2.3  $—  $21.4  
    __________________________
    (1)Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments.
    XML 91 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurements
    		 12 Months Ended
    Dec. 31, 2019
    Fair Value Disclosures [Abstract]  
    Fair Value Measurements Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
    •Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
    •Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
    •Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
    The following tables present the assets and liabilities recorded at fair value on a recurring basis:

     Balance atBasis of Fair Value Measurements
    ($ in millions)December 31,
    2019    		Level 1Level 2Level 3
    Assets:    
    Deferred compensation assets$11.3  $11.3  $—  $—  
    Foreign currency contracts7.7  —  7.7  —  
    Commodity call options0.1  —  0.1  —  
     $19.1  $11.3  $7.8  $—  
    Liabilities:    
    Contingent consideration$3.3  $—  $—  $3.3  
    Deferred compensation liabilities12.8  12.8  —  —  
    Cross-currency swap1.4  —  1.4  —  
    Foreign currency contracts0.3  —  0.3  —  
     $17.8  $12.8  $1.7  $3.3  

     Balance atBasis of Fair Value Measurements
    ($ in millions)December 31,
    2018    		Level 1Level 2Level 3
    Assets:    
    Deferred compensation assets$8.7  $8.7  $—  $—  
    Foreign currency contracts6.5  —  6.5  —  
     $15.2  $8.7  $6.5  $—  
    Liabilities:    
    Contingent consideration$1.7  $—  $—  $1.7  
    Deferred compensation liabilities9.8  9.8  —  —  
    Foreign currency contracts0.2  —  0.2  —  
     $11.7  $9.8  $0.2  $1.7  

    Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 11, Derivative Financial Instruments, for further discussion of our derivatives.

    Level 3 Fair Value Measurements

    The fair value of the contingent consideration liability related to the SmartDose technology platform (the "SmartDose contingent consideration") was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this
    obligation are recorded as income or expense within other (income) expense in our consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.

    The following table provides a summary of changes in our Level 3 fair value measurements:

     ($ in millions)
    Balance, December 31, 2017$4.9  
    Decrease in fair value recorded in earnings(2.6) 
    Payments(0.6) 
    Balance, December 31, 20181.7  
    Increase in fair value recorded in earnings2.1  
    Payments(0.5) 
    Balance, December 31, 2019$3.3  

    Other Financial Instruments

    We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

    The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million compared to a carrying amount of $255.0 million. At December 31, 2018, the estimated fair value of long-term debt was $192.6 million and the carrying amount was $196.0 million.
    XML 92 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense
    		 12 Months Ended
    Dec. 31, 2019
    Other Income and Expenses [Abstract]  
    Other (Income) Expense Other (Income) Expense
    Other (income) expense consisted of:
    ($ in millions)201920182017
    Restructuring and related charges:
    Severance and post-employment benefits$2.6  $3.1  $—  
    Asset-related charges0.3  2.2  —  
    Other charges2.0  3.8  —  
    Total restructuring and related charges$4.9  $9.1  $—  
    Argentina currency devaluation1.0  1.1  —  
    Tax recovery(4.7) —  —  
    Venezuela deconsolidation—  —  11.1  
    Development and licensing income(0.9) (0.9) (10.6) 
    Contingent consideration2.1  (2.6) (2.4) 
    Other items(4.9) (4.8) 3.9  
    Total other (income) expense$(2.5) $1.9  $2.0  

    Restructuring and Related Charges

    In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of the approval. The plan was expected to require restructuring and related charges of approximately $16.0 million. Since its approval, we recorded $13.7 million in restructuring and related charges associated with this plan. The plan is now considered complete.

    During 2019, we recorded $4.9 million in restructuring and related charges associated with this plan, consisting of $2.6 million for severance charges, $0.3 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $2.0 million for other non-cash charges.

    During 2018, we recorded $8.8 million in restructuring and related charges associated with this plan, consisting of $3.1 million for severance charges, $2.2 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $3.5 million for other non-cash charges.

    The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

    ($ in millions)Severance and benefitsAsset-related chargesOther chargesTotal
    Balance, December 31, 2017$—  $—  $—  $—  
    Charges3.1  2.2  3.5  8.8  
    Cash payments(0.8) —  —  (0.8) 
    Non-cash asset write-downs—  (2.2) (3.5) (5.7) 
    Balance, December 31, 2018$2.3  $—  $—  $2.3  
    Charges2.6  0.3  2.0  4.9  
    Cash payments(3.5) —  —  (3.5) 
    Non-cash asset write-downs—  (0.3) (2.0) (2.3) 
    Balance, December 31, 2019$1.4  $—  $—  $1.4  
    On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. During 2018, we recorded $0.3 million in additional charges related to this restructuring plan. Our remaining restructuring obligations related to our 2016 restructuring plan as of December 31, 2019 were $0.1 million.

    Other Items

    During 2019, we recorded a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. During 2018, we recorded a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018.

    During 2019, we recognized a tax recovery of $4.7 million related to previously-paid international excise taxes, following a favorable court ruling.

    On February 17, 2016, the Venezuelan government announced a devaluation of the Bolivar, from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD, and streamlined the previous three-tiered currency exchange mechanism into a dual currency exchange mechanism. In 2017, as a result of the continued deterioration of conditions in Venezuela as well as our continued reduced access to USD settlement controlled by the Venezuelan government, we recorded a charge of $11.1 million related to the deconsolidation of our Venezuelan subsidiary, following our determination that we no longer met the U.S. GAAP criteria for control of that subsidiary. This charge included the derecognition of the carrying amounts of our Venezuelan subsidiary’s assets and liabilities, as well as the write-off of our investment in our Venezuelan subsidiary, related unrealized translation adjustments and the elimination of intercompany accounts. As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary.

    During 2019, 2018 and 2017, we recorded development income of $0.9 million, $0.9 million and $1.5 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information. In addition, during 2017, we recorded income of $9.1 million attributable to the reimbursement of certain costs related to a technology that we subsequently licensed to a third party. The license of technology to the third party may result in additional income in the future, contingent on commercialization of the related product.

    Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 12, Fair Value Measurements, for additional details.
    Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. Other items primarily changed in 2019 as a result of foreign exchange transaction gains of $5.6 million in 2019 and a $1.9 million gain on the sale of fixed assets as a result of our restructuring plan, as compared to foreign exchange transaction gains of $5.5 million in 2018 and a $1.1 million gain on the sale of fixed assets as a result of our restructuring plans.
    XML 93 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies Summary of Significant Accounting Policies
    Principles of Consolidation: The consolidated financial statements include the accounts of West after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

    In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our consolidated financial statements since the acquisition date.

    As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 16, Other (Income) Expense, for further discussion.

    Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

    Cash and Cash Equivalents: Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.

    Accounts Receivable: Our accounts receivable balance was net of an allowance for doubtful accounts of $0.5 million and $2.0 million at December 31, 2019 and 2018, respectively. We record the allowance based on a specific identification methodology.

    Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. The following is a summary of inventories at December 31:

    ($ in millions)20192018
    Raw materials$100.9  $90.4  
    Work in process37.4  42.2  
    Finished goods97.4  81.9  
    $235.7  $214.5  

    Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other (income) expense. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

    Leases: Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured
    at the present value of the unpaid lease payments at the lease commencement date. We had no finance leases as of December 31, 2019. Please refer to Note 6, Leases, for additional information.

    Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

    Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.

    Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.

    Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.

    Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.
    Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.

    Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience. Please refer to Note 3, Revenue, for additional information.

    Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

    Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred.

    Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations.

    Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.

    Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other (income) expense. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

    Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, Stock-Based Compensation, for a more detailed discussion of our stock-based compensation plans.
    Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.
    XML 94 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Document and Entity Information - USD ($)
    		 12 Months Ended
    Dec. 31, 2019
    Jan. 31, 2020
    Jun. 30, 2019
    Document and Entity Information [Abstract]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2019    
    Document Transition Report false    
    Entity File Number 1-8036    
    Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.    
    Entity Incorporation, State or Country Code PA    
    Entity Tax Identification Number 23-1210010    
    Entity Address, Address Line One 530 Herman O. West Drive    
    Entity Address, City or Town Exton    
    Entity Address, State or Province PA    
    Entity Address, Postal Zip Code 19341-0645    
    City Area Code 610    
    Local Phone Number 594-2900    
    Title of 12(b) Security Common Stock, par value $.25 per share    
    Trading Symbol WST    
    Security Exchange Name NYSE    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    Entity Shell Company false    
    Entity Public Float     $ 9,218,126,218
    Entity Common Stock, Shares Outstanding   73,837,449  
    Amendment Flag false    
    Current Fiscal Year End Date --12-31    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2019    
    Entity Central Index Key 0000105770    
    XML 95 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED BALANCE SHEETS - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Current assets:    
    Cash and cash equivalents $ 439.1 $ 337.4
    Accounts receivable, net 319.3 288.2
    Inventories 235.7 214.5
    Other current assets 64.6 54.3
    Total current assets 1,058.7 894.4
    Property, plant and equipment 1,820.1 1,752.7
    Less: accumulated depreciation and amortization 980.8 930.7
    Property, plant and equipment, net 839.3 822.0
    Operating lease right-of-use assets 70.1 0.0
    Investments in affiliated companies 192.7 91.2
    Goodwill 107.8 105.8
    Deferred income taxes 14.0 24.7
    Intangible assets, net 29.8 20.3
    Pension and other postretirement benefits 4.3 0.0
    Other noncurrent assets 24.7 20.5
    Total Assets 2,341.4 1,978.9
    Current liabilities:    
    Notes payable and other current debt 2.3 0.1
    Accounts payable 156.8 130.4
    Pension and other postretirement benefits 2.2 2.3
    Accrued Salaries, Wages, and Benefits, Current 73.0 64.5
    Income taxes payable 6.4 9.8
    Operating lease liabilities 9.6 0.0
    Other current liabilities 91.3 76.6
    Total current liabilities 341.6 283.7
    Long-term debt 255.0 196.0
    Deferred income taxes 15.5 13.1
    Pension and other postretirement benefits 52.5 56.2
    Operating lease liabilities 62.4 0.0
    Other long-term liabilities 41.2 33.6
    Total Liabilities 768.2 582.6
    Commitments and contingencies (Note 16)
    Equity:    
    Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding in 2019 and 2018 0.0 0.0
    Common stock, par value $.25 per share; 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million in 2019 and 2018; shares outstanding: 74.1 million and 74.1 million in 2019 and 2018 18.8 18.8
    Capital in excess of par value 272.7 282.0
    Retained earnings 1,549.4 1,353.4
    Accumulated other comprehensive loss (149.6) (154.2)
    Treasury stock, at cost (1.2 million and 1.2 million shares in 2019 and 2018) (118.1) (103.7)
    Total Equity 1,573.2 1,396.3
    Total Liabilities and Equity $ 2,341.4 $ 1,978.9
    XML 96 R92.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense Development and Licensing Income (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Jun. 30, 2013
    Development and licensing income [Line Items]        
    Development and licensing income $ 0.9 $ 0.9 $ 10.6  
    Deferred income 34.9 33.4    
    SmartDose [Member]        
    Development and licensing income [Line Items]        
    Development and licensing income $ 0.9 0.9 $ 1.5  
    Deferred income       $ 20.0
    Other [Member]        
    Development and licensing income [Line Items]        
    Development and licensing income   $ 9.1    
    XML 97 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Affiliated Companies (Textuals) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Schedule of Equity Method Investments [Line Items]      
    Unremitted income of affiliated companies $ 82.4 $ 75.8 $ 69.9
    Dividends received from affiliated companies 2.2 1.7 2.2
    Purchases and royalty payments made to affiliates 115.1 86.3 86.7
    Amount due and payable to affiliates 20.8 12.9  
    Sales to affiliates 9.2 9.6 8.1
    Amount receivable from affiliates 1.9 1.6  
    Equity method investments 179.3 77.8  
    Aggregate carrying amount of investment in affiliated companies that are not accounted for under the equity method 13.4 13.4  
    Daikyo Seiko, Ltd. [Member]      
    Schedule of Equity Method Investments [Line Items]      
    Equity in unrealized gains (losses) in securities available-for-sale and derivative instruments $ (0.4) $ (0.4) $ (0.5)
    XML 98 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Current Liabilities (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Other Current Liabilities [Abstract]      
    Deferred income $ 27.5 $ 25.5  
    Dividends payable 11.8 11.3 $ 10.4
    Accrued commissions, rebates and royalties 9.7 5.7  
    Accrued retirement plans (excluding pension) 7.9 2.3  
    Accrued taxes other than income 6.5 5.5  
    Accrued professional services 5.9 4.9  
    Accrued interest 3.3 3.4  
    Restructuring obligations 1.5 3.3  
    Other 17.2 14.7  
    Other current liabilities $ 91.3 $ 76.6  
    XML 99 R96.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Components of Income Tax Expense) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Current:      
    Federal $ 10.8 $ 2.1 $ 2.1
    State 2.4 3.3 0.1
    International 30.5 35.1 37.0
    Current income tax provision 43.7 40.5 39.2
    Deferred:      
    Federal and state 10.3 1.4 41.8
    International 5.0 (0.5) (0.1)
    Deferred income tax provision 15.3 0.9 41.7
    Income tax expense $ 59.0 $ 41.4 $ 80.9
    XML 100 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Income Tax Disclosure [Abstract]  
    Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits
    A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:

    ($ in millions)20192018
    Balance at January 1$3.9  $3.2  
    Increase due to current year position1.6  0.8  
    Increase due to prior year position—  0.4  
    Reduction for expiration of statute of limitations/audits(0.5) (0.5) 
    Balance at December 31$5.0  $3.9  
    Schedule of Components of Income Before Income Taxes
    The components of income before income taxes are:
    ($ in millions)201920182017
    U.S. operations$161.2  $132.9  $96.5  
    International operations130.6  107.8  125.9  
    Total income before income taxes$291.8  $240.7  $222.4  
    Schedule of Components of Income Tax Expense
    The related provision for income taxes consists of:

    ($ in millions)201920182017
    Current:
    Federal$10.8  $2.1  $2.1  
    State2.4  3.3  0.1  
    International30.5  35.1  37.0  
    Current income tax provision43.7  40.5  39.2  
    Deferred:
    Federal and state10.3  1.4  41.8  
    International5.0  (0.5) (0.1) 
    Deferred income tax provision15.3  0.9  41.7  
    Income tax expense$59.0  $41.4  $80.9  
    Schedule of Deferred Tax Assets and Liabilities
    The significant components of our deferred tax assets and liabilities at December 31 are:

    ($ in millions)20192018
    Deferred tax assets
    Net operating loss carryforwards$21.9  $18.4  
    Tax credit carryforwards2.8  10.5  
    Pension and deferred compensation25.6  27.2  
    Other9.2  11.4  
    Valuation allowance(15.9) (16.0) 
    Total deferred tax assets43.6  51.5  
    Deferred tax liabilities:
    Accelerated depreciation37.9  31.3  
    Tax on undistributed earnings of subsidiaries6.3  6.6  
    Other0.9  2.0  
    Total deferred tax liabilities45.1  39.9  
    Net deferred tax (liability) asset$(1.5) $11.6  
    Schedule of Effective Income Tax Rate Reconciliation
    A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:

    201920182017
    U.S. federal corporate tax rate21.0 %21.0 %35.0 %
    Tax on international operations other than U.S. tax rate2.7  4.8  (4.5) 
    Reversal of prior valuation allowance—  —  (0.5) 
    Adjustments to reserves for unrecognized tax benefits0.4  0.2  (0.2) 
    U.S. tax on international earnings, net of foreign tax credits0.4  (0.2) 0.1  
    State income taxes, net of federal tax effect1.4  2.3  0.2  
    U.S. research and development credits(1.0) (0.9) (0.8) 
    Excess tax benefits on share-based payments(3.5) (6.0) (14.1) 
    Impact of 2017 Tax Act—  (2.9) 15.9  
    Tax on undistributed earnings of subsidiaries(0.2) (1.3) 4.4  
    Venezuela deconsolidation—  —  1.7  
    Other business credits and Section 199 Deduction—  —  (0.6) 
    Other(1.0) 0.2  (0.2) 
    Effective tax rate20.2 %17.2 %36.4 %
    XML 101 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Accumulated Other Comprehensive Loss (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Equity [Abstract]  
    Components of Accumulated Other Comprehensive Loss
    The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
    ($ in millions)(Losses) gains on derivativesUnrealized gains on investment securitiesDefined benefit pension and other postretirement plansForeign currency translationTotal
    Balance, December 31, 2017  $(4.2) $0.5  $(39.0) $(74.6) $(117.3) 
    Other comprehensive income (loss) before reclassifications2.6  (0.1) (1.0) (39.2) (37.7) 
    Amounts reclassified out1.2  —  (0.4) —  0.8  
    Other comprehensive income (loss), net of tax3.8  (0.1) (1.4) (39.2) (36.9) 
    Balance, December 31, 2018  (0.4) 0.4  (40.4) (113.8) (154.2) 
    Other comprehensive income (loss) before reclassifications5.4  —  (1.9) 4.9  8.4  
    Amounts reclassified out(5.8) —  2.0  —  (3.8) 
    Other comprehensive (loss) income, net of tax(0.4) —  0.1  4.9  4.6  
    Balance, December 31, 2019$(0.8) $0.4  $(40.3) $(108.9) $(149.6) 
    Reclassification out of Accumulated Other Comprehensive Loss
    A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):

    Detail of components20192018Location on Statement of Income
    Gains (losses) on derivatives:
    Foreign currency contracts$1.0  $(0.7) Net sales  
    Foreign currency contracts1.0  (0.5) Cost of goods and services sold  
    Foreign currency contracts6.9  —  Other expense  
    Forward treasury locks(0.5) (0.4) Interest expense  
    Total before tax8.4  (1.6) 
    Tax expense(2.6) 0.4  
    Net of tax$5.8  $(1.2) 
    Amortization of defined benefit pension and other postretirement plans:
    Prior service credit0.6  2.0  (a) 
    Actuarial gains (losses)0.2  (1.4) (a) 
    Settlements(3.5) —  (a) 
    Total before tax(2.7) 0.6  
    Tax expense0.7  (0.2) 
    Net of tax$(2.0) $0.4  
    Total reclassifications for the period, net of tax$3.8  $(0.8) 

    (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
    XML 102 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Revenue Recognition (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Disaggregation of Revenue [Line Items]    
    Contract with customer, liability $ 34.9 $ 33.4
    Percentage of net sales 100.00% 100.00%
    SmartDose [Member]    
    Disaggregation of Revenue [Line Items]    
    Contract with customer, liability $ 5.6  
    Product Concentration Risk [Member] | Revenue Benchmark [Member] | High-Value Components [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 42.00% 41.00%
    Product Concentration Risk [Member] | Revenue Benchmark [Member] | Standard Packaging [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 29.00% 32.00%
    Product Concentration Risk [Member] | Revenue Benchmark [Member] | Delivery Devices [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 5.00% 3.00%
    Product Concentration Risk [Member] | Revenue Benchmark [Member] | Contract Manufactured Products [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 24.00% 24.00%
    Biologics Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 25.00% 21.00%
    Generics Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 20.00% 21.00%
    Pharma Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 31.00% 34.00%
    Contract-Manufactured Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 24.00% 24.00%
    Americas [Member] | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 48.00% 48.00%
    EMEA [Member] | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 44.00% 44.00%
    Asia Pacific [Member] | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]    
    Disaggregation of Revenue [Line Items]    
    Percentage of net sales 8.00% 8.00%
    XML 103 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Accumulated Other Comprehensive Loss
    		 12 Months Ended
    Dec. 31, 2019
    Equity [Abstract]  
    Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
    The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
    ($ in millions)(Losses) gains on derivativesUnrealized gains on investment securitiesDefined benefit pension and other postretirement plansForeign currency translationTotal
    Balance, December 31, 2017  $(4.2) $0.5  $(39.0) $(74.6) $(117.3) 
    Other comprehensive income (loss) before reclassifications2.6  (0.1) (1.0) (39.2) (37.7) 
    Amounts reclassified out1.2  —  (0.4) —  0.8  
    Other comprehensive income (loss), net of tax3.8  (0.1) (1.4) (39.2) (36.9) 
    Balance, December 31, 2018  (0.4) 0.4  (40.4) (113.8) (154.2) 
    Other comprehensive income (loss) before reclassifications5.4  —  (1.9) 4.9  8.4  
    Amounts reclassified out(5.8) —  2.0  —  (3.8) 
    Other comprehensive (loss) income, net of tax(0.4) —  0.1  4.9  4.6  
    Balance, December 31, 2019$(0.8) $0.4  $(40.3) $(108.9) $(149.6) 
    A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):

    Detail of components20192018Location on Statement of Income
    Gains (losses) on derivatives:
    Foreign currency contracts$1.0  $(0.7) Net sales  
    Foreign currency contracts1.0  (0.5) Cost of goods and services sold  
    Foreign currency contracts6.9  —  Other expense  
    Forward treasury locks(0.5) (0.4) Interest expense  
    Total before tax8.4  (1.6) 
    Tax expense(2.6) 0.4  
    Net of tax$5.8  $(1.2) 
    Amortization of defined benefit pension and other postretirement plans:
    Prior service credit0.6  2.0  (a) 
    Actuarial gains (losses)0.2  (1.4) (a) 
    Settlements(3.5) —  (a) 
    Total before tax(2.7) 0.6  
    Tax expense0.7  (0.2) 
    Net of tax$(2.0) $0.4  
    Total reclassifications for the period, net of tax$3.8  $(0.8) 

    (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
    XML 104 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2019
    Income Tax Disclosure [Abstract]  
    Income Taxes Income TaxesAs a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. During 2019, the statute of limitations for the 2015 U.S. federal tax year lapsed, leaving tax years 2016 through 2019 open to examination. For U.S. state and local jurisdictions, tax years 2015 through 2019 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2012 through 2019.
    A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:

    ($ in millions)20192018
    Balance at January 1$3.9  $3.2  
    Increase due to current year position1.6  0.8  
    Increase due to prior year position—  0.4  
    Reduction for expiration of statute of limitations/audits(0.5) (0.5) 
    Balance at December 31$5.0  $3.9  

    In addition, we had balances in accrued liabilities for interest and penalties of $0.2 million at both December 31, 2019 and 2018. As of December 31, 2019, we had $5.0 million of total gross unrecognized tax benefits, which, if recognized, would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $0.5 million during the next twelve months, which would favorably impact our effective tax rate.
    The components of income before income taxes are:
    ($ in millions)201920182017
    U.S. operations$161.2  $132.9  $96.5  
    International operations130.6  107.8  125.9  
    Total income before income taxes$291.8  $240.7  $222.4  

    The related provision for income taxes consists of:

    ($ in millions)201920182017
    Current:
    Federal$10.8  $2.1  $2.1  
    State2.4  3.3  0.1  
    International30.5  35.1  37.0  
    Current income tax provision43.7  40.5  39.2  
    Deferred:
    Federal and state10.3  1.4  41.8  
    International5.0  (0.5) (0.1) 
    Deferred income tax provision15.3  0.9  41.7  
    Income tax expense$59.0  $41.4  $80.9  

    Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.
    The significant components of our deferred tax assets and liabilities at December 31 are:

    ($ in millions)20192018
    Deferred tax assets
    Net operating loss carryforwards$21.9  $18.4  
    Tax credit carryforwards2.8  10.5  
    Pension and deferred compensation25.6  27.2  
    Other9.2  11.4  
    Valuation allowance(15.9) (16.0) 
    Total deferred tax assets43.6  51.5  
    Deferred tax liabilities:
    Accelerated depreciation37.9  31.3  
    Tax on undistributed earnings of subsidiaries6.3  6.6  
    Other0.9  2.0  
    Total deferred tax liabilities45.1  39.9  
    Net deferred tax (liability) asset$(1.5) $11.6  

    A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes follows:

    201920182017
    U.S. federal corporate tax rate21.0 %21.0 %35.0 %
    Tax on international operations other than U.S. tax rate2.7  4.8  (4.5) 
    Reversal of prior valuation allowance—  —  (0.5) 
    Adjustments to reserves for unrecognized tax benefits0.4  0.2  (0.2) 
    U.S. tax on international earnings, net of foreign tax credits0.4  (0.2) 0.1  
    State income taxes, net of federal tax effect1.4  2.3  0.2  
    U.S. research and development credits(1.0) (0.9) (0.8) 
    Excess tax benefits on share-based payments(3.5) (6.0) (14.1) 
    Impact of 2017 Tax Act—  (2.9) 15.9  
    Tax on undistributed earnings of subsidiaries(0.2) (1.3) 4.4  
    Venezuela deconsolidation—  —  1.7  
    Other business credits and Section 199 Deduction—  —  (0.6) 
    Other(1.0) 0.2  (0.2) 
    Effective tax rate20.2 %17.2 %36.4 %

    During 2019, we recorded a tax benefit of $0.3 million due to the impact of federal law changes enacted during the year, as well as a tax benefit of $10.3 million associated with stock-based compensation.

    During 2018, we recorded a net tax benefit of $2.5 million for the estimated impact of the 2017 Tax Act and a tax benefit of $14.3 million associated with stock-based compensation.

    During 2017, we recorded a discrete tax charge of $48.8 million related to the 2017 Tax Act and the impact of changes in enacted international tax rates on previously-recorded deferred tax asset and liability balances, as well as a tax benefit of $33.1 million associated with stock-based compensation.
    The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include, but are not limited to, a federal statutory rate reduction from 35.0% to 21.0% effective for tax years beginning after December 31, 2017. Changes in tax rates and tax laws are accounted for in the period of enactment. As a result, during the year ended December 31, 2017, we recorded a discrete charge based upon our understanding of the 2017 Tax Act and the guidance available as of the date of that filing. A significant portion of the discrete tax liability was attributable to a one-time mandatory deemed repatriation tax of post-1986 undistributed foreign subsidiary earnings and profits (the “Transition Toll Tax”) of $27.9 million. Additionally, due to the reduction of the federal statutory rate, we revalued our deferred assets and liabilities and recorded a provisional $11.4 million federal tax expense, net of state tax impact, during the year ended December 31, 2017.

    On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. We recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities and included these amounts in our consolidated financial statements for the year ended December 31, 2017. As of December 31, 2018, we finalized our calculations and tax positions used in our analysis of the impact of the 2017 Tax Act in consideration of proposed regulations and other guidance issued during 2018. As a result, we recorded a $7.5 million tax benefit related to a reduction of the Transition Toll Tax and an incremental tax expense of $4.0 million related to other adjustments. The final measurement reduced the Transition Toll Tax expense to $20.4 million from $27.9 million. The net impact of these adjustments resulted in a benefit of 1.45% to the 2018 effective tax rate.

    The 2017 Tax Act created a provision known as global intangible low-tax income (“GILTI”) that imposes a U.S. tax on certain earnings of controlled foreign subsidiaries. We made an accounting policy election to reflect GILTI taxes, if any, as a current income tax expense in the period incurred.

    As of December 31, 2019, we have fully utilized all of our U.S. federal net operating loss carryforwards. State operating loss carryforwards of $226.9 million created a deferred tax asset of $15.5 million, while foreign operating loss carryforwards of $49.4 million created a deferred tax asset of $6.4 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been fully reserved. State loss carryforwards expire as follows: $15.4 million in 2020 and $211.5 million thereafter. Foreign loss carryforwards will begin to expire in 2027, while $48.7 million of the total $49.4 million will not expire.

    As of December 31, 2019, we have utilized all available foreign tax credit carryforwards against the Transition Toll Tax. During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. The $2.0 million of state research and development credits expire as follows: $0.5 million expire in 2023, $0.5 million expire in 2024, and $1.0 million expire after 2024.

    In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. In general, it is our practice and intention to permanently reinvest the earnings of our foreign subsidiaries and repatriate earnings only when the tax impact is de minimis, and that position has not changed subsequent to the one-time transition tax under the 2017 Tax Act, except as noted above. Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $214.2 million of undistributed earnings from foreign subsidiaries to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.
    XML 105 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Principles of Consolidation
    Principles of Consolidation: The consolidated financial statements include the accounts of West after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

    In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our consolidated financial statements since the acquisition date.
    As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 16, Other (Income) Expense, for further discussion.
    Use of Estimates Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.
    Cash and Cash Equivalents Cash and Cash Equivalents: Cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with maturities of three months or less at the time of purchase.
    Accounts Receivable Accounts Receivable: Our accounts receivable balance was net of an allowance for doubtful accounts of $0.5 million and $2.0 million at December 31, 2019 and 2018, respectively. We record the allowance based on a specific identification methodology.
    Inventories Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value.
    Property, Plant and Equipment Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other (income) expense. Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.
    Leases Leases: Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. We had no finance leases as of December 31, 2019. Please refer to Note 6, Leases, for additional information.
    Impairment of Long-Lived Assets Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment and operating lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other (income) expense for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.
    Impairment of Goodwill and Other Intangible Assets
    Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our 2017, 2018, and 2019 annual impairment tests. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment tests in 2017, 2018, and 2019.

    Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 5 to 25 years, and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable.
    Employee Benefits Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.
    Financial Instruments Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as hedging the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as hedging the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as hedging the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.
    Foreign Currency Translation Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.
    Revenue Recognition Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience. Please refer to Note 3, Revenue, for additional information.
    Shipping and Handling Costs Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.
    Research and Development Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include primarily salaries and outside services for those directly involved in research and development activities and are expensed as incurred.
    Environmental Remediation and Compliance Costs Environmental Remediation and Compliance Costs: Environmental remediation costs are accrued when such costs are probable and reasonable estimates are determinable. Cost estimates include investigation, cleanup and monitoring activities; such estimates are adjusted, if necessary, based on additional findings. Environmental compliance costs are expensed as incurred as part of normal operations.
    Litigation Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.
    Income Taxes Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. In response to the 2017 Tax Act, we reevaluated our position regarding permanent reinvestment of foreign subsidiary earnings and profits through 2017 (with the exception of China and Mexico) and decided that those profits were no longer permanently reinvested. As of January 1, 2018, we reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other (income) expense. The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.
    Stock-based Compensation Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, Stock-Based Compensation, for a more detailed discussion of our stock-based compensation plans.
    Net Income Per Share Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.
    XML 106 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Statement of Comprehensive Income [Abstract]      
    Prior service credit arising during period, tax $ 0.0 $ 0.0 $ 0.0
    Net actuarial gain (loss) arising during period, tax (0.3) (0.2) 1.3
    Settlement effects arising during period, tax 0.8 0.0 0.0
    Less: amortization of actuarial loss, tax 0.0 0.3 0.5
    Less: amortization of prior service credit, tax (0.1) (0.5) (0.5)
    Net gain (loss) on investment securities, tax 0.0 (0.1) (2.5)
    Net gain (loss) on derivatives, tax $ (0.2) $ 1.5 $ (0.1)
    XML 107 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Cash flows from operating activities:      
    Net income $ 241.7 $ 206.9 $ 150.7
    Adjustments to reconcile net income to net cash provided by operating activities:      
    Depreciation 100.0 101.7 94.3
    Amortization 3.4 2.7 2.4
    Stock-based compensation 24.4 15.1 16.1
    Non-cash restructuring charges 2.3 2.2 0.7
    Pension settlement charge 3.5 0.0 0.0
    Venezuela deconsolidation 0.0 0.0 11.1
    Contingent consideration payments in excess of acquisition-date liability (0.5) (0.6) 0.0
    Loss on sales of equipment 0.8 1.8 1.6
    Deferred income taxes 15.3 0.9 41.7
    Pension and other retirement plans, net (2.6) (7.9) (6.9)
    Equity in undistributed earnings of affiliates, net of dividends (6.7) (5.9) (7.0)
    Changes in assets/liabilities, net of acquisitions:      
    Increase in accounts receivable (33.3) (43.8) (39.7)
    Increase in inventories (18.6) (7.0) (3.6)
    Decrease (increase) in other current assets 2.6 (6.2) 0.3
    Increase in accounts payable 25.3 0.4 12.6
    Changes in other assets and liabilities 9.6 28.3 (11.0)
    Net cash provided by operating activities 367.2 288.6 263.3
    Cash flows from investing activities:      
    Capital expenditures (126.4) (104.7) (130.8)
    Purchase of investment in affiliated companies (85.1) 0.0 0.0
    Acquisition of business 18.9 0.0 0.0
    Cash related to deconsolidated Venezuelan subsidiary 0.0 0.0 (6.0)
    Other, net 2.4 3.9 3.2
    Net cash used in investing activities (228.0) (100.8) (133.6)
    Cash flows from financing activities:      
    Borrowings under revolving credit agreements 108.5 0.0 0.0
    Repayments of Lines of Credit (136.3) 0.0 0.0
    Issuance of long-term debt 90.0 0.0 0.0
    Repayments of Long-term Debt (0.1) (0.1) (34.9)
    Debt issuance costs (1.2) 0.0 0.0
    Dividend payments (45.1) (42.1) (39.1)
    Contingent consideration payments up to amount of acquisition-date liability 0.0 0.0 (0.7)
    Proceeds from stock-based compensation awards 25.1 27.4 35.7
    Employee stock purchase plan contributions 5.4 4.9 4.4
    Shares repurchased under share repurchase program (83.1) (70.8) (74.4)
    Net cash used in financing activities (36.8) (80.7) (109.0)
    Effect of exchange rates on cash (0.7) (5.6) 12.2
    Net increase in cash and cash equivalents 101.7 101.5 32.9
    Cash, including cash equivalents at beginning of period 337.4 235.9 203.0
    Cash, including cash equivalents at end of period 439.1 337.4 235.9
    Supplemental cash flow information:      
    Interest paid, net of amounts capitalized 8.6 8.4 8.0
    Income taxes paid, net 47.5 42.0 31.0
    Accrued capital expenditures 17.0 15.0 20.1
    Dividends declared, not paid 11.8 11.3 10.4
    Purchase of investment in affiliated companies, treasury stock $ 4.9 $ 0.0 $ 0.0
    XML 108 R93.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Textuals) (Details)
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    Dec. 31, 2017
    USD ($)
    Income tax expense $ 59,000,000.0 $ 41,400,000 $ 80,900,000
    Other Income Tax Expense (Benefit), Continuing Operations (300,000)    
    Discrete tax charge, Tax Cuts and Jobs Act of 2017   (2,500,000) 48,800,000
    Accrued liabilities for interest and penalties 200,000    
    Total gross unrecognized tax benefits 5,000,000.0 3,900,000 3,200,000
    Estimated reduction in the liability for unrecognized tax benefits 500,000    
    Discrete tax charge, Tax Cuts and Jobs Act of 2017   (2,500,000) 48,800,000
    Income tax expense (benefit) 59,000,000.0 41,400,000 80,900,000
    Provisional Transition Tax, Tax Cuts and Jobs Act of 2017     27,900,000
    Provisional tax charge, Tax Cuts and Jobs Act of 2017     11,400,000
    Reduction in Transition Tax, Tax Cuts and Jobs Act of 2017   7,500,000  
    Measurement period adjustment, Tax Cuts and Jobs Act of 2017   4,000,000.0  
    Transitional Tax, Tax Cuts and Jobs Act of 2017   $ 20,400,000  
    Net impact to the 2018 effective tax rate, Tax Cuts and Jobs Act of 2017   0.0145  
    Undistributed earnings of foreign subsidiaries 214,200,000    
    Accounting Standards Update 2016-09 [Member]      
    Income tax expense (10,300,000) $ (14,300,000) (33,100,000)
    Income tax expense (benefit) $ (10,300,000) $ (14,300,000) $ (33,100,000)
    XML 109 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Goodwill and Intangible Assets (Goodwill) (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Goodwill [Roll Forward]    
    Balance, beginning $ 105,800,000 $ 107,700,000
    Goodwill recorded due to acquisition 2,600,000  
    Foreign currency translation (600,000) (1,900,000)
    Balance, ending 107,800,000 105,800,000
    Proprietary Products [Member]    
    Goodwill [Roll Forward]    
    Balance, beginning 76,000,000.0 77,600,000
    Goodwill recorded due to acquisition 2,600,000  
    Foreign currency translation (500,000) (1,600,000)
    Balance, ending 78,100,000 76,000,000.0
    Contract-Manufactured Products [Member]    
    Goodwill [Roll Forward]    
    Balance, beginning 29,800,000 30,100,000
    Goodwill recorded due to acquisition 0  
    Foreign currency translation (100,000) (300,000)
    Balance, ending $ 29,700,000 $ 29,800,000
    EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

    C6NV1K>0BQ(LUOE8Y#FQ"P*#4EH&:Y0:/P)@E M,FG\GCGQ(FD#U_LW]L^N=E/+A2IX%.Q75^DVQRE&%=3TRO23&+_ 7$^,T5S\ M-[@!,W";B=$H!5/NB\JKTH+/+"853E^GM>O=.DXG<3R'^0/".2!< E*G0R8A ME_DGJFF123$B.=W]0.T3[XZAN9O2.MU5N#.3O#+>6Q&E449NEFC&G"9,N,+L M%@0Q[(M$Z),XA>_"0W]XY,TPXW)?HPL5\D]HK$ M'H+#1L2'2?PB!Z_(P4.0;D1\F'N_2.(52=X3W <;$1_F@W\B]8JD'H)P(^+# M1!L1LOK/.0A=G_R#3Q/H.Y5-URMT$=ITF^N)6@@- M)I7@SCQ=:X;>8C"HM=TF9B^GUI\,+89YJI%EM!9_ 5!+ P04 " 7EU50 M4Z-H(08" T!@ &0 'AL+W=ONE*.4K^[P]520T&4$ M'"KC))A=;O $G#LEF\?O491,GHXXW]_5/_OB;3%'IN%)\E_-R=0%V9#@!&=V MY>99]E]@+&A%@K'Z;W #;N$N$^M12:[];U!=M9%B5+&I"/8VK$WKUW[4O]-P M0CP2X@6!#D8^\T_,L#)7L@_4\/([YGH<[6+[;BH7]*_"/[/):QN]EG- M"8V8_8")9YAH0E"K/EG$F,4^?D>/<7J"9IAX>C*G9RM<($4%4B^0_E?B:E$B MAEGC)BO49(4(9 L3#+/!3=:HR1H1V"Y,WF/2,,1-,M0D0P2BA0F&^:"I&]1D M@P@D"Q,,D^(F6]1DBP@L&X]A/FB\'3[H#0H1B67K4="R]W1V:06HBQ]7.JCD MM?6SEWGPG769 MJ]$*WL-9(S-*R?2?$P@U%3C%;XYGWG;6.TB9#ZR%[V!_#&?M++*JU%Q";[CJ MD8:FP _I\;3W^ #XR6$RFSWRE5R4>O'&E[K B4\(!%36*S"W7.$1A/!"+HW? MBR9>0WKB=O^F_BG4[FJY, ./2OSBM>T*?,"HAH:-PCZKZ3,L]>PQ6HK_"E<0 M#NXS<3$J)4SXHFHT5LE%Q:4BV>N\\CZLTWR2'19:G$ 7 ET)AQ"'S(%"YD_, MLC+7:D)ZOON!^1:G1^KNIO+.\-^BBK'L^HW/!M6#7 M55 '!$I7[@$ &8% 9 >&PO=V]R:W-H965TL&=\ MYIP9FYEL%/)%M0#:>^6L5[G?:CT<"5%E"YRJ.S% ;TYJ(3G5QI0-48,$6KD@ MSD@4! ?":=?[1>9\9UEDXJI9U\-9>NK*.95_3L#$F/NA_^9X[II66P+%&E^JW ]L M0L"@U):!FN4&C\"8)3)I_)XY_472!J[W;^R?7.VFE@M5\"C8KZ[2;>ZGOE=! M3:],/XOQ,\SU['UO+OXKW( 9N,W$:)2"*??URJO2@L\L)A5.7Z>UZ]TZ3B?) M_1R&!T1S0+0$I$Z'3$(N\R>J:9%),7IRNON!VB<.CY&YF](ZW56X,Y.\,MY; M$8=Q1FZ6:,:<)DRTPH0+@ACV12+")$[1N_ (#]^A&>Y<^&X=GGY $*,$L2.( M_RMQORD1PQQPD3TJLD<(DHT(ADEQD0,J),4%4D1@MU&!,/$&Q&R^L\YR,9UN/)*<>W==%EYER'R$+D^^0>?)M W*INN M5]Y%:--MKB=J(3285(([\W2M&7J+P:#6=IN8O9Q:?S*T&.:I1I;16OP%4$L# M!!0 ( !>755!AXVJ@TP$ )P$ 9 >&PO=V]R:W-H965TI7G4#8-"[X)W.<&-,?R1$%PT(IN]D#YU=J:02S-A0 MU43W"ECI28(3&D4Q$:SM<)[ZW%GEJ1P,;SLX*Z0'(9CZ\-+"J%=SY#JY2/GJ M@F]EAB-7$' HC%-@=KC"(W#NA&P9;[,F7BP=<3W_4'_RO=M>+DS#H^2_V](T M&4XP*J%B S?/8/=?B_%-BR',(6RR#YKL P+)C4D(!;71C$L+<_BZR.AT" M5.WOA4:%'#I_)U?9Y>H]4'^Z_L&G>_N#J;KM-+I(8\^H/TF5E 9L*=&=;;BQ M3\42<*B,FQ[L7$T79@J,[.>W@"P/4OX74$L#!!0 ( !>755"*,O]OV0( M -L* 9 >&PO=V]R:W-H965T_L90RFU+]66'P&;<^\Y]P*'N[I* M]=R=A-#!2UTUW3H\:=W>Q'&W.XF:=Y%L16.N'*2JN39+=8R[5@F^MT%U%1.$ MTKCF91-N5G;O06U6\JRKLA$/*NC.=LZQ.'KQF-Y/.E^(]ZL6GX4 MWX7^T3XHLXJG+/NR%DU7RB90XK .;_'-%A=]@$7\+,6UFYT'?2E/4C[WBR_[ M=8AZ1:(2.]VGX.9P$?>BJOI,1L?O,6DXUG]*O?Z MM [S,-B+ S]7^E%>/XNQH"0,QNJ_BHNH#+Q78CAVLNKL?[ [=UK68Q8CI>8O MP[%L[/$Z7,FR,0P.(&, F0)P^F$ '0/H6P#[,("- L_4Q*8%54+!0:N/I7 5%< (&)F V 7LGDCF%#)C,8IJA M4WE4P"P)R)( +(G#,F#R&0N+$I@D!4E2@"1U2%*/!$4I3)*!)!E DCDDF4=" MEDARD"0'2'*')/=O"HX6GIT"9"D EL)Y20J/!47.C=L.F&1>+BP#(_AE1;X0 MAMRW%7E-Q0A%CMXM "M0Q-#LM_"6XP4GP8 X[(K#'BO-(N9J\U&,+-TR#+K. M+2: ',_9B-^$;*D)HS8_),=1\2]]@XT)4T H=852[_$B-(DR5QP PXOF@&&C MPX#3,;:0 G8QG'ANR]B2"MBC,&!2+'7; H&R!1[8IC#@4RQ?2 &;$,[_HUK8 M83!@,7ZU$,C]NL2S+W\MU-%.55VPD^?&CG2SW6ERNR5V%PIW3D> ! 3!0 &0 'AL+W=O)4U@/+>6];)#-5*]5N,95%#2^6&]]#I)Q47 M+56Z%"P&TM*26X=#W$]S2ID-Y:GL'D:?\K%C3P4%X\MRV5/QY!,:'# 7H MVGAN3K4R#9RG/3W!3U"_^H/0%9Y4RJ:%3C:\\P14&?H2;/>)P5O 2P.#G.T] MD^3(^:LIOI49\HTA8% HHT#U*IJG@@^>&/_= MGII#%&R)GGYAFG;8]ID>C]3=2TYB/\47(^0PCR,FG&'"6\1NB4CN(/LEA,3! MA,':Y.0T7'4:6H'H1B!<%XA6!2(K0&8" ;F/.F(>+*8;,3'YO"%W>5=@41S- M8#=VR*H=LK!#XFA=(%X5B#\^D&15(/G_0/;),FFPR(EGI\U<%S^H.#6=](Y< MZ8-KCU?%N0(MZ&^T[5K?4%/!H%)F^Z#W8OQ.QT+QWEU!>+H'\[]02P,$% M @ %Y=54$IQU8!Q P I!$ !D !X;"]W;W)K&ULE5C;CILP%/P5Q <$;'/+*HFT256U4BNM6K5]9A,G00LX!2?9_GV-8=D MXRR\!'#FC,\9&-\65U&\E$?.I?6:I7FYM(]2GAX>1:7,W'BN?IG+XHL MENJQ.#CEJ>#Q3@=EJ4-=-W"R.,GMU4*W/16KA3C+-,GY4V&5YRR+BW]KGHKK MTB;V6\./Y'"458.S6ISB __)Y:_34Z&>G)9EEV0\+Q.16P7?+^U'\K#Q=(!& M_$[XM;RYMZI2GH5XJ1Z^[I:V6V7$4[Z5%46L+A>^X6E:,:D\_C:D=MMG%7A[ M_\;^61>OBGF.2[X1Z9]D)X]+.[*M'=_'YU3^$-P_P=/%U M9KK43[&,5XM"7*VB?ENGN/HHR -38FZK1JV=_D]56ZK6R\KSO85SJ8@:S+K& MT!L,:1&.8F^[H*B+-1V$TVX'FR$BH+@'!HM@.IYUBO Q@0<)/$W@=0B"G@HU M)M287&.8-YOW*@$@-O-P*CY,Q0>IA+U4$";J97(?TTDD@(D$@&"."4)($(Y_ M*Q$DB$:\E6@@N#\+<"=SV,E\V$G@8@+B8@NYXPLE!A>2$6\=@0+2>^T09# 3 M@7Y])!10, ,%-B29X$B"+4F0)P>2 %#@]25!(%,RV)0$N"DP?&8$VXD$$R3! MAB+A&$D * C[DB"0870@V)P$N#,PC \$6X_,QTM"L?>H.T(2! K=_AQT']1- M!KN8 N^%IJD2>X_2"9)@[U$V1A( "@?3,@(9!@**74R!]T+#?$BQ]Z@_01+L M/8KFLH$D !3Z?4D0R"0)=C$%W@L-8PG%WJ/1!$FP]RB8]X:2 %#8'TL@R#"6 M,.QBAKQG&$L8]AXCXR5AV'L,S'L#21!H,)9\ .HF8UC2 N]%)@KL/>9-D 1[ MCXU9C2)0U%^7? #J)H-=S(#W(M,^ 7N/35B3,NP]AE:E TD *&)]2>Z#NLE@ M%S/@O<@PO'K8>]Z$U:N'O>>-6;TB4-0?7C\ U*>ISR^^Q\4AR4OK64BU\];[X[T0DJL&ULA9;;CILP M$(9?!7%?L#D3D4A-JJJ56FFUU;;73N(D: %3VTFV;U_;L"C80YN+@,T_\_T^ M,*:Z,_XJ+I1*[ZUM.K'V+U+VJS 4APMMB0A83SOUY,1X2Z1J\G,H>D[)T02U M31@AE(4MJ3M_4YF^)[ZIV%4V=4>?N">N;4OXGRUMV'WM8_^]X[D^7Z3N"#=5 M3\[T!Y4O_1-7K7#*P9>]6- MK\>UC[0CVM"#U"F(NMSHCC:-SJ1\_!Z3^A-3!S[>OV?_; :O!K,G@NY8\ZL^ MRLO:+WSO2$_DVLAG=O]"QP&EOC>._AN]T4;)M1/%.+!&F'_O V(K(!R>L "@X69JT$N24 ">U5K!TMG^$ NL]VI6.&8S1 MDA>,X+*! #>971.00XJ6YA8OE"?LGDEUX)AC MX<28I"HA"M1[?U%?"E.CH2>I;]7!YO'AN!P:DO7CIT X?8]L_@)02P,$% M @ %Y=54"QRE%&U 0 T0, !D !X;"]W;W)K&UL?5/M;ML@%'T5Q ,$?R3-&MF65D]3)VU2U&GM;V)?QZA\N$#B[NT'F+IN M&NV/N?=RSN'<:RA&I9]-#V#1J^#2E+BW=M@18IH>!#4K-8!T.YW2@EJ7ZB,Q M@P;:!I+@)$N2&R(HD[@J0FVOJT*=+&<2]AJ9DQ!4_[T#KL82I_BM\,".O?4% M4A4#/<)OL'^&O789F55:)D :IB32T)7X:[JK$'!HK%>@;CE##9Q[(6?C)6KB^4A/7,9OZM]#[ZZ7 S50*_[$6MN7^ M& M+73TQ.V#&N\A]K/!*#;_$\[ '=P[<6J_7M;4'.7BAB[B9,ML!D'Q'U9\3-.X0X [.+[*J++/#S!7^3)-<% M\JL">1!8?Q!(+]J8,-N D0&3)JL+4/T9M%EM+YR0Q7#]9?]%]9%)@P[*NO\4 MIMDI9<'I)2MW@WKWON:$0V=]N'6QGF[9E%@UQ =$YE=<_0-02P,$% @ M%Y=54**M!,7: 0 ;P0 !D !X;"]W;W)K&UL M?539;MLP$/P50A]@RCJ&.4J#SJMASW&JNJ $;41 W"ST@C)B#:A;+$:))#: MD1C%41CN,",]#XK,Y8ZRR,2H:<_A*)$:&2/R[P&HF/)@&[PGGONVTS:!BVP@ M+?P$_6LX2A/A1:7N&7#5"XXD-'GPN-V7B<4[P.\>)G4Q1[:2DQ O-OA6YT%H M#0&%2EL%8H8SE$"I%3(V7F?-8-G2$B_G[^I/KG93RXDH* 7]T]>ZRX-/ :JA M(2/5SV+Z"G,]:8#FXK_#&:B!6R=FCTI0Y;ZH&I46;%8Q5AAY\V//W3CYE?3S M3%LG1#,A6@AF[_\1XID0?Q!VKGCOS)7ZA6A29%),2/K+&HA]$]M]; ZSLDEW M=F[-5*M,]ERD893ALQ6:,0>/B:XP\36FO,=L%P0V#A8;T9J-0W1'W]VX*.\A MT?H.\6JAL:/'5T4DZP+)JD#B!)(K@?3FI#SFP6&X/X7MYO:H[D'IYM8)OK@_ M!K)U3UVA2HS*W02VKPB=]>-$!J,E7!CWG=G MNG\)*#3:3A_,7/H>\($6P]S>>/G'%/\ 4$L#!!0 ( !>755#G+'%XM0( M /P) 9 >&PO=V]R:W-H965T_ME06RZRWO)"V_&?F-P.V,[M2 M]LI/A CGK:E;/G=/0G1/OL]W)])@[M&.M/+)@;(&"SEE1Y]WC."]-FIJ/PR" MU&]PU;J+F5[;L,6,GD5=M63#''YN&LS^EJ2FU[F+W-O"),N8[+^3"ZFE7)'(&#M:<_WK[,YIZ-JLL<"+&:-7A_6OM\/J M*T)/L:S^3BWJ8NMGLCQ M!UA-%:DE60.2"(:(P#PC;1^-(>(/LHA!![%V$-\5*K,*U6LRK6EO03Q+M0)4 M0>H55L)3%4J"D:\[Y 1$3@#DW$+N->DH3!8'^K*H 6%4 ,+U)X1W["G(G@+L M5HG*=!()Q1 ZH$L@9Q/J0'9 QP4P%MJ, %"J;U5&-&G M0WVP>R,@E/T7-Z+Q5I)'7E",+ZL.@$D6>);C-:2*/;-]]-<'6RP"3XHE"H%7 M&=GI]*+B[@N,O+RP0OFC([ A[*C;"^[LZ+D5ZB09K0XMS%)W,-9ZJ5H;?;2^ MN^G[HA^8':N6.ULJY &MC]$#I8)(S,"3^^!)MF+#I"8'H8:9'+.^'^DG@G:F MU_*'AF_Q#U!+ P04 " 7EU50,8F/MK(# !'$@ &0 'AL+W=O MZOK\X/O5[J3SI/+,61?--P=3YDG=W)9'OSJ7.MEW@_+,IR (_3Q)"W>[[IZ] ME-NUN=196NB7TJDN>9Z4/YYT9JX;5[CO#[ZDQU/=/O"WZW-RU/_H^M_S2]G< M^3,^BH=G&;8#.L5_J;Y6HVNG#>75F*_MS9_[C1NT'NE, M[^K61-)\O.EGG66MI<:/;X-1]S9G.W!\_6[]?.\_ MTZ+[O [VWX?A 30,H-L $?YV \#^-< V07?>]:%^BFID^VZ-%>G['^M<](6 MA7C@)IF[]F&7N^Z[)MJJ>?JV54*N_;?6T*!YZC4TTHB;PF^LWZ8@-,4338;3 MQPF>IXJ0\ P,@^!N/'\(0F$#$AJ0G0$YCE#<.?G4:U:=IN@U$06>N(L%R%:* MO!5V1T%WU,0=)4)L((0&POD)64$#JQD)Z371*%*B23J */!B[$H$78E ,BS9 MC*&!>'XR1( A"6:D8Q"-?WFUHE&L?4(&V3@C*HP]"U'"0JT 28DL)B"5CX(6 MI 5C)QAX$=^G!8@HL,R#Z113/!79$H:)$FI!M)@I$( M+28P,B):$"V&1L1S2KX7J5$M1R,VAX*/)P4?!:%M021,($T)5"0M)C S).8G MA3 S1#-* (G(-@\&BQ SE@V ,#,D%T2+F2&T#4VB!2*R_;88+$+,6!8SPLS0 M:D&TF!F:[C/3@A]$'W9W8B^Z*_E!-BYY(91GBPD32%,"%5EV3L;4<# _+8RI M8;33W!,%@-JV++&LZ4+7- &,J:&P4XSC1:(V-:O8K084,.6-9XQ M-;R@QV-,#<_I\@;1AY)7R@OO2IZGC9Y0PM;6,&:00:_'EE6>,36\H-N3F!H) M]II)$2 1V^;!:$E$C665EY@:N:")DY@:.:>)0R*VK/+2\HJ%J+&LB!)3(Q35U;?+N%?Y@3*T;SP*O2=1))_O;3:8/=7NY M:J[+_FBCOZG->3BV\6]G1]N?4$L#!!0 ( !>755#E(PC4< ( %L( 9 M >&PO=V]R:W-H965T4Y%( M)=&T29L4=5KWV2%.0 7,;"=T_WZVH93@:[1\"/;Y>>Z>NYB[9#WCKZ*D5#IO M3=V*M5M*V3TB)(J2-D0\L(ZVZN3$>$.DVO(S$AVGY&A(38U\SXM10ZK6W63& MMN>;C%UD7;5TSQUQ:1K"_^:T9OW:Q>Z[X;DZEU(;T";KR)G^I/)7M^=JAR8O MQZJAK:A8ZW!Z6KM/^'&'#<$@7BK:B]G:T:D<&'O5FV_'M>MI1;2FA=0NB'I< MZ9;6M?:D=/P9G;I33$V*3!!'\D M^!,!QW<)P4@(/@CA74(X$L(% 0VIF-KLB"2;C+/>XMU$P2I#5^UHQ.0#QI]A\(1 ROL4PH="Y+Y%]V\#;&U$O(#L $@ MBPC / /##^9YX@AV$((.0N,@G!%&C"1P;0#QAL_BXPA)$X Y,Y&KL+@ M%GBC/@+51Y;Z*%Q$R@=,/(NT5'T/<2,B!D7$@ B\$!%;(3!80!NW@JIGP_SD M3O$24'<"Z%[V',].4WG_G SC-T?A)^K5C@')E7_-UWZQ)BD2J;WH 26:M)/ MFYJ>I%XF:LV'<3=L).O&48ZF_Q.;?U!+ P04 " 7EU50Z>SSNE(" 1 M" &0 'AL+W=OZ]XK=9^H76S0D@="E91]20:5IN5DY 5U68HST@UDM&C"ZHX"H,@014M M:S_/W-Q.YIFX:%[6;"<]=:DJ*O\\,R[:M8_]CXF7\EQH.X'RK*%G]H/IG\U. MFA$:6(YEQ6I5BMJ3[+3V/^'5%A,;X!"O)6O5J._94O9"O-G!U^/:#VQ&C+.# MMA34-%>V89Q;)I/'[Y[4'S1MX+C_P?[9%6^*V5/%-H+_*H^Z6/L+WSNR$[UP M_2+:+ZPO*/:]OOIO[,JX@=M,C,9!<.6^O<-%:5'U+":5BKYW;5F[MNU6TK0/ M@P/"/B < D+\SX"H#X@>#2!] )D%H*X4MS=;JFF>2=%ZLOMY&VI/$5X1L_L' M.^DVVZV9[5%F]IK'),G0U1+UF.<.$TXPZ12S@3"+*68+898#!ID\AV1#,-G0 M$40C A*',$$$$D2.@(PSB(-9M1TF=IC:8=([&@34(#<:&,W2^8E%HZO6/I;?J3R7M?+V M0IM;V]VM)R$T,WS!DV$JS/L\##@[:=M-35]VCU0WT*+I'V T_ O(_P)02P,$ M% @ %Y=54 3[GG(@ @ "P8 !D !X;"]W;W)K&UL?53K;ILP%'X5Q -@[J01(#6)IDW:I*C3NM\..0FH!C/;"=W;SQ=* M*7C]$]N'[W+.B7WR@;(77@,(Y[4E'2_<6HA^BQ"O:F@Q]V@/G?QRH:S%0A[9 M%?&> 3YK4DM0Z/LI:G'3N66N8T=6YO0F2-/!D3G\UK:8_=T!H4/A!NY;X*FY MUD(%4)GW^ H_0?SJCTR>T*1R;EKH>$,[A\&E UX;F#@L[VC*CE1 M^J(.W\Z%ZZN$@$ EE *6RQWV0(@2DFG\&37=R5(1Y_LW]2^Z=EG+"7/84_*[ M.8NZ<#>NO,-:3N,Y8_'>X Y%PE8GTJ"CA^M>I;ES0=E21J;3X MU:Q-I]?!?(F3D68GA",AG A!^BDA&@G1.R'^E!"/A'A!0*84W9L#%KC,&1T< M9O[='JM+%&QCV?U*!76S]3?9'BZC]S))LAS=E="(V1E,.,,$$P))]1@@43V)")KG9'F1_,DXLPN$%L%8BT0?VC49M$H@\DTIC.- M"KT'NTMB=4DL+@\+%X/9S%Q\;V,W2:TFZ=HD]1U"*^ MDY/.#*9W&3,F?V!V;3KNG*B0#U8_JPNE F2.OB?+K.5DG@X$+D)M,[EG9CZ9 M@Z#].'K1-/_+?U!+ P04 " 7EU50F2.?_] ! Z! &0 'AL+W=O M0U*B\U'I9],!6/0BN#0%[JP=#H28 MJ@/!S$8-(-U)H[1@UIFZ)6;0P.H0)#BAV^T=$:R7N,R#[Z3+7%TL[R6<-#(7 M(9C^P/X:3=A:96>I>@#2]DDA#4^#[W>&8 M>GP _.QA-(L]\I6ZP%N?$'"HK&=@;KG" W#NB5P:OR=./$OZP.7^ ME?U3J-W5V*_ 'C&IHV(7;)S5^AJF>%*.I^*]P!>[@/A.G42EN MPA=5%V.5F%A<*H*]Q+6781WC299-8>L!= J@&5H1SESRQGFO97I'VG065GW@L(] M-TI9<*EL-RZ7S@WR;'!HK-]F;J_CD+A[^QW8L=S(^V*X MX_?G[@QI9^RGJP$\^=*J<1FMO6^WC+FB!BW.+Q89I(1N:IS&WMWEJ3E[)!O:6N)/6PO[=@3)=1I?TDGB5Q]J'!,O35ASA M#?Q[N[<8L5&EE!H:)TU#+%09?5AN=TG 1\"'A,Y-]B1T-'E2P%"V^^E4V<>WZD_7]0)LG M\(' 1P+?Q%YZHUCYD_ B3ZWIB.UGWXKPBY=;CK,I0C*.(IYA\0ZSYWR]6:?L M'(0&S*['\ F&CPB&ZJ,%G[7@D;Z:TI/;>8'5K, J"B3?:MQZO3-AD\N%B_Q+V*!M'#L;C3XRCKHSQ@'J+&[PM-;ZE,5!0^;"] MQ;WM;U0?>-,.CX6-+S;_!U!+ P04 " 7EU50K&YS#9$" "T"0 &0 M 'AL+W=O\1=QH50ZKTW= MBHU[D;)[\CQQN-"&B!7K:*N^G!AOB%1#?O9$QRDY&J>F]@+?3[R&5*U;Y&9N MQXN<765=M73''7%M&L+_;&G-^HT+[MO$O#EN'%]G1&MZ4'J$$0] M;K2D=:TCJ3Q^CT'=.U,[3M_?HG\RQ:MB]D30DM6_JJ.\;-S,=8[T1*ZU?&;] M9SH6%+O.6/U7>J.U,M>9*,:!U<+\.H>KD*P9HZA4&O(Z/*O6//OA2YJ,;KA# M,#H$=P>(_NL0C@[AS,$;,C.E?B22%#EGO<.'W>J(_E/ 4Z@6\Z GS=J9;ZI: MH69O19SZN7?3@4:;[6 33&R"]Q:E;9'\,_%4 O:-([ HL+#[@"L?'I!^.1K-5!DO@'#QPP/J+\&6_Z)F )<_/*#_$NP&D*S6 M"QR\ \ #+: $NP?$B^N&-P' ND RY]AM(%Q>.+P1@-T)(+9 F74*9&!5Y$V. M3WV?^4;XN6J%LV=2G<3FO#PQ)JF*J/Y&KG-15ZC[H*8GJ5]3]\0PD*P; M[TC>_:)6_ 502P,$% @ %Y=54*W5>='# @ = L !D !X;"]W;W)K M&ULE5;M;ILP%'T5Q ,$;# ?41*I:3IMTB9%G;;] M=A,G007,;"?IWGZVH93 ):+Y$6QSSO$])B?LU'<.7!14Z:DX>K(2C.XMJ<@][/N15]"L=%<+N[85JP4_JSPK MV58X\EP45/Q;LYQ?ERYRWQ>>L^-)F05OM:CHD?UDZE>U%7KFM2K[K&"ES'CI M"'98N@]H_H0#0["(WQF[RL[8,59>.'\UDV_[I>N;BEC.=LI(4'VYL$>6YT9) MU_&W$77;/0VQ.WY7_V+-:S,O5+)'GO_)]NJT=!/7V;,#/>?JF5^_LL80<9W& M_7=V8;F&FTKT'CN>2_OM[,Y2\:)1T:44]*V^9J6]7NL[A#0TF( ; FX)*+I+ M"!I"\$$([Q+"AA!.)9"&0'H$K_9N#W-#%5TM!+\ZHOX]5-3\[-"U,XOV MZ=A[^CRE7KVL2)PNO(L1:C#K&H,[&-0B/*W>;H&A+=9X0,>W&SP.$5$/L@$@ MP2WD:0@AB0\7&H!G$5B!X$9@Q&D("H16(+P1Z!E9UYC88DJ+2X*9N 99-!V2A.>F630=GA+(4WB 1G :73W6(X#-B?X!8$D?X[9@@*8]Q_A=Q7NJT8SAX&8I6._!UC.%88?^+< MX%CA8,JY0:"^6Z_3211,'&U;)YT=/Y?*O&T[JVWK^(!-)]);7Z/YIFX /V3J M?O0'%<>LE,X+5[K/L=W(@7/%=(W^3(?NI%O@=I*S@S+#6(]%W0?6$\6KIL?U MVD9[]1]02P,$% @ %Y=54'+J7%/0 @ ?PH !D !X;"]W;W)K&ULE9;;CILP$(9?!7%?P)Q9D4B;1%4KM=)JJ[;7WL1) MT *FMI-LW[ZV(03LR;;E(MC./^-O!FL\Y86R5WXD1#AO3=WRA7L4HGOP?;X] MD@9SCW:DE?_L*6NPD%-V\'G'"-YIHZ;VPR!(_097K;LL]=H36Y;T).JJ)4_, MX:>FP>SWBM3TLG"1>UUXK@Y'H1;\9=GA _E&Q/?NB45;AY'] MPGU$#QL4*P.M^%&1"Y^,'17*"Z6O:O)YMW #141JLA7*!9:O,UF3NE:>),>O MP:D[[JD,I^.K]X\Z>!G,"^9D3>N?U4X<%V[N.CNRQZ=:/-/+)S($E+C.$/T7 M6UES_.ML3%[09O$B4!K_U[ZK5[\O@_VH&&X2#03@:H/1=@V@P MB&X&\;L&\6 0&P9^'XK.S08+O"P9O3BL_[P=5J<(/<0R^UNUJ).M_Y/IX7+U MO$P*5/IGY6C0K'I-.-'<%+[T/FX10ENL0LL\G&^PMA6I(=D D@B&B, X(VT? M3>/,[T01@PYB[2">)S M2!(PD@2()#(BZ37Y9,O0,[^:K4%>9J"_[V<&FX*P*0 ;&["I#8(2STRUK*B8/087 M9&%XW=B:W+MS1@L0O0#0C;.U*H#S9\)"FA0&00%<( , )3PN1!-D_DQ2;.7U1S'+"X/Z+0QLGOG%($EV;T'[49P<49 MV=4Y#0(S*78=_1#82?D7U096)0:T/[F%&\(.NL/ASI:>6J$NL\GJV$4]ANH6 M-]97JKO2M_O-3=^:?<7L4+7<>:%"]@CZ)M]3*HB$E#RN755!;6:B$T ( & + 9 M>&PO=V]R:W-H965TU'6_(98A2'HCMG)DY,QX.L[@Q_B;.E$KGO&(5+=6;(^,%D6K+3YZH."4'8U3D'O;]R"M(5KJKA3E[ MYJL%N\@\*^DS=\2E* C_NZ$YNRU=Y'X5K]FNT7R+4FU@$+\R>A.MM:-3V3'VIC??#DO7UXQH3O=2NR#J M<:5;FN?:D^+QQSIUFYC:L+W^\/[%)*^2V1%!MRS_G1WD>>DFKG.@1W+)Y0N[ M?:4VH=!U;/;?Z97F"JZ9J!A[E@OS[>PO0K+">E%4"O)>/[/2/&_UFPA;,]@ M6P/<&*!HU""P!L'=8&:2KYF95#\3258+SFX.KV^K(KHIT#Q0Q=SK0U,[\TYE M*]3I=17Y:.%=M2.+V=08W,+<$9[RWH3 4(@-'ICC;H#M$!%A.$( )A$8^Z"3 MQ ,',]#!S#B8=1P$O2K4F-!@RKH*?ICX^M-+!T+&<1?9(16"I$* U*Q'JL9$ MK5 X&@D4@8$B(%#8"Q0- GV*H-P!'$I'&,4@HQA@%/48Q8-(JLK@?4#(_LUU M2"4@J00@%<,.4M!!.KU-D0__6OT)C6I![7SC^J[ZA8&0\5C_H XVFYP>I5[&:LWKF:_>2%;9>=9KANK5/U!+ P04 " 7EU509J/#X$T# M #D#P &0 'AL+W=O'U4W-D3%@O95$U2_LHQ.G.=9OMD959X_ 3J^0O>UZ7F9#-^N VIYIENRZH M+%STO,@ML[RR5XNN[[Y>+?A9%'G%[FNK.9=E5O]=LX)?EC;8KQT/^>$HV@YW MM3AE!_:#B9^G^UJVW&N675ZRJLEY9=5LO[0_PMW&]]J 3O$K9Y=&N;?:4AXY M?VH;7W=+VVL=L8)M19LBDY=GMF%%T6:2/OX,2>WKF&V@>O^:_7-7O"SF,6O8 MAA>_\YTX+NW$MG9LGYT+\< O7]A04&A;0_7?V#,KI+QU(L?8\J+IOJWMN1&\ M'+)(*V7VTE_SJKM>AORO870 #@%X#8#@S0!_"/ G 6[OK"OU4R:RU:+F%ZON MG]8I:Q<%W/ER,K=M9S=WW6^RVD;V/J\B+UVXSVVB0;/N-:AH<*S8Z(KHO\25 M!JXND'2!7;ROQH-')_#)!'Z7(!@E@$D9O2;N-%6GB1/'2]7/I"P](@J=F<(" MTE= ^)I,WKK7),HH'X+$\2=>*%7@I+29D#03$F8FPZQ#;1A,G63BA1!YBN&1 ME8BT$A%6 CI!3":(S5=,0B9(#%9,HM<)3CB9#%T$J1/15E+22FJP2'I-I#Y^ MB"9.4GV)0.@ ;04\F@>>P2(91.I(H38OA"A01&,S,W "PLQ<"IHL< -:@&8+ MF,!E$*G5^MH[_(YH;(8&"I@0!0A8Z N75LW@#6BD@ E30.<%:$PA1#B[=FFH M $65F3<1:*S #5P!&BQ@0I9!I+[/VI[ZEF1LA,8*F' %*&CH#^<=U7B+I\F" M)F1!'1J>,YV9=T1C,S19D")+/)-BYC_+#61!FBQH0A;4H1%X&EH(E=RX9]B" M-%O0A"U(4$/NBM.]:)"--BR?[]G]2&O&NN1"WERZ\Y7>\X%DPD]1Z[%HSQR M7QL%VXOV-I;W=7_N[!N"GX8SM7L]V*_^ 5!+ P04 " 7EU50L#GY&((" M "&" &0 'AL+W=O@@$2 JI5:Z715VV<#!J)+XM0VI&QFOB]V)UH1X;&&UNK-@?&*2#7E1U\TG)*](56ECX,@ M\2M2U.XB,VM/?)&QLRR+FCYQ1YRKBO"_.2W9=>XB]VWAN3B>I%[P%UE#CO0' ME3^;)ZYF?A]E7U2T%@6K'4X/)9AN$-<$@?A7T*@9C1Z>R9>Q%3[[NYVZ@ M'=&2[J0.0=3C0E>T+'4DY>-/%]3M-35Q.'Z+_MDDKY+9$D%7K/Q=[.5I[DY< M9T\/Y%S*9W;]0KN$8M?ILO]&+[14<.U$:>Q8*6W?I$E'@PFX(^">@#XFA!TA?"=$'Q*BCA ]2H@[0FP1_#9WLYEK(LDBX^SJ M\/8^-$1?.S2+U7'M]*(Y'?-.[:=0JY=%@J:9?]&!.DS>8O @WJ$KZ+W$AB2 MR/&(CF\%5F-$8D'6 "2\A6S&D"@,8:,AN!>A"1 . T0Q'" " T0F0'231V!M M9HM)#:8VF$^!9Z6R^@_HQDH,6HD!*\BRTF(F Y70BRPG\<@)]E+K;"!,!)M- M0+,)8-:Z 'F+208B=R124"(%)*Q=SU-@/^Z<_P04F0 BUH;FD\=%IJ#(%!") M+9'I2 1[4U@$!7!=" "9Q"X, 7#RR1V=._4'C72BT+I@FP[TF Y8A)8( SH3 M6P>/=!#RL"7D#VIK1?G1-#KA[-BYEKK^#%;[9KHTO=1:S]%LW;;$]S!MA_Y. M^+&HA;-E4E5^4Y\/C$FJ3 :>^KN=U$=!/RGI0>IAJL:\[8SM1+*FZ_I^_^FQ M^ =02P,$% @ %Y=54".Y!?&0 @ 2@D !D !X;"]W;W)K&ULC9;;CILP$(9?!?$ @#F&%8G4$%6MU$K15MU>.XD3T *F MMI-LW[ZV(8C80]5>46(<#[:IN-KMQ*B?_%]?JQ(B[E' M>]+).V?*6BSDE%U\WC."3]JH;?PP"%*_Q77G;@J]MF>;@EY%4W=DSQQ^;5O, M_FQ)0^]K%[F/A=?Z4@FUX&^*'E_(#R)^]GLF9_[DY52WI.,U[1Q&SFOW$WK9 MH5 9:,5;3>Y\-G94*@=*W]7DZVGM!HJ(-.0HE LL+S=2DJ91GB3'[]&I.\54 MAO/QP_MGG;Q,YH Y*6GSJSZ):NVN7.=$SOC:B%=Z_T+&A!+7&;/_1FZDD7)% M(F,<:'NLJ@B]Q'+WCVI1;[:^)[>'R]7;)@VSPK\I M1Z-F.VC"F29\5I2V(C4D.T 231)?,DZ@(0@::OMH#I%DL(,(=!!I!_$3X\K( M=-!D6M,-03(O,9(%1,E,](02@R@Q@)(;*(-F-8N"D&?PEJ H,G8^MGA1X,4P M;P+R)C9O%!B\B862>VG^]#/@;8O$6WBB*8B5 EC(P$JM()EG@MB:T%NHS0P$ MR0 0H_ZWF14DM2K+UBP6U@H$60$@1CEL5T 0= A3SN M]*%TIE00Z3[P9+.HY(?--&G(6:AA)L=L.-V'B:#]^.7B3Y]/F[]02P,$% M @ %Y=54)Q 75]< P 6Q$ !D !X;"]W;W)K&ULE9CICILP%(5?!?$ 2]LHR12)U752JTTFJKM;R9Q$C2 4W"2Z=O7+),2 M?%S!G[#DW.-[;3X;L[S*ZK4^"J&GM*#^"[4C]-3I:^\F\LN*T199[)T*K%?N1_(PX;S M)J!5_,S$M1Z<.TTI+U*^-A=?=BO7;S(2N=BJQB+5AXO8B#QOG'0>OWM3]]9F M$S@\?W?_U!:OBWE):[&1^:]LIXXK-W:=G=BGYUP]R^MGT1<4N$Y?_5=Q$;F6 M-YGH-K8RK]M?9WNNE2QZ%YU*D;YUQZQLC]?NGR#JPW [0/H+8#P_P:P/H"- M KPNL[;4CZE*U\M*7IVJ&ZU3VCP4Y('ISMPV-]N^:__3U=;Z[F4=LFCI71JC M7O/8:>A 0^\5&U,1_I-X.H%;%A1F0=MX=I=%C T8-&"M ;\S2$9E=)JHU92M MQE^,2MT@38@3X3 1;B;"_5$BG288-$*#8)1(IPD'&I)8$@E@(@%(A&"#$!J$ MT\HC!3S%QA MS+'K1<.QBVR98N[8%.Z@R+*$,,M+X13N>M&D0=AF#LV@SN&N6-3 MN&,F=XEEE6&8.X:0LLS<#"/%9BQ4#./"3%Q LX<$2"L:>@QLXECA867CCFA4]YM4.BP+9%LNR1T*O=>+?&S5V2\:AZ@UUN M\]GA6UH=LK)V7J32&^9V6[N74@GMYR^TTU&DN]M%+O:J.8WT>=5M][L+)4_] MIPSO]CUE_1=02P,$% @ %Y=54'1?/J&ULE9K=;N,V$(5?Q? #V.(_N7 "Q F*%FB!8(NV MUXK#Q,;:EBLIR?;M*\F*5^:<64A[L;:50PZ'FH\SI+3Z*,IOU3;&>O;]L#]6 M-_-M79^^+)?59AL/>;4H3O'8_.6E* ]YW?PL7Y?5J8SY<]?HL%_*++/+0[X[ MSF]7W;7'\G95O-7[W3$^EK/J[7#(R__6<5]\W,S%_//"U]WKMFXO+&]7I_PU M_AGKOTZ/9?-K>>GE>7>(QVI7'&=E?+F9WXDO#R+K6G22OW?QHQI\G[6^/!7% MM_;';\\W\ZP=4MS'3=WVD3MR!AAWHK@,][$!GR42=-:;3',^>&I/X2C4B6#P0 P=BR$"<2,9QEOB!C;#0 MR3B01F7#?TFO#^<6;CCR;&'PT"T .'.S $=^-2R)E[8AC&-&:LQ*@E0"L)/=H'<:[(C*,=P;,F)3OC-@12BT8/ 2SD A@R::6 MSB([L.0XA^!B7X6968& F((;,*14P 2(R51)F8S"H2.<8.9D\" MK$S&=(&QDBCA<;.*B9&(F'#M[7TONEKO_(*+ ,R5I&G/6BX.,5\Q$CDF'!53 P/X M#)/3%(9/3"J I^&&BO%4$_#4&$]-\10J7>,UQ=,PSFI,IT8)+0T136M)U@R&4R/NTA#I M1:.\P=AI5$JF(0)%S/*KF1TJR'GL4#&;VDP($ 4R1G7PO&L:(XLH\@\$S #RRE^]%5W8X,\S!#TB<9"_? MBX9F."N87P/R)MG']Z*KDXG@N,,@@Q$V%&%:&QEZG",6R7)R;VC]FW'EK\&@ M&Y1?.7\PQ&9"?K683XOX3,M22X]KV-,-BR&V-,'2J>]%_FI6F9+#8M(M(#U= MI=>]:!BR@8E9BT&W:%>9QFPO,F/,8,[MF)TG$ADF%BT&W:(*.3WCLO0XUKL% MDPXL@Z@YYE5PF&LW(2')@XCXP -/DV-O>CZN)99>QU&Q@%D/-<% MAL%-.*QQS.,)4)3Z=!URM"CE"@&'@7&(!89\AUEP$W*5QRQXD*N(LY[N!27C MK,>\>(0"-U*,@I]PN.DQ"AZ5DBFU2.29YUL>\^(!+UR6\A@%C_9PW"@P"A[D MA9#NX3RM 15'K<>\>,!+8)8YSSRLF_ XP&,6/,@+]-X"4> >^&%@ @ F,&?? M <,0)FR^ H8AH,U7ZBT2!>;>!DQ, #!P#[H#AB&@PT8FD@.&(8"\0"(YT#T3 M=ULP+P'QPBS( :,0)M11 :,0QM112!0X.\R3:X0"OVO9/!UR?>$FN;YNWX3J7L3Y MTG_M6LY>7]L-O_ 5!+ P04 " 7EU50[>C&BL4# "#$P &0 M 'AL+W=O[GGSL#Z(HO?Y4D(9?W- MTKSESE>.4^Y/(HO+E3R+O/KE*(LL5M5E\>R4YT+$AX:4I0YU7=_)XB2W MM^OFWF.Q7"RL\B7+XN+?3J3RLK&)_7;C6_)\4O4-9[L^Q\_BNU _ MSH]%=>5T*H8I+<2W37\E!G39V M:%L'<8Q?4O5-7NZ%#LBS+1W]%_$JT@I>SZ0:8R_3LOEO[5]*)3.M4DTEB_^V MQR1OCA>M_T;#!*H)M",P\BZ!:0*;2^":P.<2/$WPYA)\3? [ GV?$&A",)<0 M:D(XEQ!I0M012-"42/O\FH*XB56\71?R8A5M39_CVCKD*JI*;E_?;"JL^:VJ MB;*Z^[H-7+)V7FLAC=FU&#K T"'F&F'8$'.#,'R(N448;XBY0QA_B/D\Q7@\ M&F+ND4XPQ#P@3-AAG"JW78(I3#!M!/A (,("# JP1H#U!8B+!3@4X-,9D/$C M;C'$;4"YGN:JFFGO;_3$EU-NEE-N%U$&R?!@,CR0C%$M[UJ,WQN2,"_R1Z5Q M/0]V,P]V.P_V,(4QC_HAQ3GP80Y\D .&!0(H$,POR1 *A& &HTYPUV((Z6?$ M,$@$!XG (!X6J.L+-4=W?J#$T%\)F(4_;HPM*!@\_!4?M[0/4,/IX&Y$0#LB M@4$"]R.RH"$1W)$(:DF3I/!)J4>F8;#7"3*[H7D3;!7B+P@6FX4$+ M+460IPRMD6##D&A^L!0[AKHS@M6@L-_$0E,A4^PK"GQ%37,UK,QT0;C8"Y1] M'.Y.@PCMQ\M6DZRP20F8)H-=18&K*#%(8,=0;T%*L&,H6%WH>+>H083UZSUT M32-A8U%@+&I8QR@V#0T7Q(M-0\$R,XVW!1'>B]?W/-=4] R[BP%W49,$]@TC M\R-FV#<,K2'CHM>@OL>I.ZEY@&+!RM"BF6%_##Q(#>L\P\YA?$%2L',86FM& MX=YJ4'\%]UVR&KW?W'\(&TX(^Y A'_H&"6PPMF"?Q[#!&%J5)FD))_'2R&@- M;$.&;&C8V'#L+KY@M\>QN_B,W=Y.@P;K 9]8@X/=GC^I :?WGE]_GOH:%\]) M7EI/4BF9-2_V1RF5J!3=5556)Q$?NHM4'%5]&E3G1?M9J+U0\JP_>3G==[?M M?U!+ P04 " 7EU501=V3DI@$ ]&@ &0 'AL+W=O\LU*OY7) M)5,ON5>\I6F<_[=5B;ZM?>9_//AZ.9W+^D&P65WCD_I+E7]?7_+J+KA;.5Q2 ME147G7FY.J[]9_:TBYH!#>*?B[H5O6NO7LJKUM_JF]\/:S^L/5*)VI>UB;CZ M>%<[E22UIP=UC-^2 M\JN^_::Z!4G?ZU;_AWI7206O/:GFV.ND:/Y[^[>BU&EGI7(EC7^TGY>L^;QU M]C^&X0&\&\#O UCT<(#H!HB? ZA9?.M9L]1?XS+>K')]\_(V6]>XWA3L253! MW-@ M(V@@&A^&.30P!QX8N=JVF$5_D;/("(2-X3W,P)$%=&0!'!&&(PMKDE_8S-Q9 M-JB/&7BRA)XL@2>$#; 0,RP0H2.8]DP 1Z3#!"8^HPG)P;1EB+>1&0X)PDYF0&Q0E4&'!#"L M 2P"WLP=)K *L/F$F&#^,D1@:\/:Y"3G5L3L9(B>UE9@HG, M.MF!!A-%LZ6198P2#G>P(' D"$O3'9OJBUFT'/R9OME#Q,RQ>SA6!P[4@YB0F,["8%I+ "-R=%) M",P],:'[%IA[8DS_+5 #OC #@D"N#&,6BS$]N( L-I4-H)S*)C"+!6*QPP1A M%M,$%A-F,8WIPPGVX>8/$X#BKE\FA&E,8_IPLBLMT%F $B4RH'EL9LBNML_$DS'9";;85^VA"XTE8$PAI@JF29-,=-)X8Y

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�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

    ;F!MAQ#*8(1'=C M'50"-H8UY[Z6*VDR@HJ,9! M+VH628CQ$Z2*Z7& ?G!;@+@4G=4VAIGMJ%AOE;D0C@=GW8)!WI0H Y2MI"(O M*V,3^B.L]4&XN4C1(^]-9G9YVB$QT2ZQ=NVT^0 V;7>;0'9F=6!"W:@:+N#8 MW<[(IJ?!JSW!S0O@5*^9+W;.#GE6R?JWU>4GIXJ<*72[CWA3:/=)/B:U'FC1 M@BCK12H(4!%M;GQT"R6;$'BYD#GKD&$- >P;@<3,R(_F8#5&-E>^0C< NK*$ M6 !*$A,2N4 6;F^T-7?.9ZLVM7CD-7/FT1'7#H"5OD_1)FQ5\IC#$N0J53%PD&:-DJ M$OP<3$5NY=)C1ZL4V$NN0$.Q"4]L',7Q6R(WY#7N5\I'QWQ'-ATK+8U@"RAT M_-MFI01@91E>F\Q-:BHGKJN=O;6+T[6,&$\;&#^6=]!<<],V>6)/1UXGQYI[]D M7_U6<.4QMY<5;:BJZA4+676]VL*4.J@S(\T2HXBM- EB-[;/OHH!5KI0@5A_MUXCZ_%<_;9:KICTBV M[#&^07]GT!](IAOX61'EMQ6Z#CH=H&KQ@)X04N=8K'>3N=JSZ_T#&;3 MI(;PPTR6NG/Q;T"W1&4'P<(V^+NKY:1<=I2+RBXW@@5PQH_!H0@?QDD'1[5A MMM+G(+?;Q##+(*0+7WDQQC$.@X:506$0"*SH!%?B>B'7@5DF=/L05U@ 3],Q MNSRH&DS2#0DAX,8U&7B]@V*A#:/N%@H=%!@AA +)#5BM6'8(&M.<*V*]V0&A0#Q+XX+%!8:G%^('0C:%(*CU MMG"T/+%GXLXI1%1$^ZVP)H1080T:*6T:#'#44.4R]M=I]RCV_C_XW3^-\3I#!O5Q]U$BJ<& MLEP)(&]3;3QB6T>R+=' Z\EXV)MA! M>(9!3,"@18H$1,S,*'QA;P)W MV7A$.X*4%L9$)-N]03:3V.CF##,I A6N D^@7PFPG%,!EA-^[HWWG-(3OAKL M4&%[,RCBV -Q6,?0>>C>L2R]B,);8BT J>K(63>"# 4C1E$Y]LE9:6'>=: C M*B>T(Q%.[&)-<^%&'/@V<&RYTJO8/[BNM(Z@C1E5\\UJIGIY-;_;X%W9R&$T MQL06\*";1(>9%S/)8L(QA-E=ENJ>58K(GNCPHC?4FWY(!>=-) ,A6\82 _P;Y"$4/UX1Y!Z M0!.M/[I$ #H@T?PIR8&_K0$W)H-G\(>:"//S)3ND[7Q@'KY5FKKLU"]*RAP3 ME_JI!8D: /W< 'IP!3L=3I!+C6&89%/H&3QQIG$+SPB++X%QR?\[=/FVV*CS MY^%.R6H=N")[?7(/LZ:.P,$$.@H_".:HFWQ8+A:JXO,9I(J@=.C6_@Q)"RO3?7[,95WD9$<#ZNAD J=1(LM2)\ MH>MR#BP9*]U'I0DRD.V'OE=?V)RZI70#^ =*WO32Y@>GZK$),Z3QE=UIWW&R MU)3E':7,XU]'",LPKE["PZWHY#E [#0^.U5/#@!9P;9E4;GD'Z->RTW0C3&\ MJZT4C)AL_,S8>H*LE301=?"=P1&M6A$J\,DKR(#Y<> PJ1PRR%Z@FD-SKN.* M$=X-X6IE=/@%-SGT^&L8Q7J,0'X%@&I2.GCZA-0#D&9C=8&IJ$Y2S2H=_64, MJ&1C@ /"'V>^MD.^4U9ENBUT&613!> N.!N]IG ;?+5K#/AL^L?$6RWU>9\M M-(_: EHMDQ.I>A#U>T-RCLLIC39&%.=V$566G2])SDURBXQ?[6#4JEP;[S%A M.,F8J!PTFC?[)3(JZ$10]$"02SX='N?#9#@&RO;A" 31!Z4IJ\L-1VK;/@R/ MTTRI.8 P->D#SM 'I::7#+*J6C(X'BL6F>S2#'!-)E.-HY3U^:_Q, O '7$B5VPA MO*<,2S#KMQ8)+I'XRLFJ0^.(9(0)JIO59#F\R*H^P+!?0:8G!7N*+P&'YC<= M^"8^!YPN F=Q2X)YJ?85HKR+HLM/8E;^6PB"@XFXVC_H?%['ZM$.ECKRLK2* M<"(>\E$V#0\V#?/_\ 9KB/'LB;OSPYJ]M$.9%"M"!3$@HY(:5]+@#Y//@111 MDWY=#;- %UY-VB,L47^]T1S8IO$*?&\31C\0AL%CJ['_X >!'(OPYF/S0O5 MMO#O@%?$^PCYJG"P4O@;L#01(RY3P@ HY_M9CD!M0%BD_LA!>64B*Z4WJR\F M@(0$H_ :) \>=CIEE')VC4 8XU<&$]T<%99&F:K6LO]V)" MSDE7^$!ZP(6Q\[8;]C#UAGM*SFS3YJ9I-(@./;!E+6+]A703R+5EW_RG[^JT M X ANR)!Z".0TRG;_B<](%@Z[?W6XP^3P53=AE9[=>ZK%V(/\%WX MR^RAZ9'/^VOH=^RIBW^=W3_\Y6_ZZ7=P-T_>OS^MX.O"HV>SY>^/F^37F>H" M?E"=,2>[T,LK;#71NHCV9ZD;0AS(J3>)0]+V%&5I?[BL'JQ?S,OT7AIBCZ11B_.^HC(":^6N&&W&G2@VC'&*'P M(4Q10*\)0G9=&PRP[>:1_7BP,\#:JU^IY!"ISEAC$NICC;G>G M$>2YQ2/53FBK?@Y\L47)U-4FW MP/0> [\A/F0,,5@]@,7]VF!1D("JL4'B* MY@(A@!&0G20A1U;S#+G:V)00;L> I^U9K@&C*WKU,DEM^-@GT1H"E ?G-%=I M-:^7,OW9E#H$$A-C8=(F),(*H8V5Y5Z&5D&4$C?0XHYU*]?[GB4Z@*F@R)7R M#D)PX%H[@]&* X6D7(A>#R*ZI;+2,H14 M39/WSL>TZ @@&B]8TU'@DB,29,*I?+&]]DF8]KS\$*T,M=3&:TF!%XX5T4MU ML@<*Y.)JMR1%#"OMQM#B(+0:^''I1=I64LES]L(5O&NZ]*G,XP_Y>K)-1=SB$"VQ.MR/UZ=6[,SB\!@ 3/$P& :%VSNES. IF/N0L MP"V"SC0G%X5MT)U_^W1Z\6\49J-C6%Y"JMD<1@X!,6V3*51NUE0UNPX5<0\> M5 !KHG,5NZ$CGM'BZ,,9OP;UB%7X=S"GGYTL(AX+<^M2_[\R47>H/])81:7> M6V@Y^>=^P98',INP2V+- 6([Z2&=D46(]U!Y]!W8??A/'?VNM5!U#>:AB(?B MR=E@7I^S<&JK#/=>#!HP0>A.=LTBD:TJ0^#.]AIIPW MN<\II996YEF+@<@P!#[Z #1B^TG#\FAZW1I8#VA3'POM$X@X\WN 6+($#(V% M$'(W1";0O0Y4[M/Z# TH%,.AC.,&W*QE@*8D3X)\&WI,B&\DXXL-L[.HEI + MSBSGV( <*SU\P^B.=%KJ(ON5P6Z8HU/PPAR;(2J_SQX8B[W:I9:33=?E>#O^ M.TB':\#&71-]V0O*\1K-4[""R,7:M-KLNHR,.FTE/;;>:M/+,*X>E: 5JV[( M\?R%4Y/C^ A_XK$;35C^,\Y;E+(L<5_XV 5RZLT"#*=SC+GE #1S2K-5W^TI MV1-3#UY+OI WA*]YDT1[7YD81PU_CZ!E*?_.^'=N<.&,&<1E9#;<#721YU^^ MB/,.'GOD@/'34O78OR.K!:X_DOG*UL7\$=R&L2-LWTO7WFF,0OD5FC%"[:=O MPH,@)R\%8A[\43TC0J=**JX5\N^:T0+1)4]4T7WJ,58.!^>8&_W?98D0HPC] M/&B!P%U*/R;_1C*:S)0Y0JO1MI#WS1/.)@JIX'IKIW"3$QA)JNDUDQ9 MC\NX%34!**?6!:*G(S*W3SZNF &P$B4K?"]P!.G*A< 2+O: 9Z76/P)VR#,= MZN6#;# EB$WBZ&1PY!L?;8-+8H*#>K%N7SZ8S67IPP:'1Q[0+YQK2N""3^=N MY( Z=:)&VA3UC.D6P:%5#YO3#.E+B<-GV!NFOPCP!@G(#(S#OG: I+ZN35J) M^5XHKB6U$ZF,+J"<2J.D. 77J:+'!C#BE1L3J^7'J;+=XF!+&Z\T%9@)PB3K?1 M0D5$'C9<,MZA0.BL6'ZXDB-@+)%FDA2-Y&HFU ZJ,8T(_R7X*U'JMS"%Q+68 M:<5>H&^D$?N)<;(/CF(V$\V)H-8C+'V*$H!$47,7SNBR/- ^,7@4?,@38V-Q M'-&4#_L$60H<*4L!)#,G'Q%< M&$123,V"L.I LB;3T%P_8GM>RJD:3274DUK%Q0>OCRK-)%Y3@,<"8NH P9=" MSC4IUC,L57C:7XF)<10#/>Q2X'=1''[")RL\U)+7.R+ M!#B^,W09I?%7P(YGWJA>@Z-O+3A"P2'1@BVG::,-\"_%VQO'&D*K0L@W_3>) M7(88Q!=14(#^C_ +* V2,A7A4 2O*;#*TJYKG&I(0B#.2U,S(L@0 MWH>(@7R43 :]_E0,S&V1)/NQ-U<92BV)2.UN+/F(7F5 MC,:]?N:UJ7%X7D&,00HO#K"^5]"FP:#%6CZ1\N4SR9<3U!-^P.J^.OGL!+R1 M"%0?1I?LM#M1#P_3;CZ"\*=1MS\9FZG*U:<#]7,PZ2=9=ZQ&7"SAD?H E^^@ M.\JF0(4^[@[35"YEI2?#$_C3!(=XK9'CG@^[4S5/;K/PE>A49>/N>*+>['>S MR1#>'(\.7M)U0_0*%^6$UO$0;HQYVDMSL9[5"9!"4"SY*3GO3UO-6S^GWIR>EU=?^73R5KEJ\3$W.?:.G-5LJI9ZK@3F M(.U.!Q ,,NGV1YF954B4!TX/I@Y1@JJ;*TFE)EO]'BM9U.VK*3T1R*:SZ\VW MXN<.\H<:S4&SMX9P>;-O-'PM@\.2W(&R<;"3OF\ M*<#XP0EH"Z-!+X?5/!S [HE-@3TXU,C#P9$VC[_:CY,IA/Y,1K 7E8 (CCOO MX:DZ/OO)L-_KC^0^G<(9-9K [AWGL,L/'F?5Q5&OGWM=?NH6_(HL'C]H"SKZ M:[L=&'E%SG[:':KS1"VWL5I^W<$PC6\]-1O#D9J7Z:3%ALOZL!UR/)GZX]@^ MR^"@ZDQATW2FXWX;_:M-]QP-2^U?MYO/WE4MAE6ML"D=#4I=RCC>.9O4;"KO M]&HCM,6FFHQ _WKY4:8TYSSW.E[=6NY5O(U'V37>8ZR_ MOO[KPIZ10AHU)PB+C65RKH9J>4D.EVSNX9)*ME7YM!.^L["RW@(IYL%VOH8( M7#(:>%>.#[4W7+A!!,<*+1-3?#RY/)>;;L)YHH)LWH M_C0$4U(G=8Q.U=]5<]E#V.R5PG6,DG7R([8URI_58F;&.(8FU>)505DQ.GI>I-NNE M9-8GOU"[=1A>U='^!157G#(VB11@C:D6LX/(8R3GITQ3E9,XA M? EC#W(+J)=H5'P?2QAC:;0^>95RW""9:.-+/(QF@UA0/T(8(D =6X83J MB-!QS5Z[(-A6MOG2VRGF &5HK_E3-WKM 6>W_Z4A2])'FTW-Z4KE!, S0%2( M<*NWQ!UUA=Q1?XK_.D"SI%$X:VBE! T7/EFEN$)O 3M!7FC!Z( Y@XKCM_RU M&>&-&&&IP'4R,%K15$+F/(>CLX\:1(MS\+(+)NU+-VGXC.V0!WB*+Z";A7Y> MSI14 ZIS-?Y,K4,>,(#G0]'/*:Q]3F<=Z[]/P@(PQ\9DZ$/&&E+T\!;K!:J5 M/VNR IQAX?#._1YH6KN?C4L 02)&$*\%V3S:N!H0J^FP9GWV(>EQ'&N. M,WFN/JHF;CU\%B[$YD-!CTYZH'@-T>DJ*L5^&M4>>"LPC"!G$7R M,*-(\,\18]@:$,-"),M<2CBF0?'C<5?1Y/(U*WC]!) M":"[^' C8:@;T2P;9I8+4 MCF*L'8GJ)C+>K GR;EP#T.&N6+.C>]8 <'&F5E2IA'%%N:118[R>C )F**PZ MPRL(@O?D",>60ZXWH\/@00GQ'@@AA3@Q:8[.P2'%ZF(*+K\XA8\0_H=8<_O9 M%-QQ0_@^AXG"ZW\^QGG+.+Y\. E RU3"]S5E;/*U+!:M9LD#E!/$LX2OYV U MQR\HSY%^]3>&,\EM#RXJ7F8-:&7U/XUV?F?'7<[ ;= M45T]4GP3P3;1%/Y3](A\7T,DR[)XV!L"H.<('*SP:S"N*>_ 40\K\.7+C;D& M?*B.-"*S@K<7?F5].]*-8SN-#VKM&G:B<,0UJ;70]W"N?<)AX,G #S6 K>$@ ME^2X'B)!MPX7A:&:1&1N#L"U68ZPMM=.S.X(%ND85@M-3\8HMW'P6D2]U!1^ M;$+V^\4H+\4#70?M5VH^UY@X^(5?M=^<5!X*=:2O^C'^*3E67?([,U;?CO#; M<:X[Q#/]4]+'MX)0O&Y"D'L'K4Z%T2Z)M,,P@HHL[*6:[.W\[E$#M9,N05%D M63>:]=%$>&,RZ_W6./#Y:S,AU!Y-3/OQY#?\*_W+47*G5B0S[PZ@9D KX[FD+0AV6^7 M?Q0&4$:6]$&^FZ48B#.!T]3&CEX&)J%F[,#FQNH4GJ Y87G6E2:G5$V=&C, M42?U3??\*D429: M'DM(:S-QZ03R %I-7!!CGN38N8XE;N'JHC?XHH)@N/1RJX,KDL_K7D,:[*PN M2!%%)=*%9WX'8A_("8'+B!;HFCC5CPLT7;BJ@E8TI-"[:0QP:T.\94L2@LXP?HZJF(#86H:+BS M(Z)\9P!7HNKB_$UU^;_VJG* US:IQ%!8]4FX+4F2PPI8F<[=H!LR_4S1O!=- MP -I1-XL\FS1R$$2>LDN#_5S B:TJ0,GY:T2M%&8FN4>)8+M!=M\8@%;E05S.[M.P>?W%[RYELW3#B]1=E"W2F^H,*L*TP@7" M/B%/Q#"9 &8SX?#:I+F 59F]- ASJIYF[BXE6XOCQ>;[VF)(J+G%E".TV*"; MMB;OZ!6ZR<*MAF].S;X<\<[MXTZKM#CH2Z-/V[2XS^[:_A&[;FOS@M*HEQN^ MJ:/%:T2W%^#VQ>URO=;BYIRB-6\H>09N8:>&'K"\IZS<:JDC(UG-=XP+&\HK/512DG/>48G M'^1TNPJ;>#[-P35 <*)I-C0G1$VS %LR1<-2-B 7/9!!HI*U?TI1YON@'.V]2/VW!].<2\,2(1.^@U[PM2'A(I!L(_6,UH*[BIW M:[ QUZ>]K(!]5#8VT:&U ",516*&FX4&]_E,T7J*APPD"4*W.3[%?0R1*V!Z M+X71>1',^4AC_ ,H.MY0$Q3([*&A&0"NWA!,Q4XO'5#^ MD_F\6$%7"VB:2)#(X8JI' M'Z,I^J%&RDD;X(:9JH=A[)W'.N8<.V+E0#/5(+J##PCHN!K052E/*6,9$OP&W9"OB',=-B!(VZ+0R/D.),T]720?TML# #VJAZ5T:M M(@$>[O>R02V!([]/J&E*435M\_KB(>]IE,N=V994&!74-S)*$4Z:$5-)C=G)QV 1+^X?Y@1 MS4\FB&NE+J]J2O&\/FBO<@@!1E1"=N !]U:U.FB'&[IOW7OD+V&ZZG0*L"-: M;PLLCY&!?<0QLQ-N=ZY=D?#M3X2&_!-DS Q\(K,KQJ&_$+0G;E$ %)6JNGF^!@3,-_'8;< M!XJ>?$IIM>JOOOXK@TRD)D#^ 428*\T%["CY*-,JI28!H/3_ C3QM8&WSXYL MJ%*.]@O;)\N)AQQ">! @AU ZILCE[G :HF_Q9Q 6'\:#U]%(=6&BWYE@1;7= M3^ F\OP9MOU@VNT+M K M8YF_T=T"NB/TGL:B80S@P0-C+!T2"V E&5#0Z&B$^O$X'Y"!+Z4O6&D@U4#>7 1QZZ0#L$$/0SX<@[H>I44>(/7&VY@$'&9@A MOU66$S,+G)U#6&I#B.,:Y48AR](<7>N(13\%.C:X4@W,3TZNKEF\:KSR*8[' M),M0P9X@NG3MHN8=]1F%!,$E&B&"JX>?> Y^'H)1V8RC17)CP*RER-+.3"VE M7H;;XU3K,3\GYU9@_*S6&GL3U<,7:+QT) :NS(^.V-#2C(33*Y8Y=DXL10]1 MI^,"S>D5FI\.K&.B2P -UH,(J9Y?$S3,#>V#K%($3%R3(P<39[U9VPN&@1;1 M%MCJ^QI7X*+N&E[MRY@10.EZKA>2A1>$U&':K9,17??&%#"==7.\^9W.'I:@ MM&/SU,F^!T+ *9@3,(*$#'$I;N S>7% P22C\77_)F#,1,];CEN=-]2D.H]\ M%M'Q\HK/"[NC O.8C484\4UQ:]!W3%C(!D%X7'\>!_A?XSQ2]@#^#,QC[*T1 M1L+AS]H9#/2BKWLQ#LU@/B"S;-ZGFWJ>$WH?Y+1-T/P:F,$Q!1*I$N&/%#V1 M+>(5*P9R_D@.AN9O0+%)0%?"^Y!H2[*AMG;4S1^8 MJ\;RP=A,B 2B ^8OYYR1M&G^JKV8PI1K@UAH_C@&*YO0Q /; -,HCC(T^ ?F M#ZQS&1@>1FCX 9/=I.4$CN%83D=HN\H2Y%IX#HTX 4XIN7^,D/Z=5]!9=2!\ MX /!NU0_;'M)GRWT7A*@OD8("J4NA0S/Z/: M _M7G-":HE[O)J*V_QF17WK MNOK;P<7=AKFXVO2@0KL4@ABB^S=RUF[VUSN@(-4TR)X70_*J5[^L\*I[,, . MN;K';L[&XAAW_%\U!> _/J!]SJ-'A^)WQ?%[=>T+49[]XSU$K:$VX+UZ7NZ0 M<5LPL-Z@"G5#9:ZPS,:Q'%*4I]?PV1^U#<\B[VEF^),%XQQ!+-K5:3+JCP[? M/[_.UF;_3'R:YN_.+MTJR;97:X)QJ[BF>>BHGBW+V>WMMK@UACY=;-V0N(3IIVH./G'\Y/_NR*@R-^4BYG(*1 =?Z3&Q#LN'[=T(C%^!>>I7]X M^KN1-X&,O;#&TOB&7X=18>;NNZH')DF@LV"8<\_>7_&+MVABXQLU35Q4O/#' M:-^AEB6ZC=[K3L"4N@04K+8FL\4WT+-BLRV]:'>S'1*[5U%3JRWB-,-PC&I@ M/ .]:APP#@%J?&YM4@1C/416^T=08U4SF&Y/*0$'K^)(.?\XN2YQ27F[[ MG M1#-ZLTG:5%.#UG_*-2NIV#D6>V.*G2G-,L@68/KUVV:E2H0[MU)C@9;CX![E MR0>U'>Y*B#_STK/^ZI4?[^FE$T;SP$H(I21YM1*'%"ZD2V#$1NBY<-M_)DT&&=2[RU93=H V5GM='2P_ MA!RECWT 7TBATG!BAC.E,#B">,^A> ]"1^HFY-#=T*XS&-14 !&%VKU=6*GOM6B$:S0$"6MPJ(,CY=+((C6U<33;R:(X-RNX6# M[E[MZ3V*2G ZC&X("B&EH_]M4Y$"=J)_ZB9.'W&5N KC8W._Q'K)R6K[7H7/Z,HINFJA]0 M7BF9@!)4X6*M3OHR/FD-HNA+\0>D/87%C:\EHE\ M3W$M_T>0C8^U<>B+/R'(FD6?(-DYL!*MH8.Q?22$M MDO>AVP%^V)6AJ?0!Y7-C+*#ZR]/GWFBJ'1$NL*"KKTNOE<+K%N\U%,/2Y7[U*SH;HM[U0Y;%4.^XHM.*/Y7S33:YZ)[UDH81$[[=>5!Y^^J[T MS?)N^1 =RD'0\7&RVC^L9JK65K6P)?O+[ &>;_OXY_TU7/5:U7 V6_[^N$FN MBN7OJNOO=XOXHQ?_.KM_^,O?$JX%XW"3]^]/VZVA6IVJ?CE!TM[]SQC(P M_@2FVNL<<\,(XQV*Y3;OZD7&W"^;Q]E*[K/[V0(3#$Q1_FE+^7^03X?QI[-' M/+IJWZ%0T3;%"I.7VR7O!=YC;.JP^\4OF1VO!27.N#F,+?89FCI!EP?X"[;- MP8AC8L&B('ZB0K8FTM3E&C,1'&Y$PZ:%Q$@&F&3V3:TD&(5C5XJU-.YPTE$%4QJ^/+RG8 M".Z,-K%&@B)T+BX_XU%P=A0MY\M6R4=PE]6L'>WA_%S00H73M,7CUI7VU.7U MC*.H%D;3E50!P>T% <:->[/U&H!70I&#W22DA;9_U5-6V[_JZ;3M7_54W_:O M>AHRHT=R-N^S%/JS!A>:T2#X_ [ M;6^'/ .$W(ZIJOY:XG+R;V.'7D F8[N%+ MXZMB#;F7)XA 5B9GR$F2Q6THV NKCW0IF]R.-%Y[_1ON:!Q(K,.:W[@U#^+6 MV-XDBQ5RZA8RCMNK>WV_$ 1?NV3=]DRSLD2M2)6A#AZ6GXMOF]4W''_*XU:* M!=YRNZ@)(6IGK +N$_5(!JP=.%4-Y;0>^(9R6H_]%QBS]QNUPVV59QLPT+1Z M-!8^U1M/O!FE'?J,,Q+W)@!+T.R]Y=FKW;3V[L&'P;UCPUDYZZ;&:6X7V!DN M,&L*ZD+:EKZ] >PD!=MBB'3R$5!E06^'5??E>[%2%XYH8_ A.EM MWE_WJUXR[/Z/?_F7T.'I?.L=K/=4KK=?/:@OO4#@Z-%"#;B MYE+X;7,Y->R\YBB"-5WL($L7+?GX?*PM]&U=5$ZTU?OUOM3*"5W>DP0=1%=0W)T+/X1>K/:=[;@NA62H%<@)/\20FW-0@ZM0H6Q1_)U??9 WWS M0C4/@Q')56_Y,ROY# HWD=DK ;_;).=O+KZG? TQ.G"[5/A1S<_]2[&*AZJ)^:[- M*S./=8VSF$B@,2:>JDJN=MOE[_J+?R;10;%E?=RL[S=K,B@K=95T*/9B_#/T M,L!")-27Y%0C0W01+4*]P(;U%F9 MQ'5BGF6?.N!1-5 _A+,F^@F9^IZ %[M M%VK"4RH^A>LRV[WFCS;#&L6'B>"/->;E:U O4."Q\0W]4BQN:RXD;9H RJBL M06L*YSH60@^_D_4%4'5D3"RQ$83.80U&SV@0AJ;\L!;]JNX4ZV[R]V+][ EO MV@ @-6NK_Z%3X=3\8\?\2CTW4Y>=XFF[//CZ#QV[8 M^[!@V:Q7GS%2&()7F M8?F(7WGQ% -4N/1N(F,LVYV$\?==.JL+SH^X6%NPP4NZ/*,3@#?=N1/R;ZXF M"#CP!:YKZUM$@O).?1.NUB!?3XR_/M[63Z<7\=Q$K$;630? 5CL MH[;83B>V^[+ M0VIJ.W!_5OV'CRN\U+A=]%GS16=@O8<$+%%$=.*?U=%CM3'7&PK(7A"OT7/[ M>IAHB]S8GC;A3Y&39BC0UO5#^APEP'$)DL.IT$\X\*F@UU'?O@/N'(::\0([ M='2]G\UA)A03.#F=S_/"81QZB([&-]Y; &B_KC"O2+N>U@2'(?M!87W[XZA,\WKJ,R+-/\7K6E]@0%FCH%SI;#="+ MH8Z"Q0.3XCW!W1H>$]GE$7S\XS:.FL/8>6]O4ZI,=EZG@1&F@3Y$5 M4H=M8J&M1QURR=!E^$,K%VJ5666-YKD?W4+7>HC:8+-MZ__! M,/K7A!_1O!<6.A4>[V" QS]2WX!C*,-9ND-,L2>;9D= MEHZ?$4S@D!U,&8J MH!)17N>>Z@QJ'UO0(\&A3)RJPZX=#NPM@7Z(6)@%"<.>9Y $>(WC-X@><2IU MTI!OL8V[#D-C$9>BUJW6_,BX^9%1^)$KP0_A].EDBZRZQ*_XF,CG6"%+3LC. M6B/-&73#C:*X507O?M910Z&3UEAP',U?8\SB;"FU8KU9$QR*!D?Y9_*J6IH7 M $9+!LY"J9Z!L?$#EM7NQ>CADUL=E<2C5'SO.;TP]B? M'ZOP)ZAG]$]FH+R9DW=5FOH\.SKM.#! ,.EY M,$;QA.*"+Q"L#_TK=2@6+["#_&TCMP%O@"XH+#?%DL+X 7LKL,M!WSDNB]T. MF$(NK[YJ(1QM/!Z>![Q@S#].5^L5E+#): X'Q185G_W:UUBL% T3IU$"RS_Q M=XMW"80+*JJ1UZ&G339M)+>[S8"@.75];&31F5+LYKO-MFE>0DK-";%CL)X5 M77QP8WM2\B+V/'3"AY]DP8^>QP/$LEJ]B'VAMMBQ/K=8+6GSRC?W%61;A;G2 M.52XH[XIN5P'DA4?8_?@.6$2XMAH!E#N[ U83F)\VXM7C6GM[-S]:, M[@%OBP%O\1:$7A[?;(N&=(>LEP<0NGOCT(%;YKLAUH*;F!4'T'.103IH:='Z#2D>T[X/+'GB%>3NO4] M=T\X>B$56"-]7:VP^7'U0&MQU4I,?6J6*N=Q:?)I_[1]+]]KO=G.#]ID\57S MT=A-I*)#FMW3UDV#RDF&R(.5>2A5-U1=%T[XNE [Z<%W DN:SLTS.#>%&['1 MGKS??:EW4;5B@E_JJ680FGO5E[_/3U/8_QIG96*F>UJ"DF#-_5 YLZAU]$34C?5 ME0N,ZWA];E'+P9?80+[,H2W-PGPM@9(/;IUK!W].>K3G: [QMFRG*\VX)BO M!Y]Q%%>X94?"6;3W8K[?0NO0KA%R)0SZ:=+Y_8B*PLL%L!0W^N-_/WN)G7$,3%R?ZT,0@O(-3G?KC;7 M( [CFV^2]R8^*J4-=-ERMPG+/XG&I U#G1L'&6]XN]$W@?"350"Z(^3U?/%*U+W&7PB#7C_U/ASVA@/OPU%O[#\Y MZ@U\!(.@V_>-9HRO'>N\EP7HN$(?LIFY15C,%[*.SXRMT:LT>/J-@NX-C(1M M4>DX6&8>++-R1KH!4<@#KH69?A(,HB]TA'9%#4[YJB&X#H]J@M!.[3$97@0? M)36I#A'C0.6XKXJCMFR-0&6DS M$FXJRQG!"UZA,A0:@BN]GP-'CPDJ"7UIM( F2>=@HX%FTR)ZHOK.S(@W%&T= M4'=\-;WMD?I1BT@J)U$E(W#>@F"OPN[J@^L"^/;V>SA__@C7RR7F#3W99S M/[G]V'Q:S!^C^$RMQK]1PCYA3N 4:W4N5DXN5!;H_ H1]P7$_/D?"!I;I^@A M^$Y--QM&S2@3YG-.=CAJR].0];,A:#KJMX=*3VM#GX0&**[@2IMF%&P#[.#Y M6A:+FN!&SPRI@%EOZM]F\MX@= ,?^$\&23-;-3&@NGJ-4^WP M;]-YR#]4'4\GGD(<&$_8 Z'>.->H %]/>1?/YY-?0EAS0_93'N04SH*?HC*] MGG%L[8<]'@2$8U6;+EO_2HM&'E)*/)'KD%+BZ5OCX)JLS^1M-51/'9RG#L=3 M!\!1(UE/NEA#Q+>39KM4JWD[OWM\\7):#,FSBXZ/FBY:7I7O*6<-'2 ?3WZ+ MC[COAFAO7FEA1!5I3)>;U7+^R/&O8-"[?80;4#G?+A]"ZFB_YV-X!IK;UBS3 M[XW:%%>_:U"WS3P(F("[I/TH]GNYA_0=*+!]/\=MBJOO9[_7]PJA-W2J^>$1 M>04<)J N([>'.IF/*6J6 DM9T8_:@T)$;?J:+M&U$4"\GM_M-U77?^W5,S9U M>5& BRB2*&QQ_*'PE6$$"".',_TPZ.7A]I+1-A*-Z [R9Z]KG[EKI]2UI^36 MR2)/M?T"J NV#7!G6GL$A? $F#6V$+3AT )V75[ ^!J(3 UUWYW1R*-N1TS[ MVU&)5'FP?3;(<*40 8",9:01?=\"M\1B\]T?YVA5'DFWNS'T1JC7IAXB6@T8+5T-QS]"Y=_V&/= M&IMQW()K<>19*(KK7I*.PU]>[>_O 1$0Z5@LKL2&.6IKG>#!?-X9L7^^"]A) M:U^@NW7UE0JX#R"_5! KB"?SPO)D1M;2;^5ZT >%0P?KK?JTFMH]SYYV=38=([>QQB[X@Q>8U M>VBSIG9$WNWE>@]-8(Z\T()>*NVL %Y.50C)B2X6>+KG.?UU+94DF:[4@-& (/'W# M@J?<7Y?+Q7*V#9/3-%#%QDD^W!WN)*E"#[05_&E0"IOU')GGV#04+;V=[@07 MRE]GZSV<1!XMDL%D8?XU;6'&?%?-SMST$GDR:U^QRQIS46V&*\3_@7F?HD56 M)GNP_'FV7P1VMNB4T-/JIX?_]8:\;_*[IQ U]JYZFK(U\+5K'ZI[3K;0#2/P MSX&G>*9H)CU[Y=L" ):\U$/TU=5V)N:R6%I9^Z E8,#N@/&^L=80LD>H"17N MJOIJW$$UK\) OA@.EZ#:1=Q:H)&\H1U8K]()8EMX<2Y?[&J!==A+.&*DGFSF M_@R9 8!!"WO8$)RGI@[O((!SC7S^M<])9(E@&J6G0NK;/!JMOX=2W60-VZBBGQN(WVN[L-4@$]I>0NTJ:JP0)_/;'!ZX.@ M6LS?X31!+<&):'Y"5[&D$Z":?IGR#&'8%D3WVG';P:&;9#^V] MKC7_\;7J^7Z!NMU#Q7*MB%/:U=EJ[GFH/-SPF3??;!\V&">KU=^(W%E&= I) MBH@EQ\H9A)+8.@-(>/.S\<"X54(].D3M6[-H[O2#917'Q M5%].0QW$1F\E/>U"6"0B;>L@)90W &I M7 :=4;!9Z2 TE!=T3^0;'QTZ_IAULF"7TF'(\:Z&)0\\/ B->QI*TR3SS/6^ M7"*,.8\^P]B2]$BG4W4AX4M.8*1'H9'V[K^^D3:TSM-QZ--\%.K/J:%%H_8: MM-7YO]N^6M M![9!=W"$)OVJ=OG:@(,97!\9>5=W"Q"L9GNG) E[,!>SIGGU'G1-D%4Q^PZD MC 6$/"E1L]\9A%LUQ47,F1.H>]U0.=_PKPL,XX/E$.)EOEB7>W*(G*YFR_NX M9X*N3,X2K&7,!%ND:A'9'W4=-72\#/*OA/C]]7Y+N;'7CT1+:-Z':\AL[26 M'\)#A3[^".V=U^;?=[!^> BK#I7\N>,"!$.!;L=X75F<##P*ZC^HM^C"'7-HY MF*G6]=BJ-?V"B;R\/(?^O2LVM]O9PQUP&'*DUI-,AMBEDBDW_D 59Y5H-GFV M>D!JUGMUV+02U.\*R ./W_+>TE:J]U,"F]5#@4F7S' 55[(_G[\_^7C6;A3Y M0XG";+Y^B47B5%>+9\AOQLP0 H@!IB!$_NZ?5/I2@'YYN])JX(3F=TKQ4'OL MXD)U61A25 '_KC;_\N81.L7F[B=$(%R=GR:ZDFZ29L?]:3?YL/E& DN]:.L\ MT3>$4@8I'&"IMEGL/$PIQ4/\$="H;[P =#-SD2@H V0FX:.LEDIBG/Y?E[J__%U!+ P04 M" 7EU50@.#)1J0" Z$ #0 'AL+W-T>6QEIE2:2P IC)4A;I4J3MJE2N=A=98@#EOR1.0Z#7NY==K>GV*/L2>:/?$!: M8# ZD9O&/L?G?W[^2#CN(%5+BN]F&"NP8)2G(9PIE;SUO'0RPPRE+9%@KCVQ MD PIW953+TTD1E%J@ACUVK[?]1@B' X'/&,W3*5@(C*N0M@O3<#%7XL(A_#^ M_.773*BK%\ ]SUZ=G?GW%U=U^[EU7$#@-#Y$(0RZKZ'W]Z*MS;*MNO#E!N%* M:$-@=S^B;4AUZ=X.Z=_??VY8P\KSY"J^V4^XM4WZT8+T=XC_^K$!NG0\Q=SS M]Y)M;1&N$_>"[7OO^ZO;[]>WJ=#6/#J'>A 9]#ZB&$P1S2$UXB2 ML20F*D:,T*4S6YF)H$("I5\^G=]RI0_.';B>>2]S'4:XD#:WR^#^CO/A-4?1 M,X"$TA*P#9UA.$B04ECR&]VQ@ZWQD0OD[=$RT813B99!^Q)6 ?:ADXR%C+ L MTP2P, T'%,<&1Y+IS#R52#SC5$HPW8@(F@J.+$,1D3>T[ 13>F<^6E_B->U% M#-P8LR4^!(:B:.I9Y\UJU^QI\E;5G/:J;/<@79"0N5#O,ST=;OOFY.%;B6.R ML/U%7 )H=90D=/F.DBEGV$UF9\+@P(3# 2KR@)F0Y$'KF:,RT08L(9ACJP=XJ^I5RRLTUA?Y-7T=&^$8 M953=FBE:9PBK]D<#KHO<8M2HE AAU?Z$(Y(Q>Z?SJO\6#/\ 4$L#!!0 ( M !>755!9AH:DI < "I$ / >&PO=V]R:V)O;VLN>&ULQ9Q=<]HX%$#_ MBH:G[,QV 8,-=)K.4"!;9A*@<9I]W%&, &UMB97M?/37KR1#*GG,G7VY\$2P MC3E(ELZ]UW(^O4CUXTG*'^0U2T5^W=H5Q?YCNYTG.Y;1_ ^Y9T+OV4B5T4*_ M5=MVOE>,KO,=8T66MH-.)VIGE(O6YT_'M[HMLN$J+V+SW?;(C N> M\9]L;=_E._GR52K^4XJ"IG&B9)K:3YD=]D/Z&_+W+8],%3SQ#BSHTSW5K->M MJ*-/^,QS_L137KQ=M^S?*6OI7]%V?H9MA^-KU8@?U?]I1KG9\(1-95)F3!15 M.RJ6FF\7^8[O\Q81-&/7K>,AA(HUF8E"TY"YJ$ZECS6_17_U?%W]KD*WV"]8 MHCYRO4/-UUT#C@U\.GZ834G\H%_N9HN'F"QOR'PQ63J0 0 97 QR MLKQ;.9 ] +)W0R#T#VSPCY97P[7DQF)/XZFSW$#F ( (87 R17*^I M1@!D=(FN-CT]^_9]_N! #@#(P>6NQW'\U8$< I!#7,BXS#*JWHC)+/6,Z4". ,@1+N1"B^Y()+8D+O2$3M4Z=V?P#C2%=W#Y[MDS$R4C MAU<7"S0+LEH6^KQSD=<2$@H762CW#*:,^\J@\S115;'6!^82XE9(TNLC:6Q4Z/@TFIE(D*;SFU(6JM&2%C=)&5 M,65/WL4/B:&+;(8I4_R9FNR"W'!!1<)IJKLV+U19'Z.0&KK(;KBA7)%'FNKI M]TX/UU(Q\P&W1P-(#0&R&K2VRJQ,[:@]7'YZ["JV8R+73>MB0JH(D%41%S+Y M\>&+GNZJR473U7.D ,P_D'7QA0FVX865A=>WD!X"9#U4_3E[-:WE]21DB0#9 M$@?A/]!7;UH+(#L$V#F%S#)>V'%I!3&1-I!C>D[Q(2$Y!,ARB-G6%@N:*P0! MI(4 60NQ/L>ZU#J=S\D'.]G98VQ;?BO=G"R C!%<,I?P$O ,D: ; P8L^<6 M,R!S],Z;5)"K!ZH!\M]Y)+> M!3*.1DA(+KV+IA[$Q83TTKM4[E$UJ(L)J:9WA@RDL8LAL?0NF8IX8NE!8NE= M)A4Y-J=;@(;$TK]D2N+7R2&_]"^4DAR:T\6$#-,_9V;2-'+ZD%CZYTQ1&NG M>R%GS%4:X2"O])&]TI /-#)"4NECYRQ@*-MW,2&I])&E<@QAQVNYM^VH>IY'Q/23!]9,T<\DT4KFFC!'$(=$P#= MNK=L0D@SX9GRE[C<[],W,ME1+H[Z%ELW+@LAS83(FCEB/LJTU,&C'DRZVZD. M)W6/%]1K34@S(;)FFK,MBYAZ\U$(Z29$U@V8;GFA10AY)T3V#HSI5@!"\$X\ MLH'JT^6P'S1W.:2@$%E!-G75-+-!W@F1O7-@H_F.W*3RQ?:SG8YL8.[6 MS4+(.R&R=RK,OQC?[DQ,/GYFBF[?1[?7FI!W0F3OW-&B5%7*JB_(I1Y!U-Z. MK_!OW94AD'A1Y!W M(F3OP)CNA!Y!WHF0O0-CNN%Z!'DG0O8.4*HRP\C%!-> (9NG*E4U#6S(.=%Y M"FC'@=P,"-DFNF@QS1LKD&TB9-O F.Y8&4"V&2#;YF3-K]KA8D*Z&2#KYB2F M3LO$UDUM!Y!N!LBZ.859S4@W+B:DFP&R;JZ,LJ6P:"8V7T[FS0-] -EF@&R; M*YW(IC3/;57([O5(74S(-@/L.MOI.J^91%U,R#8#[%+;2XF)"$!MA+!2!,+ZX<0!(:8"\5.(FYD,);O36$)#1$EE#]'D0M^' Q M(0D-D254P_0GT877FI"$AN>]HU,9,B=F=PG M,34XL345! =S!-EGA&P?'[-Z-R]8=C"1BPG99X1L'Q]SRIY9*O?OCX>ZYW1M!]AF==87!X=T7IL_% MS.TT%Q.RSPC9/CZF'QC5,"'[C)#MXV-.V88I=>AP4\)T,2'[C)#MXV/.-AMF M'Y(_WC]U,2'[C)#M ZZ*]]:FCL!G+[%SH,9U,._SDH/9[< /82)[J!$TIJEN MS*P@NZ@9]+#QAGN@X'.:'60;@0](>$E& MMP,^PMFQ/FK;P_//G]8ZBA5LO=!?DNOM"4V3E2+FQ9XKZ(?FV;=-F:83O6TI M;B4UV^TYCO^FX_-_4$L#!!0 ( !>755!*FHJN# , *H] : >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%VSMNVT 4A>&M&%J R7G/!+:K-&Z3 M;("0J0>L%T@&L7 M8_'T<+WFW?/+XV)X?C&+NQ_=L.ZGQT7SMFM^'8?7<=/WT]A<+N;^O,'YEO=3 M_S_;'U>K[;+_>ES^W/>'Z8,4?S=8-!\'LO.!K#R0FP_DY('\?" O#Q3F P5Y MH#@?*,H#I?E 21XHSP?*\D!E/E"1!S(MR-CJ(Q'6>JT-<&WT7AL V^C%-D"V MT9MM &VC5]L VT;OM@&XC5YN W0;O=T&\#9ZO2WH;?5Z6]#;5GC6IH=MO=X6 M]+9ZO2WH;?5Z6]#;ZO6VH+?5ZVU!;ZO7VX+>5J^W!;VM7F\'>CN]W@[T=GJ] M'>CM*IR5T&&)7F\'>CN]W@[T=GJ]'>CM]'H[T-OI]7:@M]/K[4!OI]?;@]Y> MK[<'O;U>;P]Z>[W>'O3V%;P]Z>[W>'O3V>KT]Z.WU>GO0 MV^OU#J!WT.L=0.^@USN WD&O=P"]@U[O 'J'"N\JZ66E7N\ >@>]W@'T#GJ] M ^@=]'H'T#OH]8Z@=]3K'4'OJ-<[@MY1KW<$O:->[PAZ1[W>$?2.%69-:-A$ MKW<$O:->[PAZ1[W>$?2.>KT3Z)WT>B?0.^GU3J!WTNN=0.^DUSN!WDFO=P*] MDU[O!'JG"K."-"RHUSN!WDFO=P*]DU[O#'IGO=X9],YZO3/HG?5Z9] [Z_7. MH'?6ZYU![ZS7.X/>6:]W!KUSA5EO&O;6ZYU![ZS7NX#>1:]W ;V+7N\">A>] MW@7T+GJ]"^A=]'H7T+OH]2Z@=]'K74#OHM>[@-ZE0E>'RCHUVCI8UZG0UVFI ML--6:.RT5-EI*W1V6BKMM!5:.RW5=MH*O9WV"O)QTPW]R_=IV![6XZVC_+/X MYW&N$!^G]UU_^QR753\/<$7V=-ZF;RZ?-_]C75;]DZ*YCC$^_0902P,$% M @ %Y=54#2ZTVEN @ 7!E&ULS=O? M;ILP%,?Q5XFXG0+8@(&IZ. D*_V2[7?KV;'X^S<:OCT(]N$^V]GS\FB6OV9M NGF8SALIVLH/VX=3NDEDW M![TSB4Q3E333Z,WHU_[4([J]^6RV^K[WJT]/UT^M-Y&>Y[YKM.^F,7D8VU=- MU\\-8VOZ98W;=[/[$!9$JR_'T,6%:YLH5%V4O&'"ZQM/Y^&^;P_&VJXU_Q5M MVFZ[QK13]]8OET-"755 ?(\\#P !," + " 0 !?755 GZ(<.@@ +$ 0 " >D M !D;V-0&UL4$L! A0#% @ %Y=54(QSPCWN *P( M !$ ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% M @ %Y=54)E&PO=V]R:W-H965T&UL4$L! A0#% M @ %Y=54 BID&WB P 3A$ !@ ( !I0P 'AL+W=O755!$]+%V0@( *@' 8 " =P; M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ %Y=54-'3FG1B!@ 6B0 !@ M ( ![R, 'AL+W=O7 M55"?PMJ/M $ -(# 8 " 8;";8! #2 P &0 M @ %Q+ >&PO=V]R:W-H965T755 ]BV*JMP$ -(# 9 " 5XN !X;"]W;W)K M&UL4$L! A0#% @ %Y=54 A>MEFR 0 T@, M !D ( !3# 'AL+W=O&PO=V]R:W-H965T755#/"08N MMP$ -(# 9 " 2 T !X;"]W;W)K&UL4$L! A0#% @ %Y=54#?)C[.T 0 T@, !D M ( !#C8 'AL+W=O&PO=V]R:W-H965T M755!TD;#NM0$ -(# 9 M " >4Y !X;"]W;W)K&UL4$L! A0# M% @ %Y=54$:QTC>U 0 T@, !D ( !T3L 'AL+W=O M&PO=V]R:W-H965T755#[L.WFM0$ -(# 9 " :D_ M !X;"]W;W)K&UL4$L! A0#% @ %Y=54&&PO=V]R:W-H965T755!XO"GAM0$ -(# 9 " 6Q% !X;"]W;W)K&UL4$L! A0#% @ %Y=54%2QN;RX 0 T@, !D M ( !6$< 'AL+W=O&PO M=V]R:W-H965T755"O8)\CM0$ M -(# 9 " 3)+ !X;"]W;W)K&UL4$L! A0#% @ %Y=54/SNO NU 0 T@, !D ( ! M'DT 'AL+W=O&PO=V]R:W-H965T755"XYE? P@( 'P+ 9 M " ?A0 !X;"]W;W)K&UL4$L! A0#% M @ %Y=54!\#@R2V 0 T@, !D ( !\5, 'AL+W=O50 >&PO=V]R:W-H965T755#2\RH%N $ -(# 9 " =I7 !X M;"]W;W)K&UL4$L! A0#% @ %Y=54' ]@Q&U M 0 T@, !D ( !R5D 'AL+W=O&PO=V]R:W-H965T7 M55#*)2[5MP$ -(# 9 " >)= !X;"]W;W)K&UL4$L! A0#% @ %Y=54-Y7^X#& 0 -P0 !D M ( !T%\ 'AL+W=O&PO=V]R M:W-H965T755#?%LK_MP$ -(# M 9 " ;UC !X;"]W;W)K&UL M4$L! A0#% @ %Y=54$-:M:G/ 0 G 0 !D ( !JV4 M 'AL+W=O&PO=V]R:W-H965T755 A&!"?Q@$ #<$ 9 M " :QI !X;"]W;W)K&UL4$L! A0#% @ M%Y=54!#^/F;O 0 9@4 !D ( !J6L 'AL+W=O&PO=V]R:W-H965T755#[=A'.Q@$ #<$ 9 " 0QP !X;"]W M;W)K&UL4$L! A0#% @ %Y=54 <$2E?N 0 M9@4 !D ( !"7( 'AL+W=O-JH-,! "&PO=V]R:W-H965T755"* M,O]OV0( -L* 9 " 3AV !X;"]W;W)K&UL4$L! A0#% @ %Y=54'J=TY'@ 0 $P4 !D M ( !2'D 'AL+W=OP >&PO=V]R:W-H M965T755"JOR&F=0( )L( 9 M " 0=_ !X;"]W;W)K&UL4$L! M A0#% @ %Y=54"QRE%&U 0 T0, !D ( !LX$ 'AL M+W=O&PO=V]R:W-H965T755#G+'%XM0( /P) 9 " M ;"% !X;"]W;W)K&UL4$L! A0#% @ %Y=5 M4#&)C[:R P 1Q( !D ( !G(@ 'AL+W=O&PO=V]R:W-H965T755#I[/.Z4@( !$( 9 " 2R/ !X;"]W;W)K M&UL4$L! A0#% @ %Y=54 3[GG(@ @ "P8 M !D ( !M9$ 'AL+W=O&PO=V]R:W-H965T755!2>NPB MI@$ +T# 9 " 1.6 !X;"]W;W)K&UL4$L! A0#% @ %Y=54*QN&PO=V]R:W-H965T M755!RZEQ3T ( '\* 9 M " ;*= !X;"]W;W)K&UL4$L! A0# M% @ %Y=54%M9J(30 @ 8 L !D ( !N: 'AL+W=O M&PO=V]R:W-H965T755"P.?D8@@( (8( 9 " 42G M !X;"]W;W)K&UL4$L! A0#% @ %Y=54".Y M!?&0 @ 2@D !D ( !_:D 'AL+W=O&PO=V]R:W-H965T755!T7SZG)08 "LF 9 " 5>P !X;"]W;W)K&UL4$L! A0#% @ %Y=54.WHQHK% P @Q, !D M ( !L[8 'AL+W=O&PO M=V]R:W-H965T755".TDK*?P, M /$1 9 " 7Z_ !X;"]W;W)K&UL4$L! A0#% @ %Y=54!/ARSPD @ 8 !D ( ! M-,, 'AL+W=O&PO=V]R:W-H965T755!<:=&UL4$L! A0#% M @ %Y=54.?*E9A ! E10 !D ( !&\P 'AL+W=O&PO=V]R:W-H965T7 M55 *IVZ=%P8 -\A 9 " =_@ !X;"]W;W)K&UL4$L! A0#% @ %Y=54(6M;\R1! =!@ !D M ( !+>< 'AL+W=O&PO=V]R M:W-H965T755!TQ2UCS00 "H; M 9 " >GQ !X;"]W;W)K&UL M4$L! A0#% @ %Y=54+-F_[UV @ ( D !D ( ![?8 M 'AL+W=O&PO=V]R:W-H965T755!AD?C*X0( 'P, 9 M " 8O\ !X;"]W;W)K&UL4$L! A0#% @ M%Y=54*TIR!*9 @ VPD !D ( !H_\ 'AL+W=O&PO=V]R:W-H965T755 $T=JOXP( (+ 9 " :\' 0!X;"]W M;W)K&UL4$L! A0#% @ %Y=54'#2O)IZ! M&Q@ !D ( !R0H! 'AL+W=O&PO=V]R:W-H965T755 + M9?',;P( $8( 9 " 3,2 0!X;"]W;W)K&UL4$L! A0#% @ %Y=54$&:=HLB P 6@T !D M ( !V10! 'AL+W=O&PO=V]R:W-H M965T755#AU?\9,P( $<& 9 M " 9T: 0!X;"]W;W)K&UL4$L! M A0#% @ %Y=54'>!1&R_ @ !@H !D ( !!QT! 'AL M+W=O&PO=V]R:W-H965T755#IAO5S$ , /<- 9 " M ?4C 0!X;"]W;W)K&UL4$L! A0#% @ %Y=5 M4'=R:QYN @ 4 @ !D ( !/"&PO=V]R:W-H965T&PO=V]R M:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T&PO=V]R:W-H965T-?_+ "A0P, % M @ $7/ $ >&PO&PO755!9AH:DI < "I$ / " 1<+ M @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " 7EU502IJ*K@P# "J/0 M&@ @ 'H$@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " 7EU50-+K3:6X" !S.P $P @ $L%@( I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 <0!Q X? #+& ( ! end XML 111 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Debt (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Debt Instrument [Line Items]    
    Unamortized debt issuance expense $ 0.7 $ 0.6
    Long-term debt, excluding current portion $ 255.0 196.0
    Senior A Notes Due 2022 [Member]    
    Debt Instrument [Line Items]    
    Debt instrument, stated interest rate 3.67%  
    Senior B Notes Due 2024 [Member]    
    Debt Instrument [Line Items]    
    Debt instrument, stated interest rate 3.82%  
    Senior C Notes Due 2027 [Member]    
    Debt Instrument [Line Items]    
    Debt instrument, stated interest rate 4.02%  
    Note Payable Due 2019 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt, gross   0.1
    Revolving credit facility, due 2020 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt, gross   28.6
    Senior Notes [Member] | Senior A Notes Due 2022 [Member]    
    Debt Instrument [Line Items]    
    Debt instrument, stated interest rate 3.67%  
    Long-term debt, gross   42.0
    Senior Notes [Member] | Senior B Notes Due 2024 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt $ 53.0  
    Debt instrument, stated interest rate 3.82%  
    Long-term debt, gross   53.0
    Senior Notes [Member] | Senior C Notes Due 2027 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt $ 73.0  
    Debt instrument, stated interest rate 4.02%  
    Long-term debt, gross   $ 73.0
    Term Loan Due 2024 [Domain]    
    Debt Instrument [Line Items]    
    Long-term debt $ 90.0  
    Senior A Notes Due 2022 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt 42.0  
    Term Loan Due 2024 [Member]    
    Debt Instrument [Line Items]    
    Long-term debt, excluding current portion $ 87.7  
    Debt instrument, stated interest rate 2.78%  
    Long-term debt, gross $ 90.0  

    XML 112 R97.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards, foreign $ 6.4  
    Operating loss carryforwards, state and local 15.5  
    Deferred tax assets    
    Net operating loss carryforwards 21.9 $ 18.4
    Tax credit carryforwards 2.8 10.5
    Pension and deferred compensation 25.6 27.2
    Other 9.2 11.4
    Valuation allowance (15.9) (16.0)
    Total deferred tax assets 43.6 51.5
    Deferred tax liabilities:    
    Accelerated depreciation 37.9 31.3
    Tax on undistributed earnings of subsidiaries 6.3 6.6
    Other 0.9 2.0
    Total deferred tax liabilities 45.1 39.9
    Net deferred tax (liability) asset (1.5) $ 11.6
    State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards 226.9  
    Foreign Tax Authority [Member]    
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards 49.4  
    Operating loss carryforwards, not subject to expiration 48.7  
    Year 2018 [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards 15.4  
    Year After 2018 [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Operating loss carryforwards 211.5  
    Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Tax credit carryforward 2.0  
    Research Tax Credit Carryforward [Member] | Year 2022 [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Tax credit carryforward 0.5  
    Research Tax Credit Carryforward [Member] | Year 2023 [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Tax credit carryforward 0.5  
    Research Tax Credit Carryforward [Member] | Year After 2023 [Member] | State and Local Jurisdiction [Member]    
    Operating Loss Carryforwards [Line Items]    
    Tax credit carryforward $ 1.0  
    XML 113 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Adoption of ASC 606 (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Jan. 01, 2018
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
    Retained earnings $ 1,549.4 $ 1,353.4  
    Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]      
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
    Retained earnings     $ 11.4
    XML 114 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Expense (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Other Income and Expenses [Abstract]  
    Schedule of Other Income and Expense
    Other (income) expense consisted of:
    ($ in millions)201920182017
    Restructuring and related charges:
    Severance and post-employment benefits$2.6  $3.1  $—  
    Asset-related charges0.3  2.2  —  
    Other charges2.0  3.8  —  
    Total restructuring and related charges$4.9  $9.1  $—  
    Argentina currency devaluation1.0  1.1  —  
    Tax recovery(4.7) —  —  
    Venezuela deconsolidation—  —  11.1  
    Development and licensing income(0.9) (0.9) (10.6) 
    Contingent consideration2.1  (2.6) (2.4) 
    Other items(4.9) (4.8) 3.9  
    Total other (income) expense$(2.5) $1.9  $2.0  
    Schedule of Restructuring Obligations
    The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

    ($ in millions)Severance and benefitsAsset-related chargesOther chargesTotal
    Balance, December 31, 2017$—  $—  $—  $—  
    Charges3.1  2.2  3.5  8.8  
    Cash payments(0.8) —  —  (0.8) 
    Non-cash asset write-downs—  (2.2) (3.5) (5.7) 
    Balance, December 31, 2018$2.3  $—  $—  $2.3  
    Charges2.6  0.3  2.0  4.9  
    Cash payments(3.5) —  —  (3.5) 
    Non-cash asset write-downs—  (0.3) (2.0) (2.3) 
    Balance, December 31, 2019$1.4  $—  $—  $1.4  
    XML 115 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurements (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Fair Value Disclosures [Abstract]  
    Schedule of Assets and Liabilities at Fair Value
    The following tables present the assets and liabilities recorded at fair value on a recurring basis:

     Balance atBasis of Fair Value Measurements
    ($ in millions)December 31,
    2019    		Level 1Level 2Level 3
    Assets:    
    Deferred compensation assets$11.3  $11.3  $—  $—  
    Foreign currency contracts7.7  —  7.7  —  
    Commodity call options0.1  —  0.1  —  
     $19.1  $11.3  $7.8  $—  
    Liabilities:    
    Contingent consideration$3.3  $—  $—  $3.3  
    Deferred compensation liabilities12.8  12.8  —  —  
    Cross-currency swap1.4  —  1.4  —  
    Foreign currency contracts0.3  —  0.3  —  
     $17.8  $12.8  $1.7  $3.3  

     Balance atBasis of Fair Value Measurements
    ($ in millions)December 31,
    2018    		Level 1Level 2Level 3
    Assets:    
    Deferred compensation assets$8.7  $8.7  $—  $—  
    Foreign currency contracts6.5  —  6.5  —  
     $15.2  $8.7  $6.5  $—  
    Liabilities:    
    Contingent consideration$1.7  $—  $—  $1.7  
    Deferred compensation liabilities9.8  9.8  —  —  
    Foreign currency contracts0.2  —  0.2  —  
     $11.7  $9.8  $0.2  $1.7  
    Summary of Changes in Level 3 Fair Value Measurements
    The following table provides a summary of changes in our Level 3 fair value measurements:

     ($ in millions)
    Balance, December 31, 2017$4.9  
    Decrease in fair value recorded in earnings(2.6) 
    Payments(0.6) 
    Balance, December 31, 20181.7  
    Increase in fair value recorded in earnings2.1  
    Payments(0.5) 
    Balance, December 31, 2019$3.3  
    XML 116 R86.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Expected Benefit Payments) (Details)
    $ in Millions
    Dec. 31, 2019
    USD ($)
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
    2019 $ 22.3
    2020 14.8
    2021 17.0
    2022 15.2
    2023 15.4
    2025 to 2029 73.8
    Total benefit payments expected 158.5
    Foreign Plan [Member]  
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
    2019 1.3
    2020 1.3
    2021 2.0
    2022 1.5
    2023 1.9
    2025 to 2029 13.3
    Total benefit payments expected 21.3
    United States [Member]  
    Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
    2019 21.0
    2020 13.5
    2021 15.0
    2022 13.7
    2023 13.5
    2025 to 2029 60.5
    Total benefit payments expected $ 137.2
    XML 117 R101.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Segment Information (Sales by Product Group) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Segment Reporting, Revenue Reconciling Items [Line Items]      
    Net sales $ 1,839.9 $ 1,717.4 $ 1,599.1
    Contract-Manufactured Products [Member]      
    Segment Reporting, Revenue Reconciling Items [Line Items]      
    Net sales 441.5 409.1 362.5
    Proprietary Products [Member]      
    Segment Reporting, Revenue Reconciling Items [Line Items]      
    Net sales 1,398.6 1,308.6 1,236.9
    Intersegment Elimination [Member]      
    Segment Reporting, Revenue Reconciling Items [Line Items]      
    Net sales $ (0.2) $ (0.3) $ (0.3)
    XML 118 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Stock-Based Compensation (Textuals) (Details)
    		 12 Months Ended
    Dec. 31, 2019
    USD ($)
    plan
    shares
    Dec. 31, 2018
    shares
    Dec. 31, 2017
    shares
    Dec. 31, 2016
    shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Shares available for grant/issuance 3,119,314      
    Unrecognized compensation expense for all nonvested awards | $ $ 21,200,000      
    Weighted average period for recognition 1 year 7 months 6 days      
    Share-based Payment Arrangement, Option [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Awards, expiration period 10 years      
    Number of shares reduced for each award granted 1      
    Stock Appreciation Rights (SARs) [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Vesting period 4 years      
    Awards, expiration period 10 years      
    Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 35,993 39,819 51,368 116,087
    Award Types Other than Stock Options and Stock Appreciation Rights [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares reduced for each award granted 2.5      
    Employee Stock Purchase Plan (ESPP) [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Shares available for grant/issuance 3,800,000      
    Percentage of current market price for sales to eligible employees 85.00%      
    Limitation on payroll deductions of employee's base salary, percent 25.00%      
    Limitation on payroll deductions of employee's base salary, amount | $ $ 25,000      
    Maximum number of shares per employee 2,000      
    Maximum number of shares per employee, per year   8,000    
    Purchases of shares 51,391 55,669 56,218  
    Restricted Stock [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted at target level 13,308 0    
    Annual Incentive Plan [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted at target level 1,300 1,500 1,800  
    Vesting period 4 years      
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 0 200 800  
    Cash-settled PSU awards [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted at target level 806 560 598  
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 0 0 0  
    Stock-settled PSU awards [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted at target level 84,309 102,307 92,045  
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 16,204 23,946 110  
    Deferred Compensation Plans [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Deferred compensation conversion unit 1      
    Number of deferred compensation plans | plan 2      
    Number of deferred stock units 366,159      
    Number of deferred stock units payable in cash 6,274      
    Deferred Compensation Plans [Member] | Non-Employee Directors [Member]        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted at target level 14,579      
    XML 119 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Fair Value Measurements (Changes in Level 3 Fair Value Measurements) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Level 3 Fair Value Measurements [Roll Forward]    
    Balance, beginning $ 1.7 $ 4.9
    Increase (reduction) in fair value recorded in earnings 2.1 (2.6)
    Payments (0.5) (0.6)
    Balance, ending $ 3.3 $ 1.7
    XML 120 R82.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Benefit Plans (Components of Net Periodic Benefit Cost) (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Curtailment $ (3.5) $ 0.0 $ 0.0
    Other Nonoperating Income (Expense) [Member]      
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
    Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 3.5    
    Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 3.5    
    Pension Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Service cost 1.4 10.8 10.4
    Interest cost 9.2 9.4 9.8
    Expected return on assets (12.0) (15.7) (13.5)
    Amortization of prior service credit 0.1 (1.3) (1.3)
    Amortization of actuarial loss (gain) 2.1 3.8 4.9
    Net periodic benefit cost 4.3 7.0 10.3
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
    Net loss (gain) arising during period 1.5 3.5 (9.0)
    Prior service credit arising during period 0.0 0.3 0.0
    Amortization of prior service credit (0.1) 1.3 1.3
    Amortization of actuarial (loss) gain (2.1) (3.8) (4.9)
    Foreign currency translation 0.6 (1.2) 2.6
    Total recognized in OCI (3.6) 0.1 (10.0)
    Total recognized in net periodic benefit cost and OCI 0.7 $ 7.1 0.3
    Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 3.5    
    Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax $ (3.5)    
    Rate of compensation increase 2.49% 4.01%  
    Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement $ 3.5    
    Other Postretirement Benefits Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Service cost 0.0 $ 0.0 0.0
    Interest cost 0.2 0.2 0.3
    Expected return on assets 0.0 0.0 0.0
    Amortization of prior service credit (0.7) (0.7) (0.7)
    Amortization of actuarial loss (gain) (2.3) (2.4) (2.6)
    Net periodic benefit cost (2.8) (2.9) (3.0)
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
    Net loss (gain) arising during period 0.1 (1.4) (1.1)
    Prior service credit arising during period 0.0 0.0 0.0
    Amortization of prior service credit 0.7 0.7 0.7
    Amortization of actuarial (loss) gain 2.3 2.4 2.6
    Foreign currency translation 0.0 0.0 0.0
    Total recognized in OCI 3.1 1.7 2.2
    Total recognized in net periodic benefit cost and OCI $ 0.3 $ (1.2) (0.8)
    Foreign Plan [Member]      
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
    Rate of compensation increase 2.49% 2.60%  
    Foreign Plan [Member] | Pension Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Net periodic benefit cost $ 1.9 $ 2.2 3.0
    Foreign Plan [Member] | Other Postretirement Benefits Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Net periodic benefit cost $ 0.0 $ 0.0 0.0
    United States [Member]      
    Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
    Rate of compensation increase 4.25% 4.25%  
    United States [Member] | Pension Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Net periodic benefit cost $ 2.4 $ 4.8 7.3
    United States [Member] | Other Postretirement Benefits Plan [Member]      
    Defined Benefit Plan, Net Period Benefit Cost (Credit) [Abstract]      
    Net periodic benefit cost $ (2.8) $ (2.9) $ (3.0)
    XML 121 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Revenue Supply Chain Financing (Details) - USD ($)
    $ in Millions
    Dec. 31, 2019
    Dec. 31, 2018
    Supply Chain Financing [Abstract]    
    Transfer of accounts receivable under supply chain financing agreements $ 10.1 $ 5.7
    XML 122 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Property, Plant and Equipment (Textuals) (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Dec. 31, 2017
    Property, Plant and Equipment [Line Items]      
    Depreciation $ 100,000,000.0 $ 101,700,000 $ 94,300,000
    Capitalized leases 0 0  
    Capitalized interest 1,000,000.0 900,000 2,700,000
    Gain (Loss) on Disposition of Assets 1,900,000 1,100,000  
    Asset-related charges 300,000 $ 2,200,000 $ 0
    2018 Restructuring Plan [Member]      
    Property, Plant and Equipment [Line Items]      
    Asset impairment charges, patent and equipment $ 300,000    
    XML 123 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Lease Weighted Average (Detail)
    Dec. 31, 2019
    Leases [Abstract]  
    Weighted average remaining lease term for operating leases 11 years 8 months 12 days
    Weighted average discount rate for operating leases 3.76%
    XML 124 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Debt (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Debt Disclosure [Abstract]  
    Long-term Debt Obligations , Net of Current Maturities
    The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of December 31, 2019.

    ($ in millions)20192018
    Note payable, due December 31, 2019$—  $0.1  
    Credit Facility, due October 15, 2020—  28.6  
    Term Loan, due December 31, 2024 (2.78%)90.0  —  
    Series A notes, due July 5, 2022 (3.67%)42.0  42.0  
    Series B notes, due July 5, 2024 (3.82%)53.0  53.0  
    Series C notes, due July 5, 2027 (4.02%)73.0  73.0  
    258.0  196.7  
    Less: unamortized debt issuance costs0.7  0.6  
    Total debt257.3  196.1  
    Less: current portion of long-term debt2.3  0.1  
    Long-term debt, net$255.0  $196.0  
    XML 125 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Leases (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Dec. 31, 2018
    Leases [Abstract]    
    Lease, Cost
    The components of lease expense were as follows:

    ($ in millions)2019
    Operating lease cost$12.9  
    Short-term lease cost0.8  
    Variable lease cost3.3  
    Total lease cost$17.0  
    		  
    lessee, lease Cash Flow and Supplemental information
    Supplemental information related to leases was as follows:

    ($ in millions)2019
    Cash paid for amounts included in the measurement of lease liabilities:
    Operating cash flows from operating leases$12.5  
    Right-of-use assets obtained in exchange for new operating lease liabilities9.1  
    		  
    Lessee, Operating Lease, Liability, Maturity
    Maturities of lease liabilities as of December 31, 2019 were as follows:

    ($ in millions)Operating
    YearLeases
    2020$12.1  
    202110.4  
    20228.6  
    20237.8  
    20247.3  
    Thereafter41.8  
    88.0  
    Less: imputed lease interest(16.0) 
    Total lease liabilities$72.0  
    		  
    Schedule of Future Minimum Rental Payments for Operating Leases  
    Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows:

    ($ in millions)Operating
    YearLeases
    2019$13.0  
    202010.5  
    20217.8  
    20226.9  
    20235.5  
    Thereafter37.8  
    Total$81.5  
    XML 126 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2019
    Accounting Policies [Abstract]  
    Summary of Inventories The following is a summary of inventories at December 31:
    ($ in millions)20192018
    Raw materials$100.9  $90.4  
    Work in process37.4  42.2  
    Finished goods97.4  81.9  
    $235.7  $214.5  
    XML 127 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Property, Plant and Equipment
    		 12 Months Ended
    Dec. 31, 2019
    Property, Plant and Equipment [Abstract]  
    Property, Plant and Equipment Property, Plant and Equipment
    A summary of gross property, plant and equipment at December 31 is presented in the following table:

    ($ in millions)Expected useful lives (years)20192018
    Land$22.1  $20.9  
    Buildings and improvements15-35572.9  569.1  
    Machinery and equipment5-12817.0  806.7  
    Molds and dies4-7123.8  115.8  
    Computer hardware and software3-10155.6  151.1  
    Construction in progress128.7  89.1  
    $1,820.1  $1,752.7  

    Depreciation expense for the years ended December 31, 2019, 2018 and 2017 was $100.0 million, $101.7 million and $94.3 million, respectively.

    There were no capitalized leases included in buildings and improvements and machinery and equipment at December 31, 2019 and 2018.

    We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2019, 2018 and 2017 was $1.0 million, $0.9 million and $2.7 million, respectively.

    During 2019 and 2018, as part of our 2018 restructuring plan, we recorded within other (income) expense $0.3 million and $2.2 million, respectively, for non-cash asset write-downs associated with the discontinued use of certain equipment. During 2019 and 2018, as part of our restructuring plans, we recorded within other (income) expense $1.9 million and $1.1 million, respectively, for gains on the sale of fixed assets.
    XML 128 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
    Other Current Liabilities
    		 12 Months Ended
    Dec. 31, 2019
    Other Current Liabilities [Abstract]  
    Other Current Liabilities Other Current Liabilities
    Other current liabilities as of December 31 included the following:

    ($ in millions)20192018
    Deferred income$27.5  $25.5  
    Dividends payable11.8  11.3  
    Accrued commissions, rebates and royalties9.7  5.7  
    Accrued retirement plans (excluding pension)7.9  2.3  
    Accrued taxes other than income6.5  5.5  
    Accrued professional services5.9  4.9  
    Accrued interest3.3  3.4  
    Restructuring obligations1.5  3.3  
    Other17.2  14.7  
    Total other current liabilities$91.3  $76.6  

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